Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Page 85
Page 86
Page 87
Page 88
Page 89
Page 90
Page 91
Page 92
Page 93
Page 94
Page 95
Page 96
Page 97
Page 98
Page 99
Page 100
Page 101
Page 102
Page 103
Page 104
Page 105
Page 106
Page 107
Page 108
Page 109
Page 110
Page 111
Page 112
Page 113
Page 114
Page 115
Page 116
Page 117
Page 118
Page 119
Page 120
Page 121
Page 122
Page 123
Page 124
Page 125
Page 126
Page 127
Page 128
Page 129
Page 130
Page 131
Page 132
Page 133
Page 134
Page 135
Page 136
Page 137
Page 138
Page 139
Page 140
Page 141
Page 142
Page 143
Page 144
Page 145
Page 146
Page 147
Page 148
Page 149
Page 150
Page 151
Page 152
Page 153
Page 154
Page 155
Page 156
Page 157
Page 158
Page 159
Page 160
Page 161
Page 162
Page 163
Page 164
Page 165
Page 166
Page 167
Page 168
Page 169
Page 170
Page 171
Page 172
Page 173
Page 174
Page 175
Page 176
Page 177
Page 178
Page 179
Page 180
Page 181
Page 182
Page 183
Page 184
Page 185
Page 186
Page 187
Page 188
Page 189
Page 190
Page 191
Page 192
Page 193
Page 194
Page 195
Page 196
Page 197
Page 198
Page 199
Page 200
Page 201
Page 202
Page 203
Page 204
Page 205
Page 206
Page 207
Page 208
Page 209
Page 210
Page 211
Page 212
Page 213
Page 214
Page 215
Page 216
Page 217
Page 218
Page 219
Page 220
Page 221
Page 222
Page 223
Page 224
Page 225
Page 226
Page 227
Page 228
Page 229
Page 230
Page 231
Page 232
Page 233
Page 234
Page 235
Page 236
Page 237
Page 238
Page 239
Page 240
Page 241
Page 242
Page 243
Page 244
Page 245
Page 246
Page 247
Page 248
Page 249
Page 250
Page 251
Page 252
Page 253
Page 254
Page 255
Page 256
Page 257
Page 258
Page 259
Page 260
Page 261
Page 262
Page 263
Page 264
Page 265
Page 266
Page 267
Page 268
Page 269
Page 270
Page 271
Page 272
Page 273
Page 274
Page 275
Page 276
Page 277
Page 278
Page 279
Page 280
Page 281
Page 282
Page 283
Page 284
Page 285
Page 286
Page 287
Page 288
Page 289
Page 290
Page 291
Page 292
Page 293
Page 294
Page 295
Page 296
Page 297
Page 298
Page 299
Page 300
Page 301
Page 302
Page 303
Page 304
Page 305
Page 306
Page 307
Page 308
Page 309
Page 310
Page 311
Page 312
Page 313
Page 314
Page 315
Page 316
Page 317
Page 318
Page 319
Page 320
Page 321
Page 322
Page 323
Page 324
Page 325
Page 326
Page 327
Page 328
Page 329
Page 330
Page 331
Page 332
Page 333
Page 334
Page 335
Page 336
Page 337
Page 338
Page 339
Page 340
Page 341
Page 342
Page 343
Page 344
Page 345
Page 346
Page 347
Page 348
Page 349
Page 350
Page 351
Page 352
Page 353
Page 354
Page 355
Page 356
Page 357
Page 358
Page 359
Page 360
2016 NEXTGENERATION LEARNING SCHEDULE GENERAL INFO d PD-L1 answers can trust s two new FDA-approved PD-L1 pharmDx kits. ng is a promising new tool for pathologists oncologists and ts opening new treatment possibilities. Only Dako provides th two FDA-approved PD-L1 tests for patients with NSCLC. HC 22C3 pharmDx HC 28-8 pharmDx QR codes to the right for more information on either r contact your local sales representative. visit us at booth 630 during USCAP16 Annual Meeting. e at www.dako.com. PD-L1 IHC 28-8 pharmDx PD-L1 IHC 22C3 pharmDx Shield_White_2013 Version 1.1 25 October 2013 Sharing multiplies your knowledge IntelliSite is a new innovative platform to advance your digital pathology initiatives. High resolution images collaboration features and case management support tools can help you make that next step in workflow improvement and accelerate knowledge sharing between care providers. Leveraging decades of Philips experience in clinical digital transformation the IntelliSite pathology solution can provide you the speed quality and scalability you need. Helping you to build and share valued knowledge amongst your clinical colleagues. IntelliSite Pathology Solutions Visit us at USCAP 2016 at booth 1002 or www.philips.comdigitalpathology The sponsor of this ad verifies that they had no input into decision making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Order Online 247 www.biocare.net 800 949 9799 facebook.combiocaremedical Stand Out with Biocare Visit Biocare at Booth 801 to see how your laboratory can partner with Biocares extensive product portfolio of IHC and ISH reagents to stand above the rest. With innovative IHC antibodies advanced FISH probes and automated instrumentation Biocare can meet all of your clinical and research laboratory needs. Learn more about our top IHC antibodies like p40 BC28 CDH17 SOX10 M and ERG. Biocare has also released a new IVD Multiplex of CK HMW p63 AMACR RM and additional double-stains to aid in solving complex clinical cases. TRIDENT FISH probes are generated using the most advanced genomic data minimizing false positives and false negatives while providing clear and concise signals. del-TECT 4-color probes minimize false positives seen in FFPE tissues. CytoFISH CK HMW p63 AMACR RM The sponsor of this ad verifies that they had no input into decision making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Inspirata and Philips are delivering on the promise and value aorded by digital pathology. Together our goal is to transform the pathology workow with automated tools cloud-based technologies and a unique delivery model that will enable cancer institutions to address the growing demand for cancer diagnostic servicesboth locally and globally. Learn more about PathologyNEXTSM at Booth 1102 during USCAP. www.inspirata.com The sponsor of this ad veries that they had no input into decision making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Seattle Genetics and are US registered trademarks of Seattle Genetics Inc. 2015 Seattle Genetics Inc. Bothell WA 98021 All rights reserved. Printed in USA USP-DIS-2015-0108 WHEN YOU SUSPECT LARGE CELL LYMPHOMA... IHC TESTING FOR CD30 CAN AID IN YOUR DIFFERENTIAL DIAGNOSIS.1 To learn more about the role of CD30 IHC in lymphoma VISIT BOOTH 1007 Reference 1. Higgins RABlankenship JEKinney MC.Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma.Arch Pathol Lab Med.20081323441-461. The sponsor of this ad verifies that they had no input into decision making regarding selection of educational programscontent or faculty for this 2016Annual Meeting. Need PD-L1 answers you can trust Dako has two new FDA-approved PD-L1 pharmDx kits. PD-L1 testing is a promising new tool for pathologists oncologists and their patients opening new treatment possibilities. Only Dako provides your lab with two FDA-approved PD-L1 tests for patients with NSCLC. PD-L1 IHC 22C3 pharmDx PD-L1 IHC 28-8 pharmDx Scan the QR codes to the right for more information on either product or contact your local sales representative. Be sure to visit us at booth 630 during USCAP16 Annual Meeting. The sponsor of this ad veries that they had no input into decision making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Learn more at www.dako.com. 50242 2015NOV06 PD-L1 IHC 28-8 pharmDx 50242 2015NOV06 PD-L1 IHC 22C3 pharmDx 50242 2015NOV06 USCAP16 Program Advert_halfpage_horizontal.indd 1 06-11-2015 141145 To learn more about our test offerings please visit www.integratedoncology.com. Because Knowledge is a Powerful Tool. Prosigna is a registered trademark of NanoString Technologies Inc. 2015 Laboratory Corporation of America Holdings. All rights reserved. onc-887-v1-1115 l PD-L1 by IHC for Non-Small Cell Lung Cancer l Expanded RAS and RAF Predictive Testing for Colorectal Cancer l IntelliGEN Next Generation Sequencing Therapeutic Panel l Prosigna Breast Cancer Prognostic Gene Signature Assay l Reveal SNP Array for Hematologic Malignancies Comprehensive Diagnostic and Predictive Molecular Pathology Services including Official Silver Sponsor of USCAP 16 Booth 1018 The sponsor of this ad veries that they had no input into decision making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Pathologists Subspecialties Lab for all your Anatomic Molecular Pathology Needs Empower your practice with support from the largest most diverse private laboratory in the Pacic North West. CellNetix was built by pathologists with the commitment to provide unbeatable accuracy service and value to our patients and providers. SymbiodxTM Powered by CellNetix and PAMLPAMLP The sponsor of this ad verifies that they had no input into decision-making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. Bristol-Myers Squibb At the Forefront of Immuno-Oncology IOUS1600010-01-01 0116 2016 Bristol-Myers Squibb Company. Discover how our exploration of immune biomarkers is continuing to shape research advances in Immuno-Oncology Visit us at Booth 433 and ImmunoOncologyHCP.com The sponsor of this ad verifies that they had no input into decision-making regarding selection of educational programs content or faculty for this 2016 Annual Meeting. ADVANCING IMMUNE BIOMARKER RESEARCH Creating a Better Pathologist for a Healthier World. GLOBAL. EMPATHY. UNDERSERVED. PHILANTHROPY. TECHNOLOGY. NEED. DIGITAL OUTREACH. KNOWLEDGE TRANSFER. RESPONSIBILITY. www.USCAPFoundation.org WHATISTHESINGLEBIGGESTCAUSEOFDEATHFORWOMEN FORCHILDRENUNDERAGE5INTHEDEVELOPINGWORLD This lecture reinforces the humanitarian power of art in the context of diseases affecting women in low-resource countries. SPECIAL EVENT Monday March 14 615-700 PM Hall 4E Washington State Convention Center Distinguished Pulmonary Pathologist International Photojournalist HUTLUNGAPOIGNANTPORTRAIT THOMAS V. COLBY M.D. ANNIE GRIFFITHS AMI VITALE RIPPLE EFFECT IMAGES NEXTGENERATION LEARNING 2016 1 2016 TABLE OF CONTENTS NEXTGENERATION LEARNING 20 TAB 1 SCHEDULE GENERAL INFORMATION Certicate of CMESAM Credit or Participation ........................... p. 3 Coffee BreaksHeadshot Lounge Open......................................... p. 4 Daily Program OutlineMeeting at a Glance............................p. 5-12 Sheraton Convention Hall Floor Plans........................................ p. 13 Washington State Convention Center Floor Plans................p. 14-17 Exhibit Hall Information and Floor Plan...................................... p. 18 Poster Pickup and Viewing Station ............................................. p. 19 USCAP Secretariat Information................................................... p. 19 Past Presidents and Secretary-Treasurers.................................. p. 20 In Memoriam of Past Members................................................... p. 21 USCAP Board and Committee Members...............................p. 22-30 2016 Business Meeting Agenda ................................................. p. 31 2015 Business Meeting Minutes.............................................p. 32-34 International Academy of Pathology Session............................ p. 35 2016 Afliate Events................................................................p. 36-38 TAB 2 PATHOLOGISTS-IN-TRAINING Welcome Message from Resident Advisory Chair .................... p. 39 Fellowship Fair.........................................................................p. 40-41 Resident Advisory Committee..................................................... p. 42 TAB 3 COMPANION SOCIETY MEETINGS Saturday Companion Meetings...........................................p. 43-48 Sunday Companion Meetings .............................................p. 49-70 TAB 4 SPECIALTY CONFERENCES Sunday Gynecologic Pathology............................................... .p. 71 Sunday Pulmonary Pathology................................................. .p. 71 Sunday Renal Pathology.......................................................... .p. 72 Sunday Pediatric Pathology..................................................... .p. 72 Sunday Housestaff..................................................................... p. 73 Sunday Ophthalmic Pathology................................................. p. 73 Monday Surgical Pathology..................................................... .p. 74 Monday Cardiovascular Pathology ......................................... .p. 74 Monday infectious Disease Pathology.................................... .p. 75 Tuesday Genitourinary Pathology............................................ p. 75 Tuesday Liver Pathology .......................................................... .p. 76 Tuesday Bone and Soft Tissue Pathology................................ p. 76 Tuesday Head Neck and Endocrine Pathology...................... .p. 77 Wednesday Hematopathology ................................................ .p. 77 Wednesday Cytopathology...................................................... .p. 78 Wednesday Neuropathology ................................................... .p. 78 Thursday Gastrointestinal........................................................ .p. 79 Thursday Evening Specialty Conferences Thursday Dermatopathology........................................................................ p. 79 Thursday Evening Specialty Conferences Thursday Breast Pathology........................................................................... p. 80 TAB 5 SPECIAL COURSES Saturday Residents Workshop Genomic Medicine for Pathologists What You Need to Know..................................p. 81-82 Saturday Residents Workshop Leadership Collaboration and Change in Health Care Essential Skills. ........................................................................p. 83-84 Monday Clinical Application of Next Generation Sequencing for the Management of Patients with Solid Tumors................................................................................. p. 85 Monday Tumor Immunology Implications for TNM Staging and Therapeutics..............................................p. 86-87 Tuesday Molecular Diagnostic and Genomic Applications in Cancer A Primer for the Pathologist...........p. 88-90 Monday Interactive Microscopy. .........................................p. 91-92 Tuesday Interactive Microscopy ..........................................p. 92-93 Thursday Interactive Microscopy ........................................p. 93-94 Monday Hot Topics In Pathology.............................................. p. 95 Tuesday Hot Topics In Pathology ............................................. p. 95 Wednesday Hot Topics In Pathology........................................ p. 95 Thursday Hot Topics In Pathology............................................ p. 96 Monday Practice Changers ....................................................... p. 97 Tuesday Practice Changers ....................................................... p. 98 Timely Topics Lecture................................................................... p. 98 Hut Lung A Poignant Portrait...................................................... p. 98 Maude Abbott Lecture ................................................................. p. 98 TAB 6 LONG COURSE Diagnosing Distinctive Lesions of the Head and Neck.......p. 99-100 TAB 7 SHORT COURSES Wednesday...........................................................................p. 101-102 Thursday...............................................................................p. 103-106 Friday....................................................................................p. 107-108 TAB 8 SPECIAL LECTURES TAB 9 USCAP HONORS TAB 10 ABSTRACT Proffered Papers Monday AM..........................................................................p. 109-114 Monday PM..........................................................................p. 135-140 Tuesday AM .........................................................................p. 163-169 Tuesday PM..........................................................................p. 190-194 Poster Sessions I Monday AM.....................................................................p. 115-135 II Monday PM ....................................................................p. 141-162 III Tuesday AM .................................................................. p.169 - 190 IV Tuesday PM...................................................................p. 195-215 V Wednesday AM .............................................................p. 215-235 VI Wednesday PM.............................................................p. 235-254 Abstract Review Board............................................................... p. 255 Abstract Disclosure Information.........................................p. 256-271 TAB 11 - INDEX Index ............................................................................................ p. 273 NEXTGENERATION LEARNING20162 NOTES NEXTGENERATION LEARNING 2016 3 ACCREDITATION STATEMENT The United States and Canadian Academy of Pathology USCAP is accredited by the Accreditation Council for Continuing Medical Education ACCME to provide continuing medical education for physicians. AMA CREDIT DESIGNATION STATEMENT The USCAP designates this live activity for a maximum of 55.5 AMA PRA Category 1 Credits. Physicians should only claim the credit commensurate with the extent of their participation in the activity. INTERNATIONAL PHYSICIANS The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits. HEALTH PROFESSIONALS Health Professional participants including residents and fellows-in-training may claim hours to receive a Certicate of Participation for an activity designated for AMA PRA Category 1 Credits. SELF-ASSESSMENT MODULE CREDITS The USCAP is approved by the American Board of Pathology to offer Self-Assessment Module SAM credits for the purpose of meeting the American Board of Pathology ABP requirements for Maintenance of Certication MOC. Registrants must take and pass the post-test in order to claim SAM credits. The number of SAM credits has increased again this year. There will be more than 302 SAMs credits offered during this years meeting. Since many of these offerings are presented in overlapping time slots an individual may earn a maximum of 50.25 SAMs credit hours during the Annual Meeting. SESSION TYPES FOR WHICH AMA PRA CATEGORY 1 CREDITS ARE OFFERED SCIENTIFIC ABSTRACT PRESENTATIONS 8.75 TOTAL CREDITS SPECIALTY CONFERENCES 2.0 CREDITS EACH KAUFMAN TIMELY TOPICS LECTURE 1.0 CREDIT MAUDE ABBOTT LECTURE 1.0 CREDIT LONG COURSE 6.0 CREDITS SHORT COURSES 3.0 CREDITS EACH MOLECULAR DIAGNOSTIC AND GENOMIC APPLICATIONS IN CANCER 7.25 CREDITS TUMOR IMMUNOLOGY IMPLICATIONS FOR TNM 3.0 CREDITS NEXT GENERATION SEQUENCING SPECIAL COURSE 3.75 CREDITS PRACTICE CHANGERS 0.25 CREDITS EACH INTERACTIVE MICROSCOPY 1.5 CREDITS EACH HOT TOPICS IN PATHOLOGY 1.0 CREDIT EACH CERTIFICATE OF CMESAM CREDIT OR PARTICIPATION JOINT ACCREDITATION STATEMENT The Association for Molecular Pathology Special Course Molecular Diagnostic and Genomic Applications in Cancer A Primer for the Pathologist has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education ACCME through the joint providership of the United States and Canadian Academy of Pathology and Association for Molecular Pathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians. The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education ACCME through the joint providership of the United States and Canadian Academy of Pathology and American Society for Clinical Pathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians. Practice Changers- Health Information Technology and Clinical Informatics Practice Changers- Workforce Issues in Pathology and Laboratory Medicine NEXTGENERATION LEARNING20164 DAY DATE START TIME END TIME SUNDAY MARCH 13 ...................................................1000 AM 1030 AM SUNDAY MARCH 13 .....................................................300 PM 330 PM MONDAY MARCH 14 .....................................................930 AM 1100 AM MONDAY MARCH 14 .....................................................300 PM 430 PM TUESDAY MARCH 15 .....................................................930 AM 1100 AM TUESDAY MARCH 15 .....................................................245 PM 400 PM WEDNESDAY MARCH 16 .....................................................930 AM 1100 AM WEDNESDAY MARCH 16 .....................................................230 PM 400 PM THURSDAY MARCH 17 .....................................................930 AM 1000 AM THURSDAY MARCH 17......................................................230 PM 300PM FRIDAY MARCH 18......................................................930 AM 1000 AM FRIDAY MARCH 18......................................................230 PM 300 PM Stop by CC 303 any time during the coffee breaks March 13-16 to get your headshot taken by our professional photographers. This service will be complimentary for members and only 50 for non-members. To schedule an appointment please contact Ethan Kaminsky at ethankamprod.com COFFEE BREAKS HEADSHOT LOUNGE 201 COMPANION SOCIETY MEETINGS EXCEPT HISTORY OF PATHOLOGY SOCIETY AND PALEOPATHOLOGY CLUB 3.0 CREDITS EACH 1.5 CREDITS EACH American Association of Neuropthologists American Association of Ocular Oncologists and Pathologists American Society for Clinical Pathology in collaboration with the APF American Society for Cytopathology American Society of Dermatopathology American Society for Investigative Pathology Arthur Purdy Stout Society of Surgical Pathologists Association for Molecular Pathology Association for Pathology Informatics Binford-Dammin Society of Infectious Disease Pathologists College of American Pathologists Endocrine Pathology Society Hans Popper Hepatopathology Society History of Pathology Society International Society of Bone Soft Tissue Pathology International Society of Breast Pathology International Society of Gynecological Pathologists International Society of Urological Pathology North American Society of Head Neck Pathology Paleopathology Club Papanicolaou Society of Cytopathology Pulmonary Pathology Society Renal Pathology Society Rodger C. Haggitt Gastrointestinal Pathology Society Society for Cardiovascular Pathology Society for Hematopathology Society for Ultrastructural Pathology JOINT ACCREDITATION STATEMENT CONTINUED The USCAP jointly provides the programs of the following Companion Societies whose activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education ACCME through the joint providership of the societies and the USCAP. The USCAP is accredited by the ACCME to provide continuing medical education for physicians. NEXTGENERATION LEARNING 2016 5 MEETING AT A GLANCE INFORMATION IN THIS SECTION WAS CURRENT AS OF MARCH 1. PLEASE CHECK THE LAST MINUTE UPDATES DOCUMENT DISTRIBUTED AT THE REGISTRATION DESK FOR ANY CHANGES IN PRESENTATION TIMES OR DATES. ADDITIONALLY YOU CAN GO ONLINE AT WWW.USCAP.ORG OR VIEW IN THE USCAP MOBILE APP USCAP365 AVAILABLE AT THE APP STORE AND GOOGLE PLAY. USCAP 2016 NEWS EMBARGO POLICY Unless otherwise noted all abstracts presented at the USCAP Annual Meeting are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The USCAP reserves the right to lift the embargo on specic abstracts that are selected for promotion prior to or during the USCAP Annual Meeting. USCAP 2016 DISCLAIMER STATEMENT The information presented at the USCAP news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of the USCAP. The USCAP makes no representation as to the truth or warranty accuracy or originality of the information presented. 2016 NEXTGENERATION LEARNING20166 MEETING AT A GLANCE SATURDAY MARCH 12 2016 900 AM - 500 PM SPECIAL COURSE Residents Workshop Genomic Medicine for Pathologists......................................... p. 81-82 .......................... CC 602-604 1200 AM - 500 PM SPECIAL COURSE Residents Workshop Leadership Collaboration and Change in Health Care ......... p. 83-84 .......................... CC 611-612 700 PM - 1000 PM COMPANION SOCIETY MEETINGS American Association of Neuropathologists ............................................................... p. 43 ............................... CC 608-609 Association for Pathology Informatics ......................................................................... p. 44 ............................... CC 613-614 Endocrine Pathology Society ........................................................................................ p. 45 ............................... CC 606-607 International Society of Urological Pathology............................................................. p. 48 ...................... CC Ballroom 6 B Papanicolaou Society of Cytopathology ...................................................................... p. 46 ............................... CC 602-604 Pulmonary Pathology Society....................................................................................... p. 47 ...................... CC Ballroom 6 A SUNDAY MARCH 13 2016 830 AM - 1200 PM COMPANION SOCIETY MEETINGS Arthur Purdy Stout Society of Surgical Pathologists .................................................. p. 49 ...................CC Ballroom 6 BC Binford-Dammin Society of Infectious Disease Pathologists ..................................... p. 50 ....................... CC Ballroom 6A College of American Pathologists................................................................................. p. 51 ............................... CC 602-604 Hans Popper Hepatopathology Society........................................................................ p. 52 .......................CC Ballroom 6 E Renal Pathology Society................................................................................................ p. 53................................ CC 606-607 Society for Cardiovascular Pathology .......................................................................... p. 54................................ CC 608-609 Society for Ultrastructural Pathology ........................................................................... p. 55....................................... CC 605 130 PM - 330 PM COMPANION SOCIETY MEETINGS Paleopathology Club .................................................................................................... p. 62................................ CC 602-604 130 PM - 500 PM COMPANION SOCIETY MEETINGS American Association of Ocular Oncologists and Pathologists................................. p. 56....................................... CC 605 American Society for Investigative Pathology............................................................. p. 58................................ CC 606-607 ASCP in collaboration with the APF.............................................................................. p. 57................................ CC 618-620 International Society of Bone and Soft Tissue Pathology........................................... p. 60................................ CC 608-609 International Society of Gynecological Pathologists................................................... p. 64........................CC Ballroom 6 E North American Society of Head and Neck Pathology ............................................... p. 61................................ CC 615-617 Rodger C. Haggitt Gastrointestinal Pathology Society ............................................... p. 59....................CC Ballroom 6 BC Society for Hematopathology ....................................................................................... p. 63....................... CC Ballroom 6 A 330 PM - 500 PM COMPANION SOCIETY MEETINGS History of Pathology Society......................................................................................... p. 65 ............................... CC 602-604 730 PM - 930 PM EVENING SPECIALTY CONFERENCES Evening Specialty Conference - Gynecologic Pathology............................................ p. 71 ...................... CC Ballroom 6 B Evening Specialty Conference - Housestaff ................................................................. p. 73 ............................... CC 613-614 Evening Specialty Conference - Ophthalmic Pathology ............................................ p. 73 ...................................... CC 605 Evening Specialty Conference - Pediatric Pathology .................................................. p. 72 ............................... CC 606-607 Evening Specialty Conference - Pulmonary Pathology............................................... p. 71 ...................... CC Ballroom 6 A Evening Specialty Conference - Renal Pathology........................................................ p. 72 ............................... CC 615-617 730 PM - 1030 PM COMPANION SOCIETY MEETINGS American Society for Cytopathology............................................................................ p. 67-68 ................. CC Ballroom 6 C American Society of Dermatopathology...................................................................... p. 69 ............................... CC 608-609 Association for Molecular Pathology............................................................................ p. 70 .......................CC Ballroom 6 E International Society of Breast Pathology.................................................................... p. 66 ................................CC Hall 4 E TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING 2016 7 MEETING AT A GLANCE MONDAY MARCH 14 2016 800 AM - 930 AM INTERACTIVE MICROSCOPY Interactive Microscopy Pathology of Common Interstitial Lung Diseases - The Essentials for Practicing Pathologists ................................................................... p. 91 ...................................... CC 305 Interactive Microscopy Unusual and Problem Cases in Head and Neck Cytopathology...................................................................................... p. 91 ...................................... CC 304 Interactive Microscopy Fatty Tumors of the Retroperitoneum.................................. p. 91 ...................................... CC 306 800 AM - 1200 PM PROFFERED PAPERS Proffered Papers Section A - Genitourinary Pathology............................................... p. 109 ..............................CC Hall 4 E Proffered Papers Section B - Breast Pathology............................................................ p. 109-110 ............. CC Ballroom 6 C 800 AM - 1200 PM PROFFERED PAPERS Proffered Papers Section C - Cytopathology................................................................ p. 110-111 ............. CC Ballroom 6 B Proffered Papers Section D - Gastrointestinal Pathology ........................................... p. 111-112 ............. CC Ballroom 6 A Proffered Papers Section E - Gynecologic Pathology ................................................. p. 112 ............................. CC 602-604 Proffered Papers Section F - Techniques...................................................................... p. 112-113 ...................... CC 606-607 Proffered Papers Section G - Pulmonary Pathology ................................................... p. 113-114 ...................... CC 608-609 Proffered Papers Section H - Potpourri ........................................................................ p. 114 ............................. CC 615-617 800 AM - 1200 PM SPECIAL COURSE Clinical Application of Next Generation Sequencing.................................................. p. 85 .......................CC Ballroom 6 E 930 AM - 1200 PM POSTER SESSIONS Poster Presentations - Monday AM .............................................................................. p. 115-117 ...CC Exhibit Hall 4 ABC 945 AM - 1005 AM PRACTICE CHANGERS Practice Changers-Adverse Event Disclosure and Management for Pathologists Where do We Stand Now............................................................................................. p. 97 ................... CC Sky Bridge 4 D Practice Changers-Pathologists in Gross Anatomy..................................................... p. 97 ................... CC Sky Bridge 4 D 1000 AM - 1130 AM INTERACTIVE MICROSCOPY Interactive Microscopy Diagnostic Challenges in Cutaneous Soft Tissue Tumors.. p. 91 ...................................... CC 304 Interactive Microscopy Tumor and Tumor-like Proliferations of the Spleen............ p. 91 ...................................... CC 305 Interactive Microscopy Surgical Pathology of Pancreatobiliary Tract ...................... p. 91 ......................................CC 306 1020 AM - 1040 AM PRACTICE CHANGERS Practice Changers-Prostate Biopsy Billing ................................................................... p. 97 ................... CC Sky Bridge 4 D Practice Changers-Replacing Karyotyping with SNPM............................................... p. 97 ................... CC Sky Bridge 4 D 1200 PM - 100 PM HOT TOPICS Hot Topics in Pathology 01-Hematopathology ............................................................ p. 95 ...................................... CC 605 100 PM - 300 PM PROFFERED PAPERS Proffered Papers Section A - Genitourinary Pathology............................................... p. 135-136 .......................CC Hall 4 E Proffered Papers Section B - Pulmonary Pathology.................................................... p. 136-137 ............. CC Ballroom 6 C Proffered Papers Section C - Hematopathology.......................................................... p. 137 .................... CC Ballroom 6 B Proffered Papers Section D - Breast Pathology ........................................................... p. 137-138 ............. CC Ballroom 6 A Proffered Papers Section E - KidneyRenal Pathology ................................................ p. 138 ............................. CC 602-604 Proffered Papers Section F - Head and Neck Pathology ............................................. p. 139 ............................. CC 606-607 Proffered Papers Section G - Quality Assurance ......................................................... p. 139-140 ...................... CC 608-609 Proffered Papers Section H - Endocrine Pathology..................................................... p. 140 ............................. CC 615-617 100 PM - 430 PM POSTER SESSIONS Poster Presentations - Monday PM............................................................................... p. 141-162 ...CC Exhibit Hall 4 ABC 100 PM - 500 PM SPECIAL COURSE Tumor Immunology Implications for TNM Staging and Therapeutics.................... p. 86-87 ..................CC Ballroom 6 E 130 PM - 300 PM INTERACTIVE MICROSCOPY Interactive Microscopy Interesting Lesions in Patients with Testicular Neoplasms .................................................................................................... p. 91 ...................................... CC 306 Interactive Microscopy Look at that Bug Interesting Infectious Disease Cases...... p. 91 ...................................... CC 305 Interactive Microscopy Uncommon Types of Invasive Mammary Carcinoma ........ p. 91 ...................................... CC 304 TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING20168 MEETING AT A GLANCE MONDAY MARCH 14 2016 ...CONTINUED 315 PM - 335 PM PRACTICE CHANGERS Practice Changers-Facebook Twitter How Pathologists can Change Their Practice with Social Media............................................................................................. p. 97 ................... CC Sky Bridge 4 D Practice Changers-Wikis A Gateway to Quick Pathology Information and Online Collaboration .................................................................................................... p. 97 ................... CC Sky Bridge 4 D 350 PM - 410 PM PRACTICE CHANGERS Practice Changers- Health Information Technology and Clinical Informatics........... p. 97 ................... CC Sky Bridge 4 D Practice Changers- Workforce Issues in Pathology and Laboratory Medicine.......... p. 97 ................... CC Sky Bridge 4 D 430 PM - 530 PM SPECIAL LECTURES Nathan Kaufman Timely Topics Lecture - Riffs on Future Path The Fall of Paper the Rise of Smarties and the Quest for Seles ............................ p. 98 ................................CC Hall 4 E 430 PM - 600 PM INTERACTIVE MICROSCOPY Interactive Microscopy Correlation of Tumorous and Non-Tumorous Conditions of Bones and Joints with Clinical Imaging How does the Pathology Create hte Imaging Features and What You Need to Know About Them ................. p. 92 ...................................... CC 305 Interactive Microscopy Mesenchymal Tumors of the Breast A Conceptual Framework for the Practicing Pathologist ............................................ p. 92 ...................................... CC 306 Interactive Microscopy When and How to Use Molecular Studies in the Diagnosis of Melanocytic Lesions................................................................................. p. 92 ...................................... CC 304 615 PM - 700 PM SPECIAL LECTURES Special Lecture - Hut Lung A Poignant Portrait ......................................................... p. 98 ................................CC Hall 4 E 730 PM - 930 PM EVENING SPECIALTY CONFERENCES Evening Specialty Conference - Cardiovascular Pathology........................................ p. 74 .......................CC Ballroom 6 E Evening Specialty Conference - Infectious Disease Pathology .................................. p. 75 ............................... CC 608-609 Evening Specialty Conference - Surgical Pathology ................................................... p. 74 ............... CC Ballroom 6 ABC TUESDAY MARCH 15 2016 800 AM - 930 AM INTERACTIVE MICROSCOPY Interactive Microscopy Diagnostic Pitfalls in Prostate Pathology............................ p. 92 ...................................... CC 306 Interactive Microscopy Glioma Diagnosis-2016 What Pathologists Need to Know.................. ............................................................................................... p. 92 ...................................... CC 304 Interactive Microscopy Sneaky Cancers and Their Mimics ....................................... p. 92 ...................................... CC 305 800 AM - 1200 PM PROFFERED PAPERS Proffered Papers Section A - Genitourinary Pathology............................................... p. 163 ..............................CC Hall 4 E Proffered Papers Section B - Breast Pathology............................................................ p. 164 .................... CC Ballroom 6 A Proffered Papers Section C - Hematopathology.......................................................... p. 164-165 ............. CC Ballroom 6 C Proffered Papers Section D - Gastrointestinal Pathology ........................................... p. 165-166 ...................... CC 602-604 Proffered Papers Section E - Gynecologic Pathology ................................................. p. 166-167 ...................... CC 606-607 Proffered Papers Section F - Cytopathology................................................................ p. 167-168 ...................... CC 608-609 Proffered Papers Section G - Bone and Soft Tissue Pathology.................................. p. 168 ............................. CC 611-612 Proffered Papers Section H - Liver Pathology.............................................................. p. 169 ............................. CC 615-617 800 AM - 515 PM SPECIAL COURSES Molecular Diagnostic and Genomic Applications in Cancer A Primer for the Pathologist.......................................................................................... p. 88-90 ................. CC Ballroom 6 B 930 AM - 1200 PM POSTER SESSIONS Poster Presentations - Tuesday AM .............................................................................. p. 169-190 ...CC Exhibit Hall 4 ABC 945 AM - 1005 AM PRACTICE CHANGERS Practice Changers - 3D Printed Microscopy and Alternatives to Glass Slide Pathology .................................................................................................... p. 98 ................... CC Sky Bridge 4 D Practice Changers - Novel Simple Method of Formalin Fixed Parafn Embedded Cell Block Preparation of Cytology Specimens ........................................ p. 98.................... CC Sky Bridge 4 D TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING 2016 9 MEETING AT A GLANCE TUESDAY MARCH 15 2016...CONTINUED 1000 AM - 1130 AM INTERACTIVE MICROSCOPY Interactive Microscopy An Approach to Problematic Vascular Tumors Benign Borderline Malignant and Pseudomalignant ................................................ p. 92....................................... CC 304 Interactive Microscopy Crazy Gynecologic Acronyms LMP SBT STIC TILT and STIL A Review of Challenging Uterine Adnexal Neoplasms .................... p. 92 ...................................... CC 306 Interactive Microscopy Practical Approach to Papillary Problems and Other Dilemmas in Breast Core Needle Biopsy Interpretation................................... p. 92 ...................................... CC 305 1020 AM - 1040 AM PRACTICE CHANGERS Practice Changers - Disclosing Harmful Pathology Errors to Colleagues ................. p. 98 ................... CC Sky Bridge 4 D Practice Changers - Impact of Genomics and Personalized Medicine....................... p. 98 ................... CC Sky Bridge 4 D 1200 PM - 100 PM HOT TOPICS Hot Topics in Pathology 02-Molecular Pathology........................................................ p. 95 ...................................... CC 605 100 PM - 245 PM PROFFERED PAPERS Proffered Papers Section A - Informatics ..................................................................... p. 190 .................... CC Ballroom 6 A Proffered Papers Section B - Autopsy .......................................................................... p. 190-191 ............. CC Ballroom 6 C Proffered Papers Section C - Neuropathology............................................................. p. 191 ............................. CC 602-604 Proffered Papers Section D - Gastrointestinal Pathology ........................................... p. 191-192 ...................... CC 606-607 Proffered Papers Section E - Dermatopathology......................................................... p. 192 ............................. CC 608-609 Proffered Papers Section F - Pancreas and Biliary Tree Pathology............................ p. 192-193 ...................... CC 611-612 Proffered Papers Section G - Hematopathology.......................................................... p. 193-194 ...................... CC 615-617 Proffered Papers Section H - Pathobiology.................................................................. p. 194 ............................. CC 618-620 100 PM - 430 PM POSTER SESSIONS Poster Presentations - Tuesday PM............................................................................... p. 93 ............CC Exhibit Hall 4 ABC 130 PM - 300 PM INTERACTIVE MICROSCOPY Interactive Microscopy Endometrial Pathology - Selected Challenging and Informative Cases .................................................................................................... p. 93 ...................................... CC 305 Interactive Microscopy Sneaky GI Biopsies with Hidden Diagnoses Lessons in Applying a Systematic Approach............................................................... p. 93 ...................................... CC 306 Interactive Microscopy The Well Differentiated Squamous Cell Carcinoma of Head and Neck A Practical Approach to Biopsy Interpretation............................ p. 93 ...................................... CC 304 430 PM - 600 PM INTERACTIVE MICROSCOPY Interactive Microscopy GIDeadliestCatch Practical Approaches to Trending Topics in GI Pathology ................................................................................... p. 93 ...................................... CC 304 Interactive Microscopy Frozen Section in Ovarian and Peritoneal Lesions Challenges and Controversies....................................................................................... p. 93 ...................................... CC 305 Interactive Microscopy High Risk Non-Melanoma Skin Cancers Lessons from UV-Drenched New Zealand ........................................................................................... p. 93 ...................................... CC 306 500 PM - 550 PM SPECIAL LECTURES Maude Abbott Lecture ................................................................................................... p. 95.................................CC Hall 4 E 730 PM - 930 PM EVENING SPECIALTY CONFERENCES Evening Specialty Conference - Bone and Soft Tissue Pathology ............................. p. 76 ...................... CC Ballroom 6 A Evening Specialty Conference - Genitourinary Pathology.......................................... p. 75 .......................CC Ballroom 6 E Evening Specialty Conference - Head and NeckEndocrine Pathology ..................... p. 77 ...................... CC Ballroom 6 B Evening Specialty Conference - Liver Pathology......................................................... p. 76 ...................... CC Ballroom 6 C TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING201610 MEETING AT A GLANCE WEDNESDAY MARCH 16 2016 800 AM - 1200 PM SHORT COURES SC05-The Nerve Of Some Nerve Sheath Tumors A Practical Approach To Common Problems In Surgical Pathology ......................... p. 101 ............................. CC 615-616 SC11-Contemporary Cardiovascular Pathology from Bench to Bedside How Emerging Ancillary Tools are Transforming the Field ........................................ p. 101..................................... CC 608 SC22 Practical Guide to Error Reduction Effective Communication and Damage Control in Surgical Pathology ........................................................................ p. 101..................................... CC 604 SC25-Colorectal Dysplasia in IBD Diagnosis Implications and Pitfalls .................... p. 101 .............................. CC 602-603 SC30-Diagnosis of Renal Neoplasms Using Integrated Histologic Cytologic and Molecular Approaches in the Era of Precision Medicine .................... p. 101 ..................................... CC609 SC31-Doing More with Less A Cytology-Histology Correlation of Pulmonary Masses .................................................................................................... p. 101.............................. CC 613-614 SC36-Inherited Gynecologic Cancer Syndromes - Pathologically and Clinically Based Risk Assessment and Genetic Counseling What every practicing pathologist should know ............................................................................................... p. 101..................................... CC 606 SC45-Problematic Ductal Proliferations of the Breast ................................................. p. 101 ............................. CC 611-612 SC55-A Practical Approach to Infectious Disease Pathology ..................................... p. 101..................................... CC 607 800 AM - 515 PM LONG COURSE Long Course Diagnosing Distinctive Lesions of the Head and Neck ........................ p. 99-100 ........ CC Ballroom 6 ABC 930 AM - 1200 PM POSTER SESSIONS Poster Presentations - Wednesday AM ........................................................................ p. 215-235 ...CC Exhibit Hall 4 ABC 1200 PM - 100 PM HOT TOPICS Hot Topics in Pathology 03-Genitourinary ................................................................... p. 95 ...................................... CC 605 100 PM - 400 PM POSTER SESSIONS Poster Presentations - Wednesday PM......................................................................... p. 235-254 ...CC Exhibit Hall 4 ABC 130 PM - 530 PM SHORT COURSES SC04-Autopsy in the 21st Century An Update for Pathologists Performing Hospital Autopsies Today .............................................................................................. p. 102 .................................... CC 607 SC18-Diagnostic Criteria of The Paris System for Reporting Urinary Cytology ....... p. 102 ............................. CC 613-614 SC33-Ovarian Carcinoma An Update On Histotype Diagnosis Primary Site Assignment And Staging .............................................................................................. p. 102 .............................CC 611-612 SC39-Bone Marrow Manifestations of Systemic Disease........................................... p. 102 .................................... CC 608 SC43-Medical Liver Biopsies Translating Morphologic Patterns Into Meaningful Pathology Reports ...................................................................................... p. 102 ............................. CC 602-603 SC59-Occupationally Related Pleural and Pulmonary Disorders in the 21st Century Challenges Pitfalls and No-Nos ............................................................ p. 102 ..................................... CC 609 SC62-Algorithmic Approach to Diagnosis of Inammatory Disorders of the GI Tract .................................................................................................... p. 102..................................... CC 606 730 PM - 930 PM EVENING SPECIALTY CONFERENCES Evening Specialty Conference - Cytopathology .......................................................... p. 78 ...................... CC Ballroom 6 B Evening Specialty Conference - Hematopathology..................................................... p. 77 ...................... CC Ballroom 6 A Evening Specialty Conference - Neuropathology........................................................ p. 78 ...................... CC Ballroom 6 C TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING 2016 11 MEETING AT A GLANCE THURSDAY MARCH 17 2016 800 AM - 930 AM INTERACTIVE MICROSCOPY Interactive Microscopy An Approach to Intraoperative Consultation in Neuropathology................................................................................... p. 93....................................... CC 304 Interactive Microscopy Diagnostic Issues in DLBCL A 2016 Perspective .............. p. 93....................................... CC 306 Interactive Microscopy Medical Liver Biopsies - How to Stay Out of Trouble ........ p. 93....................................... CC 305 800 AM - 1130 AM SHORT COURSES SC06-Diagnostic Dilemma in Neoplastic and Non-Neoplastic Bone Pathology....... p. 103.............................. CC 615-616 SC08-The Pathologists Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy .................................................................................................... p. 103.............................. CC 619-620 SC10-Diagnostic Challenges in Prostate Pathology .................................................... p. 103 .............................. CC 611-612 SC16-Pathology of the Previable Fetus and Stillborn Infant for the General Pathologist .................................................................................................... p. 103..................................... CC 604 SC20-Challenging Cases in Thyroid Cytopathology How Can Ultrasound Findings and Molecular Tests Help .................................................................................. CC 602-603 SC21-Important Aspects of Skin Adnexal Tumor Pathology ...................................... p. 103..................................... CC 606 SC28-Pulmonary Infections Morphologic And Molecular Tips For The Surgical Pathologist................................................................................................................................................ CC 617 SC32-Predictive Biomarkers Lessons from Clinical Trials......................................... p. 103..................................... CC 607 SC37-Head and Neck Pathology in the Human Papillomavirus Era A Crash Course .................................................................................................... p. 103..................................... CC 608 SC40-Hematolymphoid Lesions at the Borderline Between Benign and Malignant - Finding Your Way Out of Uncertainty....................................................... p. 104..................... CC Ballroom 6 C SC46-Open Confession is Good for the Soul Memorable Mistakes and What Weve Learned .................................................................................................... p. 104..................................... CC 609 SC50-Clinical Realities of Next-Generation Sequencing ...................................................................................... CC 613-614 SC56-Nerve and Muscle Biopsies A Patient-Centered Approach for the General Pathologist .................................................................................................... p. 104 .................................... CC 618 1000 AM - 1130 AM INTERACTIVE MICROSCOPY Interactive Microscopy Diagnostic Dilemmas in Skin Adnexal Tumour Pathology .................................................................................................... p. 94....................................... CC 306 Interactive Microscopy Mesenchymal Tumors of the Uterus An Update in Classication Immunostains and Differential Diagnosis .......................................... p. 94....................................... CC 305 Interactive Microscopy Twists in Liver Pathology Unsuspected Findings that Changed Everything ............................................................................................ p. 94....................................... CC 304 1200 PM - 100 PM HOT TOPICS Hot Topics in Pathology 04-Gastrointestinal................................................................ p. 96 ...................................... CC 605 100 PM - 230 PM INTERACTIVE MICROSCOPY Interactive Microscopy Dont Be Duped Look-alikes in Genitourinary Pathology ... p. 94....................................... CC 306 Interactive Microscopy GI Biopsy Interpretation in Modern Medicine Drugs Dysplasia and Other Dilemmas......................................................................... p. 94....................................... CC 305 Interactive Microscopy Pitfalls in Effusion Cytology The Usual the Unusual and the Mimickers .................................................................................................... p. 94....................................... CC 304 100 PM - 430 PM SHORT COURSES SC03-Uses and Limitations of Immunohistochemistry and other Adjunctive Studies in Breast Pathology .......................................................................................... p. 105 ............................. CC 602-603 SC07-Its not as Bad as it Looks Look-Alike Lesions in Surgical Neuropathology... p. 105..................................... CC 618 SC12-Medical Renal Pathology for the General Surgical Pathologist ....................... p. 105..................................... CC 617 SC14-Biopsies of Mediastinal Lesions Challenges Pitfalls and Practical Tips......... p. 105..................................... CC 607 SC17-Trapdoors in Testicular Pathology ...................................................................... p. 105..................................... CC 604 SC19-Melanocytic Lesions A Practical Approach to Diagnosis Adjunctive Molecular Studies and Appropriate TherapyManagement ...................................... p. 105..................... CC Ballroom 6 C SC23-Surgical and Molecular Pathology of Thyroid Neoplasia ................................. p. 105 .............................. CC 619-620 SC26-Colonic Polyps - Daily Problems Only Pathologists Understand ..................... p. 105 .............................. CC 611-612 SC35-Going with the Flow of Bile An Update on Tumors of the Liver Bile Ducts and Gallbladder ............................................................................................ p.105...................................... CC 609 SC41-Expanding the Differential Diagnosis in Urologic Pathology Controversies and New Entities .................................................................................................... p. 106..................................... CC 608 SC42-Difcult Diagnoses in Pediatric Hematopathology............................................ p. 106.............................. CC 615-616 SC47-Late Intrauterine Demise Placental and Fetal Postmortem Pathology .......... p. 106.............................. CC 613-614 SC54-Practical Informatics Solutions for Anatomic Pathology Quality Management .................................................................................................... p. 106 .................................... CC 606 TIME SESSION PAGE LOCATION NEXTGENERATION LEARNING201612 MEETING AT A GLANCE THURSDAY MARCH 17 2016...CONTINUED 300 PM - 430 PM INTERACTIVE MICROSCOPY Interactive Microscopy Application of The Paris System for Reporting Urinary Cytopathology on Liquid-Based Preparations............................................... p. 94........................................ CC 304 Interactive Microscopy Common Diagnostic Dilemmas in Urinary Bladder Pathology ..................................................................................................... p. 94........................................ CC 305 Interactive Microscopy Neoplastic Lung Disease........................................................ p. 94 ....................................... CC 306 730 PM - 930 PM EVENING SPECIALTY CONFERENCES Evening Specialty Conference - Breast Pathology....................................................... p. 80 ....................... CC Ballroom 6 C Evening Specialty Conference - Dermatopathology.................................................... p. 79 ................................ CC 611-612 Evening Specialty Conference - Gastrointestinal Pathology....................................... p. 79 ...........................CC Ballroom E FRIDAY MARCH 18 2016 800 AM - 1130 AM SHORT COURSES SC02-Striving for Excellence Leveraging CLIA Accreditation ISO 15189 and Lean for Anatomic and Molecular Pathology Laboratories.................................. p. 107............................... CC 619-620 SC09-Recent Developments in Heart and Lung Transplant Pathology Navigating the Shifting Sands....................................................................................... p. 107 ..................................... CC 604 SC15-Practical Ocular Pathology for Pathologists........................................................ p. 107 ..................................... CC 607 SC24 -Bacterial Infection and the Kidney Diagnostic Difficulties in Kidney Biopsies........................................................................................ p. 107 .............................. CC 613-614 SC27-A Pattern-Based Approach to the Diagnosis of Soft Tissue Tumors................. p. 107 .............................. CC 602-603 SC29-Pathology in the Era of Genomic Medicine New Frontiers and New Challenges ..................................................................................................... p. 107 ..................................... CC 606 SC34-Non-Invasive Nightmares in Breast Pathology................................................... p. 107...................................... CC 609 SC44-Endocrine Tumor Board Clinicopathological Correlations in Endocrine Pathology ..................................................................................................... p. 107...................................... CC 608 SC52-Difficult Endometrial Biopsies Malignancy Mimics Molecular and Mishaps................................................................................................... p. 107............................... CC 611-612 SC53- Problems Pitfalls and an Integrated Approach to Lymphoproliferative Disorders in the Skin ..................................................................................................... p. 107............................... CC 615-616 100 PM - 430 PM SHORT COURSES SC38-Common Diagnostic Dilemmas in Head and Neck Pathology Pitfalls Pearls and Clinical Insights............................................................................................. p. 108............................... CC 611-612 SC48-Problematic Areas in the Pathology of the Uterine Cervix................................ p. 108...................................... CC 608 SC49-Interstitial Lung Disease What Your Clinician Wants to Know........................ p. 108............................... CC 602-603 SC51-High Yield Urological Pathology Common and Important Diagnoses Not To Be Missed in Daily Practice................................................................................ p. 108...................................... CC 606 SC57-Diagnosis of Challenging Plasma Cell Neoplasms............................................. p. 108...................................... CC 607 SC58-Second Opinions and Discrepancies in Fine Needle Aspiration FNA Cytology An Interactive Approach to Diagnostic Work-up.............................. p. 108...................................... CC 604 SC60-Practical Statistics for Pathologists Case-based Instruction with Methods.... p. 108...................................... CC 609 13NEXTGENERATION LEARNING 2016 NEXTGENERATION LEARNING 20 CONVENTION HALL 13 10 12 11 14 EUNEVAht7 PIKE STREET EUNEVAht8 PIKE STREET CONVENTIONPLACE GroundTransportationandShuttle UNION STREET Entrance Entrance Entrance Entrance ecnartnE Entrance The Conference Center Wild Rye Caf Bakery Office Tower Retail Business Center Retail Retail Public Restroom Pike Street Lobby ACT Theatre Levels 1-4 and to Atrium Lobby Levels 1-4 and to Skybridge Lobby To Convention Center Parking Garage Entrance FE FE N Washington State Convention Center Level One Entrances Shops and Services NEXTGENERATION LEARNING201614 To Two Union Square WSCC Admin. Office Intl. Meeting Place Ramp Ramp Open Ramp Open 210 211 212 213 214 201 203 202 204 205 2B 2A 2AB Lobby 209 208 ToFrom Level 1 ToFrom Level 3 W M W M FE FE FE FE FE FE FE 67 12 11 10 Washington State Convention Center Level Two Meeting Rooms N 307 308 309 310 306 305 304 303 302 301 Open Open 3B 3A 3AB Lobby To Garages and Freeway Park Garage Open Main Entrance to Parking Garage ToFrom Level 2 ToFrom Level 4 To301-310 To Skybridge Lobby 8thAVENUE 10 7 11 12 6FE FE FE FE FE FE W M Meeting Rooms Level Three CONVENTION HALL NEXTGENERATION LEARNING 2016 15 Washington State Convention Center Level Four Exhibition Halls N UPUPUP DOWNDOWNDOWN DOWN UPUP WSCC Use llirG North Loading Dock Ellis Plaza Atrium Lobby South Service Corridor Skybridge Lobby Skybridge Lobby Skybridge Solera Deli Open egdirBkcurT Skybridge Waterfall Suite UP DOWNDOWN Open Grand Staircase South Loading Dock TruckRam ptoHubbellPlace 4C-4 4C-3 4C-2 4C-1 4D 400 4C 4E 4F 4B 4A 401 439 438 454 416 Levels1to4 ToFrom The Conference Center To Skybridge Lobby Skybridge Lobby Skybridge ToFrom Levels 56 ToFrom 6 ToAtriumLobby ToFrom Level 6 ToFrom Level 3 444 10 12 7 6 11 21 N-2 N-1 5 3 PIKE STREET Below FE FE FEFE FE FE FE FE FE FE FE FE FEFE FE FE WM M W FE M W MMWWWW W M FE FE FEFE FEFEFE FE FE FE FFE CONVENTION HALL NEXTGENERATION LEARNING201616 W FE FE FE FE FEEFEF M FE FE FE FE FEEFEF FE M W MW 602 610 609 608 607 606 605 603 604 6016ABC Lobby 614 612 611 615 Atrium Lobby Below 6E Lobby 620 619 618 617 6E 6C 6B 6A 613 616 657657657 Suite C SuiteA Terrace Service Service Service Service Kitchen Fireplace Fireplace Fireplace Escalators ToFrom Level 4 ToFrom Level4 ToFrom Levels 4 5 Stairs 10 67 4 5 3 1 2 Washington State Convention Center Level Six Ballrooms Meeting Rooms N CONVENTION HALL NEXTGENERATION LEARNING 2016 17 SHERATON CONVENTION HALL NEXTGENERATION LEARNING201618 EXHIBIT HALL Now that you are chock-full of new knowledge heres a great opportunity to apply it to current technology. Weve assembled over 140 vendors in our Exhibition Hall this year. From software to services to equipment you have a one-stop shop of experts awaiting the opportunity to explain how their company can support your professional development. Stop by and please remember to thank our exhibitors their support is an integral component to our annual meeting. Exhibition Hall Schedule same hours as the posters sessions MONDAY MARCH 14 930 AM 500 PM TUESDAY MARCH 15 930 AM 500 PM WEDNESDAY MARCH 16 900 AM 400 PM Exhibit Hall Location Washington State Convention Center Exhibit Halls 4A-4C Schedule a Meeting with a Vendor Thanks to our mobile app you can now nd all vendors and their locations within the Exhibition Hall. If youre pressed for time or want to be assured of quality time with one of our vendors utilize the app to schedule a time to speak with the vendor. Go to www.tripbuilder.comuscap365 to download the app today. NEXTGENERATION LEARNING 2016 19 POSTER PICKUP POSTER VIEWING STATION SECRETARIAT INFORMATION USCAP East 404 Town Park Blvd. Suite 201 Evans GA 30809 p. 706 7337550 f. 706 733-8033 USCAP West 500 South Palm Canyon Drive Suite 321 Palm Springs CA 92264 p. 760 327-6777 f. 760 327-6477 Poster Pick-up Location Call4Posters and iPosters on Level 4 4C in the Washington State Convention Center. The hours are Monday and Tuesday 700 AM 500 PM and Wednesday 700 AM 300 PM. Posters that were created or submitted for printing and shipping using Learners Digest International Call4Posters may be picked up at their section. All poster presenters have the option of submitting their posters electronically free of charge and having them posted on the USCAP website in the iPosters where they will be available for viewing after the meeting. Please visit the iPosters booth for details. David B. Kaminsky MD FIAC Executive Vice President executivevpuscap.org Darlynne L. Baki Director of Operation USCAP West darlynneuscap.org Tina Bowie Membership Services Assistant tinauscap.org Krista M. Cairns Educational Program Coordinator Annual Meeting kristauscap.org Denice Chinn Educational Program Coordinator deniceuscap.org LaToya Collier Educational Program Assistant latoyauscap.org John C. Garrard Director of Innovative Communications and Product Design john2uscap.org Carolyn Lane Director of Membership Services carolynuscap.org Paul Lewin Director of International Development pauluscap.org Travis Newman Managing Director travisuscap.org Teresa Powers Membership Services Coordinator teresauscap.org Cindy Pugh Director of Information Technology Education Digital Coordinator cindyuscap.org Deborah Waterhouse Interactive Coordinator deborahuscap.org Nancy West Director of Meeting Services nancyuscap.org The United States and Canadian Academy of Pathology NEXTGENERATION LEARNING201620 PAST PRESIDENTS 1907-08 James Carroll 1908-10 W. G. MacCallum 1910-13 A. S. Warthin 1913-15 R. M. Pearce 1915-16 A. S. Warthin 1916-20 O. Klotz 1920-21 W. M. L. Coplin 1921-22 James Ewing 1922-24 F. B. Mallory 1924-29 James F. Coupal 1929-32 H. E. Robertson 1932-33 George R. Callender 1933-34 Victor Jacobsen 1934-36 William Boyd 1936-38 V. H. Cornell 1938-39 Carl V. Weller 1939-40 James E. Ash 1940-41 Tracy B. Mallory 1941-42 William H. Feldman 1942-47 Samuel R. Haythom 1947-48 Ralph D. Lillie 1948-49 Everett L. Bishop 1949-50 James E. Ash 1950-51 G. Lyman Duff 1951-52 Granville A. Bennett 1952-53 James B. McNaught 1953-54 Averill A. Liebow 1954-55 Harold L. Stewart 1955-56 Jesse E. Edwards 1956-57 Edward B. Smith 1957-58 William O. Russell 1958-59 Chapman H. Binford 1959-60 Robert E. Stowell 1960-61 F. W. Wiglesworth 1961-62 Benjamin Castleman 1962-63 John B. Hazard 1963-64 J. Lowell Orbison 1964-65 David E. Smith 1965-66 Henry D. Moon 1966-67 A. James French 1967-68 Robert H. More 1968-69 Joshua L. Edwards 1969-70 Edward A. Gall 1970-71 T. C. Jones 1971-72 William Christopherson 1972-73 F. K. Mosto 1973-74 Nathan Kaufman 1974-75 Richard E. Palmer 1975-76 Murray R. Abell 1976-77 Jack M. Layton 1977-78 Benjamin F. Trump 1978-79 Jack P. Strong 1979-80 William Hartmann 1980-81 Kenneth M. Earle 1981-82 Leland D. Stoddard 1982-83 Bernard M. Wagner 1983-84 F. Stephen Vogel 1984-85 David M. Robertson 1985-86 Robert McCluskey 1986-87 John Yardley 1987-88 Robert Leader 1988-89 Ronald S. Weinstein 1989-90 Cecilia Fenoglio-Preiser 1990-91 David F. Hardwick 1991-92 Costan W. Berard 1992-93 Peter A. Ward 1993-94 Ramzi S. Cotran 1994-95 Hector Battifora 1995-96 William Gardner 1996-97 Richard L. Kempson 1997-98 Sharon W. Weiss 1998-99 Elaine S. Jaffe 1999-00 Harvey Goldman 2000-01 Deborah Powell 2001-02 Ronald DeLellis 2002-03 Louis P. Dehner 2003-04 Virginia A. LiVolsi 2004-05 Ricardo V. Lloyd 2005-06 Sylvia L. Asa 2006-07 Henry D. Appelman 2007-08 Christopher P. Crum 2008-09 Victor R. Reuter 2009-10 Richard J. Zarbo 2010-11 Stuart J. Schnitt 2011-12 Gregory N. Fuller 2012-13 Linda D. Ferrell 2013-14 Jeffrey L. Myers 2014-15 Celeste N. Powers Past Secretary-Treasurers 1907-40 Maude Abbott 1940-49 James E. Ash 1949-51 Ruell Sloan 1951-52 Harold Stewart 1952-70 F. K. Mosto 1970-79 Leland D. Stoddard 1979-91 Nathan Kaufman 1991-99 F. Stephen Vogel 1999-2011 Fred G. Silva 2011-2014 Bruce R. Smoller NEXTGENERATION LEARNING 2016 21 Carrie Besanceney MD Charles H. Bridges DVM William Henry Chase MD Robert D. Collins MD Robert Coon MD Salomon Grinspan MD Carlos Jaramillo MD John Stephen Jobe MD George F. Kipkie MD Risa B. Mann MD Florabel G. Mullick MD Richard Otis MD Samuel H. Paplanus MD Livia Ross MD George E. Yee MD Wei Zhao MD PhD IN MEMORIAM THESE MEMBERS OF THE USCAP FAMILY HAVE A LEFT AN INDELIBLE IMPRINT IN OUR MEMORIES ALMOST EVERYONE IS OBSESSED WITH LEAVING A MARK UPON THE WORLD. BEQUEATHING A LEGACY. OUTLASTING DEATH. WE ALL WANT TO BE REMEMBERED. JOHN GREEN The Fault in Our Stars F. Stephen Vogel MD Past-President Bernard M. Wagner MD Past-President NEXTGENERATION LEARNING201622 EXECUTIVE COMMITTEE TERM ENDING John R. Goldblum M.D. President 2016 N. Volkan Adsay M.D. President-Elect 2016 Christopher Fletcher M.D. FRCPath Vice-President 2016 Celeste N. Powers M.D. Ph.D. Past-President 2016 John Sinard M.D. Ph.D. Secretary 2017 Wendy L. Frankel M.D. Treasurer 2016 David B. Kaminsky M.D. FIAC Executive Vice-President BOARD OF DIRECTORS Marie Christine Aubry M.D. 2016 Marc Ladanyi M.D. 2016 David John Grignon M.D. 2017 Julia C. Iezzoni M.D. 2017 Audrey J. Lazenby M.D. 2017 Suzanne Z. Powell M.D. 2018 Sanja Dacic M.D. Ph.D. 2018 Daniel A. Arber M.D. 2018 JOURNAL EDITORS LABORATORY INVESTIGATION TERM ENDING Gene P. Siegal M.D. Ph.D. 123118 Robert W. Hardy M.D. Ph.D. 123118 Alexander Lazar M.D. Ph.D. 123118 Catherine Ketcham Ph.D. Managing Editor JOURNAL EDITORS MODERN PATHOLOGY TERM ENDING John N. Eble M.D. 63020 Harvey M. Cramer M.D. 63020 Catherine Ketcham M.D. Ph.D. Managing Editor BOARD COMMITTEE MEMBERS NEXTGENERATION LEARNING 2016 23 BOARD COMMITTEE MEMBERS EDUCATION COMMITTEE MEMBERS TERM ENDING Laura W. Lamps M.D. Chair 2017 Edi Brogi M.D. Ph.D. 2016 Laura C. Collins MBBS 2016 John A. Hart M.D. 2016 Megan S. Lim M.D. Ph.D. 2016 Adeboye O. Osunkoya M.D. 2016 Robert A. Soslow M.D. 2016 Kiril Trpkov M.D. 2016 Alyssa M. Krasinskas M.D. 2017 Melinda E. Sanders M.D. 2017 Paul E. Wakely Jr. M.D. 2017 Anthony Tony Yachnis M.D. 2017 Rhonda K. Yantiss M.D. 2017 Amy Chadburn M.D. 2018 Dan A. Milner Jr. M.D. 2018 John D. Reith M.D. 2018 Raja R. Seethala M.D. 2018 Aleodor Doru Andea M.D. MBA 2019 Michelle S. Hirsch M.D. Ph.D. 2019 Carol F. Farver M.D. 2019 Meera R. Hameed M.D. 2019 SUBCOMMITTEE CHAIRS HOUSE STAFF Jeffrey Prichard D.O. Chair Education Informatics Subcommittee 2016 Jason L. Hornick M.D. Ph.D. Abstract Assignment Committee 2017 Marisa R. Nucci M.D. Subcommittee for Unique Live Course Offerings 2017 Eva Vertes George M.D. House Staff 2017 Michael Gerald Drage M.D. House Staff 2017 Bradley Brad J. Quade M.D. Ph.D. 2017 Steven D. Billings M.D. Short Course Coordinator 2019 David B. Kaminsky M.D. FIAC Ex-Ofcio NEXTGENERATION LEARNING201624 BOARD COMMITTEE MEMBERS ABSTRACT ASSIGNMENT COMMITTEE TERM ENDING Jason L. Hornick M.D. Ph.D. Chair 2017 Jonathan L. Hecht M.D. Ph.D. 2016 Xiaohua Qian M.D. Ph.D. 2016 Justine Barletta M.D. 2016 Sarah M. Dry M.D. 2016 Simion I. Chiosea M.D. 2016 Daniel J. Brat M.D. Ph.D. 2016 Paul VanderLaan M.D. Ph.D. 2016 Keith K. Lai M.D. 2016 Leona Doyle M.D. 2018 Kristin Jensen M.D. 2018 Dylan V. Miller M.D. 2018 Rajiv Patel M.D. 2018 Raga Ramachandran M.D. Ph.D. 2018 Sean R. Williamson M.D. 2018 Charles M. Quick M.D. 2018 Elizabeth Morgan M.D. 2018 Bobbi S. Pritt M.D. 2018 Shree Sharma M.D. 2018 Alton B. Brad Farris III M.D. 2018 Maria Westerhoff M.D. 2018 EDUCATION INFORMATICS SUBCOMMITTEE TERM ENDING Jeffrey Prichard D.O. Chair 2017 Shree G. Sharma M.D. 2016 Chiraag Patel M.D. 2016 Rish K. Pai M.D. Ph.D. 2017 Darren T. Wheeler M.D. 2017 Liron Pantanowitz M.D. 2017 Laura Lamps M.D. Ex-Ofcio 2019 David B. Kaminsky M.D. FIAC Ex-Ofcio John Garrard Director of CommunicationsInnovative Products NEXTGENERATION LEARNING 2016 25 BOARD COMMITTEE MEMBERS CME SUBCOMMITTEE MEMBERS TERM ENDING Bradley J. Quade M.D. Ph.D. Chair 2017 Sara C. Shalin M.D. Ph.D. 2017 Amy Chadburn M.D. 2018 John D. Reith M.D. 2018 Melinda E. Sanders M.D. 2018 Yaolin Zhou M.D. Resident 2017 SUBCOMMITTEE FOR UNIQUE LIVE COURSE OFFERINGS TERM ENDING Marisa Nucci M.D. Chair 2016 John A. Hart M.D. 2016 Megan S. Lim M.D. Ph.D. 2016 Alyssa M. Krasinskas M.D. 2017 Raja Seethala M.D. 2019 Dan A. Milner Jr. M.D. 2019 Rhonda K. Yantiss M.D. 2019 SUBCOMMITTEE FOR INTERACTIVE MICROSCOPY TERM ENDING Steven D. Billings M.D. Chair 2018 Laura W. Lamps M.D. 2018 Laura C. Collins M.D. 2018 Paul E. Wakely Jr. M.D. 2018 FINANCE COMMITTEE MEMBERS TERM ENDING David J. Grignon M.D. Chair 2016 Wendy L. Frankel M.D. Treasurer 2016 Mahul B. Amin M.D. 2016 Henry Tazelaar M.D. 2018 Robert P. Hasserjian M.D. 2018 Mary S. Richardson M.D. 2018 Allen Gown M.D. 2018 John R. Goldblum M.D. Ex-Ofcio David B. Kaminsky M.D. FIAC Ex-Ofcio Travis Newman Managing Director Accountant NEXTGENERATION LEARNING201626 MEMBERSHIP COMMITTEE MEMBERS TERM ENDING Tarik Tihan M.D. Ph.D. Chair 2017 Suntrea TG Hammer M.D. 2016 Josette Ragheb M.D. Ph.D. 2016 Esmeralda C. Marginean M.D. 2017 Robert M. Najarian M.D. 2017 Laura C. Collins MBBS Representative for Resident Advisory Committee 2017 Kristie White M.D. 2018 Patricia E. Goldhoff M.D. MA Resident 2018 Christina Magi-Galluzzi M.D. Ph.D. 2018 Lydia P. Howell M.D. 2018 David B. Kaminsky M.D. FIAC Ex-Ofcio Carolyn Lane Director of Membership NOMINATING COMMITTEE MEMBERS TERM ENDING Celeste N. Powers M.D. Ph.D. Chair 2016 Gregory N. Fuller M.D. Ph.D. 2016 Linda D. Ferrell M.D. 2017 Christina Isacson M.D. Member at Large 2016 Esther Oliva M.D. Member at Large 2017 David B. Kaminsky M.D. FIAC Ex-Ofcio PUBLICATIONS COMMITTEE MEMBERS TERM ENDING Murray B. Resnick M.D. Ph.D. Chair 2019 Arie Perry M.D. 2016 Elaine Jaffe M.D. 2018 Rajiv M. Patel M.D. 2019 Brian Rubin M.D. Ph.D. 2019 Romil Saxena MBBS FRCPath 2019 John R. Goldblum M.D. Ex-Ofcio David B. Kaminsky M.D. FIAC Ex-Ofcio John Garrard Director of Innovative Comm. Product Design BOARD COMMITTEE MEMBERS NEXTGENERATION LEARNING 2016 27 CASTLEMAN AWARDS COMMITTEE TERM ENDING William C. Faquin M.D. Ph.D. Chair 2018 Michael Mike Bayerl M.D. 2016 Rana S. Hoda M.D. 2016 Mary S. Richardson M.D. 2017 Victor E. Reuter M.D. 2017 Gregory N. Fuller M.D. Ph.D. 2017 David N. Louis M.D. Ex-Ofcio John R. Goldblum M.D. Ex-Ofcio David B. Kaminsky M.D. FIAC Ex-Ofcio GOLDMAN AWARDS COMMITTEE TERM ENDING Stuart Schnitt M.D. Chair NA Jeffrey E. Saftz M.D. Ph.D. NA Laura W. Lamps M.D. NA John R. Goldblum M.D. NA Steven D. Billings M.D. NA David B. Kaminsky M.D. FIAC Ex-Ofcio STOWELL-ORBISON AWARDS COMMITTEE TERM ENDING Omar Hameed MBChB Chair 2016 Deborah J. Chute M.D. 2017 Leona A. Doyle M.D. 2018 Wayne Tam M.D. Ph.D. 2018 Andrew M. Bellizzi M.D. 2018 VOGEL AWARDS COMMITTEE 2 YEAR TERMS TERM ENDING Adeboye O. Osunkoya M.D. Chair 2016 Laura Collins MBBS 2016 John A. Hart M.D. 2016 Brian P. Rubin M.D. Ph.D. 2016 John N. Eble M.D. Ex-Ofcio 2016 Gene P. Siegal M.D. Ph.D. Ex-Ofcio David B. Kaminsky M.D. FIAC Ex-Ofcio BOARD COMMITTEE MEMBERS NEXTGENERATION LEARNING201628 BOARD COMMITTEE MEMBERS YOUNG INVESTIGATOR AWARDS COMMITTEE TERM ENDING Marc Ladanyi M.D. Chair 2016 Audrey J. Lazenby M.D. 2017 Julia C. Iezzoni M.D. 2017 Cristina R. Antonescu M.D. 2017 Celina G. Kleer M.D. 2017 David B. Kaminsky M.D. FIAC Ex-Ofcio FOUNDATION COMMITTEE MEMBERS TERM ENDING Gregory N. Fuller M.D. Ph.D. Chair 2018 Julia A. Bridge M.D. 2018 Mary S. Richardson M.D. 2018 Steven C. Smith M.D. Ph.D. 2018 Martha Bishop Pitman M.D. 2018 Celeste N. Powers M.D. Ph.D. 2017 Linda D. Ferrell M.D. 2016 Marie E. Robert M.D. 2016 Ann Marie Nelson M.D. 2016 John R. Goldblum M.D. Ex-Ofcio 2016 Wendy L. Frankel M.D. Ex-Ofcio as Treasurer 2018 David B. Kaminsky M.D. Ex-Ofcio Paul M. Lewin Director of International Development USCAP CANADA FOUNDATION TERM ENDING David F. Hardwick M.D. Chair 2016 Michael F. Allard M.D. 2016 Sylvia L. Asa M.D. Ph.D. 2016 C. Blake Gilks M.D. 2016 John Veinot M.D. 2016 Ilan Weinreb M.D. 2016 John R. Goldblum M.D. Ex-Ofcio 2016 David B. Kaminsky M.D. FIAC Ex-Ofcio Paul M. Lewin Director of International Development NEXTGENERATION LEARNING 2016 29 BOARD COMMITTEE MEMBERS COURSE DIRECTORS TERM ENDING Diagnostic Cytopathology Kristen A. Atkins M.D. 2016 Diagnostic Cytopathology - Ritu Nayar M.D. 2019 Practical Pathology Seminars - Jesse K. McKenney M.D. 2016 Diagnostic Pathology Update Wendy L. Frankel M.D. 2016 Diagnostic Pathology Update Adam Bagg M.D. 2019 Interactive Microscopy Steven D. Billings M.D. 2017 AMERICAN MEDICAL ASSOCIATION TERM ENDING Nicole D. Riddle M.D. Delegate 2016 James Michael Mitchell M.D. Alternate 2016 Daniel C. Zedek M.D. 2016 David B. Kaminsky M.D. FIAC Pathology Section Representative David S. Wilkinson M.D. Ph.D. CPT Advisor AMERICAN REGISTRY OF PATHOLOGY Ronald A. DeLellis M.D. BIOLOGICAL STAIN COMMISSION Paul E. Swanson M.D. INTERSOCIETY COMMITTEE ON PATHOLOGY INFORMATION Margaret M. Grimes M.D. INTERSOCIETY PATHOLOGY COUNCIL David B. Kaminsky M.D. FIAC John R. Goldblum M.D. PROGRAM DIRECTORS SECTION OF ASSOCIATION OF PATHOLOGY CHAIRS PRODS Suzanne Z. Powell M.D. NEXTGENERATION LEARNING201630 BOARD COMMITTEE MEMBERS SOCIAL MEDIA SUBCOMMITTEE TERM ENDING Jerad M. Gardner M.D. Chair 2017 Samson W. Fine M.D. 2017 Roseann I. Wu M.D M.P.H. 2017 Sean R. Williamson M.D. 2017 Nicole D. Riddle M.D. 2017 Xiaoyin Sara Jiang M.D. 2017 Nathan Lee M.D. 2017 Matthew Wasco M.D. 2017 Rashna Meunier M.D. 2017 Raul Gonzalez M.D. 2017 Ethan Kaminsky 2017 John Garrard Ex-Ofcio Director of Innovative CommunicationsProduct Design NEXTGENERATION LEARNING 2016 31 2016 BUSINESS MEETING AGENDA 1. CALL TO ORDER .......................................................................................................... Dr. John R. Goldblum 2. INTRODUCTION........................................................................................................... Dr. John R. Goldblum 3. APPROVAL OF MINUTES 2015 BUSINESS MEETING.............................................. Dr. John R. Goldbum 4. REPORT OF THE PRESIDENT General Information Recognition of Dignitaries Announcements 5. REPORT OF THE EXECUTIVE VICE PRESIDENT ..................................................... Dr. David B. Kaminsky 6. REPORT OF THE EDUCATION COMMITTEE....................................................................... Dr. Laura Lamps 7. REPORT OF THE FINANCE COMMITTEE........................................................................ Dr. David Grignon 8. REPORT OF THE MEMBERSHIPRAC COMMITTEES ............................................................Dr. Tarik Tihan 9. REPORT OF THE FOUNDATION.............................................................................................. Dr. Greg Fuller 10. REPORT OF THE PUBLICATIONS COMMITTEE............................................................Dr. Murray Resnick 11. REPORT OF THE NOMINATING COMMITTEE ......................................................... Dr. Celeste N. Powers 12. ELECTION OF OFFICERS........................................................................................... Dr. Celeste N. Powers 13. INSTALLATION OF THE PRESIDENT ....................................................................... Dr. John R. Goldblum 14. PRESENTATION OF THE PRESIDENTS MEDAL TO THE PAST-PRESIDENT ..............Dr. John Goldblum 15. REPORT OF THE IAP.......................................................................................................Dr. David Hardwick Future Congresses Cologne Germany 2016 Amman Jordan 2018 16. OTHER BUSINESS................................................................................................... Dr. John R. Goldblum 17. ADJOURNMENT ........................................................................................................ Dr. John R. Goldblum SPECIAL AWARDS PRESENTATIONS STOWELL-ORBISON.................................................................................................................. Dr. Laura Lamps AUTOPSY SURGICAL PATHOLOGY .................................................................................... Dr. Teri Longacre CASTLEMAN AWARD ................................................................................................................. Dr. David Louis VOGEL AWARD................................................................................................................. Dr. John R. Goldblum DISTINGUISHED PATHOLOGIST AWARD....................................................................... Dr. John R. Goldblum MOSTOFI AWARD ............................................................................................................ Dr. John R. Goldblum RAMZI COTRAN YOUNG INVESTIGATOR AWARD............................................................... Dr. Mark Ladanyi HARVEY GOLDMAN MASTER TEACHER AWARD.................................................................Dr. Stuart Schnitt DR. L. CLARKE JR. ELAINE F. STOUT ENDOWMENT AWARD.................................. Dr. John R. Goldblum DR. FLORABEL G. MULLICK AWARD.............................................................................. Dr. John R. Goldblum 500 PM INTRODUCTION OF MAUDE ABBOTT LECTURER AND PRESENTATION OF MAUDE ABBOTT MEDALLION .................................................................................. Dr. John R. Goldblum 505-550 PM.....................................................................................................................Maude Abbott Lecture NEXTGENERATION LEARNING201632 INTRODUCTION The President Dr. Celeste Powers and the Executive Vice-President Dr. David B. Kaminsky opened the Business Meeting at 330 PM. Both delivered monologues regarding the new leadership and direction of USCAP. Dr. Kaminsky described the progressive atmosphere at the Annual Meeting and how each physician leaves the meeting knowing that USCAP is creating a better pathologist. Dr. Powers addressed her leadership vision the beginning of the reimagined USCAP. I. CALL TO ORDER The 2015 USCAP Business Meeting was called to order by Dr. Celeste Powers on Tuesday March 24 2015 at 337 PM at the Hynes Convention Center in Boston Massachusetts. II. ADOPTION OF THE AGENDA A motion CARRIED to adopt the agenda published in the Program Book verbal vote no oppositions. III. APPROVAL OF MINUTES 2014 BUSINESS MEETING A motion CARRIED to approve the minutes of the 2014 Annual Business Meeting as posted on the USCAP website verbal vote no oppositions. IV. VOTE ON BYLAWS REVISIONS Dr. Powers requested a motion to approve the Bylaws revisions that were posted to the USCAP website and circulated through e-mail. These revisions addressed new member categories and revised the general language to be compliant with modern 501c3 Non-prot organizational standards. The motion CARRIED verbal vote no oppositions and the Bylaws revisions were accepted. V. RECOGNITION OF DIGNITARIES Dr. Powers recognized several dignitaries in attendance at the meeting. Their names were listed in the Program Book. VI. REPORT OF THE PRESIDENTEXECUTIVE VICE-PRESIDENT Dr. Kaminsky thanked the staff of USCAP for their dedication. Dr. Celeste Powers described the two-day strategic plan meeting in Chicago facilitated by CFAR consulting group to reinforce member engagement with denition of value strengthening governance supporting operations and the EVP global outreach leveraging relationships and alliances and the delivery of digital products. Dr. Kaminsky described the presentation to the Board by Sheri Jacobs author of The Art of Membership on membership value and introduced the Memorandum of Understanding with the American Society for Clinical Pathology and highlighted the resident engagement program as an example of the intended collaboration. Dr. Powers explained that the Board of Directors had adopted the management style reected by a metaphorical rewall separating governance and operations. She introduced the new initiative of providing concierge services to recognize the extraordinary volunteer work by the faculty and committees. Dr. Kaminsky explained that to enhance functionality navigability and a new website design the Academy prepared surveys held focus groups and a three-day vendor summit prior to selection of a new web vendor and designer. The website is under construction and will be launched soon. Dr. Kaminsky also explained the Academys efforts to develop new educational products focusing on digital assets designed for delivery on hand-held and mobile devices. Dr. Powers described Dr. Kaminskys visits to Vancouver to meet with Dr. David Hardwick for strengthening the relationship between the USCAP and the IAP. Dr. Kaminsky announced the opening of a West Coast ofce USCAP West and the capabilities of the staff. Dr. Powers introduced the 2014 Interactive Microscopy documentary and then asked Dr. Steven Billings to describe the new Interactive Center in Palm Springs via a short video in which Dr. Billings explaining the oor planlayout of the interactive laboratory spaces. Dr. Kaminsky concluded the report by describing his time in Evans Georgia during the summer to interact with staff rene operations standardize procedures and assure risk managementnancial security. VII. REPORT OF THE EDUCATION COMMITTEE - DR. LAURA LAMPS Dr. Laura Lamps announced that the registration for the 2015 Annual Meeting had already exceeded 5000 people representing 87 countries. She presented the 2015 Annual Meeting Statistics. She indicated that 3096 abstracts were submitted with 2126 accepted 69. 1846 abstracts were assigned to posters and 280 to platforms. Registered attendance for the long course this year is 696 Special Courses 1093 Companion Societies 5975 Evening Specialty Conferences 7103 and Short Courses 4025. Dr. Lamps explained the total number of possible CMEs per person was 58.5 of a total of 445.5 CMEs available for the meeting. Maximum SAMs credits per person were 55.25 of a total of 309.25. 2015 BUSINESS MEETING MINUTES Tuesday March 24 2015 Auditorium Hynes Convention Center Boston MA 330 PM NEXTGENERATION LEARNING 2016 33 2015 BUSINESS MEETING MINUTES Dr. Lamps explained the excitement surrounding the new digital products interactive Microscopy the Interactive Center the opportunity to enhance mentoring and a reinvigorated subcommittee on Informatics. She concluded with a slide on a Formula for Success which contained all the above-referenced totals. VIII. REPORT OF THE FINANCE COMMITTEE DR. WENDY FRANKEL TREASURER Dr. Wendy Frankel presented the names of the Finance Committee members and explained the evolution of the Academys Operating Budget. Dr. Frankel notied the attendees of the unqualied opinion on the most current audit an unqualied opinion for an audit means there was no evidence of wrong-doing and the nancial statements were error- free. Next the allocation of operating revenue for the Academy was presented. IX. REPORT OF THE MEMBERSHIP COMMITTEE DR. TARIK TIHAN Dr. Tihan reviewed the members structure and terms of ofce of the Membership Committee. He acknowledged Dr. Iezzoni for her service as the past Chair. Dr. Tihan then presented the mission of the Membership Committee Provide true value and purpose for membership that will respond to the members professional needs in accordance with the mission of the Academy. Dr. Tihan discussed the action plan for the next cycle - the membership committee will rene its operating guidelines implement the mission of the committee and draft guidelines for adopting initiatives which had been presented to the EVP. He presented charts on member demographics by institution type region and then sub-specialty. Moving forward the Membership Committee proposed the following priorities for 2015 trend analysis of member data increasing membership from the private pathology community developing a welcome package for new members supporting the re-imagined ambassador program and supportingempowering the Resident Advisory Subcommittee. He ended by providing detail on the 10 travel scholarships given by the Foundation in collaboration with the Resident Advisory Subcommittee. X. REPORT OF THE FOUNDATION COMMITTEE DR. LINDA FERRELL Dr. Linda Ferrell explained that philanthropy has always been at the Academys cornerstone but that now more than ever USCAP needs to become more visible in supporting pathologists globally particularly in low-resource settings. She presented the nancial data supporting the G20 campaign and the travel grants for 10 trainees to attend the Annual Meeting. Dr. Ferrell thanked Dr. and Mrs. Stout for partnering with the USCAP Foundation by providing an endowment. She detailed the grants for Haiti including supporting three Haitian pathologists to attend the Annual Meeting and implementation of on-site education and laboratory development assistance in Haiti. Grant money has also been awarded to Dr. Cooke for the development of an Atlas of Infectious Diseases. The USCAP Foundation commits to contributing resources and tools to Africa. Dr. Ferrell described the annual Miles for Mentors event. She announced the formation of the USCAP Canadian Foundation. Dr. Ferrell concluded with special thanks to CytoTest and Virginia Commonwealth University for their Foundation support the latter in honor of Dr. Celeste Powers presidency. XI. REPORT OF THE PUBLICATIONS COMMITTEE DR. MURRAY RESNICK Dr. Resnick commenced his presentation by acknowledging this has been a very successful year for both journals Modern Pathology and Laboratory Investigation. He thanked the partnership between USCAP and Nature Publishing Group explained the structure of the journals and thanked the editors for their dedication. Laboratory Investigation is among the top three journals devoted to general experimental pathology. New developments for this journal include the addition of a Senior Associate Editor Dr. Akihiro Umezawa as a consequence of the increased interest in the journal in Asia and upcoming special issues of Pathobiology in Focus. Dr. Resnick expressed his appreciation to Dr. Gene Siegal for his leadership. Dr. Resnick remarked that Modern Pathology is one of the leading journals devoted to general diagnostic anatomic surgical pathology. He acknowledged the contribution of Dr. John Eble who will begin his unprecedented fourth term as editor in chief. The 2014 projected impact factors for Laboratory Investigation is 3.86 and for Modern Pathology is 7.11. This data was presented in comparison to competitors. Next slides for the most cited papers noted for both journals were presented. The submission processes were described by Dr. Resnick who concluded by thanking Dr. Catherine Ketcham Martha Simmons and the Editorial Boards and reviewers of Laboratory Investigation and Modern Pathology. NEXTGENERATION LEARNING201634 2015 BUSINESS MEETING MINUTES XII. REPORT OF THE NOMINATING COMMITTEE DR. LINDA FERRELL Dr. Ferrell began by thanking the members of the committee Drs. Greg Fuller Christina Isacson and Fred Silva. Dr. Fred Silva is rotating off. She announced that Drs. Sanja Dacic Suzanne Powell and Daniel Arber were elected by the USCAP membership prior electronic election as the new members of the Board of Directors effective April 1 2015. XIII. ELECTION OF OFFICERS DR. LINDA FERRELL Dr. Ferrell introduced Dr. Christopher Fletcher as the new USCAP Vice-President effective April 1 2015. She concluded her report by thanking the Executive Committee and the Board of Directors for their dedication and leadership. IV. INSTALLATION OF THE PRESIDENT DR. CELESTE POWERS Dr. Powers described the highlights of Dr. John Goldblums career. As the incoming President of USCAP Dr. Goldblum ofcially takes ofce on April 1 2015. XV. PRESENTATION OF THE PRESIDENTS MEDAL TO THE PAST-PRESIDENT DR. CELESTE POWERS Dr. Jeffrey Myers was not in attendance for the presentation. XVI. REPORT OF THE INTERNATIONAL ACADEMY OF PATHOLOGY IAP DR. DAVID HARDWICK Dr. Hardwick announced that the 2016 IAP Congress will be held on September 24-30th in Cologne Germany. The 2018 Congress will take place in Amman Jordan with the 2020 IAP Congress following in Glasgow Scotland. Dr. Hardwick was presented with a plaque by Dr. Powers to acknowledge his contribution to creation of the USCAP Canadian Foundation. XVII. IN MEMORIAM Dr. Kaminsky requested a minute of silence in memory of USCAP members who died during the previous year. Their names were displayed. XVIII. OTHER BUSINESS DR. CELESTE POWERS Dr. Powers asked if there were other business to conduct. There was no other business. XIX. ADJOURNMENT DR. CELESTE POWERS Dr. Powers adjourned the 2015 Annual Business Meeting at 412 PM. John Sinard M.D. Ph.D. Date Approved Secretary SEPTEMBER 15 2015 NEXTGENERATION LEARNING 2016 35 International Academy of Pathology Pathology Education in Africa and Other Low Resource Countries TUESDAY MARCH 15 2016 1200PM 145PM CC 613-614 MODERATOR H.K. Ng MBChB Chinese University of Hong Kong Hong Kong 1200PM AFRICA CALLS David Kaminsky M.D. FIAC USCAP Executive Vice President 1220PM PATHOLOGY SAFARI Dan Berney MB BChir MA FRCPath Consultant GU Pathologist Dept. Cellular Pathology Royal London Hospital 1240PM A COOKES ROUND THE WORLD TOUR OF MEDICAL MUSEUMS Robin Cooke MD FRCPA FRCPath FACTM Mayne Medical School University of Queensland and Pathology Queensland Australia 100PM BREAKING BARRIERS IN PATHOLOGY EDUCATION MONGOLIA AND KOREA Shin K. Khang MD PhD Department of Pathology Asan Medical Center University of Ulsan College of Medicine Seoul Korea 120PM TO GO OR NOT TO GO IS THIS A QUESTION ANYMORE H.K. Ng MBChB Chinese University of Hong Kong Hong Kong IAP SESSION NEXTGENERATION LEARNING201636 PLEASE NOTE For Alumni Receptions You are invited to attend if you are an alumnus a guest of an alumnus or a friend of the institution. For SpecialtyCompanion Society Receptions You are invited if you are a member of this society or are considering joining the society and wish to learn more about it. All luncheons are by invitation only. SH SHERATON SEATTLE HOTEL CC WASHINGTON STATE CONVENTION CENTER FRIDAY MARCH 11TH 800 AM - 500 PM INTL ASSOCIATION FOR THE STUDY OF LUNG CANCER SH Cedar 600 PM - 1000 PM ADASP COUNCIL MTG DINNER SH Greenwood SATURDAY MARCH 12TH 730 AM - 500 PM ADASP ANNUAL MEETING SH Grand Ballroom A 800 AM - 300 PM INTL ASSOCIATION FOR THE STUDY OF LUNG CANCER SH Cedar 800 AM - 600 PM VHA NATIONAL DX ELECTRON MICROSCOPY AD HOC CMTE MEETING SH Boren 900 AM - 200 PM INTL SOCIETY OF GYN PATH WORKING MTG SH Willow B 1000 AM 500 PM PAPANICOLAOU SOCIETY MEETING SH Redwood 1200 PM - 130 PM ADASP LUNCHEON AND BUSINESS MEETING SH Grand Ballroom B 1200 PM - 600 PM CHINESE AMERICAN PATH ASSOC. SH Metro Ballroom A 200 PM - 600 PM INTL SOCIETY OF GYN PATHOLOGY EXEC COMMITTEE MTG SH Diamond 130 PM - 400 PM INTL SOCIETY OF UROLOGICAL PATH EXEC. MTG SH Greenwood 300 PM - 500 PM PULMONARY PATH SOCIETY COUNCIL MEETING SH Eagle Boardroom 345 PM - 545 PM RENAL PATHOLOGY SOCIETY BOARD MTG SH Aspen 400 PM - 600 PM INTL SOCIETY OF UROLOGICAL PATH RECEPTION SH Issaquah 500 PM - 730 PM ASSOCIATION OF INDIAN PATH EXEC COMMITTEE MTG SH Madrona 500 PM - 700 PM PAPANICOLAOU SOCIETY RECEPTION SH Willow A 500 PM - 700 PM SOCIETY FOR ULTRASTRUCTURAL PATHOLOGY COMMITTEE MTG SH Seneca 530 PM - 700 PM ENDOCRINE SOCIETY RECEPTION SH University 530 PM 900 PM SOCIETY FOR HEMATOPATH EXECUTIVE COMMITTEE MTG SH Juniper 530 PM 730 PM AFRICAN IAP ASSEMBLYASAP GROUP BOARD OF DIRECTORS MTG SH Spruce 600 PM 700 PM CANCER CYTOS 20TH ANNIVERSARY RECEPTION SH Ballard 615 PM - 645 PM INTL SOCIETY OF UROLOGICAL PATH AGM MTG CC BR 6B 700 PM - 800 PM RENAL PATHOLOGY SOCIETY ANNUAL RECEPTION SH Cedar 800 PM - 1000 PM RENAL PATHOLOGY SOCIETY ANNUAL DINNER SH Redwood SUNDAY MARCH 13TH 700 AM - 800 AM ENDOCRINE PATHOLOGY EDITORIAL BOARD MTG SH Diamond 700 AM - 1000 AM SOCIETY FOR HEMEPATH FELLOWSHIP DIRECTORS BREAKFAST SH Grand Ballroom A 715 AM - 830 AM ARTHUR PURDY STOUT SOCIETY COUNCIL BREAKFAST SH Madrona 730 AM - 900 AM WILEY-DIAGNOSTIC CYTOPATH ED BOARD MTG SH Issaquah 800 AM - 1200 PM DICOM PATHOLOGY WORKING GROUP SH Ballard 2016 AFFILIATE EVENTS NEXTGENERATION LEARNING 201 NEXTGENERATION LEARNING 2016 37 2016 AFFILIATE EVENTS 800 AM 330 PM DIGITAL PATHOLOGY ASSOCIATION MEETING SH Metro Ballroom A 800 AM - 330 PM ASCP RESIDENTS COUNCIL SH Greenwood 800 AM - 500 PM MESOTHELIOMA PANEL SH Redwood 1200 PM - 100 PM RENAL PATHOLOGY SOCIETY BUSINESS MTG CC 606-607 1230 PM - 500 PM ISUP INTERACTIVE CONFERENCE SH Willow 130 PM - 330 PM INTERNATIONAL BREAST PATH MEETING SH Kirkland 130 PM - 430 PM SOCIETY FOR CARDIOVASCULAR PATH EXEC COMMITTEE MTG SH Seneca 300 PM - 500 PM INTL SOCIETY OF BREAST PATH COMMITTEE MTG SH Medina 500 PM - 645 PM ARTHUR PURDY STOUT SOCIETY RECEPTION SH Madrona 500 PM - 730 PM ASSOCIATION OF INDIAN PATH RECEPTION SH Cirrus 500 PM - 700 PM CYTO JOURNAL EDITORIAL BOARD ACTIVITY SH Grand Ballroom D 500 PM - 700 PM HEAD NECK RECEPTION SH Virginia 500 PM - 645 PM INTL SOCIETY OF BREAST PATHOLOGY RECEPTION SH Leschi 530 PM - 730 PM ALBANY MEDICAL COLLEGE RECEPTION SH Boren 530 PM - 730 PM COLUMBIA UNIV. PRES HOSPITAL ALUMNI REC. SH Juniper 530 PM - 730 PM GI PATHOLOGY SOCIETY RECEPTION SH Grand Ballroom A 530 PM - 730 PM IRANIAN PATHOLOGISTS ASSOCIATION OF NA RECEPTION SH Capitol Hill 530 PM - 630 PM IRISHNORTH AMERICAN PATHOLOGY MTG CC 605 530 PM - 800 PM SOCIETY FOR HEMATOPATH RECEPTION SH Ravenna 530 PM - 730 PM STANFORD UNIVERSITY RECEPTION SH Ballard 530 PM - 730 PM UNIVERSITY OF MIAMI RECEPTION SH University 530 PM 730 PM DUKE PATHOLOGY RECEPTION SH Cedar 530 PM - 700 PM UPMC FACULTY AND ALUMNI RECEPTION SH Columbia 700 PM - 1200 AM UCSF RECEPTION SH Jefferson 530 PM 730 PM FRIENDS OF AFRICA INITIATIVE MTG SH Issaquah 700 PM - 800 PM HEAD AND NECK JOURNAL BOARD MTG SH Diamond 700 PM - 720 PM INTL SOCIETY OF BREAST PATH AGM MTG CC Hall 4E MONDAY MARCH 14TH 700 AM - 800 AM ASSOCIATION FOR MOLECULAR PATHOLOGYS MEET N GREET CAF FOR TRAINEES SH Ballard 700 AM - 900 AM TAYLOR FRANCIS EDITORIAL BOARD MEETING SH Kirkland 700 AM - 900 AM ELSEVIER CV PATH EDITORIAL BOARD MEETING SH Issaquah 700 AM - 930 AM HUMAN PATH ASSOCIATE EDITORS MEETING SH Medina 800 AM - 1230 PM TRIG COMMITTEE MEETING SH Chelan 830 AM 230 PM APC CHAIRS MEETING SH Metro Ballroom B 1000 AM - 1200 PM MD SURVEY TASK FORCE SH Aspen 1030 AM - 300 PM PANCREATIC GROUP-EMORY SH Redwood 1130 AM - 200 PM HUMAN PATH EDITORIAL BOARD MEETING SH Ravenna 1130 AM - 130 PM INTL JOURNAL OF GYN PATHOLOGY ED BOARD SH Madrona 1200 PM - 130 PM MCGILL UNIVERSITY LUNCHEON SH Willow A 1200 PM 600 PM AFRICAN IAP ASSEMBLYASAP GROUP MEETING SH Capitol Hill 1130 AM 230 PM PRODS MEETING SH Grand Ballroom C 400 PM 530 PM ENUP BOARD MEETING SH Medina 500 PM - 630 PM ARCHIVES OF PATH RECEPTION SH Issaquah 500 PM - 700 PM MT. SINAI ALUMNI RECEPTION SH Ravenna A 500 PM - 700 PM HOUSTON METHODIST HOSPITAL RESIDENT RECEPTION SH Boren 500 PM - 700 PM UNIVERSITY OF PENNSYLVANIA RECEPTION SH Juniper 500 PM - 700 PM UNIVERSITY OF TEXAS MEDICAL BRANCH REUNION SH Jefferson B 530 PM - 730 PM ALUMNI FRIENDS OF YALE RECEPTION SH Jefferson A 530 PM - 730 PM ARAB DIVISION OF IAP RECEPTION SH Ballard NEXTGENERATION LEARNING201638 2016 AFFILIATE EVENTS MONDAY MARCH 14TH...CONTINUED 530 PM - 730 PM UNIVERSITY OF ROCHESTER MEDICAL CENTER ALUMNI RECEPTION SH Madrona 530 PM - 730 PM BRIGHAM WOMENS HOSPITAL RECEPTION SH Virginia 530 PM - 730 PM CLEVELAND CLINIC ALUMNI RECEPTION SH Cirrus 530 PM - 730 PM DARTMOUTH-HITCHCOCKFLETCHER ALLEN RECEPTION SH Diamond 530 PM - 730 PM EMORY UNIVERSITY RECEPTION SH Redwood 530 PM - 730 PM JOHNS HOPKINS RECEPTION SH Willow A 530 PM - 700 PM LABORATORY MEDICINE PATHOLOGY UNIV. OF TORONTO RECEPTION SH Ravenna B 530 PM - 730 PM LATIN AMERICAN PATH FOUNDATION RECEPTION SH Grand Ballroom D 530 PM - 730 PM MAYO CLINIC ALUMNI ASSOCIATION RECEPTION SH Willow B 530 PM - 730 PM MD ANDERSON RECEPTION SH Grand Ballroom B 530 PM - 730 PM NORTHWESTERN UNIVERSITY RECEPTION SH Columbia 530 PM - 730 PM VCU RECEPTION SH Aspen 530 PM - 730 PM UCLA ALUMNI RECEPTION SH Seneca 530 PM - 700 PM UMASS MEDICAL SCHOOL ALUMNI RECEPTION SH Ravenna C 530 PM - 730 PM UNIVERSITY OF CHICAGO RECEPTION SH Metro Ballroom A 530 PM - 730 PM UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS RECEPTION SH Leschi 530 PM - 730 PM VANDERBILT ALUMNI RECEPTION SH Cedar 530 PM - 730 PM UNIVERSITY OF MICHIGAN A. JAMES FRENCH ALUMNI SOCIETY SH Greenwood 530 PM - 730 PM WASHINGTON UNIVERSITY IN ST. LOUIS RECEPTION SH Kirkland 530 PM 730 PM MASSACHUSETTS GENERAL RECEPTION SH University 600 PM 800 PM NYU SCHOOL OF MEDICINE ALUMNI RECEPTION SH Grand Ballroom A 600 PM - 800 PM HOUSTON METHODIST HOSPITAL RESIDENT RECEPTION SH Boren 600 PM 800 PM MOFFITT CANCER CENTER RECEPTION SH Metro Ballroom B 900 PM - 1100 PM INTL ASSN OF CHINESE PATH ANNUAL REC SH Capitol Hill TUESDAY MARCH 15TH 730 AM - 930 AM APPLIED IMMUNOHISTOCHEMISTRY MOLECULAR MORPHOLOGY ED. BOARD MEETING SH Madrona 730 AM - 930 AM ANNALS OF DIAGNOSTIC PATH ELSEVIER SH Ravenna 1130 AM - 230 PM AMERICAN JOURNAL OF SURGICAL PATH ED BOARD SH Jefferson 1200 PM - 300 PM SCVP MEETING SH Cedar 500 PM - 700 PM LWW - ADVANCES IN ANATOMIC PATH MTG. SH Capitol Hill 530 PM - 730 PM BETH ISRAEL DEACONESS HOSPITAL RECEPTION SH Issaquah 530 PM - 730 PM HISTOPATHOLOGY EDITORIAL BOARD RECEPTION SH Redwood 530 PM - 730 PM JAPANESE DIVISION OF IAP RECEPTION SH Greenwood 530 PM - 730 PM MSKCC ALUMNI RECEPTION SH Jefferson 530 PM - 730 PM SEMINARS IN DIAGNOSTIC PATH ELSEVIER SH Ravenna 530 PM - 730 PM UNC RECEPTION SH Ballard 600 PM - 730 PM UNIVERSITY OF MARYLAND RECEPTION SH Kirkland 2016 NEXTGENERATION LEARNING PATHOLOGISTS-IN-TRAINING Topics of Discussion Include... MeetYourMentors. Here is your opportunity to rub elbows with the rockstars of the Pathology world Gain valuable insight and knowledge in a casual and engaging setting. March 14 2016 Breakfast Lynette M. Sholl M.D. John Sinard M.D. Ph.D. Catherine M. Ketcham Ph.D. Gene P. Siegal M.D. Ph.D. Laura Collins M.D. Rhonda Yantiss M.D. March 14 2016 - Lunch Christopher Fletcher M.D. FRCPath Celeste Powers M.D. Ph.D. Miguel Sanchez M.D. E. Blair Holladay Ph.D. John R. Goldblum M.D. Jerad M. Gardner M.D. March 15 2016 Breakfast John Sinard M.D. Ph.D. Catherine M. Ketcham Ph.D. Gene P. Siegal M.D. Ph.D. Stuart J. Schnitt M.D. Murray Resnick M.D. Ph.D. March 15 2016 Lunch Laura Lamps M.D. Wendy Frankel M.D. Marisa Nucci M.D. Yael Kushner Hehr M.D. MPH FRCPC Jerad M. Gardner M.D. Richard L. Haspel M.D. Ph.D. Whats concrete about the abstract Grasping informatics Life cycle of the pathology trainee The patient-centered cytopathology practice Next Generation SequencingMolecular Pathology IAMUSCAP and how to engage social media Conflict management Finding empathy How to get published Quality starts during training Topics of Discussion Include... MeetYourMentors. Here is your opportunity to rub elbows with the rockstars of the Pathology world Gain valuable insight and knowledge in a casual and engaging setting. March 14 2016 Breakfast Lynette M. Sholl M.D. John Sinard M.D. Ph.D. Catherine M. Ketcham Ph.D. Gene P. Siegal M.D. Ph.D. Laura Collins M.D. Rhonda Yantiss M.D. March 14 2016 - Lunch Christopher Fletcher M.D. FRCPath Celeste Powers M.D. Ph.D. Miguel Sanchez M.D. E. Blair Holladay Ph.D. John R. Goldblum M.D. Jerad M. Gardner M.D. March 15 2016 Breakfast John Sinard M.D. Ph.D. Catherine M. Ketcham Ph.D. Gene P. Siegal M.D. Ph.D. Stuart J. Schnitt M.D. Murray Resnick M.D. Ph.D. March 15 2016 Lunch Laura Lamps M.D. Wendy Frankel M.D. Marisa Nucci M.D. Yael Kushner Hehr M.D. MPH FRCPC Jerad M. Gardner M.D. Richard L. Haspel M.D. Ph.D. Whats concrete about the abstract Grasping informatics Life cycle of the pathology trainee The patient-centered cytopathology practice Next Generation SequencingMolecular Pathology IAMUSCAP and how to engage social media Conflict management Finding empathy How to get published Quality starts during training TABLETABLE MENTORSat the Christopher Fletcher M.D. FRCPath Yael Kushner Hehr M.D. MPH FRCPC WashingtonStateConventionCenter-3AB 700am -300pm RESIDENTS ON THE VERGE NEXTGENERATION LEARNING 2016 39 Id like to extend a warm welcome to you our pathologists-in-training and congratulate you on taking the opportunity to attend one of the greatest events in pathology in Seattle Washington The USCAP Annual Meeting. We continue to provide many offerings especially designed for you. Begin your experience at the special trainee registration and information booth in the registration area. Dont miss these two workshops specically targeted to trainees Genomic Medicine for Pathologists and Leadership Collaboration and Change in Health Care. Both address core competencies that are critical to succeeding in a health care environment increasingly delivered by integrated health care teams. Both events are topped off by a special reception for residents and fellows attending the workshop which is a great way to meet the instructors USCAP ofcials and your peers. Other courses including the Long Course entitled Diagnosing Distinctive Lesions of Head and Neck Special Courses like Clinical Application of Next Generation Sequencing and Molecular Diagnostic and Genomic Applications in Cancer A Primer for the Pathologist and popular programs like Hot Topics in Pathology are led by world-class instructors and are not to be missed nor are our plenary lectures the Maude Abbott Lecture and the Nathan Kaufman Timely Topics Lecture which will push your pathology knowledge to new boundaries and grow your mind. A special lecture by Dr. Thomas Colby and National Geographic Magazine photojournalist Annie Grifths looks at Hut Lung A Poignant Portrait. Three Practice Changers are targeted to pathologists-in-training co-branded with ASCP. Practice Changers have been relocated external to the Exhibit Hall. Stop by any of the 12 sessions held Monday and Tuesday during the coffee breaks to pick up tips from the most contemporary pathology practices. The Evening Specialty Conference on Sunday March 13 is dedicated to Preparing for Life Beyond Residency. Find your future fellowship at the Fellowship Fair on Sunday evening where you can meet faculty and fellowship directors from over 40 institutions. Before going check out the Fellowship Fair charts found under this tab. Theyre designed to help you quickly target the institutions and fellowships you seek. Our annual Abstract Competition with its many awards draws the foremost pathology research from around the world. Make sure you attend the Poster and Proffered Papers sessions early in the week. Awards for the leading presentations by pathologists- in-training will follow on Tuesday March 15. We hope youll join the crowd to celebrate your peers achievements. The Annual Business Meeting will generate buzz and reference our re-imagined Ambassador Program and social media outreach. TheExhibitionHallislledagainwiththeleadingcompaniesandservicesthatcompriseourindustryknowledgeablerepresentatives are available to explain how their company can support your future pathology practice. Finally theres no better place to meet the world of USCAP than at the numerous receptions scheduled throughout the week. Several have been created especially for you see information under this tab and present an ideal situation to meet our world- renowned attendees. And should you need a place to recharge the Mentors at the Table formerly House Staff Hospitality Room Convention Center 3AB March 14-15 700 a.m.-300 p.m is a wonderful place to meet friends and grab breakfast lunch and snacks while chatting with USCAP leaders throughout the day. This year the USCAP Foundation supported Pathologist-in-Training Travel Awards through ten 1000 scholarships for pathologists in training So much to do Enjoy your visit to the worlds largest pathology meeting. Laura C. Collins MBBS Resident Advisory Committee Chair Beth Israel Deaconess Medical Center PATHOLOGISTS-IN-TRAINING NEXTGENERATION LEARNING201640 FELLOWSHIP FAIR SUB SPECIALTIES 1 BLOOD BANKING 2 BONE SOFT TISSUE 3 BREAST 4 CANCER BIOMARKER 5 CARDIOVASCULAR PATHOLOGY 6 CHEMICAL PATHOLOGY 7 CLINICAL BIOCHEMICAL GENETICS 8 CLINICAL BIOCHEMISTRY 9 CLINICAL CHEMISTRY 10 CLINICAL CYTOGENETICS 11 CLINICAL IMMUNOLOGY 12 CLINICAL MICROBIOLOGY 13 CLINICAL MOLECULAR GENETICS 14 CYTOGENETICS 15 CYTOPATHOLOGY 16 DERMATOPATHOLOGY 17 ENDOCRINE 18 FORENSIC 19 GENITOURINARY 20 GENOMIC PATHOLOGY 21 GI PATHOLOGY 22 GYNECOLOGIC PATHOLOGY 23 HEAD NECK 24 HEMATOPATHOLOGY 25 HLA 26 IMMUNOPATHOLOGY 27 INFORMATICS 28 LABORATORY MEDICINE 29 LIVERHEPATIC PATHOLOGY 30 MEDICAL GENETICS 31 MEDICAL MICROBIOLOGY 32 MICROBIOLOGY 33 MOLECULAR GENETICS 34 MULTIDISCIPLINARY SUBSPECIALTY PATHOLOGY 35 MUSCULOSKELETAL PATHOLOGY 36 NEUROPATHOLOGY 37 ONCOLOGIC MOLECULAR 38 ONCOLOGIC SURGICAL PATHOLOGY 39 OPTHALAMIC PATHOLOGY 40 ORTHOPEDIC PATHOLOGY 41 PEDIATRIC PATHOLOGY 42 PERINATAL DEVELOPMENTAL 43 PULMONARY PATHOLOGY 44 RENAL PATHOLOGY 45 RESEARCH 46 SELECTIVE PATHOLOGY 47 SPECIAL COAGULATION 48 SURGICAL PATHOLOGY 49 THORACIC PATHOLOGY 50 TRANSFUSION 51 TRANSPLANTATION IMMUNOLOGY 52 UROPATHOLOGY 53 VIROLOGY 54 WOMENS PATHOLOGY INSTITUTION TABLE FELLOWSHIPS OFFERED BAYLOR COLLEGE OF MEDICINE 17 1 9 15 16 24 33 36 41 48 50 BROWN UNIVERSITY ALPERT MEDICAL SCHOOL 20 3 21 22 36 41 42 48 54 CLEVELAND CLINIC - PATHOLOGY AND LABORATORY MEDICINE 6 1 2 5 8 12 15 16 19 21 24 33 50 EMORY UNIVERSITY 36 15 16 18 21 24 31 33 36 41 48 50 HARTFORD HOSPITAL 41 15 24 46 HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA 27 15 21 24 33 48 HOUSTON METHODIST HOSPITAL 4 1 9 15 24 25 33 36 39 48 50 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 32 3 15 16 17 19 20 21 22 23 24 29 33 36 44 INDIANA UNIVERSITY 30 1 15 16 18 19 21 24 31 36 48 50 JACKSON MEMORIAL HOSPITAL UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE 22 1 3 15 19 21 22 23 24 33 41 50 MAYO CLINIC ROCHESTER 9 2 3 5 7 9 10 12 13 16 21 24 33 36 43 44 47 48 50 MD ANDERSON CANCER CENTER 5 1 2 3 4 6 15 16 19 21 22 23 243334 48 49 50 MEMORIAL SLOAN KETTERING CANCER CENTER 26 3 15 16 19 21 22 24 33 38 49 MOFFITT CANCER CENTER 34 15 16 21 24 33 48 NEPHROPATH 1 44 NORTH SHORE LIJ HEALTH SYSTEM 18 15 24 48 NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE 7 3 15 19 21 24 36 41 48 NYU LANGONE MEDICAL CENTER 11 15 21 24 36 52 54 OREGON HEALTH SCIENCE UNIVERSITY 8 15 24 33 36 48 PATHOLOGYOUTLINES.COM INC. 12 FELLOWSHIP ADS ROSWELL PARK CANCER INSTITUTE 10 15 38 THE CHILDRENS HOSPITAL OF PHILADELPHIA 43 41 THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - DEPARTMENT OF PATHOLOGY 25 9 15 19 21 22 24 29 31 33 36 44 48 50 TUFTS MEDICAL CENTER 42 48 THE UNIVERSITY OF VERMONT MEDICAL CENTER 37 15 16 24 48 UNIVERSITY OF ALABAMA AT BIRMINGHAM 35 15 18 24 33 36 48 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES 33 1 15 16 24 48 NEXTGENERATION LEARNING 2016 41 FELLOWSHIP FAIR UNIVERSITY OF CALIFORNIA - IRVINE UCI 23 15 48 UNIVERSITY OF CALIFORNIA SAN FRANCISCO 14 1 15 16 21 22 24 33 36 44 48 50 UNIVERSITY OF CHICAGO 38 1 9 15 16 21 24 25 31 33 44 48 49 50 51 UNIVERSITY OF MARYLAND 29 15 24 UNIVERSITY OF MICHIGAN 31 2 3 6 15 16 18 19 21 22 24 25 27 33 36 41 43 48 50 UNIVERSITY OF ROCHESTER MEDICAL CENTER 2 3 15 19 21 24 48 UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 3 15 24 48 50 UNIVERSITY OF UTAH 19 7 9 10 11 13 15 21 24 30 31 33 36 41 48 UNIVERSITY OF VIRGINIA HEALTH SYSTEM 16 9 15 16 22 24 36 50 UNIVERSITY OF WASHINGTON 21 2 3 15 16 18 21 22 24 33 36 41 44 48 UNIVERSITY OF WISCONSIN- MADISON 39 15 24 48 50 VANDERBILT UNIVERSITY MEDICAL CENTER 24 12 15 21 24 33 36 41 44 48 50 VIRGINIA COMMONWEALTH UNIVERSITY HEALTH SYSTEMS 13 15 18 24 33 36 48 WASHINGTON UNIVERSITY IN ST. LOUIS 40 15 16 21 23 24 29 33 36 48 50 YALE UNIVERSITY SCHOOL OF MEDICINE 15 3 15 17 19 21 23 24 29 32 33 44 50 INSTITUTION TABLE FELLOWSHIPS OFFERED SUB SPECIALTIES 1 BLOOD BANKING 2 BONE SOFT TISSUE 3 BREAST 4 CANCER BIOMARKER 5 CARDIOVASCULAR PATHOLOGY 6 CHEMICAL PATHOLOGY 7 CLINICAL BIOCHEMICAL GENETICS 8 CLINICAL BIOCHEMISTRY 9 CLINICAL CHEMISTRY 10 CLINICAL CYTOGENETICS 11 CLINICAL IMMUNOLOGY 12 CLINICAL MICROBIOLOGY 13 CLINICAL MOLECULAR GENETICS 14 CYTOGENETICS 15 CYTOPATHOLOGY 16 DERMATOPATHOLOGY 17 ENDOCRINE 18 FORENSIC 19 GENITOURINARY 20 GENOMIC PATHOLOGY 21 GI PATHOLOGY 22 GYNECOLOGIC PATHOLOGY 23 HEAD NECK 24 HEMATOPATHOLOGY 25 HLA 26 IMMUNOPATHOLOGY 27 INFORMATICS 28 LABORATORY MEDICINE 29 LIVERHEPATIC PATHOLOGY 30 MEDICAL GENETICS 31 MEDICAL MICROBIOLOGY 32 MICROBIOLOGY 33 MOLECULAR GENETICS 34 MULTIDISCIPLINARY SUBSPECIALTY PATHOLOGY 35 MUSCULOSKELETAL PATHOLOGY 36 NEUROPATHOLOGY 37 ONCOLOGIC MOLECULAR 38 ONCOLOGIC SURGICAL PATHOLOGY 39 OPTHALAMIC PATHOLOGY 40 ORTHOPEDIC PATHOLOGY 41 PEDIATRIC PATHOLOGY 42 PERINATAL DEVELOPMENTAL 43 PULMONARY PATHOLOGY 44 RENAL PATHOLOGY 45 RESEARCH 46 SELECTIVE PATHOLOGY 47 SPECIAL COAGULATION 48 SURGICAL PATHOLOGY 49 THORACIC PATHOLOGY 50 TRANSFUSION 51 TRANSPLANTATION IMMUNOLOGY 52 UROPATHOLOGY 53 VIROLOGY 54 WOMENS PATHOLOGY NEXTGENERATION LEARNING201642 Laura C. Collins MBBS Chair Marwan Yared M.D. Jane Bernstein M.D. Sean M. Kirby M.D. Amber Nolan M.D. Ph.D. Drew G. Davis M.D. Kurt W. Fisher M.D. Ph.D. Lindsay Alpert M.D. Martin J. Magers M.D. Lauren Ritterhouse M.D. Ph.D. Christine E. Fuller M.D. Benjamin C. Calhoun M.D. Ph.D. Jessica Davis M.D. RESIDENT ADVISORY COMMITTEE 2016 NEXTGENERATION LEARNING COMPANION MEETINGS USCAP2016 Surround yourself with the dreamers and the doers the believers and the thinkers - Edmund Lee COMPANY THE Subspecialty companions to USCAP impact learning and connectivity from a collective diverse knowledge base. Twenty-seven Societies comprise a unique sphere of influence dramatically enhancing the USCAP experience. Thanks to our Companion Societies and attendees for making the USCAP Annual Meeting the worlds largest pathology event. See you next year in Texas WE KEEP American Association of Neuropathologists American Association of Ophthalmic Oncologists and Pathologists American College of Veterinary Pathologists American Society for Clinical Pathology American Society for Investigative Pathology American Society of Cytopathology American Society of Dermatopathology Arthur Purdy Stout Society of Surgical Pathologists Association for Molecular Pathology Association for Pathology Informatics Binford-Dammin Society of Infectious Disease Pathologists College of American Pathologists Endocrine Pathology Society Hans Popper Hepatopathology Society History of Pathology Society International Society of Bone Soft Tissue Pathology International Society of Breast Pathology International Society of Gynecological Pathologists International Society of Urological Pathology North American Society for Head and Neck Pathology Paleopathology Club Papanicolaou Society of Cytopathology Pulmonary Pathology Society Renal Pathology Society Rodger C. Haggitt Gastrointestinal Pathology Society Society for Cardiovascular Pathology Society for Hematopathology Society for Ultrastructural Pathology NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 43 AMERICAN ASSOCIATION OF NEUROPATHOLOGISTS Neuropathology Companion Society Meeting A Tribute to Dr. F. Stephen Vogel SATURDAY MARCH 12 2016 700 PM 1000 PM CC 608 609 MODERATORS Gregory Fuller MD PhD MD Anderson Cancer Center Houston TX Tarik Tihan MD PhD University of California San Francisco CA COURSE DESCRIPTION Understanding of the underlying molecular drivers of malignant human brain tumor genesis and progression has increased dramatically and exponentially over the past 10 years. This expanded knowledge has led to the implementation of clinically-critical molecular signature determination for the major group of pediatric brain tumors primitive neuroectodermal or embryonal tumors including medulloblastoma as well as the major group of adult brain tumors the diffuse gliomas including glioblastoma. The degree of maturity that the eld has reached led to an international colloquium in Haarlem The Netherlands in April 2014 in which the principles of a major revision of the World Health Organization Classication of Tumours of the Central Nervous System were debated and the conclusions codied 1. Based on this foundation a new fully revised Brain Tumor Classication will be released in March 2016 which will include for the rst time the incorporation of clinically-critical molecular signature elements into the denition and diagnosis of the major classes of malignant brain tumors including the most common childhood brain malignancy medulloblastoma and the most common adult brain tumor glioblastoma among others. There is therefore an urgent need to educate pathologists at all levels of career from trainees to seasoned private practicioners and professors on the new Brain Tumor Diagnosis and Classication system and how to implement it in the real world of clinical practice. This program will directly address this pressing need. Upon completion of this educational activity participants should be able to Understand the major clinically-relevant molecular alterations that underlie human brain malignancy tumorigenesis and that have strong predictive power with regard to response to therapy and prognosis Implement the determination and incorporation of clinically-critical molecular signatures into the diagnosis of individual patient tumors using immunostain surrogate markers and other techniques that are commonly available in the diagnostic pathology laboratory Learn how molecular signature determination can facilitate accurate diagnosis in the face of problematic tumors and in tumor histologic mimicry situations and will be able to incorporate the new changes in brain tumor diagnosis into their daily clinical practice 700 PM Opening Remarks A Tribute to Dr. F. Stephen Vogel Gregory Fuller MD PhD MD Anderson Cancer Center Houston TX 710 PM REFLECTIONS ON A CAREER IN SURGICAL NEUROPATHOLOGY Peter Burger MD The Johns Hopkins Hospital Baltimore MD 800 PM WHAT DO I DO WITH THIS LOW GRADE GLIOMA Craig Horbinski MD PhD University of Kentucky Lexington KY 830 PM IF THIS IS NOT GLIOBLASTOMA THEN WHAT IS IT Murat Gokden MD University of Arkansas for Medical Sciences Little Rock AR 900 PM HOW DO I REPORT THIS EMBRYONAL TUMOR Maria Martinez-Lage Alvarez MD Hospital of University of Pennsylvania Philadelphia PA COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201644 ASSOCIATION FOR PATHOLOGY INFORMATICS A Showcase of Image-based Analytics and Diagnostic Digital Pathology in Clinical Practice and Research SATURDAY MARCH 12 2016 700 PM 1000 PM CC 613 614 MODERATOR J. Mark Tuthill MD Henry Ford Health System Detroit MI COURSE DESCRIPTION Digital pathology and analytics is being increasingly appreciated as a critical area of pathology practice. The goal of the symposium is to present several aspects of digital pathology and image based analytics and to apply these approaches to current and future pathology practice. As digital pathology becomes more mainstream pathologists and pathologists in training need to not only understand the use of this technology in routine practice but how this technology will change the pathology practice and research through advanced techniques leveraging image analysis utilizing both content based image retrieval as well as quantitative analysis. Very little exposure to these concepts is available in most pathology practices. This symposium will look at both clinical and research oriented applications of image based analytics. Upon completion of this educational activity participants should better able to Have a greater familiarity with the most recent advancement in the growing eld of Digital Pathology and image analysis Understand the requirements for image based analysis of pathology specimens and systems implementation Understand the opportunities afforded by the availability of digital pathology for computational analysis and creation of decision support analytical tools Apply concepts of digital image analysis to clinical practice and research such as multiplex analysis of pathology samples Present practical examples of image analysis in support of clinical diagnosis and pathology research 700 PM INTRODUCTION AND SYMPOSIUM OVERVIEW J. Mark Tuthill MD Henry Ford Health System Detroit MI 705 PM IMAGE ANALYSIS IN CURRENT CLINICAL PRACTICE Liron Pantanowitz MD UPMC Shadyside UMPC Cancer Pavilion Pittsburgh PA 740 PM STROMALTUMOR INTERACTION AND DIGITAL ANALYSIS Andrew Beck MD Harvard Medical School Beth Israel Deaconess Medical Center Boston MA 815 PM CDIR AUTOMATED DIFFERENTIAL DIAGNOSIS Ulysses Balis MD University of Michigan Health System Ann Arbor MI 850 PM WHOLE SLIDE IMAGING IN IMAGING RESEARCH AND CLINICAL Yukako Yagi PhD Harvard Medical School Massachusetts General Hospital Boston MA 925 PM MULTIPLEX IMMUNOHISTOCHEMISTRY Michael Feldman MD University of Pennsylvania Hospital of the University of Pennsylvania Philadelphia PA NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 45 ENDOCRINE PATHOLOGY SOCIETY MEETING Impact of Large-Scale Genomic Data on Practicing Endocrine Pathology SATURDAY MARCH 12 2016 700 PM 1000 PM CC 606 607 MODERATORS Justine A. Barletta MD Harvard University Medical School Boston MA Giovanni Tallini MD University of Bologna School of Medicine Bologna Italy COURSE DESCRITION The Endocrine Pathology Society members determined the title contents and speakers of this companion meeting. The target audience includes practicing pathologists academic pathologists pathology residents and fellows who have interests in the pathology of endocrine neoplasms. This topic was chosen in order to present to the pathologist an updated overview of the most signicant advances in the molecular analysis of thyroid pancreatic neuroendocrine and adrenocortical tumors. Recently many large-scale genomic papers have been published on endocrine tumors. The impact of these genomic studies on diagnosis prognosis and therapy is considerable. The molecular data its correlations with histopathology and the clinical features of these neoplasms will be reviewed and their inuence on the daily pathology practice emphasized. Upon completion of this educational activity participants should be able to Appreciate the relevance of molecular alterations in papillary thyroid carcinoma and their clinical and pathologic implications Have an overview of the main molecular events in poorly differentiated and anaplastic thyroid carcinomas and their impact on classication risk stratication and therapy Update their knowledge on the novel genomic data in pancreatic neuroendocrine tumors and its implications for diagnosis and therapy Understand the importance of genomics in the pathologic assessment of adrenocortical carcinomas 700 PM PAPILLARY THYROID CARCINOMA TCGA AND BEYOND IMPACT ON THYROID CANCER PRE-OPERATIVE DIAGNOSIS PROGNOSTICATION AND RECLASSIFICATION OF ENCAPSULATED FOLLICULAR VARIANT OF PAPILLARY CARCINOMA Yuri E. Nikiforv MD PhD University of Pittsburgh Pittsburgh PA 740 PM GENOMIC LANDSCAPES OF POORLY-DIFFERENTIATED AND ANAPLASTIC THYROID CARCINOMA CLUES FOR BETTER CLASSIFICATION RISK STRATIFICATION AND THERAPY Ronald Ghossein MD Memorial Sloan-Kettering Cancer Center New York NY 820 PM NEW GENETICS DATA OF PANCREATIC NEUROENDOCRINE TUMORS IMPLICATIONS FOR DIAGNOSIS TREATMENT AND TARGETED THERAPIES Anja Schmitt Kurrer MD University of Bern Zurich Switzerland 900 PM GENOMIC APPRAISAL OF ADRENOCORTICAL CARCINOMAS WHAT PRACTICING PATHOLOGISTS NEED TO KNOW Thomas Giordano MD PhD University of Michigan Ann Arbor MI COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201646 PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY Small Specimens vs. Big Questions in the Era of Precision Medicine and Cost Containment SATURDAY MARCH 12 2016 700 PM 1000 PM CC 602 604 MODERATOR Zubair W. Baloch MD PhD University of Pennsylvania Perelman School of Medicine Philadelphia PA COURSE DESCRIPTION The PSC solicited topics of interest from their membership at the annual business meetings. Several potential topics were discussed at the Executive Board meeting and the topic for the 2016 session was chosen in agreement with the chairs of the scientic program committees. New approaches and challenges that pertain to the diagnosis of FNA and small tissue biopsies and related ancillary studies are of high interest to the PSC membership and are currently cited as an important topic in cytopathology. Our needs assessment process was based on the evaluation of the current literature and the feedback by PSC members. The following topic will be discussed Diagnosing mesothelioma in limited tissue samples Dos and donts of Immunohistochemistry of limited tissue samples Update on molecular testing of cytology samples Regulatory and cost containment issues affecting molecular diagnostic laboratory The rst presenter will address various aspects of the diagnosis of malignant mesothelioma in small biopsy specimens core and ne needle aspiration biopsy including diagnostic pitfalls and the incorporation of ancillary studies as an aid to the diagnosis of these challenging and controversial lesions. The second presentation will focus on employing immunohistochemistry studies in small biopsy specimen including the use and abuse of various markers judiciously using marker-panels and diagnostic pitfalls. The third presenter will provide an overview of what is new and exciting in the eld of molecular testing on cytology specimens. This speaker will present their own institutional experience and how it measures against what is published in the literature. The nal presentation will have a much broader appeal as the topic addresses the biggest challenge we face that is to provide the best patient care possible in era of cost containment. 700 PM INTRODUCTION OF PROGRAM AND SPEAKERS Zubair Baloch MD PhD University of Pennsylvania Perelman School of Medicine Philadelphia PA 705 PM PSC AWARDS PRESENTATION Tarik Elsheikh MD Cleveland Clinic Cleveland OH 720 PM DIAGNOSING MESOTHELIOMA IN LIMITED TISSUE SAMPLES Sanja Dacic MD PhD University of Pittsburgh PA 750 PM DOS AND DONTS OF IMMUNOHISTOCHEMISTRY OF LIMITED TISSUE SAMPLES Andrew Bellizzi MD University of Iowa Hospitals and Clinics Iowa City IA 820 PM UPDATE ON MOLECULAR TESTING OF CYTOLOGY SAMPLES Dara Aisner MD PhD University of Colorado Denver CO 850 PM REGULATORY AND COST CONTAINMENT ISSUES AFFECTING MOLECULAR DIAGNOSTIC LABORATORY Jennifer Hunt MD University of Arkansas for Medical Sciences Little Rock AR 920 PM DISCUSSION AND OPEN MICROPHONE SESSION NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 47 PULMONARY PATHOLOGY SOCIETY Emerging Topics in Pulmonary Pathology SATURDAY MARCH 12 2016 700 PM 1000 PM CC BALLROOM 6 A MODERATORS Kirtee Raparia MD Northwestern University Chicago IL Keith M. Kerr MD Aberdeen University School of Medicine Aberdeen Scotland COURSE DESCRIPTION Emerging areas in lung pathology include liquid biopsy circulating tumor cells and cell free DNA in patient plasma for lung cancer diagnostics and biomarker testing immuno-oncology biomarker testing for immune checkpoint inhibitor therapy cryobiopsy as a modality for diagnosing interstitial lung diseases without surgical biopsy and new multidisciplinary approaches to diagnosing interstitial lung diseases and new targeted therapies for these diseases. The technology and knowledge in these topics are embryonic but rapidly developing creating a need for education and update in these elds for practicing pathologists. This program addresses each of these emerging topics as described in the objectives. Upon completion of this educational activity participants should be able to Discuss recent developments in lung cancer targeted therapy and companion diagnostics including liquid biopsy and immuno-oncology Appreciate how cryobiopsy is done what the complications are and its usefulness in ILD Understand the importance of combining of pathologic radiologic and clinical evidence in the diagnosis of interstitial lung diseases and discuss the therapeutic and prognostic implications of these diagnoses Comprehend the current evidence supporting use of new targeted therapies in idiopathic pulmonary brosis and other brosing lung diseases and the rationales for the agents currently being evaluated in clinical trials 700 PM WELCOME Donald Guinee MD Virginia Mason Medical Center Seattle WA 705 PM INTRODUCTION Aliya N. Husain MD University of Chicago Chicago IL 715 PM NEW FRONTIERS IN LUNG CANCER DIAGNOSTICS Ming S. Tsao MD University of Toronto University Health Network Toronto Ontario Canada 800 PM INTERSTITIAL LUNG DISEASES WHY THE DIAGNOSIS MATTERS Linda P. Hariri MD PhD Wellman Center for Photo-medicine Massachusetts General Hospital and Harvard Medical School Boston MA Lynette Sholl MD Brigham and Womens Hospital Boston MA Andrew M. Tager MD Massachusetts General Hospital and Harvard Medical School Charlestown MA 900 PM CRYOBIOPSY FOR INTERSTITIAL LUNG DISEASE Thomas V. Colby MD Mayo Clinic Scottsdale AZ Sara Tomassetti MD GB Morgagni Hospital Forli Italy COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201648 INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY Update on the 2016 WHO Classication of Tumors of the Urinary System and Male Genital Organs SATURDAY MARCH 12 2016 700 PM 1000 PM CC BALLROOM 6 B MODERATORS Jesse McKenney MD Cleveland Clinic Cleveland OH Steven Shen MD PhD Houston Methodist Hospital Bellaire TX COURSE DESCRIPTION The WHO committee for the classication of Genitourinary Tumors met in Zurich Switzerland in March of 2015 to update the ofcial classication categories and criteria that were last published in 2004. The book that outlines the WHO classication is planned for release in January of 2016. Given that the changes will be very recently published at the time of the 2016 USCAP Annual Meeting and not well-known to the audience we decided that an update on these recent changes would be quite timely and useful for practicing surgical pathologists. This update session will be presented by the four lead authors of the 2016 edition of WHO classication of genitourinary tumors including prostate Peter Humphrey urinary bladder Victor Reuter kidney Holger Moch and testis Thomas Ulbright. Upon completion of this educational activity participants should be better able to Understand changes to the latest WHO classication of prostate cancer emphasizing histologic genetic and molecular changes Understand changes to the latest WHO classication of bladder cancer emphasizing histologic genetic and molecular changes Understand changes to the latest WHO classication of kidney cancer emphasizing histologic genetic and molecular changes Understand changes to the latest WHO classication of testis cancer emphasizing histologic genetic and molecular changes 700 PM INTRODUCTION AND WELCOME FROM THE ISUP Lars Egevad MD PhD Karolinska University Hospital Stockholm Sweden 715 PM UPDATE ON THE 2016 WHO CLASSIFICATION OF PROSTATE NEOPLASIA Peter Humphrey MD Yale School of Medicine New Haven CT 800 PM UPDATE ON THE 2016 WHO CLASSIFICATION OF BLADDER NEOPLASIA Victor Reuter MD Memorial Sloan-Kettering Cancer Center New York NY 845 PM UPDATE ON THE 2016 WHO CLASSIFICATION OF KIDNEY NEOPLASIA Holger Moch MD University Hospital Zurich Zurich Switzerland 930 PM UPDATE ON THE 2016 WHO CLASSIFICATION OF TESTICULAR NEOPLASIA Thomas Ulbright MD Indiana University School of Medicine Indianapolis IN NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 49 ARTHUR PURDY STOUT SOCIETY OF SURGICAL PATHOLOGISTS How Has Molecular Pathology Recently Changed My Diagnostic Surgical Pathology Practice SUNDAY MARCH 13 2016 830 AM 1200 PM CC BALLROOM 6 BC MODERATORS Jason L. Hornick MD PhD Brigham and Womens Hospital Boston MA Vania Nos MD PhD Massachusetts General Hospital Boston MA COURSE DESCRIPTION Surgical pathology continues to evolve as genetic alterations and increasingly specic immunohistochemical markers are identied. These new tools improve the ability of surgical pathologists to arrive at specic diagnoses for optimal patient care. This symposium will focus on the ways in which molecular pathology has recently changed surgical pathology practice in a wide range of organ systems. Upon completion of this educational activity participants should be better able to Approach the differential diagnosis of challenging areas in surgical pathology Understand how to apply new diagnostic immunohistochemical markers and molecular genetic ndings to select differential diagnoses in surgical pathology 830 AM INTRODUCTION Peter A. Humphrey MD Yale University School of Medicine New Haven CT Jason L. Hornick MD PhD Brigham and Womens Hospital Boston MA Vania Nos MD PhD Massachusetts General Hospital Boston MA 835 AM PRESIDENTS AWARD Peter A. Humphrey MD Yale University School of Medicine New Haven CT 845 AM HEAD AND NECK PATHOLOGY Ilan Weinreb MD University Health Network Toronto Ontario Canada 910 AM PULMONARY PATHOLOGY Lynette M. Sholl MD Brigham and Womens Hospital Boston MA 935 AM THYROID PATHOLOGY Yuri E. Nikiforov MD PhD University of Pittsburgh Pittsburgh PA 1000 AM BREAK 1030 AM PRIZE 1040 AM NEUROPATHOLOGY Daniel J. Brat MD PhD Emory University School of Medicine Atlanta GA 1105 AM HEPATIC PATHOLOGY Sanjay Kakar MD University of California San Francisco CA 1130 AM UROLOGIC PATHOLOGY Pedram Argani MD The Johns Hopkins University Baltimore MD COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201650 BINFORD - DAMMIN SOCIETY OF INFECTIOUS DISEASE PATHOLOGISTS Infectious Diseases of the Lung SUNDAY MARCH 13 2016 830 AM 1200 PM CC BALLROOM 6A MODERATORS Corinne Fligner MD University of Washington Seattle WA David Myerson MD PhD University of Washington Seattle WA COURSE DESCRIPTION Pulmonary infections remain a diagnostic challenge for diagnostic anatomic and clinical pathologists. Known and emerging pathogens continue to challenge our diagnostic techniques. This symposium is designed to provide information on integrated histopathologic and molecular diagnostic techniques in this rapidly evolving area. Experts in diagnosis of viral fungal and parasitic pathology will provide an update on current and evolving histopathologic and molecular diagnosis of pulmonary infections. Upon completion of this educational activity participants should be better able to Describe the histopathologic features of viral infections of the lungs including those of inuenza and novel emerging respiratory infections Describe available and emerging molecular diagnostic tests for pulmonary viral infections Describe histopathologic features of common and uncommon pulmonary fungal infections and the available molecular diagnostic techniques for identication and conrmation Describe histopathologic features of parasitic lung infections as well as artifacts mimicking infectious organisms 830 AM VIRAL INFECTIONS OF THE LUNG INCLUDING INFLUENZA AND EMERGING INFECTIONS HISTOPATHOLOGY AND MOLECULAR DIAGNOSIS Atis Muehlenbachs MD PhD Centers for Disease Control Atlanta GA 940 AM PARASITIC INFECTIONS OF THE LUNG AND INFECTIOUS MIMICS Bobbi Pritt MD MSc DTMH Mayo Clinic Rochester MN 1015 AM BREAK 1030 AM FUNGAL INFECTIONS OF THE LUNG HISTOPATHOLOGY AND MOLECULAR DIAGNOSIS Jeannette Guarner MD Emory University Atlanta Georgia Andrew Bryan MD PhD University of Washington Seattle WA 1140 AM QUESTIONS NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 51 COLLEGE OF AMERICAN PATHOLOGISTS Molecular Testing in Everyday Pathology Practice Evolving Evidence-Based Guidelines in the Workup of Common Neoplasms SUNDAY MARCH 13 2016 830 AM 1200 PM CC 602 604 MODERATORS Robert M. Najarian MD Beth Israel Deaconess Medical Center Boston MA Jennifer Laudadio MD University of Arkansas for Medical Sciences Little Rock AR COURSE DESCRIPTION The Curriculum Committee of the College of American Pathologists considers the list of past offerings the current and evolving state of anatomic pathology priority learning needs of pathologists and expert opinion in selecting the topic for the 2016 CAP Companion Society education symposium. Molecular oncology testing is rapidly evolving and changing the landscape of diagnostic medicine and the practice of pathology. Given this rapid evolution the practicing pathologist may nd it challenging to navigate the landscape of what molecular tests are essential from a patient prognostic and treatment perspective versus those that are more experimental or esoteric. Experts at the CAP and partner organizations identied a need for evidence based practice guidelines related to molecular testing. The CAP Pathology and Laboratory Quality Center CAP Center along with our professional partners advance the practice of pathology and laboratory medicine by bringing evidence-based guidelines and consensus recommendations to the forefront of clinical decision making including many recently published or active evolving guidelines on molecular testing of tumors. These guidelines help pathologists and clinicians make more informed decisions about diagnosis and optimal treatment and place emphasis on the pathologists role at the center of patient care. Adopting these guidelines helps pathologists and laboratory professionals to provide more effective testing consistent and high-quality results and expert interpretations. The CAP Center develops evidence-based guidelines by following the Institute of Medicines Standards for Developing Trustworthy Clinical Practice Guidelines to ensure a transparent and unbiased approach. Upon completion of this educational activity participants should be better able to Describe the Institute of Medicine standards for developing evidence based guidelines Identify and apply existing evidence-based guidelines in the work-up of common neoplastic entities Discuss upcoming guidelines that can be applied in future practice 830 AM INTRODUCTION Robert M. Najarian MD Beth Israel Deaconess Medical Center Boston MA Jennifer Laudadio MD University of Arkansas for Medical Sciences Little Rock AR 850 AM HPV TESTING IN HEAD AND NECK CARCINOMAS William Faquin MD PhD Massachusetts General Hospital Boston MA 920 AM HER2 TESTING GUIDELINES FOR ADENOCARCINOMAS OF THE STOMACH AND GASTROESOPHAGEAL JUNCTION Angela N. Bartley MD St. Joseph Mercy Hospital Ann Arbor MI 950 AM BREAK 1010 AM RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR 2 TESTING IN BREAST CANCER M. Elizabeth Hammond MD LDS Hospital Salt Lake City UT 1040 AM REVISION OF THE CAPIASLCAMP MOLECULAR TESTING GUIDELINE FOR LUNG CANCER BIOMARKERS Philip T. Cagle MD Houston Methodist Hospital Houston TX 1110 AM MOLECULAR MARKERS FOR THE EVALUATION OF COLORECTAL CANCER Stanley R. Hamilton MD MD Anderson Cancer Center Houston TX COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201652 HANS POPPER HEPATOPATHOLOGY SOCIETY Liver Pathology 2016 New Perspectives on Old Themes SUNDAY MARCH 13 2016 830 AM 1200 PM CC BALLROOM 6E MODERATOR M. Isabel Fiel MD Icahn School of Medicine at Mount Sinai New York NY COURSE DESCRIPTION The topics were chosen in order to update the audience on issues pertinent to both the practicing general pathologist and liver pathology subspecialists alike. The presentations will cover drug-induced liver injury and the histological features that a pathologist needs to be aware of when confronted with a liver biopsy the newly-described entity atypical hepatocellular lesions and how these are managed as well as an update on metabolic liver diseases with a focus on how these diseases present in adults. Additional lectures will cover recent developments in primary biliary cholangitis and primary sclerosing cholangitis a presentation on the overlap syndromes of primary biliary cirrhosis and autoimmune hepatitis and primary sclerosing cholangitis and autoimmune hepatitis with the nal presentation being on pre-neoplastic lesions of the biliary tree and what is recently known. Upon completion of this educational activity participants should be able to Understand what the pathologist needs to know regarding drug-induced liver injury DILI and to summarize the role of the pathologist in diagnosing and helping manage a patient with DILI Discuss the histological features of atypical hepatocellular lesions and the approach to their diagnosis and management Review the different metabolic liver diseases that may present in adults with emphasis on the lesser known entities Explain what is new on primary biliary cholangitis PBC and primary sclerosing cholangitis PSC Discuss what is known about overlap syndromes of PBC and autoimmune hepatitis as well as PSC and autoimmune hepatitis Discuss what is known about novel ndings of pre-neoplastic lesions in the biliary tree 830 AM MEETING CALL TO ORDER AND INTRODUCTORY REMARKS M. Isabel Fiel MD Icahn School of Medicine at Mount Sinai New York NY 835 AM DRUG-INDUCED LIVER INJURY ROLE OF THE PATHOLOGIST Romil Saxena MBBS FRCPath Indiana University Indianapolis IN 900 AM ATYPICAL WELL-DIFFERENTIATED HEPATOCELLULAR NEOPLASMS CRUISING THROUGH THE MAZE OF CRITERIA TERMINOLOGY AND RISK ASSESSMENT Sanjay Kakar MD University of California San Francisco CA 925 AM ADULT PRESENTATION OF METABOLIC LIVER DISEASES John Hart MD University of Chicago Chicago IL 950 AM PANEL QUESTIONS AND ANSWERS 1000 AM COFFEE BREAK 1030 AM PRIMARY BILIARY CHOLANGITIS AND PRIMARY SCLEROSING CHOLANGITIS REVISITED Marcela Salomao MD Columbia University Medical Center New York NY 1055 AM THE OVERLAP SYNDROMES DO THEY EXIST Kay Washington MD PhD Vanderbilt University Medical Center Nashville TN 1120 AM PRE-INVASIVE NEOPLASIA OF THE BILIARY TRACT N. Volkan Adsay MD Emory University Hospital Atlanta GA 1145 AM PANEL QUESTIONS AND ANSWERS NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 53 RENAL PATHOLOGY SOCIETY Recently Described Entities in Nephropathology SUNDAY MARCH 13 2016 830 AM 1200 PM CC 606 607 MODERATORS Samih Nasr MD Mayo Clinic Rochester MN Jeffrey Hodgin MD PhD University of Michigan Ann Arbor MI COURSE DESCRIPTION Over the past few years several novel entities in renal ptvathology have been described. Warfarin nephropathy is a recently recognized complication of warfarin anticoagulation that can result in acute kidney injury. Membranous-like glomerulopathy with masked IgG kappa deposits is a newly described lesion in which antigen retrieval on formalin-xed parafn-embedded tissue is required to detect the monoclonal immunoglobulin by immunouorescence. This lesion is clinically distinct from other glomerulopathies with non-organized monoclonal IgG deposits and typically occurs in young adults who have clinical evidence of autoimmune phenomenon. Mesoamerican nephropathy is a primary tubulointerstitial disease occurring with increasing frequency in Central America. It mainly affects men working in hot conditions in agricultural communities particularly workers in sugar cane elds and may represent a form of chronic dehydration renal disease. Acute kidney injury in the context of liver disease is mainly described as a hemodynamic phenomenon hepatorenal syndrome. However recent studies have shed light into an obstructive role of bile in distal tubules. The term bile cast nephropathy is recently introduced to describe the spectrum of pathologic ndings in patients with bile nephrosis. Upon completion of this educational activity participants should be able to Describe the risk factors clinicopathologic characteristics and pathophysiology of Warfarin nephropathy Describe the clinicopathologic characteristics of membranous-like glomerulopathy with masked IgG kappa deposits and the indications for parafn immunouorescence in the detection of masked monoclonal immunoglobulin deposits Recognize the emerging epidemic of mesoamerican nephropathy and recognize the renal biopsy ndings in this condition Describe the pathologic ndings and pathomechanisms of bile cast nephropathy 830 AM WARFARIN NEPHROPATHY Sergey V. Brodsky MD PhD The Ohio State University Columbus OH 915 AM MEMBRANOUS-LIKE GLOMERULOPATHY WITH MASKED IGG KAPPA DEPOSITS Chris Larsen MD NephroPath Little Rock AR 1000 AM BREAK 1030 AM MESOAMERICAN NEPHROPATHY Annika Wernerson MD Department of Clinical Science Intervention and Technology Stockholm Sweden 1115 AM BILE CAST NEPHROPATHY Anthony Chang MD FASN University of Chicago Medical Center Chicago IL COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201654 SOCIETY FOR CARDIOVASCULAR PATHOLOGY Advances in the Autopsy Assessment of Sudden Cardiac Death SUNDAY MARCH 13 2016 830 AM 1200 PM CC 608 609 MODERATORS James R. Stone MD PhD Massachusetts General Hospital Boston MA Cristina Basso MD PhD University of Padua Padova Italy COURSE DESCRIPTION Cardiovascular diseases remain a signicant cause of morbidity and mortality in developed countries. Sudden unexpected cardiac death is particularly devastating as it often involves people otherwise thought to be relatively healthy. These cases are routinely encountered by autopsy and forensic pathologists. This session will update the audience on the latest developments in the eld including instructions for doing autopsies on these cases and updates on the utility of molecular approaches to ascertain a genetic diagnosis. Information gained from such cases can have a signicant impact on living family members and on furthering our understanding of these diseases. The session will be capped by Dr. Jeffrey Saftz the recipient of the SCVP Distinguished Achievement Award speaking on the anatomic pathology of sudden cardiac death. In addition there will be a portion of the session devoted to short presentations by a selected subset of young investigators who have submitted heart- and vessel-oriented posters to USCAP. This will provide an important opportunity to develop and build fellowship amongst junior and senior members of USCAP with an interest in cardiovascular pathology. Moreover the brief presentations will allow for a fairer judging of posters being considered for award of the SCVP Young Investigator prize with excellent feedback from an increased number of cardiovascular pathologists at the meeting. Upon completion of this activity participants should be able to Describe the approach to investigate sudden unexpected death at autopsy Describe the sudden death in the young registry and how to utilize this registry Describe cardiac conditions that can result in sudden unexpected death Describe cardiac conditions for which molecular analyses may be useful at autopsy 830 AM THE SUDDEN DEATH IN THE YOUNG REGISTRY A RESOURCE FOR MEDICAL EXAMINERS CORONERS PATHOLOGISTS RESEARCHERS Sam P. Gulino MD City of Philadelphia Medical Examiners Ofce Philadelphia PA 900 AM SUDDEN UNEXPLAINED DEATH THE MOLECULAR AUTOPSY AND GENETIC PURGATORY Michael J. Ackerman MD PhD Mayo Clinic Rochester MN 930 AM MOLECULAR INVESTIGATION OF SUDDEN CARDIAC DEATH THE NEW YORK EXPERIENCE Barbara Sampson MD PhD Ofce of Chief Medical Examiner of the City of New York New York NY 1000 AM BREAK 1030 AM YOUNG INVESTIGATOR PRESENTATIONS 1100 AM THE ANATOMIC PATHOLOGY OF SUDDEN CARDIAC DEATH Jeffrey E. Saftz MD PhD Beth Israel Deaconess Medical Center Harvard Medical School Boston MA NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 55 SOCIETY FOR ULTRASTRUCTURAL PATHOLOGY Small Blue Cell Tumors SUNDAY MARCH 13 2016 830 AM 1200 PM CC 605 MODERATOR Guillermo A. Herrera MD LSU Health Shreveport LA COURSE DESCRIPTION The topic of this years meeting was determined by the Society for Ultrastructural Pathology Board of Directors. Open deliberation of its members concluded this was a timely topic to address at the USCAP. Topic was chosen as this group of tumors often requires the use of various techniques for their speciation. The value of the use of ancillary diagnostic techniques including electron microscopy in the diagnosis of this group of neoplasms is well recognized. Ultrastructural pathology plays a key role in the diagnosis of small blue cell tumors. The target audience includes general surgical pathologists trainees academic pathologists and ultrastructural pathologists and techniciansscientists who engage in diagnostic transmission electron microscopy. Upon completion of this educational activity participants should be able to Dene role of ancillary diagnostic techniques in the diagnosis of small blue cell tumors in different sites Address the specic role of electron microscopy in todays healthcare environment in the evaluationclassication of these neoplasms Emphasize the important complementary role of ancillary diagnostic techniques in the evaluationdiagnosis of small blue cell tumors in children and adults and in cytopathology specimens Evaluate cost-efcient use of ancillary diagnostic techniques when confronted with small blue cell tumors 830 AM SMALL BLUE CELL TUMORS IN THE LUNG Victor Roggli MD Duke University Medical Center Durham NC 915 AM SMALL BLUE CELL TUMORS IN CHILDREN John Hicks MD PhD Texas Childrens Hospital Houston TX 1000 AM BREAK 1030 AM CYTOLOGY OF SMALL BLUE CELL TUMORS Elba A. Turbat-Herrera MD LSU Health Shreveport LA 1115 AM SMALL BLUE CELL TUMORS IN SOFT TISSUE AND BONE Cyril Fisher MD DSc FRCPath Sarcoma Unit Royal Marsden Hospital London England COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201656 AMERICAN ASSOCIATION OF OCULAR ONCOLOGISTS AND PATHOLOGISTS Pathology of the Orbit Current Diagnostic Approach SUNDAY MARCH 13 2016 130 PM 500 PM CC 605 MODERATOR Patricia Chevez-Barrios MD The Houston Methodist Hospital Houston TX COURSE DESCRIPTION The topics are determined by a USCAP companion committee in our society that is formed by three members. The current topic of orbital and lacrimal gland pathology was selected because this is a frequent type of pathology encountered that is challenging for those not used to see these lesions. This topic has not been selected before for the companion meeting. The target audience is surgical pathologists dermatopathologists and neuropathologists that usually sign out cases from these areas. It is also targeted to residents and fellows. Upon completion of this activity participants should be better able to Describe the importance of recognizing the most frequent pathologic diseases by location in the orbit Describe the most frequent differential diagnosis in orbital pathology Describe the impact of appropriate diagnosis in management of orbital tumors Describe the indications for frozen sections ow cytometry and other molecular tests in orbital pathology 130 PM INTRODUCTION TO ORBIT AND ORBITAL BIOPSY Patricia Chevez-Barrios MD The Houston Methodist Hospital Houston TX 150 PM INFLAMMATORY AND BENIGN ORBITAL LESIONS Diva Salomao MD Mayo Clinic College of Medicine Rochester MN 235 PM BREAK 305 PM BONE AND ORBITAL WALL LESIONS Tatyana Milman MD University of Pennsylvania Philadelphia PA 350 PM PRIMARY ORBITAL TUMORS Sander Dubovy MD University of Miami Miami FL 435 PM QUESTIONS AND ANSWERS Patricia Chevez-Barrios MD The Houston Methodist Hospital Houston TX NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 57 AMERICAN SOCIETY FOR CLINICAL PATHOLOGY ASCP IN COLLABORATION WITH THE AMERICAN PATHOLOGY FOUNDATION APF Improving Diagnosis in Pathology The IOM Report Safety Culture Teamwork Effective Communication and More SUNDAY MARCH 13 2016 130 PM 500 PM CC 618 620 MODERATOR Omar Hameed MD FASCP Vanderbilt University Medical Center Nashville TN COURSE DESCRIPTION The recently released Improving Diagnosis in Health Care a continuation of the landmark Institute of Medicine reports To Err Is Human Building a Safer Health System 2000 outlines goals to reduce diagnostic error and improve diagnosis. Tom Gallagher a member of the IOM committee which wrote this report will discuss the report goals and their potential impact for pathologists. High reliability organizations HROs have systems in place that make them exceptionally consistent in accomplishing these goals and avoiding potentially catastrophic errors. Elements of HROs and include preoccupation with failure reluctance to simplify robust communication transparency and non-punitive response to error reporting. This course will discuss the goals outlined in the recent IOM report and their potential impact for pathologists introduce the concepts of HRO and safety culture and describe how different components were independently implemented in two large pathology labs almost 2500 miles apart. Upon completion of this educational activity participants should be better able to Discuss the recent IOM report Diagnosis in Health Care Dene High Reliability Organizations and identify the basic concepts of high reliability Recognize the importance of a positive safety culture teamwork and robust communication practices in improving outcomes in anatomic pathology Evaluate the safety culture in participant workplace using standardized tools Recognize barriers in discussing pathology errors Utilize gained knowledge to develop and implement plans for expanding high reliability in anatomic pathology 130 PM INTRODUCTION AND OVERVIEW Omar Hameed MD FASCP Vanderbilt University Medical Center Nashville TN 140 PM IMPROVING DIAGNOSIS IN HEALTH CARE IMPACT IN PATHOLOGY Thomas Gallagher MD University of Washington Seattle WA 240 PM BREAK 250 PM HIGH RELIABILITY PRACTICE AND SAFETY CULTURE Omar Hameed MD FASCP Vanderbilt University Medical Center Nashville TN 400 PM COMMUNICATING WITH COLLEAGUES TREATING CLINICIANS AND PATIENTS Suzanne Dintzis MD PhD University of Washington Seattle WA 445 PM PROGRAM WRAP-UPDISCUSSION COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201658 AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY The Pathologist and the Development of Targeted Therapies SUNDAY MARCH 13 2016 130 PM 500 PM CC 606 607 MODERATORS Maria J. Merino MD National Cancer Institute Bethesda MD Danny A. Milner MD MSc Brigham and Womens Hospital Boston MA Mark E. Sobel MD PhD American Society for Investigative Pathology Bethesda MD COURSE DESCRIPTION The integration of anatomic molecular and genomic pathology into surgical pathology practice is conspicuous in oncology where denition of molecular pathways important for specic tumors has enabled development of drugs and innovative immunological approaches to target these pathways and companion tests to predict which tumors are likely to respond to these targeted agents. The role of the surgical pathologist as part of the oncologic healthcare team is rapidly evolving. This session will focus on targeted therapies for melanoma and cancers of the brain breast and lung. Upon completion of this activity participants should be better able to Describe the new morphologic and molecular classication scheme of gliomas Describe approaches to cancer immunotherapies Describe immune targeting in breast cancer Describe the evolving molecular classication of lung cancer 130 PM INTRODUCTION TO THE ASIP COMPANION MEETING Mark E. Sobel MD PhD American Society for Investigative Pathology Bethesda MD 135 PM INTEGRATED MORPHOLOGIC AND MOLECULAR GLIOMA DIAGNOSTICS BASED ON THE 2016 WHO CLASSIFICATION SCHEME Arie Perry MD University of California San Francisco CA 215 PM CANCER IMMUNOTHERAPY THE ROLE OF THE PATHOLOGIST IN THE ONCOLOGY TEAM James C. Yang MD National Cancer Institute Bethesda MD 300 PM BREAK 330 PM IMMUNE TARGETING IN BREAST CANCER Ashley Cimino-Mathews MD The Johns Hopkins Hospital Baltimore MD 415 PM BENCHTOP TO BEDSIDE EVOLUTION OF MOLECULAR CLASSIFICATION OF LUNG CANCER Neal Lindeman MD Brigham and Womens Hospital Boston MA NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 59 RODGER C. HAGGITT GASTROINTESTINAL PATHOLOGY SOCIETY Genetic Mechanisms Underlying Gastrointestinal Diseases New Developments for the Surgical Pathologist SUNDAY MARCH 13 2016 130 PM 500 PM CC BALLROOM 6 BC MODERATOR John Hart MD University of Chicago Chicago IL COURSE DESCRIPTION The mission of the Rodger C. Haggitt Gastrointestinal Pathology Society is to emphasize the importance of gastrointestinal pathology as a sophisticated and complex area of pathology. The Education Committee in consultation with Society ofcers determined the title contents and speakers of this companion meeting. The topics chosen address new advances in our understanding of the genetic alterations that underlie a variety of gastrointestinal disorders. The program will emphasize the role of the surgical pathologist in the proper workup and reporting of these disease states with an emphasis on the facets of most importance in proper patient management. In the era of personalized medicine the utility of an understanding of the genetic pathogenesis of gastrointestinal tumorigenesis is essential to improving patient prognosis. Upon completion of this education activity participants should be able to Use new histologic features and molecular testing to aid in the diagnosis of rare gastrointestinal polyposis syndromes Identify the recently recognized hereditary forms of gastric cancer Understand the molecular alterations that are useful in the diagnosis and management of patients with pancreatic cancer Understand how molecular analysis contributes to the proper diagnosis and management of gastrointestinal stromal tumors Become familiar with the recently opened NCI MATCH Trial as it pertains to gastrointestinal tumors and the role of pathologists in the initiative 130 PM INTRODUCTION 135 PM THE ROLE OF THE SURGICAL PATHOLOGIST IN THE DIAGNOSIS OF RARE POLYPOSIS SYNDROMES Christophe Rosty MD University of Queensland Queensland Australia 205 PM HEREDITARY GASTRIC CANCER SYNDROMES Maria Fatima Carneiro MD PhD Institute of Molecular Pathology and Immunology University of Porto Porto Portugal 235 PM NEW DEVELOPMENTS IN THE MOLECULAR MECHANISMS IMPORTANT IN PANCREATIC CANCER PATHOGENESIS Ralph H. Hruban MD The Johns Hopkins Hospital Baltimore MD 300 PM BREAK 330 PM GENETIC ALTERATIONS IN GASTROINTESTINAL STROMAL TUMORS IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT Christopher Corless MD PhD Oregon Health Science University Portland OR 400 PM RODGER C. HAGGITT MEMORIAL LECTURE THE NCI MATCH INITIATIVE AND THE ROLE OF THE GI PATHOLOGIST IN ONCOLOGIC MANAGEMENT Stanley R. Hamilton MD The University of Texas MD Anderson Cancer Center Houston TX COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201660 INTERNATIONAL SOCIETY OF BONE AND SOFT TISSUE PATHOLOGY The Evolving Concepts of Mesenchymal Tumor SUNDAY MARCH 13 2016 130 PM 500 PM CC 608 609 MODERATORS Jean-Michel Coindre MD Institut Bergoni Bordeaux France Cristina R. Antonescu MD Memorial Sloan-Kettering Center New York NY COURSE DESCRIPTION The symposium theme and content is selected by the President with input from the Societys executive ofcers of the International Society of Bone and Soft Tissue Pathology. The agenda has been designed to meet the educational needs of general surgical pathologists as well as bone and soft tissue tumor subspecialists who are involved in the management of patients with mesenchymal neoplasms. During the last 20 years the classication of mesenchymal neoplasms has witnessed striking transformation. In this companion meeting the evolution of concepts regarding important mesenchymal tumor families is emphasized concurrent with new developments and application particularly in molecular biology. Upon completion of this activity participants should be better able to Understand important concepts regarding mesenchymal tumor families Recognize recent developments in genomic mechanisms in soft tissue and bone tumors Describe the role of biomarkers in the diagnostic classication and management of soft tissue and bone tumors Associate morphologic variants with specic genetic changes 130 PM OPENING REMARKS Jean-Michel Coindre MD Institut Bergoni Bordeaux France 135 PM MDM2 AMPLIFIED SARCOMAS Raf Sciot MD KU Leuven Leuven Belgium 205 PM GIST FROM LEIOMYOBLASTOMA TO WILD TYPE GIST Markku M. Miettinen MD National Cancer Institute Bethesda MD 235 PM EWING AND EWING-LIKE SARCOMAS Cristina R. Antonescu MD Memorial Sloan-Kettering Cancer Center New York NY 305 PM BREAK 330 PM SWISNF DEPENDENT TUMORS Francois Le Loarer MD Centre Leon Berard Lyon France 400 PM ALK FUSION POSITIVE MESENCHYMAL TUMORS Jason L. Hornick MD Brigham and Womens Hospital Boston MA 430 PM CONCLUDING REMARKS Cristina R. Antonescu MD Memorial Sloan-Kettering Cancer Center New York NY NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 61 NORTH AMERICAN SOCIETY OF HEAD NECK PATHOLOGY Genodermatoses Affecting the Skin Mucosa of the Head Neck Clinicopathologic Genetic Molecular Aspects SUNDAY MARCH 13 2016 130 PM 500 PM CC 615 617 MODERATOR Mark R. Wick MD University of Virginia Health System Charlottesville VA COURSE DESCRIPTION Head and neck pathology is complex with numerous different tissue types and lesions occurring in a myriad of different forms arising from mucosal surfaces salivary glands soft tissue and bone thyroid parathyroid glands lymph nodes and skin. Further with the advances in molecular medicine which is delineating the molecular basis of many tumor types and genetic syndromes practicing pathologists must stay up to date on pathology of many different types and the manifestations and diagnostic features of common and uncommon genetic syndromes. This program will provide in depth information on several important genodermatoses affecting the head and neck. Upon completion of this educational activity participants should be better able to Enumerate the clinicopathologic components of Gorlin syndrome Discuss the similarities and differences of pathologic entities encompassed by the Brooke-Spiegler syndrome Identify tissues besides the skin that are affected by the PTEN syndrome Outline the current diagnostic approach to diagnosis of the MEN2b syndrome Describe the component lesions and evolution of the xeroderma pigmentosum syndrome 130 PM INTRODUCTION Mark R. Wick MD University of Virginia Health System Charlottesville VA 140 PM BASAL CELL-NEVUS GORLIN SYNDROME Scott Granter MD Brigham and Womens Hospital Boston MA 210 PM BROOKE-SPIEGLER SYNDROME Dmitry Kazakov MD Charles University Czech Republic 240 PM COWDEN-PTEN SYNDROME Vania Nose MD PhD Massachusetts General Hospital Boston MA 310 PM BREAK 330 PM MULTIPLE ENDOCRINE NEOPLASIA TYPE IIB Peter M. Sadow MD PhD Massachusetts General Hospital Boston MA 400 PM XERODERMA PIGMENTOSUM SYNDROME Jennifer Black MD Childrens Hospital of Colorado Aurora CO COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201662 PALEOPATHOLOGY CLUB Paleopathology Around the Globe SUNDAY MARCH 13 2016 130 PM 300 PM CC 602 604 MODERATORS Enrique Gerszten MD Virginia Commonwealth University Medical College of Virginia Campus Richmond VA Pedro L. Fernndez MD PhD Hospital Clinic and University of Barcelona Barcelona Spain COURSE DESCRIPTION Paleopathology has a close relation with the history of medicine. This symposium focuses on the use of modern techniques available to determine the diseases of the past. The topics were suggested by members of the Paleopathology Club and they were selected by the Chairmen of the Program. This symposium has been designed for Pathologists to learn about the diseases that were present in the antiquity in different areas of the globe. Upon completion of this educational activity participants should be better able to Identify the diseases presented in the symposium Explain why some diseases in the antiquity have disappeared 130 PM BLACK DEATH AND WHITE PLAGUE IN AN ENGLISH MEDIEVAL CEMETERY Darlene A. Weston University of British Columbia Vancouver Canada 200 PM PALEOPATHOLOGY OF BONE-FORMING CONDITIONS INDICATORS OF CULTURE AND THE ENVIRONMENT Cynthia A. Wilczak San Francisco State University San Francisco CA 230 PM KUKU AND PIGBEL DISEASES THAT HAVE DISAPPEARED FROM PAPUA NEW GUINEA Robin A. Cooke MD University of Queensland Brisbane Australia NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 63 SOCIETY FOR HEMATOPATHOLOGY Current Concepts in Aggressive B-Cell LeukemiaLymphoma SUNDAY MARCH 13 2016 130 PM 500 PM CC BALLROOM 6A MODERATORS Eric Hsi MD Cleveland Clinic Cleveland OH John Choi MD PhD St. Jude Childrens Research Hospital Memphis TN COURSE DESCRIPTION The Society for Hematopathology SH Ofcers and Executive Committee deliberated extensively on the selection of the 2016 USCAPSH Companion Meeting topic and assessed need through review of prior topics input for surveys and discussions with the SH membership and consideration of current progress in the eld to include projected updates in the WHO Classication for Hematolymphoid Neoplasms. This session will bring experts in the diagnosis classication and treatment of B lymphoid malignancies. Aggressive B-cell Neoplasms are among the most common types of B-cell neoplasms in the adult Diffuse Large B-cell Lymphoma not otherwise specied DLBCL Nos and pediatric populations B-cell Acute Lymphoblastic Leukemia B-ALL. Our understanding of the biology molecular sub-classication and clinical features of the diffuse aggressive B-cell lymphomas has advanced since the 2008 WHO Classication such that pathologists must be able to accurately diagnosis and assess molecular biomarkers so that clinicians can appropriately risk stratify and manage patients. Likewise diagnosis molecular characterization and disease monitoring for B-ALL has evolved beyond routine morphologic phenotypic and cytogenetic classications. Six lectures by authorities in the eld discuss the latest advances in EBV B-cell lymphomas Dr. Natkunam diagnosis of DLBCL Nos and their related diffuse aggressive B-cell lymphomas Dr. Medeiros biomarker assessment for DLBCL nos Dr. Rimsza and treatment of diffuse aggressive B-cell lymphomas Dr. Leonard. These will be followed by a review of the advances in the molecular genetic classication Dr. Mullighan and diagnosismonitoring Dr. Wood of patients with B-ALL. This balanced program addresses both lymph node and bone marrow topics that pathologists may face in daily practice. This activity has been designed to meet the educational needs of pathologists pathology trainees and other health care professionals who are involved in diagnosis and management of patients with aggressive B-cell leukemias and lymphomas as well as researchers who investigate the mechanisms of these diseases. Upon completion of this educational activity participants should be able to Incorporate EBV B-cell lymphoproliferative disorders in the differential diagnostic considerations and workup of B-cell lymphomas and understand how to select appropriate immunophenotypic and molecular ancillary studies to support this spectrum of diagnoses Recognize morphologic variants and subtypes of diffuse large B-cell lymphoma recognized by the World Health Organization classication Describe the clinical signicance biology and methodologies for measuring DLBCL cell-of-origin oncogene and immunemicroenvironment biomarkers in order to provide precision healthcare for patients Describe how the diagnosis of DLBCL Nos and differentiation from other diffuse aggressive B-cell lymphomas informs prognosis risk stratication and treatment decisions. Participants will also become familiar with promising novel therapeutic options in these lymphomas Discuss the different types of next generation sequencing used to analyze cancer genomes understand the nature of genetic alterations contributing to the pathogenesis of high risk and relapsed B-ALL and describe the potential for clinical sequencing in the management of ALL Understand the application of modern laboratory testing to diagnose and monitor patients with B-ALL 130 PM THE SPECTRUM OF EBV B-CELL LYMPHOPROLIFERATIVE DISORDERS Yaso Natkunam MD PhD Stanford University School of Medicine Stanford CA 200 PM DIAGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA L. Jeffrey Medeiros MD MD Anderson Cancer Center Houston TX 230 PM DIFFUSE LARGE B-CELL LYMPHOMA BIOMARKERS FOR PRECISION HEALTHCARE Lisa M. Rimsza MD Mayo Clinic Phoenix AZ 300 PM BREAK 330 PM DLBCL NOS FROM THE CLINICIAN PERSPECTIVE John P. Leonard MD Weill Cornell Medical College New York NY 400 PM ADVANCES IN THE GENETICS OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Charles Mullighan MBBS MD St. Jude Childrens Research Hospital Memphis TN 430 PM DIAGNOSIS AND FOLLOW-UP OF B LYMPHOBLASTIC LEUKEMIA Brent L. Wood MD PhD Hematopathology Laboratory Seattle WA COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201664 INTERNATIONAL SOCIETY OF GYNECOLOGICAL PATHOLOGISTS Genetic Susceptibility Syndromes and Gynecological Neoplasia SUNDAY MARCH 13 2016 130 PM 500 PM CC BALLROOM 6 E MODERATOR Glenn McCluggage MD FRCPath The Royal Hospitals Belfast Ireland COURSE DESCRIPTION Advances in knowledge about genetic susceptibility disorders have expanded the spectrum of gynecologic malignancies associated with such syndromes. This has led to the generation of altered protocols for the processing and handling of gynecological specimens and inuences what additional studies need be performed to allow appropriate patient management. Pathologists need to be aware of these genetic associations to guide the clinician with respect to the choices and circumstances for genetic testing. Pathologists should have sufcient familiarity with these tests to avoid over-utilization and counsel clinicians on the implications of test results. This symposium aims to update the pathologist on recent advances in inherited and genetic susceptibility disorders affecting the female genital tract. Specically it will provide the pathologist with 1 an overview of the genetic susceptibility syndromes that predispose to neoplasms in the female genital tract 2 update pathologists on the associations of the various genetic syndromes in the female genital tract 3 advise on the use of immunohistochemistry and molecular PCR based testing in the setting of Lynch syndrome 4 update pathologists on the implications of BRCA mutations with respect to processing and diagnosis of gynecologic neoplasms and 5 introduce the pathologist to more recently described molecular signatures of mesenchymal and non-epithelial tumors of the female genital tract and advise on the importance of making these diagnoses. Practical approaches to addressing these issues will be highlighted using a case based format. Upon completion of this symposium participants should be better able to Describe the associations of the major gynecologic susceptibility disorders in the female genital tract in particular Lynch and BRCA associated Syndromes Describe tumor types and tumor characteristics which if present should result in reex implementation of additional testing either by immunohistochemistry or molecular methods to aid recognition of gynecologic susceptibility disorders Describe how patients at increased risk for hereditary breast and ovarian cancer HBOC can be identied at the time of diagnosis of their tub-ovarian carcinoma and managed appropriately Describe the rationale for suspecting a familial cancer syndrome when dealing with an apparently sporadic gynecologic tumor Identify the connections between pathology molecular genetics and oncology that are becoming increasingly relevant in oncological gynecological pathology practice Identify specic clinical scenarios in which PCR-based MLH1 methylation analysis and MSI analysis provides useful data beyond that which immunohistochemistry can provide Describe the characteristics of uterine mesenchymal tumors that should raise the possibility of a hereditary syndrome Implement a comprehensive and integrated reex biomarker driven approach to identify Lynch syndrome in patients with gynecologic malignancies 130 PM IDENTIFYING LYNCH SYNDROME IN PATIENTS WITH GYNECOLOGIC CANCERS ARRIVING WHERE WE STARTED Blaise Clark MD Toronto General Hospital Toronto Ontario Canada 200 PM HEREDITARY OVARIAN AND BREAST CANCER SYNDROME C. Blake Gilks MD Vancouver General Hospital Vancouver BC Canada 230 PM PATHOLOGICAL AND MOLECULAR FEATURES OF COWDEN AND PEUTZ-JEGHERS SYNDROME Xavier Matias-Guiu MD PhD Hospital Universitari Arnau de Vilanova de Lleida Lleida Spain SESSION 2 RARE GENETIC SUSCEPTIBILITY SYNDROMES AND GYNECOLOGICAL NEOPLASIA 330 PM ANNOUNCEMENTSAWARDS 335 PM IMPORTANCE OF PCR-BASED TUMOR TESTING IN THE EVALUATION OF LYNCH SYNDROME Russell Broaddus MD PhD MD Anderson Cancer Houston TX 355 PM BRAVE NEW GENOMIC WORLD DO WE STILL NEED CLINICAL CANCER GENETICISTS AND IF SO WHY Will Foulkes MBBS PhD Jewish General Hospital Montreal Quebec Canada 415 PM UTERINE MESENCHYMAL TUMORS HEREDITARY ASPECTS Karuna Garg MD University of California San Francisco CA 435 PM DICER1 AND SMARCA4 MUTATIONS IN OVARIAN NEOPLASIA RECENT DEVELOPMENTS Esther Oliva MD Harvard Medical School Massachusetts General Hospital Boston MA 455 PM ROUND TABLE QA NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 65 HISTORY OF PATHOLOGY SOCIETY Beginnings SUNDAY MARCH 13 2016 330 PM 500 PM CC 602 604 MODERATOR Stephen A. Geller MD Weill Cornell Medical College New York NY 330 PM TIME-TRAVELLING TO THE ORIGINS OF LUNG CANCER Anthony A. Gal MD Emory University School of Medicine Atlanta GA 400 PM ALFREDS MORGAGNI KLEMPERER CROHN DISEASE Stephen A. Geller MD Weill Cornell Medical College New York NY 430 PM HOW NEUROPATHOLOGIC OBSERVATIONS HAVE DETERMINED THE TREATMENT OF NEUROLOGIC DISEASES AN HISTORICAL PERSPECTIVE Harry Vinters MD David Geffen School of Medicine University of California Los Angeles CA COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201666 INTERNATIONAL SOCIETY OF BREAST PATHOLOGY Second Opinions and Diagnostic Concordance in Breast Pathology SUNDAY MARCH 13 2016 730 PM 1030 PM CC HALL 4 E MODERATORS Aysegul Sahin MD MD Anderson Cancer Center Houston TX Gelareh Farshid MD The University of Adelaide Australia COURSE DESCRIPTION The topics for the symposium were determined by the Executive Committee members of International Society of Breast Pathology after soliciting input from membership. Our needs assessment process was based on the evaluation of the current literature and feedback provided by audience participating in our prior companion symposiums. An accurate diagnosisclassication of breast lesions is essential to ensure that the patients receive the most effective treatment. Many Breast Cancer Advocacy groups have recommended that every patient with diagnosis of breast cancer should obtain second opinion on both diagnosispathology and on treatment choices. Obtaining second opinions is an established part of pathology practice and many healthcare institutions have implemented policies requiring them. Many hospitals in the United States mandate a second review of pathology slides from outside laboratories before surgical interventions or for all cancer diagnoses before treatment planning. Second opinions may also be important for high-risk non-malignant borderline breast lesions which have greater diagnostic disagreement than malignant lesions to assure that cancer is not misdiagnosed and assess patient risk for development of breast cancer to guide surveillance and risk reduction strategies. Although second opinions may improve diagnostic accuracy and the quality of patient care as well as provide opportunities to educate physicians policies and practices for obtaining second opinions are not well established. In this session a multidisciplinary panel of breast cancer experts will discuss importance and impact of pathology second opinions in breast cancer management. The purpose of the companion meeting is to inform the audience regarding the most recent changes in the practice of breast pathology. The current program will cover assessment of diagnostic accuracy of breast pathology and signicance of second opinions in breast pathology. Upon completion of this educational activity participants should be able to Discuss the clinical importance of prognostic and predictive factors in the classication of breast cancer and understand the technical issues that may cause diagnostic difculty Evaluate and articulate the responsibility of the pathologists to provide second opinions Identify common entities that may have borderline histopathologic ndings and subjective evaluations that may cause diagnostic discrepancies among different pathologists Summarize the clinical uses and limitations of second opinion in breast pathology 700 PM BUSINESS MEETING 720 PM INTRODUCTION AND PRESIDENTS REMARKS Ira Bleiweiss MD Mount Sinai Hospital New York NY 720 PM PRESENTATION OF TRAINEE AWARDS Puay Tan Hoon MD Singapore General Hospital Singapore 730 PM HOW GOOD ARE YOU AT BREAST PATHOLOGY LESSONS FROM THE UK EQA PROGRAM Ian O. Ellis MD University of Nottingham Nottingham England 800 PM BREAST CANCER DIAGNOSIS AND SURGICAL PATHOLOGY A CRITICAL GLOBAL ONCOLOGY ISSUE Benjamin O. Anderson MD University of Washington Seattle WA 830 PM DISCREPANT DIAGNOSES WHERES THE HARM Jean F. Simpson MD Breast Pathology Consultants Nashville TN 900 PM HOW ANCILLARY TECHNIQUES MAY BE UTILIZED TO IMPROVE DIAGNOSTIC ACCURACY IN BREAST PATHOLOGY Allen M. Gown MD PhenoPath Laboratories Seattle WA 930 PM QUESTIONS ANSWERS NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 67 AMERICAN SOCIETY FOR CYTOPATHOLOGY Everything That Shines Aint Always Gonna Be Gold - Insights into CytologyHistology Correlations SUNDAY MARCH 13 2016 730 PM 1030 PM CC BALLROOM 6 C MODERATOR Eva M. Wojcik MD Loyola University Medical Center Maywood IL COURSE DESCRIPTION The ASCs diverse membership shares a vision of education research and continuous improvement in the standards and quality of patient care. From the diverse membership the educational committees of the ASC determine a set of educational standards that guide the committees as to the educational needs of the cytopathology community. Evaluation of data from prior meetings and advances in medicine related to pathologycytopathology are important sources of information used by the education committees to plan ASC educational activities. The programs are reviewed and approved by the ASC Executive Board. Correlation of cytology ndings with histologic biopsies is essential for successful quality assuranceimprovement programs. Traditionally the diagnosis rendered on histologic specimens has been considered the gold standard against which cytologic interpretations are measured. In reality both types of material are often complementary and in many cases different features necessary to make a correct diagnosis are present only on one type of preparation. It is imperative to convey this information to clinicians who usually consider the results of histologic examination as nal. Currently with an explosion of personalized approach to diagnostic medicine less and less material is available for diagnostic purposes. It is important for pathologists to be comfortable with an evaluation of both cytology and histology specimens. It is essential to understand specic limitations for each type of specimens particularly in regards of how precise diagnosis can be made on cytology and small histological material. In addition it is important to realize that interpretation of adjuvant particularly immunohistochemical studies on cytology and histology material may be different. New classication systems and revision of the existing classication systems for surgical pathology diagnoses necessitate that the cytopathologist adapt accordingly their diagnostic terminology. It can be challenging when the revised surgical pathology terminology reclassies neoplasms previously diagnosed as malignant to now benign neoplasms--or the other way around. The question arises how to avoid over diagnosis of malignancy in thyroid FNA specimens if most cases of encapsulated follicular variant of papillary carcinoma of the thyroid are diagnosed as Non-invasive follicular thyroid neoplasm with papillary-like nuclear features NIFT. In few areas is ne needle aspiration as controversial as in the diagnosis and management of salivary gland lesions while some head and neck surgeons use it routinely others deny its usefulness. This may in part be due to a lack of a practical terminology and classication system for salivary gland aspirates that is useful for clinical decision-making. A new clinically-oriented classication system and reporting terminology specically geared to ne needle aspiration cytology are being proposed. Soft tissue tumors are the bane of both the surgical pathologist and the cytopathologist. An aspirate showing predominantly spindle cells inspires well-founded fear in most pathologists however once the initial angst is overcome careful review of the morphology coupled with judicious use of immunohistochemistry and molecular tests is frequently helpful to establish a diagnosis or at least give enough information to orient further management of the patient. Gynecologic cytopathology remains one of the most difcult areas of cytopathology. Cytology- histology correlation is a requirement. Many factors inuence this correlation. Some are intrinsic to colposcopy others relate to inter-observer variability and still others pertain to the approaches that can be taken at the time of biopsyLEEP sign out including ancillary testing. Together these approaches can serve to rene interpretations and possibly improve the correlation. Upon completion of this educational activity participants should be better able to Incorporate the new developments in thyroid pathology in their reporting of thyroid ne needle aspirates Understand the need and rationale of a new standardized cytology reporting of salivary gland ne needle aspirates Determine which types of specimens should be sent for molecular testing in lung and mediastinal biopsies and FNAs Use an algorithmic diagnostic approach to spindle cell aspirates and determine what ancillary tests should be used Understand the limitations of GYN cyto-histology correlations and practical approaches for improvement CONTINUED ON NEXT PAGE COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201668 AMERICAN SOCIETY FOR CYTOPATHOLOGY...CONTINUED Everything That Shines Aint Always Gonna Be Gold - Insights into CytologyHistology Correlations 730 PM WELCOME AND INTRODUCTION Eva M. Wojcik MD Loyola University Medical Center Maywood IL 745 PM THE NEW DIAGNOSTIC PARADIGMS IN THYROID SURGICAL PATHOLOGY AND EFFECTS ON REPORTING OF THYROID FINE-NEEDLE ASPIRATION SPECIMENS Zubair W. Baloch MD PhD University of Pennsylvania Perelman School of Medicine Philadelphia PA 810 PM TIME TO STANDARDIZE THE CYTOLOGY REPORTING OF SALIVARY GLANDS INTRODUCTION OF THE MILAN SYSTEM William Faquin MD PhD Massachusetts General Hospital Boston MA 835 PM IN AN ERA OF PERSONALIZED APPROACH TO LUNG CANCER WHICH TYPE OF SPECIMEN RULES SUPREME Swati Mehrotra MD Loyola University Medical Center Maywood IL 900 PM EVERYTHING IS SPINDLE HOW FAR CAN WE GO WITH LIMITED MATERIAL Paul Wakely Jr. MD The Ohio State University Wexner Medical Center Columbus OH 925 PM CYTOLOGYBIOPSYLEEP CORRELATION PRACTICAL CONSIDERATIONS AND APPROACHES Fadi W. Abdul-Karim MD Med Cleveland Clinic Cleveland OH 950 PM GLANDULAR LESIONS ON PAP STILL DIFFICULT AFTER ALL THESE YEARS Dina Mody MD The Methodist Hospital Houston TX 1015 PM QUESTIONS AND ANSWERS NEXTGENERATION LEARNING 2016 COMPANION SOCIETY MEETING 69 AMERICAN SOCIETY OF DERMATOPATHOLOGY Dermatopathology Insights from Pathology Consults Cases I Remember and Learned From SUNDAY MARCH 13 2016 730 PM 1030 PM CC 608 609 MODERATOR Meera Mahalingam MBBS PhD FRCPath VA Boston Healthcare System West Roxbury MA COURSE DESCRIPTION This activity has been designed to meet the educational needs of general pathologists both in private practice as well as in an academic setting. The purpose of this topic is to highlight entities that present a diagnostic conundrum for the general pathologist as well as the consultant dermatopathologists. Each dermatopathologist will present a minimum of ve cases received for consultation from a pathologist that were instructive. Cases discussed will encompass a spectrum of lineage-unrelated tumors as well as inammatory dermatoses. Relevance of clinicopathologic correlation as well as teaching pointstake home messages will be emphasized. Upon completion of this educational activity participants should be able to Select entities commonly encountered in daily practice that can present a diagnostic challenge for the pathologist as well as the dermatopathologist Utility of clinicopathologic correlation in dermatopathology Clues and confounding issues associated with a spectrum of lineage-unrelated tumors as well as inammatory dermatoses encountered by a general pathologist both in private practice as well as an academic setting 730 PM INTRODUCTION Meera Mahalingam MBBS PhD FRCPath Veteran Affairs Boston Healthcare System Veteran Affairs Medical Center West Roxbury MA 735 PM Asok Biswas MD FRCPath DipRCPath Western General Hospital Edinburgh UK 810 PM Mai Hoang MD Harvard Medical School Massachusetts General Hospital Boston MA 845 PM Rossitza Lazova MD Yale Dermatopathology Laboratory New Haven CT 920 PM Meera Mahalingam MBBS PhD FRCPath Veteran Affairs Boston Healthcare System Veteran Affairs Medical Center West Roxbury MA 1000 PM Rajendra Singh MD Icahn School of Medicine at Mount Sinai New York NY COMPANION SOCIETY MEETING NEXTGENERATION LEARNING201670 ASSOCIATION FOR MOLECULAR PATHOLOGY Implementing Molecular Testing to Make Treatment Decisions SUNDAY MARCH 13 2016 730 PM 1030 PM CC BALLROOM 6 E MODERATORS Eric Duncavage MD Washington University School of Medicine St. Louis MO James R. Cook MD PhD Cleveland Clinic Cleveland OH COURSE DESCRIPTION In order to fully realize the goals of precision medicine in cancer accurate methods are needed to gauge treatment response and monitor for cancer recurrence and progression. In the last several years next generation sequencing NGS approaches have provided us with an unprecedented view of cancer genomics and have identied several key genes involved in cancer pathogenesis. Clinical sequencing-based cancer gene panels are now being adopted in the routine evaluation of many cancer types. While such panels can be used to identify therapeutic targets and stratify risk when performed on the initial primary tumor sequencing across serial time points can provide additional prognostic information and may be used to monitor cancer patients over time to determine the efcacy of a particular treatment and the extent to which a tumor is cleared. This companion meeting will focus on recent advances and future applications for the use of sequencing-based technologies to monitor tumor burden in hematologic malignancies and solid tumors. Upon completion of this educational activity participants should be better able to Identify key methodological approaches and challenges in sequencing-based tumor burden monitoring Compare the major advantages of multi time point tumor burden monitoring over current single time point cancer panels to predict patient outcome Describe how tumor burden monitoring is now being applied in the research setting and the impact of incomplete molecular disease clearance in leukemia Recognize new concepts and challenges in solid tumor monitoring including cell free DNA and liquid biopsy applications 730 PM NEW INSIGHTS INTO MOLECULAR MONITORING IN CANCER Eric J. Duncavage MD Washington University School of Medicine St. Louis MO 745 PM MOLECULAR MONITORING IN AML CAN INFORM PROGNOSIS Jeffery M. Klco MD PhD St. Jude Childrens Research Hospital St. Louis MO 820 PM CLINICAL APPLICATION OF NGS FOR MRD MONITORING IN LYMPHOID NEOPLASMS David Wu MD PhD University of Washington Seattle WA 855 PM CELL-FREE TUMOR DNA FOR CANCER MONITORING Christina Lockwood PhD DABCC FACB University of Washington Seattle WA 930 PM SUMMARY OVERVIEW James Cook MD PhD Cleveland Clinic Cleveland OH 1000 PM QUESTIONS AND ANSWERS 2016 NEXTGENERATION LEARNING SPECIALTY CONFERENCES Visit Us Online for More Information www.USCAPInteractiveCenter.org OPENING SPRING 2016 Broadcast television studio and conference theater Real-time broadcasting for global educational outreach Unites pathologists world-wide with live courses at the Powers-Sanchez Interactive Center for interactive discussions Digital asset productions targeted to global outreach particularly in low-resource countries USCAP is Building its Future and Yours Linder Learning Center NEXTGENERATION LEARNING 2016 EVENING SPECIALTY CONFERENCES 71 GYNECOLOGIC PATHOLOGY Problematic Topics in Gynecologic Pathology Gestational Trophoblastic Disease Metastases Mimicking Primary Tumors and Other Challenges SUNDAY MARCH 13 2016 730 PM-930 PM CC BALLROOM 6 B MODERATOR Robert Soslow MD Memorial Sloan Kettering Cancer Center New York NY PANELISTS Bojana Djordjevic MD University of Ottawa Ottawa ON Matthew Cesari MD Sunnybrook Health Sciences Centre Toronto ON Elizabeth Euscher MD MD Anderson Cancer Center Houston TX Anais Malpica MD MD Anderson Cancer Center Houston TX Upon completion of this educational activity participants should be able to Recognize some uncommonly encountered pelvic tumors that feature in the differential diagnosis with primary gynecologic malignancies Become familiar with situations in which one should consider an extra-gynecologic cancer in the differential diagnosis Become familiar with some unusual manifestations of gestational trophoblastic disease PULMONARY PATHOLOGY I Finally Learned Something New SUNDAY MARCH 13 2016 730 PM- 930 PM CC BALLROOM 6 A MODERATOR Sanja Dacic MD PhD University of Pittsburgh Medical Center Center Pittsburgh PA PANELISTS E. Handan Zeren MD Acibadem University School of Medicine Istanbul Turkey Lucian Chirieac MD Brigham and Womens Hospital Harvard Medical School Boston MA Luka Brcic MD PhD Institute of Pathology Medical University of Graz Graz Austria Andrew Churg MD University of British Columbia Vancouver BC Andras Khoor MD PhD Mayo Clinic Florida Jacksonville FL Upon completion of this educational activity participants should be able to Recognize mimickers of idiopathic interstitial lung disease Understand signicance of diagnostic molecular testing Be aware of diagnostic limitations of small specimens EVENING SPECIALTY CONFERENCES NEXTGENERATION LEARNING201672 RENAL PATHOLOGY Talking Points in Renal Pathology SUNDAY MARCH 13 2016 730 PM-930 PM CC 615-617 MODERATOR Vanesa Bijol MD Brigham and Womens Hospital Boston MA Tibor Nadasdy MD The Ohio State University Columbus OH PANELISTS Erika Bracamonte MD University of Arizona Medical Center Tucson AZ Anthony Chang MD University of Chicago Medicine Chicago IL Lynn Cornell MD Mayo Clinic Rochester MN Charles J. Jennette MD University of North Carolina at Chapel Hill Chapel Hill NC Ivy A. Rosales MD Massachusetts General Hospital Boston MA Upon completion of this educational activity participants should be able to Work up the renal biopsy cases to the highest standard of practice based on clinical presentation of individual patients Demonstrate the ability to identify and explain the etiology pathogenesis relevant investigations and the differential diagnosis of discussed entities Correlate the important clinical features of the disease with the pathologic changes PEDIATRIC PATHOLOGY Enteropathies of Infancy and Childhood SUNDAY MARCH 13 2016 730 PM- 930 PM CC 606-607 MODERATOR Kyle Kurek MD Alberta Childrens Hospital and University of Calgary Calgary AB Canada Megan K. Dishop MD Childrens Hospitals and Clinics of Minnesota Minneapolis-St. Paul MN PANELISTS Jeffrey Goldsmith MD Beth Israel Deaconess Medical Center and Childrens Hospital Boston MA Marie-Anne Brundler MD CLSAlberta Childrens Hospital AB Canada Sarangarajan Ranganathan MD Childrens Hospital of Pittsburgh of UPMC Pittsburgh PA Pierre A. Russo MD Childrens Hospital of Philadelphia Philadelphia PA Upon completion of this educational activity participants should be able to Provide a differential diagnosis of inammatory enteropathies in the pediatric population Identify the histopathologic patterns associated with specic pediatric enteropathies Select ancillary studies which aid in the diagnosis of pediatric enteropathies List the known genetic determinants and syndromes associated with pediatric enteropathies NEXTGENERATION LEARNING 2016 EVENING SPECIALTY CONFERENCES 73 HOUSESTAFF Preparing for Life Beyond Residency SUNDAY MARCH 13 2016 730 PM- 930 PM CC 613-614 MODERATOR Barbara S. Ducatman MD West Virginia University School of Medicine Morgantown WV PANELISTS Kym Gyure MD West Virginia University Hospital Morgantown WV Melissa Upton MD University of Washington Seattle WA Ann Thor MD University of Colorado HSC Aurora CO Upon completion of this educational activity participants should be able to Identify and dene activities for immediate adoption during residency and fellowship to enhance their ability to obtain the fellowship andor jobs of their choice Dene those competencies skills and abilities that fellowship directors and department chairs seek in hiring decisions Design and implement a ve to ten year career development plan OPHTHALMIC PATHOLOGY Ophthalmic Pathology Unexpected and Challenging Cases SUNDAY MARCH 13 2016 730 PM-930 PM CC 605 MODERATOR Patricia Chevez-Barrios MD Weill Cornell Medicine Houston Methodist Hospital Houston TX PANELISTS Sander Dubovy MD University of Miami Bascom Palmer Eye Institute Miami FL Diva Salomao MD Mayo Clinic Rochester MN Abelardo Rodriguez MD Hospital Luis Snchez Bulnes Mxico City Mxico Tatyana Milman MD Perelman School of Medicine University of Pennsylvania Philadelphia PA Upon completion of this educational activity participants should be able to Enumerate differential diagnosis of most common ocular and adnexal tumors List different histopathologic and molecular techniques to approach ocular specimens Correlate imaging ndings with histopathologic diagnosis EVENING SPECIALTY CONFERENCES NEXTGENERATION LEARNING201674 SURGICAL PATHOLOGY Beyond the HE Where Morphology Meets Molecular Maladies MONDAY MARCH 14 2016 730 PM-930 PM CC BALLROOM 6 ABC MODERATOR Kumarasen Cooper MBChB DPhil University of Pennsylvania Hospital Philadelphia PA PANELISTS Zubair Baloch MD Hospital of University of PA Philadelphia PA Abbas Agaimy MD Friedrich-Alexander University Erlangen-Nuremberg Erlangen Germany Runjan Chetty MBBCh University Health Network Toronto ON Canada Ondej Hes MD PhD Biopticka Laboratory Plzen Czech Republic Cristina Antonescu MD Memorial Sloan Kettering Cancer Center New York NY Upon completion of this educational activity participants should be able to Interpret and be aware of distinctive morphologies associated with unique molecular aberrations Understand complex diagnostic processes and differential diagnoses of certain hereditary syndromic tumors Appreciate the evolving molecular concepts as pertains to recently recognized entities CARDIOVASCULAR PATHOLOGY A Tale of Two Tickers Pre- and Post-Transplant Pathology MONDAY MARCH 14 2016 730 PM-930 PM CC BALLROOM 6E MODERATOR Robert F. Padera MD PhD Brigham and Womens Hospital Boston MA PANELISTS Elizabeth Pavlisko MD Duke University Medical Center Durham NC Frederick Schoen MD Brigham and Womens Hospital Boston MA Carmela Tan MD Cleveland Clinic Cleveland OH Karen Kelly MD East Carolina University Greenville NC Jon Kobashigawa MD Cedars-Sinai Medical Center Beverly Hills CA Upon completion of this educational activity participants should be able to Identify clinically important pathologies in native heart biopsies and explants Identify complications of mechanical circulatory support devices Identify clinically important pathologies in post-transplant biopsies Identify cardiovascular causes of death in heart transplant patients NEXTGENERATION LEARNING 2016 EVENING SPECIALTY CONFERENCES 75 INFECTIOUS DISEASE PATHOLOGY Pathogen Detection From Morphology to Molecular Testing MONDAY MARCH 14 2016 730 PM-930 PM CC 608-609 MODERATOR Atis Muehlenbachs MD PhD Centers for Disease Control and Prevention Atlanta GA PANELISTS Gary Procop MD Cleveland Clinic Cleveland OH Bobbi Pritt MD Mayo Clinic Rochester MN Steve Salipante MD PhD University of Washington Medical Center Seattle WA Sherif Zaki MD PhD Centers for Disease Control and Prevention Atlanta GA Upon completion of this educational activity participants should be able to Recognize the morphologic differential of selected infectious diseases the contribution of special stains and immunohistochemistry and when molecular tests are indicated to further characterize the organism Interpret molecular test results and their pitfalls for infectious disease diagnosis from pathology specimens Describe cutting edge molecular techniques for the diagnosis of infectious diseases in formalin-xed parafn-embedded tissues GENITOURINARY PATHOLOGY Uncommon Lesions with Papillary andor Cribriform Architecture TUESDAY MARCH 15 2016 730 PM-930 PM CC BALLROOM 6E MODERATOR Cristina Magi-Galluzzi MD PhD Cleveland Clinic and Lerner Research Institute Cleveland OH PANELISTS Elsa F. Velazquez MD Tufts University and Miraca Life Sciences Boston MA Christopher G. Przybycin MD Cleveland Clinic Cleveland OH L. Priya Kunju MD University of Michigan Ann Arbor MI Ming Zhou MD PhD New York University Medical Center New York NY Upon completion of this educational activity participants should be able to Familiarize with uncommon and recently described entities in genitourinary pathology Sharpen existing expertise and enhance the participants spectrum of professional competence Review pitfalls and pearls to pathologic diagnosis as well as an approach to ancillary diagnostic techniques EVENING SPECIALTY CONFERENCES NEXTGENERATION LEARNING201676 LIVER PATHOLOGY Secrets From the Consult Files Great Liver Cases with Key Teaching Points TUESDAY MARCH 15 2016 730 PM- 930 PM CC BALLROOM 6C MODERATOR Micheal Torbenson MD Mayo Clinic Rochester MN Rish Pai MD Mayo Clinic Scottsdale AZ PANELISTS Taoc Mounajjed MD Mayo Clinic Rochester MN Matthew M. Yeh MD PhD University of Washington Medical Center Seattle WA Cynthia D. Guy MD Duke University Medical Center Durham NC Maha Guindi MD Cedars-Sinai Medical Center Beverly Hills CA Andrew Clouston MD Envoi Pathology Kelvin Grove Australia Upon completion of this educational activity participants should be able to Integrate clinical information and laboratory testing into the interpretation of liver biopsy injury patterns Understand the appropriate approach for biopsies with fatty liver disease and elevated autoimmune markers Effectively use immunohistochemical stains when evaluating biopsies BONE AND SOFT TISSUE PATHOLOGY Recent Changes in my Bone and Soft Tissue Pathology Practice TUESDAY MARCH 15 2016 730 PM-930 PM CC BALLROOM 6A MODERATOR Jason L. Hornick MD PhD Brigham and Womens Hospital Boston MA PANELISTS Wei-Lien Billy Wang MD MD Anderson Cancer Center Houston TX Karen J. Fritchie MD Mayo Clinic Rochester MN Narasinham P. Agaram MBBS Memorial Sloan Kettering Cancer Center New York NY Abbas Agaimy MD University of Erlangen Erlangen Germany Sarah M. Dry MD University of California Los Angeles CA Upon completion of this educational activity participants should be able to Discuss recent updates in the diagnosis and classication of bone and soft tissue tumors Apply new immunohistochemical markers for differential diagnosis Interpret the results of molecular genetic ndings in the context of histology NEXTGENERATION LEARNING 2016 EVENING SPECIALTY CONFERENCES 77 HEAD NECK AND ENDOCRINE PATHOLOGY Emerging Molecular Findings and Interesting Cases in Head Neck and Endocrine Pathology TUESDAY MARCH 15 2016 730 PM-930 PM CC BALLROOM 6B MODERATOR Ilan Weinreb MD University Health Network Toronto ON PANELISTS Vickie Y. Jo MD Brigham and Womens Hospital Harvard Medical School Boston MA Lori A. Erickson MD Mayo Clinic Rochester MN Simon Chiosea MD University of Pittsburgh Medical Center Pittsburgh PA Alena Skalova MD PhD Charles University Faculty of Medicine Plzen Czech Republic Upon completion of this educational activity participants should be able to Appreciate new diagnostic entities in head and neck and endocrine pathology Help navigate the overlapping features of traditional head and neck and endocrine malignancies and their mimics Appreciate the role of diagnostic nuances on sub classication and reporting in head and neck and endocrine cancer HEMATOPATHOLOGY Current Controversies in Hematopathology WEDNESDAY MARCH 16 2016 730 PM- 930 PM CC BALLROOM 6A MODERATOR James R. Cook MD PhD Cleveland Clinic Cleveland OH Tracy George MD University of New Mexico Albuquerque NM PANELISTS Scott J. Rodig MD PhD Brigham and Womens Hospital Boston MA Andrew L. Feldman MD Mayo Clinic Rochester MN Yi-Hua Chen MD Northwestern University Chicago IL Sherrie Perkins MD PhD University of Utah Salt Lake City UT Upon completion of this educational activity participants should be able to Provide a differential diagnosis of hematopathology disorders based on select clinical and pathologic ndings Identify the key histopathologic features associated with specic hematopathology disorders Select ancillary studies that aid in determining the diagnosis for specic hematopathology disorders EVENING SPECIALTY CONFERENCES NEXTGENERATION LEARNING201678 CYTOPATHOLOGY New and Recent Developments in Cytopathology A Case Based Approach WEDNESDAY MARCH 16 2016 730 PM-930 PM CC BALLROOM 6B MODERATOR Dina Mody MD The Methodist Hospital Houston TX PANELISTS Charles Sturgis MD Cleveland Clinic Cleveland OH Sara Monaco MD UPMC Shadyside Hospital Pittsburgh PA Mary Schwartz MD Houston Methodist Houston TX Ron Balassanian MD University of California San Francisco CA Upon completion of this educational activity participants should be able to Understand challenges associated with diagnosing common and uncommon entities on cytology specimens Be familiar with new developments in classication schemes molecular testing and Immunohistochemical stains as they apply to cytology specimens Understand the benets and challenges associated with newer methods of obtaining cytology specimens and how to optimize the specimen for denitive diagnosis NEUROPATHOLOGY The Newly Updated WHO 2016 Blue Book WEDNESDAY MARCH 16 2016 730 PM- 930 PM CC BALLROOM 6C MODERATOR Arie Perry MD University of California San Francisco CA PANELISTS Cristina Antonescu MD Memorial Sloan Kettering Cancer Center New York NY Jason Huse MD PhD Memorial Sloan Kettering Cancer Center New York NY Tarik Tihan MD PhD University of California San Francisco San Francisco CA David Ellison MD PhD St. Jude Childrens Research Hospital Memphis TN Beatriz Lopes MD PhD University of Virginia Health System Charlottesville VA Upon completion of this educational activity participants should be able to Recognize new nervous system tumor entities in the WHO 2016 that incorporate not only morphologic but also molecular ndings into their denition Identify useful immunohistochemical surrogates that can be utilized to identify molecular subtypes in the WHO 2016 classication scheme Appreciate some of the molecular differences between common adult type and pediatric type brain tumor counterparts NEXTGENERATION LEARNING 2016 EVENING SPECIALTY CONFERENCES 79 GASTROINTESTINAL Coffee Talk A Blend of Cases in GI Pathology THURSDAY MARCH 17 2016 730 PM-930 PM CC BALLROOM E MODERATOR Alyssa Krasinskas MD Emory University Atlanta GA PANELISTS Wendy Frankel MD The Ohio State University Wexner Medical Center Columbus OH Olca Basturk MD Memorial Sloan Kettering Cancer Center New York NY Bastiaan de Boer MBBS BMedSci FRCPA PathWest QE II Medical Centre Nedlands Perth Western Australia Laura Lamps MD University of Arkansas for Medical Sciences Little Rock AR John Hart MD The University of Chicago Chicago IL Upon completion of this educational activity participants should be able to Include uncommon entities in the differential diagnosis of more common diseases of the GI tract Describe a new polyposis syndrome Recognize an uncommon intraepithelial neoplasm of the pancreas DERMATOPATHOLOGY I Cant Believe It Surprises In Dermatopathology THURSDAY MARCH 17 2016 730 PM-930 PM CC 611-612 MODERATOR Victor G. Prieto MD PhD University of Texas MD Anderson Cancer Center Houston TX PANELISTS Richard Danialan DO Tufts Medical Center Boston MA Thuy Phung MD PhD Baylor College of Medicine Houston TX Chandra Smart MD University of California Los Angeles CA Michael Tetzlaff MD University of Texas MD Anderson Cancer Center Houston TX Upon completion of this educational activity participants should be able to Utilize immunohistochemistry to help in the differential diagnosis of primary and metastatic lesions to the skin Distinguish histologically among the several cutaneous supercial neoplasms that display brohistiocytic lesions Determine the clinical and histologic features of internal neoplasms metastatic to the skin EVENING SPECIALTY CONFERENCES NEXTGENERATION LEARNING201680 BREAST PATHOLOGY Interesting Case Presentation THURSDAY MARCH 17 2016 730 PM-930 PM CC BALLROOM 6C MODERATOR Jean Simpson MD Breast Pathology Consultants Nashville TN PANELISTS Anna Marie Mulligan MB BCH MRCPath University of Toronto ON Xiaoxian Li MD Emory University Atlanta GA Benjamin Calhoun MD PhD Cleveland Clinic Cleveland OH Ian Ellis MD The University of Nottingham Nottingham England Deborah A. Dillon MD Brigham and Womens Hospital Boston MA Upon completion of this educational activity participants should be able to Recognize the salient diagnostic features of selected breast lesions Integrate the imaging and pathology ndings in the appropriate clinical context Recognize the clinical management implications 2016 NEXTGENERATION LEARNING SPECIAL COURSES www.USCAP.org 247 around-the-globe contact with the USCAP family on Twitter puts you in the NOW with flash ideas and info you need to be a better pathologist. Plus join us on Facebook Instagram and YouTube for even more interaction. Follow New Paths Yet Untraveled IAMUSCAP USCAP2016 IAMUSCAPIAMUSCAPIAMUSCAP IAMUSCAP IAMUSCAP IAMUSCAP IAMUSCAPIAMUSCAP IAMUSCAPIAMUSCAP IAMUSCAP IAMUSCAP IAMUSCAP USCAP2016 USCAP2016 USCAP2016USCAP2016 USCAP2016 USCAP2016 USCAP2016 NEXTGENERATION LEARNING 2016 SPECIAL COURSES 81 Residents Workshop Genomic Medicine for Pathologists What You Need to Know SATURDAY MARCH 12 2016 900 AM 500 PM CC 602 604 COURSE DIRECTOR Richard Haspel MD PhD Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA FACULTY Debra G.B. Leonard MD PhD University of Vermont College of Medicine Burlington VT Tamara Williams PhD University of Vermont College of Medicine Burlington VT COURSE DESCRIPTION Next-generation sequencing methods and multi-gene panels have entered clinical practice. Pathologists as directors of molecular pathology laboratories are already playing a leading role in applying genomic technology to patient care. Regardless of your planned specialty genomic pathology will become an important part of your career as a pathologist. Using a case-based interactive small-group approach workshop participants will learn principles related to the development of genomic assays and interpretation of results. The workshop will also include practical hands-on instruction with the use of online genomic pathology tools. The workshop was developed and will be led by members of the Training Resident in Genomics TRIG Working Group. Established in 2010 this group made up of experts in molecular pathology medical education and genetic counseling was formed to provide genomic pathology educational resources. The workshop will utilize a team-based learning approach. While there will be short lectures at the beginning and end of each session the majority of learning will take place in small resident teams with faculty support. Upon completion of this educational activity participants should be able to Determine the clinical signicance of genetic variants using online tools Describe the benets and limitations of integrative genomic analyses Describe the reporting issues related to genomic analyses 900 AM SESSION 1 SINGLE GENE TESTING Upon completion of this educational activity participants should be able to List the factors that go into the determination of who is an appropriate candidate for cancer susceptibility genetic testing Determine the clinical signicance of variant related to cancer susceptibility genetic testing with the use of online tools 1030 AM BREAK 1045 AM SESSION 2 PROGNOSTIC GENE-PANEL TESTING Upon completion of this educational activity participants should be able to Describe the role of pathologists in facilitating prognostic gene-panel testing Compare utility of prognostic gene-panel testing to histologic methods Interpret a prognostic gene panel report and consider important components to ensure appropriate interpretation by the ordering clinician Describe the process of selecting genes for expression proles for clinical use 1215 PM LUNCH 100 PM SESSION 3 DESIGN OF A MULTIGENE ASSAY CANCER GENE PANEL Upon completion of this educational activity participants should be able to Describe different methods for detecting DNA variants PCR vs. Sanger-based vs. NGS-based Determine the appropriate methodology for a selected gene panel Describe the factors that determine the utility of inclusion of a specic gene in a multigene assay in this case a cancer gene panel SPECIAL COURSES NEXTGENERATION LEARNING201682 230 PM BREAK 245 PM SESSION 4 WHOLE EXOME SEQUENCING Upon completion of this educational activity participants should be able to Describe key aspects of informed consent for genomic analyses Describe the benets and limitations of integrative genomic analyses for advanced cancer patients Describe the reporting issues related to unintended ndings Use online tools to interpret the clinical signicance of genomic data 415 PM WRAP-UPQUESTION AND ANSWER SESSION NEXTGENERATION LEARNING 2016 SPECIAL COURSES 83 Residents Workshop Leadership Collaboration and Change in Health Care Essential Skills SATURDAY MARCH 12 2016 1200 PM 600 PM CC 611 612 COURSE DIRECTORS Carol Farver MD MS Cleveland Clinic Cleveland OH Dani Zander MD Penn State Milton S. Hershey Medical Center Hershey PA James K. Stoller MD MS Cleveland Clinic Cleveland OH COURSE DESCRIPTION The delivery of health care in todays world is increasingly complex. Historically medical training has centered exclusively on developing clinical and research competence in the medical sciences. However as healthcare is being delivered more and more by integrated teams and organizations medical education must teach physicians core competencies of working in and leading healthcare organizations. This workshop is designed to educate residents in leadership collaboration and communication in healthcare organizations. The course syllabus and bibliography are developed from studies specic to the health care industry that focus on the role of leadership and the functioning of teams within healthcare organizations. The workshop will serve as an introduction to these concepts and an extensive bibliography for further reading will be provided. The curriculum will provide an opportunity for residents to undertake a guided exploration of the following areas of study The characteristics of effective leaders in health care Emotional intelligence Importance of mindful self-examination and mentoring in career success Dening strategies for advancing your professional goals The characteristics of effective teams and their importance in health care Models of organizational change Basic tools to manage conict 1200 PM SESSION 1 LEADERSHIP AND CHANGE IN HEALTH CARE THE TOOLS PHYSICIANS NEED TO LEAD Carol Farver MD MS Cleveland Clinic Cleveland OH James K. Stoller MD MS Clevelad Clinic Cleveland OH Upon completion of this educational activity participants should be able to Dene emotional intelligence and the evidence for its importance in leadership Discuss the important physician competencies needed to lead healthcare organizations Dene the models of organizational change Review examples of change management in health care organizations 115 PM SESSION 2 THE NEW PHYSICIAN LEADER GOING BEYOND SURVIVAL TO SUCCESS Dani Zander MD Penn State Milton S. Hershey Medical Center Hershey PA Upon completion of this educational activity participants should be able to Understand how mindful self-examination and mentorship contribute to professional development Describe strategies for advancing your professional goals in an organization 215 PM SESSION 3 BUILDING AN EFFECTIVE HEALTH CARE TEAM James K. Stoller MD MS Cleveland Clinic Cleveland OH Upon completion of this educational activity participants should be able to Review the importance of teams in health care Dene characteristics of effective health care teams Summarize and reect on ones own role in a team SPECIAL COURSES NEXTGENERATION LEARNING201684 430 PM SESSION 4 IDENTIFYING AND RESOLVING CONFLICT EFFECTIVE TOOLS FOR TOMORROWS LEADERS Carol Farver MD MS Cleveland Clinic Cleveland OH Upon completion of this educational activity participants should be able to Review the types of conict Complete a standard inventory on how one handles conict List tools for conict resolution Discuss case scenarios of conict that residents experience 530 PM WRAP-UP AND EVALUATIONS NEXTGENERATION LEARNING 2016 85 SPECIAL COURSES Clinical Application of Next Generation Sequencing for the Management of Patients with Solid Tumors MONDAY MARCH 14 2016 800 AM 1200 PM CC BALLROOM 6E COURSE DIRECTOR Jeffrey S. Ross MD Albany Medical Center Albany NY and Foundation Medicine Inc. Cambridge MA CO-COURSE DIRECTORS Neal I. Lindeman MD Brigham and Womens Hospital and Dana Farber Cancer Institute Boston MA Stephen Yip MD PhD University of British Columbia and Vancouver General Hospital Vancouver BC COURSE DESCRIPTION This half-day course is designed to familiarize the registrant with both the technical aspects and clinical applications of NGS for the solid tumor cancer patient. The rst section of the course is organized into a didactic series of short lectures given by the course instructors to highlight the history of clinical DNA sequencing on cancer specimens focused on the search for potential therapy targets for patients with relapsed and refractory disease. The technical section will emphasize practical issues for pathologists including the types of samples that can be used the quantity and proportion of tumor cells needed and the pre-analytic factors that can inuence NGS test results. Both formalin xed parafn embedded tissues and blood-based liquid biopsies will be considered. The remaining sections of the course will consist of a case by case analysis that includes lung cancer breast cancer colorectal cancer melanoma brain tumors and cancer of unknown primary origin. Upon completion of this educational activity participants should be able to Contrast the differences advantages and disadvantages between next generation sequencing NGS technologies and traditional Sanger Sequencing methods Understand the current limitations of one off single gene hotspot sequencing tests versus comprehensive genomic proling by NGS Contrast the advantages and disadvantages of the targeted NGS panel approach versus whole exome and whole genome sequencing Understand how next generation sequencing technologies can be applied to detect all classes of genomic alterations including base substitutions short insertionsdeletions fusions and translocations and copy number alterations including amplications and homozygous deletions in a clinical grade regulatory agency approved CLIACAP format using routine clinical FFPE samples Know how to preserve and prepare surgical pathology and cytologic samples including uids and ne needle aspirations for NGS testing Contrast the uses and limitations of using a blood sample for analysis of circulating tumor cell and cell free DNA for NGS Be familiar with the potential of NGS to alter a cancer patients clinical outcome by identifying a genomic alteration that can lead to a specic targeted therapy that would not have been considered if the NGS results had not been available Have a basic understanding of assessing quality assurance prociency testing and general validation of NGS procedures used in clinical testing of patient samples 800 AM INTRODUCTORY LECTURES HISTORY OF DNA SEQUENCING TRADITIONAL AND NGS SEQUENCING TECHNOLOGIES AND THE ROLES OF PATHOLOGISTS IN THE PROVIDING OF NGS RESULTS DESIGNED TO DIRECT PERSONALIZED CANCER TREATMENT 920 AM CASE 1 NON-SMALL CELL LUNG CANCER 940 AM CASE 2 BREAST CANCER 1000 AM BREAK 1020 AM CASE 3 MELANOMA 1040 AM CASE 4 COLORECTAL CANCER 1100 AM CASE 5 CANCER OF UNKNOWN PRIMARY ORIGIN 1120 AM CASE 6 BRAIN TUMORS 1140 AM QUESTIONS AND DISCUSSION NEXTGENERATION LEARNING201686 SPECIAL COURSES Tumor Immunology Implications for TNM Staging and Therapeutics MONDAY MARCH 14 2016 100 PM 500 PM CC BALLROOM 6E COURSE DIRECTORS Janis M. Taube MD The Johns Hopkins University School of Medicine Baltimore MD Robert A. Anders MD PhD The Johns Hopkins University School of Medicine Baltimore MD COURSE DESCRIPTION The focus of the course is TNM-Immune staging and the emerging use of surgical pathology specimens for immune-based assays including immunologic biomarkers for therapeutic selection and monitoring. To date the majority of the ndings emphasizing the role of the immune tumor microenvironment have been presented in the New England Journal of Medicine Science and Nature Medicine etc. and oncology journals such as Journal of Clinical Oncology Cancer Research and Clinical Cancer Research amongst others. In fact this body of work was awarded Science Magazines Breakthrough of the Year for 2013. There is a general lack of cutting-edge peer-reviewed publications on this topic in the pathology literature however based on the interest level at the 2014 USCAP Annual Meeting evidenced by posters on the topic and the number of new immunohistochemical assays and associated reports the pathology community is now rapidly embracing and participating in this new aspect of surgical pathology. Upon completion of this educational activity participants should be able to Summarize how the activity of checkpoint agents differs from that of more traditional therapeutics Summarize the latest concepts regarding the immune contexture of malignant neoplasms Discuss the histologic features associated with adaptive immune resistance Understand the limitations of PD-L1 evaluation Identify additional markers and associated detection techniques that will likely be employed in future Immunopathology assays 100 PM IMMUNE CHECKPOINTS CHECKPOINT BLOCKADE THERAPY AND RATIONAL PATIENT SELECTION AN OVERVIEW Janis M. Taube MD The Johns Hopkins University School of Medicine Baltimore MD Upon completion of this educational activity participants should be able to Familiarize participants with the immune synapse Introduce checkpoint blocking agents and how their activity and side effects differ from other therapeutic agents Summarize recent FDA approvals for this class of therapeutics and the specic indications 115 PM THE IMMUNE CONTEXTURE IN HUMAN TUMORS IMPACT ON CLINICAL OUTCOME Jerome Galon MD PhD Cordeliers Research Center Paris France Upon completion of this educational activity participants should be able to Identify the key inammatory components in a malignant neoplasm Summarize how the Immunoscore compares to current TNM staging Understand how an Immunoscore is calculated and the status of the Immunoscore Task force in validating this approach 150 PM ADAPTIVE IMMUNE RESISTANCE BIOMARKER IMPLICATIONS Robert M. Anders MD The Johns Hopkins University School of Medicine Baltimore MD Upon completion of this educational activity participants should be able to Discuss the histologic features of adaptive immune resistance by tumor Discuss the limitations of PD-L1 IHC evaluation in predicting response to anti-PD-1PD-L1 therapies Explain the pre- and post-analytic variables that inuence determining if a malignancy expresses PD-L1 NEXTGENERATION LEARNING 2016 SPECIAL COURSES 87 225 PM COMPARISON OF DIFFERENT ASSAY TECHNIQUES FOR IMMUNE MARKERS David Rimm MD PhD Yale University School of Medicine New Haven CT Upon completion of this educational activity participants should be able to Compare current chromogenic IHC testing methods for PD-L1 Highlight advantages for methods beyond chromogenic IHC for measuring PD-L1 and other checkpoint expression in the tumor microenvironment Explain the advantage of quantitative assessment of immune markers 300 PM COFFEE BREAK 400 PM IMMUNOARCITECTURAL FEATURES OF THE TUMOR MICROENVIRONMENT BEYOND PD-L1 Scott Rodig MD PhD Brigham and Womens Hospital Boston MA Upon completion of this educational activity participants should be able to Identify additional checkpoints and other markers in the tumor microenvironment thought to have clinical impact Compare and contrast the tumor microenvironment of hematologic malignancies as compared to solid tumors Summarize state-of-the-art methods used to evaluate the immunoarchitecture of FFPE specimens including multiplex IHCIF 440 PM CLOSINGQA NEXTGENERATION LEARNING201688 SPECIAL COURSES Molecular Diagnostic and Genomic Applications in Cancer A Primer for the Pathologist TUESDAY MARCH 15 2016 800 AM 515 PM CC BALLROOM 6B COURSE DIRECTORS George J. Netto MD The Johns Hopkins University Baltimore MD Karen Kaul MD PhD North Shore University Health System Evanston IL COURSE DESCRIPTION The pathologist is increasingly expected to play a central role in the management of cancer patients in the era of personalized oncology. Molecular diagnostic and genomic applications are rapidly penetrating the daily practice of the pathologist as the list of actionable genetic alteration in solid and hematologic tumors continues to expand. As highlighted in the USCAP 2012 combined companion meeting of the Association for Molecular Pathology Joint Meeting with American Society for Clinical Pathology In Coordination With American Society for Investigative Pathology efforts to develop residency curricula that will address the educational needs in molecular and genomic pathology for pathologists in training are underway by some academic institutions and others. These initiatives include the efforts sponsored by the Training Residents in Genomics TRIG working group of the Pathology Residency Directors Section of the Association of Pathology Chairs. Similar educational needs are evident among practicing pathologists in the community and academic centers pathology residents and fellows in institutions that are yet to develop a formal curriculum. A survey of the positive responses from attendees of the sold out special course titled Basic Principles and Practice of Molecular Pathology in Cancer which was in its nal iteration at USCAP 2012 is very indicative of an urgent and important educational need. The current course proposal intends to build upon and extend the role that the latter course that is no longer offered fullled. In fact the proposal stems from the shared recognition of the AMP ASIP and ASCP organizations that sponsored the 2012 combined companion meeting and from the director and faculty of the previous special course that there is the continuous need to offer educational opportunities to augment medical knowledge and to address competency deciencies among the intended target audience which is primarily the group of anatomic pathologists. Upon completion of this educational activity participants should be able to Select the appropriate and most cost-effective molecular and cytogenetic testing for workup of lymphomas and tissue-based leukemic inltrates of various types Assess the technology limitations and benets of next generation mutation array and transcriptional proling in lymphomas Describe the emerging role of exomewhole genome sequencing in the management of patients with lymphoma 800 AM INTRODUCTION George J. Netto MD The Johns Hopkins University Baltimore MD 810 AM CURRENT NEXT GENERATION SEQUENCING TECHNOLOGY A PRIMER TO THE ANATOMIC PATHOLOGIST Wayne W. Grody MD PhD University of California Los Angeles School of Medicine Los Angeles CA Upon completion of the educational activity participants should be able to Discuss the overall principles of massively parallel sequencing next generation sequencing technologies Illustrate practical examples of NGS based clinical diagnostics and how it will be impacting daily practice of pathology 850 AM NEXT-GEN SURGICAL PATHOLOGY NEW OPPORTUNITIES AND CHALLENGES Karen Kaul MD PhD North Shore University Health System Evanston IL Upon completion of the educational activity participants should be able to Discuss how the evolving understanding of molecular events underlying cancer development is making molecular characterization of tumors a necessity for diagnosis and prognostication in the practice of the pathologist Present an overview of the evolution of molecular testing from single gene or mutation analysis to multiplex capabilities including next generation sequencing Discuss the challenges and opportunities associated with the incorporation of these tools into the daily practice of the pathologist NEXTGENERATION LEARNING 2016 SPECIAL COURSES 89 920 AM MOLECULAR MARKERS FOR TARGETED LUNG CANCER THERAPY John Iafrate MD PhD Massachusetts General Hospital Boston MA Upon completion of the educational activity participants should be able to State the current genetic landscape of lung tumors Identify the role of genetic testing in guiding targeted therapies in lung cancer Appreciate the importance of advanced technologies in the future of pathologic assessment of tumors 1000 AM BREAKPOSTER SESSION 1030 AM MOLECULAR TESTING IN THE MANAGEMENT OF PATIENTS WITH BREAST CANCER CURRENT STATUS AND FUTURE DIRECTIONS Stuart J. Schnitt MD Beth Israel Deaconess Medical Center Boston MA Upon completion of the educational activity participants should be able to Explain the molecular classication of breast cancer and its clinical implications Review the uses and limitations of currently available molecular prognostic tests for patients with breast cancer Describe the emerging role of exome whole genome sequencing in the management of patients with breast cancer 1100 AM CLINICAL CYTOGENETIC AND MOLECULAR GENETIC TESTING IN BONE AND SOFT TISSUE TUMORS Julia A. Bridge MD University of Nebraska Medical Center Omaha NE Upon completion of the educational activity participants should be able to Review sample requirements and handling for RT-PCF FISH and cytogenetic analysis as they pertain to evaluating mesenchymal neoplasms Describe the advantages and limitations of genetic approaches commonly used in the classication of mesenchymal neoplasms to include conventional karyotyping FISH and RT-PCR Recognize the diagnostic prognostic and therapeutic value of molecular markers in mesenchymal neoplasia 1140 PM GIST AND MELANOMA THE KIT CONNECTION AND SO MUCH MORE Alexander Lazar MD PhD University of Texas MD Anderson Cancer Center Houston TX Upon completion of the educational activity participants should be able to Illustrate the techniques and results of molecular testing for gastrointestinal stromal tumor GIST and melanoma Recognize the association between histologic and molecular features in GIST and melanoma Interpret the emerging role of molecular diagnostics in patient management for GIST and melanoma 1210 PM LUNCH BREAK 110 PM MOLECULAR DIAGNOSTICS OF LYMPHOMA ASSAYS FOR CLASSIFICATION OUTCOME PREDICTION AND THERAPY RESPONSE Dan Jones MD PhD Quest Diagnostics Nichols Institute Chantilly VA Upon completion of the educational activity participants should be able to Select the appropriate and most cost-effective molecular and cytogenetic testing for workup of lymphomas and tissue-based leukemic inltrates of various types Assess the technology limitations and benets of next generation mutation array and transcriptional proling in lymphomas Describe the emerging role of exomewhole genome sequencing in the management of patients with lymphoma SPECIAL COURSES NEXTGENERATION LEARNING201690 150 PM COLORECTAL CANCER MOLECULAR TESTING FOR THE SURGICAL PATHOLOGIST Kevin C. Halling MD PhD Mayo Clinic Rochester MN Upon completion of the educational activity participants should be able to Discuss how MSI and DNA mismatch repair IHC testing and germline DNA mismatch repair gene sequencing are used to identify diagnose and manage patients with HNPCC Explain how microsatellite instability testing can be used to assess stage II and III CRC patients prognosis and response to 5FU treatment. Describe how KRAS and BRAF testing can be used to predict response to anti-EGFR therapies for patients with metastatic colorectal cancer CRC Describe the emerging role of exomewhole genome sequencing in the management of patients with colorectal cancer 230 PM EMERGING IMMUNOLOGIC BIOMARKERS PD-L1 AND BEYOND Janis Taube MD PhD The Johns Hopkins University Baltimore MD Upon completion of the educational activity participants should be able to Introduce the CTLA-4CD80 or CD86 and PD-1PD-L1 checkpoints including physiologic and pathologic expression Discuss the association of immunoarchitectural features of the tumor microenvironment and relationship to response with anti-PD-1PD-L1 checkpoint blockade Compare available assays for PD-L1 detection in surgical pathology specimens 300 PM BREAKPOSTER SESSION 330 PM MOLECULAR DIAGNOSTICS OF CNS TUMORS Arie Perry MD University of California San Francisco School of Medicine San Francisco CA Upon completion of the educational activity participants should be able to Review the most common molecular alterations in CNS tumors Recognize the association between histologic and molecular features in CNS tumors Interpret the emerging role of molecular diagnostics in patient management for CNS tumors 400 PM MOLECULAR DIAGNOSTICS OF LEUKEMIA CLASSIFICATION OUTCOME PREDICTION AND THERAPY RESPONSE Daniel Arber MD Stanford University Stanford CA Upon completion of the educational activity participants should be able to Select the appropriate and most cost-effective molecular and cytogenetic testing for workup of leukemia Assess the technology limitations and benets of next generation mutation array and transcriptional proling in leukemia Describe the emerging role of exomewhole genome sequencing in the management of patients with leukemia 430 PM MOLECULAR DIAGNOSTICS OF THYROID CANCER Yuri E. Nikiforov MD PhD University of Pittsburgh UPMC Presbyterian Pittsburgh PA Upon completion of this educational activity participants should be able to Review the most common molecular alterations in thyroid tumors and their histopathologic correlates Discuss specimen requirements and techniques for molecular testing of thyroid surgical resections and ne needle aspiration FNA samples Describe the diagnostic and prognostic application of specic molecular markers in thyroid cancer 500 PM QUESTION PERIOD AND CONCLUDING REMARKS George J. Netto MD The Johns Hopkins University Baltimore MD NEXTGENERATION LEARNING 2016 91 INTERACTIVE MICROSCOPY MONDAY MARCH 14 2016 800 AM 930 AM CC 304 UNUSUAL AND PROBLEM CASES IN HEADNECK CYTOPATHOLOGY Paul Wakely Jr. MD The Ohio State University Wexner Medical Center Columbus OH CC 305 PATHOLOGY OF COMMON INTERSTITIAL LUNG DISEASES- THE ESSENTIALS FOR PRACTICING PATHOLOGISTS Carol Farver MD Cleveland Clinic Cleveland OH CC 306 FATTY TUMORS OF THE RETROPERITONEUM Karen Fritchie MD Mayo Clinic Rochester NY MONDAY MARCH 14 2016 1000 AM 1130 AM CC 304 DIAGNOSTIC CHALLENGES IN CUTANEOUS SOFT TISSUE TUMORS Steven Billings MD Cleveland Clinic Cleveland OH CC 305 TUMOR AND TUMOR-LIKE PROLIFERATIONS OF THE SPLEEN Daniel Arber MD Stanford University Medical Center Stanford CA CC 306 SURGICAL PATHOLOGY OF PANCREATOBILIARY TRACT N. Volkan Adsay MD Emory University Hospital Atlanta GA MONDAY MARCH 14 2016 130 PM 300 PM CC 304 UNCOMMON TYPES OF INVASIVE MAMMARY CARCINOMA Timothy DAlfonso MD Weill Cornell Medicine New York NY CC 305 LOOK AT THAT BUG INTERESTING INFECTIOUS DISEASE CASES Kathleen Montone MD University of Pennsylvania Philadelphia PA CC 306 INTERESTING LESIONS IN PATIENTS WITH TESTICULAR NEOPLASMS Thomas Ulbright MD Indiana University School of Medicine Indianapolis IN NEXTGENERATION LEARNING201692 INTERACTIVE MICROSCOPY MONDAY MARCH 14 2016 430 PM 600 PM CC 304 WHEN AND HOW TO USE MOLECULAR STUDIES IN THE DIAGNOSIS OF MELANOCYTIC LESIONS Aleodor Doru Andea MD University of Michigan Ann Arbor MI CC 305 CORRELATION OF TUMOROUS AND NON-TUMOROUS CONDITIONS OF BONES AND JOINTS WITH CLINICAL IMAGING HOW DOES THE PATHOLOGY CREATE THE IMAGING FEATURES AND WHAT YOU NEED TO KNOW ABOUT THEM Michael Klein MD The Hospital for Special Surgery New York NY CC 306 MESENCHYMAL TUMORS OF THE BREAST A CONCEPTUAL FRAMEWORK FOR THE PRACTICING PATHOLOGIST Jordi Rowe MD Cleveland Clinic Cleveland OH TUESDAY MARCH 15 2016 800 AM 930 AM CC 304 GLIOMA DIAGNOSIS- 2016 WHAT PATHOLOGISTS NEED TO KNOW Anthony Yachnis MD University of Florida Gainesville FL CC 306 DIAGNOSTIC PITFALLS IN PROSTATE PATHOLOGY Adeboye O. Osunkoya MD Emory University School of Medicine Atlanta GA CC 305 SNEAKY CANCERS AND THEIR MIMICS Rhonda K. Yantiss MD Weill Cornell Medical College New York NY TUESDAY MARCH 15 2016 1000 AM 1130 AM CC 304 AN APPROACH TO PROBLEMATIC VASCULAR TUMORS BENIGN BORDERLINE MALIGNANT AND PSEUDOMALIGNANT Andrew L. Folpe MD Mayo Clinic Rochester MN CC 305 PRACTICAL APPROACH TO PAPILLARY PROBLEMS AND OTHER DILEMMAS IN BREAST CORE NEEDLE BIOPSY INTERPRETATION Andrea Dawson MD Cleveland Clinic Foundation Cleveland OH CC 306 CRAZY GYNECOLOGIC ACRONYMS LMP SBT STIC TILT STIL A REVIEW OF CHALLENGING UTERINE ADNEXAL NEOPLASMS Rob Soslow MD Memorial Sloan Kettering Cancer Center New York NY NEXTGENERATION LEARNING 2016 93 INTERACTIVE MICROSCOPY TUESDAY MARCH 15 2016 130 PM 300 PM CC 304 THE WELL DIFFERENTIATED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK A PRACTICAL APPROACH TO BIOPSY INTERPRETATION Olga Gologan MD Research Center of the University of Montreal Hospital Center CRCHUM Montreal QC CC 305 ENDOMETRIAL PATHOLOGY- SELECTED CHALLENGING AND INFORMATIVE CASES Charles Quick MD University of Arkansas for Medical Sciences Little Rock AR CC 306 SNEAKY GI BIOPSIES WITH HIDDEN DIAGNOSIS LESSONS IN APPLYING A SYSTEMATIC APPROACH Dora Lam-Himlin MD Mayo Clinic Scottsdale AZ TUESDAY MARCH 15 2016 430 PM 600 PM CC 304 GIDEADLIESTCATCH PRACTICAL APPROACHES TO TRENDING TOPICS IN GI PATHOLOGY Christina Arnold MD The Ohio State University Wexner Medical Center Columbus OH CC 305 FROZEN SECTION IN OVARIAN AND PERITONEAL LESIONS CHALLENGES AND CONTROVERSIES Andres Roma MD Cleveland Clinic Foundation Cleveland OH CC 306 HIGH RISK NON-MELANOMA SKIN CANCERS LESSONS FROM UV-DRENCHED NEW ZEALAND Patrick Emanuel MD DML St. Heliers Auckland New Zealand THURSDAY MARCH 17 2016 800 AM 930 AM CC 304 CC 305 CC 306 AN APPROACH TO INTRAOPERATIVE CONSULTATION IN NEUROPATHOLOGY Richard Prayson MD Cleveland Clinic Cleveland OH MEDICAL LIVER BIOPSIES HOW TO STAY OUT OF TROUBLE John Hart MD University of Chicago Chicago IL DIAGNOSTIC ISSUES IN DLBCL A 2016 PERSPECTIVE Megan Lim MD University of Pennsylvania Philadelphia PA NEXTGENERATION LEARNING201694 INTERACTIVE MICROSCOPY THURSDAY MARCH 17 2016 1000 AM 1130 AM CC 304 TWISTS IN LIVER PATHOLOGY UNSUSPECTED FINDINGS THAT CHANGED EVERYTHING Oyedele Adeyi MD Toronto General Hospital Toronto ON CC 306 DIAGNOSTIC DILEMMAS IN SKIN ADNEXAL TUMOUR PATHOLOGY Thomas Brenn MD Western General Hospital Scotland CC 305 MESENCHYMAL TUMORS OF THE UTERUS AN UPDATE IN CLASSIFICATION IMMUNOSTAINS AND DIFFERENTIAL DIAGNOSIS Joseph Rabban MD University of California San Francisco CA THURSDAY MARCH 17 2016 100 PM 230 PM CC 304 CC 305 CC 306 PITFALLS IN EFFUSION CYTOLOGY THE USUAL THE UNUSUAL AND THE MIMICKERS Claire Michael MD Case Western Reserve University Cleveland OH GI BIOPSY INTERPRETATION IN MODERN MEDICINE DRUGS DYSPLASIA AND OTHER DILEMMAS Marie Robert MD Yale University School of Medicine New Haven CT DONT BE DUPED LOOK-ALIKES IN GENITOURINARY PATHOLOGY Brian Robinson MD Weill Cornell Medical College New York NY THURSDAY MARCH 17 2016 300 PM 430 PM CC 304 APPLICATION OF THE PARIS SYSTEM FOR REPORTING URINARY CYTOPATHOLOGY ON LIQUID-BASED PREPARATIONS Rana Hoda MD New York Presbyterian Hospital-Weill Cornell Medical College New York NY CC 305 COMMON DIAGNOSTIC DILEMMAS IN URINARY BLADDER PATHOLOGY Qihui Jim Zhai MD Mayo Clinic Jacksonville FL CC 306 NEOPLASTIC LUNG DISEASE Lucian Chirieac MD Brigham and Womens Hospital Boston MA NEXTGENERATION LEARNING 2016 95 HOT TOPICS IN PATHOLOGY Hot Topics in Pathology Hematopathology MONDAY MARCH 14 2016 1200 PM 100 PM CC 605 MODERATOR Adam Bagg MD University of Pennsylvania Philadelphia PA PANELISTS Ahmet Dogan MD PhD Memorial Sloan Kettering Cancer Center New York NY Lisa Rimsza MD Mayo Clinic Scottsdale AZ Steven Swerdlow MD University of Pittsburgh Pittsburgh PA Hot Topics in Pathology Molecular TUESDAY MARCH 15 2016 1200 PM 100 PM CC 605 MODERATOR Dan Jones MD PhD The Ohio State University Columbus OH PANELISTS Dara L. Aisner MD PhD University of Colorado Anshutz Medical Campus Aurora CO Nikoletta Sidiropoulas MD The University of Vermont Burlington VT Carl Morrison MD Roswell Park Cancer Institute Buffalo NY Colin Pritchard MD PhD University of Washington Seattle WA Hot Topics in Pathology Genitourinary WEDNESDAY MARCH 16 2016 1200 PM 100 PM CC 605 MODERATOR Peter Humphrey MD PhD Yale University School of Medicine New Haven CT PANELISTS Donna Hansel MD PhD University of California San Diego La Jolla CA Adebowale Adeniran MD Yale University School of Medicine New Haven CT Cristina Magi-Galluzzi MD PhD Cleveland Clinic Cleveland OH NEXTGENERATION LEARNING201696 HOT TOPICS IN PATHOLOGY Hot Topics in Pathology Gastrointestinal THURSDAY MARCH 17 2016 1200 PM 100 PM CC 605 MODERATOR Liz Montgomery MD The Johns Hopkins Medical Institutions Baltimore MD PANELISTS Rhonda Yantiss MD Weill Cornell Medical College New York NY Dora Lam-Himlin MD Mayo Clinic Scottsdale AZ Michael Vieth MD Institut fuer Pathologie Bayreuth Germany NEXTGENERATION LEARNING 2016 97 PRACTICE CHANGERS MONDAY MARCH 14 2016 945 AM- 1040 AM CC SKY BRIDGE 4D 945 AM PATHOLOGISTS IN GROSS ANATOMY POD 1 Charles M. Quick MD University of Arkansas for Medical Sciences Little Rock AR 945 AM ADVERSE EVENTS DISCLOSURE MANAGEMENT FOR PATHOLOGISTS WHERE DO WE STAND NOW POD 2 Yael Kushner Heher MD MPH FRCPC Beth Israel Deaconess Medical Center Boston MA 1020 AM REPLACING KARYOTYPING WITH SNPM POD 1 Ravindra Kolhe MD PhD Georgia Regents University Augusta GA 1020 AM PROSTATE BIOPSY BILLING POD 2 Debra Zynger MD The Ohio State University Wexner Medical Center Columbus OH MONDAY MARCH 14 2016 315 PM-410 PM CC SKY BRIDGE 4D 315 PM FACEBOOK TWITTER HOW PATHOLOGISTS CAN CHANGE THEIR PRACTICE WITH SOCIAL MEDIA POD 1 Jerad M. Gardner MD University of Arkansas for Medical Sciences Little Rock AR 315 PM WIKIS A GATEWAY TO QUICK PATHOLOGY INFORMATION ONLINE COLLABORATION POD 2 Michael Bonert MD University of Calgary Calgary AB 350 PM HEALTH INFORMATION TECHNOLOGY CLINICAL INFORMATICS POD 1 Jeffrey W. Prichard DO Geisinger Medical Laboratories Danville PA 350 PM WORKFORCE ISSUES IN PATHOLOGY LABORATORY MEDICINE POD 2 Jennifer Hunt MD University of Arkansas for Medical Sciences Little Rock AR NEXTGENERATION LEARNING201698 PRACTICE CHANGERS TUESDAY MARCH 15 2016 945 AM-1040 AM CC SKY BRIDGE 4D 945 AM 3D PRINTED MICROSCOPY ALTERNATIVES TO GLASS SLIDE PATHOLOGY POD 1 Hany Osman MD Indiana University School of Medicine Indianapolis IN 945 AM NOVEL SIMPLE METHOD OF FORMALIN FIXED PARAFFIN EMBEDDED CELL BLOCK PREPARATION OF CYTOLOGY SPECIMENS POD 2 Kathryn Lindsey MD Medical University of South Carolina Charleston SC 1020 AM IMPACT OF GENOMICS PERSONALIZED MEDICINE POD 1 John Pfeifer MD Washington University Saint Louis MO 1020 AM DISCLOSING HARMFUL PATHOLOGY ERRORS TO COLLEAGUES POD 2 Suzanne M. Dintzis MD PhD University of Washington Medical Center Seattle WA MONDAY MARCH 14 430 PM - 530 PM CC HALL 4 E NATHAN KAUFMAN TIMELY TOPICS LECTURE - RIFFS ON FUTURE PATH THE FALL OF PAPER THE RISE OF SMARTIES AND THE QUEST FOR SELFIES Eric F. Glassy MD Afliated Pathologists Medical Group Torrance CA MONDAY MARCH 14 615 PM - 700 PM CC HALL 4 E HUT LUNG A POIGNANT PORTRAIT Thomas V. Colby MD Mayo Clinic Scottsdale AZ Annie Grifths National Geographic Magazine International Photojournalist TUESDAY MARCH 15 500 PM - 550 PM CC HALL 4 E MAUDE ABBOTT LECTURE - THE ESSENTIAL ROLE OF THE PATHOLOGIST IN GUIDING MANAGEMENT OF PATIENTS WITH BREAST DISEASE FROM MORPHOLOGY TO MOLECULES Stuart J. Schnitt MD Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA SPECIAL LECTURES 2016 NEXTGENERATION LEARNING LONG COURSE For more information or to apply for Ambassadorship please contact us www.USCAP.org USCAP AMBASSADORS TAKING OUTREACH TO NEXT GENERATION CONNECTIVITY USCAP West 500 South Palm Canyon Drive Suite 321 Palm Springs CA 92264 Phone 760.327.6777 Fax 760.327.6477 deborahuscap.org The re-imagined Ambassador Program is designed to achieve connectivity with future generations of pathologists. Engagement of pathologists-in-training as members for life in USCAP is critical to their career development and to becoming better pathologists. Ambassadors function to communicate to pathologists-in-training the value of membership in USCAP engaging their interest participation and loyalty. Dr. Gerardo Vides Almonacid left is the first international Ambassador and Dr. Jerad Gardner is the first domestic Ambassador. NEXTGENERATION LEARNING 2016 99 LONG COURSE Diagnosing Distinctive Lesions of the Head and Neck WEDNESDAY MARCH 16 2016 800 AM- 530 PM CC BALLROOM 6 ABC COURSE DIRECTOR Lester D.R. Thompson MD Woodland Hills Medical Center Woodland Hills CA COURSE DESCRIPTION There has been a remarkable increase in the knowledge about tumors tumor development and tumor genetics in the past 15 years since the last long course devoted to head and neck pathology. Many new entities have been described with their diagnostic criteria and ancillary supporting ndings elucidated. The differential diagnostic considerations of the head and neck are broad due in part to the wide diversity of organs many tissue types and the often very limited size of biopsy samples. The differences between benign reactive lesions and lethal malignancies may be quite subtle. The primary goal of this course is to present practical common every-day cases across a broad spectrum of anatomic sites discussing the development of differential diagnoses based on clinical and imaging ndings histologic features and additional techniques that allow for an appropriate diagnosis to be reached. These diagnoses will be put in the context of management and outcome differences highlighting entities that provoke a broad differential diagnosis. The major topics will include sinonasal tract tumors newly described and basaloid salivary gland tumors oropharyngeal carcinomas lichenoid lesions of the oral cavity the viral-associated tumors of the nasopharynx odontogenic cysts and tumors squamous lesions of the larynx with a focused discussion on how and when to use molecular and genetic techniques. Information to be included in the 2016-17 WHO classication will be discussed. The lectures are intended for general surgical pathologists oral pathologists and pathology residents and fellows. 800 AM AN APPROACH TO DIAGNOSING SMALL SAMPLES OF ROUND BLUE CELL TUMORS OF THE SINONASAL TRACT Lester D.R. Thompson MD Woodland Hills Medical Center Woodland Hills CA Upon completion of this educational activity participants should be able to Develop a clinical imaging and histolopathology differential diagnosis for small round blue cell lesions of the sinonasal tract Understand the fundamental treatment differences between the various diagnoses and how to reach a diagnostic category based on selecting special studies to aid in separation 845 AM NEWLY DESCRIBED SALIVARY GLAND TUMORS Alena Skalova MD PhD Charles University in Prague Czech Republic Upon completion of this educational activity participants should be able to Recognize the characteristic histologic immunohistochemical and genetic features of diagnostically challenging and newly described tumor entities in salivary gland pathology in particular mammary analogue secretory carcinoma MASC cribiform cystadenocarcinoma of tongue and other minor salivary glands CATS and sclerosing polycystic adenoma SPA Describe the differential diagnosis for those entities emphasizing the benign and low grade malignant possibilities. Discussion of each entity will include histopathological features differential diagnosis utility of ancillary studies impact on surveillance and management and insight into molecular pathogenesis 930 AM BREAK 1030 AM HPV-RELATED OROPHARYNGEAL CARCINOMAS- CATCH ME IF YOU CAN James Lewis Jr. MD Vanderbilt University Medical Center Nashville TN Upon completion of this educational activity participants should be able to Learn the numerous morphologic patterns that HPV-related oropharyngeal carcinomas can display in the primary and in the neck and how to recognize them Understand the clinical signicance for diagnosing these tumors including the signicance of morphologic subtypes 1115 AM ORAL LICHENOID LESIONS DISTINGUISHING THE BENIGN FROM THE DEADLY Susan Muller DMD Emory University Medical Center Atlanta GA Upon completion of this educational activity participants should be able to Distinguish the pathologic ndings of oral lichenoid lesions from oral lichen planus Recognize the diagnostic criteria of premalignant oral lichen planus LONG COURSE NEXTGENERATION LEARNING2016100 1200 PM LUNCH 100 PM VIRUS-ASSOCIATED NEOPLASMS OF THE NASOPHARYNX AND SINONASAL TRACT DIAGNOSTIC ISSUES John K-C. Chan MD Queen Elizabeth Hospital Hong Kong Upon completion of this educational activity participants should be able to Be familiar with the problems in rendering a histologic diagnosis of nasopharyngeal carcinoma and in particular the mimickers Be familiar with the problems in diagnosing extra nodal NKT-cell lymphoma and the differential diagnosis 130 PM BASALOID BLUE SALIVARY GLAND TUMORS Raja R. Seethala MD UPMC Presbyterian Pittsburgh PA Upon completion of this educational activity participants should be able to Apply an algorithmic approach incorporating tumor border stromal characteristics and cell types to distinguish between various basaloid salivary gland tumors Use morphologic and immunohistochemical ndings to easily delineate polymorphous low grade adenocarcinoma from adenoid cystic carcinoma 200 PM HOW TO DIAGNOSE THE MOST COMMON ODONTOGENIC AND OSSEOUS LESIONS OF THE JAW Robert Robinson MD PhD University of Iowa Hospitals and Clinics Iowa City IA Upon completion of this educational activity participants should be able to Discriminate between periapical cyst dentigerous cyst and keratocystic odontogenic tumor utilizing histologic and radiographic criteria Describe the clinical radiographic and histologic differences between bro-osseous lesions of the jaw 230 PM USING MOLECULAR ASSAYS TO RESOLVE CHALLENGING DIFFERENTIALS AND TREATMENT DECISIONS IN HEAD AND NECK CANCERS Jennifer L. Hunt MD University of Arkansas for Medical Sciences Little Rock AR Upon completion of this educational activity participants should be able to Understand the benets and limitations for molecular testing in head and neck cancers Be able to utilize molecular assays to resolve challenging differential diagnosis in head and neck cancers 300 PM BREAK 415 PM SQUAMOUS CELL CARCINOMA OF THE UPPER AERODIGESTIVE TRACT PREMALIGNANT LESIONS INVASIVE CARCINOMA AND SELECT VARIANTS Bruce M. Wenig MD The Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel Medical Center New York NY Upon completion of this educational activity participants should be able to Identify the diagnostic criteria and clinical relevance for keratinizing intraepithelial dysplasia of the upper aerodigestive tract Recognize the features of invasive squamous cell carcinoma and distinguish it from look-alike benign Identify the clinical and pathologic features for select variants of squamous cell carcinoma 500 PM WRAP- UP Lester D.R. Thompson MD Woodland Hills Medical Center Woodland Hills CA COMPILATION OF THE COURSE FOR THE DAY 2016 NEXTGENERATION LEARNING SHORT COURSES www.USCAP.org REGISTRATION NOW OPEN REGISTRATION NOW OPEN July 10-15 Snow King Lodge Jackson Hole WY 2016 Pragmatic Approaches to Daily Practice Diagnostic Pathology Update REGISTRATION NOW OPEN USCAP2016 2016 Practical Pathology Seminars April 28 - May 1 New Orleans Louisiana Sheraton New Orleans Hotel NEXTGENERATION LEARNING 2016 SHORT COURSES 101 WEDNESDAY MARCH 16 2016 800 AM 1200 PM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 930 AM - 1030 AM Indicates this is a new course Indicates this is an ending course 05 THE NERVE OF SOME NERVE SHEATH TUMORS A PRACTICAL APPROACH TO COMMON PROBLEMS IN SURGICAL PATHOLOGY Caterina Giannini MD PhD Mayo Clinic College of Medicine Rochester MN Fausto J. Rodriguez MD The Johns Hopkins University Baltimore MD Arie Perry MD University of California San Francisco CA Andrew Folpe MD Mayo Clinic Rochester MN 11 CONTEMPORARY CARDIOVASCULAR PATHOLOGY FROM BENCH TO BEDSIDE HOW EMERGING ANCILLARY TOOLS ARE TRANSFORMING THE FIELD Joseph J. Maleszewski MD Mayo Clinic Rochester MN Peter T. Lin MD Mayo Clinic Rochester MN 22 PRACTICAL GUIDE TO ERROR REDUCTION EFFECTIVE COMMUNICATION AND DAMAGE CONTROL IN SURGICAL PATHOLOGY Carolyn Mies MD University of Pennsylvania Philadelphia PA Raouf E. Nakhleh MD Mayo Clinic Jacksonville FL 25 COLORECTAL DYSPLASIA IN IBD DIAGNOSIS IMPLICATIONS AND PITFALLS Alexandros D. Polydorides MD PhD Icahn School of Medicine at Mount Sinai New York NY Steven Itzkowitz MD Icahn School of Medicine at Mount Sinai New York NY Noam Harpaz MD PhD Icahn School of Medicine at Mount Sinai New York NY 30 DIAGNOSIS OF RENAL NEOPLASMS USING INTEGRATED HISTOLOGIC CYTOLOGIC AND MOLECULAR APPROACHES IN THE ERA OF PRECISION MEDICINE Christopher Przybycin MD Cleveland Clinic Cleveland OH Jordan Reynolds MD Cleveland Clinic Cleveland OH Ming Zhou MD PhD New York University New York NY 31 DOING MORE WITH LESS A CYTOLOGY-HISTOLOGY CORRELATION OF PULMONARY MASSES Michele Hirsch MD PhD Brigham and Womens Hospital Boston MA Donna E. Hansel MD PhD University of California at San Diego La Jolla CA Mahul B. Amin MD Cedar-Sinai Medical Center Los Angeles CA 36 INHERITED GYNECOLOGIC CANCER SYNDROMES PATHOLOGICALLY AND CLINICALLY BASED RISK ASSESSMENT AND GENETIC COUNSELING WHAT EVERY PRACTICING PATHOLOGIST SHOULD KNOW Teri Longacre MD Stanford University Medical Center Stanford CA Robert Soslow MD Memorial Sloan Kettering Cancer Center New York NY Course Material Contributed by Angela Arnold MS CGC Memorial Sloan Kettering Cancer Center New York NY 45 PROBLEMATIC DUCTAL PROLIFERATIONS OF THE BREAST Melinda F. Lerwill MD Massachusetts General Hospital Boston MA Kimberly H. Allison MD Stanford University Stanford CA Kristin C. Jensen MD Stanford University Stanford CA 55 A PRACTICAL APPROACH TO INFECTIOUS DISEASE PATHOLOGY Bobbi S. Pritt MD MSc Mayo Clinic Rochester MN Laura Lamps MD University of Arkansas for Medical Sciences Little Rock AR SHORT COURSES NEXTGENERATION LEARNING2016102 WEDNESDAY MARCH 16 2016 130 PM 530 PM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 300 PM - 4 00 PM Indicates this is a new course Indicates this is an ending course 04 AUTOPSY IN THE 21ST CENTURY AN UPDATE FOR PATHOLOGISTS PERFORMING HOSPITAL AUTOPSIES TODAY Jody E. Hooper MD The Johns Hopkins University Baltimore MD Alex K. Williamson MD North Shore-LIJ Health System Hofstra North Shore-LIJ School of Medicine Long Island NY 18 DIAGNOSTIC CRITERIA OF THE PARIS SYSTEM FOR REPORTING URINARY CYTOLOGY Dorothy L. Rosenthal MD FIAC The Johns Hopkins University Baltimore MD Christopher J. VandenBussche MD The Johns Hopkins University Baltimore MD Matthew T. Olson MD The Johns Hopkins University Baltimore MD Gliz A. Barkan MD FIAC Loyola University Medical Center Maywood IL Eva M. Wojcik MD Loyola University Medical Center Maywood IL 33 OVARIAN CARCINOMA AN UPDATE ON HISTOTYPE DIAGNOSIS PRIMARY SITE ASSIGNMENT AND STAGING C. Blake Gilks MD University of British Columbia Vancouver BC M. Kbel MD University of Calgary Calgary AB Naveena Singh MD FRCPath Barts Health NHS Trust London UK 39 BONE MARROW MANIFESTATIONS OF SYSTEMIC DISEASE Dita Gratzinger MD PhD Stanford Medicine Stanford CA David Czuchlewski MD University of New Mexico Albuquerque NM C. Tracy George MD University of New Mexico Albuquerque NM 43 MEDICAL LIVER BIOPSIES TRANSLATING MORPHOLOGIC PATTERNS INTO MEANINGFUL PATHOLOGY REPORTS Michael Torbenson MD Mayo Clinic Rochester MN Sanjay Kakar MD University of California San Francisco CA 59 OCCUPATIONALLY RELATED PLEURAL AND PULMONARY DISORDERS IN THE 21ST CENTURY CHALLENGES PITFALLS AND NO-NOS Victor L. Roggli MD Duke University Medical Center Durham NC Thomas A. Sporn MD Duke University Medical Center Durham NC Henry D. Tazelaar MD Mayo Clinic Scottsdale AZ 62 ALGORITHMIC APPROACH TO DIAGNOSIS OF INFLAMMATORY DISORDERS OF THE GI TRACT Amitabh Srivastava MD Brigham and Womens Hospital Boston MA Robert D. Odze MD Brigham and Womens Hospital Boston MA Gregory Y. Lauwers MD Massachusetts General Hospital Boston MA NEXTGENERATION LEARNING 2016 SHORT COURSES 103 THURSDAY MARCH 17 2016 800 AM 1130 AM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 930 AM - 1000 AM Indicates this is a new course Indicates this is an ending course 06 DIAGNOSTIC DILEMMA IN NEOPLASTIC AND NON-NEOPLASTIC BONE PATHOLOGY John D. Reith MD University of Florida College of Medicine Gainesville FL Gunnlaugur Petur Nielsen MD Massachusetts General Hospital Harvard Medical School. Boston MA Scott E. Kilpatrick MD Forsyth Regional Medical Center Winston-Salem NC 08 THE PATHOLOGISTS ROLE IN GUIDING BREAST CANCER TREATMENT IN THE ERA OF NEOADJUVANT THERAPY Veeryle Bossuyt MD Yale University New Haven CT Elena Provenzano MD Addenbrookes Hospital Cambridge UK W. Fraser Symmans MD The University of Texas MD Anderson Cancer Center Houston TX 10 DIAGNOSTIC CHALLENGES IN PROSTATE PATHOLOGY Adeboye O. Osunkoya MD Emory University School of Medicine Atlanta GA Cristina Magi-Galluzzi MD PhD Lerner College of Medicine Cleveland Clinic Cleveland OH 16 PATHOLOGY OF THE PREVIABLE FETUS AND STILLBORN INFANT FOR THE GENERAL PATHOLOGIST Debra S. Heller MD Rutgers New Jersey Medical School Newark NJ Ona M. Faye-Petersen MD University of Alabama at Birmingham Birmingham AL 20 CHALLENGING CASES IN THYROID CYTOPATHOLOGY HOW CAN ULTRASOUND FINDINGS AND MOLECULAR TESTS HELP Helen H. Wang MD DrPH Beth Israel Deaconess Medical Center Boston MA Pamela Hartzband MD Beth Israel Deaconess Medical Center Boston MA Michiya Nishino MD PhD Beth Israel Deaconess Medical Center Boston MA 21 IMPORTANT ASPECTS OF SKIN ADNEXAL TUMOR PATHOLOGY Thomas Brenn MD PhD FRCPath Western General Hospital and The University of Edinburgh Edinburgh UK Alexander Lazar MD PhD The University of Texas MD Anderson Cancer Center Houston TX Melissa Pulitzer MD Memorial Sloan Kettering Cancer Center New York NY Jaime Eduardo Calonje MD DipRCPath St. Johns Institute of Dermatology St. Thomas Hospital London UK 28 PULMONARY INFECTIONS MORPHOLOGIC AND MOLECULAR TIPS FOR THE SURGICAL PATHOLOGIST Sanjay Mukhopadhyay MD Cleveland Clinic Cleveland OH Gary Procop MD Cleveland Clinic Cleveland OH Carol Farver MD Cleveland Clinic Cleveland OH 32 PREDICTIVE BIOMARKERS LESSONS FROM CLINICAL TRIALS Sunil S. Badve MD Indiana University Indianapolis IN Josef Ruschoff MD Targos Molecular Pathology GmbH Kassel Germany Reinhard Buttner MD University of Cologne and Center for Integrated Oncology Cologne Germany 37 HEAD AND NECK PATHOLOGY IN THE HUMAN PAPILLOMAVIRUS ERA A CRASH COURSE James S. Lewis Jr. MD Vanderbilt University Nashville TN Justin A. Bishop MD The Johns Hopkins University Baltimore MD Rebecca D. Chernock MD Washington University St. Louis MO SHORT COURSES NEXTGENERATION LEARNING2016104 40 HEMATOLYMPHOID LESIONS AT THE BORDERLINE BETWEEN BENIGN AND MALIGNANT FINDING YOUR WAY OUT OF UNCERTAINTY Eric D. Hsi MD Cleveland Clinic Cleveland OH Carlos E. Bueso-Ramos MD PhD The University of Texas MD Anderson Cancer Center Houston TX Megan O. Nakashima MD Cleveland Clinic Cleveland OH 46 OPEN CONFESSION IS GOOD FOR THE SOUL MEMORABLE MISTAKES AND WHAT WEVE LEARNED Rhonda K. Yantiss MD Weill Cornell Medical College New York NY Laura Lamps MD University of Arkansas for Medical Sciences Little Rock AR 50 CLINICAL REALITIES OF NEXT-GENERATION SEQUENCING John D. Pfeifer MD PhD Washington University School of Medicine St. Louis MO Nikoletta Sidiropoulos MD University of Vermont College of Medicine Burlington VT Jennifer Sehn MD Washington University School of Medicine St. Louis MO Eric Duncavage MD Washington University School of Medicine St. Louis MO 56 NERVE AND MUSCLE BIOPSIES A PATIENT-CENTERED APPROACH FOR THE GENERAL PATHOLOGIST Peter Pytel MD University of Chicago Chicago IL Douglas Anthony MD PhD Brown University Providence RI NEXTGENERATION LEARNING 2016 SHORT COURSES 105 THURSDAY MARCH 17 2016 100 PM 430 PM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 230 PM - 300 PM Indicates this is a new course Indicates this is an ending course 03 USES AND LIMITATIONS OF IMMUNOHISTOCHEMISTRY AND OTHER ADJUNCTIVE STUDIES IN BREAST PATHOLOGY Stuart J. Schnitt MD Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA Laura C. Collins MD Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA 07 ITS NOT AS BAD AS IT LOOKS PAIRS OF LOOK-ALIKE LESIONS IN SURGICAL NEUROPATHOLOGY Bette K. Kleinschmidt-DeMasters MD University of Colorado Denver CO Richard A. Prayson MD Cleveland Clinic Cleveland OH 12 MEDICAL RENAL PATHOLOGY FOR THE GENERAL SURGICAL PATHOLOGIST Anthony Chang MD University of Chicago Medical Center Chicago IL Vanesa Bijol MD Brigham and Womens Hospital Boston MA 14 BIOPSIES OF MEDIASTINAL LESIONS CHALLENGES PITFALLS AND PRACTICAL TIPS Anja C. Roden MD Mayo Clinic Rochester MN Marie Christine Aubry MD Mayo Clinic Rochester MN 17 TRAPDOORS IN TESTICULAR PATHOLOGY Daniel M. Berney MBBChir MA FRCPath Barts and The London School of Medicine and Dentistry Queen Mary University London UK Muhammed T. Idrees MD Indiana University Medical Center Indianapolis IN 19 MELANOCYTIC LESIONS A PRACTICAL APPROACH TO DIAGNOSIS ADJUNCTIVE MOLECULAR STUDIES AND APPROPRIATE THERAPYMANAGEMENT Daniela Massi MD University of Florence Florence IT Martin C. Mihm Jr. MD Brigham and Womens Hospital Boston MA Richard A Scolyer MD Royal Prince Alfred Hospital Sydney AU 23 SURGICAL AND MOLECULAR PATHOLOGY OF THYROID NEOPLASIA Thomas J. Giordano MD PhD University of Michigan Health System Ann Arbor MI Bruce M. Wenig MD Mount Sinai Health System New York NY 26 COLONIC POLYPS-DAILY PROBLEMS ONLY PATHOLOGISTS UNDERSTAND David F. Schaeffer MD University of British Columbia Vancouver BC Hector Li-Chang MD University of British Columbia Vancouver BC Rish K. Pai MD Mayo Clinic Scottsdale AZ 35 GOING WITH THE FLOW OF BILE AN UPDATE ON TUMORS OF THE LIVER BILE DUCTS AND GALLBLADDER N. Volkan Adsay MD Emory University Atlanta GA Alyssa M. Krasinskas MD Emory University Atlanta GA Matthew M. Yeh MD PhD University of Washington Seattle WA 40 HEMATOLYMPHOID LESIONS AT THE BORDERLINE BETWEEN BENIGN AND MALIGNANT FINDING YOUR WAY OUT OF UNCERTAINTY Eric D. Hsi Cleveland Clinic Cleveland OH Carlos E. Bueso-Ramos The University of Texas MD Anderson Cancer Center Houston TX Megan O. Nakashima Cleveland Clinic Cleveland OH SHORT COURSES NEXTGENERATION LEARNING2016106 THURSDAY MARCH 17 2016 100 PM 430 PM ...continued 41 EXPANDING THE DIFFERENTIAL DIAGNOSIS IN UROLOGIC PATHOLOGY CONTROVERSIES AND NEW ENTITIES Michele Hirsch MD PhD Brigham and Womens Hospital Boston MA Donna E. Hansel MD PhD University of California at San Diego La Jolla CA Mahul B. Amin MD Cedar-Sinai Medical Center Los Angeles CA 42 DIFFICULT DIAGNOSES IN PEDIATRIC HEMATOPATHOLOGY Richard L. McMasters MD Cincinnati Childrens Hospital Medical Center Cincinnati OH Dehua Wang MD Cincinnati Childrens Hospital Medical Center Cincinnati OH Robert B. Lorsbach MD PhD Cincinnati Childrens Hospital Medical Center Cincinnati OH 47 LATE INTRAUTERINE DEMISE PLACENTAL AND FETAL POSTMORTEM PATHOLOGY Theonia K. Boyd MD Boston Childrens Hospital Brigham and Womens Hospital and Harvard Medical School Boston MA Drucilla J. Roberts MD Massachusetts General Hospital and Harvard Medical School Boston MA 54 PRACTICAL INFORMATICS SOLUTIONS FOR ANATOMIC PATHOLOGY QUALITY MANAGEMENT Jeffrey Prichard DO Geisinger Health System Danville PA Steven Meschter MD Geisinger Health System Danville PA NEXTGENERATION LEARNING 2016 107 SHORT COURSES FRIDAY MARCH 18 2016 800 AM 1130 AM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 930 AM - 1000 AM Indicates this is a new course Indicates this is an ending course 02 STRIVING FOR EXCELLENCE LEVERAGING CLIA ACCREDITATION ISO 15189 AND LEAN FOR ANATOMIC AND MOLECULAR PATHOLOGY LABORATORIES Richard J. Zarbo MD Henry Ford Health System Detroit MI Gaurav Sharma MD Henry Ford Health System Detroit MI 09 RECENT DEVELOPMENTS IN HEART AND LUNG TRANSPLANT PATHOLOGY NAVIGATING THE SHIFTING SANDS Dylan V. Miller MD Intermountain Medical Center and University of Utah Salt Lake City UT Gerald J. Berry MD Stanford University Stanford CA Henry D. Tazelaar MD Mayo Clinic- Arizona Scottsdale AZ John P. Veinot MD The Ottawa Hospital Ottawa ON 15 PRACTICAL OCULAR PATHOLOGY FOR PATHOLOGISTS Nora V. Laver MD New England Eye Center Tufts University and Tufts Medical Center Boston MA Anat Stemmer-Rachamimov MD Massachusetts General Hospital Boston MA Charles S. Specht MD Penn State Hershey Medical Center Hershey PA 24 BACTERIAL INFECTION AND THE KIDNEY DIAGNOSTIC DIFFICULTIES IN KIDNEY BIOPSIES Anjali A. Satoskar MD The Ohio State University Wexner Medical Center Columbus OH Tibor Nadasdy MD PhD The Ohio State University Wexner Medical Center Columbus OH 27 A PATTERN-BASED APPROACH TO THE DIAGNOSIS OF SOFT TISSUE TUMORS Leona A. Doyle MD Brigham and Womens Hospital Harvard Medical School Boston MA Jason L. Hornick MD PhD Brigham and Womens Hospital Harvard Medical School Boston MA 29 PATHOLOGY IN THE ERA OF GENOMIC MEDICINE NEW FRONTIERS AND NEW CHALLENGES George M. Yousef MD PhD FRCPC University of Toronto ON George Netto MD The Johns Hopkins University School of Medicine Baltimore MD 34 NON-INVASIVE NIGHTMARES IN BREAST PATHOLOGY Timothy W. Jacobs MD Virginia Mason Medical Center Seattle WA Yunn-Yi Chen MD PhD University of California San Francisco CA 44 ENDOCRINE TUMOR BOARD CLINICOPATHOLOGICAL CORRELATIONS IN ENDOCRINE PATHOLOGY Ozgur Mete MD University Health Network Toronto ON Sylvia L. Asa MD PhD University Health Network Toronto ON Shereen Ezzat MD University Health Network Toronto ON 52 DIFFICULT ENDOMETRIAL BIOPSIES MALIGNANCY MIMICS MOLECULAR AND MISHAPS Bojana Djordjevic MD University of Ottawa Ottawa ON Anais Malpica MD The University of Texas MD Anderson Cancer Center Houston TX Russell Broaddus MD PhD MD Anderson Cancer Center Houston TX 53 PROBLEMS PITFALLS AND AN INTEGRATED APPROACH TO LYMPHOPROLIFERATIVE DISORDERS IN THE SKIN Melissa Pulitzer MD Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University New York NY John Goodlad MD Western General Hospital The University of Edinburgh Edinburgh UK NEXTGENERATION LEARNING2016108 SHORT COURSES FRIDAY MARCH 18 2016 100 PM 430 PM Room locations are printed on the Short Course Ticket A COFFEE BREAK IS SCHEDULED FOR 230 PM - 300 PM Indicates this is a new course Indicates this is an ending course 38 COMMON DIAGNOSTIC DILEMMAS IN HEAD AND NECK PATHOLOGY PITFALLS PEARLS AND CLINICAL INSIGHTS Qihui Jim Zhai MD Mayo Clinic Jacksonville FL John Casler MD Mayo Clinic Jacksonville FL 48 PROBLEMATIC AREAS IN THE PATHOLOGY OF THE UTERINE CERVIX Esther Oliva MD Massachusetts General Hospital Harvard Medical School Boston MA Carmen Tornos MD Stony Brook University Hospital Stony Brook University NY 49 INTERSTITIAL LUNG DISEASE WHAT YOUR CLINICIAN WANTS TO KNOW Kristen L. Veraldi MD PhD University of Pittsburgh PA Frank Schneider MD University of Pittsburgh Pittsburgh PA 51 HIGH YIELD UROLOGICAL PATHOLOGY COMMON AND IMPORTANT DIAGNOSES NOT TO BE MISSED IN DAILY PRACTICE Ming Zhou MD PhD New York University Medical Center New York NY Kiril Trpkov MD University of Calgary Calgary AB Rajal B. Shah MD Miraca Life Sciences Irving TX 57 DIAGNOSIS OF CHALLENGING PLASMA CELL NEOPLASMS Robert B. Lorsbach MD PhD Cincinnati Childrens Hospital Medical Center Cincinnati OH Marwan A. Yared MD Baylor College of Medicine Houston TX 58 SECOND OPINIONS AND DISCREPANCIES IN FINE NEEDLE ASPIRATION FNA CYTOLOGY AN INTERACTIVE APPROACH TO DIAGNOSTIC WORK-UP Tarik M. Elsheikh MD Cleveland Clinic Cleveland OH Syed A. Hoda MD New York Hospital Cornell Medical Center New York NY Rana S. Hoda MD New York Presbyterian Hospital New York NY 60 PRACTICAL STATISTICS FOR PATHOLOGISTS CASE-BASED INSTRUCTION WITH METHODS Dan A. Milner Jr. MD Brigham and Womens Hospital Boston MA Thing Rinda Soong MD Brigham and Womens Hospital Boston MA 2016 NEXTGENERATION LEARNING SPECIAL LECTURES Snow King Lodge Jackson Hole WY USCAP opened its Interactive Center in Palm Springs CA on October 30 2015 to provide a state-of-the-art facility for teaching interactive microscopy ultra- sound-guided fine needle aspiration biopsy procedures and related moleculargenomic sciences. The Center is yet another expression of USCAPs commitment to global health through education and creating better pathologists. It is a place like no other for mentoring and for learning. Pathology at the Speed of Thought USCAP opened its Interactive Center in Palm Springs CA on Pathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of Thought Interactive Center in Palm Springs CA on October 30 2015 to provide a state-of-the-art facility for teaching interactive microscopy ultra sound-guided fine needle aspiration biopsy procedures and related moleculargenomic sciences. The Center is yet another expression of USCAPs commitment to global health through education and creating better pathologists. It is a place like no other for mentoring and for learning. Pathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of Thought Palm Springs CA on October 30 2015 to state-of-the-art facility for teaching interactive microscopy ultra- sound-guided fine needle aspiration biopsy procedures and related moleculargenomic sciences. The Center is yet another expression of USCAPs commitment to global health through education and creating better pathologists. It is a place like no other for mentoring and for learning. USCAP opened its Interactive Center in Palm Springs CA on Pathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of ThoughtPathology at the Speed of Thought Palm Springs CA on October 30 2015 to provide a state-of-the-art facility for teaching interactive microscopy ultra sound-guided fine needle aspiration biopsy procedures and related moleculargenomic sciences. The Center is yet another expression of USCAPs commitment to global health through education and creating better pathologists. It is a place like no other for mentoring and for learning. Two laboratory spaces each with an 18-head teaching microscope High definition digital cameras with telepathy software 17 personal-use microscopes Ultrasound equipment for hands-on instruction in performing ultrasound-guided fine needle aspiration biopsies with interpretations Weekend courses offered year around in all subspecialties of anatomic pathology taught by the most accomplished pathologists in the field An intimate learning experience that simulates daily sign out Interactive Center featuresUSCAP opened its Interactive Center inInteractive Center in Palm Springs CA on October 30 2015 to provide a state-of-the-art facility for teaching interactive microscopy ultra Interactive Center in Snow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King LodgeSnow King Lodge COURSE SCHEDULE AVAILABLE ONLINE www.USCAPInteractiveCenter.org THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY RESONATES WITH EXCELLENCE. WE ARE PROUD TO INTRODUCE THESE AWARD RECIPIENTS WHO HAVE MADE OUTSTANDING CONTRIBUTIONS IN THE FIELD OF PATHOLOGY. HIGH PERFORMANCE ACHIEVEMENT USCAP HONORS 2 0 1 6 2016 Executive Committee announces that USCAP is going green for the 2017 Annual Meeting. To preserve USCAPs portal to a new world of learning we are respecting the lives of trees in the spirit of eco-balance by limiting the printing of traditional educational materials including the Program Book. Please use your digital devices at the Annual Meeting for downloading handouts from our website. USCAP Is Gradually Going Green www.uscap.orgprogrambook Download now at 2016NEXTGENERATION LEARNING ABSTRACTS www.USCAP.org your Academy YOUR FORMULA FOR SUCCESS With an exceptional education track for trainees networking receptions a huge fellowship fair and trainee conference rates the worlds largest pathology meeting is the perfect place to advance your career. Evening Specialty Courses with 7103 total attendees Scientific abstracts were submitted for evaluation 3096 HOURS HOURS 50212015 Annual Meeting Attendance Attendees were from 87 countries other than the U.S. or Canada. 1382726Long Course attendees 60Short Courses offered this year 4025 attendees 19 27 87 Countries represented Possible CME Per Person 58.5 Possible SAMS Per Person 55.25 HOURS HOURS Total Possible CME 445.5 Total Possible SAMS 309.25 Companion Meeting 5975 attendees total NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 109NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM 109 CC HALL 4E SECTION A - GENITOURINARY CHAIRED BY OMAR HAMEED AND TAMARA LOTAN 800 Validation of Reporting Percentage High Grade Prostate Cancer in 988 Conservatively Treated Patients with Long Term Outcome 863 Daniel Berney Gabrielle Fisher Bernard North Henrik Moller Peter Scardino Jack Cuzick Luis Beltran Queen Mary University of London London United Kingdom Memorial Sloan-Kettering Cancer Center New York NY Kings College London London United Kingdom 815 Do Specic Gleason Pattern 4 Morphologies Detected on Transrectal Ultrasound TRUS-Guided Biopsies Predict Upgrading or Upstaging in Gleason Score 347 Prostate Cancer 950 Kevin Hogan Susan J Robertson Nicola Schieda Kien T Mai Daniel T Keefe Eric C Belanger Rodney H Breau Chris Morash Trevor A Flood The Ottawa Hospital Ottawa ON Canada The University of Ottawa Ottawa ON Canada 830 Metastatic Potential of Gleason Score 7 Tumor at Radical Prostatectomy RP Using the 2014 Modied Gleason Score Effect of High Grade Tertiary Patterns 899 Mairo L Diolombi Jonathan I Epstein Johns Hopkins Hospital Baltimore MD 845 Signicance of Percentage of Gleason Pattern 4 at Needle Biopsy in Predicting Final Gleason Score and Correlation with Pathologic Outcomes at Radical Prostatectomy 956 Mohsin Jamal Sean R Williamson Mireya Diaz-Insua Mani Menon Hans Stricker James Peabody Craig G Rogers Nilesh S Gupta Henry Ford Hospital Detroit MI 900 Radical Prostatectomy Findings in the Post-PSA Screening Era 904 Liz Edmund Andres Matoso Rhode Island Hospital and Brown University Providence RI 915 Validation of Reactive Stroma as an Adverse Prognostic Factor for Gleason Grade 336 and 347 Prostatic Adenocarcinomas PCA In the Canary Retrospective Radical Prostatectomy RP Cohort 993 Jesse K McKenney Wei Wei Sarah J Hawley Heidi Auman Lisa Newcomb Hilary Boyer Ladan Fazli Jeff Simko Antonio Hurtado-Coll Dean Troyer Maria S Tretiakova Funda Vakar-Lopez Peter R Carroll Matthew R Cooperberg Martin E Gleave Raymond Lance Daniel Lin Peter S Nelson Ian Thompson Lawrence True Ziding Feng James D Brooks Cleveland Clinic Cleveland OH UT MD Anderson Houston TX Canary Foundation Palo Alto CA Fred Hutchinson CRC Seattle WA University British Columbia Vancouver BC Canada UCSF San Francisco CA Eastern Virginia MS Norfolk VA UW Medical Center Seattle WA UT San Antonio San Antonio TX Stanford University Stanford CA 1100 Predictive Value of Intraductal Carcinoma and Cribriform Architecture in Prostate Biopsies of Patients Treated by Radiotherapy 1067 Theodorus H Van der Kwast Jure Murgic Melania Pintilie Michelle Downes Michael Fraser Rob G Bristow University Health Network Toronto ON Canada Princess Margaret Cancer Centre Toronto ON Canada 1115 Overexpression of the Long Non-Coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer 1065 Aaron Udager Arul M Chinnaiyan Joshua Petimar Xuhong Cao Felix Y Feng Massimo Loda Thomas Ahearn Philip W Kantoff Lorelei A Mucci Rohit Mehra University of Michigan Health System Ann Arbor MI Michigan Center for Translational Pathology Ann Arbor MI Dana-Farber Cancer Institute Boston MA Harvard T. H. Chan School of Public Health Boston MA 1130 Concurrent TMPRSS2-ERG and SLC45A3-ERG Rearrangements Plus PTEN Loss Are Associated with an Aggressive Tumor Subset of Prostate Cancer 947 Silvia Hernandez Alba Font-Tello Nuria Juanpere Silvia de Muga Marta Lorenzo Lluis Fumado Sergio Serrano Josep Lloreta Universitat Pompeu Fabra Barcelona Spain Hospital del Mar-Parc de Salut Mar-IMIM Barcelona Spain Autonomous University of Barcelona Barcelona Spain 1145 Multi-Tumor Sampling Tissue Microarray Approach from Radical Prostatectomies to Screen Biomarkers Relevant to Active Surveillance 970 Ibrahim Kulac Gunes Guner Helen Fedor Stephanie Glavaris Tamara Lotan H Ballentine Carter Jonathan I Epstein Angelo M De Marzo Johns Hopkins University Baltimore MD 1200 BREAK CC BR 6C SECTION B - BREAST CHAIRED BY FOUAD BOULOS AND KRISTIN C JENSEN 800 Microglandular Adenosis and Risk of Breast Cancer A Mayo Benign Breast Disease Cohort Study 119 Melanie C Bois Zahraa Al-Hilli Daniel W Visscher Tanya L Hoskin Marlene H Frost Derek C Radisky Ruth Kraft Amy Degnim Jodi M Carter Mayo Clinic Rochester MN 815 Are Microglandular Adenosis and Breast Acinic Cell Carcinomas Related Lesions 160 Felipe C Geyer Salvatore Piscuoglio Charlotte KY Ng Elena Guerini-Rocco Caterina Marchio Zsolt Hodi Emad Rakha Ian O Ellis Stuart Schnitt Britta Weigelt Jorge S Reis-Filho Memorial Sloan Kettering Cancer Center New York NY European Institute of Oncology Milan Italy University of Turin Turin Italy University of Nottingham Nottingham United Kingdom Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016110 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016110 830 A Longitudinal Study of LCIS on CNB 224 Lavinia Middleton MD Anderson Houston TX 845 Atypical Ductal Hyperplasia ADH Versus Ductal Carcinoma In-Situ DCIS in a Papilloma Comparison of Linear Dimension and Proportion Criteria 184 Elizabeth Kalife Kamaljeet Singh C James Sung M Ruhul Quddus Women and Infants Hospital Providence RI 900 Intraductal Papillomas without Atypia Need Not Be Excised A Hispanic Cohort Study 245 Lurmag Orta Eugenio Marcano Mayra Maldonado- Duran San Pablo Pathology Group Bayamn Puerto Rico University of Puerto Rico Rio Piedras Puerto Rico HIMA San Pablo Hospital Bayamn Puerto Rico 915 Intraductal Papillomas of the Breast on Core Biopsy Re-Visiting 10 Years Experience with More Than 500 Cases 179 Shabnam Jaffer Bailey A Reindl Ira J Bleiweiss Anupma Nayak Mount Sinai Medical Center New York NY 1100 The Mutational Landscape of Breast Adenomyoepitheliomas 250 Anastasios D Papanastasiou Huei Chi Wen Anne M Schultheis Charlotte KY Ng Marcia Edelweiss Salvatore Piscuoglio Luciano G Martelotto Felipe C Geyer Kathleen Burke Maria Rosaria De Filippo Gabriel S Macedo Zsuzsanna Varga Emad Rakha Ian O Ellis Brian P Rubin Britta Weigelt Jorge S Reis-Filho Memorial Sloan Kettering Cancer Center New York NY Nottingham University Nottingham United Kingdom University Hospital Zurich Zurich Switzerland Cleveland Clinic Cleveland OH 1115 Evaluation of EZH2 Protein Expression in Normal Epithelium as a Marker of Risk of Breast Cancer Development Results from the Nurses Health Study 117 Francisco Beca Kevin Kensler Benjamin Glass Rulla M Tamimi Andrew H Beck Beth Israel Deaconess Medical Center Boston MA Harvard Medical School Boston MA Harvard T.H. Chan School of Public Health Boston Brigham and Womens Hospital Boston MA 1130 TP53 Alteration in Morphologically NormalBenign Cells in Breast Terminal Ductal Lobular Units TDLU in Patients with or without BRCA Germline Mutation A Marker for Early Detection of High Risk Patients underline 303 Xi Wang Amber A El-Halaby Todd S Laughlin Paul G Rothberg Kristin Skinner David G Hicks University of Rochester Rochester NY 1145 Histologic Features of Lymph Node Metastases and Their Prognostic Signicance in Node Positive Breast Cancer 110 Sura M Aziz Elisabeth Wik Goril Knutsvik Tor Audun Klingen Ying Chen Benedicte Davidson Hans Aas Turid Aas Ingunn Stefansson Lars A Akslen University of Bergen Bergen Norway Haukeland University Hospital Bergen Norway Vestfold Hospital Trust Tnsberg Norway Akerhus University Hospital Lrenskog Norway 1200 BREAK CC BR 6B SECTION C - CYTOPATHOLOGY CHAIRED BY JENNIFER HIPP AND CHARLES D STURGIS 800 Is There a Value for Age-Based Anal Cancer Screening in HIV-Infected Males 433 Rana Naous Lucinda Steele Kamal K Khurana SUNY Upstate Medical University Syracuse NY 815 Anal Cytology Institutional Review of Statistics and Histologic Correlation 430 Elizabeth Morency Nazneen Fatima Tracey Harbert Dawn Heagley Kruti Maniar Ritu Nayar Northwestern University Chicago IL 830 Human Papillomavirus HPV Genotypes and Anal Squamous Intraepithelial Neoplasia AIN in HIV Positive Women 454 Qiusheng Si Arnold H Szporn Fadi Salem Zesong Zhang David Zhang Tamara L Kalir David C Chhieng Icahn School of Medicine at Mount Sinai New York NY 845 Trends in Rates of Failure of Care in Women with Invasive Cervical Cancer A Meta-Analysis 367 Rohini Chennuri Frida Rosenblum Isam Eltoum University of Alabama at Birmingham Birmingham AL 900 PCR Human Papillomavirus Detection in Invasive Cervical Cancers with Prior Negative HC2 Test Results 482 Chengquan Zhao Xiang Tao BaoWen Zheng Fufen Yin Christopher C Grifth Zaibo Li Bing Luo Xiangdong Ding Xianrong Zhou Uiversity Pittsburgh Medical Center Pittsbrugh PA Obstetrics and Gynecology Hospital of Fudan University Shanghai China Kingmed Diagnostics Guangzhou China Qingdao University Shool of Medicine Qingdao China Emory University Hospital Atlanta GA Ohio State University Wexner Medical Center Columbus OH NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 111NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM 111 915 Improved Detection of CIN 2 Lesions by the Becton Dickinson Focal Point GS Slide Proler No Further Review Technology 437 David Nuttall John OLeary Cara Martin Nick Dallimore Sharon Hillier Sonia Sloan Amanda Savage Helen Clayton Rosemary Fox Public Health Wales Cardiff United Kingdom Royal Gwent Hospital Newport United Kingdom Trinity College Dublin Ireland Glan Clwyd Hospital Bodelwyddan United Kingdom 1100 Atypical Squamous Cells Cannot Exclude High Grade ASC-H High Risk Human Papillomavirus hrHPV- Negative Risk Group Should There Be an Alternative Management 369 Jennifer A Collins Vanessa DeVilla Christopher J VandenBussche Johns Hopkins University School of Medicine Baltimore MD University of Santo Tomas Hospital Manila City Manila Philippines 1115 Bethesda System Reporting of Benign-Appearing Endometrial Cells in Women 40 and Older Analysis of Predictive Value from a Large Academic Womens Hospital Database 479 Jing Yu Agnieszka Onisko R Marshall Austin Magee-Womens Hospital of UPMC Pittsburgh PA 1130 Comparison of Molecular Platforms for Detection of HPV in FNA Biopsies of the Head and Neck 431 Zoltan Nagymanyoki William Karlon William C Faquin Jeffrey F Krane Neal Lindeman Dimity Hall Brenda J Sweeney Britt-Marie Ljung Ronald Balassanian Annemieke van Zante University of California San Francisco San Francisco CA Massachusetts General Hospital Boston MA Brigham and Womens Hospital Boston MA West Pacic Medical Laboratory Santa Fe Springs CA 1145 Trichomonas vaginalis Is an Under-Described Infection in Urine Cytologies from Men 378 Erika E Doxtader Tarik M Elsheikh Cleveland Clinic Foundation Cleveland OH 1200 BREAK CC BR 6A SECTION D - GASTROINTESTINAL CHAIRED BY WADE SAMOWITZ AND EFSEVIA VAKIANI 800 Mutation Prole of Colorectal Neuroendocrine Neoplasm 721 Sun Mi Lee Russell Broaddus Rajesh Singh Rajyalakshmi Luthra Hui Chen The University of Texas MD Anderson Cancer Center Houston TX 815 Clinical Utility of Tumor Hotspot Sequencing in Colorectal Cancer 701 Ryan Jones Siraj M Ali Julia A Elvin Ritu Nayar Nike Beaubier Northwestern University Chicago IL Foundation Medicine Cambridge MA 830 KRAS Mutations Are Frequently Identied in Colorectal Carcinoma with BRAF Wild-Type Sporadic MLH1 Deciency from MLH1 Promoter Hypermethylation 673 Lama Farchoukh Reetesh K Pai Shih-Fan Kuan University of Pittsburgh Medical Center Pittsburgh PA 845 Discrete Punctate Nuclear Staining Pattern For MLH1 Protein Does Not Represent Intact Nuclear Expression 830 Zhaohai Yang Penn State Milton S. Hershey Medical Center Hershey PA 900 Colorectal Carcinomas with Isolated Loss of PMS2 by IHC An Unusual Subset of MSI-H Tumors 632 Lindsay Alpert Xiuli Liu Rish Pai Namrata Setia Shu- Yuan Xiao John Hart Reetesh K Pai University of Chicago Chicago IL Cleveland Clinic Cleveland OH Mayo Clinic Phoenix AZ University of Pittsburgh Pittsburgh PA 915 Microsatellite Instability Is Associated with Reduced Disease Specic Survival in Stage III Colon Cancer in a Series of 1250 Colorectal Cancers Prospectively Tested for MSI 680 Robert Geraghty Helen Mohan Rory Kennelly Ishwaria Balasubramanian Francesco G Sclafani Y-Ling Khaw Elizabeth J Ryan David Fennelly Ray McDermott Diarmuid ODonoghue John Hyland Sean T Martin Ronan OConnell Des Winter Kieran Sheahan St. Vincents University Hospital Dublin Ireland University College Dublin Dublin Ireland 1100 Novel Mutations in African American Colon Cancers Dene a Distinct Clinicopathological Entity Linked to Poor Outcome 822 Joseph Willis Li Li Martina Veigl Alexander Miron Susan Lewis James Lutterbaugh Sanford Markowitz Zhenghe Wang Kishore Guda Case Medical Center Case Comprehensive Cancer Center Cleveland OH Case Comprehensive Cancer Center Cleveland OH 1115 Overall Tumor Budding and Hotspot Scores in Colorectal Cancer A Simplication of the 10 HPF Method 662 Heather Dawson Gregor Rieger Viktor Koelzer Lena Sokol Daniel Inderbitzin Inti Zlobec Alessandro Lugli Institute of Pathology University of Bern Bern Switzerland Inselspital Bern Bern Switzerland 1130 Tumor Deposits and Venous Invasion in Colorectal Cancer Clarication of Morphologic Criteria and Role of These Parameters in Staging 727 Su-Yang Liu Sanjay Kakar University of California San Francisco San Francisco CA PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016112 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016112 1145 Comprehensive Morphological Assessment of Colorectal Cancers Characterized by The Cancer Genome Atlas TCGA Identies Specic Morphology- Molecular Alteration Associations 795 Jinru Shia Deborah Kuk Nikolaus Schultz Michael Berger Sumit Middha Efsevia Vakiani Jaclyn Hechtman Zsoa Stadler Martin Weiser Mithat Gonen David Klimstra Memorial Sloan Kettering Cancer Center New York NY 1200 BREAK CC 602-604 SECTION E - GYNECOLOGIC CHAIRED BY BROOKE E HOWITT AND RUSSELL BROADDUS 800 Fumarate Hydratase Alteration and Other Molecular Changes in Two Histologic Variants of Atypical Leiomyomas 1205 Kate Poropatich Qing Zhang Julianne Martinez de Ubago Norma Frizzell Beihuan Kong Jian-Jun Wei Northwestern University Chicago IL Qilu Hospital Jinan Shandong China University of South Carolina Columbia SC 815 Current Practices in the Processing Diagnosis and Reporting of Endometrial Carcinoma. Results of a Web Based Survey by the International Society of Gynecological Pathologists ISGyP 1199 Vinita Parkash Anais Malpica Xavier Matias-Guiu Esther Oliva W Glenn McCluggage Yale University School of Medicine Bridgeport Hospital New Haven CT The University of Texas MD Anderson Cancer Center Houston TX Hospital Universitari Arnau de Vilanova University of Lleida IRBLleida Lleida Spain Massachusetts General Hospital Boston MA Belfast Health and Social Care Trust Belfast Ireland 830 Intraoperative Consultation in Low Grade Endometrial Endometrioid Adenocarcinoma Is Frozen Section Superior to Gross Examination 1167 Barrett C Lawson Esther Soundar Shilpa Jain Matthew L Anderson Ramya P Masand Baylor College of Medicine Houston TX 845 Lymph Node Metastases in Low Grade Endometrial Carcinoma LGEC What Matters 1124 Elizabeth D Euscher Genevieve R Lyons Roland L Bassett Elvio Silva Anais Malpica MD Anderson Cancer Center Houston TX 900 CTNNB1 Beta Catenin Mutation Identies Patients with Grades 1 or 2 Endometrioid-Type Endometrial Carcinoma at Risk of Recurrence 1164 Katherine Kurnit Bryan Fellman Diana Urbauer Gordon Mills Russell Broaddus MDACC Houston TX 915 The Utility of a Next-Generation Sequencing NGS Panel to Identify Germline Mutations Associated with Endometrial Cancer 1214 Kari Ring Amanda Bruegl Brian Allen Eric Elkin Nanda Singh Anne-Renee Hartman Molly Daniels Russell Broaddus M.D. Anderson Cancer Center Houston TX Myriad Genetics Inc. Salt Lake City UT 1100 Hysterectomy Specimens of Patients with Lynch Syndrome Clinicopathologic Study of 70 Cases 1203 Ana S Pires-Luis Carla Bartosch Catarina Meireles Carla Pinto Jose M Lopes Kristen M Shannon Manuel R Teixeira Esther Oliva IPO-Porto Porto Portugal CHSJ Porto Portugal Massachusetts General Hospital Boston MA 1115 Inter-Observer Agreement in Endometrial Carcinoma EC Diagnosis Varies Depending on TCGA Subgroup Assignment 1139 Lien Hoang Mary A Kinloch Katherine Grondin Cheng-Han Lee Carol Ewanowich Martin Kobel David G Huntsman Jessica N McAlpine Robert Soslow Blake Gilks Memorial Sloan Kettering Cancer Center New York NY Saskatoon City Hospital Saskatoon SK Canada Laval University Quebec City QC Canada University of Edmonton Edmonton AB Canada University of Calgary Calgary AB Canada BC Cancer Agency Vancouver BC Canada Vancouver General Hospital Vancouver BC Canada 1130 Proactive Molecular Risk Classier for Endometrial Cancer ProMisE for Improved Endometrial Cancer Management 1132 Blake Gilks Aline Talhouk Melissa McConechy David G Huntsman Cheng-Han Lee Jessica N McAlpine University of British Columbia Vancouver Canada University of Alberta Edmonton Canada 1145 The Cancer Genome Atlas-Based Molecular Classier Identies Prognostically Signicant Subgroups of Grade 3 Endometrioid Carcinoma of the Endometrium 1235 Robert Soslow Blake Gilks Douglas A Levine Memorial Sloan Kettering Cancer Center New York NY Vancouver General Hospital Vancouver Canada 1200 BREAK CC 606-607 SECTION F - TECHNIQUES CHAIRED BY MICHAEL CRUISE AND KUMARASEN COOPER 800 Mass Spectrometry of Formalin-Fixed Parafn- Embedded Tissue Proteome Phosphoproteome and Histone Post-Translational Modications 2087 John Wojcik Simone Sidoli Benjamin A Garcia Kumarasen Cooper Hospital of the University of Pennsylvania Philadelphia PA University of Pennsylvania Philadelphia PA NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 113NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM 113 815 Feasibility of Ex-Vivo Confocal Fluorescence Microscopy for Rapid Evaluation of Tissues in Surgical Pathology Practice 2049 Savitri Krishnamurthy Andrea Cortes Mirtha Lopez Michael Wallace Sharjeel Sabir Gordon Mills Kenna Shaw MD Anderson Cancer Center Houston TX 830 Front End Genomics Using an Alternative Approach for the Recovery of High Quality DNA from Core Needle Biopsies 2060 Wilfrido Mojica Paul Mojica Rama Dey-Rao Don Sykes University at Buffalo Buffalo NY UCLA Los Angeles CA 845 In Situ Evaluation of Telomerase Expression and Function in Human Cells and Tissues 2040 Nancy Greenland Ajay Ravindranathan Beth Cimini Morgan Diolaiti Bradley Stohr University of California San Francisco CA 900 Predicting DNA Yield by Calculation of Extracted Tissue Area Combining Digital and Molecular Pathology to Empower Genetic Testing 2064 Mariana Petaccia de Macedo Lauren E Haydu Tiffany L Calderone Khalida Wani Sheila Duncan Michael T Tetzlaff Victor G Prieto Michael A Davies Jeffrey E Gershenwald Alexander Lazar MD Anderson Cancer Center Houston TX 915 Fluorescein A Quick Inexpensive Supplement to Frozen Section for Diagnosing Myometrial Invasion in Endometrial Cancer 2065 Charles Quick Kristin Zorn Alexander Burnett University of Arkansas for Medical Sciences Little Rock AR 1100 Ex Vivo Confocal Laser Endomicroscopy Is Useful in the Evaluation of Pancreatic Cystic Lesions 2072 Benjamin J Swanson Wendy Frankel Darwin L Conwell Peter Muscarella Somashekar G Krishna The Ohio State University Wexner Medical Center Columbus OH Monteore Medical Center Bronx NY 1115 New Laser Based Imaging Approaches for Infrared Spectroscopy Examples in Colon and Liver Tissue 2063 Ramayee Periakaruppan Vishal Varma Hari Sreedhar Francesca Gambacorta Grace Guzman Michael Walsh University of Illinois Hospital and Health Sciences System Chicago IL 1130 Deep Convolutional Neural Network-Based Mitosis Detection in Invasive Carcinoma of Breast by Smartphone-Based Histologic Image Acquisition 2048 Seokhwi Kim Jungin Lee Soohyun Hwang Sooyoun Cho Sangheum Hwang Hyo-Eun Kim Hyemin Shim Miso Yang Sangyong Song Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea Lunit Inc. Seoul Republic of Korea Seoul National University Seoul Republic of Korea 1145 Fusion Gene Detection in Sarcomas by the NanoString nCounter Fusion Gene Analysis Assay 2030 Kenneth Chang Angela Goytain Xiu Qing Wang Tony Ng KK Womens and Childrens Hospital Singapore Singapore Duke-NUS Graduate Medical School Singapore Singapore University of British Columbia Vancouver BC Canada Vancouver General Hospital Vancouver BC Canada 1200 BREAK CC 608-609 SECTION G - PULMONARY CHAIRED BY NATASHA REKHTMAN AND RODNEY A SCHMIDT 800 Reproducibility in Classication of Small Lung Adenocarcinomas An International Interobserver Study 1920 Angela R Shih Alona Muzikansky Emine Bozkurtlar Jin-Haeng Chung Yuko Minami Lida P Hariri Andre Moreira Hironori Uruga He Wang Akihiko Yoshizawa Mari Mino-Kenudson Massachusetts General Hospital Boston MA Marmara University Istanbul Turkey Seoul National University Bundang Hospital Seongnam Republic of Korea National Hospital Organization Ibarakihigashi National Hospital Naka Japan Memorial Sloan Kettering Cancer Center New York City NY Temple University School of Medicine Philadelphia PA Kyoto University Hospital Kyoto Japan 815 Bilateral Invasive Mucinous Adenocarcinomas Former Mucinous Bronchioloalveolar Carcinoma Molecular Analysis Conrms Intrapulmonary Spread Rather Than Separate Primary Tumors 1880 Charles Leduc Kay See Tan Shaozhou Tian Snjezana Dogan Marc Ladanyi William Travis Natasha Rekhtman MSKCC NY NY 830 Dissecting Intra-Tumor Heterogeneity of Lung Adenocarcinoma Reveals Dominant Branching and Private Gene Mutations within Individual Tumor Nodules 1903 Giuseppe Pelosi Alessio Pellegrinelli Alessandra Fabbri Adele Busico Giulio Settanni Barbara Valeri Angelica Sonzogni Federica Perrone Elena Tamborini Ugo Pastorino Fondazione IRCCS Istituto Nazionale Tumori and Universit degli Studi Milan Italy Fondazione IRCCS Istituto Nazionale Tumori Milan Italy 845 Next Generation Sequencing Reveals Genomic Heterogenity of ALK Fusion Breakpoints in Non -Small Cell Lung Cancer 1914 Jason N Rosenbaum Julie Branson Catherine E Cottrell John D Pfeifer Shashikant Kulkarni Eric J Duncavage Washington University School of Medicine Department of Pathology and Immunology St. Louis MO PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016114 PROFFERED PAPERS Monday March 14 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016114 900 Identication of a Novel Partner Gene KIAA1217 Fused to RET Functional Characterization and Inhibitor Sensitivity of Two Isoforms in Lung Adenocarcinoma 1858 Yoon-La Choi Mi-Sook Lee Jhingook Kim Samsung Medical Center Seoul Korea 915 ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung Adenocarcinoma Application in Clinical Practice 1900 Prodipto Pal Peter Hammerman David J Kwiatkowski Bruce E Johnson Lynette M Sholl Brigham and Womens Hospital Boston MA Dana Farber Cancer Institute Boston MA 1100 Two Plasma MicroRNA Panels for Diagnosis and Subtype Discrimination of Lung Cancer 1885 Shaohua Lu Hui Kong Yingyong Hou Hongguang Zhu Chunxue Bai Zhongshan Hospital Fudan University Shanghai China Fudan University Shanghai China 1115 Histologic Findings of Video-Assisted Thoracoscopic Surgery Lung Biopsies Performed in Patients with Treatment-Resistant Severe Asthma 1930 Humberto Trejo Bittar Daniel Doberer Mitra Mehrad Sally Wenzel Samuel A Yousem University of Pittsburgh Medical Center Pittsburgh PA 1130 Venous Infarcts and Pathologic Changes Mimicking Pulmonary Venoocclusive Disease Caused by Pulmonary Vein Obstruction outside the Lungs 1895 Sanjay Mukhopadhyay Andrea V Arrossi Carol Farver Cleveland Clinic Cleveland OH 1145 Identication of Steroid Receptor Expression in Patients with Usual Interstitial Pneumonia 1890 Mitra Mehrad Humberto Trejo Bittar Samuel A Yousem University of Pittsburgh Medical Center Pittsburgh PA 1200 BREAK CC 615-617 SECTION H - POTPOURRI CHAIRED BY MARA H RENDI AND BOBBI PRITT 800 Evaluation For Heritable Cardiovascular Disorders Using Targeted Next-Generation Sequencing on Formalin-Fixed Parafn Embedded Tissue 324 Charles Leduc Laura J Train Rajeswari Avula Katrina E Kotzer Michelle L Kluge Michael J Ackerman Linnea M Baudhuin Joseph J Maleszewski Mayo Clinic Rochester MN 815 Long Term Durability of Edwards SAPIEN Transcatheter Aortic Valves A Pathology Study 322 Elena Ladich Kazuyuki Yahagi Robert Kutys Michelle Olson Renu Virmani CVPath Institute Gaithersburg MD 830 C4d-Negative DSA Positive Antibody-Mediated Rejection in Heart Allograftsunderline 334 Kelly Smith Karen Nelson University of Washington Seattle WA BloodWorks Northwest Seattle WA 845 TdT-Positive Cells in Inamed Pediatric Kidney A Potential Diagnostic Pitfall 1833 Jennifer Dunlap Xavier Stacey Sarah Click Michael J Cascio Megan Troxell OHSU Portland OR 900 Frequent HRAS Mutations in Ectomesenchymoma ECM Overlapping Genetic Abnormalities with Embryonal Rhabdomyosarcoma ERMS 1836 Shih-Chiang Huang Rita Alaggio Yun-Shao Sung Narasimhan P Agaram Cristina Antonescu Memorial Sloan Kettering Cancer Center New York NY Chang Gung Memorial Hospital Taoyuan Taiwan Padova University Hospital Padova Italy 915 NDER A Novel Web Application for Teaching Histology to Medical Students 560 Elizabeth U Parker Nicholas P Reder Daniel Glasser Jonathan C Henriksen Mara H Rendi University of Washington Seattle WA 1100 Correlation between USMLE Scores and Resident In- Service Examination RISE Scores Should USMLE Scores Be Used as a Benchmark When Selecting Residents 542 Yasemin Akdas Kamran M Mirza Guliz A Barkan University of Florida Gainesville FL Loyola University Medical Center Maywood IL 1115 Impact of Pathologist Involvement in Sarcoma and Rare Tumor Patient Support Groups on Facebook A Survey of 541 Patients 552 Jasmine Haller Marjorie David Nathan Lee Pamela Holtzclaw Williams Sara C Shalin Jerad Gardner University of Arkansas for Medical Sciences Little Rock AR 1130 Validity of Minimally Invasive Autopsy MIA in Assessing Cause of Death in Adults from Developing Countries 1535 Paola Castillo Miguel J Martinez Esperanca Ussene Dercio Jordao Lucilia Lovane Carla Carrilho Mamudo R Ismail Cesaltina Lorenzoni Jordi Vila Clara Menndez Quique Bassat Jaume Ordi ISGlobal Barcelona Center International Health Research CRESIB Hospital Clnic Barcelona Spain Maputo Central Hospital Maputo Mozambique Maputo Mozambique 1145 Immunohistochemistry Is Rarely Justied for the Diagnosis of Viral Infections 1544 Isaac H Solomon Jason L Hornick Alvaro C Laga Brigham and Womens Hospital Boston MA 1200 BREAK NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 115NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 115 STOWELL-ORBISON AWARD POSTERS AUTOPSY 1 Total Articial Heart An Autopsy Case Series 8 Craig Dunseth Dennis J Firchau University of Iowa Iowa City IA 2 Malignant Transformation in Neurocutaneous Melanosis 11 Andrew Guajardo Christopher J VandenBussche D Ashley Hill Miguel Reyes-Mugica Cheng-Ying Ho The Johns Hopkins University Baltimore MD Chrildrens National Medical Center Washington DC Childrens Hospital of Pittsburgh Pittsburgh PA 3 Beckwith-Wiedemann Syndrome with Placental Mesenchymal Dysplasia in a Male 46XY Infant Unique Findings at Autopsy 16 Annie Laib Jerzy Stanek University of Cincinnati Medical Center Cincinnati OH Cincinnati Childrens Hospital Cincinnati OH 4 Comparison of Clinical Diagnoses and Autopsy Findings 6 Year Retrospective Study 17 Hyejong S Marshall Clara Milikowski Jackson Memorial Hospital University of Miami Miami FL 5 Different Strokes for Different Folks A Case Series of Abdominal Apoplexy 24 Varsha Podduturi Joseph M Guileyardo Southwestern Institute of Forensic Sciences Dallas TX Baylor University Medical Center Dallas TX 6 Pulmonary Emboli and the Risk of Mortality in a Diverse Disease Environment 25 Maryam Shabihkhani Jody E Hooper Johns Hopkins Hospital Baltimore MD Johns Hopkins University School of Medicine Baltimore MD STOWELL-ORBISON AWARD POSTERS BONE AND SOFT TISSUE PATHOLOGY 7 Ewing Sarcoma ES with ERG Gene Rearrangements A Molecular Study Focusing on the Prevalence of FUS- ERG and Common Pitfalls in Detecting EWSR1-ERG Fusions by FISH 47 Sonja Chen Kemal Deniz Yun-Shao Sung Lei Zhang Sarah M Dry Cristina Antonescu Memorial Sloan Kettering Cancer Center New York NY Erciyes University Kayseri Turkey UCLA Los Angeles CA 8 MDM2 and CDK4 Immunohistochemistry Is Inadequate in the Diagnosis of Problematic Low-Grade Lipomatous Tumors A Follow-Up Study 48 Michael Clay Anthony Martinez Mark A Edgar Emory University Hospital Atlanta GA 9 Identication of Recurrent Copy Number Alterations Specic to the De-Differentiated Component of Liposarcoma Using Capture-Based Next Generation Sequencing NGS 51 Brianne H Daniels Daniel E Roberts Nancy Joseph Andrew E Horvai University of California San Francisco San Francisco CA 10 Expression of TLE-1 and CD99 in Carcinoma Pitfalls in Diagnosis of Synovial Sarcoma 99 Daniel Zaccarini Xiaobing Deng Jamie Tull Charlene Maciak Alfredo Valente Shengle Zhang SUNY Upstate Medical University Syracuse NY STOWELL-ORBISON AWARD POSTERS BREAST PATHOLOGY 11 Histologic Characteristics of Breast Carcinomas with Genetic Variants of Uncertain Signicance 103 Ahmed Abdulrahman Rebecca Heintzelman Melanie Corbman Fernando Garcia Drexel University College of Medicine Philadelphia PA Cancer Treatment Centers of America at Eastern Regional Medical Center Philadelphia PA 12 Outcomes of Benign Intraductal Papillomas IDP Diagnosed on Core Biopsy Do All Need to Be Excised 108 Jaya R Asirvatham Angela Wu Julie Jorns University of Michigan Ann Arbor MI 13 Axillary Lymph Node FNA vs CNB in Breast Cancer Patients A Blinded Prospective Study 115 Gonzalo Barraza Robert L Schmidt Elke Jarboe Jason M Wells Nicole Winkler Rachel E Factor University of Utah Health Sciences Center Salt Lake City UT 14 Do Breast Papillomas without Atypia on Core Biopsy Require Excision A 10-Year Single Institution Study and Review of the Literature 120 Christine Bookhout Sheryl Jordan Thomas Lawton UNC Health Care Chapel Hill NC 15 Repeat HER-2neu Testing on Grade 3 Invasive Breast Carcinoma Resections 131 Cody Carter Julie Jorns University of Michigan Ann Arbor MI 16 Micropapillary Mucinous Breast Carcinoma An Underrecognized Variant 140 Katrina Collins Andrew Ricci Hartford Hospital Hartford CT 17 Optimizing Intraoperative Sentinel Lymph Node Evaluation 142 Margaret Compton Emily S Reisenbichler Vanderbilt University Medical Center Nashville TN Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016116 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016116 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 18 miR-139 in Breast Cancer Tumors and Serum a Surrogate Marker for Tumor Aggression 143 Hongyan Dai Sarah Schmitt Ziyan Pessetto Fang Fan Andrew K Godwin Ossama Tawk Kansas University Medical Center Kansas City KS 19 Sentinel Node Metastasis in Breast Cancer Size Matters 144 Joanna Dalland Patrick C McGrath Reed Spaulding Robert McDonald Shannon Crook Luis Samayoa University of Kentucky Lexington KY 20 The Detection of IHC-FISH- ERBB2 Non-Amplication Mutations in 5606 Cases of Refractory and Metastatic Breast Cancer An Emerging Opportunity for Anti-HER2 Targeted Therapies 146 Siddhartha Dalvi Katherine Pinheiro Ann B Boguniewicz Kai Wang Siraj M Ali Julia A Elvin Jo- Anne Vergilio James Suh Vincent A Miller Philip J Stephens Jeffrey S Ross Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA 21 Decreased Expression of miR-26b in Advanced Breast Cancer 149 Qingqing Ding Yan Wang Zhuang Zuo Naoto T Ueno Wei Wei Lei Huo University of Texas MD Anderson Cancer Center Houston TX 22 Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterationsunderline 152 Alana R Donaldson Shashirekha Shetty Christine Rivera Bryce P Portier James R Cook G T Budd Erinn Downs-Kelly Roger D Klein Christopher P Lanigan Raymond Tubbs Benjamin C Calhoun Cleveland Clinic Cleveland OH Houston Methodist Hospital Houston TX University of Utah Salt Lake City UT 23 Apocrine Carcinomas Represent a Distinct Androgen Receptor-Positive Clinicopathologic Subset of Triple- Negative Breast Cancers 162 Chelsea E Gottlieb Emaculate V Tebit Scott M Wendroth Kristen A Atkins Tiffany Pierson Christiana M Brenin Anne M Mills UVA Charlottesville VA 24 Correlation of p16 Expression on Cancer and Stromal Cells with Clinicopathological and Immunohistochemical Features of Lobular Breast Carcinoma 169 Aparna Harbhajanka Ihab Lamzabi Richa Jain Ritu Ghai Vijaya B Reddy Paolo Gattuso Rush University Medical College Chicago IL 25 Distant Metastases in Breast Cancer Patients with Oncotype Dx Recurrence Score Lower Than 18 201 Melissa Krystel-Whittemore Edi Brogi Zenica L Bowser Maura Dickler Clifford Hudis Hannah Y Wen The University of Kansas Medical Center Kansas City KS Memorial Sloan Kettering Cancer Center New York NY 26 Androgen Receptor Expression in HER2-Positive Breast Carcinomas 203 Alexandra Larson Irene B Helenowski Jennifer Pincus Julianne M Ubago Adriana Rosca Luis Z Blanco Kalliopi P Siziopikou Northwestern University Feinberg School of Medicine Chicago IL 27 Intratumoral Heterogeneity of Common Protein Biomarkers Assessed by Immunohistochemistry in Breast Cancer Tissues 206 Jie Li Theresa Dawidek Veronika Liegsalz Vasilis Tzalis Anette Feuchtinger Stefanie Avril Case Western Reserve University and University Hospitals Case Medical Center Cleveland OH Technische Universitt Mnchen Munich Germany Helmholtz Zentrum Mnchen Neuherberg Germany 28 Analysis of Malignant Phyllodes Tumor MPT Genomic Landscape Using Capture-Based Next Generation Sequencing Cb-NGS 213 Su-Yang Liu Nancy Joseph Yunn-Yi Chen Poonam Vohra Gregor Krings UCSF San Francisco CA 29 Breast Core Biopsy of Vascular Neoplasms -Pathologic Features Imaging and Clinical Findings 216 Jose Mantilla Arango Esperanza Villanueva-Siles Susan A Fineberg Monteore Medical Center Bronx NY 30 Is It Worth Performing ER PR and HER2 Assays on All Concurrently Sampled Ipsilateral Breast Cancers Study of 174 Biopsies from 85 Patients 218 Shivali Marketkar Kamaljeet Singh Katrine Hansen Margaret Steinhoff Women and Infants Hospital Providence RI Rhode Island Hospital Providence RI 31 Intraoperative Consultation of Sentinel Lymph Nodes for Metastatic Breast Carcinoma in the Context of the ASCOSOG Z0011 Trial 219 Robert McDonald Patrick C McGrath Reed Spaulding Joanna Dalland Shannon Crook Luis Samayoa University of Kentucky Lexington KY 32 Expression of Traditional Melanocytic Markers in Invasive Mammary Carcinoma 220 Stephanie McGregor Gabrielle M Baker University of Chicago Hospitals Chicago IL 33 Validation of Modied Magee Equation to Predict the Oncotype DX Recurrence Score 238 Cameron Neely Jing Yang Shristi Bhattarai Limin Peng Uma Krishnamurti Ritu Aneja Xiaoxian Li Emory University School of Medicine Atlanta GA Rollins School of Public Health Emory University Atlanta GA Georgia State University Atlanta GA 34 Reactive Squamous Metaplasia in the Breast A 20-Year Review 239 Emily R Nelson Pedram Argani Ashley Cimino- Mathews Johns Hopkins Baltimore MD Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 117NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 117 35 Adrogen Receptor AR Expression in Resected Ductal Carcinoma In Situ DCIS of Breast 240 Laila Nomani Olaronke O Oshilaja Benjamin C Calhoun Christine N Booth Charles D Sturgis Clevleland Clinic Cleveland OH 36 Clinically Advanced and Metastatic Mucinous Carcinoma of the Breast A Comprehensive Genomic Proling Study 241 Sahar Nozad Kai Wang Siraj M Ali Ann B Boguniewicz Depinder Khaira Julia A Elvin Jo- Anne Vergilio James Suh Vincent A Miller Philip J Stephens Jeffrey S Ross Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA 37 Stromal ColX1 and Tumor-Inltrating Lymphocytes Predict Response to Neoadjuvant Therapy in HER2- Positive Breast Cancer Depending on Estrogen Receptor Status 246 Madhu Ouseph Alexander Brodsky Jinjun Xiong Dongfang Yang Murray B Resnick Yihong Wang Rhode Island Hospital Brown University Providence RI Women and Infants Hospital Brown University Providence RI 38 Papillomas without Atypia Can Excision Be Spared 252 Fresia Pareja Sandra Brennan Melissa Murray Zenica L Bowser Elizabeth Morris Edi Brogi Adriana D Corben MSKCC NYC NY 39 Tumor Inltrating Lymphocytes TILs in Triple Negative Breast Cancer TNBC A Three-Tier System Predicts Survival 253 Fresia Pareja Edi Brogi Li Fu Zenica L Bowser Muzaffar Akram Larry Norton Hannah Y Wen MSKCC NYC NY Tianjin Medical University Tianjin China 40 p16 Is Highly Expressed in TNT and Is Associated with Worse Overall Survival OS in All Breast Cancers BC 260 Kimberly S Point du Jour Rachel Geller Zachary J Dureau Yuan Liu Cynthia Cohen Gabriela M Oprea- Ilies Emory University Atlanta GA Winship Cancer Institute 41 Integrated Radiopathologic Approach to Improve Diagnostic Accuracy of Nodal Metastasis in Breast Cancer 265 Deepthi Rao Irfanullah Haider Fang Fan Onalisa Winblad Ossama Tawk Kansas University Medical Center Kansas City KS 42 Impact of Cavity Shave Margins in Lumpectomies for Breast Carcinoma on Final Margin Status and Rate of Re-excision 273 Nagla Salem Sudeshna Bandyopadhyay Vishakha Pardeshi MHD Fayez Daaboul Lydia Choi-Kim Rouba Ali-Fehmi Shashi Madan WSUDMC Detroit MI 43 Benign Vascular Lesions of the Breast Do Not Require Excision 277 Christopher Sebastiano Lucas Gennaro Edi Brogi Elizabeth Morris Muzaffar Akram Zenica L Bowser Adriana D Corben Sandra Brennan Melissa Murray Memorial Sloan Kettering Cancer Center NY NY 44 Immunohistochemical Prole of Male Breast Carcinoma 279 Kate M Serdy David Dabbs Rohit Bhargava Magee-Womens Hospital of University of Pittsburgh Medical Center Pittsburgh PA 45 Basal Biomarkers Nestin and INPP4b Accurately Identify Intrinsic Subtype in ER Weakly-Positive Breast Cancer 281 Brandon S Shefeld Karama Asleh-Aburaya Xiuqing Wang Dongxia Gao Jennifer Won Christine Chow Robert Wolber Blake Gilks Nickolas Myles Malcolm M Hayes Philip Bernard Torsten O Nielsen Stephen KL Chia Zuzana Kos University of British Columbia Vancouver BC Canada University of Utah Salt Lake City UT University of Ottawa Ottawa ON Canada 46 Incidence of Axillary Metastasis in Breast Carcinomas Measuring 1cm or Less 286 Reed Spaulding Patrick C McGrath Joanna Dalland Robert McDonald Shannon Crook Luis Samayoa University of Kentucky Lexington KY 47 High Subcapsular CD4CD8 Lymphocyte Ratio in the Positive SentinelAxillary Lymph Node in Breast Cancer 289 Hongxia Sun Min Li Yan Gao Robert L Hunter Songlin Zhang The University of Texas Health Science Center at Houston Houston TX 48 Suggested Management of Breast Sclerosing Intraductal Papilloma without Atypia SIP wo A Diagnosed on Core Biopsy CBX A Semiquantitative Approach 290 Brittany Symbol Andrew Ricci Hartford Hospital Hartford CT 49 PD-L1 Expression and the Immune Microenvironment in Primary Invasive Lobular Carcinomas of the Breast 293 Elizabeth Thompson Janis Taube Rebecca J Asch- Kendrick Aleksandra Ogurtsova Haiying Xu Rajni Sharma Alan Meeker Pedram Argani Leisha Emens Ashley Cimino-Mathews Johns Hopkins Hospital Baltimore MD 50 Mucocele-Like Lesions Diagnosed on Breast Core Biopsy and the Risk of Upgrade to Carcinoma on Excision 310 Gloria Zhang Dana Ataya Paulette Lebda Benjamin C Calhoun Cleveland Clinic Cleveland OH Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016118 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016118 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC STOWELL-ORBISON AWARD POSTERS CARDIOVASCULAR PATHOLOGY 51 Regional Differences in Ascending Aortic Histology A Comparative Histomorphologic Assessment with Implication for Pathologic Classication 314 Md Shahrier Amin Cecilia Wu Charles Leduc Peter T Lin Sarah M Jenkins William D Edwards Joseph J Maleszewski Mayo Clinic Rochester MN 52 Repair of the Injured Adult Heart Involves Regionally Specic c-Kit Cardiac Stem Cells and New Myocyte Formation 315 David Angert Remus Berretta Hajime Kubo Tim Starosta Daniel Luthringer Steven R Houser Cedars-Sinai Medical Center Los Angeles CA Temple University School of Medicine Philadelphia PA 53 Endothelial Cell Chimerism in Human Cardiac Allografts 320 Gregory A Fishbein Maristela L Onozato Adriana Luk Michael M Givertz Robert F Padera Jr. Anthony J Iafrate Richard N Mitchell Brigham and Womens Hospital Boston MA Massachusetts General Hospital Boston MA 54 Sudden Cardiac Death in Young Athletes Are There Gender Differences in the Cause of Death 328 Kalliopi Pilichou Stefania Rizzo Elisa Carturan Marialuisa Valente Gaetano Thiene Cristina Basso University of Padua Padua Italy 55 Morphologic and Genetic Features of Arrhythmogenic Cardiomyopathy Are There Differences between Sudden Death and Cardiac Transplantation Cases 329 Kalliopi Pilichou Stefania Rizzo Elisabetta Lazzarini Elisa Carturan Marco Cason Rudy Celeghin Annalisa Angelini Marialuisa Valente Gaetano Thiene Cristina Basso University of Padua Padua Italy 56 Sudden Cardiac Death with Structurally Normal Heart ECG Tracing and Molecular Autopsy as a Guide for Conduction System Investigation 330 Kalliopi Pilichou Federico Migliore Marco Cason Stefania Rizzo Rudy Celeghin Emanuele Bertaglia Elisabetta Lazzarini Elisa Carturan Marialuisa Valente Gaetano Thiene Cristina Basso University of Padua Padua Italy 57 Formalin Perfusion-Fixation of Autopsy Hearts for a More Accurate Evaluation of Coronary Artery Stenosis 336 Jonathan Vaucher Justine Turmel-Roy Olga Sazonova Sylvain Page Sylvain Trahan Christian Couture Philippe Joubert Institut Universitaire de Cardiologie et de Pneumologie de Qubec Quebec QC Canada 58 Beta Amyloid Precursor Protein in Carotid Artery Plaque Macrophages Correlation with Features of Plaque Stability 339 Michael B Ward Tyler A Jensen Krishna Narra Scott McNally Dylan Miller Intermountain Medical Center University of Utah School of Medicine Salt Lake City UT University of Utah School of Medicine Salt Lake City UT 59 Implementation of the New AECVPSCVP Aorta Consensus Grading Scheme 340 Kevin Waters Andrew Guajardo Marc K Halushka Johns Hopkins University SOM Baltimore MD STOWELL-ORBISON AWARD POSTERS CYTOPATHOLOGY 60 The Development of a Telomerase Immunocytochemical Assay for the Detection of Urothelial Neoplasms in Urinary Tract Cytopathology Specimens 345 Derek B Allison Minesh Lalla Sterling E Ford Jennifer A Collins Christopher J VandenBussche The Johns Hopkins University School of Medicine Baltimore MD Sienna Cancer Diagnostics Ltd. Melbourne Australia 61 ATRX and DAXX Immunohistochemistry IHC in Pancreatic Neuroendocrine Tumor PNET Fine Needle Aspirations FNA- Can They Be Clinically Useful 349 Vaidehi Avadhani Abigail Goodman Cynthia Cohen Momin T Siddiqui Emory University Hospital Atlanta GA 62 PLAG1 An Immunohistochemical IHC Marker with Limited Utility in Separating Pleomorphic Adenoma PA from Other Basaloid Salivary Gland Tumors 350 Vaidehi Avadhani Cynthia Cohen Momin T Siddiqui Emory University Hospital Atlanta GA 63 ALK Rearrangement Fluorescent In-Situ Hybridization Testing for Pulmonary Adenocarcinoma Utilizing Fine Needle Aspiration Smears 357 Scott Bibbey Julie Branson Anjum Hassan Tu Dung T Nguyen Brian T Collins Washington University in St. Louis St. Louis MO 64 Bile Duct Brushings Accuracy and Interobserver Agreement 361 Mary Anne Brett Jennifer Ramsay Leyo Ruo Jessica Bogach Shangguo Tang Tariq Aziz Joseph Beyene Binod Neupane Anne Ecobichon-Morris Arlene Murray Lidia E Siek Daniel Kowalsky-Moskaliuk Alice Lytwyn McMaster University Hamilton ON Canada 65 Candida and Trichomonas and High-Risk HPV Infection 368 Adam Cloe Tatjana Antic University of Chicago Chicago IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 119NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 119 66 False Negative HPV Tests in Women with High Grade Squamous Intraepithelial Lesion or Carcinoma Pap Tests Clinical-Pathological Correlation 371 Suzanne M Crumley Haijun Zhou Genevieve R Lyons Roland L Bassett Abha Khanna Gregg Staerkel Ming Guo The University of Texas MD Anderson Cancer Center Houston TX 67 Morphologic Criteria for Atypia in Upper Urinary Tract Cytology Should It Be Different from the Lower Urinary Tract Criteria of the Paris System of Reporting Urinary Tract Cytology TPS 384 Ozlem Fidan-Ozbilgin Burak Bahar Stefan E Pambuccian Eva M Wojcik Guliz A Barkan Loyola University Medical Center Maywood IL 68 Cytopathologist-Performed Ultrasound-Guided Fine Needle Aspiration of PET-Detected Lesions 389 Adam J Gomez David Levy Christina S Kong Steven R Long Stanford Health Care Stanford CA 69 Benign Endometrial Cells Reporting on Pap Smears The 2014 Bethesda System Is 45-Year Cutoff Appropriate A Study Based on 672000 Pap Smears with Follow-Up 390 Zakaria Grada Cherie Paquette Claire M Eklund C James Sung Margaret Steinhoff M Ruhul Quddus Women Infants HospitalAlpert Medical School of Brown University Providence RI 70 PSMA Is a Sensitive Marker for the Diagnosis of Metastatic Prostatic Carcinoma in Cytology Specimens 406 Yuying Jiang Claire W Michael University Hospitals Case Medical Center Cleveland OH 71 Relative Value of a Cytopathologist 409 Shivani Kandukuri Steven Meschter Jeffrey Prichard Geisinger Medical Center Danville PA 72 Fluorescent In-Situ Hybridization with Bile Duct Brushing Specimens Correlation and Outcomes with Reex Testing Algorithm 411 Stanley Kwong Brian T Collins Washington University in St. Louis St. Louis MO 73 The Impact of Application of the Proposed Paris System on Concordance Rates and Frequency of Diagnosis of Low-Grade Urothelial Carcinoma on Voided Urine Cytology 422 Martin J Magers Judy C Pang Xin Jing Michael H Roh Brian Smola Madelyn Lew University of Michigan Ann Arbor MI 74 Utility of BRCA1-Associated Protein 1 BAP1 Immunoperoxidase Stain in Cytology SmearCell Block Preparations to Differentiate Benign Versus Malignant Mesothelial Proliferations 426 Zula McCroskey Gregg Staerkel Sinchita Roy Chowdhuri MD Anderson Cancer Center Houston TX 75 Pancreatic Endoscopic Ultrasound-Guided Fine Needle Aspiration The Impact of Rapid On-Site Evaluation 427 Ross A Miller Mary R Schwartz Kumar Krishnan Dina R Mody Houston Methodist Houston TX 76 Utility of Immunohistochemistry and ETV6 12p13 Gene Rearrangement in Identifying Mammary Analog Secretory Carcinoma of Salivary Gland among Previously Diagnosed Cases of Acinic Cell Carcinoma 432 Rana Naous Shengle Zhang Alfredo Valente Melissa Stemmer Kamal K Khurana SUNY Upstate Medical University Syracuse NY 77 Next Generation Sequencing Adds Value to the Pre- Operative Diagnosis of Pancreatic Cysts 442 Matthew W Rosenbaum Martin Jones Jonathan Dudley Long Le A John Iafrate Martha Pitman Massachusetts General Hospital Boston MA Stanford University Palo Alto CA 78 Evaluation of Flow Cytometry Results from Serial Lymph Node Specimens Shows Equally Robust Results for FNA and Core Needle Biopsy Specimens in Comparison to Open Biopsy Specimens 443 Julie A Rosser Kaleigh E Lindholm Kathleen C Torkko Jeffrey T Schowinsky University of Colorado School of Medicine Aurora CO 79 Accuracy of Grading Pancreatic Neuroendocrine Tumors on Fine Needle Aspiration Samples 449 Kurt Schaberg Hubert D Lau Allison J Zemek Teri A Longacre Christina S Kong Stanford University Stanford CA 80 RAS Mutations Are the Most Common Genetic Alteration in Indeterminate Thyroid Cytology -2 Years Institutional Experience 452 Maryam Shahi Rupendra Shrestha Andrew Nelson Lynn Burmeister Maria Evasovich Swenson Khalid Amin University of Minnesota Minneapolis MN 81 Utility of Folate Receptor Alpha FRA Immunohistochemistry IHC in Cell Blocks CB of Breast Ductal Carcinoma Mllerian Serous Carcinoma and Lung Adenocarcinoma 453 Umer Sheikh Cynthia Cohen Momin T Siddiqui Emory University Hospital Atlanta GA 82 On-Site Adequacy Evaluation Does Not Affect the Rate of Nondiagnostic Thyroid Fine Needle Aspiration 466 Janice Tyler Helen Wang Pamela Hartzband James V Hennessey Michiya Nishino Beth Israel Deaconess Medical Center Boston MA Harvard Medical School Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016120 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016120 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 83 Next Generation Sequencing of NSCLC in EBUS-FNA vs. Corresponding FFPE Samples 486 Yaolin Zhou Jordan P Reynolds Maureen A Jakubowski Zhen Wang Patrick C Feasel Roger D Klein Yu-Wei Cheng Cleveland Clinic Cleveland OH STOWELL-ORBISON AWARD POSTERS DERMATOPATHOLOGY 84 Laser Microdissection and Mass Spectrometric- Based Proteomic Analysis of Sclerotic Bodies Elastocollagenous Balls in Nephrogenic Systemic Fibrosis 489 Naziheh Assarzadegan Michael J Imber Patrick Vanderboom Cristine Charlesworth Wonwoo Shon University of Florida Gainesville FL Mayo Clinic Rochester MN 85 Melanoma Micronuclei Identication Using Integrative Nuclear Grade Analysis 511 Ying-Chun Lo Alexander Baras Robert W Veltri Nemanja Rodic Yale-New Haven Hospital New Haven CT Johns Hopkins University School of Medicine Baltimore MD Yale University School of Medicine New Haven CT 86 Blood Staging in Mycosis Fungoides 521 William Munday Chris Tormey Alexa Siddon Yale School of Medicine New Haven CT 87 Comprehensive Genomic Proling of Cutaneous Merkel Cell Carcinoma 528 Aseeb Rehman Mark Bailey Siraj M Ali Julia A Elvin Jo-Anne Vergilio James Suh Ling Gao Sara Shalin David M Jones J Andrew Carslon Martin C Mihm Vincent A Miller Philip J Stephens Jeffrey S Ross Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA University of Arkansas Medical Systems Little Rock AR Brigham and Womens Hospital and Harvard Medical School Boston MA 88 Immunodetection of Mitotic Figures and G2 Tumor Nuclei with Histone Markers in Stage III Melanoma Samples 540 Daniel Wimmer Michael T Tetzlaff Carlos A Torres- Cabala Denai R Milton Priyadharsini Nagarajan Phyu P Aung Victor G Prieto Jonathan L Curry The University of Texas MD Anderson Cancer Center Houston TX 89 BRAF Mutation V600E Induces Expression Change of Signaling Transduction Molecules in Metastatic Melanoma Cell Lines 541 Chunhui Yi Fei Ye Qiong Gan David Zhang St. Lukes-Roosevelt Hospital Mount Sinai Medical Center New York City NY Mount Sinai Medical Center New York City NY STOWELL-ORBISON AWARD POSTERS EDUCATION 90 Broadening Our Scope A Conceptual Framework for a Curriculum in Bioethics and Professionalism for Pathology Trainees 559 Ifeoma Nwadei Cheryl Maier Stewart Neill Charles E Hill Kathy Kinlaw Benjamin K Stoff Emory University Atlanta GA Emory University Center for Ethics Atlanta GA STOWELL-ORBISON AWARD POSTERS ENDOCRINE PATHOLOGY 91 Incidental Metastatic Papillary Thyroid Carcinoma A Clinicopathologic Study 574 Kathleen Byrnes Rebecca Chernock Washington University in St. Louis St. Louis MO 92 Molecular and Histopathologic Characteristics of Radioiodine-Refractory Papillary Thyroid Cancer 576 Sung-eun Choi Ju Yeon Pyo Ji-seop Kim Eunah Shin Soon Won Hong Gangnam Severance Hospital Seoul Republic of Korea Hanyang University Guri Hospital Guri-Si Kyeonggi-Do Republic of Korea CHA Gangnam Hospital Seoul Republic of Korea 93 DAXX Gene A Higher Rate of Mutation than ATRX Gene in Neuroendocrine Tumors 580 Abigail L Goodman Vaidehi Avadhani Cynthia Cohen Momin T Siddiqui Emory University Hospital Atlanta GA 94 Anaplastic Thyroid Carcinoma Arising Outside the Thyroid Gland A Comparison of Clinical Outcomes 588 Jonathon Mahlow Deborah J Chute Cleveland Clinic Cleveland OH 95 Low PASS Is an Effective Tool for Predicting Non- Metastatic Pheochromocytomas 589 Julia R Maisel Lauren Fishbein Katherine L Nathanson Virginia A LiVolsi Debbie L Cohen Kathleen Montone Perelman School of Medicine University of Pennsylvania Philadelphia PA 96 BRAF and RAS Mutation Analysis to Distinguish Benign Ectopic Thyroid Tissue and Metatastatic Thyroid Carcinoma 594 Diana Murro Sara Javidiparsijani Alexandra Vardouniotis Lela Buckingham Paolo Gattuso Rush University Medical Center Chicago IL 97 Paradoxical Decrease of TSPO Expression in Adrenocortical Carcinomas Confers a Worse Prognosis 602 Roberto Ruiz-Cordero Mouhammed A Habra Alia Gupta Merce Jorda Kanishka Sircar MD Anderson Cancer Center Houston TX University of Miami Jackson Memorial Hospital Miami FL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 121NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 121 98 Sclerosing Mucoepidermoid Carcinoma with Eosinophilia Clinicopathologic Molecular Analysis of a Distinct Entity 605 Akeesha Shah Kristin La Fortune Stacey E Mills Zubair Baloch Virginia LiVolsi Sanja Dacic Alyssa M Luvison Marina Nikiforova Yuri E Nikiforov Raja R Seethala University of Pittsburgh Pittsburgh PA Indiana University Indianapolis IN University of Virginia Charlottesville VA University of Pennsylvania Philadelphia PA 99 Mathematical Modeling of Epithelial-to-Mesenchymal Transition in Thyroid Carcinoma Progression 607 Kaitlin Sundling Darya Buehler Zhenying Guo Heather A Hardin Rakesh Mandal Celina Montemayor- Garcia Ricardo V Lloyd University of Wisconsin Madison WI 100 Recurrent and Aggressive Pituitary Adenomas and Carcinomas A Comprehensive Genomic Proling Study 611 Olga Voronel Kyle Fedorchak Siraj M Ali Julia A Elvin Jo-Anne Vergilio James Suh Shakti H Ramkissoon Vincent A Miller Philip J Stephens Jeffrey S Ross Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA Brigham and Womens Hospital Boston MA 101 Long Non-Coding RNA MALAT1 Expression in Thyroid Tissues and Tumors 618 Ranran Zhang Heather A Hardin Wei Huang Darya Buehler Soa Asioli Alberto Righi Francesca Maletta Anna Sapino Ricardo V Lloyd University of Wisconsin School of Medicine and Public Health Madison WI University of Bologna Bologna Italy Rizzoli Institute Bologna Italy University of Turin Turin Italy STOWELL-ORBISON AWARD POSTERS GASTROINTESTINAL PATHOLOGY 102 Mcl-1 Myeloid Cell Leukemia-1 as a Biomarker and Prognosticator in Colorectal Adenocarcinomas CRCs Protein Expression and Molecular Proling 629 Sanaz Ainechi Sahar Nozad Bryan Firestone David M Jones Hwa Jeong Lee Christine E Sheehan Jeffrey S Ross Albany Medical College Albany NY 103 An Optimized Strategy for Candida Detection Insights from a Morphologic and Cost Comparison Study 634 Mohammed Alsomali Michael Arnold Wendy L Frankel Rondell Graham Phil A Hart Dora Lam-Himlin Bita V Naini Christina A Arnold OSU Columbus OH Nationwide Childrens Hospital Columbus OH Mayo Clinic Rochester MN Mayo Clinic Scottsdale AZ UCLA David Geffen School of Medicine Los Angeles CA 104 Increased Mucosal IgG4 Inltration Is Associated with Poor Clinical Outcomes in Ulcerative Colitis 641 Brian T Brinkerhoff Kian Keyashian Laura Bradley Benjamin Larson Jeong Lim Nir Modiano Judy Collins Terry K Morgan Jody E Hooper Oregon Health Science University Portland OR Johns Hopkins University School of Medicine Baltimore MD 105 Characterization of Colorectal Cancer Metastasis- Associated Genes Using Next-Generation Sequencing 647 Michael D Chang Jesse L Kresak Amy Collinsworth Kimberly J Newsom Ryan A Hlady Keith D Robertson Petr Starostik Chen Liu The University of Florida Gainesville FL The Mayo Clinic Rochester MN 106 Loss of Hes1 Expression Is Associated with Microsatellite Instability in Human Colorectal Carcinoma 661 Min Cui Amad Awadallah Lan Zhou Wei Xin University Hospitals Case Medical Center Cleveland OH Case Western Reserve University Cleveland OH 107 Combined GATA3 and BRST2 Immunohistochemistry Is Both Sensitive and Specic in the Identication of Metastatic Signet Ring Cell Carcinoma of Breast Origin in the Upper GI Tract 669 Elena D Diaconescu Catherine J Streutker Kiran Jakate University of Toronto Toronto ON Canada Saint Michaels Hospital Toronto ON Canada 108 Are Mesenteric Tumor Deposits in Small Intestinal Neuroendocrine Tumors a Stronger Indicator for Liver Metastasis and Poor Prognosis Than Nodal Metastasis 674 Cynthia Fata Raul S Gonzalez Justin M Cates Chanjuan Shi Vanderbilt University Nashville TN University of Rochester Medical Center Rochester NY 109 Spectrum of Non-Synonymous Variants in Appendiceal Epithelial Neoplasms Identied by Targeted Clinical Next-Generation Sequencing 684 Bella Goyal Eric J Duncavage Washington University in St. Louis Saint Louis MO 110 EBV Status and Molecular Alterations in Gastric Carcinomas with Lymphoid Stroma 693 Erika Hissong Helen Fernandes Pan Zhang David Klimstra Jinru Shia Rhonda K Yantiss Weill Cornell Medical College New York NY Memorial Sloan Kettering Cancer Center New York NY 111 Human Papillomavirus Genotyping of Unexpected Malignant and Pre-Malignant Lesions on Hemorrhoidectomy Specimens 696 Yiang Hui M Ruhul Quddus Jayasimha N Murthy Dongfang Yang C James Sung Shaolei Lu Murray B Resnick Li Juan Wang Warren Alpert Medical School of Brown University Providence RI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016122 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016122 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 112 Yttrium-90 Microspheres as a Cause of Non-Healing Gastric Ulcer Histologic Features Often Mimic Chemical Gastropathy 699 Taylor M Jenkins Stuti G Shroff T Danielle Samulski Rashmi Tondon Emma E Furth Kristen Stashek University of Pennsylvania Philadelphia PA 113 Molecular Analysis of Neurobromatosis Type 1 Associated Gastrointestinal Stromal Tumors 710 Heewon Kwak Lei Zhao Sabah Kadri Jeremy Segal Bradley Long Larissa V Furtado Peter Pytel University of Chicago Chicago IL University of Alabama at Birmingham Birmingham AL 114 An Intimate Dance Patterns and Clinical Relevance of PD-L1 and PD-1 Expression in Colorectal Carcinoma 718 Lik Hang Lee Marcela Santos Cavalcanti Neil Segal Jaclyn Hechtman Efsevia Vakiani David Klimstra Jinru Shia Memorial Sloan Kettering Cancer Center New York NY 115 A Prospective Evaluation of Incidental Fundic Gland Polyps with Epithelial Dysplasia Implications for Clinical Management 728 Isaac Lloyd Wendy K Kohlmann Erinn Downs-Kelly Wade S Samowitz Mary P Bronner University of Utah and ARUP Laboratories Salt Lake City UT University of Utah Salt Lake City UT 116 Histologic Features of Gastrointestinal Tract Biopsy in Henoch-Schnlein Purpura 729 Christine Y Louie Teri A Longacre Stanford Hospital Clinics Stanford CA 117 The Notch Pathway Is Activated in Neoplastic Progression in Esophageal Squamous Cell Carcinoma 731 Daniel Lubin Stuti G Shroff Kristen Stashek Emma E Furth Hospital of the University of Pennsylvania Philadelphia PA 118 Goblet Cell Carcinoid of the Appendix An Interobserver Variability Study Using Two Proposed Classication Systems 732 Chelsea Maedler Thomas Arnason Alastair P Dorreen Heidi Sapp Mathieu Castonguay Joanne Murphy Sorin Selegean Weei-Yuarn Huang Dalhousie University Halifax NS Canada 119 Intestinal Helminths in a Vey Large US Patient Cohort- A Retrospective Review of over 81000 Coloscopy Samples 743 Catherine S Morris Nadeem Zafar Richard S Kinsey UTHSC Memphis TN Gastrointestinal Pathology Memphis TN 120 Pediatric Focal Active Colitis. A Retrospective Review 757 Allison Osmond Dhandapani Ashok Courtney A Francoeur Michael Miller Joanna C Walsh Western University London Health Sciences Centre London ON Canada Childrens Hospital of Western Ontario London ON Canada 121 Comparison of Morphology and Proliferation Markers of the Primary vs. Metastatic Lesions of Gastroenteropancreatic Neuroendocrine Tumors 759 Lincoln Pac Claire E Murphy Veena Shankaran Suntrea Hammer Jingmei Lin Maria Westerhoff University of Washington Seattle WA Indiana University Indianapolis IN UT Southwestern Dallas TX 122 Clinicopathologic Features of Tumor Inltrating Neutrophils in MSI-H Colorectal Carcinoma 761 Natalie Patel Monika Vyas Margaret Cho Romulo Celli Buqu Hu Xiting Yan Dhanpat Jain Xuchen Zhang Yale University School of Medicine New Haven CT 123 Vasodilator-Stimulated Phosphoprotein VASP Immunoreactivity Is Associated with Lymphovascular Invasion of Colorectal Adenocarcinoma CRC Leading to Liver and Lymph Node Metastases 767 Jinhua Piao Joanne KL Rutgers Grant Kolar Barbara Nagel Yongxin Chen Nancy J Phillips Susan E Crawford Ningling Kang Jinping Lai Saint Louis University School of Medicine Saint Louis MO Cedars-Sinai Medical Center Los Angeles CA The Hormel Institute University of Minnesota and Mayo Clinic Austin MN 124 Histopathologic Features of Colorectal Carcinoma in Patients with HIV Infection 783 Marcela Santos Cavalcanti Keith Sigel Jinru Shia Tanisha Daniel Efsevia Vakiani Carlie Sigel Memorial Sloan Kettering Cancer Center New York NY Mount Sinai School of Medicine New York NY 125 Pathologic Features and Pouch Outcome in Patients with Ulcerative Colitis and Extended Backwash Ileitis 786 Erica Savage John R Goldblum Ana E Bennett Luca Stocchi Deepa Patil Cleveland Clinic Cleveland OH 126 MicroRNA 150-5p Has a Role in Progression and Possibly Therapy in Colorectal Cancer 789 Aisha Sethi Stefan Costinean Prasanthi Kumchala Veronica Balatti Luciano Cascione Carlo Croce Wendy L Frankel The Ohio State University Columbus OH Institute of Oncology Bellinzona Switzerland University of Nebraska Medical Center Omaha NE Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 123NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 123 127 Comprehensive Multiplex Molecular Genomic Signature in Barretts Carcinogenesis Potential Predictive Prognostic Early Diagnostic Therapeutic Role 791 Seema Sethi Shashirekha Shetty Prashanthi N Thota Christine Rivera Erica Savage Kaveh Hajifathalian Mary Torrez John R Goldblum Deepa Patil Cleveland Clinic Cleveland OH 128 Immunostaining of Tyrosine Kinase PTK6 Decreases in the Colonic Epithelium Ranging from Normal Hyperplasia Dysplasia and Carcinoma While Stromal Immunostaining Increases as Tumorigenesis Progresses 793 Asma Sharif Yanmin Zhang Priya Mathur Kyle Meinke Anish Shah Roshan S Patel Marlene Gallegos Ming Jin Michael Walsh Frederick Behm Virgilia Macias Andre Kajdacsy-Balla Angela Tyner Grace Guzman University of Illinois at Chicago Chicago IL Jesse Brown Veterans Affairs Chicago IL 129 Programmed Cell Death Ligand 1 PD-L1 Expression in Pancreatic Ductal Adenocarcinoma 794 Brandon S Shefeld Steve E Kalloger Katy Milne Brad H Nelson Daniel Renouf David F Schaeffer Vancouver General Hospital Vancouver BC Canada British Columbia Cancer Agency Victoria BC Canada British Columbia Cancer Agency Vancouver BC Canada 130 Helicobacter Heilmannii-Gastritis Why Its Not Okay to Wash Your Cats Bowl in the Kitchen Sink and Boys Shouldnt Kiss Their Pigs 798 Devin L Shrock Andrew M Bellizzi University of Iowa Iowa City IA 131 Comparative Study of Genome-Wide Copy Number Aberrations in Colonic Mixed AdenoNeuroEndocrine Carcinoma Adenocarcinoma and Neuroendocrine Carcinoma 800 Namita Sinha Weei-Yuan Huang Dalhousie University QEII Health Sciences Center Halifax NS Canada 132 Ipilimumab Induced Perforating Colitis Severe Cases Mimic Crohn Disease and Ulcerative Colitis 807 Rashmi Tondon Stuti G Shroff Emma E Furth Kristen Stashek University of Pennsylvania Philadelphia PA 133 Is Sloughing Esophagitis SE All That Its Cracked Up to Be Clinicopathologic Comparison of SE in Adults and Children 809 Yun-An Tseng Evgeny Yakirevich Shaolei Lu Andres Matoso Murray B Resnick Shamlal Mangray Brown UniversityRhode Island Hospital Providence RI 134 Bile Reux May Play an Important Role in the Development of GastroesophagealGastric Cardia Intestinal Metaplasia and Carcinoma 813 Monika Vyas Romulo Celli Manpreet Singh Natalie Patel Harry Aslanian James J Farell Daniel Boffa Dhanpat Jain Yale School of Medicine New Haven CT 135 Epithelial to Mesenchymal Transition Predicts Distant Metastasis in MMR-Intact Colonic Adenocarcinoma 821 Erik Williams Lawrence Zukerberg Kshitij Arora David T Ting Vikram Deshpande Massachusetts General Hospital Boston MA 136 Gluten Free Diet Alleviates Irritable Bowel Syndrome through Intestinal Epithelial Tight Junction Regulation 824 Richard L Wu Artur Rangel David Andrews Michael Camilleri Jerrold R Turner Jackson Memorial Hospital University of Miami Miami FL Mayo Clinic Rochester MN University of Chicago Chicago IL 137 WNT Signaling Markers LGR5 and AXIN2 Show Unique Patterns of Expression in Colonic Polyps 831 Osman Yilmaz Tanupriya Agrawal Kanchan Kantekure Yvelisse Suarez Omer Yilmaz Vikram Deshpande Massachusetts General Hospital Boston MA Tufts Medical Center Boston MA Massachusetts Institute of Technology Cambridge MA 138 Post-Appendectomy Colorectal Adenocarcinomas Associate with Low Rates of Lymph Node Metastasis and High Rates of Mismatch Repair Deciency 840 Menglei Zhu Wei Xin University Hospitals Case Medical Center Case Western Reserve University Cleveland OH STOWELL-ORBISON AWARD POSTERS GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 139 Prognostic Signicance of Depth of Invasion in Transurethral Resection of Bladder Specimens 843 Mahmut Akgul Matthew Bream Naseh Janaki Hammad Tashkandi Gregory MacLennan University Hospitals Case Medical Center Cleveland OH 140 Does Multifocality Matter An Evidence Based Study of Multifocal Renal Carcinomas of Clear Cell Type 855 Burak Bahar Lu Wang Nicole Andeen Funda Vakar- Lopez Maria S Tretiakova Neriman Gokden Tatjana Antic Ming Zhou Ximing Yang Roberto Gamez Stefan Pambuccian Maria M Picken Eva M Wojcik Guliz A Barkan Loyola University Medical Center Maywood IL Norhwestern University Feinberg School of Medicine Chicago IL University of Washington Seattle WA University of Arkansas Little Rock AR University of Chicago Chicago IL NYU Medical Center Tisch Hospital New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016124 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016124 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 141 Comparison of PTEN Expression in Mucinous Prostatic Adenocarcinoma Prostatic Adenocarcinoma with Mucinous Features and Adjacent Conventional Prostatic Adenocarcinoma Potential Evidence of Clonality 865 Elizabeth Bertsch Cristina Magi-Galluzzi Liang Cheng Adeboye O Osunkoya Emory University School of Medicine Atlanta GA The Cleveland Clinic Cleveland OH Indiana University School of Medicine Indianapolis IN 142 Divergent Molecular Pathogenesis of EBV-Negative Lymphoepithelial Carcinomas Arising in the Nasopharynx and Urinary Bladder Revealed by Next- Generation Sequencing 869 Benjamin Buelow Samia Naccache Guixia Yu Nancy Joseph Charles Chiu University of California San Francisco San Francisco CA 143 Mixed Epithelial and Stromal Tumor of Kidney 874 Anna Calio John N Eble David J Grignon Brett Delahunt University of Verona Verona Italy Indiana University Indianapolis IN Wellington Medical School Wellington New Zealand 144 Expression of Heterochromatin Protein 1 in Renal Cortical Tumors and Identication of Its Target Genes 880 Lin Cheng Tracy K Hale Maria S Tretiakova University of Washington Seattle WA Massey University Palmerston North 4410 New Zealand 145 Breaking down the Contemporary Gleason Pattern GP 4 in Prostate Cancers Should We Report the Percentage of Pattern 4 in Radical Prostatectomies RPs 882 Bonnie Choy Blake Anderson Gladell P Paner The University of Chicago Chicago IL 146 Human Hemochromatosis Protein HFE Immunoperoxidase Stain Highlights Choriocarcinoma within Mixed Germ Cell Tumors 888 Jesse L Cox Geoffrey A Talmon Scott A Koepsell University of Nebraska Medical Center Omaha NE 147 Molecular Subtypes of Bladder Cancer and Their Signature Markers in Multi-Institutional Cohorts 891 Vipulkumar Dadhania Charles C Guo Miao Zhang Tadeusz Majewski Li Zhang Jolanta Bondaruk Shizhen Zhang Woonyoung Choi David McConkey Colin Dinney Keith Baggerly Bogdan Czerniak The University of Texas MD Anderson Cancer Center Houston TX 148 Potential Pitfalls in the Utility of Programmed Death-1 Expression in the Prediction of Prognosis in Patients with Metastatic and Non-Metastatic Clear Cell Renal Cell Carcinoma An Analysis of 72 Cases 898 Michelle DiMarco Rishi R Sekar Dattatraya Patil Viraj A Master Adeboye O Osunkoya Emory University School of Medicine Atlanta GA 149 Pathologic Correlation of Targeted Sampling in Patients with 3D Magnetic Resonance ImagingTransrectal Ultrasound Fusion Biopsies 902 Zachary J Dureau M Andrew Toussaint Adeboye O Osunkoya Emory University School of Medicine Atlanta GA 150 Clinicopathologic Features and Outcomes of Anterior- Dominant Prostate Cancer APCa Implications for Diagnosis and Treatment 905 Sara Falzarano Ming Zhou Jesse K McKenney Christopher G Przybycin Eric A Klein Cristina Magi- Galluzzi Cleveland Clinic Cleveland OH NYU New York NY 151 Pathologic Findings in Patients with Targeted Magnetic Resonance Imaging-Guided Prostate Needle Core Biopsies Following Prior Negative Transrectal Ultrasound-Guided Prostate Needle Core Biopsies 918 Rachel Geller Zachary J Dureau M Andrew Toussaint Sherif G Nour Adeboye O Osunkoya Emory University School of Medicine Atlanta GA 152 MAGI-2 Is a Sensitive and Specic Marker of Prostatic Adenocarcinoma Comparison with AMACR 925 Jeffery Goldstein Rajen Goyal Joseph T Roland Lan L Gellert Peter E Clark Giovanna A Giannico Omar Hameed Vanderbilt University Medical Center Nashville TN 153 Human Epidermal Growth Factor Receptor 2 Expression in Micropapillary Urothelial Carcinoma of the Bladder An Analysis of 27 Cases 926 Abigail L Goodman Adeboye O Osunkoya Emory University School of Medicine Atlanta GA 154 Molecular Evidence of Preneoplastic Potential of Intestinal Metaplasia in the Urinary Bladder 928 Zakaria Grada Andres Matoso Virginia Breese Cynthia Jackson Ali Amin Rhode Island HospitalBrown University Providence RI 155 Oncocytic Adrenal Cortical Neoplasm a Clinical and Pathological Study of 39 Cases 951 He Huang Priya Rao Kanishka Sirca Mouhammed A Habra Miao Zhang The University of Texas MD Anderson Cancer Center Houston TX 156 Interobserver Agreement of Clear Cell Renal Cell Carcinoma CCRCC Grading Systems among Genitourinary Pathologists 957 Matt Jeffreys Jesse K McKenney Neriman Gokden Shree G Sharma Stephen M Bonsib Christopher G Przybycin Cristina Magi-Galluzzi Jordan P Reynolds Christina Stallworth Jonathan Myles Katherine Watts Emily Holthoff Andres A Roma Roni M Cox UAMS Little Rock AR Nephropath Little Rock AR Cleveland Clinic Cleveland OH Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 125NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 125 157 Whole-Mounting of Prostates from Radical Cystoprostatectomies Enhances the Staging of Both Bladder and Prostate Cancers within the Specimens 958 Liwei Jia Robin M Elliott Gregory MacLennan Case Western Reserve University Cleveland OH 158 Genomic Analysis of Pure Adult Yolk Sac Tumor of the Testisunderline 962 Jennifer Katzenberg John A Thorson Thomas M Ulbright Donna Hansel University of California at San Diego San Diego CA Indiana University Indianapolis IN 159 Gleason Grade 4 Prostate Cancer Growth Patterns An Interobserver Study among Expert Genitourinary Pathologists 971 Charlotte Kweldam Daan Nieboer Theodorus H Van der Kwast Geert van Leenders Gleason Grade 4 Subtype Collaborative Group Erasmus Medical Center Rotterdam Netherlands University Health Network Toronto Canada 160 Disease-Specic Survival of Patients with Invasive Cribriform and Intraductal Prostate Cancer at Diagnostic Biopsy 972 Charlotte Kweldam Intan Kummerlin Daan Nieboer Esther Verhoef Ewout Steyerberg Theodorus H Van der Kwast Monique Roobol Geert van Leenders Erasmus Medical Center Rotterdam Netherlands University Health Network Toronto Canada 161 Pediatric Cystic Nephromas Are Morphologically Immunohistochemically and Genetically Distinct from Most Adult Cystic NephromaMixed Epithelial Stromal Tumor MEST Family Lesions 980 Yunjie LI Bruce R Pawel Dana A Hill George J Netto Jonathan I Epstein Pedram Argani Johns Hopkins University School of Medicine Baltimore MD Childrens Hospital of Pennsylvania Philadelphia PA Childrens National Medical Center Washington DC 162 FOXA1 A Transcription Factor Specic for Neuroendocrine Differentiation in Prostate Adenocarcinoma 1014 Vamsi Parimi Jung Kim Jindan Yu Ximing Yang Maria M Picken Loyola University Medical Center Maywood IL Northwestern University Chicago IL 163 Clinical Utility of FISH for the Detection of Chromosome 3p Deletion in FFPE Tissue 1016 Carmen M Perrino Jason Orien Weiqiang Zhao Debra L Zynger The Ohio State University Medical Center Columbus OH 164 Next Generation Sequencing NGS-based Molecular Characterization of High Grade Urothelial Carcinoma 1017 Dinesh Pradhan Leonard J Appleman Rahul Parikh Sheldon I Bastacky Rajiv Dhir Yuri E Nikiforov Marina Nikiforova Somak Roy UPMC Pittsburgh PA 165 Papillary Renal Cell Carcinoma Is More Than One Entity. Molecular Subtyping and Pathway Analysis 1033 Rola Saleeb Pamela Plant Eriny Tawedrous Adriana Krizova Sahar Al-Haddad Andrew Evans Fadi Brimo Samantha J Wala George M Yousef University of Toronto Toronto ON Canada St. Michaels Hospital Li Ka Shing Knowledge Institute Toronto ON Canada Toronto General Hospital Toronto ON Canada Montreal General Hospital McGill University Montreal QC Canada 166 The MiR-200 Family Has Prognostic Signicance in Clear Cell Renal Cell Carcinoma through Regulation of BAP1 and Related Molecular Pathways 1034 Rola Saleeb Heba WZ Khella Qiang Ding George M Yousef University of Toronto Toronto ON Canada Li Ka Shing Knowledge Institute St. Michaels Hospital Toronto ON Canada 167 Extensive Retraction Clefts in Invasive Urothelial Carcinoma Are Associated with Aggressive Tumor Behavior 1043 Tanmay Shah Matthew G Kaag Jay D Raman Wilson Chen Truc Tran Sudhir Kunchala David J DeGraff Guoli Chen Joshua I Warrick Penn State Hershey Medical Center Hershey PA 168 Prostate Cancer PCa with Overlapping Features of Small Cell Carcinoma and Acinar Adenocarcinoma A Critical Appraisal of Morphology and Correlation with Immunohistochemical IHC Markers 1045 Deepika Sirohi Steven Smith Chisato Ohe Mariza de Peralta-Venturina Daniel Luthringer Scott A Tomlins Moushumi Suryavanshi Arkadiusz Gertych Beatrice Knudsen Mahul B Amin Cedars-Sinai Medical Center Los Angeles CA Virginia Commonwealth University Health System Richmond VA University of Michigan Medical School Ann Arbor MI Rajiv Gandhi Cancer Institute and Research Center New Delhi India 169 Tumors Involving the Ureteral Orice A Clinicopathologic Analysis of 93 Cases 1050 Keith Stevens Adeboye O Osunkoya Emory University Atlanta GA 170 Comparison of GRP52 mTOR HoxB13 NKX3.1 and Prostein in Metastatic Prostatic Adenocarcinoma 1069 Hai Wang Yiang Hui Dongfang Yang Kara A Lombardo Evgeny Yakirevich Murray Resnick Lijuan Wang Shaolei Lu Brown University Providence RI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016126 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016126 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 171 The Correlation of TP53 and RB1 Genetic Alterations and Immunohistochemical IHC Expression in Invasive and Non-Invasive Urothelial Carcinomaunderline 1080 Xiaoyong Zheng Qinghu Ren Judy Sarungbam Emmet J Jordan Satish K Tickoo Samson Fine Ying- Bei Chen Michael F Berger Anuradha Gopalan S Joseph Sirintrapun Gopa Iyer Byron H Lee Eugene K Cha Michael F Berger David B Solit Victor E Reuter Hikmat Al-Ahmadie Memorial Sloan Kettering Cancer Center New York NY 172 PD-L1 Protein Expression and PD-L1 Gene Amplication in Urothelial Carcinoma of the Urinary Bladder 1082 Chunlai Zuo Bhaskar VS Kallakury Bryan Firestone Olga Voronel Christine E Sheehan Tipu Nazeer Jeffrey S Ross Albany Medical College Albany NY Georgetown University Hospital Washington DC STOWELL-ORBISON AWARD POSTERS GYNECOLOGIC AND OBSTETRIC PATHOLOGY 173 Discoidin Domain Receptor 1 in Advanced Stage Ovarian Carcinoma Prognostic Implications and Epithelial-to-Mesenchymal Transition Associations 1084 Eman Abdulfatah Marta Marco Rafael Fridman Vishakha Pardeshi Sharif Sakr Robert T Morris Sudeshna Bandyopadhyay Rouba Ali-Fehmi WSU Detroit MI 174 Rare Subtypes and Frequency of Multi-Viral Subtype High-Risk HPV infection in High-Grade SIL and Squamous Cell Carcinoma in a Cervical Carcinoma Prevalent Developing Country - A Multiplex Real-Time PCR-Based Study 1088 Shabnam Akhter Pradip Manna Mohammed Kamal C James Sung W Dwayne Lawrence M Ruhul Quddus Women Infants HospitalAlpert Medical School of Brown University Providence RI BSM Medical University Dhaka Bangladesh Physicians Reference Laboratory Overland Park KS 175 Prognostic Indicators of Uterine Carcinosarcoma in Comparison to Uterine Serous Carcinoma 1090 Baraa Alosh Nagla Salem MHD Fayez Daaboul Rac Beydoun Dongping Shi Paul Tranchida Sudeshna Bandyopadhyay Rouba Ali-Fehmi WSU Detroit MI 176 Intervillous Thrombi Are Increased in Placentas from Pregnancies Complicated by Diabetes 1096 Kristen M Basnet Rhonda Bentley-Lewis Deborah Wexler Fusun Kilic Drucilla Roberts Massachusetts General Hospital Boston MA University of Arkansas for Medical Sciences Little Rock AR 177 The Role of Pathologic Evaluation of Endometrial Ablation Resections in Predicting Ablation Failure and Adenomyosis in Hysterectomy 1105 Aurelia Busca Carlos Parra-Herran University of Ottawa Ottawa ON Canada 178 Cell Polarity Reversal in Ovarian Low-Grade Serous Carcinomas and Micropapillary Serous Borderline Tumors - Are They Bilogically Similar An Immunohistochemical Study 1145 Yiang Hui Joyce J Ou Shahrzad Slater C James Sung W Dwayne Lawrence M Ruhul Quddus Women Infants HospitalAlpert Medical School Providence RI 179 The Microcystic Elongated and Fragmented MELF Pattern of Invasion Is Associated with Non-Vaginal Recurrences and Increased Lymph Node Metastases Even When Compared to Myoinvasive Inltrative Cases without MELF 1148 Amy S Joehlin-Price Kelsey McHugh Julie A Stephens David E Cohn David Cohen Adrian A Suarez The Ohio State University Columbus OH 180 Vulvar Elastosis An Under-Recognized Entity Often Confused with Lichen Sclerosus. Report of a Series 1150 Elizabeth Kalife M Ruhul Quddus Katrine Hansen Kamaljeet Singh W Dwayne Lawrence Women and Infants Hospital Providence RI 181 Loss of SWISNF Complex Protein Expression Is Associated with Dedifferentiation in Endometrial Carcinomas 1153 Anthony Karnezis Lien Hoang Noorah Almadani Basile Tessier-Cloutier Julie A Irving Bojana Djordjevic Robert Soslow David G Huntsman C Blake Gilks Martin Kobel Cheng-Han Lee University of British Columbia Vancouver BC Canada Royal Jubilee Hospital Victoria BC Canada The Ottawa Hospital Ottawa ON Canada Memorial Sloan Kettering Cancer Center New York NY Calgary Laboratory Services and University of Calgary Calgary AB Canada Royal Alexandra Hospital and University of Alberta Edmonton AB Canada 182 Utility of Uroplakin-II Immunohistochemical Studies in Differentiating Primary Cutaneous Vulvar Paget Disease from Pagetoid Urothelial Intraepithelial Neoplasia 1187 Kent J Newsom Layla Alizadeh Samer Z Al-Quran Edward J Wilkinson University of Florida Gainesville FL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 127NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 127 183 Intravenous Leiomyomatosis IVL from Molecular Genetics to Clinical Biomarkers A Study of 26 Cases 1195 Zehra Ordulu Anna G McDonald Michele De Nictolis Eugenia Garcia-Fernandez David Hardisson Jaime Prat Esther Oliva Massachusetts General Hospital Boston MA San Salvatore Hospital Pesaro Italy Hospital Universitario La Paz Madrid Spain Wake Forest Baptist Medical Center Winston-Salem NC Hospital de la Sta Creu i Sant Pau Barcelona Spain 184 Frequency of High-Risk Human Papillomavirus Types in a Rural Appalachian Population 1215 Ibrahim A Robadi Majed Pharaon Barbara Ducatman West Virginia University Morgantown WV 185 Mucinous Differentiation with Tumor Inltrating Lymphocytes Is a Feature of Sporadically Methylated Endometrial Carcinomas 1231 Emily A Sloan Christopher A Moskaluk Anne M Mills University of Virginia Charlottesville VA 186 False Negative Endometrial Sampling in Patients with Endometrial Carcinoma 1242 Catalin Taraboanta Heidi Britton Blake Gilks University of British Columbia Vancouver BC Canada 187 Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations 1254 Shabnam Zarei Sarah E Kerr Yan Wang Sarah M Jenkins Debra A Bell Mayo Clinic Rochester MN STOWELL-ORBISON AWARD POSTERS HEAD AND NECK PATHOLOGY 188 LEF-1 Expression in Basaloid Tumors of the Salivary Gland 1283 Reuben P Jacob Shannon OBrien Cynthia Cohen Momin T Siddiqui Emory University School of Medicine Atlanta GA 189 Comprehensive Genomic Proling of Esthesioneuroblastoma Reveals a Relatively Low Overall Genomic Alteration Frequency but Identies Numerous Potential Opportunities for Targeted Therapies 1287 Sungeun Kim Kyle Fedorchak Siraj M Ali Julia A Elvin Jo-Anne Vergilio James Suh Vincent A Miller Philip J Stephens Jeffrey S Ross Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA 190 Diagnostic and Prognostic Utility of Mastermind- Like 2 MAML2 Gene Rearrangement Detected by Fluorescent In-Situ Hybridization FISH in Mucoepidermoid Carcinoma 1292 Peter P Luk James Wykes Christina I Selinger Rafael Ekmejian Jessica Tay Kan Gao Timothy J Eviston Trina Lum Sandra A OToole Jonathan R Clark Ruta Gupta Royal Prince Alfred Hospital Sydney NSW Australia Chris OBrien Lifehouse Sydney NSW Australia University of New South Wales Sydney NSW Australia The University of Sydney Sydney NSW Australia 191 Investigation of High Risk HPV E6E7 mRNA Transcriptional Activity by In Situ Hybridization in Sino- Nasal Inverted Papilloma with Associated Dysplasia and Malignant Transformation 1298 Shobha Parajuli Rashmi Tondon Amy Ziober Kathleen Montone Kumarasen Cooper Hospital of the University of Pennsylvania Philadelphia PA 192 Nuclear B-catenin Expression Provides a Consistent Immunohistochemical Correlate for PAX3 Rearrangements in Biphenotypic Sinonasal Sarcoma 1304 Lisa M Rooper Shih-Chiang Huang Cristina Antonescu William H Westra Justin A Bishop Johns Hopkins Hospital Baltimore MD Memorial Sloan Kettering Cancer Center New York NY 193 Expression of an Androgen Receptor Splice Variant in Salivary Duct Carcinoma An Instrument of Resistance 1306 Dipti Sajed Chin-Lee Wu Vania Nose Vikram Deshpande Massachusetts General Hospital Boston MA 194 Programmed Cell Death-Ligand 1 PD-L1 Expression in Oral Cavity Squamous Cell Carcinoma OSCC 1308 Laveniya Satgunaseelan Jason Madore Noel Chia Trina Lum Carsten E Palme Michael Boyer Richard A Scolyer Jonathan R Clark Ruta Gupta Royal Prince Alfred Hospital Sydney NSW Australia University of Sydney Sydney NSW Australia Melanoma Institute of Australia Sydney NSW Australia University of New South Wales Sydney NSW Australia Chris OBrien Lifehouse Sydney NSW Australia Sydney Head and Neck Cancer Institute Sydney NSW Australia 195 Head and Neck Phosphaturic Mesenchymal Tumor A Report of 5 Cases with FGFR1 Fluorescence In Situ Hybridization Analysis 1314 Jason K Wasserman Bibianna Purgina Chi K Lai Alyssa Mahaffey Denis Gravel Diana Bell Simion I Chiosea The Ottawa HospitalUniversity of Ottawa Ottawa Canada University of Pittsburgh Medical Center Pittsburgh PA MD Anderson Cancer Center Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016128 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016128 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 196 Prognostic Histological Features in the Phenotypic Spectrum of Polymorphous Low Grade Adenocarcinoma PLGA and Cribriform Adenocarcinoma of Minor Salivary Gland CAMSG A Unicenter Retrospective Study of 69 Patients 1319 Bin Xu Ronald Ghossein Nora Katabi Memorial Sloan-Kettering Cancer Center New York NY 197 Prognostic Signicance of Perineural Invasion PNI in Oral Tongue Squamous Cell Carcinoma OTSCC A Clinicopathologic Study of 381 Patients 1320 Bin Xu Jennifer Cracchiolo Jocelyn C Migliacci Snehal Patel Nora Katabi Richard Wong Ronald Ghossein Memorial Sloan-Kettering Cancer Center New York NY STOWELL-ORBISON AWARD POSTERS HEMATOPATHOLOGY 198 Transducer-like Enhancer of Split 1 TLE1 and Estrogen Receptor ER Are Expressed in Follicular Dendritic Cells and Follicular Dendritic Cell Tumors A Novel Finding 1328 Mir Alikhan Hiapeng Shao Marilyn Bui Elizabeth Hyjek M Kamran Mirza Thomas Krausz Girish Venkataraman University of Chicago Medicine Chicago IL Moftt Cancer Center Tampa FL Loyola University Medical Center Maywood IL 199 Ex Vivo Metabolic Analysis Using Isotopic Labeling A Novel Platform to Assess Cancer Metabolism in Hematopoietic Malignancies 1332 Sankha S Basu Mark A Keibler Gregory Stephanopoulos Scott B Lovitch Brigham and Womens Hospital Boston MA Massachusetts Institute of Technology Cambridge MA 200 Correlation of CD79a Expression with Additional B-Cell Markers and Brutons Tyrosine Kinase Expression in T-Cell Lymphoblastic LeukemiaLymphoma 1333 Bjorn Batdorf Gabriela Gheorghe Steven Kroft Alexandra Harrington Horatiu Olteanu Paul Hosking Medical College of Wisconsin Milwaukee WI Childrens Hospital of Wisconsin Milwaukee WI 201 The Role of EBV in Advanced Cases of Cutaneous T-Cell Lymphoma in Prognosis and the Immunologic PD-1PD-L1 Milieu 1335 Rahat Bhatti Pierluigi Porcu Bradley Haverkos Aharon Freud Robert Baiocchi Alejandro Gru University of Virginia Charlottesville VA Ohio State University Columbus OH University of Colorado Denver CO 202 Lymphoma in IgG4-Related Disease 1336 Jacob Bledsoe Zachary S Wallace John H Stone Vikram Deshpande Judith A Ferry Massachusetts General Hospital Boston MA 203 Absence of LEF1 Expression in Atypical CLLSLL Unmasks Other B-cell Lymphomas 1340 Daniel Bustamante Brittany Coffman James Gale Mohammad Vasef Tracy I George University of New Mexico Albuquerque NM Tricore Laboratories Albuquerque NM 204 Circulating D-2-Hydroxyglutarate and the D-2HGL-2HG Ratio Predict IDH Mutation in Acute Myeloid Leukemia 1348 Andrew Chu Dinesh Rakheja Richard Boriack Mihail Firan Robert Collins Arthur E Frankel Dwight Oliver Weina Chen UT Southwestern Medical Center Dallas TX 205 Programmed Death Ligand PD-L1 Expression Is Increased in Spleens of Myelobrosis Patients 1353 Ryan Craig Sheryl R Tripp Michael Deininger Mohamed E Salama University of Utah Salt Lake City UT ARUP Labs Salt Lake City UT 206 Adult Mixed Phenotype Acute Leukemia A Single Institution Experience and Recommendations on Further Renement of Classication Criteria 1355 Jake Dennis Hamid Zia Pu Chen Andrew Chu Prasad Koduru Hung S Luu Franklin Fuda Weina Chen UT Southwestern Dallas TX 207 Decreased CCNA1 and Increased NOTCH1 Gene Levels Correlate with Poor Treatment Response in Acute Myeloid Leukemia 1378 Zakaria Grada Anna Chorzalska Patrycja M Dubielecka Madhu Ouseph Kara A Lombardo Diana O Treaba Rhode Island Hospital Warren Alpert Medical School of Brown University Providence RI Warren Alpert Medical School of Brown University Signal Transduction Laboratory Providence RI 208 Expression of a Long Non-Coding RNA GATA3 AS-1 in Peripheral T-Cell Lymphoma PTCL 1380 Hua Guo Peihong Hsu Fatima-Zahra Jelloul Peng Lee Judith Brody Silvat Sheikh-Fayyaz Xinmin Zhang Hofstra North Shore-LIJ School of Medicine Lake Success NY New York University School of Medicine New York NY 209 Genetic Heterogeneity CD7 and CD34 Expression Identies a Subpopulation of Nucleophosmin 1-Mutated Acute Myeloid Leukemia NPM1 AML with Early Relapse 1393 Carlo Hojilla Mariam Thomas Mahadeo Sukhai Suzanne Kamel-Reid Amr Rajab Mark Minden Andre Schuh Anna Porwit University Health Network UHN Toronto ON Canada The Princess Margaret Cancer Center Toronto ON Canada UHN Toronto ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 129NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 129 210 A Custom Targeted Next-Generation Sequencing Mutation Panel for Pediatric Myelodysplastic Syndrome and Acute Myeloid Leukemia 1399 Albert Huho Hadi Sayeed Erica Fang Nimesh R Patel Alison A Bertuch Angshumoy Roy Jyotinder N Punia Dolores Lopez-Terrada Maria M Gramatges Kevin E Fisher Baylor College of MedicineTexas Childrens Hospital Houston TX 211 Proliferation Centers in Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma CLLSLL Show Enhanced Expression of the Therapeutic Target PI3K and Other Targets of B-cell Receptor BCR Signaling 1402 Sarika Jain Grant C Bullock Steven H Swerdlow Sarah E Gibson University of Pittsburgh School of Medicine Pittsburgh PA 212 ImmunoFISH Shows That the Proliferation Centers of Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma CLLSLL Are Not Enriched for CLL- Associated Chromosomal Abnormalities 1414 Rebecca J Leeman-Neill Wenhua Piao Carol R Sherer Kathleen M Cieply Steven H Swerdlow Sarah E Gibson University of Pittsburgh School of Medicine Pittsburgh PA 213 Objective Quantication of BCL2 by Immunouorescence in Routine Biopsy Samples Predicts Response to R-CHOP and Overall Survival in Diffuse Large B-Cell Lymphoma 1417 Yi Li Kathrin Tyryshkin Douglas Allan Stewart Adnan Mansoor Tara Baetz David P LeBrun Ariz Akhter Danielle Oh Queens University Kingston ON Canada University of Calgary Calgary AB Canada 214 Effects of the Use of a HammerMallet during Bone Marrow Biopsy Collection on Specimen Quality A Quality Improvement Project 1428 Shakuntala Mauzo Jesse M Jaso Natalia Golardi Aaron J Baxter Marylee M Kott Robert L Hunter Nghia D Nguyen Rongzhen Zhang Lei Chen University of Texas Health Science Center at Houston Houston TX 215 Characterization of CD200 RNA and Protein Expression in Large B-cell Lymphomas 1429 Austin M McCuiston Wan Rou Yang Genevieve M Crane Christopher D Gocke Michael J Borowitz Kathleen H Burns Amy S Dufeld Johns Hopkins University School of Medicine Baltimore MD 216 Further Exploration of the Complexities of Large B-cell Lymphomas LBL with MYC Abnormalities and the Importance of a Blastoid Morphology 1436 Erika M Moore Nidhi Aggarwal Urvashi Surti Steven H Swerdlow University of Pittsburgh School of Medicine Pittsburgh PA 217 Analysis of P53 and EZH2 Protein Expression Levels by Immunohistochemical Staining with Mutation Burden and Clinical Outcomes in Myelodysplastic Syndromes 1444 Johnny Nguyen Kathy McGraw Pardis Vafaii Rami S Komrokji Lynn C Moscinski Ling Zhang Moftt Cancer Center Research Institute Tampa FL 218 Clinicopathologic Features of Erdheim-Chester Disease ECD A Histiocytic Neoplasm Characterized by Deregulation of RASRAFMEKERK Pathway 1448 Neval Ozkaya Benjamin H Durham Christopher Park Marc Rosenblum Eli Diamond Ahmet Dogan Memorial Sloan Kettering Cancer Center New York NY 219 Persistent Gene Mutations Detected by Next Generation Sequencing in Acute Myeloid Leukemia Following Induction Therapy 1449 Aleksandra Paliga Juan Ma Elie Traer Rita Braziel Richard Press Guang Fan Jennifer Dunlap Oregon Health Science University Portland OR 220 MUM1 is a Potential Marker of Bortezomib Resistance in Mantle Cell Lymphoma 1451 Sanjay Patel Jens Eickhoff Mohamed E Salama Gene Shaw Brad Kahl David T Yang University of Wisconsin Madison WI Marsheld Clinic Marsheld WI Washington University St. Louis MO University of Utah Salt Lake City UT 221 Genomic Abnormalities Correlated with French- American-British FAB Subtypes of Acute Myeloid Leukemia AML 1458 Zheng Ping Dejun Shen Vishnu Reddy University of Alabama at Birmingham Birmingham AL 222 LILRB1 A Novel Marker for Distinguishing Immature and Mature B-cells from B Lymphoblastic Leukemia Blasts by Flow Cytometry 1459 Elaina Pirruccello Hywyn Churchill Weina Chen Franklin Fuda UT Southwestern Dallas TX 223 Distinct Immunophenotypic Signature of MYC- Single Hit Lymphoma from MYC-Double or Triple Hit Lymphomas 1460 Elaina Pirruccello Prasad Koduru JoEllen Krueger Franklin Fuda Weina Chen UT Southwestern Dallas TX 224 Classication of Acute Myeloid Leukemia by the Proposed 2016 World Health Organization Criteria at a Single Academic Center 1472 Meghan P Riley Michael G Bayerl David Claxton Rina Kansal PennState Hershey Medical Center Hershey PA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016130 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016130 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 225 Performance of Immunohistochemistry for Detection of IDH1 R132H in Marrow Core Biopsy Specimens with Acute Myeloid Leukemia 1477 Julie A Rosser Bradford Siegele Jeffrey T Schowinsky University of Colorado School of Medicine Aurora CO 226 Blocking a TNF Superfamily Ligand-Receptor Pair on Acute Myeloid Leukemia Blasts Reduces Stemness Promotes Asymmetric Cell Division and Results in Cellular Differentiation 1482 Christian Schurch Carsten Riether Elias Buhrer Magdalena Hinterbrandner Anne-Laure Huguenin Sabine Hoepner Inti Zlobec Ramin Radpour Adrian Ochsenbein University of Bern Bern Switzerland University Hospital and University of Bern Bern Switzerland 227 Myeloproliferative Neoplasms with Concurrent BCR- ABL1 Translocation and JAK2 V617F Mutation 1486 Craig Soderquist Mark D Ewalt David Czuchlewski Julia Geyer Heesun J Rogers Daria Babushok Elizabeth Hexner Attilio Orazi Eric D Hsi Sa Wang Carlos E Bueso-Ramos Daniel A Arber Adam Bagg University of Pennsylvania Philadelphia PA Cedars- Sinai Medical Center Los Angeles CA University of New Mexico Albuquerque NM Cleveland Clinic Cleveland OH MD Anderson Cancer Center Houston TX Stanford University Stanford CA Weill Cornell Medical College New York NY 228 A Cytogenetic and Molecular Study of Myelodysplastic Myeloproliferative Neoplasm Unclassiable MDS MPN-U 1501 Pardis Vafaii Jeffrey Lancet Johnny Nguyen Ling Zhang Moftt Cancer Center Tampa FL 229 Analysis of ASXL1 Mutations in a Large Series of Myeloid Malignancies 1503 Michael Van Ness Philippe Szankasi Kimberly Frizzell Wei Shen Todd W Kelley University of UtahARUP Laboratories Salt Lake City UT 230 Identication of Ph-Like Acute Lymphoblastic Leukemia Based on Characteristic Morphologic Immunophenotypic and Genetic Features 1504 Charles van Slambrouck Kai Lee Yap Madina Sukhanova Emily Curran Jason Cheng John Anastasi Jennifer McNeer Wendy Stock Gordana Raca Sandeep Gurbuxani University of Chicago Chicago IL 231 Pathologist-Driven Test Utilization in Hematopathology 1506 Celina Villa Tracy I George Kathryn Foucar Devon Chabot-Richards University of New Mexico Albuquerque NM 232 Risk Stratication of Additional Chromosomal Changes in Chronic Myelogenous Leukemia in Era of Tyrosine Kinase Inhibitor Therapy 1509 Wei Wang Jorge Cortes Guilin Tang Joseph D Khoury Sa Wang Carlos E Bueso-Ramos Joseph A DiGiuseppe Zi Chen Hagop Kantarjian L Jeffrey Medeiros Shimin Hu MD Anderson Cancer Center Houston TX Hartford Hospital Hartford CT 233 Biological and Clinical Signicance of Cereblon Expression in underlineDe Novounderline Diffuse Large B-Cell Lymphoma BLBCLunderline 1522 Yan Xie Zijun Y Xu-Monett Alexander Tzankov Attilio Orazi Govind Bhagat Eric D Hsi Maurilio Ponzoni Michael B Moller Miguel A Piris L J Medeiros Ken H Young The University of Texas MD Anderson Cancer Center Houston TX University of Texas Medical Branch Galveston TX University Hospital Basel Switzerland Weill Medical College of Cornell University New York NY Columbia University Medical Center New York NY Cleveland Clinic Cleveland OH San Raffaele H. Scientic Institute Milan Italy Odense University Hospital Odense Denmark Hospital Universitario Marques de Valdecilla Santander Spain STOWELL-ORBISON AWARD POSTERS INFECTIOUS DISEASE PATHOLOGY 234 Human Parechovirus and Enterovirus Initiate Divergent Innate Immune Responses in the CNS Pathogenic and Diagnostic Implications 1537 Danielle Fortuna Ana Maria Cardenas Erin H Graf Larry Harshyne Kevin Quann DCraig Hooper Mark T Curtis Thomas Jefferson University Hospital Philadelphia PA Childrens Hospital of Philadelphia Philadelphia PA 235 Whole-Genome Sequencing Analysis of blaKPC - Producing Klebsiella pneumonia in Suburban New York City 2005-2014 1539 Pallavi Khattar Henry Lin Weihua Huang Jian Zhuge Pramod Mayigowda Taliya Farooq Nevenka Dimitrova John T Fallon Guiqing Wang Westchester Medical Center at New York Medical College Valhalla NY New York Medical College Valhalla NY Philips Research North America Briarcliff Manor NY STOWELL-ORBISON AWARD POSTERS INFORMATICS 236 A Web-Based Platform-Independent Whole Slide Imaging Education Suite for Pathology Didactics 1553 Paul Christensen Nathan Lee Suzanne Z Powell Michael J Thrall Patricia Chevez-Barrios Houston Methodist Hospital Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 131NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 131 237 Validation of the Mobile Whole Slide Imaging as a Low Resource Acquisition and Transport Technique for Microscopic Pathological Specimens 1563 Fatima-Zahra Jelloul Louis J Auguste Dhaval H Palsana Tawqul Bhuiya Michael J Esposito Hofstra North Shore-LIJ Bellerose NY New York University New York NY 238 Validation of Whole Frozen Section Slide Image Diagnosis in Surgical Pathology 1576 Vamsi Parimi Adrianna Borys Yi Zhou Roberto Gamez Ewa Borys Maria M Picken Dariusz Borys Loyola University Medical Center Maywood IL NYU New York NY STOWELL-ORBISON AWARD POSTERS KIDNEYRENAL PATHOLOGY INCLUDING TRANSPLANTATION 239 mRNA Diagnosis of Antibody-Mediated Rejection from Routine Parafn Sections of Renal Transplant Biopsies in a Nonhuman Primate Model 1585 Benjamin Adam R Neal Smith Tatsuo Kawai A Benedict Cosimi Robert B Colvin Michael Mengel University of Alberta Edmonton AB Canada Harvard Medical School and Massachusetts General Hospital Boston MA 240 Acute Allograft Glomerulopathy A Distinct Form of Cellular Rejection 1586 Osamah AL-Badri Mariam P Alexander Fernando G Cosio Lynn D Cornell Mayo Clinic Rochester MN 241 The Pathologic Spectrum of Acute Myoglobulinuric Renal Failure 1587 Firas Al-Del Elba A Turbat-Herrera Guillermo A Herrera Louisiana State University Health Sciences Center in Shreveport Shreveport LA 242 Apolipoprotein A-IV Amyloidosis Has a Renal Medullary Interstitial Pattern of Deposition Report of 10 Consecutive Cases 1590 Md Shahrier Amin Surendra Dasari Paul J Kurtin Julie Vrana Jason D Theis Sanjeev Sethi Mayo Clinic Rochester MN 243 Dendritic Cells in Renal Biopsies of Patients with Light- Chain Mediated Tubular Interstitial Nephritis 1597 Mingyu Cheng Guillermo A Herrera Louisiana State University Health Sciences Center Shreveport LA 244 Capsulitis A Novel Histologic Correlate in T-Cell Mediated Rejection 1600 Alexander J Gallan Kammi J Henriksen Anthony Chang The University of Chicago Chicago IL 245 Spectrum of Glomerular Lesions in Native Renal Biopsies with TRIs 1602 Rajib Gupta Serena Bagnasco Naima Carter-Monroe Lois Arend Johns Hopkins University Baltimore MD 246 Clinicopathologic Correlation of Acute Kidney Injury in Human Patients 1604 Satoru Kudose Masato Hoshi Sanjay Jain Joseph Gaut Washington University in St. Louis St. Louis MO 247 Hypoxia in Human Renal Disease Always Suspected but Not Usually Demonstrated Analysis with Carbonic Anhydrase 9 1615 Liza Quintana Nika Aljinovic Seymour Rosen Beth Israel Deaconess Medical Center Boston MA Boston Childrens Hospital Boston MA 248 Vinyl Carbamate Induces Membranoproliferative Glomerulonephritis in an In-Bred Murine Bioassay Model 1625 Neha Varshney Paula M Kramer William T Gunning University of Toledo Toledo OH 249 Molecular Diagnostics for Glomerulonephritis in Routine Formalin-Fixed Parafn-Embedded Native Kidney Biopsies 1627 Kristalee Watson Benjamin Adam Neesh Pannu Michael Mengel University of Alberta Edmonton AB Canada 250 Immunotherapy Mitigates Racial Disparities in Lupus Nephritis Outcomes 1628 Parker Wilson Michael Kashgarian Gilbert Moeckel Yale University School of Medicine New Haven CT STOWELL-ORBISON AWARD POSTERS LIVER 251 Morphoproteomics Provides Tumorigenic Correlates in Hepatitis C-Associated Hepatocellular Carcinoma with and without TACE Treatment 1633 Manju Ambelil Suhair A AlSalihi Sadhna Dhingra Robert Brown University of Texas Health Science Center at Houston Houston TX 252 Is Von-Meyerberg Complex Preneoplastic for Intrahepatic Cholangiocarcinoma 1637 Amarpreet Bhalla Kurt Fisher Jingmei Lin Indiana University Indianapolis IN 253 Molecular and Cytogenomic Proling of Hepatic Adenocarcinoma Expressing Inhibin a Mimicker of Neuroendocrine Tumors Proposal to Reclassify as Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma 1639 David R Braxton Debra F Saxe Kristen Stashek Stuti G Shroff Naveena Damjanov Jennifer JD Morrissette Rashmi Tondon Emma E Furth University of Pennsylvania Philadelphia PA Emory University Atlanta GA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016132 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016132 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 254 Histologic Comparison of Donation after Cardiac Death DCD Liver Transplant Recipients with Non-Hepatitis C HCV Related Cirrhosis 1640 Kathleen Byrnes Neeta Vachharajani Maria M Doyle Ilke Nalbantoglu Washington University in St. Louis St. Louis MO 255 Evaluation of the Clinical TNM Staging System Pathological TNM Staging System and BCLC Staging System of Hepatocellular Carcinoma A Study of 1021 Cases of Curative Liver Resection 1655 Tian Feng Ji Yuan Department of Pathology Zhongshan Hospital Fudan University Shanghai Shanghai China 256 Applying Criteria for Hepatocellular Neoplasm of Uncertain Malignant Potential Reclassies 50 of Hepatocellular Adenomas 1668 Brent Larson Maha Guindi Cedars-Sinai Medical Center Los Angeles CA 257 Mechanical Forces Directly Modulate Hepatocellular Expression Distribution of Nuclear Lamina Proteins Lamin A B Congestive Hepatopathy as a Pure Force Injury Model 1670 Crystal Magno Emma E Furth Hospital of the University of Pennsylvania Philadephia PA 258 Caught in Action Hepatic Arteriolar Thrombi Are a Likely Cause of Ischemic Cholangiopathy IC in Donation after Cardiac Death DCD Allografts 1679 Natalia Rush Chandrashekhar Kubal Romil Saxena Indiana University Indianapolis IN 259 A Novel Histologic Diagnostic Algorithm for Hepatic Graft Versus Host Disease 1683 Ashley E Stueck Thomas Schiano M Isabel Fiel Icahn School of Medicine at Mount Sinai New York NY 260 Immature B-cells Can Be Detected in a Subset of Adult and Pediatric Liver Biopsies A Potential Pitfall in the Diagnosis of B Lymphoblastic LeukemiaLymphoma 1688 Kwun Wah Wen Ryan M Gill University of California San Francisco San Francisco CA 261 Acute Antibody-Mediated Rejection after ABO- Compatible Pediatric Liver Transplantation Histopathologic Study with Clinical Correlation 1694 Wendi Zhou Laura Wozniak Jeffrey D Whitman Bita V Naini UCLA Los Angeles CA STOWELL-ORBISON AWARD POSTERS NEUROPATHOLOGY AND OPHTHALMIC PATHOLOGY 262 Malignant Peripheral Nerve Sheath Tumors Are Negative for Estrogen Receptor by Immunohistochemistry 1700 Dylan Coss Jennifer Ju Anne M Mills University of Virginia Charlottesville VA 263 Is All Inammation within Temporal Artery Biopsies Temporal Arteritis 1708 Liwei Jia Marta Couce Mark L Cohen Case Western Reserve UniversityUniversity Hospitals Case Medical Center Cleveland OH 264 Filum Pathology of Occult Tethered Cord Syndrome in Ehlers Danlos Patients 1728 Michael Punsoni Jeffrey Julian Grant Jolly Jerrold L Boxerman David B Choi Pradeep Chopra John E Donahue Krisztina Moldovan Edward G Stopa Petra M Klinge Brown University Rhode Island Hospital Providence RI Warren Alpert Medical School of Brown University Providence RI 265 MGMT Promoter Methylation Status and Overall Survival in Glioblastoma Patients 1733 Daniel Xia Neal Lindeman Brigham and Womens Hospital Boston MA STOWELL-ORBISON AWARD POSTERS PANCREAS AND BILIARY TREE 266 Intra- and Interobserver Variability in the Assessment of Ampullary Dysplasia 1739 Felicia Allard Jeffrey Goldsmith Gamze Ayata Larry Brown Tracy Challies Robert Najarian Imad Nasser Helen Wang Eric Yee Beth Israel Deaconess Medical Center Boston MA University of Virginia Charlottesville VA 267 Oncocytic-type of Intraductal Papillary Mucinous Neoplasm IPMN An Analysis of 25 Cases 1740 Gokce Askan David Klimstra Volkan Adsay Peter Allen Bahar Memis Carlie Sigel Olca Basturk MSKCC NYC NY Emory University Atlanta GA 268 ATRXDAXX Loss Is Highly Specic for Metastatic Pancreatic Neuroendocrine Tumors 1749 Michelle Heayn Raja R Seethala Aatur Singhi University of Pittsburgh Medical Center Pittsburgh PA 269 Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells 1756 Heidi D Lehrke Rondell Graham Dora Lam-Himlin Robert R McWilliams Thomas C Smyrk Lizhi Zhang Mayo Clinic Rochester MN Mayo Clinic Scottsdale AZ 270 Concordance of Tumour Hypoxia in Resectable PDAC in Patients on the Pimo-Panc Clinical Trial and Patient Derived Xenografts Using Semi-Quantitative Image Analysis 1774 Iram Siddiqui Neesha Dhani Pinjiang Cao Jade Bilkey Trevor McKee Trevor Do Jing Xu Steven Gallinger David Hedley University of Toronto Toronto ON Canada UHN Toronto ON Canada Deniens Tissue Phenomics Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 133NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 133 271 GATA-3 Expression in Pancreas Cancer 1778 Sagar J Vishal Craig Dunseth James J Mezhir Andrew M Bellizzi University of Iowa Iowa City IA 272 The Diagnostic Utility of TCTE3 as a Novel Immunohistochemical Marker for Pancreatobiliary Tumors 1783 Chaohui L Zhao Lijuan Wang Evgeny Yakirevich Murray B Resnick Shaolei Lu Brown University Providence RI 273 Non-Mucinous Epithelium Is a Common Finding in Mucinous Cystic Neoplasms of the Pancreas and Liver and May Represent a Precursor to the Mucinous Component 1784 Kristen E Zhelnin Yue Xue Brian Quigley Michelle D Reid Hyejeong Choi Bahar Memis Volkan Adsay Alyssa M Krasinskas Emory University Atlanta GA Ulsan University Hospital Ulsan Republic of Korea STOWELL-ORBISON AWARD POSTERS PATHOBIOLOGY INCLUDING PAN-GENOMICPAN-PROTEOMIC APPROACHES TO CANCER 274 Recurrent Chromosomal 8q24.21 Abnormalities and Their Functional Relevance in Pediatric Acute Leukemias 1791 Jinjun Cheng Joy Nakitandwe Ina Radtke Gang Wu Tanja Gruber Jinghui Zhang Charles G Mullighan James Downing St Jude Childrens Research Hospital Memphis TN The University of Tennessee Health Science Center Memphis TN 275 Clinical Utility of a Next-Generation Sequencing Oncology Panel Designed for Low Input DNA 1796 Midhat S Farooqi David B Lieberman Elizabeth M Azzato Daniel DeSloover Robert Daber Jennifer JD Morrissette Hospital of the University of Pennsylvania Philadelphia PA St. Jude Childrens Research Hospital Memphis TN Color Genomics Burlingame CA Bio- Reference Laboratories Elmwood Park NJ 276 Proteomic Analysis of Formalin-Fixed Parafn- Embedded Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors Yields Valuable Insights into Tumorigenesis Biomarkers and Therapeutic Targets 1799 Michael Greenwood Stephen Luebker Audrey J Lazenby Scott A Koepsell University of Nebraska Medical Center Omaha NE 277 Somatic Mutational Landscape of Inammatory Bowel Disease-Associated Signet Ring Cell Colorectal Carcinoma 1807 Amy A Lo Helio A Costa Jim Zehnder Sam Rao Carlos D Bustamante Guang-Yu Yang Nike Beaubier Stanford School of Medicine Stanford CA Northwestern School of Medicine Chicago IL 278 Next Generation Sequencing of Tumors An Institutional Experience of 200 Consecutive Cases 1815 Snehal Patel Andy Pao Jean Lopategui Cedars-Sinai Medical Center Los Angeles CA 279 Utility of Genomic Analysis in Differentiating Synchronous Independent Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis 1817 Jad Saab Hamid Zia Susan Mathew Michael J Kluk Navneet Narula Helen Fernandes NewYork Presbyterian Hospital-Weill Cornell Medical College New York NY STOWELL-ORBISON AWARD POSTERS PEDIATRIC PATHOLOGY 280 A Strategy for Helicobacter Immunohistochemistry Utilization in the Pediatric Setting Details from a Morphologic and Cost Benet Analysis 1832 Miriam Conces Christina A Arnold Michael Arnold Nationwide Childrens Hospital Columbus OH The Ohio State University Wexner Medical Center Columbus OH 281 High Level Expression of Divergent Endodermal Lineage Markers in Gonadal and Extragonadal Yolk Sac Tumors 1842 Hadi Shojaei Hong Hong Raymond W Redline University Hospitals Case Medical Center Cleveland OH 282 Targeted Sequencing Analysis of Aggressive Pediatric Rhabdomyosarcomas 1843 Olivia L Snir Farzana D Pashankar Zenta Walther Karin E Finberg Jeffrey L Sklar Raffaella Morotti Yale University School of Medicine New Haven CT 283 Tracheal Fibromas Represent -Catenin-Mediated Fibroproliferative Disease 1847 Henry Tran David Parham Childrens Hospital Los Angeles Los Angeles CA STOWELL-ORBISON AWARD POSTERS PULMONARY PATHOLOGY INCLUDING MEDIASTINAL 284 Squamous Metaplasia Indicator of Acute Exacerbation and Poor Prognostic Factor in Usual Interstitial Pneumonia 1867 Masatake Hara Mikiko Hashisako Yasuhiko Yamano Takeshi Johkoh Yasuhiro Kondoh Hiroyuki Taniguchi Junya Fukuoka Nagasaki University School of Medicine Nagasaki Japan Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan Tosei General Hospital Seto Aichi Japan Kinki Central Hospital of Mutual Aid Association of Public School Teachers Itami Hyogo Japan Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016134 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016134 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 285 Next Generation Sequencing A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases 1872 Wendy Kadi Snehal Patel Jean Lopategui Ann E Walts Alberto M Marchevsky Andy Pao Tudor Mudalige Angela Aguiluz Cedars Sinai Medical Center Los Angeles CA 286 Primary Mediastinal Germ Cell Tumors A Clinicopathologic Study of 32 Cases 1884 Liping Liu Rafael E Jimenez John C Cheville Marie- Christine Aubry Anja C Roden Mayo Clinic Rochester MN 287 Pleuropulmonary Solitary Fibrous Tumors- A Clinicopathologic Study of 84 Cases with Comparison of Proposed Risk Stratication Systems 1893 Wadad Mneimneh Sarah M Jenkins Marie Christine Aubry Jennifer M Boland Mayo Clinic Rochester MN 288 Detection of BRAF Mutation in Lung Adenocarcinoma by Next-Generation Sequencing Beyond V600E Mutation 1916 Kevan Salimian Roghayeh Fazeli Gang Zheng Zahra Maleki The Johns Hopkins Hospital Baltimore MD 289 Programmed Cell Death 1 Biomarker Testing RNA and Protein Assessment 1919 Brandon S Shefeld Regan Fulton Katy Milne Celine Jacquemont Brad H Nelson Cheryl Ho Allen M Gown Diana N Ionescu University of British Columbia Vancouver Canada PhenoPath Seattle WA 290 Discrepancy in Detection of Anaplastic Lymphoma Kinase ALK Gene Status in Lung Cancer by Immunohistochemistry IHC and Fluorescent In Situ Hybridization FISH 1921 Hemlata Shirsat Weei-Yuarn Huang Wenda Greer Mathieu Castonguay Zhaolin Xu Dalhousie University Halifax NS Canada 291 Airway Centered Neutrophils in Post-Transplant Transbronchial Biopsies A Poor Predictor of Infection 1923 Payal Sojitra Akshay Muralidhar Sana Quddus Swati Mehrotra Vijayalakshmi Ananthanarayanan Loyola University Medical Center Maywood IL 292 Elevated Integrin 64 Expression Is Associated with Venous Invasion and Decreased Survival in Squamous Cell Lung Cancer 1926 Rachel Stewart Dava West Chi Wang Heidi Weiss Tamas Gal Eric Durbin William OConnor Min Chen Kathleen L OConnor University of Kentucky Lexington KY 293 Stromal Inammation Score A Prognostic HE Biomarker for Squamous Cell Carcinomas of the Lung 1938 Daniel Xia Ruben Casanova Alex Soltermann Andrew H Beck Brigham and Womens Hospital Boston MA University of Zurich Zurich Switzerland Beth Israel Deaconess Medical Center Boston MA 294 Malignant Melanoma Presenting as Thoracic Midline Malignancy Clinicopathological and Molecular Features 1941 Keluo Yao Weiqiang Zhao David Cohen Alejandro Gru Greg Otterson Konstantin Shilo The Ohio State University Wexner Medical Center Columbus OH STOWELL-ORBISON AWARD POSTERS QUALITY ASSURANCE 295 Ambiguous p53 Immunohistochemical Patterns and Role of Tissue Processing Correlation with DNA Sequencing 1946 Anand Annan Joe Z Zhao Kelly Smith Sanam Husain Elizabeth Gillies Rosemary Zuna University of Oklahoma Health Sciences Center Oklahoma City OK OU Medical Center Oklahoma City OK 296 Quality of Reporting in Predictive Biomarker Studies in Anatomic Pathology Journals 1955 Justin Caron Michael B Cohen Robert L Schmidt University of Utah School of Medicine Salt Lake City UT 297 Fresh Cut Versus Stored Cut Parafn-Embedded Tissue Effect on Immunohistochemical Staining for Common Breast Cancer Markers 1967 Catherine Forse Dushanthi Pinnaduwage Shelley Bull Anna Marie Mulligan Irene Andrulis University of Toronto Toronto ON Canada Mount Sinai Hospital Toronto ON Canada University Health Network Toronto ON Canada 298 HPV Status and Other Contributing Factors to Negative Pap Tests in Women with Biopsy Proven High Grade Cervical Lesions 1970 Steven Goodman Roxanne R Mody Donna Coffey Blythe Gorman Eric Luna Donna Armylagos Mary R Schwartz Dina R Mody Yimin Ge Houston Methodist Hospital Houston TX University of Texas Health Science Center Houston TX BioReference Laboratories Elmwood Park NJ 299 Impact of Changes in the Helicobacter Pylori HP Detection Protocol on Reported HP Rates 1975 Bogdan Isaila Razvan Lapadat Yi Zhou Xianzhong Ding Stefan Pambuccian Loyola University Medical Center Maywood IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 135NEXTGENERATION LEARNING 2016 POSTER SESSION I Monday March 14 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 135 300 Osteomyelitis and Lower Extremity Amputations at a Single Institution A Quality Assurance Study 1981 Valerie Lockhart Erin E Langford Guillermo A Herrera LSU Health Shreveport Shreveport LA 301 Validation of Computer-Assisted ER PR Her2 Ki-67 IHC Quantitation 1989 Charles Myers Cynthia Cohen Momin T Siddiqui Bill Li Godfrey M Guerzon Diane Lawson Geoffrey Smith Emory Atlanta GA 302 Switching from Performing Helicobacter Pylori Ancillary Studies Upfront to On Demand Impact on Reimbursements and Work Relative Value Units 1991 Reeba Omman Razvan Lapadat Yi Zhou Mohammed Atieh Xianzhong Ding Stefan E Pambuccian Swati Mehrotra Loyola University Medical Center Maywood IL STOWELL-ORBISON AWARD POSTERS TECHNIQUES INCLUDING ULTRASTRUCTURE 303 Complementary Value of Electron Microscopy and Immunohistochemistry in the Diagnosis of Non-Small Cell Lung Cancer 2024 Raquel Albero Lara Pijuan Mercedes Simon Nuria Juanpere Ivonne Vazquez Adria Lloret Jessica Munne Ignacio Sanchez Sergio Serrano Josep Lloreta Hospital del Mar Barcelona Spain Istituto Clinico Humanitas Milan Italy Autonomous University of Barcelona Barcelona Spain Pompeu Fabra University Barcelona Spain 304 A Comparison of Manual Counting with Camera Captured Images and Digital Image Analysis for Ki-67 Proliferative Index Assessment in Pancreatic Neuroendocrine Tumors 2029 Elliott Burdette Charles Myers Geoffrey Smith Cameron Neely Abigail L Goodman Diane Lawson Cynthia Cohen Emory University School of Medicine Atlanta GA 305 The Intraoperative Immunohistochemical Staining of CD56 and CK19 Improves Surgical Decision for Thyroid Follicular Lesions 2032 Sung-eun Choi Eunah Shin Ju Yeon Pyo Soon Won Hong Yonsei University Gangnam Severance Hospital Seoul Republic of Korea Hanyang University Guri Hospital Seoul Republic of Korea Gangnam CHA Hospital Seoul Republic of Korea 306 Pathologic Staging of Endometrial Cancers Is There Benet to Submitting Adipose Tissue Remaining after Gross Identication of Lymph Nodes 2037 Nicola Dundas Jordan Roberts Ekene Okoye Donna Coffey Michael Deavers Houston Methodist Hospital Houston TX 307 SOX11 Expression In 125 Neuroendocrine Tumors Increased Expression In Neuroendocrine Carcinomas 2038 Laura P Fajardo Gustavo C Verardino Anabela C Caruso Ana Lucia G Areas Cesar S Bastos Monique F Silva Fabiane C Macedo Nathalie QPC Correa Roberta AP Albieri Deborah P Siqueira Andrea RC Pires Fonte Medicina Diagnostica Niteroi RJ Brazil Universidade Federal Fluminense Niteroi RJ Brazil Hospital Naval Marcilio Dias Rio de Janeiro RJ Brazil Hospital Sao Vicente de Paulo Rio de Janeiro RJ Brazil 308 Is Mammary Analogue Secretory Carcinoma of the Salivary Glands a Distinct Entity from Acinic Cell Carcinoma An Ultrastructural Study 2041 Julie Guilmette William C Faquin G Petur Nielsen Martin Selig Vania Nose Peter M Sadow University of Montreal Medical Center Montreal QC Canada Massachusetts General Hospital and Harvard Medical School Boston MA 309 Calretinin-Positive Lung Adenocarcinoma An Ultrastructural Study 2077 Ivonne Vazquez Raquel Albero Lorena Diaz Nuria Juanpere Lara Pijuan Teresa Baro Sergio Serrano Josep Lloreta Consorci Sanitari Parc de Salut Mar Hospital del Mar Barcelona Spain University Pompeu-Fabra Barcelona Spain Autonomous University of Barcelona Barcelona Spain PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PMPROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM CC HALL 4E SECTION A - GENITOURINARY CHAIRED BY ONDREJ HES AND STEWART FLEMING 100 Clear Cell Renal Cell Tumors with Intact VHL and Chromosome 3p How Many Entities Exist 1076 Sean R Williamson Dhananjay A Chitale Laura Favazza Ravi Barod Craig G Rogers Nallasivam Palanisamy Nilesh S Gupta Henry Ford Health System Detroit MI 115 Sarcomatoid Clear Cell RCC Shows a Distinct Molecular Pathogenesis and Driver Mutation Prole 1044 Kanishka Sircar Zixing Wang Tae-Beom Kim Bo Peng Jose A Karam Chad Creighton Chi-Wan Chow Jaime Rodriguez Canales Pheroze Tamboli Gordon Mills Kenna Shaw Ken Chen MD Anderson Houston TX Baylor College of Medicine Houston TX Board Number Board Number Board Number Board Number PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016136 PROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM NEXTGENERATION LEARNING2016136 130 Detection Gene Fusions in Melanotic Xp11 Translocation Renal Cancer by RNA-seq 854 Sabina Babayeva Weihua Huang Humayun Islam John T Fallon Minghao Zhong New York Medical College Valhalla NY 145 Clinical and Immunohistochemical IHC Spectrum of Renal Cell Carcinomas RCCs with Aberrant Fumarate Hydratase FH-Related Studies Report from the High-Grade Distal Nephron Adenocarcinoma HDNA International Consortium 1046 Deepika Sirohi Cedars-Sinai Medical Center Los Angeles CA 200 Morphologic and Molecular Evaluation of Thyroid-Like Follicular Carcinoma of the Kidney 933 Previn Gulavita Ming Zhou Mahul B Amin Deepika Sirohi Elizabeth Garcia Paola Dal Cin Sean R Williamson Michelle Hirsch Brigham and Womens Hospital Boston MA New York University New York NY Cedars Sinai Medical Center Irvine CA Henry Ford Hospital Detroit MI 215 Chromosomal Abnormalities of Tumors with Features of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney yet with High Grade Cytology 1028 Evita T Sadimin Yingbei Chen Pedram Argani Jonathan I Epstein Rutgers Cancer Institute of New Jersey New Brunswick NJ Memorial Sloan Kettering Cancer Center New York NY Johns Hopkins Medical Institutions Baltimore MD 230 Eosinophilic Solid and Cystic Renal Cell Carcinoma ESC RCC A Novel Entity with Distinct Molecular Karyotype 1062 Kiril Trpkov Hatem Abou-Ouf Ondrej Hes Jose I Lopez Gabriella Nesi Eva Comperat Mathilde Sibony Daniel Berney Isabela W Cunha Adeboye O Osunkoya Neriman Gokden Ming Zhou Tarek Bismar Jesse K McKenney University of Calgary Calgary Canada Charles University Pilsen Czech Republic Cruces University Hospital Bizkaia Spain Careggi Hopsital Florence Italy Piti-Salptrire Hospital Paris France Hopital Cochin Paris France Barts Cancer Center London United Kingdom AC Camargo Cancer Center Sao Paulo Brazil Emory University School of Medicine Atlanta GA Univeristy of Arkansas Little Rock AR New York University New York City NY Cleveland Clinic Cleveland OH 245 Diagnostic Criteria for Oncocytic Renal Neoplasms A Survey of Specialist Renal Tumor Pathologists 1074 Sean R Williamson Ramya Gadde Kiril Trpkov Michelle Hirsch John R Srigley Victor E Reuter Liang Cheng L Priya Kunju Ravi Barod Craig G Rogers Brett Delahunt Ondrej Hes John N Eble Ming Zhou Jesse K McKenney Guido Martignoni Stewart Fleming David J Grignon Holger Moch Nilesh S Gupta Henry Ford Health System Detroit MI McMaster University Toronto Canada Memorial Sloan Kettering Cancer Center New York NY Indiana University Indianapolis IN University of Michigan Ann Arbor MI Wellington School of Medicine Wellington New Zealand Charles University Plzen Czech Republic New York University New York NY Cleveland Clinic Cleveland OH University of Verona Verona Italy University of Calgary Calgary Canada Brigham and Womens Hospital Boston MA University of Dundee Dundee United Kingdom University Hospital Zurich Zurich Switzerland 300 BREAK CC BR 6C SECTION B - PULMONARY CHAIRED BY ANDRE MOREIRA AND ELIZABETH PAVLISKO 100 Spread through Air Spaces STAS Is an Independent Predictor of Recurrence in Lung Squamous Cell Carcinoma 1886 Shaohua Lu KS Tan K Kadota T Eguchi S Bains P Adusumilli W Travis MSKCC New York NY Fudan University Shanghai China Kagawa University Kagawa Miki-cho Japan 115 Amplication of 3q26 and High Expression Levels of SOX2 Are Associated with a Favorable Prognosis in Patients with Lung Squamous Cell Carcinoma 1857 Hoiwan H Cheung Laura J Tafe Geisel School of Medicine at Dartmouth Hanover NH Dartmouth-Hitchcock Medical Center Lebanon NH 130 Does Strong and Diffuse PAX-8 Positivity Exclude Primary Lung Carcinoma An Immunohistochemical Study of Whole-Tissue Sections from 337 Resected Primary Lung Carcinomas and Review of 27 PAX-8- Positive Carcinomas in Lung Specimens 1889 Kelsey McHugh Andrea V Arrossi Carol Farver Sanjay Mukhopadhyay Cleveland Clinic Cleveland OH 145 Lung Adenocarcinomas with KRAS Mutations Are Biologically Heterogeneous 1871 Tiffany G Huynh Justin F Gainor Valentina Nardi Mari Mino-Kenudson Massachusetts General Hospital Boston MA 200 Non-Synonymous Mutation Burden in Lung Carcinoma Is Associated with Durable Clinical Response to Immune Checkpoint Blockade 1887 Navin Mahadevan Peter Hammerman Mark Awad Lynette M Sholl Brigham and Womens Hospital Boston MA NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 137NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM 137 215 Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Clinically-Relevant Subsets with Small Cell Carcinoma-Like and Non-Small Cell Carcinoma-Like Molecular Proles 1910 Natasha Rekhtman Jarushka Naidoo Maria Pietanza Matthew D Hellmann Arshi Arora Ronglai Shen Darragh F Halpenny Helen Won Michael F Berger Shaozhou Tian John T Poirier Paul K Paik Andre Moreira Charles M Rudin William D Travis Marc Ladanyi Memorial Sloan Kettering Cancer Center New York NY 230 Myxoid Malignant Pleural Mesothelioma A Rare Histological Subtype with Good Prognosis 1878 Sylvie Lantuejoul Nolwenn Le Stang Arnaud Scherpereel Jean-Claude Pairon Francoise Galateau- Salle Centre Lon Brard Lyon France Hpital Calmette CHRU de Lille Lille France Universit Paris-Est Creteil Crteil France 245 Pure Atypical Thymomas A Clinicopathological Analysis of 25 Cases 1936 Annikka Weissferdt Maheshwari Ramineni Neda Kalhor Cesar A Moran MD Anderson Cancer Center Houston TX 300 BREAK CC BR 6B SECTION C - HEMATOPATHOLOGY CHAIRED BY RACHEL SARGENT AND OLGA POZDNYAKOVA 100 Signicance of Gene Mutations in the Evaluation of Patients with Pancytopenia Impact of Clonal Hematopoiesis of Indeterminate Potential CHIP 1364 Sebastian Fernandez-Pol Lisa Ma Daniel A Arber Stanford University Stanford CA 115 Myelodysplastic Syndrome Unclassiable MDS-U with 1 Blasts Is a Distinct Subgroup of MDS-U with a Poor Prognosis 1427 Elizabeth Margolskee Jean Oak Daniel A Arber Robert P Hasserjian Attilio Orazi Weill Cornell Medical College New York NY Stanford University Stanford CA Massachusetts General Hospital Boston MA 130 Next-Generation Sequencing Interrogation of Molecular Proles Distinguishes between MDS and AML with MDS Related Changes 1400 Mohammad O Hussaini Hailing Zhang Haipeng Shao Lynn C Moscinski Jinming Song Moftt Cancer Center Tampa FL 145 Newly Emerged Isolated Del7q May Not Always Be Associated with Therapy-Related Myeloid Neoplasms in Patients with Prior Cytotoxic Therapies 1377 Rashmi Goswami Sa Wang Yan Li Shimin Hu Jeffrey Medeiros Guilin Tang UT MD Anderson Cancer Center Houston TX University Health Network Toronto ON Canada 200 Most Myeloid Neoplasms with Deletion of Chromosome 16q Are Distinct from Acute Myeloid Leukemia with inv16p13.1q22 1473 Heesun J Rogers Eric D Hsi Guilin Tang Sa Wang Carlos E Bueso-Ramos Daniel Lubin Jennifer JD Morrissette Adam Bagg Durga P Cherukuri Tracy I George LoAnn Peterson Yen-Chun Liu Susan Mathew Attilio Orazi Robert P Hasserjian Cleveland Clinic Cleveland OH MD Anderson Cancer Center Houston TX University of Pennsylvania Philadelphia PA University of New Mexico Albuquerque NM Northwestern University Chicago IL Weill Medical College of Cornell University New York NY Massachusetts General Hospital Boston MA 215 Mutational Status Correlates with Distinct Histologic Features in Philadelphia Chromosome Ph-Negative Myeloproliferative Neoplasms MPN 1516 Waihay Wong Robert P Hasserjian Olga Pozdnyakova Brigham and Womens Hospital Boston MA Massachusetts General Hospital Boston MA 230 Impact of Hematological and Morphological Features on the Differential Diagnosis of Prebrotic Primary Myelobrosis prePMF 1410 Hans Michael Kvasnicka Jurgen Thiele University of Frankfurt Frankfurt Germany University of Cologne Cologne Germany 245 Targeted Next Generation Sequencing NGS of Chronic Eosinophilic Leukemia Not Otherwise Specied CEL NOS and of Idiopathic Hypereosinophilic Syndrome HES 1508 Sa Wang Wayne Tam Albert Tsai Daniel A Arber Robert P Hasserjian Julia Geyer Tracy I George David Czuchlewski Kathryn Foucar Heesun J Rogers Eric D Hsi Bryan Rea Adam Bagg Paola Dal Cin Todd W Kelley Srdan Verstovsek Carlos E Bueso-Ramos Attilio Orazi MDACC Houston TX Weill Cornell New York NY Stanford Stanford CA MGH Boston MA University of New Mexico Albuquerque NM Cleveland Clinic Cleveland OH University of Penn Philadelphia PA BWH Boston MA ARUP Salt Lake UT 300 BREAK CC BR 6A SECTION D - BREAST CHAIRED BY EDI BROGI AND PUAY HOON TAN 100 TERT Hotspot Promoter Mutations and TERT Gene Amplication in Phyllodes Tumors of the Breast 268 Jorge S Reis-Filho Salvatore Piscuoglio Charlotte KY Ng Melissa Murray Kathleen Burke Marcia Edelweiss Gabriel S Macedo Felipe C Geyer Akiko Inagaki Anastasios D Papanastasiou Luciano G Martelotto Caterina Marchio Raymond Lim Ino De Bruijn Lilian Smyth Muzaffar Akram Dara S Ross Larry Norton David B Solit Jose Baselga Edi Brogi Marc Ladanyi Britta Weigelt Memorial Sloan Kettering Cancer Center New York NY PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016138 PROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM NEXTGENERATION LEARNING2016138 115 Clonal Relationship among Synchronous Ipsilateral Fibroepithelial Lesions Progression from Fibroadenomas to Phyllodes Tumors 259 Salvatore Piscuoglio Charlotte KY Ng Melissa Murray Felipe C Geyer Marcia Edelweiss Britta Weigelt Edi Brogi Jorge S Reis-Filho Memorial Sloan Kettering Cancer Center New York NY 130 Phenotype and Immunophenotype Analysis of Gene Expression Dened Indolent Risk Breast Cancers 122 Alexander Borowsky Carlie K Thompson Ronald Balassanian Christina Yau Yunn-Yi Chen Gregor Krings Bo Nordenskjold Olle Stal Tommy Fornander Laura J Esserman Laura J vant Veer Linda S Lindstrom UC Davis Sacramento CA UCSF San Francisco CA Karolinska Stockholm Sweden Linkping University Linkping Sweden 145 Predicting Metastatic Site of Triple Negative Breast Cancers Using Immunohistochemical Biomarkers 196 Sergey Klimov Andrew Green Mohammed A Aleskandarany Emad Rakha Ian O Ellis Michelle Reid Padmashree CG Rida Ritu Aneja Georgia State University Atlanta GA University of Nottingham Nottingham United Kingdom Emory University Atlanta GA United Kingdom 200 Reproducible Evaluation of Tumor-Inltrating Lymphocytes TILs Using the Recommendations of International TILs Working Group 2014 197 Yumi Kojima Frances Compton Hongxia Sun Xiaohong I Wang Michael Covinsky Songlin Zhang University of Texas Health Science Center at Houston Houston TX 215 Evaluation of Histopathologic Features That Affect Interobserver Agreement on Tumor Inltrating Lymphocyte TIL Quantities in Breast Cancer 307 Fei Yang Shannon Swisher Elizabeth A Mittendorf Genevieve R Lyons Coya Tapia Xiuhong Wang Roland L Bassett Kelly K Hunt Aysegul A Sahin Yun Wu The University of Texas MD Anderson Cancer Center Houston TX 230 PD-L1 Protein Expression and PD-L1 Gene Amplication in Breast Cancer 300 Olga Voronel Siddhartha Dalvi Bhaskar VS Kallakury Christine E Sheehan Ann B Boguniewicz Jeffrey S Ross Albany Medical College Albany NY Georgetown University Hospital Washington DC 245 Programmed Cell Death Ligand 1 PD-L1 Expression in Estrogen Receptor Positive ER Invasive Breast Cancers BC A Pilot Study of 148 Cases 107 Javier Arias-Stella Brie Kezlarian Laura Favazza Daniel Schultz Dhananjay A Chitale Henry Ford Hospital Detroit MI 300 BREAK CC 602-604 SECTION E - KIDNEYRENAL CHAIRED BY CHARLES ALPERS AND MEGAN TROXELL 100 Apolipoprotein L1 ApoL1 High-Risk Variants Correlate with Parietal Epithelial Cell Activation among African Americans with Arterionephrosclerosis 1596 Justin H Chen Huma Fatima Haichun Yang Agnes B Fogo Vanderbilt University Medical Center Nashville TN University of Alabama at Birmingham Birmingham AL 115 Membranous Glomerulonephritis with Monotypic IgG Deposits A Clinico-Pathological Analysis of 28 Cases 1594 Alejandro Best Rocha Christopher Larsen Nephropath Little Rock AR 130 C3 Glomerulopathy in Older Adults 1607 Isaac Lloyd Hunter Huston Stephen Jenkins Kalani Raphael Dylan Miller Monica P Revelo Mazdak Khalighi University of Utah Salt Lake City UT 145 Patterns of Immune Complex Deposits in 70 Kidney Biopsies with Staphylococcus Infection Associated Glomerulonephritis 1620 Anjali Satoskar Sarah Suleiman Jessica Hemminger Sergey Brodsky Gyongyi Nadasdy Tibor Nadasdy Ohio State University Wexner Medical Center Columbus OH 200 Leukocyte Chemotactic Factor 2 Amyloidosis ALECT2 Is a Common Form of Renal Amyloidosis Among Egyptians 1611 Samih Nasr Wesam Ismail Paul J Kurtin Julie Vrana Surendra Dasari Christopher Larsen Mayo Clinic Rochester MN BeniSuef University BeniSuef Egypt Nephropath Little Rock AR 215 Accelerated Mesangial Repair by Mesenchymal Stem Cells MSCs Incubated with Cocktail of Trophic Differentiation Factors 1623 Jiamin Teng Chun Zeng Elba A Turbat-Herrera Guillermo A Herrera LSUHSC-Shreveport Shreveport LA 230 Characterizing Glomerular Injury of Pediatric Kidneys Transplanted to Adult Recipients 1619 Steven Salvatore Meredith J Aull Muthukumar Thangamani Surya Seshan Weill Cornell Medical College New York NY 245 Maximizing Information from the Renal Biopsy Computer-Generated Three-Dimensional Constructs 1599 Beverly E Faulkner-Jones Devin Rosen Seymour Rosen Kyle Harrington Charles Law BIDMC Boston MA Kitware Inc Clifton Park NY 300 BREAK NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 139NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM 139 CC 606-607 SECTION F - HEAD NECK CHAIRED BY DIANA BELL AND MANJU PRASAD 100 Molecular Analysis of Low-Grade Cribriform Cystadenocarcinoma Related In-Situ and Invasive Carcinomas 1316 Ilan Weinreb Raja R Seethala Simion I Chiosea Bayardo Perez-Ordonez Martin Hyrcza Lei Zhang Chun-Liang Chen Yun-Shao Sung Adel Assaad Lester DR Thompson Cristina Antonescu University Health Network Toronto ON Canada University of Pittsburgh Medical Center Pittsburgh PA Memorial Sloan-Kettering Cancer Center New York NY Virginia Mason Medical Center Seattle WA Kaiser Permanente Medical Center Woodland Hills CA 115 Clinicopathologic Characterization of Mammary Analogue Secretory Carcinoma 1271 Simion I Chiosea Raja R Seethala Lindsay Williams Adel M Assaad Lester DR Thompson Madalina Tuluc Bibianna Purgina Chi K Lai Nasir Ud Din Alena Skalova University of Pittsburgh Pittsburgh PA Virginia Mason Medical Center Seattle WA Southern California Permanente Medical Group Woodland Hills CA Thomas Jefferson University Philadelphia PA University of Ottawa Ottawa Canada Aga Khan University Hospital Karachi Pakistan Faculty of Medicine Plzen Plzen Czech Republic 130 A Subset of Ectomesenchymal Chondromyxoid Tumors ECTs of the Tongue Shows EWSR1 Rearrangement and Is Genetically Linked to Soft Tissue Myoepithelial Neoplasms A Study of 9 Cases 1261 Prokopios Argyris Elizabeth Bilodeau Denise Trochesset Stefan E Pambuccian Stephanie Wetzel Paul Freedman Michelle M Dolan Ioannis Koutlas University of Minnesota Minneapolis MN University of Pittsburgh School of Dental Medicine Pittsburgh PA Stony Brook Oral Pathology Stony Brook NY Loyola University Medical Center Maywood IL New York Hospital of Queens Flushing NY 145 Salivary Duct Carcinoma Relationship between Morphologic Evidence of Pleomorphic Adenoma PLAG1 HMGA2 Translocations and MutationsCopy Number Changes in 50 Cancer-Related Genes 1272 Simion I Chiosea Alyssa M Luvison Caitlyn Miller Lester DR Thompson Ilan Weinreb William E Gooding University of Pittsburgh Pittsburgh PA Southern California Permanente Medical Group Woodland Hills CA University Health Network Toronto Canada 200 Identication of a Novel Junctional Site in the Oropharynx Permissive for Human Papillomavirus Infection 1317 Robbie Woods Helen Keegan Christine White Prerna Tewari Danielle Costigan Jacqueline Barry-OCrowley Mary Toner Susan Kennedy Esther M ORegan Cara M Martin Conrad Timon John OLeary Royal Victoria Eye and Ear Hospital Dublin Ireland Dublin University Trinity College Dublin Ireland St. Jamess Hospital Dublin Ireland The Coombe Women and Infants University Hospital Dublin Ireland Cerviva Research Consortium Dublin Ireland 215 Comparison of p16 Antibody Clones for the Evaluation of Oropharyngeal Squamous Cell Carcinoma 1311 Jeremy Shelton Bibianna Purgina Nicole A Cipriani James Lewis Vanderbilt University Medical Center Nashville TN University of Ottawa Ottawa ON Canada University of Chicago Chicago IL 230 Activating KRAS Mutations Are Characteristic of Oncocytic Sinonasal Papilloma and Associated Sinonasal Squamous Cell Carcinoma 1313 Aaron Udager Raja R Seethala Evgeny Yakirevich Jonathan McHugh Bryan Betz Megan S Lim Kojo Elenitoba-Johnson Noah Brown University of Michigan Health System Ann Arbor MI University of Pittsburgh Medical Center Pittsburgh PA Rhode Island Hospital and Brown University Providence RI Perelman School of Medicine at the University of Pennsylvania Philadelphia PA 245 Head and Neck Presentation of Cutaneous Leishmania in Syrian Refugees 1276 Gabriel Dunya Robert Habib Roger Moukarbel Ibrahim Khalifeh American Univeristy of Beirut Beirut Lebanon 300 BREAK CC 608-609 SECTION G - QUALITY ASSURANCE CHAIRED BY YAEL K HEHER AND RAOUF E NAKHLEH 100 Results of College of American Pathologists Prociency Testing for Highly Sensitive ALK Immunohistochemistry in Lung Adenocarcinoma 1950 Andrew M Bellizzi Robert A Schwartz Jason L Hornick CAP Immunohistochemistry Committee University of Iowa Iowa City IA Manchester Memorial Manchester CT Brigham and Womens Boston MA 115 Prospective Quality Assurance of Breast Core Biopsies Minimizes Errors and Improves Patient Safety 2005 Sejal S Shah Natalie S Campbell Gary L Keeney Beiyun Chen Daniel W Visscher Mayo Clinic Rochester MN PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016140 PROFFERED PAPERS Monday March 14 2016 100 PM - 300 PM NEXTGENERATION LEARNING2016140 130 Switching from FDA-Approved to Laboratory- Developed HER2 IHC Testing Decreases Costs by 85 A Micro-Costing Analysis 2000 Carolyn Rysgaard Ellen Abusada Lisa Horning Rose Meyer Kent Becker Andrew M Bellizzi University of Iowa Hospitals and Clinics Iowa City IA 145 Identifying Targets for Reducing Immunohistochemical Utilization An Audit of 18760 Casesunderline 1999 Lisa M Rooper Jonathan I Epstein Ashley Cimino- Mathews Johns Hopkins Hospital Baltimore MD 200 Pathology MM Rounds A Focus on Transparency and Process Improvement 1958 Yigu Chen Jeffrey Goldsmith Yael K Heher Beth Israel Deaconess Medical Center Boston MA 215 A Quantitative Method to Measure Pathology Assistants Productivity Using Standardized Relative Value Units 2015 Vladimir H Volel Tarush Kothari Raheela Querishi Diane Groppi Mike Raugnath Claudine Alexis Tylis Y Chang Oksana Yaskiv James M Crawford Tawqul Bhuiya North Shore - LIJ Health System Lake Success NY 230 Elimination of Cutting and Saving Unstained Sections of GI Biopsy Specimens Yields Signicant Benets with No Untoward Effects on Quality 2002 Saa N Salaria Craig W Self Mary F Abbuhl Omar Hameed Lan L Gellert Vanderbilt University School of Medicine Nashville TN 245 The Effect of Prolonged Duration of Formalin Fixation on the Yield of Ampliable DNA for Molecular Testing 1990 Niru Nahar Caleb King Celeste N Powers Gorge A Almenara Catherine I Dumur Michael O Idowu Virginia Commonwealth University Health System Richmond VA 300 BREAK CC 615-617 SECTION H - ENDOCRINE CHAIRED BY BRUCE M WENIG AND ELHAM KHANAFSHAR 100 Clinico-Pathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas Non-ANA FCDCs 614 Bin Xu Tihana Ibrahimpasic Laura Wang R Michael Tuttle Ian Ganly Ronald Ghossein Memorial Sloan-Kettering Cancer Center New York NY 115 Metastatic Follicular Thyroid Carcinoma Retrospective Institutional Experience and Insight into Primary Follicular Thyroid Neoplasia 579 Krzysztof Glomski Peter M Sadow Massachusetts General Hospital and Harvard Medical School Boston MA 130 TERT Promoter Mutation as a Prognostic Marker in Follicular Carcinomas 612 Michelle D Williams Ying C Henderson Gary L Clayman Gilbert Cote University of Texas MD Anderson Cancer Center Houston TX 145 The Presence of Combined BRAF TP53 and PIK3CA Mutations Have Prognostic Impact in the Hobnail Variant of Papillary Thyroid Carcinoma 569 Soa Asioli Luca Morandi Francesca Maletta Alberto Righi Marco Gallo Anna Sapino Ricardo V Lloyd University of Bologna Bologna Italy University of Turin Turin Italy Rizzoli Institute Bologna Italy University of Wisconsin School of Medicine and Public Health Madison WI 200 Clinical-Pathological Features of 55 Papillary Thyroid Carcinomas Carrying BRAF Mutations Other Than V600E 570 Fulvio Basolo Elisa Sensi Mirella Giordano Liborio Torregrossa DIPINT-University of Pisa Pisa Italy AOUP Pisa Italy 215 Prospective Experience with Routine SSTR2A Immunohistochemistry in Neuroendocrine Epithelial Neoplasms 568 Deema Alkapalan Jessica E Maxwell Thomas ODorisio James R Howe Andrew M Bellizzi Iowa NET SPORE University of Iowa Iowa City IA 230 Ampullary and Duodenal Somatostatin-Producing Neuroendocrine Tumors Two Histologically and Clinico-Pathologically Distinct Entities 609 Alessandro Vanoli Stefano La Rosa Luca Albarello Federica Grillo Frediano Inzani Rachele Manca Michele Martino Ombretta Luinetti Roberta Maragliano Catherine Klersy Fausto Sessa Roberto Fiocca Claudio Doglioni Guido Rindi Carlo R Capella Enrico Solcia IRCCS San Matteo Hospital and University of Pavia Pavia Italy University of Insubria Varese Italy Ospedale di Circolo Varese Italy San Raffaele Hospital Milan Italy University of Genoa IRCCS San Martino IST Genoa Italy Catholic University Rome Italy 245 Genomic Proling of Neuroendocrine and Neuroepithelial Neoplasms by Targeted Next Generation Sequencing 601 Jason N Rosenbaum Chad Storer Catherine E Cottrell Eric J Duncavage Washington University Medical School Department of Pathology and Immunology St. Louis MO 300 BREAK NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 141NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 141 BREAST PATHOLOGY 1 Breast Pathologic Diagnosis and BIRADS Classes Correlation Study on 4118 Patients 174 Shaomin Hu James Szymanski Yungtai Lo Yanhua Wang Monteore Medical CenterAlbert Einstein College of Medicine Bronx NY Albert Einstein College of Medicine Bronx NY 2 Diagnostic Terminology of Atypia on Breast Core Needle Biopsy Correlation with Excision and Upgrade Rates 159 Michael George Debra L Zynger Gary Tozbikian The Ohio State University Columbus OH 3 Isolated FEA Is Not Associated with a Signicant Upgrade Rate Correlation of Biopsy and Excision Specimens 153 Kathryn S Dyhdalo Hannah Gilmore Philip Bomeisl University Hospitals Case Medical Center Cleveland OH 4 Expression of the Autophagy Protein p62 in FEA Does Not Predict for Upgrading to Atypical Hyperplasia or Carcinomaunderline 285 Jordan Sim Jason K Wasserman Susan J Robertson The Ottawa Hospital Ottawa ON Canada 5 Impact of Atypia within Multiple Non-Synchronous Biopsies on Breast Cancer Risk A Mayo Benign Breast Disease Cohort Study 133 Jodi M Carter Ryan D Frank Robert A Vierkant Stacey Winham Derek C Radisky Marlene H Frost Ruth Kraft Amy Degnim Daniel Visscher Mayo Clinic Rochester MN Mayo Clinic Jacksonville FL 6 Clinical-Pathological Analysis of Women with Proliferative Breast Disease Undergoing Multiple Benign Biopsies A Mayo Benign Breast Disease Cohort Study 132 Jodi M Carter Derek C Radisky Ryan D Frank Robert A Vierkant Stacey Winham Marlene H Frost Amy Degnim Daniel W Visscher Mayo Clinic Rochester MN Mayo Clinic Jacksonville FL 7 Risk of Breast Cancer among African American Women with Sclerosing Adenosis and Radial Scar 251 Vishakha Pardeshi Michele L Cote Julie J Ruterbusch Eman Abdulfatah Woodlyne Roquiz Baraa Alosh Muhammad K Alsafadi Daniel W Visscher Sudeshna Bandyopadhyay Rouba Ali-Fehmi WSU Detroit MI Mayo Clinic Rochester MN 8 Subareolar Sclerosing Ductal Hyperplasia SSDH Further Characterization of a Distinct Clinicopathological Entity Based on Review of 35 Cases 137 Esther Cheng Maria Arafah Paula S Ginter Timothy DAlfonso Syed Hoda Weill Cornell Medical College New York NY College of Medicine King Saud University Riyadh Saudi Arabia 9 Computational Image Analysis of Breast Biopsy Specimens with Atypia - Through the Looking Glass of Diagnostic Concordance among Pathologists 116 Francisco Beca Irshad Humayun Donald L Weaver Joann Elmore Andrew H Beck Beth Israel Deaconess Medical Center Boston MA Harvard Medical School Boston MA University of Vermont School of Medicine Burlington VT University of Washington School of Medicine Seattle WA 10 Increasing Concordance for Intraductal Proliferative Lesions of the Breast Using NDER a Novel Web Application 266 Nicholas P Reder Daniel Glasser Mara H Rendi Suzanne M Dintzis Rochelle L Garcia Jonathan C Henriksen Mark R Kilgore University of Washington Medical Center Seattle WA 11 Concordance in the Cloud- A Multidisciplinary Software Tool for Breast Core Biopsy Correlation 118 Michael W Bennett Tim Manning Brian Kelly Noel Murphy Paul Walsh Tara Jane Browne Fionnuala OConnell Cork University Hospital Cork Ireland nSILICO Cork Ireland Health Innovation Hub Cork Ireland 12 When Pathological and Radiological Correlation Is Achieved Excision of Fibroadenoma with Lobular Neoplasia on Core Biopsy Is Not Warranted 127 Tara Jane Browne Cassie Fives Michael W Bennett Linda Feeley Rose Murphy Mark Corrigan Fionnuala OConnell Cork University Hospital Cork Ireland 13 Is Excision Biopsy of Fibroadenomas Based Soley on Size Criteria Warranted 128 Tara Jane Browne Michael W Bennett Linda Feeley Mark Corrigan Fionnuala OConnell Cork University Hospital Cork Ireland 14 Indeterminate Fibroepithelial Lesions on Breast Core- Needle Biopsy Patient Characteristics Management and Outcomes 226 Kelly Mooney Kara-Lee Pool David Y Lu Peggy Sullivan David Geffen School of Medicine at UCLA Los Angeles CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016142 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016142 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 15 Lipophyllodes of the Breast A Multi-Institutional Study of 22 Cases with Clinicopathological Correlations Molecular Insight and Follow Up 111 Carlos E Bacchi Sheila Wludarski Janez Lamovec David Ben Dor Giovanna De Maglio Stefano Pizzolitto Elisa Ober Fabrizio Zanconati Giovanni Falconieri Consultoria em Patologia Botucatu Sao Paulo Brazil Institute of Oncology Ljubljana Slovenia Barzilai Medical Center Askelon Israel University Hospital Udine Italy University Hospital Trieste Italy 16 Epithelial-Mesenchymal Transition and Cancer Stem Cells Interactions in Phyllodes Tumours Clinical Relevance and Prognostic Signicance 104 Syed Salahuddin Ahmed Jabed Iqbal Aye Aye Thike Jeffry Chun Tatt Lim Puay Hoon Tan Singapore General Hospital Singapore Singapore 17 Analysis of MED12 and TERT Promoter Mutations in Fibroepithelial Lesions FEL Metaplastic Carcinomas MC and Spindle Cell Lesions SCL of the Breast 214 Su-Yang Liu Yunn-Yi Chen Nancy Joseph Poonam Vohra Gregor Krings UCSF San Francisco CA 18 Management of Benign Papilloma of the Breast Diagnosed on Core Biopsy a Review of 4182 Cases 208 Xiaoxian Bill Li Emory University Atlanta GA 19 Non-Atypical Intraductal Papillomas of the Breast Diagnosed in Core Biopsies Are Pathologic Factors Predictive of Upgrade 262 Morad Qarmali Oluwole Fadare UC San Diego San Diego CA 20 Dysregulation of the PIK3CAAKT Pathway in Spindle Cell Metaplastic Carcinomas Arising from Papillary Adenomyoepithelial Tumors 136 Esther Cheng Timothy DAlfonso Yifang Liu Sandra J Shin Weill Cornell Medical College New York NY 21 Role of Epithelial-to Mesenchymal Transition Markers in Metaplastic Breast Cancer with Coexistent Ductal Carcinoma In-Situ 102 Eman Abdulfatah Rahman Chaudhry Vishakha Pardeshi Muhammad K Alsafadi Sherif Shazly Rouba Ali-Fehmi Sudeshna Bandyopadhyay WSU Detroit MI Mayo Rochester MN 22 Expression Analysis of Epithelial-Mesenchymal Transition Related Genes in Triple Negative Breast Cancer 311 Shuling Zhou Anqi Li Ming Li Yan Xu Yaoxing Xiao Wentao Yang Fudan University Shanghai Cancer Center Shanghai China 23 Metaplastic Breast Carcinoma with an Admixed Invasive Ductal Carcinoma Component Does It Matter 255 John M Pike Katie Dennis Ossama Tawk Fang Fan University of Kansas Medical Center Kansas City KS 24 RNA-Seq of Pleomorphic Classic Lobular Carcinoma In Situ Identies Signicant Differences in Gene Expression Indicating Pleomorphic LCIS Resembles Luminal B-type Breast Cancerunderline 182 Arthur Johnson Christine Henzler Molly Klein Stuart Cameron James Richter Sumaya Al Rawi Jessica Gruenberg Aqsa Nasir Maryam Shahi Evan W Sell Kathryn L Schwertfeger Richard Zera Andrew C Nelson HCMC Minneapolis MN University of MN Minneapolis MN 25 Genomic Characterization of CDH1- Unaltered Invasive Lobular Carcinoma of the Breast 257 Zheng Ping Gene P Siegal Shuko Harada Dejun Shen University of Alabama at Birmingham Birmingham AL 26 Secretory Carcinoma of the Breast Molecular Characterization of 12 Cases by Standardized Quantitative RT-PCR Analysis 113 Helen Bailey Debbie McCullough Frederick L Baehner Carolyn Mies Genomic Health Inc. Redwood City CA 27 An Appraisal of Epithelial and Myoepithelial Markers in Adenoid Cystic Carcinoma of the Breast A Unique Reverse Staining Pattern of Cytokeratin 56 Excludes Its Mimickers 236 Tokiko Nakai Shu Ichihara Tomonori Kawasaki Suzuko Moritani Akiko Kada Noriko Ito Tomoko Uchiyama Hiroe Itami Kouhei Morita Masato Takano Maiko Takeda Kinta Hatakeyama Chiho Ohbayashi Nara Medical University Kashihara Nara Japan Nagoya Medical Center Nagoya Aichi Japan Iwate Medical University School of Medicine Morioka Iwate Japan Shiga Medical University Otsu Shiga Japan Clinical Research Center Nagoya Medical Center Nagoya Aichi Japan 28 SOX10 Is a Novel Sensitive Diagnostic Marker for Adenoid Cystic Carcinoma of the Breast Immunohistochemical Analysis of Adenoid Cystic Carcinoma 306 Chen Yang Lingxin Zhang Souzan Sanati Washington University School of Medicine St. Louis MO 29 Analysis of MYB IHC and FISH in Breast Adenoid Cystic Carcinomas Microglandular Adenosis and Collagenous Spherulosis 261 Justin Poling Raluca Yonescu Rajni Sharma Yi Ning Ashley Cimino-Mathews Johns Hopkins Medical Institutions Baltimore MD Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 143NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 143 CYTOPATHOLOGY 30 Ultrasound Guided Fine Needle Aspiration of Salivary Gland Nodules by Cytopathologists at The University of Toledo Medical Center. A Fast Safe and Accurate Approach 417 Weihong Li Stacy L Molnar Richard Cantley Lorene Yoxtheimer Luis De Las Casas University of Toledo Medical Center Toledo OH 31 Risk-Stratied Triage of Salivary Gland Fine-Needle Aspiration Specimens 428 Jelena Mirkovic Liena Zhao William C Faquin Vickie Y Jo Jeffrey F Krane Brigham and Womens Hospital Boston MA Massachusetts General Hospital Boston MA Harvard Medical School Boston MA 32 MYB Immunohistochemical IHC Stain Potential Role in Separating Adenoid Cystic Carcinoma ACC from Pleomorphic Adenoma PA 429 Andres Moon Cynthia Cohen Momin T Siddiqui Emory University School of Medicine Atlanta GA 33 A Multiinstitutional Interobserver Variability IOV Study Interpreting Thyroid FNA using the Bethesda System for Classication of Thyroid Cytology TBSCTC - A Focus on Atypical Cells of Undetermined Signicance AUS Follicular Lesion of Undetermined Signicance FLUS 438 Vijayalakshmi Padmanabhan Carrie B Marshall Guliz A Barkan Mohiedean Ghofrani Idris T Ocal Charles D Sturgis Rhona J Souers Daniel FI Kurtycz DHMC Lebanon NH University of Colorado Aurora CO Loyola University Chicago IL PeaceHealth Laboratories Vancouver WA Mayo Clinic Scottsdale AZ Cleveland Clinic Cleveland OH CAP Chicago IL University of Wisconsin Madison WI 34 Quality Management of Thyroid Fine Needle Aspiration Inter and Intra-Pathologist Diagnostic Variation 360 Tamar C Brandler Melissa Klein Gianna Ballon Mohamed S Aziz Hofstra North Shore-LIJ School of Medicine Lake Success NY 35 The Bethesda System Class III Thyroid Nodules Follow Up Data and Conclusions Based on 13194 Thyroid Fine Needle Aspirates 415 Marcos Lepe Mariana Canepa Bassam Aswad Latha R Pisharodi Rhode Island Hospital Providence RI Brown University Providence RI 36 The Value of Negative Diagnosis in Thyroid Fine- Needle Aspiration A Retrospective Study with Histologic Follow-Up 342 Rita Abi-Raad Rebecca Baldassarri Kevin Schoeld Adebowale Adeniran Yale University School of Medicine New Haven CT 37 Differential Outcomes of Patients with FNA Diagnoses of AUS Versus FLUS The Potential Need for Separation in the Bethesda System 374 Georgios Deftereos Tracy S Tylee Emily E Waner Malak Itani Manjiri K Dighe Stephen C Schmechel University of Washington Seattle WA 38 Indeterminate Thyroid Nodules Does Asuragen Testing Improve the Specicity of Arma Test Results 359 Shikha Bose Ann E Walts Wendy Sacks Cedars-Sinai Medical Center Los Angeles CA 39 Rene Risk of Malignancy by Subclassifying Atypia of Undetermined Signicance AUS in Thyroid Cytopathology 473 Huaitao Yang Wei Liu David Steward Abid Yaqub Universiy of Cincinnati Medical Center UCMC Cincinnati OH UCMC Cincinnati OH 40 Comparison of Malignancy Rates in Thyroid Fine Needle Aspiration Using the Bethesda Category System in a Tertiary Care Center and a Comprenhensive Cancer Center Institutional Statistics 375 Victor Delacruz Claudia P Rojas Elvia Goez-Gutierrez Carmen Gomez-Fernandez Merce Jorda Monica Garcia-Buitrago University of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL Jackson Memorial Hospital Miami FL 41 Fine-Needle Aspiration Cytology of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features NIFT Single Institutional Study with Comparison to Invasive Follicular Variant of Papillary Thyroid Carcinoma 404 Ashley Ibrahim Kristin A La Fortune Howard Wu Indiana University School of Medicine Indianapolis IN 42 Applying Strict Cytomorphologic Criteria and Minimizing Interobserver Variability in Diagnosing Atypia of Uncertain Signicance Increases the Positive Predictive Value of the Arma GEC Assay in Thyroid Fine Needle Aspiration 447 Rovin Saxena Brant McCall Nikhil Neelkantan Michael S Ballo Northwest Hospital Randallstown MD Howard University Hospital Washington DC International American University College of Medicine Vieux Fort Saint Lucia Trinity School of Medicine Kingstown Saint Vincent and the Grenadines 43 Impact of ThyroSeqv.2 Next-Generation Sequencing Assay on Fine Needle Aspiration Cytology of Thyroid Nodules 376 Anita Deshpande Huihong Xu Sandra Cerda Boston Medical Center Boston MA 44 Utility of Next Generation Sequencing NGS Cotesting to Recategorize Bethesda-I Thyroid FNAs 386 Reyhan Gedik Anita Deshpande Huihong Xu Sandra Cerda Boston Medical Center Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016144 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016144 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 45 The Diagnostic Accuracy of Thyroid Fine Needle Aspirates for Atypia Suspicion for Malignancy and Malignancy in Hashimoto Thyroiditis a Single Institutional Experience 370 Jennifer A Collins Christopher J VandenBussche Syed Z Ali Johns Hopkins University School of Medicine Baltimore MD 46 Fine-Needle Aspiration of Thyroid Malignancies Arising in Graves Disease A Diagnostic Challenge 441 Marc Pusztaszeri Peter M Sadow Jeffrey F Krane Gilbert Daniels William C Faquin Geneva University Hospitals Geneva Switzerland Massachusetts General Hospital Boston MA Brigham and Womens Hospital Boston MA 47 Correlation of Fine-Needle Aspiration FNA and Frozen Section FS Interpretations with the Final Pathological Diagnosis in Thyroid Lesions Possible Combined Utility of FNA and FS in Managing Thyroid Lesions 364 Michael M Burt Rashna Madan Fang Fan University of Kansas Medical Center Kansas City KS 48 Multiple Squamous Cells in Thyroid Fine Needle Aspiration Friends or Foes 385 Heather M Gage Laurentia Nodit University of Tennessee Medical Center Knoxville Knoxville TN 49 Stromal Tissue as an Adjunct Tool in the Diagnosis of Follicular Thyroid Lesions by Fine Needle Aspiration Biopsy 400 Kevin Hogan Jason K Wasserman Kien T Mai The Ottawa Hospital and University of Ottawa Ottawa ON Canada 50 Nuclear Size Does Not Predict Clinical Outcomes When Evaluating Thyroid AFLUS by FNA 372 Elizabeth Dacey Terry K Morgan OHSU Portland OR 51 Factors Impacting the Performance Characteristics of Bile Duct Brushings BDBs an Analysis in 444 Patients 392 Ezgi Hacihasanoglu Vaidehi Avadhani Zerife Yusii Bahar Memis Alexa Freedman Michael Goodman Volkan Adsay Michelle Reid Emory University Hospital Atlanta GA 52 When We Say Maybe We Mean Yes We Just Dont Want to Say It and Probably for a Good Reason Pathologists Own View on Their Uncertain Diagnosis in Bile Duct Brushings 393 Ezgi Hacihasanoglu Krisztina Z Hanley Rhonda Everett Vaidehi Avadhani Alyssa M Krasinskas Uma Krishnamurti Adeboye O Osunkoya Alexa Freedman Bahar Memis Michael Goodman Volkan Adsay Michelle Reid Emory University Atlanta GA 53 Indenite to Positive and Indenite to Negative Ratios Represent Potential Quality Measures for Biliary Cytology 410 Dina Kokh Lynette Parker Paul Staats University of Maryland Baltimore MD 54 The Clinical Impact of Biliary Tract FISH Analysis 467 Nilam Virani Madelyn Lew Bryan Betz Michael H Roh Xin Jing Amer Heider Robertson Davenport Judy C Pang University of Michigan Ann Arbor MI 55 Rened Diagnostic Criteria for the Cytopathologic Diagnosis of Mucinous Colloid Adenocarcinoma of the Pancreas 475 Xiu Yang Houda Alatassi Mostafa M Fraig University of Louisville Louisville KY 56 Can the Ki-67 Index Evaluated on Fine Needle Aspiration Cellblock Material Reliably Grade Pancreatic Neuroendocrine Tumors 341 Rita Abi Raad Andrea L Barbieri Xuchen Zhang Malini Harigopal Rebecca Baldassarri Angelique W Levi Susan V Fernandez Diane Kowalski Adebowale Adeniran Guoping Cai Yale School of Medicine Nerw Haven CT 57 FNA-Based Grading of Pancreatic Neuroendocrine Neoplasms Using Ki-67 469 Vivian L Weiss Colleen M Kiernan Jesse P Wright Nipun B Merchant Alice Coogan Chanjuan Shi Vanderbilt University Medical Center Nashville TN 58 A Comparison of Automated Digital Image Analysis DIA and Manual Count of Camera-Captured Images in Calculating Ki-67 Proliferation Index PI in Cytologic Samples from Pancreatic Neuroendocrine Neoplasms PanNENs 435 Cameron Neely Elliott Burdette Charles Myers Geoffrey Smith Cynthia Cohen Michelle Reid Emory University Atlanta GA 59 Diagnostic Accuracy of Pancreatic Fine Needle Aspiration and Evaluation of Discordant Cases 413 Hubert D Lau Michael A DiMaio Teri A Longacre Christina S Kong Stanford University Stanford CA 60 Indeterminate Cytologic Diagnoses in EUS-Guided FNA of the Pancreas Confusion or Comprehension 358 Anna Biernacka Xiaoying Liu Jonathan Marotti Edward Gutmann Thanapoom Boonipat Timothy B Gardner Stuart R Gordon Kerrington D Smith J Marc Pipas Vijayalakshmi Padmanabhan Dartmouth-Hitchcock Medical Center Geisel School of Medicine at Dartmouth Lebanon and Hanover NH 61 Pancreatic Metastases Potential for Misdiagnosis on Fine Needle Aspiration 423 Brock A Martin Teri A Longacre Christina S Kong Stanford University Stanford CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 145NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 145 62 Efcacy of EUS-Guided Fine Needle Aspiration in the Diagnosis of Upper Gastrointestinal Lesions 381 Abdulwahab Ewaz Reid Sakamoto William Kawahara Renn Putorak Pamela Tauchi-Nishi Thomas Namiki University of Hawaii Honolulu HI Queens Medical Center Honolulu HI 63 Cytotechnologist Assisted Adequacy Assessment of Image Guided Fine Needle Aspiration Specimens 450 Joshua Segal Carol Anderson Christina S Kong Stanford Health Care Stanford CA EDUCATION 64 A Patient Safety Curriculum for Pathology Trainees A Data Driven Institutional Endeavor 564 T Danielle Samulski Zubair Baloch Hospital of the University of Pennsylvania Philadelphia PA 65 The Creation and Implementation of a Points-Based System for Distributing Specimens to Residents at a Tertiary Care Academic Residency Program 557 Chelsea Mehr Amrom Obstfeld Amanda Barrett Kathleen Montone Lauren Schwartz Hospital of the University of Pennsylvania Philadelphia PA 66 Quantitative Assessment of Competency in Surgical Pathology Initial Promising Roll-Out Results at the UNM Department of Pathology 562 Benjamin Ramos Fred Schultz Teresa Quintana Joshua A Hanson Sam Reynolds Von G Samedi Therese Bocklage University of New Mexico School of Medicine Albuquerque NM 67 Introducing a Virtual Reality Experience in Anatomic Pathology Education 554 Emilio Madrigal Shyam Prajapati Jelena Krcedinac Juan C Hernandez-Prera Mount Sinai Health System New York NY 68 Fine Needle Aspiration Cytology FNAC Simulation Using Phantoms. University Teaching Experience 543 Eduardo Alcaraz-Mateos Alexandra Kundisova Aleksijs Stopinskijs Joanna Lenik Iga Leszczynska Iva Cerna Martina Andrasova Robert Roland Agnes Gilberte Cristina Martin Mauricio Borbolla Gerardo Valenzuela Valeria Hernandez Belen Roldan Laura Martinez Fuensanta Caballero Morales Meseguer University Hospital Murcia Spain University of Murcia Murcia Spain Bratislava Bratislava Slovakia Slovak Republic Riga Riga Latvia Krakow Krakow Poland Prague Prague Czech Republic Montpellier Montpellier France Salamanca Salamanca Spain Veracruz Veracruz Mexico Juarez Durango Mexico Zaragoza Zaragoza Spain Castelln Castelln Spain 69 Development of a Web-Based Question Database 553 Mark Lincoln Jeff Lacombe Melissa Austin Walter Reed National Military Medical Center Bethesda MD Freelance Information Technologist Liverpool NY 70 An Interactive Online Unknown Conference with a System for Ordering Immunostains and Molecular Genetic Studies 555 Leonel Maldonado Brett Baskovich University of South Alabama Medical Center Mobile AL 71 Development of an Online Case Simulator as an Educational Tool in Anatomic Pathologyunderline underline 546 Michael Bonert Jens Schittenhelm Vinita Parkash Yuan Gao Kiril Trpkov McMaster University Hamilton Canada University of Tuebingen Tuebingen Germany Yale University New Haven CT Memorial University of Newfoundland St. Johns Canada University of Calgary Calgary Canada 72 A Searchable Database of Anatomic Pathology Diagnoses A Tool Optimized for Trainee Eduction 563 Scott A Robertson Alexander Baras Johns Hopkins Hospital Baltimore MD Cleveland Clinic Cleveland OH 73 Implementation of Resident Sign Out Application with Functions to Compare Resident and Attending Reports 549 Bryan J Dangott Shuhua Ma Renuka Malenie Peter Kragel East Carolina University Greenville NC 74 Improving the Resident Selection Process 544 Candice C Black Dartmouth Hitchcock Medical Center Lebanon NH 75 Development of a Dynamic Leadership Curriculum to Enhance Residency Education in Pathology and Laboratory Medicine 548 Carolyn Cambor David B Roth Craig Loundas Monica Heuer Christopher D Watt Kathleen Montone Deborah Sesok-Pizzini University of Pennsylvania Health System and the Perelman School of Medicine Philadelphia PA 76 A Histologic Checklist for Appropriate Diagnosis of Melanocytic Lesions 547 Ryanne Brown Uma Sundram Stanford Health Care Stanford CA Currently at Associated Pathology Medical Group Los Gatos CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016146 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016146 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 77 CyTEST- A Pan European Project for Training Testing in Cytopathology 556 Caterina Marchio Helena Barroca Roberto Dina Emanuela Ovcin Martin Toetsch Ambrogio Fassina Gianni Bussolati University of Turin Turin Italy IPATIMUP University of Porto Porto Portugal Imperial College London United Kingdom University of Graz Graz Austria University of Padua Padua Italy COREP Turin Italy 78 Fellowship In-Service Hematopathology Examination FISHE Predicts Success on the American Board of Pathology Hematology Subspecialty Certifying Examination ABP-HE 558 Sara A Monaghan Ray E Felgar Melissa Kelly Asma Ali John Anastasi Aarti Bellara Henry Rinder Rachel Sargent Jay Wagner Steven H Swerdlow Rebecca L Johnson UT Southwestern Dallas TX University of Pittsburgh Pittsburgh PA American Society Clinical Patholology Chicago IL University of Chicago Chicago IL American Board of Pathology Tampa FL Yale New Haven CT University Penn Philadelphia PA 79 Resident In-Service Exam Review Series 551 Jessica Forcucci J M Hyer David Lewin Nicholas Batalis Medical University of South Carolina Charleston SC 80 Resident Incentive Program Engaging Pathology Residents in Quality Improvement Projects through Financial Incentives 550 Jessica Forcucci Thomas Soike Jim Madory David Lewin Nicholas Batalis Medical University of South Carolina Charleston SC 81 Big Data Bioinformatics Education during Residency Demonstrates Immediate Value 566 Amelia Sybenga Riyam T Zreik Amin Mohammad Arundhati Rao Scott White Memorial Hospital Temple TX 82 Pathology Knowledge Consumption Characteristics Online Using an Open Access Pathology Wiki 545 Michael Bonert Vinita Parkash Jens Schittenhelm McMaster University Hamilton Canada Yale University New Haven CT University of Tuebingen Tuebingen Germany 83 Pathologists in Gross Anatomy - Strategies for Curriculum Integration 561 Charles Quick David L Davies University of Arkansas for Medical Sciences Little Rock AR 84 Multidisciplinary Tumor Board A Ready-Made Tool for Competencies Professionalism and Capturing Medical Student Interest in Pathology 567 Rebecca Wilcox University of Vermont Medical Center Burlington VT 85 Four Years of Virtual Pathology Teaching Using SlideAtlas a Web-Based Open-Source Digital Pathology Platform Supporting Multi-Touch Interaction 565 Kristen Smith Kuda Maloney Brian Helba Charles Law Beverly E Faulkner-Jones BIDMC Bosotn MA MD Anderson Cancer Center Houston TX Kitware Inc Clifton Park NY GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 86 Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy 906 Sheila Faraj Stephania M Bezerra Kasra Youse Helen Fedor Stephanie Glavaris Misop Han Alan Partin Elizabeth Humphreys Jeffrey Tosoian Michael H Johnson Elai Davicioni Bruce Trock Edward M Schaeffer Ashley Ross George J Netto Johns Hopkins Medical Institution Baltimore MD GenomeDx Biosciences Vancouver BC Canada 87 Can Contemporary Pure Gleason 33 ISUP Grade Group 1 Prostate Cancer Invade into the Extraprostatic Tissue or Seminal Vesicle 852 Blake Anderson Aria A Razmaria Bonnie Choy Scott Eggener Gladell P Paner University of Chicago Chicago IL 88 Small High Grade Cancer as the Largest Tumor at Radical Prostatectomy RP 872 Trevor Caldwell Jonathan I Epstein The Johns Hopkins Medical Institutions Baltimore MD 89 Does Zonal Distribution of the Index Tumor Inuence Prognostic Factors in Radical Prostatectomies 867 Athanase Billis Leandro LL Freitas Larissa BE Costa Camila M de Angelis Kelson R Carvalho Ruana M Rocha Lucas QA Bastos Gabriel LP Oliveira Marcel A Asato Karina S Araujo Daniele M Losada Amanda P Herculiani School of Medical Sciences State University of Campinas Unicamp Campinas SP Brazil 90 Is Zonal Distribution of Index Tumor Different in Radical Prostatectomies Comparing Whites vs African- Brazilians 866 Athanase Billis Leandro LL Freitas Larissa BE Costa Camila M de Angelis Kelson R Carvalho Ruana M Rocha Lucas QA Bastos Gabriel LP Oliveira Marcel A Asato Karina S Araujo Daniele M Losada Amanda P Herculiani School of Medical Sciences State University of Campinas Unicamp Campinas SP Brazil Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 147NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 147 91 PTEN Expression in Mucinous Prostatic Adenocarcinoma and Prostatic Adenocarcinoma with Mucinous Features A Multi-Institutional Study of 92 Cases 864 Elizabeth Bertsch Cristina Magi-Galluzzi Liang Cheng Adeboye O Osunkoya Emory University School of Medicine Atlanta GA The Cleveland Clinic Cleveland OH Indiana University School of Medicine Indianapolis IN 92 Mucinous Adenocarcinoma of Prostate and Prostatic Adenocarcinoma with Mucinous Components A Clinicopathological Analysis of 81 Cases 946 Samaratunga Hemamali Brett Delahunt Lars Egevad John Yaxley Shulammite Johannsen Geoff Coughlin Troy Gianduzzo Aquesta Pathology Brisbane Queensland Australia University of Queensland Brisbane Queensland Australia Wellington School of Medicine and Health Sciences Wellington Otago New Zealand Karolinska Institute Stockholm Sweden Wesley Hospital Brisbane Queensland Australia 93 Prostate Cancer Gleason Grade 4 Pattern Heterogeneity in Men on Active Surveillance Who Undergo Delayed Prostatectomy 1061 Patricia Troncoso John W Davis Elsa Li Ning Tapia Ina Prokhorova John F Ward Louis L Pisters Mary Achim Christopher J Logothetis Jeri Kim The University of Texas MD Anderson Cancer Center Houston TX 94 Proliferation Index of Gleason Grade 3 Prostate Adenocarcinoma with and without Associated Grade 4 952 Michael Hwang Liying Fu Adebowale Adeniran Peter A Humphrey Yale University School of Medicine New Haven CT 95 Proliferation Index of Different Gleason Grade 4 Prostatic Adenocarcinoma Morphologies 915 Liying Fu Michael Hwang Adebowale Adeniran Peter A Humphrey Yale University School of Medicine New Haven CT 96 Clinical Signicance of Percentage of Gleason Pattern 4 in Gleason Score 7 Prostate Cancer at Radical Prostatectomy 955 Mohsin Jamal Sean R Williamson Mireya Diaz-Insua Mani Menon Hans Stricker James Peabody Craig G Rogers Nilesh S Gupta Henry Ford Hospital Detroit MI 97 Correlation of Gleason Score 7 in Prostate Adenocarcinoma on Needle Biopsy between General and Urological Pathologists Inuence of Percent Pattern 4 and Other Histological Factors 994 Abdelrazak Meliti Francesca Khani Mairo L Diolombi Evita T Sadimin Jonathan I Epstein Johns Hopkins Hospital Baltimore MD 98 Diagnostic Accuracy of Subpatterns of Gleason Pattern 4 Prostate Cancer Morphological Subpatterns 977 Jianhong Li Rajal Shah Ali Amin Ritu Bhalla Kasturi Das Fang-Ming Deng Peng Lee Andres Matoso Jonathan Melamed Savvas Mendrinos Wei Tian Oksana Yaskiv Ming Zhou New York University New York NY Miracal Life Sciences Irving TX Brown University Providence RI Louisiana State University New Orleans LA North Shore LIJ Lake Success NY 99 Quantifying Gleason Pattern 4 Prostate Cancer in Prostate Needle Biopsy An Interobserver Reproducibility Study 979 Jianhong Li Jianbo Li Ali Amin Ritu Bhalla Kasturi Das Fang-Ming Deng Peng Lee Andres Matoso Jonathan Melamed Savvas Mendrinos Wei Tian Oksana Yaskiv Rajal Shah Ming Zhou New York University New York NY Cleverland Clinic Cleveland OH Louisiana State University New Orleans LA Northshore LIJ Health System Lake Success NY Brown University Providence RI Miracle Life Sciences Irving TX 100 Interobserver Reproducibility of Percentage Gleason Pattern 4 in Prostatic Adenocarcinoma 1029 Evita T Sadimin Francesca Khani Mairo L Diolombi Abdelrazak Meliti Jonathan I Epstein Johns Hopkins Medical Institutions Baltimore MD 101 Assessing Gleason Pattern GP 4 in Needle Biopsies An Interobserver Reproducibility Study 910 SW Fine J Sarungbam HA Al-Ahmadie Y-B Chen A Gopalan SJ Sirintrapun VE Reuter SK Tickoo Memorial Sloan Kettering Cancer Center New York NY 102 Quantitative Assessment of Perineural Invasion and Percentage of Sites with 347 Carcinoma Predicts Upstaging in Intermediate Risk Prostate Cancer 862 Justin Bateman Susan J Robertson Nicola Schieda Daniel T Keefe Eric C Belanger Kien T Mai Rodney H Breau Chris Morash Trevor A Flood The Ottawa Hospital Ottawa ON Canada The University of Ottawa Ottawa ON Canada 103 Prostate Cancer Grade Group 4 Gleason 358 and 538 Outcomes Versus 448 943 Nicholas Harding-Jackson Elizabeth Whittington Daniel C Eastwood George A Tjionas Oleksandr N Kryvenko Swikrity Upadhyay Merce Jorda Kenneth A Iczkowski Medical College of Wisconsin Milwaukee WI University of Miami Miami FL 104 Mutational Analysis of Gleason Score 7 Prostate Cancer Using Next Generation Sequencing and Fluorescent In Situ Hybridization 1081 Ming Zhou Zach Liu Roberto Zoino Chrysostomos Chrysostomou Gaurav Rajoria Szczepan Klimek Herber Lepor New York University New York NY Histopathology Services Ramsey NJ Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016148 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016148 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 105 Mutational Analysis of Prostate Cancer Using Next Generation Cancer Hotspot Panel 983 Zach Liu Ming Zhou Herber Lepor Roberto Zoino Gaurav Rajoria Szczepan Klimek Histopathology Services Ramsey NJ New York University Medical Center New York City NY 106 High-Grade Prostatic Intraepithelial Neoplasia with Adjacent Small Atypical Glands PINATYP Reappraisal of Diagnostic Criteria 978 Jianhong Li Fang Bu Fang-Ming Deng Peng Lee Jonathan Melamed Rajal Shah Ming Zhou New York University New York NY Miracal Life Sciences Irving TX 107 High Grade Prostatic Intraepithelial Neoplasia with Adjacent Small Atypical Glands PINATYP on Core Needle Biopsy A Clinicopathological Analysis of 54 Cases with Emphasis on Predictors of Prostate Cancer 1042 Rajal Shah Wei Tian Ming Zhou Jianbo Li Miraca Life Sciences Irving TX New York University Langone Medical Center New York NY Cleveland Foundation Clinic Cleveland OH 108 Radical Prostatectomy Outcomes of Prostatic Adenocarcinoma Diagnosed after Initial Diagnosis of Atypical Glands on Prostate Needle Biopsy 1040 Alpa Shah Ramya Gadde Javier Arias-Stella Sean R Williamson Nilesh S Gupta Henry Ford Hospital Detroit MI 109 Diagnosis of Limited Prostate Adenocarcinoma on Core Needle Biopsy An Improvement of Interobserver Reproducibility Using Comprehensive Morphological and Molecular Criteria 1041 Rajal Shah Gioacchino Leandro James Bentley Monica Chaterjee Gloria Romerocases Wei Tian Yousef Tadros Jiyoon Yoon Savvas Mendrinos Miraca Life Sciences Irving TX IRCCS De Bellis Castellana Grotte Italy 110 Atypical Cribriform Lesion of the Prostate Shares Similar ERG and PTEN Expression Patterns as Intraductal Carcinoma of the Prostate and Is Associated with a Higher Stage and Grade Than Invasive Cancer Alone 949 Richard Hickman Hui Yu Max Kong Rajal Shah Ming Zhou Jonathan Melamed Fang-Ming Deng NYU Langone Medical Center New York NY Miraca Life Sciences Dallas TX 111 Pathologic Outcomes and Biochemical Recurrence BCR Free Survival in Men Younger Than 45 Years with Prostate Cancer PCa Treated with Robotic Radical Prostatectomy RRP 985 Zhichun Lu Sean R Williamson Mireya Diaz-Insua Hans Stricker Mani Menon Nilesh S Gupta Henry Ford Hospital Detroit MI 112 Variant Histopathology in Young-Age Prostate Cancer 1019 Susan Prendeville Andrew Evans Rob G Bristow Theodorus H van der Kwast Laboratory Medicine Programme University Health Network Toronto ON Canada Radiation Oncology University Health Network Toronto ON Canada 113 Radical Prostatectomy RP Findings in Hispanic Men Qualifying for Active Surveillance AS 969 Oleksandr N Kryvenko Kirill Lyapichev Felix M Chinea Nachiketh S Prakash Alan Pollack Sanoj Punnen Merce Jorda University of Miami Miami FL 114 Active Surveillance for Newly Diagnosed Low Risk Prostate Cancer Institutional Experience of Initial Choice and Follow Up in a Racially Mixed Population 944 Oudai Hassan MHD Fayez Daaboul Dongping Shi Isaac Powell Michael L Cher Wael Sakr WSU Detroit MI 115 Do African Americans with Low Risk Prostate Cancer on Needle Biopsy Eligible for Active Surveillance Have More Aggressive Pathology in Radical Prostatectomy Specimens Compared to Their European American Counterparts 890 MHD Fayez Daaboul Oudai Hassan Dongping Shi Muhammad K Alsafadi Isaac Powell Michael L Cher Wael A Sakr WSU Detroit MI 116 Assessment of Differences in Prostate Cancer Characteristics between Asian and Non-Asian Men 967 Pavel Kopach Elizabeth Genega Tufts Medical Center Boston MA 117 Prostate Intraductal Carcinoma Multifocality and Bilateral Signicant Disease in Radical Prostatectomy Specimens from United States and Japan 881 Yu-Ching Peng Toyonori Tsuzuki Max Kong Jianhong Li Fang-Ming Deng Jonathan Melamed Ming Zhou New York University New York NY Japanese Red Cross Nagoya Daini Hospital Nagoya Japan 118 Identifying Additional Lymph Nodes In Radical Prostatectomy Pelvic Lymph Node Specimens 1059 Jessica Tracht Win S Lai Soroush Rais-Bahrami Jennifer B Gordetsky University of Alabama at Birmingham Birmingham AL 119 Whole-Exome Sequencing of Prostatic Stromal Sarcoma and Prostatic Stromal Tumor of Uncertain Malignant Potential 1009 Chin-Chen Pan Jonathan I Epstein Taipei Veterans General Hospital Taipei Taiwan Johns Hopkins Hospital Baltimore MD Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 149NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 149 120 Spectrum of Cystic Epithelial Tumors of the Prostate Most Cystadenocarcinomas CACs are Ductal Type with Intracystic Papillary Pattern 1011 Gladell P Paner Antonio Lopez-Beltran Toyonori Tsuzuki Jesse K McKenney University of Chicago Chicago IL Champalimaud Clinical Center Lisbon Portugal Nagoya Daini Red Cross Hospital Nagoya Japan Cleveland Clinic Cleveland OH 121 Novel and Rare Mesonephric-Type Tumors Arising from the Urologic Tract 1012 Gladell P Paner Deepika Sirohi Mukul Divatia Mahul B Amin University of Chicago Chicago IL Cedars-Sinai Medical Center Los Angeles CA GYNECOLOGIC AND OBSTETRIC PATHOLOGY 122 Vaginal Melanoma A Molecular Analysis of 32 Cases 1178 Anais Malpica Elizabeth D Euscher MD Anderson Cancer Center Houston TX 123 Vulvovaginal Smooth Muscle Tumors 1230 Shahrzad Slater Jesse Hart Maria Garcia-Moliner Ali Amin Women and Infants Hospital Providence RI Rhode Island Hospital Providence RI Warran Alpert Medical School of Brown University Providence RI 124 HPV-Independent Vulvar Squamous Cell Carcinoma Has a Signicantly Worse Prognosis Than HPV- Associated Carcinoma 1152 Anthony Karnezis Angela Cheng Samuel Leung Suzanne Jordan Naveena Singh Dianne M Miller Jessica N McAlpine C Blake Gilks University of British Columbia Vancouver BC Canada Barts Health NHS Trust London United Kingdom 125 The Prevalence of Vulvar Lichen Sclerosus in Patients with Vulvar Squamous Cell Carcinoma 1117 Jonathan Davick Colleen Stockdale James T Krone Megan I Samuelson University of Virginia Charlottesville VA University of Iowa Iowa City IA 126 Classic Vulvar Intraepithelial Neoplasia with Superimposed Lichen Simplex Chronicus A Potential Pitfall in the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia 1247 Jaclyn C Watkins Eric Yang Christopher P Crum Marisa R Nucci Brigham and Womens Hospital Harvard Medical School Boston MA Stanford University Hospital Palo Alto CA 127 Molecular Alterations in Verruciform Lesions and Keratinizing Squamous Cell Carcinomas of the Vulva 1248 Jaclyn C Watkins Brooke E Howitt Neil Horowitz Lauren L Ritterhouse Fei Dong Marisa R Nucci Christopher P Crum Brigham and Womens Hospital Harvard Medical School Boston MA 128 Proteomic Proles of Vulvar Squamous Cell Carcinoma 1142 Emily Holthoff Stephanie Byrum Thomas J Kelly Alan Tackett Steven Post Charles Quick UAMS Little Rock AR 129 Recurrent Gains of CD274 and PDCD1LG2 in Squamous Cell Carcinomas of Cervix and Vulva 1144 Brooke E Howitt Heather Sun Margaretha GM Roemer Alyssa Kelly Bjoern Chapuy Emeline M Aviki Christine Pak Evisa Gjini Youling Yang Larissa Lee Akila Viswanathan Neil Horowitz Donna Neuberg Christopher P Crum Neal Lindeman Frank Kuo Azra H Ligon Gordon J Freeman F Stephen Hodi Margaret A Shipp Scott Rodig Brigham and Womens Hospital Boston MA Dana Farber Cancer Institute Boston MA 130 PDL-1 Expression in Cervical Intraepithelial Neoplasia 1213 Carolina Reyes Deepti Adhikari Guragain Kumarasen Cooper Hospital of the University of Pennsylvania Philadelphia PA 131 Programmed Cell Death Ligand-1 Is Expressed in a Signicant Number of Uterine Cervical Carcinomas 1212 Opal L Reddy Itsushi P Shintaku Neda A Moatamed David Geffen School of Medicine at UCLA Los Angeles CA 132 Do Antibody Clones of PD-L1 and PD-1 Expressing Tumor Inltrating Lymphocytes in Cervical Tumors Matter 1107 Luis F Carrillo Peter N Bonneau Alexander C Mackinnon Irene Aguilera-Barrantes Medical College of Wisconsin Milwaukee WI 133 Demise of the Pap Smear Not So Fast Report of HPV DNA Negative Cervicovaginal Dysplasias 1146 Yiang Hui Katrine Hansen Jayasimha N Murthy Danielle B Chau C James Sung M Ruhul Quddus Women Infants HospitalAlpert Medical School of Brown University Providence RI Memorial Hospital Alpert Medical School of Brown University Pawtucket RI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016150 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016150 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 134 Application of Triage Markers for Management of HPV Positive Women Presenting at Colposcopy with Minor Cytological Abnormalities 1243 Prerna Tewari Christine White Lynne Kelly Padraig Kearney Loretto Pilkington Tom DArcy Cliona Murphy Nadine Farah Eimear Lee Dorinda Mullen Jacqui Barry-OCrowley Sharon OToole Linda Sharp John OLeary Cara Martin Trinity College Dublin Ireland Coombe Women Infants University Hospital Dublin Ireland Newcastle University Newcastle United Kingdom 135 Clinical Outcomes of hrHPV-PositiveCytology-Negative Patients 1114 Lani K Clinton Jordan K Kondo Pamela Tauchi-Nishi David Shimizu University of Hawaii Pathology Residency Program Honolulu HI Queens Medical Center Honolulu HI 136 Validation of a Novel RNA ISH Assay for HR-HPV E67 mRNA 1182 Anne M Mills Mark H Stoler UVA Charlottesville VA 137 Distribution of Cervical Lesions Associated with HPV in the Democratic Republic of So Tom and Prncipe 1193 Rita SS Oliveira Ana C Braga Lucilia Goncalves Gabriela Gasparinho Marco Ferreira Luis V Pinto Ana Matos Elizabete Carvalho Manuel Cardoso Paula Guerra Sara B Turpin Ruben R Roque Gilberto Matias Armandina Silveira Raquel Almeida Henrique Nabais Rui Nobre Hugo Prazeres Hospital Prof. Doutor Fernando Fonseca E.P.E. Amadora Portugal Pathology Laboratory Roriz Lisboa Portugal Group for Cancer Intervention in Low Resource Settings STP Cervical Cancer Mission Lisboa Portugal Marques Valle Flor Institute ONG Lisboa Portugal Champalimaud Foundation Lisboa Portugal Armed Forces Hospital Porto Portugal Ministry of Health So Tom Sao Tome and Principe Coimbra University Coimbra Portugal Portuguese Oncology Institute Coimbra Portugal 138 HPV Vaccination Status in Patients with High Grade Cervical Precancerous Lesions 1192 Fredrick D Oakley Manideepthi Pemmaraju Marie R Grifn Mohamed M Desouki Vanderbilt University Nashville TN 139 P16 Expression and Biologic Behavior of Flat Vulvar Low-Grade Squamous Intraepithelial Lesions LSIL underline 1169 Natasha Lewis Kruti Maniar Northwestern University-Feinberg School of Medicine Chicago IL 140 p16 Staining Has Limited Value in Predicting Progression in Women with Histological Low-Grade Squamous Intraepithelial Lesions of the Cervix 1220 Amaia Sagasta Natalia Rakislova Paola Castillo Adela Saco Aureli Torne Roser Esteve Lorena Marimon Marta del Pino Jaume Ordi Hospital Universitario Araba Vitoria-Gasteiz Spain Hospital Clinic Barcelona University Barcelona Spain Center Int. Health Research CRESIB Barcelona Spain 141 Overdiagnosis of HSIL CIN 2 Four Nonspecic p16 Immunohistochemistry Patterns 1113 Jennifer L Clark Yuxin Liu University of Massachusetts Medical School Worcester MA 142 Systems Biology Approaches to Cervical Pre-Cancer Diagnostics 1251 Christine White Lynne Kelly Csaba Jeney Prerna Tewari Sarah Mahan Salih Bakhiet Helen Keegan John J OLeary Cara Martin Trinity College Dublin Dublin Leinster Ireland Coombe Women and Infants University Hospital Dublin Leinster Ireland CellCall Budapest Hungary 143 The Assessment of Potential Biomarkers of Disease Progression in High Grade Squamous Cervical Lesions Promoter Methylation Analysis of Selected Tumour- Suppressor Genes and ViralMicrobial Co-Infection 1154 Jana Kaspirkova Barbora Gomolcakova Ondrej Ondic Michal Michal Biopticka Laborator Pilsen Czech Republic 144 Transitional Cell Metaplasia of the Uterine Cervix A Histopathological and Immunohistochemical Analysis Suggesting an Increased Androgenic Stimulation during Cellular Differentiation 1162 Kyu-Rae Kim Ji Young Park Su Hyun Yoo Asan Medical Center University of Ulsan College of Medicine Seoul Korea Daegu Catholic University Medical Center Daegu Korea 145 Perineural Invasion Is a Valuable Prognostic Factor in Advanced Stage andor Lymph Node Positive Cervical Cancer 1184 Bahar Muezzinoglu Cigdem Vural Busra Yaprak Bayrak Izzet Yucesoy Kocaeli University Medical School Kocaeli Turkey 146 Adenosquamous Carcinoma and Adenosquamous Intraepithelial Lesion of the Cervix Analysis of a Rigorously Classied Case Series 1156 Michael Keeney Gary L Keeney John Schoolmeester Mayo Clinic Rochester MN 147 Analysis of Pathologic Parameters in Adenocarcinoma In Situ of the Cervix Clinical Correlates and Outcomes 1244 Koah R Vierkoetter Teresa C Porter Keith Terada David Shimizu John A Burns School of Medicine Honolulu HI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 151NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 151 148 Endocervical Adenocarcinoma EEC A Retrospective Study of 75 Cases 1201 Anna Pesci Angela R Shih Esther Oliva Ospedale Sacro Cuore-Don Calabria Negrar Verona Italy Massachusetts General Hospital Boston MA 149 Pattern C Invasive Endocervical Adenocarcinomas Can We Identify the More Aggressive Subset 1257 Ranran Zhang Erin E Medlin Paul S Weisman Ahmed Al-Niaimi Aparna Mahajan University of Wisconsin Hospital and Clinics Madison WI 150 Validation of Pattern-Based Classication of Endocervical Adenocarcinoma EAC 1219 Joanne KL Rutgers Andres A Roma Kay J Park Richard Zaino Dean Daya Golnar Rasty Abbey Johnston Teri A Longacre Brigitte M Ronnett Elvio G Silva Cedars Sinai LA CA Memorial Sloan Kettering NY NY Cleveland Clinic Cleveland OH MD Anderson Houston TX Penn State Hersey Hershey PA Juravinski Hamilton Canada University Toronto Toronto Canada Ohio Health Columbus OH Stanford Stanford CA Johns Hopkins Baltimore MD 151 Architectural Overlap between Benign Endocervix and Pattern A Invasive Endocervical Adenocarcinoma Are All Pattern A Adenocarcinomas Really Invasive 1120 Greg Douglas Brooke E Howitt John Schoolmeester Lauren Schwartz Zuzana Kos Shahidul Islam Bojana Djordjevic Carlos Parra-Herran University of Ottawa Ottawa ON Canada Brigham and Womens Hospital Boston MA Mayo Clinic Rochester MN University of Pennsylvania Philadelphia PA 152 Pattern Based Classication of Invasive Endocervical Adenocarcinoma Depth of Invasion Measurement and Distinction from Adenocarcinoma In Situ Interobserver Variation among Academic Gynecologic Pathologists 1200 Carlos Parra-Herran Monica Taljaard Bojana Djordjevic Carolina Reyes Lauren Schwartz John Schoolmeester Ricardo R Lastra Charles Quick Anna Laury Golnar Rasty Marisa R Nucci Brooke E Howitt University of Ottawa Ottawa ON Canada University of Pennsylvania Philadelphia PA Mayo Clinic Rochester MN University of Chicago Chicago IL University of Arkansas for Medical Sciences Little Rock AR Cedars-Sinai Medical Center Los Angeles CA Toronto East General Hospital Toronto ON Canada Brigham and Womens Hospital Boston MA 153 Invasive Stratied Mucin-Producing Carcinoma and Stratied Mucin-Producing Intraepithelial Lesion SMILE 15 Cases Presenting a Spectrum of Cervical Neoplasia with Description of a Distinctive Variant of Invasive Adenocarcinoma 1166 Ricardo R Lastra Kay J Park John Schoolmeester University of Chicago Chicago IL Memorial Sloan Kettering Cancer Center New York NY Mayo Clinic Rochester MN 154 Expression of Claudin-18 a Novel Gastric Marker Is Associated with Poor Prognosis in Cervical Adenocarcinoma 1176 Daichi Maeda Akita University Graduate School of Medicine Akita Japan 155 Genomic Characterization of Gastric-Type Endocervical Adenocarcinomas 1185 Rajmohan Murali Maria De Filippo Britta Weigelt Kay J Park Memorial Sloan Kettering Cancer Center New York NY HEAD NECK PATHOLOGY 156 Salivary Duct Carcinoma Clinicopathologic Features Morphologic Spectrum and Somatic Mutations 1293 Peter P Luk Jared D Weston Bing Yu Christina I Selinger Rafael Ekmejian Timothy J Eviston Trina Lum Kan Gao Michael Boyer Sandra A OToole Jonathan R Clark Ruta Gupta Royal Prince Alfred Hospital Sydney NSW Australia Westmead Hospital Sydney NSW Australia The University of Sydney Sydney NSW Australia University of New South Wales Sydney NSW Australia Chris OBrien Lifehouse Sydney NSW Australia 157 Comprehensive Genomic Proling of Acinic Cell Carcinoma of Salivary Glands 1260 Siraj M Ali Kyle Fedorchak Kyle Gowan Rodolfo Bordoni Timothy A Jennings Julia A Elvin Jo- Anne Vergilio James Suh Vincent A Miller Philip J Stephens Jeffrey S Ross Foundation Medicine Inc. Cambridge MA Georgia Cancer Specialists Marietta GA Albany Medical College Albany NY 158 Role of CRTC1MAML2 Translocation in Determining Prognosis and Clinical Outcomes in Mucoepidermoid Carcinoma Patients The MD Anderson Experience 1266 Diana Bell Rami E Saade Joaquin J Garcia Dianna Roberts Randal S Weber University of Texas MD Anderson Cancer Center Houston TX Mayo Clinic Rochester MN 159 Sinonasal Tract Cribriform Adenocarcinoma of Minor Salivary Glands CAMSG Description of a Recently Recognized Neoplasm in a Previously Unrecognized Anatomic Location 1294 Abul Ala Syed Rifat Mannan Juan C Hernandez- Prera Cristina Antonescu Carlos E Bacchi Giovanni Falconieri Palmina Cataldi Bruce M Wenig Mount Sinai St.-Lukes Roosevelt Hospital Center New York NY Mount Sinai Beth Israel Medical Center New York NY Memorial Sloan Kettering Cancer Center New York NY Bacchi LabConsultoria em Patologia Botucatu Brazil University of Trieste Trieste Italy University of Udine Udine Italy Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016152 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016152 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 160 Use of p40 p63 and Ki-67 in the Differential Diagnosis of Polymorphous Low-Grade Adenocarcinoma Cellular Pleomorphic Adenoma and Adenoid Cystic Carcinoma 1299 Vatsal Patel Tina Woods Larry J Fowler Donald Cohen University of Florida Gainesville FL 161 Incidence of Recently Described Salivary Gland Carcinoma Types Presenting in an Urban Population A Retrospective Analysis 1295 Mena Mansour Juan C Hernandez-Prera G K Haines Elizabeth G Demicco Mount Sinai Hospital New York NY 162 Population-Based 30-Year Retrospective Review of Major Salivary Gland Carcinomas Identies 22 Mammary-Analogue Secretory Carcinomas MASC 1282 Martin Hyrcza Gareth Ayre Alena Skalova Amir Rahemtulla Eric Berthelet Jonn Wu Thomas Thomson University of British Columbia Vancouver BC Canada British Columbia Cancer Agency Vancouver BC Canada Charles University Faculty of Medicine Plzen Czech Republic 163 Primary Cutaneous Mammary Analogue Secretory Carcinoma Series of 4 Cases Harboring ETV6 Gene Rearrangements 1267 Justin A Bishop Janis Taube Albert Su Scott Binder William H Westra Johns Hopkins Baltimore MD University of California Los Angeles Los Angeles CA 164 Macrocystic Mammary Analogue Secretory Carcinoma An Unusual Architectural Variant of a Recently Described Salivary Gland Tumor 1279 Juan C Hernandez-Prera Alessandro Valentino Carlos E Bacchi Fredrik Petersson Vesna Najfeld Bruce M Wenig Mount Sinai Beth Israel New York NY Ospedale S. Andrea La Spezia Italy Bacchi LabConsultoria em Patologia Botucatu Brazil National University Health System Singapore Singapore Mount Sinai Hospital New York NY 165 PS100 and Mamoglobin Coexpression Are Not Sufcient to Afrm the Diagnosis of Mammary Analogue Secretory Carcinoma MASC 1273 Valerie Costes Mathieu Gallo Ariane Tempier Vanessa Szablewski Valere Cacheux Assia Hadi Benammar CHU Montpellier Montpellier France 166 Mammary Analog Secretory Carcinoma MASC with a Predominant Cystic Intraductal Component A Report of 3 Cases 1274 Jennifer L Dettloff Justin A Bishop Marino E Leon Moftt Cancer Center Tampa FL Johns Hopkins University Baltimore MD 167 MYC and MYB Are Coexpressed in Adenoid Cystic Carcinoma 1302 Marc Pusztaszeri Patrizia Bordignon Thomas McKee William C Faquin Geneva University Hospitals Geneva Switzerland Massachusetts General Hospital Boston MA 168 Diagnostic Pitfalls of Infarcted Warthin Tumor in Frozen Section Evaluation 1312 Yaohong Tan Oleksandr N Kryvenko Christina Kovacs Jennifer Chapman David J Arnald Andrew E Rosenberg Carmen Gomez-Fernandez Department of Pathology Unversity of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL Department of Surgery Unversity of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL 169 The Utility of GATA3 GCDFP-15 Mammaglobin SOX10 and ER in Differential Diagnosis of Salivary Tumors 1324 Chaohui L Zhao Evgeny Yakirevich Kara A Lombardo Douglas R Gnepp Yihong Wang Brown University Providence RI University Pathologists Fall River MA 170 Myb and Androgen Receptor Expression in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma 1303 Sydney Rooney Brennan Tesdahl Robert Robinson University of Iowa Iowa City IA 171 PSMA Expression in Non-Neoplastic and Neoplastic Salivary Gland 1270 Esther Cheng Neil H Bander Brian D Robinson Theresa Scognamiglio Weill Cornell Medical College New York NY 172 High Risk Human Papillomavirus in Primary Squamous Cell Carcinoma of the Parotid Gland 1321 Bin Xu Lu Wang Laetitia Borsu Nora Katabi Ian Ganly Snjezana Dogan Memorial Sloan-Kettering Cancer Center New York NY 173 HPV Genotyping in Head and Neck Cancer An Institutional Experience 1262 Aileen Grace P Arriola Joshua Edwards Vivianna M Van Deerlin Hospital of the University of Pennsylvania Philadelphia PA 174 Prognostic Signicance of Histologic Features in HPV- Associated Tonsillar Squamous Cell Carcinoma 1284 Jian Jing Indu Varier Joanna Dong David Zhang Andrew G Sikora Elizabeth G Demicco Icahn School of Medicine at Mount Sinai New York NY Baylor College of Medicine Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 153NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 153 175 Nonkeratinizing Carcinoma In Situ of the Upper Aerodigestive Tract An HPV-Related Entity 1323 Lingxin Zhang James Lewis Samir K El-Mofty Manoj Gandhi Rebecca Chernock Washington University School of Medicine St. Louis MO Vanderbilt University Medical Center Nashville TN Affymetrix Inc. Santa Clara CA 176 A Second-Generation Probe for HPV DNA In-Situ Hybridization Lacks Sensitivity for HPV Detection in Oropharyngeal Squamous Cell Carcinomaunderline 1305 Lisa M Rooper Justin A Bishop William H Westra Johns Hopkins Hospital Baltimore MD 177 Detection of HPV-DNA from May-Grnvald-Giemsa Stained Fine-Needle Aspiration Specimens Using Polymerase Chain Reaction 1269 Hani I Channir Christian G Larsen Lise Ahlborn Thomas van Overeem Hansen Thomas A Gerds Birgitte W Charabi Ben Vainer Christian von Buchwald Christel B Lajer Katalin Kiss Rigshospitalet Copenhagen University Hospital Copenhagen Denmark University of Copenhagen Copenhagen Denmark 178 The Utility of p16 Immunostaining in Fine Needle Aspiration FNA Material in Human Papilloma Virus HPV-Related Head and Neck Squamous Cell Carcinoma HNSCC 1318 Bin Xu Ronald Ghossein Jason Lane Oscar Lin Nora Katabi Memorial Sloan-Kettering Cancer Center New York NY 179 HPV Prevalence in HIV Patients with Head and Neck Squamous Cell Carcinoma 1301 Annabelle Picard Cecile Badoual Muriel Hourseau Caroline Halimi Helene Pere Beatrix Barry Sebastien Albert Bichat Hospital APHP Paris France European G Pompidou Hospital APHP Paris France Bichat Hospital Paris France 180 HPV-Induced HNSCC All Locations Combined Prevalence Diagnostic Tests and Prognostic Impact of HPV Status in a Heavy-Smoking French Population underline 1263 Jeremy Augustin Samah El Naderi Helene Pere Helene Roussel Cecile Badoual Georges Pompidou Eureopean Hospital Paris France Metropolitan HEMATOPATHOLOGY 181 Baseline Evaluation of Testing of Acute Leukemia Samples Results of a CAPCDC Guideline Metric Expert Panel Survey 1331 Daniel A Arber Thomas E Nicole Rhona J Souers Lisa A Fatheree Joseph A Tworek Raouf E Nakhleh Tracy I George Stanford University Stanford CA College of American Pathologists Northeld IL St. Joseph Mercy Hospital Ann Arbor MI Mayo Clinic Jacksonville FL University of New Mexico Albuquerque NM 182 Determining Educational Needs in Myelodysplastic Syndrome 1432 Timothy G Miley Mikkael A Sekeres Marilyn L Slovak Rami S Komorkji Asma Ali Eric R Parks Suzanne M Ziemnik Tracy I George Park Nicollet Methodist Hospital Minneapolis MN Cleveland Clinic Taussig Cancer Institute Cleveland OH Sonora Quest Phoenix AZ Moft Cancer Center Tampa FL American Society for Clinical Pathology Chicago IL University of New Mexico Albuquerque NM 183 Mutation Analysis in 117 Cases Newly Diagnosed Myelodysplastic Syndrome IPSS-R High and Very High Risk by Next Generation Sequencing A Clinico- Pathologic Correlation 1374 Kankana Ghosh Parsa Hodjat Priyanka Priyanka Beenu Thakral Keyur P Patel Mark Routbort Rashmi Kanagal-Shamana C Cameron Yin Zhuang Zuo Rajyalakshmi Luthra Tariq Muzzafar UT School of Public Health Houston TX UT MD Anderson Cancer Center Houston TX UT Health Science Center at Houston Houston TX 184 Mutation Analysis in 50 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myelodysplastic Syndrome by Next Generation Sequencing A Clinico- Pathologic Correlation 1388 Parsa Hodjat Priyanka Priyanka Kankana Ghosh Beenu Thakral Keyur P Patel Mark Routbort Rashmi Kanagal-Shamana C Cameron Yin Zhuang Zuo Rajyalakshmi Luthra Tariq Muzzafar UT MD Anderson Cancer Center Houston TX UT Health Science Center at Houston Houston TX UT School of Public Health Houston Houston TX 185 Mutation Analysis in 8 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myeloproliferative Neoplasms by Next Generation Sequencing A Clinico-Pathologic Correlation 1389 Parsa Hodjat Priyanka Priyanka Kankana Ghosh Beenu Thakral Keyur P Patel Mark Routbort Rashmi Kanagal-Shamana C Cameron Yin Zhuang Zuo Rajyalakshmi Luthra Tariq Muzzafar UT MD Anderson Cancer Center Houston TX UT Health Science Center at Houston Houston TX UT School of Public Health Houston Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016154 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016154 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 186 Mutation Analysis in 45 Cases of Newly Diagnosed Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities by Next Generation Sequencing A Clinico-Pathologic Correlation 1391 Parsa Hodjat Priyanka Priyanka Kankana Ghosh Beenu Thakral Keyur P Patel Mark Routbort Rashmi Kanagal-Shamana C Cameron Yin Zhuang Zuo Rajyalakshmi Luthra Tariq Muzzafar UT MD Anderson Cancer Center Houston TX UT Health Science Center at Houston Houston TX UT School of Public Health Houston TX 187 Mutation Analysis in 122 Cases of Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia by Next Generation Sequencing A Clinico-Pathologic Correlation 1390 Parsa Hodjat Priyanka Priyanka Kankana Ghosh Beenu Thakral Keyur P Patel Mark Routbort Rashmi Kanagal-Shamana C Cameron Yin Zhuang Zuo Rajyalakshmi Luthra Tariq Muzzafar UT MD Anderson Cancer Center Houston TX UT Health Science Center at Houston Houston TX UT School of Public Health Houston TX 188 Utility of a Pan Genomic Fusion Panel 1300 Genes on a Next Generation Sequencing NGS Platform in Evaluation of Hematologic Malignancies HM 1409 Ravindra Kolhe Alka Chaubey Lisa C Watson WonSok Lee Deepa Jagdale Claire Attwooll Ashis K Mondal Georgia Regents University Augusta GA Greenwood Genetic Center Greenwood SC Illumina Inc San Diego CA 189 High-Resolution Genome-Wide Single Nucleotide Polymorphism Microarray Analysis of Abnormal Genomic Lesions in Patients with Myeloid Neoplasms and Normal Karyotype 1438 Pawel Mroz Sue Miller Lauren B Smith Dale Bixby Lina Shao University of MIchigan Ann Arbor MI 190 Acute Myeloid Leukemia AML.Digital Quantication of PRAME Transcript Provides Distinct Stratication for Overall Survival OS in Various Cytogenetic Risk Groups 1469 Jabina Randev Mohammad O Mansoor Fahad Farooq Meer-Taher Shabani-Rad Ariz Akhter Foothills Medical Centre Calgary AB Canada University of Calgary Calgary AB Canada 191 Next Generation Sequencing Evaluation of ASXL1 Mutations in Large Cohort of Myeloid Malignancies 1528 Hailing Zhang Mohammad O Hussaini Xiaohui Zhang Haipeng Shao Lynn C Moscinski Jinming Song Moftt Cancer Center Tampa FL 192 De Novo Acute Myeloid Leukemia AML with RUNX1 Mutations Shows Characteristic Clinicopathologic Features 1464 Andres Quesada Rajyalakshmi Luthra Keyur P Patel Rajesh Singh Mark Routbort Sanam Loghavi Joseph D Khoury Jeffrey Medeiros Carlos E Bueso-Ramos Rashmi Kanagal-Shamanna M.D. Anderson Cancer Center Houston TX 193 Immunophenotypic Abnormalities in Acute Myeloid Leukemia Associated with NPM1 Mutation and Clinical Signicance of Minimal Residual Disease Detection 1531 Yi Zhou David Wu Xueyan Chen Jonathan R Fromm Brent L Wood University of Washington Seattle WA 194 Clinical Deep Sequencing of NPM1 for Minimal Residual Disease Detection in Acute Myeloid Leukemia 1394 Eric Hoyle Lena Murillo Shannon Nesbitt Yi Zhou Brent L Wood Stephen J Salipante David Wu University of Washington Seattle WA 195 Multi-Locus DNA Methylation Measured by xMELP Predicts Survival in Pediatric Patients with AML 1515 Gerald Wertheim Marlise Luskin Catherine Smith Li Zhou Jenna Harrison Maria Figueroa Daniel Catchpoole Richard Aplenc Sarah Tasian Martin Carroll Stephen R Master Childrens Hospital of Philadelphia Philadelphia PA Weill Cornell Medical College New York NY Perelman School of Medicine at the University of Pennsylvania Philadelphia PA University of Michigan School of Medicine Ann Arbor MI The Childrens Hospital at Westmead Westmead NSW Australia 196 Integration of Multi-Locus DNA Methylation and Genetic Alterations Outperforms Genetic Assessment Alone for Outcome Prediction in Adult Patients with Acute Myeloid Leukemia 1514 Gerald Wertheim Marlise Luskin Phyllis A Gimotty Catherine Smith Alison W Loren Maria Figueroa Jenna Harrison Zhuoxin Sun Martin S Tallman Elisabeth M Paietta Mark R Litzow Ross Levine Ari M Melnick Hugo F Fernandez Selina M Luger Martin Carroll Stephen R Master Childrens Hospital of Philadelphia Philadelphia PA Perelman School of Medicine at the University of Pennsylvania Philadelphia PA University of Michigan Medical School Ann Arbor MI Dana-Farber Cancer Institute Boston MA Memorial Sloan Kettering Cancer Center New York NY Monteore Medical Center Bronx NY Mayo Clinic Rochester MN Moft Cancer Center Tampa FL Weill Cornell Medical College New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 155NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 155 197 Bone Marrow Morphology Predicts Response to Hypomethylating Agents 1387 Lisa Hillen Lawrence Zukerberg Vikram Deshpande Arjen HG Cleven Amir T Fathi Axel zur Hausen Robert P Hasserjian Maastricht University Medical Center MUMC Maastricht Netherlands Massachusetts General Hospital Boston MA Leiden University Medical Center Leiden Netherlands 198 The Signicance of Morphologic Dysplasia in the Absence of Increased Blasts Following Induction Therapy for Acute Myeloid Leukemia 1350 Daniel Cloetingh Bruno C Medieros Daniel Arber Robert S Ohgami Stanford HealthCare Stanford CA 199 Hypoxia-Induced VEGF Overexpression Leads to Treatment Resistance in Acute Promyelocytic Leukemia 1487 Payal Sojitra Edith Cline-Kabba Ameet Kini Loyola University Medical Center Maywood IL 200 MYC Protein Expression Does Not Correlate with MYC Abnormalities but Predicts an Unfavorable Prognosis in Acute Myeloid Leukemia 1346 Pu Chen Lucas Redd Prasad Koduru Jake Dennis Crystal Montgomery-Goecker Kirthi Kumar Yao Schmidt Weina Chen UT Southwestern Medical Center at Dallas Dallas TX 201 Near Bi-Phenotypic Antigen Expression Denes an Acute Myeloid Leukemia AML Cohort with High-Risk Molecular Genetic and Cytogenetic Features 1476 Mikhail Roshal April Chiu Memorial Sloan Kettering Cancer Center New York NY 202 Assessment of Myeloid And Monocytic Dysplasia by Flow Cytometry in De Novo AML Helps Dene an AML with Myelodysplasia-Related Changes Category 1512 Olga K Weinberg Robert P Hasserjian Betty Li Olga Pozdnyakova Boston Childrens Hospital Boston MA Massachussets General Hospital Boston MA Brigham and Womens Hospital Boston MA 203 Low CD177 on Neutrophils Correlates with Granulocytic Dysplasia and Adds Value for Identifying Myelodysplasia by Flow Cytometry 1499 Samir Turakhia Howard J Meyerson University HospitalsCase Medical Center Cleveland OH 204 Low-Level BCR-ABL1 Expression in Individuals without Overt Hematologic Malignancy 1415 Rebecca J Leeman-Neill Steven H Swerdlow Catherine L Burnes Marina Nikiforova Nidhi Aggarwal University of Pittsburgh School of Medicine Pittsburgh PA 205 Differential Impact of Additional Chromosomal Abnormalities in Myeloid and Lymphoid Blast Phase of Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors 1347 Zi Chen Wei Wang Jeffrey Medeiros Shimin Hu The University of Texas MD Anderson Cancer Center Houston TX 206 T-Lymphoblastic Blast Crisis of Chronic Myelogenous Leukemia A Study of 11 Cases 1521 Wei Xie Wei Wang Yuan Ji Yi Zhou Jeffrey Medeiros Shimin Hu The University of Texas MD Anderson Cancer Center Houston TX Baylor College of Medicine Houston TX University of Nebraska Omaha NE University of Washington Seattle WA 207 Therapy-Related Chronic Myelogenous Leukemia A Retrospective Analysis of 19 Cases 1502 Bethany Vallangeon Yi Xie Chad M McCall Anand Lagoo Endi Wang Duke University Medical Center Durham NC 208 Loss of 5-Hydroxymethylcytosine Staining Correlates with Poorer Overall Survival in Patients with Chronic Myelomonocytic Leukemia 1484 William Selove Karen Dresser Benjamin J Chen University of Massachusetts Medical School Worcester MA 209 Bone Marrow Fibrosis in Chronic Myelomonocytic Leukemia Is Associated with Increased Bone Marrow Cellularity and Megakaryopoiesis Spleen Size and with a Shorter Median Time to Disease Progression 1455 Kseniya Petrova-Drus April Chiu Elizabeth Margolskee Attilio Orazi Weill Cornell Medical Center New York NY Memorial Sloan Kettering Cancer Center New York NY 210 Primary Myelobrosis Displays an Inammation- Associated Gene Prole Distinct from Polycythemia Vera and Essential Thrombocythemia 1462 Olga Pozdnyakova Jon C Aster Frank Kuo Ronald Brown Michele Baltay Robert P Hasserjian Brigham Womens Hospital Boston MA Massachusetts General Hospital Boston MA 211 Immunophenotypic Aberrancy on Basophils a Biomarker for BCR-ABL1 Negative Myeloproliferative Neoplasms 1349 Andrew Chu Kirthi Kumar Sara A Monaghan Franklin Fuda Weina Chen UT Southwestern Medical Center Dallas TX 212 Bone Marrow and Extramedullary Lesions in Patients with Myeloproliferative Neoplasms Exhibit Similar miRNA Proles 1422 Sanam Loghavi Zhuang Zuo Denaha J Doss Erika J Thompson Chong Zhao John Lee Rashmi Kanagal- Shamanna L Jeffrey Medeiros Carlos E Bueso-Ramos The University of Texas MD Anderson Cancer Center Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016156 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016156 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 213 Identication of Mutated CALR Protein Is Useful in the Diagnosis and Prognostic Stratication of JAK-2 Negative MPL-Negative Myeloproliferative Neoplasms 1475 Frances L Rosario Quinones Achim Jungbluth Raajit K Rampal Ross Levine Filiz Sen Ahmet Dogan Memorial Sloan Kettering Cancer Center New York NY 214 Performance of a Commercially Available CALR Mutation-Specic Antibody for the Immunohistochemical Assessment of Bone Marrow Biopsies 1445 Laila Nomani Kelli Schneider Juraj Bodo Lisa M Durkin James R Cook Eric D Hsi Cleveland Clinic Cleveland OH 215 Immunohistochemical Detection of Calreticulin Mutations in Bone Marrow Biopsy Samples from Patients with Myeloproliferative Neoplasms 1496 Sheryl R Tripp Anton V Rets Tsewang Tashi Mohamed E Salama ARUP Reference Laboratory Salt Lake City UT University of Utah Salt Lake City UT 216 Hypereosinophilic Syndrome with Clonal T-cell Receptor Gene Rearrangement A Retrospective Study of 51 Patients 1519 Wenbin Xiao Fei Li Kuang Sachein Sharma Jamie Hahn Maryalice Stetler-Stevenson Mark Raffeld Amy Klion Irina Maric the Clinical Center NIH Bethesda MD NIAID NIH Bethesda MD NCI NIH Bethesda MD 217 Dening Prognostic Factors of Juvenile Myelomonocytic Leukemia A Clinicopathologic Immunophenotypic and Genetic Approach 1513 Kwun Wah Wen Elliot Stieglitz Ari Molofsky Farid Chehab Kristie White Sonam Prakash UCSF San Francisco CA PANCREAS BILIARY TREE 218 Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival but Better Survival after Metastasis 1754 Joo Young Kim Jacqueline Brosnan-Cashman Soyeon An Alan Meeker Eunsil Yu Ralph H Hruban Christopher M Heaphy Seung-Mo Hong Korea University Anam Hospital Korea University College of Medicine Seoul Republic of Korea Johns Hopkins Medical Institutions Baltimore MD Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea 219 Alternative Lengthening of Telomeres in Pancreatic Carcinomas with Acinar Differentiation 1753 Jiyoon Kim Jacqueline Brosnan-Cashman Soyeon An Do Youn Park Haeryoung Kim Young-Ha Oh Ralph H Hruban Christopher M Heaphy Seung-Mo Hong Asan Medical Center University of Ulsan College of Medicine Seoul Korea Johns Hopkins Medical Institutions Baltimore MD Pusan National University Hospital Pusan National University School of Medicine Busan Korea Seoul National University Bundang Hospital Seoul National University College of Medicine Seongnam Kyung-ki do Korea Hanyang University College of Medicine Seoul Korea 220 Type 1 Autoimmune Pancreatitis AIP Conned to the Pancreatic Duct System with Massive Lobular Effacement A Type of AIP That Causes Pancreatic Atrophy after Steroid Treatment 1768 Kenji Notohara Takahiro Nakazawa Tsuyoshi Uehara Shigeyuki Kawa Kurashiki Central Hospital Kurashiki Japan Japanese Red Cross Nagoya Daini Hospital Nagoya Japan Shinshu University Matsumoto Japan 221 Pseudotumoral Pancreatitis Clinicopathological Analysis of 93 Cases Resected with Pre-Operative Diagnosis of Pancreatic Ductal Adenocarcinoma but Proved to Be Inammatory Conditions 1766 Takashi Muraki Gabriela Bedolla Michelle Reid Grace Kim Alyssa M Krasinskas Ipek E Seven Bahar Memis Field Willingham Juan Sarmiento David Kooby Shishir Maithel Pardeep Mittal Volkan Adsay Emory University Atlanta GA UCSF San Francisco CA 222 The Diagnostic Utility of Pancreatic Biopsy for Inammatory Bowel Disease-Associated Pancreatitis 1769 Kenji Notohara Shigeyuki Kawa Toshiharu Ueki Atsushi Kanno Mamoru Watanabe Tooru Shimosegawa Kurashiki Central Hospital Kurashiki Japan Shinshu University Matsumoto Japan Fukuoka University Chikushi Hospital Fukuoka Japan Tohoku University Sendai Japan Tokyo Medical and Dental University Tokyo Japan 223 Choledochal Cysts in the West Clinicopathologic Analysis of 84 Cases 1748 Ezgi Hacihasanoglu Michelle Reid Takashi Muraki Bahar Memis Pardeep Mittal Humbert Polito Nikou Zarrabi Burcu Saka Alyssa Krasinskas Brian Quigley Volkan Adsay Emory University Atlanta GA 224 Gallbladder and Cystic Duct Invasion of Distal Bile Duct Carcinomas 1750 Sun-Young Jun Soyeon An Jae Hoon Lee Kwang-Min Park Seung-Mo Hong Incheon St. Marys Hospital The Catholic University of Korea Incheon Republic of Korea Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 157NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 157 225 Mutational Proling of Oncocytic Intraductal Papillary Mucinous Neoplasms IPMN-o 1757 Jochen K Lennerz Charlotte I Wang Leona Doyle Tiffany G Huynh Neal Lindeman Amitabh Srivastava Carlos Fernandez del-Castillo Mari Mino-Kenudson Massachusetts General Hospital and Harvard Medical School Boston MA Brigham and Womens Hospital Boston MA 226 Comparative Clinicopathologic Study of Biliary Intraductal Papillary Neoplasms and Papillary Cholangiocarcinomas 1746 Kohei Fujikura Tomoo Itoh Yoh Zen Kobe University Kobe Hyogo Japan 227 Quasimesenchymal Phenotype Predicts Distant Metastasis in Pancreatic Ductal Adenocarcinoma 1747 Rajib Gupta Krishnan K Mahadevan Cristina R Ferrone David T Ting Vikram Deshpande Johns Hopkins University School of Medicine Baltimore MD Massachusetts General Hospital Harvard Medical School Boston MA 228 Genetic and Epigenetic Changes in Stromal Cells Regulate Tumor Progression and Emphasize the Genetic Complexity of the Tumor Microenvironment in Pancreatic Cancer 1780 Martin Wartenberg Stefan Haemmig Erik Vassella Aurel Perren Eva Karamitopoulou University of Bern Bern Switzerland 229 Epigenetic Regulation through Differential MicroRNA Expression by the Cellular Components of the Tumor Microenvironment Inuence the Phenotype of Pancreatic Cancer 1752 Eva Karamitopoulou Stefan Haemmig Martin Wartenberg Erik Vassella Aurel Perren University of Bern Bern Switzerland 230 The Prognostic Role of Desmoplastic Stroma in Pancreatic Cancer 1779 Lai Mun Wang Mike Silva Zenobia DCosta Robin Bockelmann Zahir Soonawalla Eric ONeill Somnath Mukherjee W Gillies McKenna Ruth Muschel Emmanouil Fokas Oxford University Hospital NHS Trust University of Oxford Oxford United Kingdom Oxford University Hospital NHS Trust Oxford United Kingdom CRUK MRC Institute for Radiation Oncology University of Oxford Oxford United Kingdom 231 Stromal Changes Related to Therapy in Pancreatic Cancer 1773 Daniel Rowan Kiyoko Oshima Medical College of Wisconsin Milwaukee WI 232 Prognosis of T2 Gallbladder Carcinomas An Analysis of 326 Cases Highlights a Prognosis Better Than the Current Impression in the West but Incomparably Worse Than What Is Reported in Asia 1763 Bahar Memis Juan Carlos Roa Takashi Muraki Kee- Taek Jang Enrique R Bellolio Juan Carlos Araya Miguel A Villaseca Juan Sarmiento Hector Losada Shishir Maithel David Kooby Nevra Dursun Humbert Polito Sudeshna Bandyopadhyay Pelin Bagci Burcu Saka Michelle Reid Volkan Adsay Emory University Atlanta GA Ponticia University Santiago Chile SMC Seoul Korea University Frontera Temuco Chile WSU Detroit MI 233 Not All T2 Gallbladder Carcinomas GBC Are Equal Proposal for Sub-Staging of T2 GBC with Signicant Prognostic Value 1764 Bahar Memis Juan Carlos Roa Takashi Muraki Ezgi Hacihasanoglu Nevra Dursun Burcu Saka Enrique R Bellolio Juan Carlos Araya Juan Sarmiento Hector Losada David Kooby Shishir Maithel Michelle Reid Brian Quigley Alyssa Krasinskas Volkan Adsay Emory University Atlanta GA Ponticia University Santiago Chile University Frontera Temuco Chile PULMONARY PATHOLOGY INCLUDING MEDIASTINAL 234 The Clinical Impact of Solid andor Micropapillary Subtypes in Resected Lung Adenocarcinoma 1940 Naoki Yanagawa Yamagata Prefectural Central Hospital Yamagata Japan 235 High-Grade Components as the Second- or Third-Most Predominant Pattern Predict Poor Prognosis in pT1 Lung Adenocarcinomaunderline 1866 Makoto Hamasaki Tomoyuki Hida Masayo Yoshimura Sousei Abe Akinori Iwasaki Kazuki Nabeshima Fukuoka University School of Medicine and Hospital Fukuoka Japan 236 Pleomorphic Carcinomas of the Lung A Clinicopathological and Immunohistochemical Study of 68 Cases 1937 Annikka Weissferdt Maheshwari Ramineni Neda Kalhor Barbara Mino Jaime Rodriguez Canales Junya Fujimoto Ignacio I Wistuba Cesar A Moran MD Anderson Cancer Center Houston TX 237 Low Expression of SerpinB2 Is Associated with Reduced Survival in Lung Adenocarcinomas 1908 Maria Ramnefjell Christina Aamelfot Lars Helgeland Lars A Akslen University of Bergen Bergen Norway Haukeland University Hospital Bergen Norway Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016158 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016158 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 238 Adipophilin Expression in Pulmonary Adenocarcinoma Is Associated with Poor Clinical Prognosis Immunohistochemical Study of 328 Cases 1864 Masakazu Fujimoto Akihiko Yoshizawa Shinji Sumiyoshi Kyoto University Hospital Kyoto Japan Wakayama Medical University Wakayama Japan Kumamoto University Hospital Kumamoto Japan 239 Lung Adenocarcinoma with Mucin-Related Antigen 4 Expression Is Associated with the Smoking Status and Poor Prognosis 1913 Mariyo Rokutan Akihiko Yoshizawa Hironori Haga Kyoto University Hospital Kyoto Japan 240 Differential Expression of SOX17 in Lung and Endometrial Carcinomas 1924 Tracy A Stein Mohamed El Hag Bo Ye Prachi Raut Guang-Qian Xiao Haodong Xu Mahmoud Khalifa Faqian Li University of Minnesota Medical Center Minneapolis MN University of Rochester Medical Center Rochester NY UCLA Medical Center Los Angeles CA 241 Prognostic Signicance of lincRNA-p21 in Non-Small Cell Lung Carcinoma NSCLC 1907 Jose Ramirez Joan J Castellano Adela Saco Jorge Moises Ana Cordeiro Ramon Marrades Nuria Vinolas Francisco Aya Laureano Molins Mariano Monzo Alfons Navarro Hospital Clinic University of Barcelona Barcelona Spain University of Barcelona Barcelona Spain Hospital Clinic Barcelona Spain 242 Cell Cycle Progression Score Is a Promising Predictor of Recurrence in Primary Lung Carcinoid Tumors 1874 Neda Kalhor Junya Fujimoto Guoping Xu Ryan Hoff Placede Tiemeny Susanne Wagner Reza J Mehran Cesar A Moran Ignacio I Wistuba MD Anderson Cancer Center Houston TX Myriad Genetics Inc. Salt Lake City UT Dali University Yunnan China 243 A Small Panel of microRNAs Effectively Separates Typical Carcinoids from Neuroendocrine Carcinomas and May Predict Outcome in Atypical Carcinoid Tumors 1856 Yao-Tseng Chen Xiaojing Yang Kathrin Tyryshkin Paula Ginter Thomas Tuschl Neil Renwick Weill Cornell Medical College New York NY Queens University Kingston ON Canada Rockefeller University New York NY 244 Borderline Neuroendocrine Carcinomas of the Lung Are Clinically and Genomically Distinct from Large Cell Neuroendocrine Carcinoma 1932 Marina Vivero Lynette M Sholl Brigham and Womens Hospital Boston MA 245 ALK Rearragnement Testing by Immunohistochemistry and Fluorescent In Situ Hybridization in Lung Cancers A Canadian Reference Testing Centers Routine Clinical Experience 1863 Pierre Fiset Jeffrey Tanguay Scott Boerner David M Hwang Ming-Sound Tsao University Health Network Toronto ON Canada 246 Prevalence of ALK and ROS1 Rearrangements in Mexican Patients with Lung Adenocarcinoma 1917 Sergio Sanchez Silvia Montilla Pamela R Matias Julieta Garcia Ivan R Gonzalez Hospital Angeles Puebla Puebla Mexico 247 Programmed Death Ligand-1 PD-L1 Expression in Operable Non-Small Cell Lung Cancer NSCLC by Immunohistochemical Analysis 1851 Sabina Babayeva Artem Dyatlov Ranjita Pallavi Michael Fanucchi Carmelo Puccio Rocco Lafaro Fouzia Shakil John T Fallon Minghao Zhong New York Medical College Valhalla NY 248 Programmed Death 1 PD-1 and PD-L1 Expression in Lung Adenocarcinoma with Lower Expression in In Situ and Minimally Invasive Tumors and Higher Expression in Larger and Invasive Tumors 1888 Osamu Matsubara Yasuto Jin Shuta Yamauchi Kazuteru Yamanaka Yuichi Ishikawa Eugene J Mark The Cancer Insitute Tokyo Japan Hiratsuka Kyosai Hospital Hiratsuka Japan Massachusetts General Hospital and Harvard Medical School Boston MA 249 Relationship between PD-L1 Expression and Epithelial Mesenchymal Transition in Adenocarcinoma of the Lung 1876 Sehui Kim Moon-Young Kim Jaemoon Koh Heounjeong Go Yoon Kyung Jeon Doo Hyun Chung Seoul National University Hospital Seoul Republic of Korea Seoul National University College of Medicine Seoul Republic of Korea Asan Medical Center Seoul Republic of Korea 250 Molecular Characterization of Invasive Mucinous Adenocarcinomas of the Lung 1901 Kyung Park Shivakumar Subramaniyam Jose Jessurun Helen Fernandes Navneet Narula NYPH-WCMC NYC NY 251 Pulmonary Mucinous Adenocarcinoma- A Molecular Genetic Study of 52 Cases 1855 Jennifer M Boland Joseph J Maleszewski Benjamin R Kipp Jason A Wamper Ping Yang Eunhee S Yi Mayo Clinic Rochester MN Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 159NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 159 252 Comprehensive Genomic Proling of Lung Cancer is Practical and Facilitates Implementation of the National Comprehensive Cancer Network NCCN Guidelines for Lung Cancer Biomarker Testing in Patients with Advanced Stage Disease 1927 James Suh Adrienne Johnson Kai Wang Garrett Frampton Juliann Chmielecki Julia A Elvin Jo-Anne Vergilio Siraj M Ali Vincent A Miller Philip J Stephens Jeffrey S Ross Foundation Medicine Inc. Cambridge MA Albany Medical College Albany NY 253 Lessons Learned from Next Generation Sequencing in Use of Immunohistochemistry IHC for EGFR L858R and ALK in Lung Cancer Predictive Testing 1894 Joseph Montecalvo C Leduc N Rekhtman A Moreira M Arcila M Berger C Rudin V Rusch D Jones W Travis MSKCC New York NY Mayo Clinic Rochester MN 254 BAP1 Immunostain and P16 FISH Clinical Applicability to Conrm Malignant Mesothelioma in Effusions 1935 Ann E Walts Kenzo Hiroshima Stephanie McGregor Aliya N Husain Alberto M Marchevsky Cedars-Sinai Medical Center Los Angeles CA Tokyo Womens Medical University Yachiyo Medical Center Yachiyo Japan University of Chicago Hospitals Chicago IL 255 Utility of BAP1 FISH and immunohistochemistry in Distinguishing between Mesothelioma and Reactive Mesothelial Proliferation. Comparison with Analysis of p16CDKN2A 1869 Kenzo Hiroshima Di Wu Mizue Hasegawa Yasuo Sekine Daisuke Ozaki Toshikazu Yusa Zhibin Gao Ann E Walts Alberto M Marchevsky Yuji Tada Hideaki Shimada Masatoshi Tagawa Tokyo Womens Medical University Yachiyo Chiba Japan Chiba Rosai Hospital Ichihara Chiba Japan Yuyao Peoples Hospital Yuyao Ningbo China CedarsSinai Medical Center Los Angeles CA Chiba University Chiba Japan Toho University Tokyo Japan Chiba Cancer Center Research Institute Chiba Japan 256 Correlation of Histologic and Radiologic Response to Neoadjuvant Treatment of Thymic Epithelial Tumors 1911 Anja C Roden Marie Christine Aubry Eunhee S Yi Sarah M Jenkins Yolanda I Garces Randolph S Marks Stephen D Cassivi Geoffrey B Johnson Mayo Clinic Rochester MN QUALITY ASSURANCE 257 A Triaging Strategy Using Absolute White Blood Cell Differential Counts and Smear Morphology Improves Diagnostic Yield of Peripheral Blood Flow Cytometry underline 1974 Amelia Huck Christine Hong Michelle E DeLelys Frederic I Preffer Aliyah R Sohani St. Barnabas Medical Center Livingston NJ Harvard College Cambridge MA Massachusetts General Hospital Boston MA 258 Ancillary Testing in Bone Marrow Staging for Lymphoma A Laboratory Utilization and Quality Management Opportunity 1979 K David Li Jerry W Hussong Sherrie L Perkins Jay L Patel University of UtahARUP Laboratories Salt Lake City UT 259 Diagnostic Value of Flow Cytometry as a Screening Tool for Cerebrospinal Fluids in Patients with or without Prior Hematologic Malignancy 1992 Nupam Patel Karthik A Ganapathi Stefanie Forest Matthew B Thomsen George Vlad Govind Bhagat Bachir Alobeid Daniela Hoehn Columbia University Medical Center New York NY 260 Cerebrospinal Fluid Specimen Evaluation in Patients with Hematopoietic Neoplasms The Need for an Integrated Approach 1954 Darren Buonocore Mikhail Roshal Samuel I McCash Oscar Lin Memorial Sloan Kettering Cancer Center New York NY 261 Cost Comparison of First Line Multiplex PCR Versus Screening with Inuenza Single PCR for the Detection of Upper Respiratory Tract Viral Infections 1953 John Cannatella Benjamin Buelow Lynn Pulliam University of California San Francisco San Francisco CA 262 Bone Marrow Biopsy Practice and Quality Trends in USA and Canada A Multicenter Study 1985 Mihai Merzianu Roswell Park Cancer Institute Buffalo NY 263 Improving Utilization of Hemochromatosis Testing 2023 Yaolin Zhou Gary Procop Jacquelyn Riley Cleveland Clinic Cleveland OH 264 Pathologists Discussing Diagnoses with Patients A Pilot Study in Lymphoma Clinic 2008 Lauren B Smith Brian Tolle William Sherman Scott R Owens Mark Kaminski University of Michigan Ann Arbor MI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016160 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016160 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 265 Communication from Referring Clinicians to Pathologists in the Electronic Health Record Era 1948 Andrea L Barbieri Oluwole Fadare Christopher Sebastian Hardeep Singh Vinita Parkash Yale University New Haven CT University of California San Diego La Jolla CA VA Health Services Research Center for Innovation Baylor College of Medicine Houston TX 266 Communication with Clinicians in Anatomical Pathology 2012 Ann Treacy John Conor OKeane Julie McCarthy Sine Phelan Howard Johnson Jennifer Martin Mairead Guinan Philip Ryan Niall Swan Kieran Sheahan Royal College of Physicians of Ireland Dublin Ireland HSE Dublin Ireland 267 Communication in a Pathology Report Differences between Pathology Attendings Residents and Clinicians 1969 Blake Gibson Robert R Klein Ronald S Weinstein Erika Bracamonte University of Arizona Tucson AZ 268 Image Documented Surgical Pathology ID-SP to Enhance Patient Safety - Lean Redesign of the Value Stream Steps from Gross Examination to Signout 1961 Dhananjay A Chitale Jason Wozniak Nelson Main Ruan Varney Mark Tuthill Richard J Zarbo Henry Ford Hospital Detroit MI 269 Quality Assurance of Anatomic Pathology Diagnoses Comparison of Alternate Approaches and Detection of Diagnostic Error 1978 Lester Layeld University of Missouri Columbia MO 270 Turnaround Time In Surgical Pathology The Patient Perspective 1994 Garrison Pease Elisheva Shanes Charnell Johnson William Watkin University of Chicago NorthShore Evanston IL 271 Adopting the Quality Dashboard in Pathology Real- Time Data Monitoring and Improvement 1959 Yigu Chen Gina McCormack Yael K Heher Beth Israel Deaconess Medical Center Boston MA 272 Laboratory Requisition Forms Often Lack Critical Information An Initiative to Improve Communication and Enhance Patient Safety at The Ottawa Hospital 2017 Jason K Wasserman Iris Teo Darren Tse John Veinot Bibianna Purgina University of Ottawa Ottawa ON Canada 273 Use of Barcode Tracking in Routine Histology Processing Signicantly Decreases Pre-Analytical Errors 1996 Mahboubeh Rahmani Kristi Bedrossian Elizabeth Genega Tufts Medical Center Tufts University School of Medicine Boston MA 274 Daily Surgical Pathology Huddles Positively Impact Quality Safety Culture and Team Engagement 1971 Omar Hameed Cheryl M Cofn Anatomic Pathology Team Vanderbilt University Medical Center Nashville TN 275 Does Expert Review of Testis Biopsies for Infertility Improve Clinicopathologic Correlation 1998 Brian D Robinson Aaron Bernie Peyman Tavassoli Theresa Scognamiglio Francesca Khani Peter N Schlegel Weill Cornell Medical College New York NY 276 Evaluating Pathologist Accuracy in Estimation of Percentage of Malignant Cells 1957 Hui Chen Russell Broaddus Bedia A Barkoh Ronald Abraham Rajesh Singh Raja Luthra Sinchita Roy Chowdhuri MD Anderson Houston TX 277 Utilization of Pathologists Assistants in the Diagnostic Arena Working Differently in the Changing Health Care Environment 1951 Melissa M Blessing David Schembri Wismayer Diva R Salomao Adam J Wood Sarah E Kerr Monica L Kendall Kenneth M Smith Carrie Y Inwards Gary L Keeney Mariam P Alexander Mayo Clinic Rochester MN 278 Can Decalcication of Thyroid Tissue Cause Overdiagnosis of Papillary Thyroid Carcinoma 1947 Dhanalakshmi Balakrishnan Chengbao Liu Laura Birney Syed Hoda James Davis Alan Heimann Jingxuan Liu State University of New York Stony Brook Stony Brook NY 279 Impact of Intradepartmental Consultation on Amended Report Rate Findings from the Irish National Quality Improvement Programme in Histopathology 2011 Niall Swan Philip Ryan Kieran Sheahan Ann Treacy Sine Phelan Julie McCarthy Mairead Guinan John Conor OKeane Royal College of Physicians of Ireland Dublin Ireland 280 Quality Assurance Protocols for Breast and Gynecologic Pathology Practice in a CLIA Laboratory Minimize Serious Events and Maximize Patient Safety underline 2010 Catherine Stoos Rohit Bhargava Gloria J Carter Abbie Mallon David Dabbs Magee Womens Hospital Pittsburgh PA 281 Cost Effectiveness Analysis of Core Needle Biopsy Diagnosis of Papillomatous Breast Lesions 1984 Clare McCormick-Baw Mae Lopez Ada Werlang- Perurena Riyam T Zreik Amin Mohammad Arundhati Rao Baylor Scott and White Memorial Hospital Temple TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 161NEXTGENERATION LEARNING 2016 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 161 282 Pathology Review of Research Biopsies Highlights Inter- and Intra-Tumor Variability Towards Improving Quality and Utility for Next-Generation Biospecimen Researchunderline 1956 Dianne Chadwick Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 283 Duodenal Polyps Resembling Peptic Duodenitis in Patients with Hereditary Cancer Syndromes 1963 Kyle Devins Lisa Wang Maryam Zenali SUNY Upstate Medical University Syracuse NY University of Vermont Burlington VT 284 A Comparative Study of Colon and Rectal Tumor Specimens Gross Examination by Biomedical Scientists Residents and Pathologists A Review of 688 Cases 1952 Ana C Braga Rita SS Oliveira Marco Ferreira Ana Lopes Katia Reis Leontino Lampreia Manuela Novo Rui Vaz Rute Matos Sara Marques Hospital Prof. Doutor Fernando Fonseca E.P.E. Amadora Portugal 285 Utility of Routine Histopathological Analysis Following Orthopaedic Procedures for Benign Indications 2018 Anna-Sophie Weidner Francesca Khani Theresa Scognamiglio Weill Cornell Medical College New York NY 286 Single Versus Multiple Levels for Routine Endometrial Biopsies Single Institution Experience 1995 Anna Plotkin Linda R Kapusta Keiyan Sy Blake Gilks University of Toronto Toronto ON Canada University of British Columbia Vancouver BC Canada 287 Comparing HE Stained and Unstained Slides of Frozen Tissue for Quality and Quantity of mRNA after Laser Capture Microdissection in Human Tissue for the Evaluation of the Microenvironment in Regressing and Progressing Primary Cutaneous Melanoma 1987 Kumaran Mudaliar Solomiya Grushchak Arielle Gray David Murray Rebecca Tung Stephanie Kliethermes Michael I Nishimura Kelli A Hutchens Loyola University Chicago Stritch School of Medicine Maywood IL Loyola University Medical Center Maywood IL TECHNIQUES INCLUDING ULTRASTRUCTURE 288 Scalable Next Generation Sequencing Workow for Mutation Screening of Solid Tumors Using Ion S5XL Sequencer 2058 Meenakshi Mehrotra Dzifa Y Duose Rajesh Singh Bedia A Barkoh Jawad Manekia Jonathan Yau Michael A Harmon Mark Routbort L Jeffrey Medeiros Ignacio I Wistuba Rajyalakshmi Luthra The UT M.D. Anderson Cancer Center Houston TX 289 Utility of a Pan Genomic Fusion Panel 1300 Genes on a Next Generation Sequencing NGS Platform in Evaluation of Cancer 2031 Alka Chaubey Ravindra Kolhe Lisa C Watson Deepa Jagdale Claire Attwooll WonSok Lee Ashis K Mondal Sadanand Fulzele Georgia Regents University Augusta GA Greenwood Genetic Center Greenwood SC Illumina Inc San Diego CA 290 Hepatitis C Virus Genotyping Using Next-Generation SequencingAn Efcient and Cost-Effective Alternative to Sanger Sequencing in the Hospital Laboratory Settingunderline 2083 Cameron Wales George Corpus Dimitri Gonzalez Chalom Sayada Chung-Che Chang UCF Orlando FL ABL SA Luxembourg Luxembourg Florida Hospital Orlando FL 291 Whole-Exome Sequencing Identies a Homozygous POLG2 Missense Variant in an Infant with Fulminant Hepatic Failure and Mitochondrial DNA Depletion 2079 Hemant Varma Phyllis L Faust Peter L Nagy Alejandro D Iglesias Stephen M Lagana Karen Wou Michio Hirano Mahesh Mansukhani Kirsten E Hoff William C Copeland Ali B Naini Columbia University Medical Center and New York Presbyterian Hospital New York NY National Institute of Environmental Health Sciences NIH Research Triangle Park NC 292 RNAscope 2.5 A Robust and High Performance RNA In Situ Hybridization Assay for Formalin-Fixed Parafn- Embedded Tissue 2026 Courtney Anderson Li-chong Wang Casey Kernag Bingqing Zhang Emerald Butko Melanie Miller Thomas Laver Nan Su Henry G Lamparski Emily Park Yuling Luo Xiao-Jun Ma Advanced Cell Diagnostics Hayward CA 293 RNAscope 2.5 Duplex - A Robust High Performance Chromogenic Duplex RNA In Situ Hybridization Technology 2085 Li-chong Wang Bingqing Zhang Casey Kernag Daniel Kim Henry G Lamparski Nan Su Xiao-Jun Ma Yuling Luo ACD Inc Hayward CA 294 Development of RNAscope 2.5 for RNA In Situ Hybridization on the Fully Automated Leica Biosystems BOND Advanced Staining Platform 2051 Henry G Lamparski Bingqing Zhang Melanie Miller Thomas Laver Casey Kernag Daniel Kim Keith Young Kuang-Jung Chang Nan Su Xiao-Jun Ma Yuling Luo Advanced Cell Diagnostics Hayward CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016162 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016162 POSTER SESSION II Monday March 14 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 295 Optimizing Metastatic Bone Biopsies for Genomic Testing in Precision Medicine 2035 Joanna Cyrta Marc Schiffman Brian Sullivan Chantal Pauli Olivier Elemento Andrea Sboner Brian D Robinson Himisha Beltran Mark Rubin Juan Miguel Mosquera Weill Medical College of Cornell University New York NY 296 EDTABased Decalcication of Bone and Bone Marrow- Ideal Tool for Protein and Nucleic Acid Preservation - A Pilot Study 2062 Peter Ntiamoah George H Ayob Richard R Clarke Doudja Nafa Paulo A Salazar Agnes Viale Ahmet Dogan Meera Hameed Memorial Sloan Kettering Cancer Center New York NY 297 Effects of Formalin Fixation Variables on DNA Integrity for Genomic Applications in Cancer 2052 Martina Lefterova Michael J Clark Ravi K Alla Shujun Luo Massimo Morra Elena Helman Sean M Boyle Scott Kirk Parin Sripakdeevong Mirian Karbelashvili Deanna M Church Michael P Snyder John West Richard Chen Stanford University Stanford Ca 298 Comparison of 5 Methods for Extraction of Cell-Free DNA 2046 Kevin Kelly Vanessa Spotlow Aleksandra Ras Samantha Helm Joan Malcolm Gregory J Tsongalis The Jackson Laboratory for Genomic Medicine Farmington CT Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth Lebanon NH 299 Lesson Learned from the Evaluation of MYC Non- IGH Translocation Partners in DLBCL- An Institutional Experience 2027 Renu Bajaj Alexander Graham Jerald Gong Zi-Xuan Wang Stephen C Peiper Guldeep Uppal Thomas Jefferson University Hospital Philadelphia PA 300 Inexpensive Improvements in Processing Techniques Can Signicantly Improve Cell Block Cellular Yields 2050 Kristin La Fortune Melissa L Randolph Harvey M Cramer Indiana University Health Indianapolis IN 301 Digital Multi-Colour CTC Detection 2034 Anthony Cooney Brendan Ffrench Cathy D Spillane Carmel Ruttle Noreen Gleeson Ciaran ORiain Richard Flavin Michael F Gallagher Cara Martin Orla Sheils Sharon OToole John OLeary Trinity College Dublin Dublin Ireland Coombe Women Infants University Hospital Dublin Ireland Dublin City University Dublin Ireland St. Jamess Hospital Dublin Ireland 302 Cytology Waste or Molecular Treasure A Proposed Algorithm for Molecular-Oriented Cytology Specimen Utilization 2075 Shaozhou Tian Maria E Arcila Andre Moreira Justyna Sadowska Sumit Middha Oscar Lin Memorial Sloan Kettering Cancer Center New York City NY 303 Utility of Dual-Color Silver In Situ Hybridization and mRNA Chromogenic In Situ Hybridization in Adipocytic Tumor MDM2 Assessment 2047 Jong T Kim John D Reith Wonwoo Shon University of Florida Gainesville FL 304 Correlation between Immunohistochemical BRAF V600E Expression and Mutational Status Detected by Two Different PCR Based Molecular Techniques in Papillary Thyroid Carcinomas 2073 Jordi Temprana-Salvador Javier Hernandez-Losa Carles Zafon Jessica Camacho Sherley Diaz Irma Ramos Rosa Somoza Ingrid Strohecker Oscar Gonzalez Amparo Garcia-Burillo Santiago Ramon y Cajal Carmela Iglesias Vall dHebron University Hospital Autonomous University of Barcelona Barcelona Spain 305 Combined Molecular Testing Mutational Analysis and MicroRNA Panel of Thyroid Nodules Can Be Accomplished on Fine Needle Aspirate Slides 2076 Maria L Torres Angela M Sanguino Ramirez Sydney D Finkelstein Jan Silverman Allegheny Health Network Pittsburgh PA Redpath Interpace Diagnostics Pittsburgh PA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 163NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM 163 CC HALL 4E SECTION A - GENITOURINARY CHAIRED BY FADI BRIMO AND DANIEL BERNEY 800 Comprehensive Molecular Characterization of 412 Muscle Invasive Urothelial Carcinomas of the Bladder Final Analysis of The Cancer Genome Atlas TCGA Project 846 Hikmat A Al-Ahmadie Seth Lerner Jaegil Kim Gad Getz David J Kwiatkowski John Weinstein Andrew Cherniack Guangwu Guo Rehan Akbani Katherine A Hoadley William Y Kim Gordon Robertson Andy Mungall Toshinori Hinoue Peter Laird Jonathan E Rosenberg Joaquim Bellmunt Margaret B Morgan Chad Creighton Dmitry A Gordenin Joshua M Stuart Xiaoping Su Raju Kucherlapati Gordon Mills Donna Hansel Brian D Robinson Bogdan A Czerniak Victor E Reuter The Cancer Genoma Atlas TCGA Bladder Cancer Working Group New York NY 815 Comprehensive Genomic Proling of Urothelial Carcinoma of the Kidney and Ureter 1025 Jeffrey S Ross Julia A Elvin Siraj M Ali Jo-Anne Vergilio James Suh Tipu Nazeer Vincent A Miller Philip J Stephens Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA 830 TERT Promoter Mutations in Aggressive Variants of Urothelial Carcinoma 1004 Doreen Nguyen Simeon Springer Morgan Cowan Diana Taheri Gunes Guner Maria Angelica Mendoza Rodriguez Stephania Bezerra Isabela W Cunha Dilek Baydar Maria DC Rodriguez Yuxuan Wang Christopher J VandenBussche Kenneth Kinzler Nickolas Papadopoulos Bert Vogelstein George J Netto Johns Hopkins Hospital Baltimore MD Sidney Kimmel Comprehensive Cancer Center Baltimore MD Isfahan University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran AC Camargo Cancer Center Sao Paulo Brazil Hacettepe University Ankara Turkey 845 Comprehensive Molecular Analysis of Plasmacytoid Variant Urothelial Carcinoma 847 Hikmat A Al-Ahmadie Gopa Iyer Byron H Lee Sasinya N Scott Rohit Mehra Aditya Bagrodia Emmet J Jordan Sizhi P Gao Ricardo Ramirez Eugene K Cha Neil Desai Emily C Zabor Irina Ostrovnaya Anuradha Gopalan Ying-Bei Chen Samson W Fine Satish K Tickoo Agnes Viale Maria E Arcila Guido Dalbagni Jonathan E Rosenberg Bernard H Bochner Dean F Bajorin Michael F Berger Victor E Reuter Barry S Taylor David B Solit Memorial Sloan Kettering Cancer Center New York NY 900 Molecular Characterization of Clinically Aggressive Micropapillary Bladder Cancer 935 Charles C Guo Vipulkumar Dadhania Li Zhang Jolanta Bondaruk Tadeusz Majewski Maciej Sykulski Weronika Wronowska Anna Gambin Ashish Kamat Colin Dinney Woonyoung Choi David McConkey John Weinstein Bogdan Czerniak The University of Texas MD Anderson Cancer Center Houston TX Institute of Statistics University of Warsaw Warsaw Poland 915 Invasion of Rete Testis Hilar Fat and Epididymis by Testicular Malignant Germ Cell Tumors MGCT Does Not Justify Upstaging to pT2 1073 Elizabeth Whittington Nicholas Harding Jackson Nicola Pavan Samarpit Rai Kenneth A Iczkowski Oleksandr N Kryvenko Merce Jorda University of MiamiJackson Memorial Hospital Miami FL Medical College of Wisconsin Milwaukee WI 1100 Lymphovascular Invasion of the Spermatic Cord in the Absence of Soft Tissue Invasion is a High Risk Finding in Testicular Nonseminomatous Germ Cell Tumors 991 Brandi C McCleskey Julie Jorns David Y Lu Andres Matoso Lauren E Schwartz Jonathan I Epstein Jennifer B Gordetsky The University of Alabama at Birmingham Birmingham AL University of Michigan Ann Arbor MI David Geffen School of Medicine at UCLA Los Angeles CA Brown University Providence RI University of Pennsylvania Philadelphia PA The Johns Hopkins Hospital Baltimore MD 1115 Morphologic Spectrum of Sertoliform Cystadenoma of the Rete Testis SCRT 14 Cases with Clinical Follow- Up 1008 Swetha Paluru Thomas M Ulbright Mahul B Amin Rodolfo Montironi Jonathan I Epstein Johns Hopkins Medical Institute Baltimore MD Indiana University Indianapolis IN Cedars-Sinai Medical Center Los Angeles CA Polytechnic University of the Marche Region Ancona Ancona Italy 1130 Prognostic and Pathologic Factors Determining Outcomes in pT2pT3 Penile Carcinoma Time for a Revised Staging System 1023 Priya Rao Jasreman Dhillon Benjamin Naovarat Vipulkumar Dadhania Xuemei Wang Hsiang-Chun Chen Philippe E Spiess Curtis A Pettaway Pheroze Tamboli MD Anderson Cancer Center Houston TX Moftt Cancer Center Tampa FL 1145 Genitourinary Rhabdomyosarcoma A Comparative Analysis of Adult vs. Pediatric Cases 945 Jing He Hernan Correa Justin M Cates Giovanna A Giannico Omar Hameed Lan L Gellert Vanderbilt University Nashville TN 1200 BREAK PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016164 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016164 CC BR 6A SECTION B - BREAST CHAIRED BY GELAREH FARSHID AND DHANANJAY A CHITALE 800 Should Multiple Ipsilateral Invasive Breast Carcinomas Routinely Undergo Biomarker Testing 237 Anupma Nayak Ira J Bleiweiss Bailey A Reindl Shabnam Jaffer Mount Sinai Hospital New York NY 815 Evolution of Practices for HER2 Testing in Breast Cancer BC in France Results of PartenHER National Survey of 109 Structures Practicing HER2 Test 254 Frederique Penault-Llorca Jerome Chetritt Bruno Poulet Marie-Pierre Chenard Magali Lacroix-Triki Gaetan MacGrogan Laurent Arnould Jean-Pierre Bellocq Centre Jean Perrin Clermont-Ferrand France Institut dHisto-Pathologie Nantes France Institut de Pathologie de Paris Malakoff France Centre Hospitalier Universitaire de Strasbourg Strasbourg France Institut Universitaire du Cancer de Toulouse - Oncopole Toulouse France Institut Bergoni Bordeaux France 7Centre Georges Franois Leclerc Dijon France AFAQAP Strasbourg France 830 Impact of 2013 ASCOCAP Guidelines on HER2 Determination of Invasive Breast Cancer A Single Institution Experience Using Frontline FISH 264 Moira Ragazzi Alessandra Bisagni Cristina Bassano Ione Tamagnini Elisa Gasparini Elisabetta Kuhn Giorgio Gardini Arcispedale Santa Maria Nuova - IRCCS Reggio Emilia Italy Azienda USL - Scandiano Reggio Emilia Italy 845 Impact of an Alternative Chromosome 17 Probe and the 2013 ASCOCAP Guidelines on FISH for the Determination of HER2 Gene Status in Breast Cancer 151 Alana R Donaldson Shashirekha Shetty Christine Rivera Bryce P Portier James R Cook G T Budd Erinn Downs-Kelly Roger D Klein Christopher P Lanigan Raymond Tubbs Benjamin C Calhoun Cleveland Clinic Cleveland OH Houston Methodist Hospital Houston TX University of Utah Salt Lake City UT 900 HER2 Gene Protein Assay Is Useful to Determine HER2 Status of Breast Carcinoma with HER2 IHC and FISH Double Equivocal Results 210 Zaibo Li Yanjun Hou Hiroaki Nitta Ohio State University Columbus OH Ventana Medical Systems Inc Tucson AZ 915 HER2 FISH Equivocal Category Does Retesting Resolve This Clinical Grey Zone 114 Morgan Ballard Sucheta Srivastava Robert B West Kristin C Jensen Richard K Sibley Kimberly Allison Stanford Healthcare Stanford CA VA Healthcare System Palo Alto CA 1100 Analysis of Estrogen Receptor ER Immunohistochemistry IHC in Breast Cancer with ESR1 Mutations Detected by Hybrid Capture-Based Next Generation Sequencing NGS 270 Dara S Ross Fumiko Konno Edi Brogi Ahmet Zehir Michael F Berger Sarat Chandarlapaty Pedram Razavi Jose Baselga Hannah Y Wen Memorial Sloan Kettering Cancer Center New York NY 1115 Cliniopathologic Features in Predicting Complete Pathologic Response pCR after Neoadjuvant Herceptin Chemotherapy in HER2 Breast Cancers 150 Qingqing Ding Elizabeth A Mittendorf Genevieve R Lyons Roland L Bassett Kelly K Hunt Aysegul A Sahin Yun Wu UT MD Anderson Cancer Center Houston TX 1130 Cytologic Characteristics of Resistant Locally Advanced Breast Carcinoma after Neoadjuvant Treatment 230 Ann M Moyer Daniel W Visscher Vera J Suman Travis J Dockter Krishna R Kalari Donald W Northfelt Sarah A McLaughlin Alvaro Moreno-Aspitia Richard J Gray Judy C Boughey Matthew Goetz Mayo Clinic Rochester MN Mayo Clinic Scottsdale AZ Mayo Clinic Jacksonville FL 1145 Prognostic Signicance of Stromal Versus Intratumoral Inltrating Lymphocytes in Different Molecular Subtypes of Breast Cancer Treated with Neoadjuvant Therapyunderlineunderline 192 Thaer Khoury Vidya Nagrale Xuan Peng Mateusz Opyrchal Dan Wang Song Yao Roswell Park Buffalo NY 1200 BREAK CC BR 6C SECTION C - HEMATOPATHOLOGY CHAIRED BY DAVID CZUCHLEWSKI AND JOHN R GOODLAD 800 The Genetic Landscape in Follicular Lymphoma Pediatric Type 1483 Janine Schmidt Itziar Salaverria Shunyou Gong Stefania Pittaluga Blanca Gonzalez Olga Balague Theresa Maraoti Anna Mozos Jose M Cabecadas Irina Bonzheim Falko Fend Elias Campo Elaine S Jaffe Leticia Quintanilla-Fend University Hospital Tbingen Germany Hospital Clinic IDIBAPS Barcelona Spain National Cancer Insitute Bethesda MD Barts and The London NHS Trust London United Kingdom Hospital de Sant Pau Barcelona Spain Instituto Portugues de Oncologa Lisboa Portugal NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 165NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM 165 815 EBV-Positive Follicular Lymphoma Another Age- Related Lymphoma with Aggressive Clinical Features 1425 Nicholas Mackrides Yvan Maque-Acosta Adrienne Moul German Campuzano-Zuluaga Yasodha Natkunam Francisco Vega Jennifer Chapman University of Miami and Sylvester Comprehensive Cancer Center Miami FL Stanford University School of Medicine Stanford CA 830 Copy Number Gain of PD-L1 and PD-L2 in T-Cell Histiocyte Rich Large B-Cell Lymphoma 1379 Gabriel K Grifn Scott B Lovitch Alyssa Kelley Margaretha GM Roemer Bjoern Chapuy Christine Pak Evisa Gjini Gordon J Freeman F Stephen Hodi Azra H Ligon Margaret A Shipp Scott Rodig Brigham and Womens Hospital Boston MA Dana- Farber Cancer Institute Boston MA 845 The Activation of the JAK3STAT3 Pathway Is Associated with Inferior Outcome in Diffuse Large B-cell Lymphoma and ALK-Positive Large B-cell Lymphoma 1352 Stefan Costinean Mei Zheng Xin Huang Bin Meng Lynette M Smith Adams K Appiah Shimin Hu Yi Zhou Zenggang Pan Timothy C Greiner Hina N Qureishi Catalina Amador Kai Fu Ji Yuan UNMC Omaha NE MD Anderson Cancer Center Houston TX University of Washington Seattle WA University of Colorado Aurora CO 900 Immunophenotypic and Molecular Proling of HIV- Associated Diffuse Large B-cell Lymphomas from sub- Saharan Africa 1362 Yuri Fedoriw Nathan Montgomery Joel Parker Sadia Salahuddin Coxcilly Kampani Steve Kamiza Tamiwe Tomoka Robert Krysiak N George Liomba Kristy Richards Satish Gopal University of North Carolina Chapel Hill NC Cornell University Ithaca NY University of Malawi College of Medicine Blantyre Malawi University of North Carolina Project Malawi Lilongwe Malawi 915 MYC Rearrangement in Chronic Lymphocytic Leukemia Is Not Often Associated with Poor Prognosis 1416 Yan Li Shimin Hu Sa Wang Yang O Huh Shaoying Li Jeffrey Medeiros Guilin Tang UT MD Anderson Cancer Center Houston TX 1100 Chronic Lymphocytic Leukemia CLL with TP53 Gene Abnormalities A Detailed Clinicopathologic and Molecular Analysis 1373 Julia T Geyer Richard R Furman Susan Mathew Attilio Orazi Yen-Chun Liu Weill Cornell Medical College New York NY 1115 Flow Cytometric Characterization of PD1 Expression in Tumor Inltrating T-cells in B-cell Lymphoproliferative Disorders Identies Distinct Disease Specic Patterns 1474 Frances L Rosario Quinones Ahmet Dogan Mikhail Roshal Memorial Sloan Kettering Cancer Center New York NY 1130 Sin1 is Upregulated by NPM-ALK and Contributes to Cell Cycle Progression and Survival in Anaplastic Large Cell Lymphoma 1497 Nikolaos Tsesmetzis George Baltatzis Dimitrios Chioureas Vasiliki Leventaki Elias Drakos Theocharis Panaretakis George Rassidakis Karolinska Institutet Stockholm Sweden St Jude Childrens Research Hospital Memphis TN University of Crete Medical School Heraklion Crete Greece 1145 Expression of Activated B-Cell Factor-1 in ALK-Negative Anaplastic Large Cell and Other Lymphomas 1363 Andrew L Feldman Yu Zeng Rebecca L Boddicker Michael Zimmermann Karen L Grogg James R Cerhan Susan L Slager Matthew Maurer Cristine Allmer Thomas Habermann Brian Link Surendra Dasari Mayo Clinic Rochester MN University of Iowa Iowa City IA 1200 BREAK CC 602-604 SECTION D - GASTROINTESTINAL CHAIRED BY GREG Y LAUWERS AND SUSAN C ABRAHAM 800 Conventional Risk Stratication Fails to Predict Progression of Succinate Dehydrogenase-Decient Gastrointestinal Stromal Tumors 736 Emily Mason Jason L Hornick Brigham and Womens Hospital Harvard Medical School Boston MA 815 PD-L1 Expression and the Tumor Immune Microenvironment of Esophageal Adenocarcinomas 806 Elizabeth Thompson Janis Taube Toby C Cornish Ronan Kelly Robert Anders Johns Hopkins Medical Institutions Baltimore MD 830 Prognostic Value of a lncRNA Signature in Gastric Cancer A lncRNA Expression Analysis 751 Shujuan Ni Midie Xu Cong Tan Dan Huang Weiwei Weng Qiongyan Zhang Weiqi Sheng Xiang Du Fudan University Shanghai Cancer Center Shanghai China 845 Stress-Induced Phosphoprotein 1 STIP1 Promotes Tumorigenesis and Predicts Poor Survival in Gastric Carcinoma Through Induction of the Phospholipase C- 1 and ERK Signaling Pathway 691 Xin He Sui Peng Ertao Zai Shirong Cai Yi Lin Rhode Island Hospital Providence RI the First Afliated Hospital of Sun Yat-sen University Guangzhou Guangdong China PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016166 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016166 900 Hepatoid Carcinomas of the Gastrointestinal Tract A Reappraisal of Morphological and Immunohistochemical Features 796 Angela R Shih Munita Bal Lawrence Zukerberg Ian Brown Gregory Y Lauwers Xiuli Liu Paul Kelly Esther Oliva Soomin Ahn Kyoung Kim Vikram Deshpande Massachusetts General Hospital Boston MA Tata Memorial Hospital Mumbai India Royal Brisbane and Womens Hospital Brisbane Australia Cleveland Clinic Cleveland OH Royal Victoria Hospital Queens University Belfast Belfast United Kingdom Samsung Medical Center Sungkyunkwan University Seoul Republic of Korea 915 Evaluation of Ki-67 Index and Mitotic Count in the Assessment of Prognosis of Small Intestinal Neuroendocrine Tumorunderline 803 Yu Sun Christine M Lohse Thomas C Smyrk Timothy J Hobday Trynda N Kroneman Lizhi Zhang Peking University Cancer Hospital Institute Beijing China Mayo Clinic Rochester MN 1100 Signicant Prognostic Factors in Invasive Ampullary Adenocarcinoma AC Clinicopathologic Analysis of 367 Cases 772 Michelle Reid Serdar Balci Yue Xue Nobu Ohike Takuma Tajiri Olca Basturk Takashi Muraki Grace E Kim Alyssa M Krasinskas Brian Quigley Burcu Saka Pelin Bagci Bassel El-Rayes David Kooby Juan Sarmiento Shishir Maithel Volkan Adsay Emory University Atlanta GA MSKCC NY NY UCSF San Francisco CA 1115 Immunohistochemical Typing of Ampullary Carcinomas May Not Be Ready for Prime Time Analysis of 136 Cases Fails to Conrm Strong Prognostic Correlation with Recently Proposed Marker Panels but Finds Strong Prognostic Value in MUC5AC 826 Yue Xue Michelle Reid Serdar Balci Brian Quigley Bahar Memis Jun Xia Takashi Muraki Ezgi Hacihasanoglu Gabriela Bedolla Grace E Kim Takuma Tajiri Nobu Ohike Ritu Aneja Alyssa M Krasinskas Volkan Adsay Emory University Atlanta GA UCSF San Francisco CA GSU Atlanta GA 1130 Regression Grading in Pancreatic Cancer An Interobserver Study 747 Sangeetha N Kalimuthu Stefano Serra Alice Wei Neesha Dhani Sara Hafezi-Bakhtiari Eva Szentgyorgyi Rajkumar Vajpeyi Runjan Chetty Toronto General Hospital Toronto ON Canada 1145 Circulating Tumor Cells and Circulating Tumor DNA in Patients with PseudoMyxoma Peritonei 665 Marie Dazza Emmanuel Toure France Blanchard Marianne Paresy Nasrin Sarafan-Vasseur Jean- Christophe Sabourin Rouen University Hospital Rouen France 1200 BREAK CC 606-607 SECTION E - GYNECOLOGIC CHAIRED BY MARTIN KOBEL AND ELIZABETH D EUSCHER 800 Detection of Serous Tubal Intraepithelial Carcinoma STIC in Incidentally Removed Fallopian Tubes from Low-Risk Women 1180 Emily Meserve Jelena Mirkovic James Conner Eric Yang Brooke E Howitt Christopher P Crum Brigham Womens Hospital Boston MA 815 Cytological Recognition of Serous Tubal Intraepithelial Carcinoma from Tubal Cytology and and Pelvic Washing Samples 1110 Hao Chen Robert R Klein Stacy J Arnold Li Li Setsuko K Chambers F Zahra Aly Wenxin Zheng University of Arizona Tucson AZ 830 HER4 Expression and Overall Survival in Ovarian Serous Carcinoma 1240 Carolina Strosberg Robert M Wenham Ardeshir Hakam Anthony M Magliocco Ozlen Saglam Moftt Cancer Center Tampa FL 845 FOXL2 Mutation Status in Ovarian Granulosa-Theca Cell Tumors 1189 Amber Nolan Charles Zaloudek Joseph Rabban Nancy M Joseph Ankur R Sangoi Karuna Garg University of California San Francisco San Francisco CA El Camino Hospital Mountain View CA 900 Distinct SMARCA4ARID1A and Genomic Proles in Classic Versus Large Cell Variant of Ovarian Small Cell Carcinoma Hypercalcemic-type 1174 Douglas Lin Joel Greenbowe Jeffrey S Ross Siraj M Ali Julia A Elvin Beth Israel Deaconess Medical Center Boston MA Foundation Medicine Cambridge MA Albany Medical College Albany NY 915 Are the Genomics in the Cancer Genome Atlas Representative of Patients with Recurrent Ovarian High Grade Serous Carcinoma That Is Refractory to Standard Therapy 1104 Emily Broaddus Scott Kopetz J Jack Lee Jiexin Zhang Kenna Shaw Russell Broaddus University of Texas Austin TX M.D. Anderson Cancer Center Houston TX 1100 Assessment of the Chemotherapy Response Score CRS System in High Grade Serous Carcinoma HGSC 1118 Helena M Ditzel Kyle Stickland Emily Meserve Mamta Gupta Jonathan H Hecht Doug I Lin Kirsten M Jochumsen William R Welch Michelle Hirsch Bradley J Quade Kenneth R Lee George L Mutter Christopher P Crum Marisa R Nucci Brooke E Howitt Brigham and Womens Hospital Harvard Medical School Boston MA Beth Israel Deaconess Medical Center Harvard Medical School Boston MA Odense University Hospital University of Southern Denmark Odense Denmark NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 167NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM 167 1115 Distribution and Potential Signicance of Placental Intravillous Particulate Microcalcications 1255 Jennifer Zeng Alan Marcus Tatiana Buhtoiarova Khushbakhat Mittal NYU Langone Medical Center New York NY 1130 Morphological Diversity in Lichen Sclerosus with Emphasis on Features of Differentiated Vulvar Intraepithelial Neoplasia 1127 William Frampton Jordan M Newell Rebecca Phaeton Joshua P Kesterson Joshua I Warrick Penn State Hershey Medical Center Hershey PA 1145 Histological Characteristics of HPV-Associated and Independent Squamous Cell Carcinomas of the Vulva A Study of 791 Cases 1194 Jaume Ordi Natalia Rakislova Omar OC Clavero Maria Alejo Belen Lloveras Laia Alemany Xavier Bosch Silvia de Sanjose Hospital Clinic - Barcelona University Barcelona Spain ISGlobal Barcelona Spain Catalan Institute of Oncology IDIBELL LHospitalet deLlobregat Barcelona Spain 1200 BREAK CC 608-609 SECTION F - CYTOPATHOLOGY CHAIRED BY SAVITRI KRISHNAMURTHY AND STEFAN E PAMBUCCIAN 800 Comparing Next-Generation Sequencing in Concurrently Acquired Cytology Fine Needle Aspirations and Surgical Core Needle Biopsies of Solid Organ Malignancies 444 Sinchita Roy Chowdhuri Rajesh Singh Jawad Manekia Bedia A Barkoh Hui Yao Savitri Krishnamurthy L Jeffrey Medeiros Gregg Staerkel John M Stewart Rajyalakshmi Luthra The University of Texas MD Anderson Cancer Center Houston TX 815 Alcohol-Fixed Direct Smears Yield High Quality Next- Generation Sequencing Data 365 Sarah Calkins Carlitos Chen Kirk Jones Britt-Marie Ljung Donald P Pizzo Nancy M Joseph Univeristy of California San Francisco San Francisco CA University of California San Diego San Diego CA 830 Suspicious AFIRMA Gene Expression Classier Test Result in Thyroid Fine Needle Aspiration Cytology Implications for Patient Management 353 Rebecca Baldassarri Susan Fernandez Angelique W Levi Malini Harigopal Diane Kowalski Guoping Cai Kevin Schoeld Adebowale Adeniran Yale University School of Medicine New Haven CT 845 Performance of the Arma Gene Expression Classier in the Evaluation of Cytologically Indeterminate Thyroid Nodules An Institutional Experience 416 Jenna Lewis Claudia Rojas Carmen Gomez- Fernandez Merce Jorda Monica Garcia-Buitrago University of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL 900 The Cytologic Diagnosis of Non-Invasive Follicular Variant of Papillary Thyroid Carcinoma A Prospective Analysis 458 Kyle C Strickland Marina Vivero Vickie Y Jo Alarice Lowe Monica Hollowell Xiaohua Qian Tad Wieczorek Christopher A French Lisa A Teot Markus Eszlinger Ralf Paschke Peter M Sadow Edmund Cibas Justine A Barletta Jeffrey F Krane Brigham and Womens Hospital Boston MA Massachusetts General Hospital Boston MA Universitt Leipzig Leipzig Germany 915 Cytologic Predictors of Malignancy in Bile Duct Brushings BDBs A Multi-Reviewer Analysis of 60 Cases 351 Vaidehi Avadhani Ezgi Hacihasanoglu Krisztina Z Hanley Uma Krishnamurti Alyssa M Krasinskas Adeboye O Osunkoya Lauren Daniels Alexa Freedman Michael Goodman Volkan Adsay Michelle Reid Emory University Atlanta GA 1100 Grading of Pancreatic Neuroendocrine Neoplasms by Ki-67 Staining on Cell Blocks Manual Count and Digital Image Analysis 407 Ming Jin Rachel Roth Vera Gayetsky Nicholas Niederberge Paul E Wakely The Ohio State University Wexner Medical Center Columbus OH Bethesda North Hospital Cincinnati OH 1115 The Diagnostic Utility of CK7 MASPIN and MUC5AC In Distinguishing Gastric-Foveolar Type Mucinous Neoplasm of the Pancreas from Gastric Contaminants on Fine Needle Aspiration Specimens 408 Shivani Kandukuri Haiyan Liu Fan Lin Geisinger Medical Center Danville PA 1130 Genetic Alterations Detected in Urine Cytology Specimens from Patients with High Risk Non-Muscle Invasive Urothelial Carcinoma Treated with BCG 418 Oscar Lin Sasinya N Scott Nancy Bouvier Caroline M Lin Bernard H Bochner Michael F Berger Memorial Sloan Kettering Cancer Center New York NY PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016168 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM NEXTGENERATION LEARNING2016168 1145 Secondary Malignancies in Salivary Glands A Multi- Institutional FNA Cohort from Trans-Atlantic Academic Institutions 468 He Wang Raza S Hoda William C Faquin Esther Rossi Nihar Hotchandani Tianlin Sun Marc Pusztaszeri Tommaso Bizzarro Massimo Bongiovanni Viren Patel Nirag Jhala Yun Gong Temple University Hospital Philadelphia PA Massachusetts General Hospital Boston MA Catholic University of Rome Rome Italy MD Anderson Cancer Center Houston TX Geneva University Hospital Geneva Switzerland University of Lausanne Lausanne Switzerland 1200 BREAK CC 611-612 SECTION G - BONE SOFT TISSUE CHAIRED BY JUDITH BOVEE AND BENJAMIN HOCH 800 Recurrent Novel CIC Gene Abnormalities in Angiosarcoma A Molecular Study of 120 Cases with Concurrent Investigation of PLCG1 KDR MYC and FLT4 Gene Alterations 58 Shih-Chiang Huang Lei Zhang Yun-Shao Sung Yu- Chien Kao Narasimhan P Agaram Cristina Antonescu Memorial Sloan Kettering Cancer Center New York NY Chang Gung Memorial Hospital Taoyuan City Taiwan Shuang Ho Hospital Taipei Medical University New Taipei City Taiwan 815 Spindle Cell Lipoma Arising at Atypical Locations A Clinicopathologic Review of 56 Cases 100 Pingchuan Zhang Nasir Ud Din Andrew L Folpe Karen Fritchie Mayo Clinic Rochester MN Aga Khan University Hospital Karachi Pakistan 830 Diagnostic Value of Histone 3 Mutations in Osteoclast- Rich Bone Tumors 80 Erik Nohr Marco Perizzolo Lik Hang Lee Justin M Cates Doug Demetrick Doha Itani University of Calgary Calgary Laboratory Services Calgary AB Canada Vanderbilt University Medical Center Nashville TN 845 Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis A Systematic Pathology Review Immunohistochemistery and Molecular Analysis in 160 Patients from the French Sarcoma Group Database 74 Sophie Le Guellec Anne-Valerie Decouvelaere Thomas Filleron Isabelle Valo Celine Charon-Barra Yves-Marie Robin Philippe Terrier Christine Chevreau Jean-Michel Coindre Institut Claudius Regaud Toulouse France Centre Lon Brard Lyon France Centre Paul Papin Angers France Centre Georges-Franois Leclerc Dijon France Centre Oscar Lambret Lille France Institut Gustave Roussy Paris France Institut Bergoni Bordeaux France 900 Loss of H3K27 Trimethylation Distinguishes Malignant Peripheral Nerve Sheath Tumors from Histologic Mimics 89 Inga-Marie Schaefer Christopher Fletcher Jason L Hornick Brigham and Womens HospitalHarvard Medical School Boston MA 915 TERT Promoter Mutations and Prognosis in Solitary Fibrous Tumor 39 Armita Bahrami Seungjae Lee Inga-Marie Schaefer Jennifer M Boland Kurt T Patton Christopher Fletcher St. Jude Childrens Research Hospital Memphis TN Brigham Womens Hospital Boston MA Mayo Clinic Rochester MN Trumbull Laboratories Germantown TN 1100 P16 Expression as a Prognostic and Predictive Marker in Osteosarcoma of Bone 82 Alberto Righi Marco Gambarotti Marta Sbaraglia Andrea Sisto Stefano Ferrari Piero Picci Paolo Dei tos Department of Pathology Rizzoli Institute Bologna Italy Department of Pathology Treviso Regional Hospital Treviso Italy Department of Oncology Rizzoli Institute Bologna Italy University of Eastern Piedmont Polis-Public Policy and Choice Alessandria Italy 1115 ETV4 Is a Useful Marker for the Diagnosis of CIC-DUX4 Round Cell Sarcomas A Study of 110 Cases Including Mimicking Lesions 73 Sophie Le Guellec Valerie Velasco Gaelle Perot Sarah Watson Franck Tirode Jean-Michel Coindre Institut Claudius Regaud Toulouse France Institut Bergoni Bordeaux France Institut Curie Paris France 1130 Recurrent BCOR Internal Tandem Duplication ITD and YWHAE-NUTM2B Fusions in Undifferentiated Round Cell Sarcoma URCS of Infancy Overlapping Genetic Features with Clear Cell Sarcoma of Kidney CCSK 65 Yu-Chien Kao Shih-Chiang Huang Pedram Argani Catherine Chung Nicole Graf Rita Alaggio Cristina Antonescu Memorial Sloan Kettering Cancer Center New York NY Shuang Ho Hospital Taipei Medical University Taipei Taiwan Chang Gung Memorial Hospital Taoyuan Taiwan Johns Hopkins University School of Medicine Baltimore MD The Hospital for Sick Children Toronto ON Canada The Childrens Hospital of Westmead Westmead Australia University of Padua Padua Italy 1145 A New Simple Low-Cost Multiplexed Targeted Sequencing Assay to Detect Recurrent Fusion Genes in Sarcomas 38 Emilie Angot Philippe Ruminy Vinciane Marchand France Blanchard lodie Colasse Marie Cornic Christian Bastard Fabrice Jardin Jean-Christophe Sabourin University Hospital Rouen France Centre Henri Becquerel Rouen France 1200 BREAK NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 169NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Tuesday March 15 2016 800 AM - 1200 PM 169 CC 615-617 SECTION H - LIVER CHAIRED BY RYAN M GILL AND HANLIN L WANG 800 PRKACA Fluorescent In Situ Hybridization Reveals Novel Findings in Fibrolamellar Carcinoma 1657 Rondell Graham Matthew Yeh Dora Lam-Himlin Luigi M Terracciano Michael Cruise Patricia Greipp Stephanie Roessler Thomas Longerich Peter Schirmacher Michael Torbenson Mayo Clinic Rochester MN University of Washington Seattle WA Mayo Clinic Scottsdale AZ University Hospital Basel Switzerland Cleveland Clinic Cleveland OH University of Heidelberg Heidelberg Germany 815 Liver Transplantation in the Setting of Hepatocellular Carcinoma Role of Tumor Differentiation in Predicting the Risk of Recurrence 1678 Daniel E Roberts Sanjay Kakar Ryan M Gill University of California San Francisco San Francisco CA University of California San Francisco San Francisco CA 830 Alpha 1-Antitrypsin A1AT Globules Are Highly Encountered in Liver Explants for Non-Alcoholic Steatohepatitis NASH and in Patients with Body Mass Index30 kgm2 underline 1646 Gregory Cheeney Purva Gopal Lincoln Pac Charles Landis Maria Westerhoff University of Washington Seattle WA University of Texas South Western Dallas TX 845 Fatty Liver Binding Protein 4 A New Mediator in Liver Carcinogenesis Related to Metabolic Syndrome 1672 Emma Norkowski Samira Laouirem Aurelie Sannier Miguel Albuquerque Julie Di Martino Frederic Saltel Olivier Soubrane Pierre Bedossa Pierre-Emmanuel Rautou Valerie Paradis INSERM UMR 1149 Inammation Research Center Paris-Montmartre France Beaujon Hospital Clichy France INSERM UMR 970 Paris Cardiovascular Research Center Paris France INSERM UMR 1053 GREF Bordeaux France 900 Clinical Signicance of Liver Biopsy Findings Suggestive of Suspicious for or Consistent with Biliary Obstructionunderline 1689 Annie Wu Hanlin L Wang UCLA Los Angeles CA 915 Novel Chromogenic RNA In Situ Hybridization Assay Is an Accurate Method for Tissue Diagnosis of Hepatitis E Virus Infection 1658 Rondell Graham Jeffrey Germer Joseph Yao Michael Leise Rish K Pai John Poterucha Michael Torbenson Mayo Clinic Rochester MN Mayo Clinic Scottsdale AZ 1100 A Panel of Three Markers H4K20me2 H4K16ac and PIVKA-II for Prediction of Microvascular Invasion in Hepatocellular Carcinoma 1677 Nicolas Pote Francois Cauchy Miguel Albuquerque Olivier Soubrane Pierre Bedossa Valerie Paradis Department of Pathology Beaujon Hospital Clichy France INSERM UMR 1149 Centre de Recherche sur lInammation Beaujon Hospital Clichy France Department of Hepatobiliary Surgery and Liver Transplantation Beaujon Hospital Clichy France 1115 Distinct Patterns of Reticulin Framework Alterations in TelangiectaticInammatory Adenoma Diagnostic Clues and Pitfalls 1648 Jason Chesser Ashwini K Esnakula Deepa Patil Thomas Plesec Cleveland Clinic Cleveland OH University of Florida Gainesville FL 1130 Different Types Of Glutamine Synthetase Immunostaining in Hepatocellular Adenoma 1638 Paulette Bioulac-Sage Brigitte Le Bail Claire Castain Christine Sempoux Charles Balabaud Universit Bordeaux Bordeaux France CHU Bordeaux Bordeaux France Centre Hospitalier Unversitaire Vaudois Lausanne Switzerland 1145 Distinctive Morphologic Pattern and In Situ Hybridization for Albumin Distinguishes Intrahepatic Cholangiocarcinoma from Metastatic Adenocarcinoma 1630 Tanupriya Agrawal Osman Yilmaz Ricard Masia Lipika Goyal Andrew Zhu Vikram Deshpande Tufts Medical Center Boston MA Massachusetts General Hospital Boston MA 1200 BREAK POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CDPOSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC Board Number Board Number Board Number Board Number BREAST PATHOLOGY 1 Cytokeratin 7-Negative Mammary Pagets Disease - A Diagnostic Pitfall 247 Ugur Ozerdem Jennifer M McNiff Fattaneh A Tavassoli Yale School of Medicine New Haven CT 2 Correlation of Protein Expression with Chromosomal Copy Number Alterations in the Progression of Early Breast Neoplasia to DCISunderline 156 Erna Forgo Sushama Varma Robert B West Stanford University School of Medicine Stanford CA NEXTGENERATION LEARNING2016170 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016170 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 3 Genomic Proling of Ductal Carcinoma In Situ Can We Predict Outcome 211 Chieh-Yu Lin Sujay Vennam Robert T Sweeney Shirley X Zhu Sushama Varma Robert B West Stanford University Medical Center Stanford CA 4 Ductal Carcinoma In Situ DCIS Invasive Carcinoma Risk Prediction Model DRPM A Novel Biomarker Model to Predict Local Recurrence in Large Cohort of Women Diagnosed with DCIS and 15yr Follow Up 129 Gautam Bulusu Adam Brufsky Jennifer Picarsic Gretchen Ahrendt Gloria Carter Mamatha Chivukula Mills-Peninsula Health Services a Sutter Health Afliate Dorothy Schneider Breast Cancer Center Burlingame CA Univeristy of Pittsburgh Magee Womens Hospital Pittsburgh PA University of Pittsbrugh Magee Womnens Hospital Pittsburgh PA 5 Role of Biomarkers CD44 E-cadherin and -catenin in Predicting Recurrence and Progression of Ductal Carcinoma In Situ of the Breast 292 Benjamin Yongcheng Tan Clara Ong Valerie Koh Aye Aye Thike Puay-Hoon Tan Singapore General Hospital Singapore Singapore 6 Negative Progesterone Receptor Status Mitotic Activity and Periductal Chronic Inammation PDCI Around DCIS Does Not Predict Recurrences in DCIS Cases 267 Bailey A Reindl Shabnam Jaffer Ira J Bleiweiss Anupma Nayak Mount Sinai Hospital New York NY 7 Comparison of Estrogen Receptor Antibody Reagents Using Prociency Testing Data 294 Megan Troxell Jason L Hornick Abiy B Ambaye Kristin C Jensen CAP Immunohistochemistry Committee OHSU Portland OR Brigham Womens Boston MA UVM Burlington VT VAPAHCS Palo Alto CA CAP Chicago IL 8 A Systematic Method of Assessing ERPRHer2 on Core Biopsy and or Excision Specimens 180 Shabnam Jaffer Bailey A Reindl Ira J Bleiweiss Anupma Nayak The Mount Sinai Medical Center New York NY 9 Characterization of Estrogen Receptor Positive Progesterone Receptor NegativeERPR- Breast Cancer BC 283 Tiansheng Shen Tao Guo Omar Hameed Gene P Siegal Shi Wei University of Alabama at Birmingham Birmingham AL 10 Gene Expression Analysis in Estrogen Receptor Subsets Dened by Immunohistochemistry in Breast Invasive Duct Carcinoma 105 Di Ai Bing Leng Kimberly L Walker Shelby Hendrickson Ada Werlang-Perurena Arundhati Rao Baylor Scott White Memorial Hospital Temple TX MD Anderson Cancer Center Houston TX 11 Correlation of OncotypeDx Recurrence Score with IHC3IHC4 and Grade in Ductal Carcinoma In Situ DCIS 299 Poonam Vohra Gregor Krings Manjiv Vohra Yunn-Yi Chen UCSF San Francisco CA 12 Histologic Grade 1 in Breast Cancer Indicates a Lack of Benet in Ordering Oncotype DX 274 Mary Ann Sanders Elizabeth C Riley University of Louisville Louisville KY 13 Progesterone Receptor and Ki-67 Discordance in African American Women with Hormone Receptor Positive Breast Cancer Submitted for Oncotype DX Testing 296 Bradley Turner Nyrie Soukiazian Ping Tang David G Hicks University of Rochester Medical Center Rochester NY University of Rochester Rochester NY 14 Interobserver Agreement of Breast Cancer IHC4 after Score the Core Training 121 Alexander Borowsky Ronald Balassanian Christina Yau Jesse A Engelberg Carlie K Thompson Hanna EG Retallack John W Bishop Robert Cardiff Philip M Carpenter Yunn Yi Chen Brian Datnow Farnaz Hasteh Gregor Krings Fritz Lin Yanhong Zhang Linda S Lindstrom UC Davis Sacramento CA UCSF San Francisco CA UCSD La Jolla CA USC LA CA UCI Irvine CA Karolinska Stockholm Sweden 15 Validation of a Random Forests Based Model Using Routine Pathologic Features to Predict OncoType Dx Risk Scores 205 Zach Lee Hyunseok Kim Tyler A Jensen Chris B Umbricht Leslie Cope Bradley Turner David G Hicks Martin Rosman W Charles Mylander Antonio C Wolff Dylan Miller University of Utah Salt Lake City UT Hopkins University School of Medicine Baltimore MD Johns Hopkins Baltimore MD University of Rochester Rochester NY Anne Arundel Medical Center Annapolis MD Intermountain Medical Center University of Utah Salt Lake City UT Intermountain Biorepository Salt Lake City UT 16 Prediction of Oncotype DX Recurrence Score Use of a Pathology-Generated Equation 172 Yanjun Hou Gary Tozbikian Debra L Zynger Zaibo Li The Ohio State University Wexner Medical Center Columbus OH 17 Adjust Cut-Off Values of Immunohistochemistry Models to Predict Risk of Distant Recurrence in Invasive Breast Carcinoma Patients 134 Yen-Ying Chen Ling-Min Tseng Ching-Fen Yang Chih- Yi Hsu Taipei Veterans General Hospital Taipei City Taiwan Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 171NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 171 18 Comparison of Magee and OncotypeDx Recurrence Scores in Luminal-B Immunophenotype Breast Cancers 302 Ann E Walts Shikha Bose Cedars-Sinai Medical Center Los Angeles CA 19 Comparison of Magee and OncotypeDx Recurrence Scores in Luminal-A Immunophenotype Breast Cancers 123 Shikha Bose Ann E Walts Cedars-Sinai Medical Center Los Angeles CA 20 Oncotype DX Test and Modied Magee Equations Are They Different 138 Sachica Cheris Jianmin Wang Bradley Turner Kristin Skinner David G Hicks Ping Tang University of Rochester Medical Center Rochester NY RTI Health Solution Research Triangle Park NC 21 Comprehensive Evaluation of Ki67 in LuminalHER2- Negative Breast Cancer in the AMBER Consortium 193 Thaer Khoury Gary Zirpoli Stephanie M Cohen Mihai Merzianu Melissa Troester Joseph Geradts Amber Worral Wiam Bshara Christine Ambrosone Roswell Park Buffalo NY University North Carolina Chapel Hill NC 22 Proportion of Estrogen Receptor Positive and HER2 Positive Breast Cancer in a Rural Rwandan Cancer Center When Considering Duration of Ischemic and Fixation Time 223 Emily Meserve Gaspard Muvugabigwi Irenee Nshimiyimana Krishan Taneja Lydia Pace Danny A Milner Lawrence N Shulman Deborah A Dillon Tharcisse Mpunga Brigham Womens Hospital Boston MA Butaro Cancer Center of Excellence Butaro Rwanda University of Pennsylvania Philadelphia PA 23 Pathologic Characteristics and Outcome of Low Positive Hormone Receptor Invasive Breast Carcinoma 233 Jodi S Music Theera Rojanapremsuk Sunati Sahoo University of Texas Southwestern Medical Center Dallas TX 24 Nuclear Grading of Breast Cancer Based on Training by Examination of Estrogen-Receptor Negative Tumors Performance with and without Incorporation into the Edinburgh Simplication of Nottingham Grade 145 Leslie Dalton South Austin Medical Center Austin TX 25 Male Breast Carcinoma Has Worse Prognosis Than Female Breast Carcinoma 209 Xiaoxian Bill Li Uma Krishnamurti Lei Huo Limin Peng Emory University Atlanta GA University of Texas MD Anderson Cancer Center Houston TX 26 Analysis of Clinical-Pathological Data with Impact on Overall Survival OS in Male Breast Carcinoma An International Multi-Institutional Study of 220 Cases 287 Simona Stolnicu Denisa Moncea Alis Dema Rares Buiga Cosmin Moldovan Rares Georgescu Cornelia Toganel Septimiu Voidazan Erika Resetkova Maria Comanescu Isabel Alvarado-Cabrero University of Medicine and Pharmacy Tg Mures Targu Mures Romania University of Medicine Victor Babes Timisoara Romania Oncologic Institute I. Chiricuta Cluj Napoca Romania MD Anderson Cancer Center Houston TX Victor Babes Institute Bucuresti Romania Oncologic Institute Mexico City Mexico 27 Male Breast Cancers Are They Different Than Female Breast Cancers 278 Kate M Serdy David Dabbs Rohit Bhargava Magee-Womens Hospital of University of Pittsburgh Medical Center Pittsburgh PA 28 The Genetic Landscape of Neuroendocrine Breast Carcinomas 217 Caterina Marchio Charlotte KY Ng Salvatore Piscuoglio Anne M Schultheis Elena Guerini-Rocco Marco Cupo Felipe C Geyer Anna Sapino Britta Weigelt Jorge S Reis-Filho University of Turin Turin Italy Memorial Sloan Kettering Cancer Center New York NY University Hospital Cologne Germany European Institute of Oncology Milan Italy 29 Clinicopathological Features of 40 Mammary Carcinomas with Neuroendocrine Differentiation 248 Ugur Ozerdem Malini Harigopal Fattaneh A Tavassoli Yale School of Medicine New Haven CT CARDIOVASCULAR PATHOLOGY 30 Biochemical Signature of Antibody-Mediated Rejection in Cardiac Allograft Biopsies 335 Imran Uraizee Michael Walsh Peter Nguyen Aliya N Husain University of Chicago Chicago IL University of Illinois at Chicago Chicago IL 31 Diagnostic Value of T helper Type 17 Th17 Cells in Moderate Acute Cellular Rejection of Cardiac Allograft 338 Yinong Wang Leland B Baskin Daniel G Fontaine Shuhong Liu Christopher Naugler Calgary Laboratory Services University of Calgary Calgary AB Canada 32 Myocardial Capillary Density in Left and Right Ventricles of Explanted Hearts from Patients after Short and Long Term Heart Transplantation 331 Jihui J Qiu Theodore Vasiliadis Xu Wang Jieliang Li Xulei Liu Nirag C Jhala He Wang Temple University Hospital Philadelphia PA Vanderbilt University Nashville TN Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016172 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016172 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 33 Left Ventricular Assist Device Can Increase Capillary Density of Human Heart 337 Jindong Wang Theodore Vasiliadis Eman Hamad Xu Wang Viren Patel Jieliang Li Xulei Liu Nirag Jhala He Wang Temple University Hospital Philadelphia PA Vanderbilt University Nashville TN 34 Erosion Is More Common as a Cause of AMI in the Elderly A Pathologic Study of Coronary Arteries in 884 Human Autopsy Cases 333 Atsuko Seki Koji Chida Akihiko Hamamatsu Motoji Sawabe Yoko Matsuda Keisuke Nonaka Shinichiro Ohkawa Tomio Arai Tokyo Metropolitan Geriatric Hospital Itabashi Tokyo Japan Kasumigaseki Clinic Chiyoda Tokyo Japan 35 Neoatherosclerosis as a Cause of Late Stent Failure Following Bare Metal and 1st - and 2nd -Generation Drug- Eluting Stent Placement An Autopsy Study 323 Elena Ladich Maria Romero Fumiyumi Otsuka Renu Virmani CVPath Institute Gaithersburg MD 36 Clinicopathologic Experience with Mitral Valve Repairs Using CorMatrix ECM Technology 318 Siddharth Bhattacharyya Shiguang Liu Nirag Jhala He Wang Temple University Hospital Philadelphia PA 37 Apolipoprotein A-IV Associated Cardiac Amyloidosis 319 Melanie C Bois Surendra Dasari Jason D Theis Julie Vrana Martha Grogan Angela Dispenzieri Paul J Kurtin Joseph J Maleszewski Mayo Clinic Rochester MN 38 NRG1-ERBB4-PSEN1 Dysfunction in Human Myocarditis and Dilated Cardiomyopathy 321 Paul J Hanson Erika L Jang Angela Y Chang Harpreet Rai Angela Y Mo Bruce M McManus Michael A Seidman University of British Columbia Vancouver BC Canada Providence Health Care Vancouver BC Canada 39 Unusual Complications of Prosthetic Vascular Reconstruction A Clinicopathologic Case Series 313 Ibrahim Aboshady Naveed U Saqib Deborah Vela Ana M Segura Kamal Khalil L Maximilian Buja Texas Heart Institute Houston TX The University of Texas HSC Houston TX 40 Cardiac Angiosarcoma Histopathologic Immunohistochemical and Molecular Genetic Analysis of 10 Cases 325 Charles Leduc William R Sukov Jeannette G Rustin Joseph J Maleszewski Mayo Clinic Rochester MN 41 Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Centers Rapid Research Autopsy Program 317 Prashant Bavi Hamidreza Sharifzad Qian Yang Leslie Oldeld Anthony Joshua Jagdish Butany Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 42 Characterization of LVAD Ventricular and Aortic Interfaces Potential Role in Device Thrombosis 327 Daniel Pelletier Stanley J Radio University of Nebraska Medical Center Omaha NE 43 Transcathether Ablation of the Atrio-Ventricular Junction Histopathology Findings and Interventional Anatomy of the Tricuspid Valve 332 Stefania Rizzo Andrea Corrado Franco Zoppo Marialuisa Valente Gaetano Thiene Cristina Basso University of Padua Padova Italy Mirano Hospital Mirano Italy Mestre Hospital Mestre Italy 44 How to Choose the Pathologic Marker of Evaluate the Irreversibility of Congenital Heart Disease Associated Pulmonary Hyptertensionunderline 326 Li Li Changming Xiong Shian Huang Chao Liu Hongyue Wang Xuejing Duan Jianguo He Fuwai Hospital National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences Peking Union Medical College Beijing China Guangdong Medical College Afliated Zhanjiang Hospital Zhanjiang China Gaozhou Peoples Hospital Gaozhou China 45 Human Plaque-Aortic Ring Co-Culture A Novel Assay for the Study of Atherosclerosis-Induced Angiogenesis 316 Alfred C Aplin Ted Kohler Roberto Nicosia University of Washington Seattle WA VA Puget Sound HCS Seattle WA ENDOCRINE PATHOLOGY 46 Non-Invasive Follicular Variant of Papillary Thyroid Carcinoma and the Arma Gene-Expression Classier 613 Kristine S Wong Trevor Angell Kyle C Strickland Erik K Alexander Edmund Cibas Jeffrey F Krane Justine A Barletta Brigham and Womens Hospital Boston MA 47 Does Reclassication of Follicular Variant of Papillary Thyroid Carcinoma Affect Rates of Malignancy by Bethesda Category 575 Allison B Cavallo Daniel N Johnson Saaduddin Saddiqui Raymon Grogan Peter Angelos Edwin L Kaplan Tatjana Antic Nicole A Cipriani The University of Chicago Chicago IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 173NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 173 48 Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Minimal Invasion Is Biologically Indolent 616 Jennifer Zeng Michael Bannan Cheng Z Liu Fang- Ming Deng NYU Langone Medical Center New York NY 49 CytologyHistology Correlation of Follicular Variant of Papillary Thyroid Carcinoma The UCSF Experience 595 Dianna Ng Zheng Ma Britt-Marie Ljung Elham Khanafshar UCSF Medical Center San Francisco CA 50 Non-Invasive Follicular Variant of Papillary Thyroid Carcinoma Accounts for over Half of Carcinomas Harboring RAS Mutations 599 Vera Paulson Priyanka Shivdasani Brooke E Howitt Matthew Ducar Trevor Angell Erik K Alexander Edmund Cibas Jeffrey F Krane Neal Lindeman Justine A Barletta Brigham and Womens Hospital Boston MA Dana- Farber Cancer Institute Boston MA 51 Node-Negative Versus Node-Positive Papillary Thyroid Carcinoma A Comparison of Clinicopathologic and Molecular Findings 584 Justin A Kotliar Peter Kragel The Brody School of Medicine at East Carolina University Greenville NC 52 Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma 604 Raja R Seethala Simion I Chiosea Cheng Z Liu Marina Nikiforova Yuri E Nikiforov University of Pittsburgh Pittsburgh PA NYU Medical Center New York NY 53 Frequency of TERT Promoter Mutations in Thyroid Carcinoma Metastases 603 Karan Saluja Ying C Henderson Maria Cabanillas Elizabeth G Grubbs Stephen Y Lai Michelle D Williams UT MD Anderson Cancer Center Houston TX 54 Metabolic Reprograming in Adrenocortical Tumors in Children A Promising New Pathway in the Biology of This Disease 617 Maria Zerbini Celine Pinheiro Sara Granja Adhemar Longatto Andre M Faria Maria CV Fragoso Silvana M Lovisolo Antonop M Lerario Madson Q Almeida Fatima Baltazar University of Sao Paulo School of Medicine Sao Paulo SP Brazil University of Minho Braga Guimaraes Portugal Barretos Cancer Hospital Barretos SP Brazil 55 Adrenal Cortical Neoplasms Are Immunostains Useful to Distinguish Benign from Malignant 573 Shikha Bose Shefali Chopra Ann E Walts Cedars-Sinai Medical Center Los Angeles CA University of Southern California Los Angeles CA 56 Oncocytic Adrenocortical Adenomas An Important Cause of False Positive Malignant Results in Preoperative Urine Steroid Proling 578 Salvador Diaz-Cano Cathy Zhang Norman Taylor Kings College HospitalKings College London London United Kingdom 57 Succinate Dehydrogenase Deciency in Pheochromocytoma and Paraganglioma 581 Evan Holleran Brandon Boldt Devin McKissic Jason L Hornick Andrew M Bellizzi University of Iowa Iowa City IA Brigham and Womens Boston MA 58 GATA3 Immunohistochemistry Differentiates Malignant Pheochromocytoma from Adrenal Cortical Carcinoma 600 Carmen M Perrino Alex Ho Debra L Zynger The Ohio State University Medical Center Columbus OH 59 Immunohistochemical Expression of OCT34 in Adrenal Gland Pheochromocytomas and Prevertebral Paragangliomas 596 Marlo Nicolas Patricia Dahia University of Texas Health Science Center at San Antonio San Antonio TX 60 Thyroglossal Duct Cyst Carcinomas A Clinicopathologic Series of 21 Cases 608 Lester DR Thompson Hannah B Herrera Sean K Lau SCPMG Woodland Hills CA SCPMG Anaheim CA 61 Can Medullary Carcinoma Arise in Thyroglossal Duct Cysts A Search for Parafollicular C-cells in 38 Resected Cases 606 Tracy A Stein Paari Murugan Faqian Li Mohamed El Hag University of Minnesota Medical Center Minneapolis MN 62 TROP-2 and CD117 Expression in Oncocytic Lesions of the Thyroid Exceptional Sensitivity and Mediocre Specicity for Oncocytic Papillary Thyroid Carcinoma 396 Christopher Hartley Peter N Bonneau Bryan Hunt Medical College of Wisconsin Milwaukee WI GASTROINTESTINAL PATHOLOGY 63 Role of Submucosal Glands in the Development and Progression of Adenocarcinoma in Barretts Esophagus 700 Melanie Johncilla Robert Odze Agoston Agoston Brigham and Womens Hospital Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016174 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016174 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 64 Role of Mucosal Glands in the Progression of Neoplasia in Barretts Esophagus 672 Jonathan England Anne-Fre Swager Simon Schlachter Brian Sundell Jacques JGHM Bergman Gregory Y Lauwers Robert Odze Massachusetts General Hospital Boston MA Brigham and Womens Hospital Boston MA NinePoint Medical Boston MA Academisch Medisch Centrum Amsterdam Netherlands 65 LGR5 Expression in Barretts Esophagus and Associated Neoplasia Support for Its Role as a Cancer Stem Cell and Diagnostic Marker 667 Vikram Deshpande Krishnan K Mahadevan Gregory Y Lauwers Antony Mattia Lawrence Zukerberg Robert Odze Massachusetts General HospitalBrigham and Womens Hospital Boston MA 66 Osmoprep-Associated Gastritis A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis 687 Dorina Gui Kristin A Olson Sooraj Tejaswi Erica F Clayton Anne Thai Karen Matsukuma University of California Davis Sacramento CA Marin Medical LaboratoriesPathGroup SF Greenbrae CA Mid Peninsula Endoscopy Center San Mateo CA 67 Gastric Intestinal Metaplasia Is It a Worrisome Feature Warranting Follow-Up 638 Pablo A Bejarano Mariana Berho Cleveland Clinic Florida Weston FL 68 See a Sleeve Today ...Save a Life Tomorrow 708 Pavel Kopach Elizabeth Genega Yvelisse Suarez Tufts Medical Center Boston MA 69 Re-Appraisal of Clinical Features Treatment and Outcome in Patients with a Histologic Diagnosis of Collagenous Sprue 835 Lisi Yuan Nan Lan Bo Shen Xiuli Liu Cleveland Clinic Cleveland OH 70 Extra-Ileal Manifestations of Crohns Disease at Initial Presentation 740 Gregory Miller Ian Brown Envoi Specialist Pathologists Brisbane Queensland Australia 71 Clinicopathologic Study of the Ipilumimab-Induced Colitis Compared to Emerging Inammatory Bowel Disease 703 Maryam Kherad Pezhouh Elizabeth M Jaffee Elizabeth A Montgomery Robert A Anders Johns Hopkins Medical Institutions Baltimore MD 72 Gastrointestinal Graft Versus Host Disease in Allogeneic and Autologous Stem Cell Transplant Patients Does Cytotoxic Helper or Regulatory T Cell Inltration Distinguish Alloimmunity from a Failure of Self Tolerance 644 Luis F Carrillo Christopher Hartley Daniel Rowan Catherine Hagen Medical College of Wisconsin Milwaukee WI 73 Is Classication of T cell Subsets Useful in the Evaluation of Gastrointestinal Graft Versus Host Disease 689 Christopher Hartley Luis F Carrillo Daniel Rowan Catherine Hagen Medical College of Wisconsin Milwaukee WI 74 Positive Fungal Testing Associated with Higher Grade Graft Versus Host Disease and Increased Mortality in Stem Cell Transplant Recipientsunderline 722 Long Li Suntrea Hammer UT Southwestern Medical Center Dallas TX 75 Comparison of Dysplastic Fundic Gland Polyps in Patients with and without Familial Adenomatous Polyposis 802 Shana Straub Raul S Gonzalez University of Rochester Rochester NY 76 Predictive Factors for Curative Endoscopic Submucosal Dissection in Supercial Esophageal Squamous Cell Carcinoma 828 Jung Wook Yang Yoon-La Choi Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea SAIHST Sungkyunkwan University Seoul Republic of Korea 77 Low Frequency of Epithelial PD-L1 Staining in Esophageal and Other Gastrointestinal Adenocarcinomas 670 Bastian Dislich Alexandra Stein Christian A Seiler Axel Walch Sabina Berezowska Inti Zlobec Jose A Galvan Rupert Langer Institute of Pathology University of Bern Bern Switzerland University of Bern Bern Switzerland Helmholtz Center Neuherberg Germany 78 PD-L1 Expression Correlated with Lymphocytes Inltrating in Gastric Cancer 713 Yumei Lai Li Sun Jing Gao Lin Shen Zhongwu Li Key Laboratory of Carcinogenesis and Translational Research Ministry of Education Peking University Cancer Hospital Institute Beijing China 79 Ideal Number of Biopsy Tumor Fragments for Predicting HER2 Status in Gastric Carcinoma Resection Specimens 720 Minju Lee Sangjeong Ahn Soomin Ahn Michael Van Vrancken Sang Yun Ha Kyoung-Mee Kim Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea Samsung Medical Center Seoul Korea 80 CD66b-Positive Tumor-Associated Neutrophils in Epstein-Barr Virus Associated Gastric Carcinoma A Comparative Study with CD8-Positive Cytotoxic T-Lymphocytes 619 Hiroyuki Abe Teppei Morikawa Ruri Saito Hiroharu Yamashita Yasuyuki Seto Masashi Fukayama The University of Tokyo Hospital Tokyo Japan Graduate School of Medicine the University of Tokyo Tokyo Japan Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 175NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 175 81 Solid-Type Gastric Carcinomas Categorization and Comparison with Solid-Type Colonic Carcinomas 682 Raul S Gonzalez Justin M Cates Mary K Washington University of Rochester Medical Center Rochester NY Vanderbilt University Medical Center Nashville TN 82 Concurrent Biopsies Improve Diagnosis of Malignancy over Bile Duct Brushings BDBs Alone 636 Vaidehi Avadhani Ezgi Hacihasanoglu Zerife Yusii Bahar Memis Serdar Balci Lauren Daniels Michael Goodman Alyssa M Krasinskas Volkan Adsay Michelle Reid Emory University Atlanta GA 83 Distinct Protein Expressions of the Key Molecules in the Activated Signaling Pathways of Solid- Pseudopapillary Neoplasm of the Pancreas 705 Eun Kyung Kim Minhee Park Hoguen Kim Department of Pathology and the Brain Korea 21 PLUS Project for Medical Science Yonsei University College of Medicine Seoul Korea 84 Transcription Factor E3 as a Novel Diagnostic Marker for Solid Pseudopapillary Neoplasm 688 Grant Harrison Amanda Hemmerich Cynthia Guy Shannon J McCall Diana M Cardona Xuefeng Zhang Duke University Durham NC 85 Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferation Index 714 Hee Eun Lee Taoc Mounajjed Lori A Erickson Tsung- Teh Wu Mayo Clinic Rochester MN 86 Synaptophysin-Ki67 Double Stain A Novel Technique That Can Improve Inter-Observer Agreement in the Grading of GI Neuroendocrine Tumors 755 Kristin A Olson Dorina Gui Regina Gandour-Edwards Karen Matsukuma University of California at Davis Sacramento CA 87 An Unusual Case of Colitis Cystica Profunda Co- Existing with Adenocarcinoma Literature Review and Case Comparisonunderline 723 Yu-I Li Yen-Chieh Chang Chia-Tung Shun National Taiwan University Taipei Taiwan New Taipei City Hospital New Taipei City Taiwan National Taiwan University Hospital Taipei Taiwan 88 High Expression of EphA4 Predicts Lesser Degree of Tumor Regression after Neoadjuvant Chemoradiotherapy in Rectal Cancer 690 Hong-Lin He Yow-Ling Shiue Ying-En Lee Chien-Feng Li Department of Pathology E-DA Hospital I-Shou University Kaohsiung Taiwan Institute of Biomedical Science National Sun Yat-sen University Kaohsiung Taiwan Department of Anesthesiology Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung Taiwan Department of Pathology Chi Mei Medical Center Tainan Taiwan 89 Prediction of Clinical Outcomes of Stage 3 Colorectal Carcinomas with FOLFOX Adjuvant Chemotherapy According to Molecular Subtypes 697 Mi Jang Hoguen Kim Department of Pathology and the Brain Korea 21 PLUS Project for Medical Science Yonsei University College of Medicine Seoul Korea 90 Development and Validation of a Prognostic Nine Gene Expression Signature for Stage IIIII Colorectal Cancer Patients 651 Liang Cheng Lisha Wang Xiaohan Shen Fei Ren Weiqi Sheng Xiaoyan Zhou Xiang Du Indiana University School of Medicine Indianapolis IN Fudan University Shanghai Cancer Center Shanghai China 91 Are the Genomics in the Cancer Genome Atlas Representative of Colorectal Cancer Patients with Recurrent Disease Refractory to Front-Line Therapy 642 Emily Broaddus Jiexin Zhang J Jack Lee Scott Kopetz Kenna Shaw Russell Broaddus University of Texas Austin TX MDACC Houston TX 92 The Genetic Landscape of Interval Colon Cancers Is Similar to Sporadic Non-Interval Colon Cancers 801 Thing Rinda Soong Matthew D Stachler Jennifer Nayor Molly Perencevich Jonathan Nowak Kunal Jajoo John R Saltzman Neal Lindeman Amitabh Srivastava Brigham and Womens Hospital Boston MA 93 Concomitant Loss of MSH6 and PCNA Expression A Putative Mechanism of Reduced MSH6 Expression in Microsatellite Stable Colorectal Cancer after Neoadjuvant Therapy 774 Bing Ren Reetesh K Pai Shih-Fan Kuan University of Pittsburgh Medical Center Pittsburgh PA 94 Clinicopathologic Features of Interval Colorectal Carcinomas in Inammatory Bowel Disease 836 Xiaofei Zhang Alexandros D Polydorides Icahn School of Medicine at Mount Sinai Hospital New York NY 95 Colorectal Adenocarcinoma with ALK Rearrangement Clinicopathologic and Molecular Characteristics 827 Evgeny Yakirevich Siraj M Ali Shamlal Mangray Michael Wheeler Kara A Lombardo Kyoung-Mee Kim Anthony J Gill Kai Wang Kyle Gowen Jeffrey S Ross Howard Safran Murray B Resnick RIH and Brown University Providence RI Foundation Medicine Inc Cambridge MA Samsung Medical Center Seoul Republic of Korea Royal North Shore Hospital St Leonards Australia Albany Medical College Albany NY 96 Objective Measurement of HER2 in Colorectal Adenocarcinomas Reveals Heterogeneity of the Proteins Extracellular Domain 649 Peter Chen David L Rimm Daniel Carvajal-Hausdorf Yale University School of Medicine New Haven CT Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016176 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016176 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 97 Comparison of Universal Screening for Lynch Syndrome in Small Bowel and Colorectal Adenocarcinoma Small Bowel Adenocarcinoma More Frequently Exhibits Lynch Syndrome-Associated Mismatch Repair Deciency but Does Not Harbor Sporadic MLH1 Deciency 825 Michelle Xia Aatur Singhi Reetesh K Pai University of Pittsburgh Medical Center Pittsburgh PA 98 PTEN- Key Molecule in Lynch Syndrome Related MicroRNA Deregulation in Colorectal Cancer 790 Aisha Sethi Stefan Costinean Prasanthi Kumchala Luciano Cascione Heather Hampel Carlo Croce Wendy L Frankel The Ohio State University Columbus OH Institute of Oncology Bellinzona Switzerland University of Nebraska Omaha NE 99 Identication of Copy Number Variation in Chromatin Regulators in Microsatellite-Stable Hereditary Non- Polyposis Colorectal Cancer 819 Chen Weixiang Ding Jun Gongli Hospital Pudong New Area Shanghai China 100 The Immune Microenvironment of Medullary Colon Cancer Differs from Other Microsatellite Unstable MSI Tumors A Gene Expression and Immunohistochemical Analysis of 105 Cases 678 Kenneth Friedman Stephanie M Wood Alexander S Brodksy Shaolei Lu Kara A Lombardo Dongfang Yang Anthony J Gill Murray B Resnick Rhode Island Hospital - Alpert Medical School at Brown University Providence RI Royal North Shore Hospital St. Leonards Australia 101 Multivisceral Transplant Is a Viable Treatment for Patients with Unresectable Intra-Abdominal Fibromatosis 652 Zhikai Chi Richard S Mangus Shaoxiong Chen Jingmei Lin Indiana University School of Medicine Indianapolis IN 102 Appendiceal Goblet Cell Carcinoid Tumors Findings after Denitive Resectionunderline 679 Kenneth Friedman Wai Chin Foo Susan C Abraham Asif Rashid Melissa W Taggart University of Texas M.D. Anderson Cancer Center Houston TX GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 103 Succinate Dehydrogenase SDH-Decient Renal Cell Carcinoma a Report of 7 Cases with an Emphasis on High Grade Morphologic Features 940 Xueli Hao Hikmat A Al-Ahmadie Anuradha Gopalan Sahussapont J Sirintrapun Samson Fine Satish K Tickoo Victor E Reuter Ying-Bei Chen Memorial Sloan Kettering Cancer Center New York NY 104 Paraganglioma Associated Renal Lesions 937 Sounak Gupta Jun Zhang Lori A Erickson Mayo Clinic Rochester MN 105 The Spectrum of Oncocytic Renal Tumors from Oncocytoma to Eosinophilic Variant Chromophobe Renal Cell Carcinoma Is There a Need to Sub-Classify and What Is the Malignant Potentialunderline underline 917 Ramya Gadde Ravi Barod Craig G Rogers Nilesh S Gupta Sean R Williamson Henry Ford Health System Detroit MI 106 Clinical Follow-Up of Renal Oncocytomas with Vascular Invasion 1077 Sara E Wobker Jonathan I Epstein The Johns Hopkins Medical Institutions Baltimore MD 107 Unclassied Renal Cell Carcinomas with Low-Grade Oncocytic Features A Histopathologic Study with Outcome 987 Martin J Magers Angela Wu Lakshmi P Kunju University of Michigan Ann Arbor MI 108 Using Next Generation Sequencing and Fluorescence In Situ Hybridization to Identify a Hemizygous Deletion of the RB1 Gene in Chromophobe Renal Cell Carcinoma Its Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma 982 Qingqing Liu Kristine M Cornejo Liang Cheng Lloyd Hutchinson Keith Tomaszewicz Ediz F Cosar Bruce A Woda Zhong Jiang University of Massachusetts Medical School and UMass Memorial Medical Center Worcester MA Indiana University School of Medicine Indianapolis IN 109 Clinico-Pathologic Analysis of 12 Cases of Primary Renal Glomus Family of Tumors 1047 Deepika Sirohi Jonathan I Epstein Bonnie L Balzer Oleksandr N Kryvenko Swetha Paluru Mariza de Peralta-Venturina Mahul B Amin Cedars-Sinai Medical Center Los Angeles CA The Johns Hopkins Hospital Baltimore MD University of Miami Miller School of Medicine Miami FL 110 A Reappraisal of Morphologic Differences between Renal Medullary Carcinoma RMC and Collecting Duct Carcinoma CDC after Exclusion of Newer Subtypes of Renal Cell Carcinoma RCC Report from the High-Grade Distal Nephron Adenocarcinoma HDNA International Consortium 1005 Chisato Ohe Cedars-Sinai Medical Center Los Angeles CA 111 A Novel Low Grade Morphologic Variant of Hereditary Leiomyomatosis-Renal Cell Carcinoma Syndrome- Associated Renal Cell Carcinoma HLRCC-RCC 1048 Steven Smith Deepika Sirohi Chisato Ohe Jonathan McHugh Jason Hornick Jigna Kalariya Sushil Karia Katie Snape Shirley Hodgson Scott Tomlins Rohit Mehra Mahul B Amin Virginia Commonwealth University Health System Richmond VA Cedars-Sinai Medical Center Los Angeles CA University of Michigan Ann Arbor MI Brigham and Womens Hospital Boston MA B T Savani Kidney Hospital Rajkot India St Georges Hospital London United Kingdom Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 177NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 177 112 Chromosome 6p Amplication Including the TFEB Gene A Novel Mechanism of Renal Cell Carcinoma Pathogenesis 1075 Sean R Williamson David J Grignon Laura Favazza Nilesh S Gupta Dhananjay A Chitale Nallasivam Palanisamy Henry Ford Health System Detroit MI Indiana University Indianapolis IN 113 Recurrent Alterations of Hippo Signaling Pathway Genes in Mucinous Tubular and Spindle Cell Carcinoma MTSCC of Kidney 1066 Aaron Udager Jesse K McKenney Pankaj Vats Fengyun Su Xuhong Cao Jincheng Pan Rui Wang Javed Siddiqui Alon Z Weizer Khaled Hafez J Stuart Wolf Ganesh Palapattu Saravana M Dhanasekaran Arul M Chinnaiyan Rohit Mehra University of Michigan Health System Ann Arbor MI Michigan Center for Translational Pathology Ann Arbor MI Cleveland Clinic Cleveland OH First Afliated Hospital Sun Yat-Sen University Guangzhou China 114 Clear Cell Papillary Renal Cell Carcinoma Shows Marked Depletion of Mitochondrial Content A Comparative Differential Diagnostic Study 1036 Judy Sarungbam Ed Reznik A Ari Hakimi Ann Bialik S Joseph Sirintrapun Hikmat Al Ahmadie Anuradha Gopalan Samson W Fine Ying-Bei Chen Chris Sander Victor E Reuter Satish K Tickoo MSKCC NY NY 115 Distinct Clinicopathological Features in Metanephric Adenoma Harboring BRAF Mutation 873 Anna Calio John N Eble Ondrej Hes Guido Martignoni Sean R Williamson Matteo Brunelli Adeboye O Osunkoya Lisha Wang Eva Comperat Mingsheng Wang Shaobo Zhang Kendra Curless Kristin Post Hsim-Yee Chang Lee Ann Baldridge Gregory MacLennan Rodolfo Montironi David J Grignon Liang Cheng University of Verona Verona Italy Indiana Univesity Indianapolis IN Charles Univesity Hospital Plzen Pilsen Czech Republic Henry Ford Health System Detroit MI Emory University Atlanta GA Fudan University Shangai Cancer Center Shangai China Groupe Hospitalier Pitie-Salpetriere Paris France Case Western Reserve University Cleveland OH Polytechnic University of the Marche Region Ancona Italy 116 Cystic Nephroma in Adults 875 Anna Calio John N Eble David J Grignon Brett Delahunt University of Verona Verona Italy Indiana University Indianapolis IN Wellington Medical School Wellington New Zealand 117 High Grade Renal Cell Carcinoma with Emperipolesis. Clinicopathological Immunohistochemical and Molecular-Genetic Analysis of 14 Cases 1027 Pavla Rotterova Petr Martinek Kristyna Kalusova Ivan Damjanov Saul Suster Isabel Alvarado-Cabrero Maris Sperga Marian Svajdler Kvetoslava Peckova Kristyna Pivovarcikova Ondrej Daum Milan Hora Michal Michal Ondrej Hes University Hospital Plzen Charles University Plzen Czech Republic University of Kansas Kansas KS Medical College of Wisconsin Milwaukee WI Centro Medico Mexico City Mexico East University Riga Latvia 118 Multicystic Chromophobe Renal Cell Carcinoma A Challenging Unusual Architectural Variant. Morphological Immunohistochemical and arrayCGH Analysis of 11 Cases 1010 Maria Pane Foix Ana Dunatov Petr Martinek Enric Condom-Mundo Saul Suster Maris Sperga Jose I Lopez Monika Ulamec Stela Bulimbasic Michal Michal Kvetoslava Peckova Kristyna Pivovarcikova Ondrej Daum Pavla Rotterova Kristyna Kalusova Milan Hora Ondrej Hes Bellvitge University Hospital Barcelona Spain University Split Split Croatia Medical Teaching School University Hospital Charles University Plzen Czech Republic Medical College of Wisconsin Milwaukee WI East University Riga Latvia Cruces University Hospital Barakaldo Spain University Hospital Zagreb Zagreb Croatia Medical Teaching School University Hospital Charles University Plzen Czech Republic 119 PTEN Expression in Chromophobe Renal Cell Carcinoma Versus Clear Cell Renal Cell Carcinoma 953 Gena Ibrahim Manal Gabril Christopher Howlett Western University London Health Sciences Centre London ON Canada 120 Characterization of Papillary Hyperplasia in Nephrectomy Specimens from Patients with Autosomal Dominant Polycystic Kidney Disease - A Study of 60 Cases 1072 Lu Wang Rajen Goyal Ondrej Hes Ximing Yang Northwestern University Feinberg School of Medicine Chicago IL Charles University Hospital Alej Svobody Plzen Czech Republic 121 Renal Tumors with Papillary Morphology 966 Max Kong Jianhong Li Fang-Ming Deng Peng Lee Jonathan Melamed Ming Zhou New York University New York NY 122 Application of ISUP Grading in a Series of Papillary Renal Cell Carcinoma Cases from a Tertiary Institution 845 Ashwin Akki Rodrigo A Ledezma Gladell P Paner University of Chicago Chicago IL Universidad de Chile Santiago Chile Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016178 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016178 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 123 Racial Disparity in Papillary Renal Cell Carcinoma 841 Adebowale Adeniran Abiodun Mafolasire Aaron Hartman Cayce Nawaf Peter A Humphrey Brian Shuch Yale University School of Medicine New Haven CT 124 Growth Pattern Analysis in Low Grade Clear Cell Renal Cell Carcinomas Prognostic Value and Biologic Signicance 897 Salvador Diaz-Cano Russel Sutherland Jane Moorhead Alfredo Blanes Richard Dobson Kings College HospitalKings College London London United Kingdom University of Malaga School of Medicine Malaga Spain 125 Comparison of Margin Status and Clinical Follow- Up between Simple Tumor Enucleation and Partial Nephrectomy of Small Renal Tumors 1071 Lu Wang Ian Hughes Connor Snarskis Gopal Gupta Maria M Picken Loyola University Chicago Maywood IL Loyola University Maywood IL Stritch School of Medicine Maywood IL 126 Needle Biopsy of Renal Masses Analysis of 121 Matched Biopsy and Resection Cases 942 Saul E Harari Daniel J Sassoon John Eble Liang Cheng Mohammed Idrees Helen E Michael David J Grignon Indiana University School of Medicine Indianapolis IN 127 Lymph Nodes Metastasis in Patients with Renal Cell Carcinoma Correlation with Histologic Subtype and Other Pathologic Features 997 Gabriel E Morey Jae Y Ro Luan D Truong Alberto G Ayala Steven S Shen Houston Methodist Hospital and Weill Medical College of Cornell University Houston TX 128 Clinical Utility of Comparative Genomic Array Testing for Unclassied and Advanced Stage Renal Cell Carcinomas 851 Nicole Andeen Xiaoyu Qu Tatjana Antic Scott Tykodi Min Fang Maria S Tretiakova University of Washington Seattle WA University of Chicago Chicago IL 129 High Fidelity of Driver Chromosomal Alterations among Primary and Metastatic Renal Cell Carcinomas Implications for Disease Evolution and Treatment 968 Erik Kouba Novae Simper John N Eble David J Grignon Mingsheng Wang Shaobo Zhang Lisha Wang Guido Martignoni Sean R Williamson Matteo Brunelli Claudio Luchini Anna Calio Liang Cheng Indiana University School of Medicine Indianapolis IN Fudan University Shanghai Cancer Center Shanghai China Universit di Verona Verona Italy Henry Ford Health System Detroit MI 130 Sunitinib Treatment Induces the Formation of Stem Cell-Like Cancer Cells in Clear Cell Renal Cell Carcinoma 981 Zsuzsanna Lichner Henriett Butz Roy Nofech-Mozes Sara Riad Andras Kapus George M Yousef Li Ka Shing Knowledge Institute St Michaels Hospital Toronto ON Canada University of Toronto Toronto ON Canada 131 Tumor Somatic Mutation Rate Predicts Response to Anti-PD-1 Therapy in RCC A Pilot Study 1053 Diana Taheri Maria Angelica Mendoza Rodriguez Mark W Ball Stephania M Bezerra Bert Vogelstein Kenneth Kinzler Janis Taube Charles Drake Mohamad E Allaf George J Netto Johns Hopkins Medical Institutions Baltimore MD Isfahan University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran 132 Higher Expression of CDKN2A Gene Is Potential Prognostic Marker for Clear Cell Renal Cell Carcinoma 1057 Eriny Tawedrous Samantha J Wala Rola Saleeb Fabio Rotondo Qiang Ding George M Yousef St. Michaels Hospital Li Ka Shing Knowledge Institute Toronto ON Canada University of Toronto Toronto ON Canada 133 EZH2 as a Novel Target for Aggressive Clear Cell Renal Cell Carcinoma 914 Paul Friedman Alana Christie Xian-Jin Xie Dinesh Rakheja James Brugarolas Payal Kapur University of Texas Southwestern Medical Center Dallas TX 134 Immunohistochemical Comparison of BAP1 Immunoexpression Status between Needle Biopsies and Nephrectomies in Clear Cell Renal Cell Carcinoma 913 Paul Friedman Farrah Homayoun Vitaly Margulis Jeffrey Cadeddu Dinesh Rakheja James Brugarolas Payal Kapur University of Texas Southwestern Medical Center Dallas TX 135 PNL2 An Adjunctive Biomarker for Renal Angiomyolipomas and PEComas 932 Previn Gulavita Christopher Fletcher Michelle Hirsch Brigham and Womens Hospital Boston MA 136 Identication of Urinary MiRNAs for the Assessment of Small Renal Masses 896 Ashley Di Meo Henriett Butz Maria D Pasic Michael Jewett Alexander Romaschin Eleftherios P Diamandis George M Yousef Li Ka Shing Knowledge Institute of St. Michaels Hospital Toronto ON Canada The Advanced Centre for Detection of Cancer at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital Toronto ON Canada University of Toronto Toronto ON Canada Princess Margaret Hospital University Health Network University of Toronto Toronto ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 179NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 179 137 Morphologic and Immunohistochemical Correlates of 99m Tc-sestamibi SPECTCT Imaging Findings of Renal Neoplasms 927 Michael A Gorin Steve P Rowe Mehrbod S Javadi Mohamad E Allaf Jonathan I Epstein Alexander Baras Johns Hopkins Baltimore MD 138 Spectrum of Phosphorylated STAT3 pSTAT3 Expression in a Large Cohort of Common Renal Tumors 1039 Benjamin Scheier Aaron Udager Tina Fields Dafydd Thomas Thomas J Giordano J Stuart Wolf Bruce Redman Lakshmi P Kunju University of Michigan Health System Ann Arbor MI GYNECOLOGIC AND OBSTETRIC PATHOLOGY 139 Expression of PD-L1 and PD-1 Positive Tumor Inltrating Lymphocytes in Ovarian Tumors 1103 Peter N Bonneau Luis F Carrillo Alexander C Mackinnon Medical College of Wisconsin Milwaukee WI 140 Expression of PD-L1 in Ovarian Tumors May Provide Potential Immunotherapy Candidates 1211 Opal L Reddy Itsushi P Shintaku Neda A Moatamed David Geffen School of Medicine at UCLA Los Angeles CA 141 B7-H4 Expression in Ovarian Serous Carcinoma A Study of 306 Tissue Samples 1171 Li Liang Yi Jiang Jun-song Chen Na Niu Jinsong Liu The University of Texas MD Anderson Cancer Center Houston TX The First Afliated Hospital of Nanjing Medical University Nanjing China 142 Objective Domain-Specic HER2 Measurement in Uterine and Ovarian Serous Carcinomas and Its Clinical Signicance 1109 Daniel Carvajal-Hausdorf Kurt Schalper Yalai Bai Jonathan Black Alessandro D Santin David L Rimm Yale University School of Medicine New Haven CT 143 OTUB1 Exhibts a Subtype-Specic Expression and Predicts Poor Prognosis by Promoting Tumor Progression in Ovarian Epithelial Cancer 1245 Yiqin Wang Midie Xu Weiwei Weng Qiongyan Zhang Xianrong Zhou Xiang Du Obstetrics and Gynecology Hospital of Fudan University Shanghai China Shanghai Cancer Center Shanghai China 144 Expression of Alcohol Dehydrogenase 5 in Ovarian Carcinoma Effect on Prognosis and Therapeutic Potential 1083 Eman Abdulfatah Giri Shailendra Rattan Ramandeep Mohammed F Daaboul Sharif Sakr Baraa Alosh Muhammad K Alsafadi Fatimah Alruwaii Vishakha Pardeshi Sudeshna Bandyopadhyay Adnan R Munkarah Rouba Ali-Fehmi WSU Detroit MI 145 Novel Marker GREB1 Is Frequently Expressed in -Major Ovarian Carcinoma Histotypes 1141 Kendra Hodgkinson Carlos Parra-Herran Barbara Vanderhyden Bojana Djordjevic Ottawa Health Research Institute University of Ottawa Ottawa ON Canada The Ottawa Hospital University of Ottawa Ottawa ON Canada 146 Usefulness of Napsin A Immunohistochemistry in the Diagnosis of Clear Cell Carcinoma of the Ovary 1100 Sarah Bell Darren Ennis Aoisha Hoyle Iain McNeish David Millan Queen Elizabeth University Hospital Glasgow Scotland United Kingdom Institute of Cancer Sciences University of Glasgow Glasgow Scotland United Kingdom 147 Clear Cell Carcinomas of the Ovary A Mono- Institutional Study of 73 Cases in China with Analysis of the Prognostic Signicance of Clinicopathologic Parameters and IMP3 Expression 1101 Rui Bi Xuxia Shen Weiwei Zhang Yufan Cheng Zheng Feng Xu Cai Wentao Yang Fudan University Shanghai Cancer Center Shanghai China School of Public Health Hong Kong Hong Kong 148 Mismatch Repair MMR Protein Deciency in Early Stage Ovarian Carcinomas. underlineunderline A Study by Spanish Ovarian Cancer Research Group GEICOunderlineunderlineunderline 1197 Jose Palacios Ana Gutierrez-Pecharroman Eva Cristobal Jose Antonio Lopez-Guerrero Ignacio Romero David Hardisson Francisco Vera Begona Vieites Angel Garcia Javier Ibarra Soa Hakin Rosa Guarch Encarna Andrada Santiago Montes Francisco Pastor Maria C Gomez Maria C Gomez Andres Poveda Hospital Universitario Ramon y Cajal Madrid Spain Instituto Valenciano de Oncologia Valencia Spain Spanish Ovarian Cancer Research Group Barcelona Spain 149 MMR Protein Expression in Ovarian Carcinoma A Clinicopathologic Study 1098 Dina Bassiouny Sharon Nofech-Mozes Nadia Ismiil Matthew Cesari Valerie Dube Guangming Han Elzbieta Slodkowska Hak Fai Chiu Eugene Hsieh Nim Li Magda Naeim Mahmoud Khalifa Fang-I Lu Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada 150 HNF1- Is Strongly Expressed in Ovarian Mucinous Carcinoma 1097 Dina Bassiouny Nadia Ismiil Matthew Cesari Valerie Dube Guangming Han Fang-I Lu Elzbieta Slodkowska Hak Fai Chiu Nim Li Magda Naeim Mahmoud Khalifa Sharon Nofech-Mozes Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016180 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016180 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 151 Mucinous Tumors Involving the Ovary GREB1 and Pax8 Immunopanel Identies Ovarian Primaries with High Sensitivity 1119 Bojana Djordjevic Sarah Strickland Kendra Hodgkinson Barbara Vanderhyden Carlos Parra- Herran The Ottawa Hospital University of Ottawa Ottawa ON Canada Ottawa Hospital Research Institute University of Ottawa Ottawa ON Canada 152 Analysis of Ovarian Mucinous Neoplasms by Single Nucleotide PolymorphismCopy Number Variation Assays 1221 Ozlen Saglam Jacob P Crowley Sean Yoder Robert M Wenham Anthony M Magliocco Moftt Cancer Center Tampa FL Affymetrix Santa Clara CA 153 A MicroRNA Whole Transcriptome Assay to Distinguish between Histological Subtypes of Ovarian Carcinomas 1092 Le Aye Jonas Pettersson Craig Stephens Miriana Moran Tiffany I Long Stephanie H Astrow Robert Makowsky Chris Roberts Louis Dubeau Pamela M Ward USC Los Angeles CA Response Genetics Los Angeles CA HTG Molecular Diagnostics Tucson AZ 154 Genomic Analysis of Low-Grade Serous Ovarian Tumors Associated with High-Grade Serous Carcinoma or Undifferentiated Carcinoma 1186 Rajmohan Murali Raghu Chandramohan Robert Soslow Donavan Cheng W Glenn McCluggage Memorial Sloan Kettering Cancer Center New York NY Illumina San Francisco CA Belfast Health and Social Care Trust Belfast United Kingdom 155 Combination of Ki-67 MCM2 p16 and p53 Expression Can Distinguish High Grade Serous Carcinoma From Low Grade Serous Tumors 1158 Sarah M Kelting Cherie Paquette Mark E Smolkin Amir A Jazaeri Megan R Barrett Mark H Stoler University of Virginia Charlottesville VA Women and Infants Hospital Providence RI MD Anderson Houston TX 156 Serous Psammocarcinoma Revisited A Single Institution Experience 1093 Keegan Barry-Holson Ann K Folkins Teri A Longacre Stanford University Medical Center Stanford CA 157 Ovarian Endometrioid Adenocarcinomas Morphology Associations and Outcomes in 79 Patients 1228 Annacarolina Silva Jennifer A Bennett Rouba Ali- Fehmi Sudeshna Bandyopadhyay Esther Oliva Dana-Farber Cancer Institute Boston MA Lahey Hospital and Medical Center Burlington MA Wayne State University Detroit MI Massachusetts General Hospital Boston MA 158 Microcystic Elongated and Fragmented MELF Pattern Invasion in Ovarian Endometrioid Carcinoma Immunohistochemical Prole and Prognostic Implications 1134 Allison Goldberg Lauren Cooper Daniel De Cotiis Norman Rosenblum Joanna Chan Thomas Jefferson University Philadelphia PA Hospital of University of Pennsylvania Philadelphia PA 159 Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations Which Are Commonly Present in Urothelial Carcinoma 1159 Francesca Khani Mairo L Diolombi Pallavi Khattar Weihua Huang John T Fallon Jonathan I Epstein Minghao Zhong The Johns Hopkins Hospital Baltimore MD New York Medical College Westchester NY 160 Whole Exon Sequencing of Malignant Brenner Tumor Differences from Conventional Urothelial Carcinoma 1160 Pallavi Khattar Francesca Khani Mairo L Diolombi Weihua Huang John T Fallon Jonathan I Epstein Minghao Zhong Westchester Medical Center at New York Medical College Valhalla NY John Hopkins University Baltimore MD 161 Glucocorticoid Receptor Expression in Ovarian Tumors 1089 Ghassan Allo Dhananjay A Chitale Sharon H Alford Adnan R Munkarah Ira Winer Manohar Ratnam Henry Ford Hospital Detroit MI Karmanos Cancer Institute Detroit MI 162 Biomarker Selection in Early Ovarian Cancer 1190 John J OLeary Sara OKane Sharon OToole John K OBrien Stephen R Pennington Dolores J Cahill Trinity College Dublin Dublin Ireland University College Dublin Dublin Ireland 163 Molecular Mechanism of Ovarian Tumor Induced Immunosuppression and Its Prevention by Metformin 1095 Animesh Barua SaRah McNeal McNeal Lindsey Franklin Paolo Gattuso Sameer Sharma Pincas Bitterman RUsh University Medical Center Chicago IL 164 Morphologic Features of High Grade Serous Carcinoma of AdnexalPeritoneal Origin Treated with Neo-Adjuvant Chemotherapy 1253 Anna Yemelyanova Anais Malpica Elizabeth D Euscher Preetha Ramalingam UT MD Anderson Cancer Center Houston TX 165 Patient Outcome Is Not Related to Chemotherapeutic Response Score CRS 1125 Elizabeth D Euscher Roland L Bassett Anna Yemelyanova Preetha Ramalingam Anais Malpica MD Anderson Cancer Center Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 181NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 181 166 Inter-Observer Agreement in Assessment of Response to Neo-Adjuvant Chemotherapy in Tubo-Ovarian High- Grade Serous Carcinoma 1229 Naveena Singh Ian Said Asma Z Faruqi Sarah L Leen Giorgia Trevisan Lynn Hirschowitz Raji Ganesan Jo Vella Glenn McCluggage Blake Gilks Steffen Boehm Barts Health NHS Trust London United Kingdom University College Hospital London United Kingdom Birmingham Womens Hospital Birmingham United Kingdom Royal Victoria Hospital Belfast United Kingdom Vancouver General Hospital Vancouver Canada 167 TLR4 and MAD2 Drivers of Chemoresistance in Ovarian Cancer 1099 Mark Bates Luke Gubbins Dorinda Mullen Eimear Lee Jacqui Barry-OCrowley Danielle Costigan Ciaran ORiain Cathy D Spillane Michael F Gallagher Cara Martin Amanda McCann Sharon OToole John J OLeary Trinity College Dublin Dublin 2 Ireland University College Dublin Beleld Dublin 4 Ireland Coombe Women Infants University Hospital Dublin 8 Ireland St Jamess Hospital Dublin 8 Ireland 168 Epidemiologic Dissociation between Two Subtypes of Molecularly Similar Tumors 1206 Julio Poveda Carmen Gomez-Fernandez Paula Espinal Ernesto Martinez-Duarte Elena Vrotsos Pan Yue Andre Pinto University of Miami Jackson Health System Miami FL University of Miami Miller School of Medicine Miami FL 169 Incidence of Occult Carcinomas in Fallopian Tubes in High-risk Patients A Prospective Study from North Shore LIJ Health System 1218 Sudarshana Roychoudhury Peter Farmer Cathy Fan Sharon Liang Hofstra North Shore -LIJ Health System Lake Success NY 170 Would Fallopian Tube Tissue Be Left Behind Quantitation of Tubal-Type Epithelium within Ovary at Time of Risk Reducing Salpingo-Oophorectomy Implications for Ovary Conserving Strategies 1177 Sarah Mahon Julie McFadden Noreen Gleeson Ciaran ORiain St. Jamess Hospital Dublin Ireland 171 Serial Sectioning and TP53 Sequencing of Occult Intraepithelial Lesions in Distal Fallopian Tubes Implications for the Origin of High-Grade Ovarian Serous Carcinoma 1234 Thing Rinda Soong Brooke E Howitt Helena M Ditzel Alexander Miron Frank Campbell Christopher P Crum Brigham and Womens Hospital Boston MA Case Western Reserve University Cleveland OH Covariance Biosciences Cleveland OH 172 Correlates of Physiologic and Neoplastic Human Fallopian Tube Stem Cells 1252 Wa Xian Yusuke Yamamoto Gang Ning Brooke E Howitt Molly Brewer Frank D McKeon Christopher P Crum National Cancer Center Research Institute Tokyo Japan The Jackson Laboratory Farmington CT Brigham and Womens Hospital Boston MA University of Connecticut Health Sciences Center Farmington CT University of Houston Houston TX 173 BRCA Status Can Be Determined Using FFPE Blocks a Feasibility Pilot Study 1087 Mohammad R Akbari Robert Royer Dina Bassiouny Nadia Ismiil Matthew Cesari Valerie Dube Guangming Han Fang-I Lu Elzbieta Slodkowska Magda Naeim Mahmoud Khalifa Sharon Nofech-Mozes Womens College Research Institute Womens College Hospital University of Toronto Toronto ON Canada Dalla Lana School of Public Health University of Toronto Toronto ON Canada Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada INFORMATICS 174 Stain Normalization in Digital Pathology Images Using Deep Learning 1561 Andrew Janowczyk Ajay Basavanhally Anant Madabhushi Case Western Reserve University Cleveland OH Inspirata Tampa FL 175 Development of New Fluorescence Virtual Slide System Equipped with the Liquid Crystal Filter Unit underline 1573 Hiroyuki Nozaka Tomisato Miura Zhongxi Zheng Hirosaki University Hirosaki Aomori Japan 176 Digital Image Analysis Reliably Estimates Bone Marrow Trephine Biopsy Cellularity 1558 Ashley S Hagiya Ali Etman Imran N Siddiqi Russell K Brynes Mohamed E Salama Keck School of Medicine University of Southern California Los Angeles CA University of Utah Salt Lake City UT 177 Fully Automated Accurate and Efcient Segmentation of Cancer Nuclei in Breast Pathology Images 1562 Andrew Janowczyk Hannah Gilmore Anant Madabhushi Case Western Reserve University Cleveland OH University Hospitals Cleveland OH 178 Computer Extracted Features of Nuclear Morphology from Digital HE Images Are Predictive of Recurrence in Stage I and II Non-Small Cell Lung Cancer 1583 Xiangxue Wang Andrew Janowczyk Yu Zhou Sagar Rakshit Vamsidhar Velcheti Anant Madabhushi Case Western Reserve University Cleveland OH Cleveland Clinic Cleveland OH Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016182 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016182 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 179 Pathology-Driven Cloud-Based Mutidisciplinary Team Meeting Software 1574 Fionnuala OConnell Tim Manning Brian Kelly Noel Murphy Paul Walsh Tara Jane Browne Michael W Bennett Cork University Hospital Cork Ireland nSILICO Cork Ireland Health Innovation Hub Cork Ireland 180 Live Remote Digital Microscopy in Peripheral Smear Evaluation Validation and Intraobserver Variability 1559 Diana M Haninger Mehdi Nassiri Elizabeth D Settembre Shanxiang Zhang Jiehao Zhou Indiana University School of Medicine Indianapolis IN 181 Implementation of Whole-Slide Imaging in the Routine Diagnosis in a Pathology Laboratory Consequences for File Storage 1577 Jose Ramirez Adela Saco Monica Hernandez Rosana Millan Margarita Mainar Paola Castillo Natalia Rakislova Jaume Ordi Hospital Clinic - Barcelona University Barcelona Spain ISGlobal Barcelona Spain 182 Can Polarizable Material Be Identied from Automatically Acquired Digital Slides 1560 Douglas J Hartman Morgan Jessup Simon Watkins Liron Pantanowitz University of Pittsburgh Medical Center Pittsburgh PA University of Pittsburgh School of Medicine Pittsburgh PA 183 Successful Secure HD Streaming Telecytology for Remote Cytologic Evaluation 1581 S Joseph Sirintrapun Dorota Rudomina Rusmir Feratovic Oscar Lin Memorial Sloan Kettering Cancer Center New York City NY 184 The Importance of Quality Control in Report Translation in an International Telepathology Practice 1564 Christopher J Kim Guofeng Wang Li-Rong Chen Jianyu Rao University of California Los Angeles Los Angeles CA Zhejiang University School of Medicine Hangzhou China 185 Central Histopathology Review of Essential Thrombocythemia and Polycythemia Vera Bone Marrow Biopsies via Digital Tools in a Clinical Trial on Pegylated Interferon Alfa-2a 1584 Delu Zhou Olga Pozdnyakova Rajan Dewar Robert P Hasserjian Ali Etman Ronald Hoffman Mohamed E Salama University of Utah Salt Lake City UT Brigham and Womens Hospital Boston MA University of Michigan Ann Arbor MI Massachusetts General Hospital Boston MA Mount Sinai School of Medicine New York NY 186 Digital Pathology and Anatomic Pathology Laboratory Information System Integration Supports Digital Surgical Pathology Sign-Outunderline 1557 Huazhang Guo Douglas J Hartman Jonhan Ho Anthony L Piccoli Matthew OLeary Jeffrey McHugh Joe Birsa Mark Nyman Curtis Stratman Jeffrey L Fine Samuel A Yousem Liron Pantanowitz University of Pittsburgh Medical Center Pittsburgh PA 187 The Inuence of Prior Laboratory Values and Patient Demographics on Physician Test Ordering Capturing Non-Linear Effects within a Population-Based Retrospective Cohort Study 1570 Eric Morgen Christopher Naugler Mount Sinai Hospital Toronto ON Canada University of Toronto Toronto ON Canada Calgary Laboratory Services Calgary AB Canada University of Calgary Calgary AB Canada 188 An Enterprise Approach for Pathology Reporting Utilizing PDF Functionality for the Electronic Medical Record 1579 S Joseph Sirintrapun Tianhao Zhao Evangelos Stamelos George Tsividakis Jonathan Gurman Mary J Mitchell Victor E Reuter David Klimstra Memorial Sloan Kettering Cancer Center New York City NY Wake Forest Baptist Health Winston Salem NC 189 Turn Around Time Monitoring in Anatomical Pathology Time to Event Analysis 1572 Nickolas Myles Douglas Filipenko Marin J Trotter University of British Columbia Vancouver BC Canada Providence Healthcare Vancouver BC Canada 190 Multi-Site Digital Pathology Validation Using Standardized Coded Checklists and Predetermined Discordance Tables 1582 Katy Wack Laura M Drogowski Murray Treloar Andrew Evans Jonhan Ho Anil Parwani Michael Montalto Omnyx LLC Pittsburgh PA Dr. Murray Treloar Medicine Professional Corp Port Hope ON Canada University Health System Toronto ON Canada University of Pittsburgh Medical Center Pittsburgh PA Ohio State University Wexner Medical Center Columbus OH 191 Machine Learning to Predict Successful Hematopoietic Progenitor Cell Collection from the Sysmex XN3000 Blood Analysis Data 1550 German Campuzano-Zuluaga Cesar A Llanos Joseph Zeitouni Artur Rangel-Filho University of Miami Health System Miami FL 192 MRI Derived Histologically Trained Maps of Epithelium Density Predict Prostate Cancer Presence 1565 Peter S LaViolette Amy Kaczmarowski Kenneth A Iczkowski Kenneth Jacobsohn Paul M Knechtges Mark Hohenwalter William See Medical College of Wisconsin Milwaukee WI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 183NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 183 193 Image Recognition Orientation and Visual Field Bias in Digital Pathology 1556 Sharon E Fox Richard S Vander Heide Charles Law Beverly E Faulkner-Jones LSU Health Sciences Center New Orleans LA Boston Childrens Hospital Boston MA Kitware Inc. Clifton Park NY Beth Israel Deaconess Medical Center Boston MA 194 The Use of Computer Vision in the Differential Diagnosis of Ovarian Carcinomas 1567 Xinyan Li Vassilios Morellas Nikolaos Papanikolopoulos Alexander M Truskinovsky University of Minnesota Minneapolis MN Roswell Park Cancer Institute Buffalo NY 195 Functional Validation of MicroRNA Activity Inferred by ActMiR in Bladder Cancer 1551 Mireia Castillo-Martin Ana Collazo Lorduy EunJee Lee Jun Zhu Carlos Cordon-Cardo Icahn School of Medicine at Mount Sinai New York NY 196 An Independent Variant-Level Assessment Exposes Gaps in Probe Design and Coverage in Sequencing- Based EGFR Testing 1549 Michelle Call Sushama Thakker Charlie Kim Glenda Anderson Farsight Genome Systems Sunnyvale CA 197 Hierarchical Clustering of Mutational Prole of Uterine Carcinosarcomas and Comparison with Uterine Endometrioid and Serous Adenocarcinomas 1569 Amir Momeni Boroujeni Elham Youse Remegio Maglantay Raavi Gupta Ning Neil Chen SUNY Downstate Medical Center Brooklyn NY 198 Data Analysis of RNA-Seq of the Bone Marrow from Patients with Myeloid Neoplasms Using Multiple Bioinformatic Pipelines 1578 Thomas Schneider Geoffrey Smith Scott Newman Linsheng Zhang Emory University Atlanta GA Winship Cancer Institute of Emory University Atlanta GA 199 Analysis of Available Clinical Trials for Targeted Therapies in Solid Tumors 1568 Susan Mockus Sara E Patterson Rangjiao Liu Cara Statz The Jackson Laboratory for Genomic Medicine Farmington CT 200 A Bioinformatics Software Pipeline for Identifying Causal Genetic Mechanisms of Antibiotic Resistance in Bacterial Pathogens 1571 Karthikeyan Murugesan Xinran Li Pramod Mayigowda Henry Lin Guiqing Wang Abhay Dhand Weihua Huang John T Fallon Nevenka Dimitrova Philips Research North America Cambridge MA New York Medical College Valhalla NY KIDNEYRENAL PATHOLOGY INCLUDING TRANSPLANTATION 201 Routine Clinical Use of Exome NGS for Diagnosis in Patients with Renal Disease 1601 Joseph Gaut Sanjay Jain John D Pfeifer Catherine E Cottrell Washington University St. Louis MO 202 IgA Dominant Post-Infectious Glomerulonephritis in the Pediatric Population 1613 Paul Persad Agnes Fogo Vanderbilt Nashville TN 203 Clinical Signicance of Glomerular IgG Deposits in IgA Nephropathy 1591 Nicole Andeen Anthony S Alvarado Sergey Brodsky Alice Hinton Tibor Nadasdy Charles Alpers Christopher Blosser Behzad Najaan Brad Rovin University of Washington Seattle WA Ohio State University Columbus OH 204 Relationship Between Glomerular Macrophage Numbers and the Oxford Classication of IgA Nephropathy 1622 Maria Fernanda Soares Clare MacEwen Aron Chakera Shuba S Bellur Ian SD Roberts Federal University of Parana Curitiba Parana Brazil Oxford University Hospitals NHS Trust Oxford Oxon United Kingdom University of Western Australia Perth Western Australia Australia 205 Quantitative Assessment of Density of Deposits in C3 Glomerulopathies 1608 Mark Lusco Agnes B Fogo Vanderbilt University Medical Center Nashville TN 206 PLA2R Membranous Nephropathy Has Greater C3 Deposition Than Non-Lupus PLA2R- Membranous Nephropathy 1624 Mirna Toukatly Behzad Najaan University of Washington Seattle WA 207 Comparison of Renal Biopsy Pathology in Adults and Children with Systemic Lupus 1606 Li Lei Craig Zuppan Loma Linda University Medical Center Loma Linda CA 208 ANA-Negative Renal-Limited Lupus Nephritis Is Associated with Poor Renal Outcomes 1614 David Portnoy Daphne Knicely Warren K Bolton James Cain Helen Cathro University of Virginia Charlottesville VA The Johns Hopkins University Baltimore MD Valley Nephrology Associates Roanoke VA 209 Utility and Patterns of C5b-9 and C4d Immunohistochemical IHC Staining in Thrombotic Microangiopathies TMA 1589 Mustafa Al-Kawaaz Steven Salvatore Surya Seshan Weill Cornell Medical College NY NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016184 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016184 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 211 Loss of Glomerular Basement Membrane Staining for COL4A5 in Alport Syndrome Correlates with Age at Diagnosis and Severity of Ultrastructural Alterations 1618 Samar Said Mary E Fidler Brooke McCann Lynn D Cornell Mariam Priya Alexander Samih Nasr Mayo Clinic Rochester MN 212 Clinical Signicance of the Pathological Evaluation of Non-Neoplastic Renal Tissue in Post-Radical Nephrectomy 1610 Madeleine Moussa Adiel Mamut Gena Ibrahim Patrick Luke Fulan Cui Neal Rowe Manal Gabril Western University London ON Canada 213 BK Virus Unveiling a Pathogen in 46 Autopsies of Allogeneic Stem Cell Transplant Recipients 912 Kenneth Friedman Rima Pai William F Glass Elizabeth Shpall Katy Rezvani Ala Abudayyeh Miao Zhang University of Texas MD Anderson Cancer Center Houston TX University of Texas Health Science Center at Houston Houston TX LIVER 214 Lymphocyte Inltration Is a Promising New Prognostic Factor for Hepatocellular Carcinoma 1661 Akimasa Hayashi Kento Misumi Junji Shibahara Junichi Arita Yoshihiro Sakamoto Kiyoshi Hasegawa Norihiro Kokudo Masashi Fukayama Graduate School of Medicine University of Tokyo Tokyo Japan 215 Poorly Differentiated Hepatocellular Carcinomas and Hepatocellular Carcinomas with a Brisk Lymphocytic Inltrate Are Enriched for PD-L1 Expression on Tumor Cells 1684 Michael Torbenson Taoc Mounajjed Robert R McWilliams Rondell Graham Mayo Clinic Rochester MN 216 BSEP and MDR3 Useful Immunohistochemical Markers for the Discrimination of Hepatocellular Carcinomas from Not Only Intrahepatic Cholangiocarcinomas but Also Hepatoid Carcinomas 1656 Kohei Fujikura Takashi Yamasaki Kyoko Otani Takanori Hirose Tomoo Itoh Yoh Zen Kobe University Kobe Hyogo Japan Hyogo Cancer Center Kobe Hyogo Japan 217 GATA4 Expression Is a Prognostic Factor of Recurrence in Hepatocellular Carcinoma 1691 Kijong Yi Rehman Abdul Yumin Chung Dong Ho Choi Dae Won Jun Seung Sam Paik Kiseok Jang Hanyang University College of Medicine Seoul Republic of Korea 218 Diagnostic Accuracy of the Liver Imaging Reporting and Data System LI-RADS for Hepatic Nodules in Cirrhotic Patients A 2 year Retrospective Analysis 1631 Hana Albrecht Richard Gilroy Ryan Ash Maura ONeil University of Kansas Medical Center Kansas City KS 219 The Prognostic Value of Mitotic Rate in the Fibrolamellar Variant of Hepatocellular Carcinoma in a Well-Characterized Series of 13 Cases Showing DNAJB1-PRKACA Transcript 1666 Andrea Jones Rondell Graham Rish K Pai Volkan Adsay Michael Torbenson Roger Moreira Mayo Clinic Rochester MN Mayo Clinic Scottsdale AZ Emory University Atlanta GA 220 Early Hepatocellular Carcinoma with High-Grade Atypia in Small Vaguely Nodular Lesions 1673 Hidenori Ojima Yohei Masugi Hanako Tsuijikawa Osamu Itano Yuko Kitagawa Michiie Sakamoto Keio University School of Medicine Tokyo Japan 221 Neuroglobin and Cytoglobin Regulators of Oxidative Stress Are Associated with Poor Prognosis in Hepatocellular Carcinoma 1675 Raghavendra Pillappa Jignesh G Parikh Wa Bibars Cameila Johns University of Tennessee Health Science Center Memphis TN University of MiamiJackson Memorial Hospital Miami FL 222 Aldoketoreductase Family 1B10 AKR1B10 Is a Sensitive Biomarker to Identify Well-Differentiated Hepatocellular Carcinoma 1635 Andrew Bandy Xiaoming You Haonan Li Jie Liao Sambasiva Rao Xiaoqi Lin Guang-Yu Yang Northwestern University Chicago IL 223 Investigating Predictive Models Based on Circulating Cell-Free INK4A DNA Methylation Alpha-Fetoprotein Platelet Count and Age for Diagnosis and Prognosis of Hepatocellular Carcinoma 1687 Rebecca Waters Yan Xie Jianli Dong Roger Soloway University of Texas Medical Branch Galveston TX 224 Associations of Tumor Response to Neoadjuvant TACE Following Liver Transplantation 1693 Yang Zhang William S Twaddell University of Maryland Baltimore MD 225 In-Situ Hybridization for Albumin RNA in Pediatric Liver Cancers Compared to Common Immunohistochemical Markers 1667 Anne K Koehne de Gonzalez Ladan Fazlollahi Amy Coffey Helen Remotti Stephen M Lagana Columbia University New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 185NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 185 226 Pathologic Features of Synchronous Hepatocellular and Renal Cell Carcinomas in Non-Cirrhotic Patients 1632 Lindsay Alpert Wendi Zhou Hanlin L Wang Lisa Yerian Lei Zhao Gladell P Paner John Hart University of Chicago Chicago IL UCLA Los Angeles CA Cleveland Clinic Cleveland OH University of Alabama at Birmingham Birmingham AL 227 Arginase Is Superior to Hepar for Distinguishing Clear Cell Hepatocellular Carcinoma from Clear Cell Tumors Metastatic to the Liver 1669 Brent Larson Deepti Dhall Maha Guindi Cedars-Sinai Medical Center Los Angeles CA 228 10 of Well Differentiated Hepatocellular Carcinomas Are Negative for Arginase-1 on Needle Biopsies An Important Diagnostic Pitfall 1643 Vishal Chandan Sejal S Shah Roger Moreira Tsung- Teh Wu Michael Torbenson Mayo Clinic Rochester MN 229 Combination of Astrocyte Elevated Gene 1 and Glypican 3 Immunochemistry Improves Diagnostic Accuracy of Hepatocellular Carcinoma 1642 Wenqing Cao Benedict Maliakkal Mark Orloff Meenal Sharma New York University Langone Medical Center New York NY University of Rochester Medical Center Rochester NY 230 Steatosis and Steatohepatitis in Hepatocellular Carcinoma What Is the Signicance 1692 Funda Yilmaz Umut Aykutlu Alper Uguz Deniz Nart Ahmet Coker University of Ege Faculty of Medicine Izmir Turkey 231 Diagnostic Utility of Clusterin Immunostaining in Differentiating Hepatocellular Carcinoma from Tumors of Other Origins 1695 Wendi Zhou Jamie Koo Hanlin L Wang Haiyan Liu Zongming E Chen Fan Lin UCLA Los Angeles CA Cedar Sinai Medical Center Los Angeles CA Geisinger Medical Center Danville PA 232 Hepar-1 Loss in TelangiectaticInammatory Hepatic Adenomas A Novel Observation with Potential Tumor Biology Implications 1665 Andrea Jones Rondell Graham Taoc Mounajjed Michael Torbenson Roger Moreira Mayo Clinic Rochester MN 233 Copper Deposition in Focal Nodular Hyperplasia and Inammatory Hepatic Adenoma 1645 Vishal Chandan Taoc Mounajjed Sejal S Shah Michael Torbenson Tsung-Teh Wu Mayo Clinic Rochester MN 234 Primary and Secondary Hepatic Presentation of Hodgkin Lymphoma A Multi-Institutional Study 1680 Rasha Salama Purva Gopal Maria Westerhoff Hwajeong Lee Jiehao Zhou Jingmei Lin Indiana University Indianapolis IN University of Texan Southwestern Medical Center Dallas TX University of Washington Seattle WA Albany Medical Center Albany NY 235 Aberrant Keratin Expression Is Common in Primary Hepatic Malignant Vascular Tumors A Potential Diagnostic Pitfall 1644 Vishal Chandan Hee Eun Lee Michael Torbenson Tsung-Teh Wu Mayo Clinic Rochester MN 236 TFE3 Immunohistochemistry Is Useful to Distinguish Epithelioid Hemangioendotheliomas from Angiosarcomas and Hemangiomas of the Liver 1671 Cheryl Mather Hsuan-Ying Huang Ting Ting Liu Benjamin Hoch Robert W Ricciotti Matthew Yeh University of Washington Seattle WA Kaohsiung Chang Gung Memorial Hospital Taiwan Taiwan NEUROPATHOLOGY OPHTHALMIC PATHOLOGY 237 Targeted Next-Generation Sequencing in the Molecular Proling of Lower-Grade Gliomas 1697 Jamal H Carter Catherine E Cottrell Eric J Duncavage Washington University St Louis MO 238 Absence of CMV Components in High Grade Gliomas by Real-Time PCR Immunohistochemistry and Chromogenic In-Situ Hybridization 1703 Gunes Guner Fausto Rodriguez Jessica Hicks Xiaobu Ye Stuart Grossman Peter Burger Charles G Eberhart Angelo M De Marzo Ravit Boger Matthias Holdhoff Johns Hopkins Medical Institutions Baltimore MD 239 Reclassication of Mixed Oligoastrocytic Tumors Including Glioblastoma with Oligodendroglioma Component by Genetics Integrated Diagnosis 1710 Seong-Ik Kim Yujin Kim Sung-Hye Park Seoul National University Hospital Seoul Republic of Korea 240 Utility of Whole Genome Single Nucleotide Polymorphism Microarray SNPM and Targeted Somatic Mutations Analysis in the Evaluation of Adult Brain Tumors 1711 Ravindra Kolhe Alka Chaubey Barbara R DuPont WonSok Lee Ashis K Mondal Amyn Rojiani Georgia Regents University Augusta GA Greenwood Genetic Center Greenwood SC 241 Genetic Alterations of EGFR in High Grade Gliomas and Its Prognostic Signicance 1714 Minju Lee So Young Kang Yeon-Lim Suh Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016186 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016186 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 242 Gliomas of Children and Young Adults-BRAFV600E Mutation 1701 Anupurva Dutta Hetakshi Kurani Aliasgar Moiyadi Prakash Shetty Jayant Sastri Tejpal Gupta Rakesh Jalali Sridhar Epari TMC Mumbai India 243 Pangenomic Analysis of BRAF Genomic Alterations Across All Types of Brain Tumors Reveals Expanded Opportunities for Targeted Therapies 1699 Zachary Chalmers Juliann Chmielecki Julia A Elvin Jo-Anne Vergilio James Suh Shakti H Ramkissoon Garrett Frampton Vincent A Miller Philip J Stephens Jeffrey S Ross Foundation Medicine Inc. Cambridge MA Brigham and Womens Hospital Boston MA Albany Medical College Albany NY 244 Thyroid Transcription Factor-1 Is a Useful Maker in Distinguishing Subependymal Giant Cell Astrocytoma and Other Mimickers 1704 Jen-Fan Hang Chih-Yi Hsu Donald M-T Ho Taipei Veterans General Hospital Taipei Taiwan 245 Infratentorial Ependymomas Clinicopathological and Immunohistochemical Characterization 1709 Gordana Juric-Sekhar Tatsuya Ozawa Jason K Barber Eric C Holland University of Washington Seattle WA Fred Hutchinson Cancer Reseach Center Seattle WA Universitiy of Washington Seattle WA 246 Mutational Proling of Ependymomas by Next- Generation Sequencing and the Potential Correlation with Clinical Outcome 1730 Yuan Rong Hope T Richard Catherine I Dumur Department of Pathology Virginia Commonwealth University Richmond VA 247 Targeted Next Generation Sequencing Reveals Unique Mutation Prole of Primary Melanocytic Tumors of the Central Nervous System 1721 Rajmohan Murali Johannes van de Nes Marco Gessi Antje Sucker Inga Moeller Mathias Stiller Susanne Horn Simone Scholz Carina Pischler Nadine Stadler Bastian Schilling Lisa Zimmer Uwe Hillen Richard A Scolyer Michael Buckland Libero Lauriola Torsten Pietsch Andreas Waha Dirk Schadendorf Klaus Griewank University Hospital Essen Essen Germany University of Bonn Medical Center Bonn Germany Medical University of Graz Graz Austria Royal Prince Alfred Hospital Sydney Australia Catholic University Rome Italy Memorial Sloan Kettering Cancer Center New York NY 248 Intracranial Fibrosarcomas Clinicopathologic Characteristics in 9 Patients 1707 Bryan Iorgulescu Brigham and Womens Hospital Boston MA 249 MiR-16 but Not MiR-519 Suppresses Tumor Cell Proliferation in Meningiomas via HuR Inhibition 1698 Jean-Matthieu Casse Abderrahim Oussalah Charlene Vigouroux Lydia Brochin Deborah Helle Rose Ghemrawi Sandra Lomazzi Helene Busby-Venner Nicolas Gambier Julien Scala-Bertola Jean-Louis Gueant Jean-Michel Vignaud Shyue-Fang Battaglia- Hsu Guillaume Gauchotte Faculty of Medicine University of Lorraine Vandoeuvre-les-Nancy France University Hospital of Nancy Nancy France University Hospital of Nancy Vandoeuvre-les-Nancy France University of Lorraine Vandoeuvre-les-Nancy France 250 Atypical TeratoidRhabdoid Tumors ATRTs of the Sellar Region in Adults Characterization of Five Cases 1724 Michael Paolini Benjamin R Kipp William R Sukov Aditya Raghunathan Emily G Barr Fritcher Derick M Aranda Karen SantaCruz Sadeq Al-Dandan Pete Fisher William McDonald Charles P Bondurant Grant Van Dyke Darkow Caterina Giannini Joseph E Parisi Mark E Jentoft Mayo Clinic Rochester MN Northwestern University Chicago IL University of New Mexico Albuquerque NM King Fahad Medical City Riyadh Saudi Arabia North Valley Hospital Kalispell MT Abbott Northwestern Hospital Minneapolis MN Boone Hospital Center Columbia MO 251 Utility of PIT-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas 1713 Julieann Lee Melike Pekmezci Arie Perry Tarik Tihan University of California San Francisco San Francisco CA 252 SSTR2a Status and Response to Somatostatin Analogues for Acromegaly 1715 Giselle Lopez Lewis S Blevins Arie Perry University of California- San Francisco San Francisco CA 253 Tumor-like Mass Arising as a Side Effect of Intrathecal Therapeutic Stem Cell Injections 1720 Michael B Miller Saad Mir Indira Guleria John H Chi Aaron L Berkowitz Keith L Ligon Brigham and Womens Hospital Boston MA Dana Farber Cancer Institute Boston MA 254 Chemotherapy Exposure Is Associated with Loss of Heterochromatin Increased Oxidative Stress and Microglial Activation in the Frontal Cortex 1732 Matthew Torre Mel Feany Brigham and Womens Hospital Boston MA Harvard Medical School Boston MA 255 CA1-Predominant Hippocampal Sclerosis in Medically Refractory Temporal Lobe Epilepsy 1702 Jordan M Gales Ruta Yardi Lara Jehi Richard Prayson Cleveland Clinic Cleveland OH Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 187NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 187 256 Expression of Nuclear Receptor NR4A3 in Multiple System Atrophy and Dementia With Lewy Bodies 1726 Itzel Pineda Nancy Edwards David Goldstein Abhik Ray-Chaudhury NINDS NIH Bethesda MD 257 Impact of Cerebral Amyloid Angiopathy on the Integrity of the Blood Brain Barrier 1716 Shino Magaki Zhaoyi Tang Darrick Lo Spencer Tung Harry V Vinters University of California Los Angeles UCLA Medical Center and David Geffen School of Medicine Los Angeles CA 258 Slide-Free Histology Via MUSE Ultraviolet Surface Excitation Microscopy for Imaging Unprocessed Tissue Applications in Neuropathology 1712 Mirna Lechpammer Kiarash Shahlaie Farzad Fereidouni Zachary T Harmany Alex R Krueger Richard Levenson University of California Davis Sacramento CA 259 Succinate Dehydrogenase B SDHB Immunohistochemistry Is an Effective Alternative to SDH Histochemistry in the Evaluation of Muscle Biopsies 1729 Michael Punsoni Kara A Lombardo Shamlal Mangray Edward G Stopa Evgeny Yakirevich Brown University and Rhode Island Hospital Providence RI 260 Low Percentage of Subsarcolemmal Mitochondrial Aggregates Is Associated with Cytochrome c Oxidase Deciency in Muscle of Children with Suspected Mitochondrial Disorder 1719 LiLi Miles Paul Horn Michael Miles Nemours Childrens Hospital Orlando FL Cincinnati Childrens Hospital Cincinnati OH 261 Histopathologic Features of Peripheral Nerve Sheath Tumors Involving the Eye and Ocular Adnexa 1734 Mingjuan L Zhang Maria J Suarez Fausto Rodriguez Johns Hopkins University School of Medicine Baltimore MD 262 Histopathological Study of 167 Cases of Blind Painful Eyes A Topographic Analysis 1736 Pablo Zoroquiain Mohammed Qutub Natalia Vila Patrick Logan Will Binotti Miguel N Burnier McGill University Montreal QC Canada 263 Malignant Apocrine Tumors of the Eyelid in a Review of 5453 Specimens 1737 Pablo Zoroquiain Sultan Aldrees Mohammed Qutub Patrick Logan Leonardo Dias Miguel N Burnier Mcgill University Montreal QC Canada 264 Combinatorial Targeted Next-Generation Sequencing and Cytogenetic Microarray Proling Identify Novel Molecular Mutations in Uveal Melanoma 1731 James Solomon David Brown Frances Wu Marie dellAquila John A Thorson Jonathan H Lin University of California San Diego San Diego CA 265 PD-L1 Expression in Intraocular Malignant Melanomas. Correlation with Morphologic Patterns and Outcome 1718 Aoife McCarthy Vanessa Moreno Xu Naizhen Susan Kennedy Maria J Merino The Royal Victoria Eye and Ear Hospital Dublin Ireland National Cancer Institute Bethesda MD 266 Intraocular Malignant Melanoma Correlation of Morphological and Molecular Findings with Outcome in an Irish Cohort 1717 Aoife McCarthy Vanessa Moreno Xu Naizhen Susan Kennedy Maria J Merino The Royal Victoria Eye and Ear Hospital Dublin Ireland National Cancer Institute National Institutes of Health Bethesda MD 267 Conjunctival Melanomas Harbor BRAF Mutations Conrmatory Exome Sequencing Analysis of 409 Cancer-Related Genes 1705 Margaret P Holmes Diana Bell Rajesh Singh Raja Luthra Russell Broaddus Michael T Tetzlaff Bita Esmaeli University of Texas MD Anderson Cancer Center Houston TX PULMONARY PATHOLOGY INCLUDING MEDIASTINAL 268 Salivary Gland-Type Primary Tumors of the Lung A Systematic Review 1905 Emilian Racila Erin Maxeld University of Minnesota Minneapolis MN 269 Are There Biologic Relationships between Pulmonary Adenobromas and Breast Fibroadenomas 1865 Nicola Fusco Elena Guerini-Rocco Davide Tosi Marco Maggioni Letterio Runza Claudia Augello Caterina Fumagalli Davide Vacirca Giulia Ercoli Silvano Bosari Massimo Barberis Stefano Ferrero Fondazione IRCSS Ca Granda - Ospedale Maggiore Policlinico Milan Italy European Institute of Oncology Milan Italy University of Milan Milan Italy 270 Aggressive B-cell Lymphomas of the Respiratory System Histologic Immunohistochemical and Genetic Evaluation of a Large Series 1896 Yalda B Naeini Annie Wu Dennis OMalley UCLA Los Angeles CA Clarient Pathology Services Aliso Viejo CA 271 Non-neoplastic Pulmonary Parenchymal Findings in Patients Undergoing Lung Resection for Mass Lesions 1870 Yin Hung Gary M Hunninghake Rachel K Putman Lynette M Sholl Marina Vivero Brigham and Womens Hospital Boston MA 272 Histologic Patterns of Resected Lung Adenocarcinoma Brain Metastases and Correlation with Molecular Analysis 1929 Laura N Toth Laura J Tafe Dartmouth-Hitchcock Medical Center Lebanon NH Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016188 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016188 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 273 Caveolin-1 Enhances Brain Metastasis in Lung Cancer Associated with SNAILunderline 1882 Jae-Hyuk Lee Kyung-Hwa Lee Kyung-Sub Moon Ji Shin Lee Chan Choi Chonnam National University Hwasun Hospital Jellanam-do Republic of Korea 274 Mcl-1 Protein Expression and MCL1 Gene Amplication in Non Small Cell Lung Cancer NSCLC 1860 Siddhartha Dalvi Sungeun Kim Christine E Sheehan Jeffrey S Ross Albany Medical College Albany NY 275 KRAS Mutations Are Predictive of Outcome in Patients with Pulmonary Sarcomatoid Carcinoma 1891 Mitra Mehrad Pimpin Incharoen Marina Nikiforova Humberto Trejo Bittar Sanja Dacic University of Pittsburgh Medical Center Pittsburgh PA Mahidol University Bangkok Thailand 276 Diagnostic Utility of Orthopedia Homeobox OTP in Pulmonary Carcinoid Tumor 1897 Daisuke Nonaka George Papaxoinis Was Mansoor The Christie Hospital Manchester United Kingdom The University of Manchester Manchester United Kingdom 277 Neuroendocrine Markers Possible Predictive Factors for Survival in Small Cell Lung Carcinoma 1883 James Lee Zahra Maleki Johns Hopkins Hospital Baltimore MD 278 Expression of Programmed Death-Ligand 1 in Small Cell Lung Cancer May Correlate with Better Patient Outcome Analysis of 29 Cases 1931 Pamela Villalobos Kathryn A Gold Edwin Parra Barbara Mino Jaime Rodriguez-Canales Reza J Mehran Cesar A Moran Ignacio I Wistuba Bonnie Glisson Neda Kalhor MD Anderson Cancer Center Houston TX 279 Programmed Death Ligand-1 PD-L1 Expression in Squamous Cell Carcinoma from Different Anatomic Sites 1852 Sabina Babayeva Hongfeng Zhang Michael Fanucchi Rocco Lafaro Yasmin Yusuf John T Fallon Minghao Zhong New York Medical College Valhalla NY Central Hospital of Wuhan Wuhan China 280 Comprehensive Analysis of EGFR Mutation Status in Lung Adenocarcinoma Combined with Nonadenocarcinoma Component 1912 Mee Sook Roh Hyoun Wook Lee Dong-A University College of Medicine Busan Korea Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon Korea 281 The High Delta Ct Value of EGFR Exon 19 Deletion by PNA-Mediated PCR Clamping Can Predict Longer Progression-Free Survival in Non-Small Cell Lung Cancer 1859 Yu-Deok Choi Chonnam National University Medical School Gwangju Republic of Korea 282 Clinical Detection of Resistance to EGFR Inhibitors in Lung Cancers by Next Generation Sequncing 1854 Deborah Belchis Li-Hui Tseng Lisa Haley Peter B Illei Christopher D Gocke James R Eshleman Ming-Tseh Lin Johns Hopkins School of Medicine Baltimore MD National Taiwan Univeristy Taipei Taiwan 283 Janus Kinase 3 JAK3 Aberrations in Non-Small Cell Lung Cancer 1928 Laura N Toth Christopher I Amos Konstantin H Dragnev Gregory J Tsongalis Laura J Tafe Dartmouth-Hitchcock Medical Center Lebanon NH Norris Cotton Cancer Center Lebanon NH 284 Predictors of High Levels of Mutant cfDNA in Plasma from Patients with Advanced Lung Adenocarcinoma 1922 Lynette M Sholl Prodipto Pal Ryan S Alden Nora Feeney Cloud Paweletz Adrian Sacher Geoffrey R Oxnard Brigham and Womens Hospital Boston MA Dana Farber Cancer Institute Boston MA Belfer Center for Applied Cancer Science Boston MA 285 Evaluation of Genomic Complexity in Next-Generation Sequencing of T1 vs Stage IV Non-Small Cell Lung Cancer 1909 Amanda J Redig Christine Lydon Pasi A Janne Lynette M Sholl Dana-Farber Cancer Institute Boston MA Harvard Medical School Boston MA Brigham and Womens Hospital Boston MA 286 Next Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Testing Yields More Actionable Results 1892 Mitra Mehrad Marina Nikiforova Humberto Trejo Bittar Sanja Dacic University of Pittsburgh Medical Center Pittsburgh PA 287 Inactivation of BRCA1 Associated Protein-1 BAP1 in Mesothelioma. Immunohistochemical and Molecular Genetic Study of 94 Cases 1862 Anna Felisiak-Golabek Bartosz Wasag Zengfeng Wang Piotr Czapiewski Wojciech Biernat Jerzy Lasota Markku Miettinen National Cancer Institute Bethesda MD Medical University of Gdansk Gdansk Poland 288 Absence of Nuclear BAP1 Protein Expression Is Highly Sensitive for Loss-of-Function BAP1 Genomic Alterations in Malignant Mesothelioma 1898 Prodipto Pal Fei Dong Marina Vivero Brigham and Womens Hospital Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 189NEXTGENERATION LEARNING 2016 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 189 289 Loss of p16INK4A Expression Predicts Worse Outcome in Thymic Carcinoma 1849 Scott W Aesif Marie-Christine Aubry Eunhee S Yi Sarah M Jenkins Grant Spears Anja C Roden Mayo Clinic Rochester MN TECHNIQUES INCLUDING ULTRASTRUCTURE 290 Clear Cell Renal Cell Carcinomas with Clear Cell Tubulopapillary Renal Cell Carcinoma-Like Features A Comparative Ultrastructural Study 2045 Nuria Juanpere Mercedes Simon Ivonne Vazquez Raquel Albero Marta Salido Anna Puiggros Albert Frances Laia Serrano Sergio Serrano Josep Lloreta Hospital del Mar-PSMar Barcelona Spain Pompeu Fabra University Barcelona Spain Autonomous University of Barcelona Barcelona Spain 291 Neuroendocrine and Non-Neuroendocrine Synaptophysin Expression in Prostatic Adenocarcinoma An Immunohistochemical qRT-PCR and Ultrastructural Study 2055 Josep Lloreta Nuria Juanpere Silvia Hernandez Alba Font Marta Lorenzo Lluis Fumado Jose A Lorente Ivonne Vazquez Raquel Albero Laia Serrano Sergio Serrano Hospital del Mar-PSMar Barcelona Spain Pompeu Fabra University Barcelona Spain Autonomous University of Barcelona Barcelona Spain Hospital Quirn Barcelona Spain 292 Drug Induced Phospholipidosis in Kidney Ultrastructural Features 2088 Guanjun Xia Sirma Koutzaki Shahad Abdulameer Shraddha Patel Suganthi Soundararajan Drexel University College of Medicine Philadelphia PA 293 Agonal-Stress Vesicles Detected on Ultrastructural Examination in Pediatrics Potential Mimicker of Metabolic Disease 2043 John Hicks Eric P Wartchow Debra Keaney Gary Mierau Texas Childrens Hospital and Baylor College of Medicine Houston TX Childrens Hospital Colorado Aurora CO 294 Comparison of Three TTF-1 Antibody Clones on Non- Small Cell Lung Carcinomas with Correlation of IHC Expression mRNA Levels and Patient Outcome 2081 Pamela Villalobos Carmen Behrens Edwin Parra Barbara Mino Jaime Rodriguez-Canales MD Anderson Cancer Center Houston TX 295 TFE3 Immunohistochemistry A Comparison of Two Methods with Discussion of the Implications for the Diagnosis of TFE3-Rearranged Neoplasms 2069 Rosalind Sandell Allen M Gown Andrew L Folpe Mayo Clinic Rochester MN PhenoPath Laboratories Seattle WA 296 Direct IHC by Using PolyHRP Labeled Trastuzumab Herceptin - A Potential New Companion Diagnostic Test for Herceptin Treatment 2084 Li Juan Wang Yihong Wang Song Q Zhao Yonghua Zhang Zhiqing Zhang Brown University Alpert School of Medicine Providence RI St Mary Hospital Madison WI Novodiax Hayward CA 297 Whole Slide Digital Imaging and Analysis of a PD- L1 Immunohistochemical Assay Is Quantiably Reproducible 2033 Jarish Cohen Sarah Bowman Daniel E Roberts Vighnesh Walavalkar Laura Laszik Zoltan Laszik University of California San Francisco San Francisco CA 298 Immunohistochemical Double and Triple Stain Strategies with CD8 CD103 PD-1 FOXP3 and CK818 in Colon Adenocarcinomaunderline 2091 Wei Yuan Jillian Tyrrell David Tacha Biocare Medical Concord CA 299 Optimization of Rapid Immunohistochemical Stains on Frozen Tissue Sections 2054 Haiyan Liu Song Q Zhao Yonghua Zhang Zhiqing Zhang Fan Lin Geisinger Medical Center Danville PA St. Marys Hospital Madison WI NovoDiax Inc. Hayward CA 300 Breast Biomarkers Can Be Reliably Tested on Tissue Fixed and Processed by Same Day Automated Microwave-Assisted Method 2071 Elzbieta Slodkowska Fang-I Lu Wedad Hanna Houman Nasi Guangming Han Patrice Boulianne Sharon Nofech-Mozes Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada 301 Digital Image Analysis Requires the Supervision by the Pathologist A Study on Immunohistochemical Scoring 2080 Pamela Villalobos Edwin Parra Barbara Mino Kathryn ODonnell Jaime Rodriguez-Canales MD Anderson Cancer Center Houston TX UT Southwestern Medical Center Dallas TX 302 Successful IHC Staining of Pancreatic Tissue after Optical Clearing for Advanced Imaging 2070 Paul D Simonson Ronnie Das Eric J Seibel Melissa P Upton University of Washington Seattle WA 303 Multiplex and Multispectral Analysis of Immune Cells in Tumor Draining Lymph Nodes of the Axilla in Breast Cancer 2039 Syed Gilani Chichung Wang Clifford C Hoyt Alejandro Contreras University of Texas M.D. Anderson Cancer Center Houston TX PerkinElmer Inc. Hopkinton MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016190 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016190 POSTER SESSION III Tuesday March 15 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 304 Validation of Multiplex Immunouorescence Assays for Use in Analysis of Tumour Inltrating Lymphocytes 2056 James Manseld Henry Galletta Richard Byers Kenneth Oguejiofor University of Manchester Manchester United Kingdom PerkinElmer Inc. Hopkinton MA 305 Development of Multiplex Immunouorescence Assays to Characterize the Tumor Microenvironment 2067 Sandra Rost Chenery Lowe Cecile M Chalouni Hartmut Koeppen Genentech South San Francisco CA 306 Immunoproling in Solid Tumors Development of a 6-plex Imaging Assay To Characterize Inltrating Immune Status in Solid Tumor Sections 2057 James Manseld Kristin Roman Chichung Wang Junya Fujimoto Ignacio I Wistuba Jing Wang Steven Lin Clifford C Hoyt PerkinElmer Hopkinton MA MD Anderson Houston TX 307 Correlation of Flow Cytometry Analysis of Minimal Residual Disease MRD in Myeloma to Serum Free Light Chain FLC Nephelometry Serum Protein Electrophoresis SPEP and Bone Marrow Chromogenic In Situ Hybridization CISH 2061 Drew Nedved Wei Cui Mark T Cunningham Da Zhang Janet Woodroof Kansas University Medical Center Kansas City KS PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PMPROFFERED PAPERS Tuesday March 15 2016 100 PM - 245 PM CC BR 6A SECTION A - INFORMATICS CHAIRED BY ULYSSES BALIS AND GAURAV SHARMA 100 Development of a Cloud-Based Histology Database for Collaborative Cancer Research 1552 Ke Cheng HistoWiz Inc Brooklyn NY SUNY Downstate Medical Center Brooklyn NY 115 HCV Genie V 2.0 A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus HCV Genotype Line Probe Assay 1554 Alex Dussaq Abha Soni Christopher D Willey Seung L Park Shuko Harada UAB Birmingham AL Community Health Systems Franklin TN 130 Assessment of Workload Measures in Anatomic Pathology 1548 Gareth W Bryson Queen Elizabeth University Hospital Glasgow United Kingdom 145 Exploring Oculus Rift for Viewing Whole Slide Images in a Virtual Reality Environment 1575 Liron Pantanowitz Navid Farahani Brian J Kolowitz Robert Post Teppituk Krinchai Isthiaque Ahmed Sara E Monaco Jeffrey L Fine Jon Duboy Douglas J Hartman University of Pittsburgh Medical Center Pittsburgh PA 200 Evaluating Reproducibility of Computer Extracted Histologic Image Features for Predicting Biochemical Recurrence in Prostate Cancer A Multi-Site Multi- Scanner Study 1566 Patrick Leo George Lee Anant Madabhushi Case Western Reserve University Cleveland OH 215 Machine-Readable Structured Pathology Report Data A Requirement for Pathologists Computer Assisted Diagnosis pCAD in Breast Cancer Signout 1555 Jeffrey L Fine Michelle Heayn Navid Farahani University of Pittsburgh School of Medicine Pittsburgh PA 230 Robotic Telecytology for Successful Remote Cytologic Evaluation without On-Site Cytopathology Stafng 1580 S Joseph Sirintrapun Dorota Rudomina Rusmir Feratovic William Alago Robert Siegelbaum Oscar Lin Memorial Sloan Kettering Cancer Center New York City NY CC BR 6C SECTION B - AUTOPSY CHAIRED BY CHRISTINE VANBEEK AND PAISIT PAUEKSAKON 100 The Role of Communication between Physician Pathologist and Family in Autopsy Rate 15 Justin Juskewitch Michael Paolini Joseph J Maleszewski R Ross Reichard Marie-Christine Aubry Mayo Clinic Rochester MN 115 Coroner Autopsy Findings in Medical Center Quality Assurance 6 John B Carter M John Spalding Lexington Medical Center West Columbia SC 130 Our Rapid Research Autopsy Program A Solid Platform for Next Generation Clinical Trials 2 Prashant Bavi Hamidreza Sharifzad Jagdish Butany Anthony Joshua Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 191NEXTGENERATION LEARNING 2016 191 PROFFERED PAPERS Tuesday March 15 2016 100 PM - 245 PM 145 Immune-Related Adverse Events irAEs Following CTLA-4 and PD-1PD-L1 Blockade in Advanced Melanoma A Comprehensive Rapid Autopsy Study 3 Prashant Bavi Rasmus Kiehl Oyedele Adeyi Ozgur Mete Carmen Avila-Casado Hamidreza Sharifzad Anthony Joshua Jagdish Butany Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 200 Medical Renal Diseases Are Frequent but Often Unrecognized in Adult Autopsies 22 Marie Perrone Anthony Chang Kammi J Henriksen University of Chicago Chicago IL 215 Hematopoietic Cell Transplant Kidney Findings at Autopsy 5 Brian T Brinkerhoff Donald C Houghton Megan Troxell OHSU Portland OR 230 Quantitation of Oil Red O Staining Via Digital Imaging Analysis in the Evaluation for Pulmonary Fat Embolization at Autopsy 4 Melissa M Blessing Toby C Cornish John R Lehman Sarah M Jenkins Joseph J Maleszewski Marie Christine Aubry Peter T Lin Mayo Clinic Rochester MN Johns Hopkins University Baltimore MD CC 602-604 SECTION C - NEUROPATHOLOGY CHAIRED BY ANAT STEMMER-RACHAMIMOV AND MARIA MARTINEZ-LAGE ALVAREZ 100 Molecularly Dened Adult Gliomas with Known ATRX Status Does TERT Have an Additional Prognostic Role 1725 Melike Pekmezci Kyle M Walsh Annette Molinaro Paul A Decker Helen M Hansen Hugues Sicotto Terri Rice Tom Kollmeyer Lucie McCoy Gobinda Sarkar Alissa A Caron Arie Perry Caterina Giannini Tarik Tihan Mitchel S Berger Joseph Wiemels Jeanette Eckel-Passow Dan Lachance John Wiencke Robert B Jenkins Margaret Wrensch University of California San Francisco San Francisco CA 115 The High Expression of Programmed Death-1 Ligand-1 PD-L1 and Its Receptor PD1 Correlates with a Poorer Prognosis In Glioblastomas 1706 Miguel A Idoate Inigo Arana Adriana Hogeboom Jose I Echeveste Alvaro Lopez-Janeiro Ricardo Diez-Valle Luis D Mejias Sosa Francisco Guillen University of Navarra Pamplona Navarra Spain 130 Targeted Next Generation Sequencing Panel GlioSeq Provides Comprehensive Genetic Proling of CNS Tumors 1722 Marina Nikiforova Abigail I Wald Somak Roy Ronald Hamilton Yuri E Nikiforov Craig Horbinski University of Pittsburgh Medical Center Pittsburgh PA Northwestern University Chicago IL 145 Molecular Characterization of 52 Glioblastomas in Young Adult Patients 1727 Helene Plouhinec Blandine Boisselier Quentin Breton Sophie Michalak Philippe Menei Philippe Guardiola Audrey Rousseau Angers University Hospital Angers France 200 Pten Deletion Synergizes with Tp53 Mutation to Drive Medulloblastoma and Highly Inltrative Gliomas in Mouse Brain 1735 Guo Zhu Suzanne J Baker St. Jude Childrens Research Hospital Memphis TN The University of Tennessee Health Science Center Memphis TN 215 Oncogenic Mutations in PI3Kinase in Skull-Based Meningioma 1696 Malak Abedalthaga Wenya L Bi Ayal A Aizer Parker Merrill Ryan Brewster Marc Listewnik Paul Van Hummelen Shakti H Ramkissoon Rebecca D Folkerth Keith L Ligon Azra H Ligon Brian M Alexander Ian F Dunn Rameen Beroukhim Sandro Santagata Brigham and Womens Hospital Harvard Medical School Boston MA King Fahad Medical City Riyadh Saudi Arabia King Abdulaziz City for Science and Technology Riyadh Saudi Arabia 230 Chronic Traumatic Encephalopathy-Like Abnormalities in a Routine Neuropathology Service 1723 Shawna Noy Sherry Krawitz Marc Del Bigio University of Manitoba Winnipeg MB Canada CC 606-607 SECTION D - GASTROINTESTINAL CHAIRED BY HENRY D APPELMAN AND AUDREY J LAZENBY 100 Esophageal Squamous Papillomas Incidentaloma or Harbinger of Human Papilloma Virus Infection 748 Robert Najarian Gyanprakash Ketwaroo Deepa Patil Anthony Lembo Beth Israel Deaconess Medical Center Boston MA Cleveland Clinic Cleveland OH 115 Substantial Interobserver Agreement in the Assessment of Barretts Esophagus within an Expert Panel of Gastrointestinal Pathologists 811 Myrtle J van der Wel Cornelis A Seldenrijk G Johan A Offerhaus Mike Visser Fiebo J ten Kate Jan G Tijssen Roos E Pouw Jacques JGHM Bergman Sybren L Meijer Academic Medical Center Amsterdam Netherlands University Medical Center Utrecht Netherlands St. Antonius Ziekenhuis Nieuwegein Netherlands Zaans Medisch Centrum Zaandam Netherlands 130 Clinicopathologic Features and IgG4 Reactivity of Eosinophilic and Collagenous Gastritis in Adult and Pediatric Populations 837 Xiaofei Zhang Huaibin Mabel Ko Margret S Magid Alexandros Polydorides Stephen C Ward Noam Harpaz Hongfa Zhu Icahn School of Medicine at Mount Sinai New York NY PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016192 NEXTGENERATION LEARNING2016192 PROFFERED PAPERS Tuesday March 15 2016 100 PM - 245 PM 145 Myointimal Hyperplasia of the Mesenteric Veins A Rare Disease with Distinct Histopathologic Features in Colonic Biopsy Specimens 659 Isabelle Cui Rhonda K Yantiss Anna-Sophie Weidner Otto Walter Zhengming Chen Nicole Panarelli Jose Jessurun New York Presbyterian-Weill Cornell Medical College New York NY Monteore Medical Center New York NY UMass Memorial Medical Center Worcester MA 200 Immune Complexes and Eosinophil Activation in Eosinophilic Esophagitisunderline 655 Frederic Clayton Kathryn Peterson Gerald Gleich Kristin Leiferman University of Utah Salt Lake City UT 215 The Duodenal Microbiome in Refractory Celiac Disease 712 Stephen M Lagana Ian S Cohn Mara R Rubinstein Benjamin Lebwohl Peter HR Green Yiping W Han Govind Bhagat Columbia UniversityNY Presbyterian Hospital New York NY Columbia University College of Physicians and Surgeons New York NY Columbia UniversityNY Presbyterian Hospital NY NY 230 Histologpic Spectrum of Ipilimumab Associated Colitis Is Narrow and Resembles Inammatory Bowel Disease 622 Atin Agarwal Dipen Maru University of Texas MD Anderson Cancer Center Houston TX CC 608-609 SECTION E - DERMATOPATHOLOGY CHAIRED BY MAY CHAN AND JENNIFER KO 100 Differential Neurobromin Protein Expression in Desmoplastic Melanoma Subtypes - Implicating NF1 Allelic Loss as a Distinct Genetic Driver 502 Alexander Kadokura Noah Frydenlund Dominick Leone Shi Yang Mai P Hoang April Deng Marier Hernandez Asok Biswas Rajendra Singh Meera Mahalingam BUSM Boston MA MGH Boston MA UMASS Medical School Worcester MA Mt Sinai Hospital New York NY Miraca LS Newton MA Western General Hospital Edinburgh Scotland United Kingdom VA Consolidated Laboratories Boston MA Carver Coll of Medicine Iowa City IA 115 The Expanded Eight-Probe Melanoma Fluorescence In Situ Hybridization FISH Assay as an Ancillary Tool in Diagnosing Ambiguous Melanocytic Lesions An Updated Clinical Pathological and Cytogenetic Review of 416 Cases 500 Ruifeng Guo Kabeer Shah Lori A Erickson Thomas Flotte William R Sukov Mayo Clinic Rochester MN 130 Validation of a New SNP-Array Platform as an Ancillary Tool for the Diagnosis of Difcult Melanocytic Lesions 487 Ahmed Alomari Paul W Harms Lori Lowe Douglas R Fullen Rajiv Patel Alexandra Hristov May P Chan Min Wang Aleodor A Andea University of Michigan Health System Ann Arbor MI 145 Melanomas of the Vulva A Retrospective Analysis of Clinical and Histopathologic Parameters in 40 Patients 523 Priyadharsini Nagarajan Jonathan L Curry Jing Ning Jin Piao Phyu P Aung Doina Ivan Carlos A Torres- Cabala Victor G Prieto Anais Malpica Michael T Tetzlaff The University of Texas MD Anderson Cancer Center Houston TX 200 Whole Exome Sequencing of 409 Cancer Associated Genes Demonstrates Frequent Clinically Actionable Mutations in Sebaceous Carcinoma 534 Michael T Tetzlaff Rajesh Singh Elena G Seviour Jonathan L Curry Diana Bell Russell Broaddus Prahlad Ram Victor G Prieto Rajyalakshmi Luthra Bita Esmaeli University of Texas MD Anderson Cancer Center Houston TX 215 Nuclear TFE3 Immunoreactivity Is Present in Angiomatoid Fibrous Histiocytomas but Not in Other Cutaneous Histiocytomas 536 Dianne Torrence Karen Fritchie John D Reith William R Sukov Wonwoo Shon University of Florida College of Medicine Gainesville FL Mayo Clinic Rochester MN 230 Efciency of Direct Immunouorescence Testing Examination of a Single Institution Experience with Bullous Pemphigoidunderline 507 Jennifer S Ko Patrick C Feasel Steven D Billings Cleveland Clinic Cleveland OH CC 611-612 SECTION F - PANCREAS CHAIRED BY LAURA WOOD AND DAVID F SCHAEFFER 100 Clinicopathologic and Molecular Analysis of Pancreatic Ductal Adenocarcinoma in Patients with Lynch Syndrome 1775 Aatur Singhi Jinru Shia Marina Nikiforova Jason L Hornick David Klimstra Sapna Syngal Beth Dudley Randall E Brand Herbert J Zeh Ralph H Hruban University of Pittsburgh Medical Center Pittsburgh PA Memorial Sloan Kettering Cancer Center New York NY Brigham and Womens Hospital Boston MA Johns Hopkins Hospital Baltimore MD NEXTGENERATION LEARNING 2016 PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM 193NEXTGENERATION LEARNING 2016 193 PROFFERED PAPERS Tuesday March 15 2016 100 PM - 245 PM 115 Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas Clinico-Pathological Analysis of 20 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated 1765 Takashi Muraki Gabriela Bedolla Kee-Taek Jang Pelin Bagci Pardeep Mittal Michelle Reid Bahar Memis Olca Basturk Sudeshna Bandyopadhyay Juan Sarmiento Alyssa Krasinskas Volkan Adsay Emory University Atlanta GA SMC Seoul Korea MSKCC NY NY DMC Detroit MI 130 A Clinicopathologic Study of ALK Rearrangements in Pancreatic Ductal Adenocarcinoma 1776 Aatur Singhi Siraj M Ali Joel Greenbowe Jeffrey S Ross Khanh Nguyen Marina Nikiforova Herbert J Zeh Inderpal S Sarkaria Nathan Bahary University of Pittsburgh Medical Center Pittsburgh PA Foundation Medicine Inc Cambridge MA 145 The Predictive Effect of Human Equilibrative Transporter 1 Stratied by Mismatch Repair Deciency in Resected Pancreatic Ductal Adenocarcinoma Patients Treated With Adjuvant Gemcitabine 1751 Steve Kalloger Maziar Riazy Joanna Karasinska Renata Peixoto Setareh Samimi Christine Chow Brandon S Shefeld Daniel Renouf David F Schaeffer University of British Columbia Vancouver BC Canada Pancreas Centre British Columbia Vancouver BC Canada British Columbia Cancer Agency Vancouver BC Canada 200 Clinicopathologic Associations of Paraduodenal Groove Pancreatitis an Under-Recognized Entity An Analysis of 47 Resected Examples with Emphasis on Imaging-Pathology Correlation 1767 Takashi Muraki Grace E Kim Pardeep Mittal Gabriela Bedolla Michelle Reid Bahar Memis Alyssa M Krasinskas Ipek Erbarut Seven Hyejeong Choi David Kooby Shishir Maithel Juan Sarmiento Volkan Adsay Emory University Atlanta GA UCSF San Francisco CA Ulsan University Seoul Korea 215 Marked Geographic Differences in the Pathologic Diagnosis of Non-Invasive Tis vs Minimally Invasive T1 Gallbladder Cancer Santiago Consensus Conference Highlights the Need for the Unifying Category Early Gallbladder Cancer EGBC 1772 Juan Carlos Roa Olca Basturk Javiera Torres Francisco Mucientes Maeva Del Pozo Miguel A Villaseca Gloria Aguayo Enrique R Bellolio Juan Carlos Araya Itaru Endo Kee-Taek Jang KyoungBun Lee Jin-Young Jang Nobu Ohike Michio Shimizu Kenichi Hirabayashi Benoit Terris Giuseppe Zamboni Michelle Reid Yue Xue Gabriela Bedolla Brian Quigley Alyssa M Krasinskas Gizem Akkas Bahar Memis David Klimstra Ralph H Hruban Bin Zhu Alison L Van Dyke Jill Koshiol Volkan Adsay Ponticia University Santiago Chile MSKCC NY NY Yokohama City University Yokohama Japan SMC Seoul Korea SNU Seoul Korea Showa Tokyo Japan Hakujikai Hospital Tokyo Japan Tokai University Tokyo Japan H Cochin Paris France University Verona Verona Italy Emory University Atlanta GA JHU Baltimore MD NIH Bethesda MD 230 Epithelial Atypia in the Gallbladder Diagnosis and Classication in an International Consensus Study 1738 Volkan Adsay Juan Carlos Roa Olca Basturk Javiera Torres Francisco Mucientes Maeva Del Pozo Miguel A Villaseca Gloria Aguayo Enrique R Bellolio Juan Carlos Araya Itaru Endo KyoungBun Lee Kee-Taek Jang Jin-Young Jang Nobu Ohike Michio Shimizu Kenichi Hirabayashi Benoit Terris Giuseppe Zamboni Michelle Reid Yue Xue Gabriela Bedolla Brian Quigley Alyssa Krasinskas Gizem Akkas Bahar Memis David Klimstra Ralph H Hruban Bin Zhu Alison L Van Dyke Jill Koshiol Emory Atlanta GA Ponticia University Santiago Chile MSKCC NY NY Yokohama City University Yokohama Japan SNU Seoul Korea SMC Seoul Korea Showa Tokyo Japan Hakujikai H Tokyo Japan Tokai Tokyo Japan H Cochin Paris France University Verona Verona Italy JHU Baltimore MD NIH Bethesda MD CC 615-617 SECTION G - HEMATOPATHOLOGY CHAIRED BY NATHANAEL G BAILEY AND ELIZABETH A MORGAN 100 miRNA Expression Proles of T Lymphoblastic LeukemiaLymphoma and Normal Thymocytes Dened by Next Generation Sequencing 1354 Magdalena Czader Andrea Moftt Mehdi Nassiri Anupama Tewari Cassandra Love Sandeep Dave Indiana University Indianapolis IN Duke University Durham NC 115 Leukemic Stem Cell Responses to Induction Chemotherapy Identify Novel Prognostic Biomarkers in Acute Myeloid Leukemia 1466 Patricia Raciti Wenhuo Hu Alec Stranahan Carolien Woolthuis Sean Devlin Christopher Park Memorial Sloan Kettering Cancer Center New York NY 130 Bone Marrow Failure in Telomere Disease in Comparison to Aplastic Anemia and GATA2 Deciency 1405 Michael E Kallen Danielle M Townsley Bogdan Dumitriu Amy P Hsu Karthik A Ganapathi Weixin Wang Charles Bolan Steven M Holland Neal S Young Katherine R Calvo NIH Bethesda MD NCI Bethesda MD 145 Additional Chromosome Structural Aberrations Are Associated with Poorer Clinical Outcomes in Multiple Myeloma Patients with Hyperdiploidy 1341 Adrian Carballo-Zarate L Jeffrey Medeiros Suyang Hao Robert Orlowski Pei Lin Lu Xinyan UT MD Anderson Cancer Center Houston TX Houston Methodist Hospital Houston TX PROFFERED PAPERS Monday March 23 2015 830 AM - 1200 PM NEXTGENERATION LEARNING2016194 NEXTGENERATION LEARNING2016194 PROFFERED PAPERS Tuesday March 15 2016 100 PM - 245 PM 200 Activating Mutations in MAPK Pathway Members in Langerhans Cell Histiocytosis A Stanford Experience underline 1430 Lisa McGinnis Grant Nybakken Lisa Ma Daniel A Arber Stanford University School of Medicine Stanford CA 215 Histologic Immunophenotypic and Chromosomal Evaluation of Reactive Lymph Node Hyperplasia with Giant Follicles a Clonal Peri-Parotid Lesion in Boys with Features Overlapping Follicular Lymphoma 1434 Kamran Mirza Gordana Raca Jennifer K Ramey Carrie A Fitzpatrick Charles Rubin James W Vardiman John Anastasi Loyola University Medical Center Maywood IL Childrens Hospital Los Angeles Los Angeles CA University of Chicago Chicago IL 230 Variability and Adequacy of Evaluable Marrow Space Length EMSL in Bone Marrow Biopsies A Multi- Institutional Study 1443 Vishala Neppalli Roswell Park Cancer Institute On Behalf of Bone Marrow Study Group Buffalo NY CC 618-620 SECTION H - PATHOBIOLOGY CHAIRED BY JUAN MIGUEL MOSQUERA AND ADRIAN MARINO-ENRIQUEZ 100 Interim Analysis of 708 Patients Enrolled in the MOSCATO 01 Molecular Screening for Cancer Treatment Optimization Trial 1822 Philippe Vielh Zsoa Balogh Adeline Perez Thierry De Baere Antoine Hollebecque Christophe Massard Charles Ferte Ludovic Lacroix Nathalie Auger Marie- Cecile Le Deley Eric Angevin Fabrice Andre Jean- Charles Soria Gustave Roussy Cancer Center Villejuif France 115 Germline Variants and Secondary Findings in a Cancer Precision Medicine Cohort 1828 Tuo Zhang Alessandro Romanel Michael J Kluk Ken Eng Ivan Iossifov Andrea Sboner Steven Lipkin Colin Pritchard Himisha Beltran Mark Rubin Francesca Demichelis Olivier Elemento Weill Cornell Medicine New York NY Cold Spring Harbor Laboratories New York NY University of Washington Seattle WA University of Trento Trento Italy 130 Integrative Immuno-Mapping of a Precision Cancer Medicine Cohort Towards Establishing Predictive Molecular Neoepitopes and TCR Signatures 1786 Bhavneet Bhinder David Redmond Bishoy Faltas Ken Eng Rohan Bareja Andrea Sboner Himisha Beltran Mark Rubin Olivier Elemento Weill Cornell Medicine New York NY 145 Comprehensive Genomic Proling of Lung Adenocarcinoma Identies Patients with Genomic Alterations beyond Clinical Testing Guidelines Who May Benet from Enrollment in Mechanism Driven Clinical Trials 1785 Lee Albacker Juliann Chmielecki Julia A Elvin Jo- Anne Vergilio Vincent A Miller Philip J Stephens Jeffrey S Ross Siraj M Ali James Suh Foundation Medicine Inc. Cambridge MA Albany Medical College Albany NY 200 Targeted Sequencing of Somatic Mutations in Plasma Circulating DNA of Patients with Primary Central Nervous System Lymphoma PLCNS 1809 Florent Marguet Maxime Fontanilles Elodie Bohers Jean-Michel Picquenot Annie Laquerriere Fabrice Jardin Jean-Christophe Sabourin Rouen University Hospital Rouen France Henri Becquerel Cancer Research Center Rouen France 215 Uterine Adenosarcoma and Phyllodes Tumor of the Breast Have Similar Repertoires of Somatic Genetic Alterations 1823 Britta Weigelt Felipe C Geyer Kathleen Burke Charlotte KY Ng Melissa Murray Dara S Ross Robert Soslow Brian P Rubin Marc Ladanyi Edi Brogi Jorge S Reis-Filho Memorial Sloan Kettering Cancer Center New York NY Cleveland Clinic Cleveland OH 230 Metaplastic Breast Carcinomas and Gynecologic Carcinosarcomas Variations of the Same Theme or Distinct Entities 1798 Felipe C Geyer Charlotte KY Ng Salvatore Piscuoglio Kathleen Burke Yong Hannah Wen Anne Vincent- Salomon Jorge S Reis-Filho Britta Weigelt Memorial Sloan Kettering Cancer Center New York NY Institut Curie Paris France NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 195NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 195 AUTOPSY 1 Retropleural Hypertension A Probable Cause of Descending Thoracic Aortic DTA Occlusion in a Traumatic DTA Tear 29 Melissa Van Dellen Zulqar Cheema Gregory Wolfe Clarke Stout University of Texas Medical Branch Galveston TX 2 Involvement of the Liver By Primary and Secondary Malignant Tumors at Autopsy in a Cohort of Male U.S. Veterans with Comparison to the General Population 20 Aqsa Nasir Hira Yousaf Richard Dykoski Juan Carlos Manivel Hector Mesa University of Minnesota Medical School Minneapolis MN Veterans Affairs Health Care System Minneapolis MN 3 Intravascular Large B Cell Lymphoma as a Mimicker of Susac Syndrome 7 Margaret Compton Hilary Higheld Nickols Claudio A Mosse Stephen J Schultenover Vanderbilt University Medical Center Nashville TN Veterans Affairs Tennessee Valley Healthcare System Nashville TN 4 CPR-Associated Right Ventricular Rupture in the Setting of Pulmonary Embolism 12 Tyler Hickey Ginjeet GK Gill Michael A Seidman Douglas Webber University of British Columbia Vancouver BC Canada Vancouver General Hospital Vancouver BC Canada St. Pauls Hospital Vancouver BC Canada 5 MonosomyTrisomy 21 Mosaicism Correlations of Karyotype to Phenotype in Multiple Tissues 9 Rachel Fielden Tracy Shipe Raymond Lewandowski Colleen Jackson-Cook Virginia Commonwealth University Richmond VA 6 Network Analysis of Placental Findings in Fetal Autopsies 19 Amir Momeni Boroujeni Derek Laskar Elham Youse Virginia Anderson SUNY Downstate Medical Center Brooklyn NY 7 The Final Timepoint of Disease Progression Rapid Autopsy in the Precision Medicine Era 23 David Pisapia Steven Salvatore Chantal Pauli Joanna Cyrta Robert Kim Bishoy Faltas Jeffrey Greeneld Brian D Robinson Andrea Sboner Olivier Elemento Himisha Beltran Mark Rubin Juan Miguel Mosquera Weill Cornell Medical College WCMC New York NY WCMC New York NY 8 Eosinophilic Myocarditis Is a Relatively Common Cause of Sudden Cardiac Death Due to Myocarditis 31 Yang Zhang Allen P Burke University of Maryland Baltimore MD 9 Architecture of Colonic Lamina Propria Stromal Cells Is Altered in Portal Hypertension 21 Joie Otto Judith Aronson University of Texas Medical Branch Galveston TX 10 Distribution of Lesions in Sudden Unexpected Deaths by Sarcoidosis 32 Yang Zhang Allen P Burke University of Maryland Baltimore MD 11 Fatal Arterial Dissections and Tears A Retrospective Review of 42 Post-Mortem Cases 18 Peter Molony Catherine Keohane Louise Burke Margot Bolster Cork University Hospital Cork Ireland 12 Novel SIX3 Mutation Leading to Holoprosencephaly 14 Samuel Hwang Lindsay Taute Michael Knapp Christian Lanciault Oregon Health Sciences University Portland OR 13 The Role of Rapid Autopsy as a Central Resource Available to All Researchers 13 Jody E Hooper Jowaly Camacho Johns Hopkins University School of Medicine Baltimore MD 14 Next Generation Sequencing NGS Solves Autopsy Mystery of Metastatic Poorly Differentiated Malignancy 30 Laura Warmke Austin Wiles Catherine I Dumur Melissa J Contos Steven Smith Virginia Commonwealth University Health System Richmond VA 15 Cardiac Conduction System Pathology in the Hospital Setting A Selection of Cases 28 Michelle Stram Jeffrey Nine UPMC Presbyterian Pittsburgh PA 16 Digitalis Intoxication and Death from Accidental Foxglove Ingestion 10 Margaret Flanagan Richard C Harruff University of Washington Seattle WA King County Medical Esaminer Seattle WA 17 Malignant Tumors Associated with Breast Cancer Analysis of 164211 Autopsy Cases in Japan 26 Yukiko Shibahara Yumi Sugawara Yasuhiro Miki Yasuhiro Nakamura Ichiro Tsuji Hironobu Sasano Tohoku University Graduate School of Medicine Sendai Miyagi Japan 18 The Autopsy Findings of 116 Fetuses with Prenatally Diagnosed Central Nervous System Anomalies 1 Hulya Akgun Mustafa Basbug Figen Ozturk Turhan Okten Erciyes University Kayseri Turkey 19 Autopsy Review of Neonatal Deaths by Disseminated Herpesvirus Infection underline 27 Emily A Sloan M Beatriz Lopes Robin LeGallo University of Virginia Charlottesville VA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016196 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016196 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC BONE SOFT TISSUE PATHOLOGY 20 Transcriptomic Reappraisal Identies Overexpressed PLCB4 as an Adverse Prognosticator in Primary Localized Gastrointestinal Stromal Tumors GISTs 75 Chien-Feng Li I-Chieh Chuang Hsuan-Ying Huang Chi Mei Medical Center Tainan Taiwan Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung Taiwan 21 RNA-Sequencing Identies ETV6-NTRAK3 as a Gene Fusion Involved in Gastrointestinal Stromal Tumors 84 Sabrina Rossi Monica Brenca Maurizio Polano Daniela Gasparotto Dominga Racanelli Lucia Zanatta Laura Valori Stefano Lamon Roberta Maestro Angelo P Dei Tos Treviso General Hospital Treviso Italy CRO National Cancer Institute Aviano Italy 22 ETV6 Gene Rearrangement in Inammatory Myobroblastic Tumor 97 Hidetaka Yamamoto Akihiko Yoshida Kenichi Kohashi Yoshinao Oda Kyushu University Fukuoka Japan National Cancer Center Hospital Tokyo Japan 23 NTRK1 Associated Gene Fusions in Pediatric Fibroblastic Myobroblastic Neoplasms A Molecular Study of 58 Cases 33 Narasimhan P Agaram Lei Zhang Yun-Shao Sung Chun-Liang Chen Catherine Chung Christopher Fletcher Cristina Antonescu Memorial Sloan Kettering Cancer Center New York NY The Hospital for Sick Children Toronto ON Canada Brigham and Womens Hospital Boston MA 24 Correlation of Histological Grade of Dedifferentiation with Clinical Outcome in 51 Cases of Dedifferentiated Liposarcomas 52 Kossivi E Dantey Oleksandr Yergiyev Karen Schoedel Uma Rao University of Pittsburgh Medical Center Pittsburgh PA 25 Man Versus FISH How Accurately Can Soft Tissue Experts Predict MDM2 Amplication of Deep Seated Adipocytic Neoplasms Based on Histology 68 Vadim Khachaturov John R Goldblum Steven D Billings Brian P Rubin Cleveland Clinic Cleveland OH 26 Spindle CellPleomorphic Lipomas of the Distal Extremities Not Just a Myth 67 Vadim Khachaturov Jennifer S Ko Jason L Hornick John R Goldblum Brian P Rubin Steven D Billings Cleveland Clinic Cleveland OH Brigham and Womens Hospital Boston MA 27 Fibrous Hamartoma of Infancy- A Clinicopathologic Study of 122 Cases Including 2 with Malignant Progression 36 Alyaa Al-Ibraheemi Anthony Martinez Sharon W Weiss Harry Kozakewich Antonio Perez-Atayde Karen Fritchie Andrew L Folpe Mayo Clinic Rochester MN Emory University Atlanta GA Boston Childrens Hospital Boston MA 28 Malignant Tenosynovial Giant Cell Tumor- A Clinicopathological and Immunohistochemical Study of 7 Cases 37 Alyaa Al-Ibraheemi Andre Oliveira Andrew L Folpe Mayo Clinic Rochester MN 29 A Novel Subgroup of Deep Myxoma with Specic Genetic and Histologic Findings and No Evidence of GNAS Mutations Analysis of Three Cases 41 Ryan Berry JIn Wu Therese Bocklage University of New Mexico Albuquerque NM 30 Analysis of GNAS Mutations in a Series of Intramuscular Myxomas with Identication of a Novel R201L Mutation 40 Ryan Berry JIn Wu Therese Bocklage University of New Mexico Albuquerque NM 31 Clinical and Pathological Correlation of ATRX Loss in Large Series of Leiomyosarcomas 61 Jolanta Jedrzkiewicz Parnian Ahmadi Davis Ingram Vinod Ravi Keila Torres Andrew Futreal Elizabeth G Demicco Alexander Lazar Wei-lien Wang MD Anderson Cancer Center Houston TX Mount Saini Hospital New York NY 32 Leiomyosarcomas and Rhabdomyosarcomas Over- Express Nicotinamide Phosphoribosyltransferase 92 Rodney E Shackelford Rabie Shanti Junaid Ansari Moiz Vora LSU Health Sciences Shreveport LA Feist Weiller Cancer Center Shreveport LA 33 Histology and Fusion Status in Metastatic Rhabdomyosarcoma 85 Erin R Rudzinski James Anderson Doug Hawkins Seattle Childrens Hospital Seattle WA Frontier Science and Technology Research Foundation Madison WI University of Washington and Fred Hutchinson Cancer Research Center Seattle WA 34 Follicular Dendritic Cell Sarcomas Insights into Its Molecular Landscape 64 George Jour Ahmet Zehir Mrinal M Gounder Omar Abdel-Wahab Jacklyn Casanova Ahmet Dogan Marc Ladanyi David Klimstra Maria E Arcila Memorial Sloan Kettering Cancer Center New York NY Memorial Sloan-Kettering Cancer Center New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 197NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 197 35 Expression of Enhancer of Zeste Homolog 2 EZH2 Protein and Intracellular Signaling Molecules p-ERK MYC and p-STAT3 in Histiocytic and Dendritic Cell Neoplasms 94 Xuejun Tian Jason L Hornick Christopher Fletcher Jie Xu Ali Shahsafaei David M Dorfman Brigham and Womens Hospital Harvard Medical School Boston MA MD Anderson Cancer Center Houston TX 36 A Subset of Epithelioid Sarcomas with Intact INI1 SMARCB1 Is Decient for SMARCA4 and SMARCA2 55 Leona A Doyle Christopher Fletcher Jason L Hornick Department of Pathology Brigham and Womens Hospital Harvard Medical School Boston MA 37 SWISNF Chromatin Remodeling Complex Status in SMARCB1INI1-Preserved Epithelioid Sarcoma Cases 70 Kenichi Kohashi Hidetaka Yamamoto Yuichi Yamada Yoshinao Oda Department of Anatomic Pathology Graduate School of Medical Sciences Kyushu University Fukuoka Japan 38 Supercial Angiomyxoma Is Characterized by Loss of PRKAR1A Expression 77 Adrian Marino-Enriquez Christopher Fletcher Leona A Doyle Department of Pathology Brigham and Womens Hospital and Harvard Medical School Boston MA 39 Identication of Novel Gene Fusion FUS-CREM in Clear Cell Sarcoma of Soft Tissue by Anchored Multiplex Polymerase Chain Reaction 44 Kenneth Chang Angela Goytain Xiu Qing Wang Tracy Tucker Amy Lum Stephen Yip Torsten O Nielsen Tony Ng KK Womens and Childrens Hospital Singapore Singapore Duke-NUS Graduate Medical School Singapore Singapore University of British Columbia Vancouver BC Canada BC Cancer Agency Vancouver BC Canada Vancouver General Hospital Vancouver BC Canada 40 RNA-seq Study of TFE3 Translocation-Associated Perivascular Epithelioid Cell Neoplasm PEComa 69 Pallavi Khattar Weihua Huang Ximing Yang Patricia V Adem John T Fallon Minghao Zhong Westchester Medical Center at New York Medical College Valhalla NY NorthWestern University Feinberg School of Medicine Chicago IL 41 SIRT5 Is Required for Viability of the Ewing Sarcoma Cell Line A673 and the Osteosarcoma Cell Line U2OS 91 David Seward Sarah Bergholtz Elizabeth Pederson Mary Skinner Jeongsoon Park Elizabeth R Lawlor David Lombard University of Michigan Ann Arbor MI 42 Primary Adult Skeletal Osteosarcoma A Clinicopathological and Molecular Study 34 Deepu Alex Lu Wang George Jour Sumit Middha Raghu Chandramohan John Healey Khedoudja Nafa Meera Hameed Memorial Sloan Kettering Cancer Center New York NY 43 Utility of SATB2 as a Quality Control Indicator in Osteosarcoma Tissue Microarray 53 Elizabeth G Demicco Jen-Wei Tsai Davis Ingram Wei- lien Wang Mount Sinai Hospital New York NY The University of Texas M. D. Anderson Cancer Center Houston TX 44 The Wnt Signaling Antagonist Sclerostin in Osteosarcoma 79 Carolyn A Meyers Jia Shen Swati Shrestha Greg Asatrian Gregory LaChaud Vi Nguyen Arun Singh Noah Federman Sarah M Dry Kang Ting Chia Soo Aaron James University of California Los Angeles Los Angeles CA 45 Identifying Unique Genome Abnormalities That Distinguish Enchondroma from Chondrosarcoma 88 John Scarborough Robert Ricciotti Yu Wu Yuhua Liu Benjamin Hoch Yajuan Liu Eleanor Chen University of Washington Seattle WA 46 Diagnostic Utility of IDH12 Mutation To Distinguish Dedifferentiated Chondrosarcoma from Undifferentiated Pleomorphic Sarcoma 46 Shaoxiong Chen Karen Fritchie Shi Wei Kendra Curless Kristin Post Liang Cheng Indiana University Indianapolis IN Mayo Clinic Rochester MN The University of Alabama at Birmingham Birmingham AL BREAST PATHOLOGY 47 HER2 FISH Testing with RAI1 Alternate Probe Will Resolve HER2 Status in Majority of Equivocal Cases 175 Ling Hui Katherine Geiersbach Erinn Downs-Kelly Rachel E Factor H Evin Gulbahce University of Utah SLC UT ARUP SLC UT 48 Droplet Digital Polymerase Chain Reaction Detection of HER2 Amplication in Formalin Fixed Parafn Embedded Breast and Gastric Carcinoma Samples 312 Ya-Zhen Zhu Dan Lu Maruja E Lira Qing Xu Yunzhi Du Jianghong Xiong Mao Mao Hyun Cheol Chung Guangjuan Zheng Guangdong Provincial Hospital of Traditional Chinese Medicine GPHTCM Guangzhou China WuXi AppTec Shanghai China Pzer Oncology San Diego CA Yonsei University College of Medicine Seoul Korea Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016198 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016198 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 49 HER2 Immunohistochemical and Fluorescence In Situ Hybridization Discordances in Invasive Carcinoma with Micropapillary Features 130 Justin Caron Erinn Downs-Kelly H Evin Gulbahce Rachel E Factor University of UtahARUP Salt Lake City UT 50 Co-Amplication of Chromosome 17 Genes Impacts HER2 Scoring 112 Sunil Badve Yesim Gokmen-Polar Indiana University School of Medicine Indianapolis IN 51 Impact of Genetic Heterogeneity on HER2 Status with Implementation of the 2013 ASCOCAP HER2 Reporting Guidelines 155 Monica V Estrada Maria G Kuba Brent Rexer Suzanne Manning Ferrin Wheeler Ashwini Yenamandra Melinda E Sanders Vanderbilt University Medical Center Nashville TN 52 Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer 168 Shuko Harada Dejun Shen Shi Wei University of Alabama at Birmingham Birmingham AL 53 The Impact of 2013 ASCOCAP Guidelines on the Practice of HER2 Testing in a Reference Laboratory 167 Wedad Hanna Elzbieta Slodkowska Fang-I Lu Guangming Han Houman Nasi Sharon Nofech- Mozes SHSC U Toronto Toronto ON Canada 54 Increased HER2 FISH-IHC Discordance and Decreased FISH Equivocals Result from 2013 ASCO-CAP HER2 Scoring Guidelines A Study of 11813 Cases 157 Regan Fulton Allen M Gown PhenoPath Seattle WA 55 HER-France A National Database Containing 105 000 Result Records of Predictive Breast Cancer Markers. Focus on HER2 Positivity 135 Marie-Pierre Chenard Caroline Egele Dominique Fetique Jean-Pierre Bellocq Hpitaux Universitaires de Strasbourg Strasbourg France AFAQAP Association Franaise dAssurance Qualit en Anatomie et Cytologie Pathologiques Strasbourg France 56 Improving the Accuracy of ERBB2 HER2 FISH Testing in Breast Cancer by Implementing a Robust Approach Encompassing Real-Time Histopathologic and Immunohistochemistry Charactieristics A Survey of 2000 Invasive Carcinomas 228 Diana Morlote Robert Poppiti Ariana Lopez Hadi Yaziji Vitro Molecular Laboratories Miami FL Mt. Sinai Medical Center Miami Beach FL 57 Establishing Recommendations for Her2 Staining in Cytology Cell Block Material 198 Fumiko Konno Nyasha Bullock Elyn Riedel Gitika Aggarwal Muzaffar Akram Marcia Edelweiss MSKCC New York NY 58 CA20 Is a Better Predictor of Breast Cancer-Specic Survival Than CIN25 244 Angela Ogden Padmashree CG Rida Michelle D Reid Ritu Aneja Georgia State University Atlanta GA Emory University Hospital Atlanta GA 59 Molecular Alterations and Clinical Test Utilization in Advanced Breast Cancer - Parallel Characterization of Two Next-Generation Sequencing Panels 166 Grzegorz T Gurda Kate M Serdy David Dabbs Rachel Jankowitz Shannon L Puhalla Adam Brufsky Rohit Bhargava Magee-Womens Hospital of University of Pittsburgh Medical Center Pittsburgh PA 60 Detection of Gene Amplications in Invasive Breast Cancers by SNP-based Chromosomal Microarray 148 Jessica L Dillon Jonathan Marotti Joel Lefferts Laura J Tafe Dartmouth-Hitchcock Medical Center Lebanon NH 61 Negative Association between GATA3 and Fascin Could Predict Relapse-Free and Overall Survival in Patients with Breast Cancer 194 Dong-Hoon Kim Kyueng-Whan Min Sung-Im Do Seoung Wan Chae Jin Hee Sohn Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Seoul Republic of Korea Hallym University Sacred Heart Hospital Hallym University College of Medicine Anyang Gyeonggi-do Republic of Korea 62 The Expression of Metallopanstimulin-1 in Low and High-Grade In Situ and Invasive Breast Ductal Carcinomaunderline 272 Daryoush Saeed-Vafa Marilin Rosa Moftt Cancer Center and Research Institute Tampa FL 63 MCL1 Is a Predictive Biomarker of Triple Negative Status and Therapy Response in Relapsed and Metastatic Breast Cancer 271 Jeffrey S Ross Sungeun Kim Aseeb Rehman Ann B Boguniewicz Christine E Sheehan Kai Wang Adrienne Johnson Julia A Elvin Jo-Anne Vergilio James Suh Vincent A Miller Philip J Stephens Siraj M Ali Albany Medical College Albany NY Foundation Medicine Inc. Cambridge MA 64 Clinical-Pathologic Analysis of Luminal B Breast Carcinoma 305 Xuemei Wu Judy C Boughey Ann M Moyer Krishna R Kalari Vera J Suman Jason P Sinnwell Erin E Carlson Travis J Dockter Alvaro Moreno-Aspitia Richard J Gray Sarah A McLaughlin Donald W Northfelt Katie N Jones Amy L Conners Eric D Wieben Liewei Wang Richard M Weinshilboum Matthew Goetz Daniel W Visscher Mayo Clinic Rochester MN Mayo Clinic Jacksonville FL Mayo Clinic Scottsdale AZ Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 199NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 199 65 RUNX3 Epigenetic Inactivation Is Associated with Estrogen-Receptor Positive Breast Cancer 212 Hui Liu Zhantao Yan Kai Cao Jaime Rodriguez- Canales Yongping Wu Xuzhou Medical College Xuzhou Jiangsu China MD Anderson Cancer Center Houston TX 66 Validation of the Rochester University Modied Magee Algorithm RUMMA for Risk Stratication of Estrogen Receptor Positive Breast Cancer Patients 295 Bradley Turner Nyrie Soukiazian Ping Tang David G Hicks Unversity of Rochester Medical Center Rochester NY University of Rochester Rochester NY 67 GATA3 Expression Is Correlated with AR and ER Expression and Negatively Correlated with Nuclear Grade in Mammary Carcinomas 124 Agedi Boto Rita Abi Raad Sara Rutter Lori Charette Malini Harigopal Yale New Haven Hospital New Haven CT 68 High EZH2 Expression Accompanied by Low H3K27me3 Predicts Poorer Outcome in Metaplastic Carcinoma of the Breast 291 Benjamin Yongcheng Tan Clara Ong Valerie Koh Aye Aye Thike Puay-Hoon Tan Singapore General Hospital Singapore Singapore 69 Molecular Features of Breast Cancers with Triple- Negative Phenotype among Older Women 164 H Evin Gulbahce Rachel E Factor Philip Bernard Bette J Caan Carol Sweeney University of Utah SLC UT ARUP SLC UT Kaiser Permanente Northern California Oakland CA 70 Breast Cancer in Women over 75 An Evaluation of Predictive Markers and Aggressive Subtypes in Non Screen Detected Cancers 126 Tara Jane Browne Michael W Bennett Linda Feeley Aoife McCarthy Mark Corrigan Fionnuala OConnell Cork University Hospital Cork Ireland 71 Feasibility of Using Confocal Fluorescence Microscopy for Imaging Breast Tissue in Surgical Pathology Practice 199 Savitri Krishnamurthy Andrea Cortes Mirtha Lopez Michael Wallace Sharjeel Sabir Gordon Mills Kenna Shaw MD Anderson Cancer Center Houston TX 72 Prediction of Breast Cancer Recurrence Risk Categories Using Automatic Mitotic Detection Algorithms Based on Deep Learningunderlineunderline 269 David Romo-Bucheli Andrew Janowczyk Hannah Gilmore Eduardo Romero Anant Madabhushi Universidad Nacional de Colombia Bogota Colombia University Hospitals Cleveland OH Case Western Reserve University Cleveland OH 73 Towards Automated Histopathology of Breast Cancer Using Spatial Light Interference Microscopy SLIM 215 Hassaan Majeed Tan Nguyen Virgilia Macias Krishnarao Tangella Andre Kajdacsy-Balla Minh Do Gabriel Popescu University of Illinois at Urbana Champaign Urbana IL University of Illinois at Chicago Chicago IL 74 Reduced BAP1 Expression in Invasive Carcinoma of the Breast 221 Stephanie McGregor Gabrielle M Baker University of Chicago Medicine Chicago IL 75 Breast Cancer Tumor Stroma Ratio and Stroma Type Are Not Associated with Hormone Receptor Status Lymph Node Status or Tumor Grade 141 Frances Compton Yumi Kojima Hongxia Sun Xiaohong I Wang Michael Covinsky Songlin Zhang The University of Texas Health Science Center at Houston Houston TX DERMATOPATHOLOGY 76 Clinicopathologic Characterization of Rare Newly Described Follicular Helper T-Cell Variant of Primary Cutaneous T-Cell Lymphoma 538 James Wang Giang H Nguyen Shabnam Montahen Cynthia Magro Weill Cornell MC New York NY University of Colorado Anschutz Aurora CO 77 Differential NFAT Expression in Primary Cutaneous CD4 Small Medium Sized Pleomorphic T Cell Lymphoma and Other Forms of Cutaneous T Cell Lymphoma and Pseudolymphoma 517 Shabnam Momtahen Aaron Muhlbauer Cynthia Magro Weill Cornell Medical College New York NY Ross School of Medicine Portsmouth Dominica 78 Cytogenetic Analysis as a Diagnostic Adjunct in Distinguishing the Borderline Melanocytic Tumor from Melanoma 518 Shabnam Momtahen Aaron Muhlbauer James Wang Cynthia Magro Weill Cornell Medical College New York NY Ross School of Medicine Portsmouth Dominica 79 A New FISH Panel and Next Generation Sequencing May Aid in Classifying Atypical Melanocytic Neoplasms 509 Luke Latario Kristine M Cornejo Xun Wu Melissa McEnery-Stonelake Xiuling Meng Keith Tomaszewicz Ediz F Cosar April Deng Lloyd Hutchinson University of Massachusetts Medical School and UMass Memorial Healthcare Worcester MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016200 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016200 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 80 Utility of Whole Genome Single Nucleotide Polymorphism Microarray SNPM and Targeted Somatic Mutations in Evaluation of Histologic Mimics of Melanoma 508 Ravindra Kolhe Alka Chaubey Deepa Jagdale WonSok Lee Barbara R DuPont Ashis K Mondal Georgia Regents University Augusta GA Greenwood Genetic Center Greenwood SC 81 A Diagnostic Algorithm for Atypical Spitzoid Tumor Guidelines for Immunohistochemical and Molecular Assessment 494 Jeong Hee Cho-Vega University of Miami Miller School of Medicine Miami FL 82 Comparison of Genomic Abnormalities and Gene Expression Analysis in Atypical Ambiguous and Malignant Melanocytic Lesions 537 Grace Wang Min Wang Ahmed Alomari Aleodor Andea University of Michigan Ann Arbor MI 83 Comparison between myPath-Melanoma Gene Expression Score and Fluorescence In-Situ Hybridization on an Extended Series of Melanocytic Lesionsunderline 515 Eugen C Minca Rami N Al-Rohil Min Wang Jennifer Ko Victor G Prieto Michael T Tetzlaff Steven D Billings Aleodor Andea Cleveland Clinic Cleveland OH MD Anderson Cancer Center The University of Texas Houston TX University of Michigan Medical Center Ann Arbor MI 84 An Independent Validation of a Gene Expression Signature to Differentiate Malignant Melanoma from Benign Melanocytic Nevi 505 Hillary Kimbrell Loren E Clarke Darl D Flake Klaus Busam Clay J Cockerell Klaus F Helm Jennifer M McNiff Jon A Reed Jaime Tschen Jinah Kim Raymond Barnhill Rosalie Elenitsas Victor G Prieto Jonathan Nelson Kathryn A Kolquist Krystal Brown M Bryan Warf Benjamin B Roa Richard J Wenstrup Myriad Genetic Laboratories Inc. Salt Lake City UT Myriad Genetics Inc. Salt Lake City UT Memorial Sloan Kettering Cancer Center New York NY University of Texas Southwestern Medical Center Dallas TX Penn State Hershey Dermatology Hershey PA Yale Dermatopathology New Haven CT Baylor College of Medicine Houston TX St. Joseph Dermatopathology Houston TX Stanford School of Medicine Stanford CA University of California Los Angeles Los Angeles CA Curie Institute Paris France MD Anderson Houston TX 85 Subungual Atypical Lentiginous Junctional Melanocytic Proliferation in Children and Adolescents A Clinicopathologic Study 503 Sameer Khatri Min Wang Aleodor Andea May P Chan University of Michigan Ann Arbor MI 86 Histopathologic Comparison of EpidermotropicDermal Metastatic Melanoma and Primary Nodular Melanoma 531 Stephanie L Skala Douglas R Fullen David P Arps May P Chan University of Michigan Ann Arbor MI 87 The Microenvironment in Primary Cutaneous Melanomas Immunophenotypic Characterization and Evaluation for T Regulatory Cells Tregs in a Subset of Tumor Inltrating T Lymphocytes TIL Associated with Primary Melanocytic Tumor Regression 520 Kumaran Mudaliar Arielle Gray Solomiya Grushchak Michael I Nishimura Stephanie Kliethermes Kyle Carey Kelli A Hutchens Loyola University Chicago Maywood IL 88 A Functional In Situ Approach to TILs in Melanoma A Critique on the Current Morphological Classication 492 Francesca Bosisio Jasper Wouters Nathalie Volders Marguerite Stas Joost van den Oord KUL Leuven Belgium Universit degli studi di Milano- Bicocca Milan Italy 89 Prognostic Signicance of Regression in Patients with Thin Primary Cutaneous Melanoma 490 Phyu P Aung Sanjita Ravishankar Kenneth Friedman Denai R Milton Jonathan L Curry Carlos A Torres- Cabala Doina Ivan Michael T Tetzlaff Jeffery E Gershenwald Victor G Prieto Priyadharsini Nagarajan UT MD Anderson Cancer Center Houston TX 90 BRAF Proling and Testing in an Irish Population 524 Odharnaith OBrien Sandra Murphy Linda Feeley Derek Power Cynthia Heffron Cork University Hospital Cork Ireland 91 BRAF and Epithelial-Mesenchymal Transition in Primary Cutaneous Melanoma Insights Provided by Snail and E-Cadherin Expression 516 Brendon Mitchell Dominick Leone John K Feller Noah Frydenlund Shi Yang Meera Mahalingam University of Florida College of Medicine Gainesville FL BUSM 72 E Concord Street Boston MA University of Iowa Carver College of Medicine Iowa City IA VA Medical center 1400 VFW PKWY West Roxbury MA 92 BRAF Mutation Analysis A New Tool for Pathologists in Metastatic Melanoma Multicenter Retrospective Evaluation on 239 Cases in French Private Pathologists Laboratories 493 Jerome Chetritt Nicolas Josselin Alain Gaillot Claude Deplechain Emmanuel Watkin Philippe Chalabreysse Delphine Raoux Nicolas Weinbreck Institut dHisto Pathologie - IHP Nantes France Sipath Clermont-Ferrand France Cypath Lyon France Medipath Frejus France Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 201NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 201 93 Clinical Signicance of BRAF V600E Mutational Status in Capsular Nevi of Sentinel Lymph Nodes in Patients with Primary Cutaneous Melanoma 530 Alan E Siroy Carlos A Torres-Cabala Michael T Tetzlaff Priyadharsini Nagarajan Denai R Milton Jonathan L Curry Victor G Prieto Phyu P Aung The University of Texas - MD Anderson Cancer Center Houston TX 94 Expression of Melanocytic Immunohistochemical Markers in Melanophages A Comparison across Platforms 533 Char-Loo Tan Priyanka Maheshwari Yiong-Huak Chan Shoa-Nian Choo Siok-Bian Ng National University Health System Singapore Singapore National University of Singapore Singapore Singapore 95 ALK-1 Expression in Metastatic Melanoma Potential for a Therapeutic Target 529 Kabeer Shah Justin Moser Aaron S Manseld Lori A Erickson Thomas Flotte Mayo Clinic Rochester MN 96 Use of a Novel Rabbit Monoclonal Phospho-Histone H3 Ser10 Versus HE Mitotic Count in Invasive Melanoma 499 Regan Fulton David Altree-Tacha Phenopath Seattle WA Biocare Medical Concord CA GASTROINTESTINAL PATHOLOGY 97 Treponema pallidum Immunohistochemistry Is a Sensitive Diagnostic Adjunct for Intestinal Spirochetosis 686 Rondell Graham Bita V Naini Sejal S Shah Christina A Arnold Rajesh Kannangai Michael Torbenson Dora Lam-Himlin Mayo Clinic Rochester MN UCLA Los Angeles CA The Ohio State University Columbus OH Christian Medical College Vellore India Mayo Clinic Scottsdale AZ 98 Rare Sarcina Ventriculi of Human Gastrointestinal Tract Six New Examples 695 Thomas Huebner Alina Iuga Adnan Khan Helen Remotti Saurabh Malhotra JC Fanburg-Smith Integrated Cellular and Molecular Diagnostics Greenbelt MD Columbia University New York NY 99 Brincidofovir CMX001 Toxicity Another Potential Mimicker of Gastrointestinal Graft Versus Host Disease 668 Claire J Detweiler Anthony D Sung Jennifer L Saullo Vinod K Prasad Diana M Cardona Duke University Medical Center Durham NC 100 A Combined Deposition of Lanthanum and Hemodialysis-Associated Amyloid in the Gastroduodenal Mucosa An Immunohistochemical Electron Microscopic and Dispersive X-Ray Spectrometric Analysis 735 Riruke Maruyama Takayoshi Komatsu-Fujii Hideyuki Onuma Tomohiko Yamamoto Youichi Miyaoka Noriyoshi Ishikawa Asuka Araki Nahoko Ishikawa Yoshikazu Kinoshita Pamela Tauchi-Nishi Shimane University Faculty of Medicine Izumo Japan Shimane Prefectural Central Hospital Izumo Japan Queens Medical CenterUniversity of Hawaii Honolulu HI 101 Lanthanum Deposition Is Frequently Observed in the Gastric Mucosa of Dialysis Patients with Lanthanum Carbonate Therapy A Clinicopathologic Study of 13 Cases Including One Colon Case and Two Non- Granulomatous Gastric Cases 683 Keisuke Goto Kumiko Ogawa Kainan Hospital Yatomi Japan National Institute of Health Sciences Tokyo Japan 102 Sleeve Gastrectomy Unanticipated Findings in the Pathology Review. More Than Anyone Expects 778 Claudia P Rojas Nyasha Bullock Jignesh G Parikh Nilesh D Kashikar Clara Milikowski Monica Garcia- Buitrago University of Miami Miller School of MedicineJackson Memorial Hospital Miami FL 103 Doxycycline Induced Gastrointestinal Injury Case Series with New Sites of Involvement 621 Kajsa Affolter Kathleen Boynton Wade S Samowitz Erinn Downs-Kelly University of Utah Health Sciences Center and ARUP Salt Lake City UT University of Utah Health Sciences Center Salt Lake City UT 104 Lymphocytic Esophagitis LE with CD8 T-Cell Predominance May Be Associated with Gastroesophageal Reux Disease GERD 756 Nicholas Olson Juan Putra Xiaoying Liu Arief A Suriawinata Mikhail Lisovsky Dartmouth-Hitchcock Medical Center Lebanon NH 105 Patterns of Lymphocytic Gastritis May Reect the Underlying Etiology 660 Isabelle Cui Zhengming Chen Nicole Panarelli Rhonda K Yantiss New York Presbyterian-Weill Cornell Medical College New York NY Monteore Medical Center New York NY 106 Lymphocytic Colitis Are There Pathologic Predictors of Response to Therapy 633 Lindsay Alpert Namrata Setia Hamed Khalili Gregory Y Lauwers University of Chicago Chicago IL Massachusetts General Hospital Boston MA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016202 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016202 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 107 Microscopic Crohns Disease Activity at Resection Margins Is Not Signicantly Associated with Post- Operative Clinical Outcomes 725 Li Liu Amit Singal Akbar Waljee Purva Gopal UT Southwestern Medical Center Dallas TX University of Michigan Medical Center Ann Arbor MI 108 Morphologic Heterogeneity of Dysplasia in Inammatory Bowel Disease A Clinicopathologic Study 764 Deepa Patil Erica Savage John Goldblum Robert Odze Cleveland Clinic Cleveland OH Brigham and Womens Hospital Boston MA 109 Clinicopathologic Predictors of Long Term and Disease-Free Survival in Esophageal Squamous Cell Carcinomas with Complete Pathologic Response to Neoadjuvant Chemoradiationunderline 625 Agoston Agoston Yifan Zheng Raphael Bueno Robert Odze Brigham Womens Hospital Boston MA 110 A Modied Tumor Regression Grade Incorporating Lymph Node Involvement for Assessing Response to Neoadjuvant Chemotherapy in Oesophageal Cancer 733 Amr Mahmoud Derek Power Tom Murphy Michael W Bennett University College Cork Cork Ireland Mercy University Hospital Cork Ireland National Cancer Screening Service Cork Ireland 111 HMGA2 Expression Correlates with High Tumor Stage Nodal Metastasis and Poor Outcomes in Patients with Esophageal Adenocarcinoma 742 Jeffrey Mito Agoston Agoston Paola Dal Cin Amitabh Srivastava Brigham and Womens Hospital Boston MA 112 WHO Morphologic Classication of Gastric Cancer Correlates with Protein Expression Based Classication 792 Namrata Setia Lindsay Alpert Gregory Y Lauwers University of Chicago Chicago IL Massachusetts General Hospital Boston MA 113 Molecular Classication in Gastric Cancer Using Immunohistochemistry 627 Sangjeong Ahn So Jeong Lee Young Geum Kim Chung Su Hwang Ahrong Kim Nari Shin Kyung Un Choi Chang Hun Lee Gi Young Huh Gregory Y Lauwers Do Youn Park Pusan National University Hospital Pusan National University Medical School Busan Korea Massachusetts General Hospital Boston MA 114 Concordance of HER2 Status between Local and Central Review in Gastric GC and gastroesophageal Junction Cancers GEJC A French Observational Study of 394 Specimens HERable Study 671 Laurent Doucet Benoit Terris Marie-Pierre Chenard Frederic Bibeau Frederique Penault-Llorca Mouna Bougrini Emmanuele Conde Da Silva Fraga Genevieve Monges Hpital Cavale Blanche Brest France Hpital Cochin Paris France Hpital Hautepierre Strasbourg France Institut du Cancer de Montpellier Montpellier France Centre Jean Perrin Clermont Ferrand France Roche Boulogne-Billancourt France Hpital Pasteur Nice France 115 As an Independent Prognostic Factor EZH2 Promotes Gastric Cancer Progression via Akt Pathway 805 Cong Tan Mi-die Xu Shujuan Ni Weiwei Weng Xiangjie Sun Qiongyan Zhang Dan Huang Weiqi Sheng Xiang Du Fudan University Shanghai Cancer Center Shanghai China 116 A New Immunohistochemistry Prognostic Score IPS for Recurrence and Survival in Pancreatic Neuroendocrine Tumors PanNET 812 Antonio Viudez Filipe LF Carvalho Zahra Maleki Marianna Zahurak Daniel Laheru Alejandro Stark Nilofer S Azad Christopher L Wolfgang Stephen Baylin James G Herman Ana De Jesus-Acosta The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions Baltimore MD Johns Hopkins University School of Medicine Baltimore MD 117 L861Q EGFR Mutation in a Metastatic Solid- Pseudopapillary Neoplasm of the Pancreas 749 Kevin Neill Xiaohui Zhang Sameer Al Diffalha Mokenge P Malafa Barbara A Centeno Anthony M Magliocco Domenico Coppola Moftt Cancer Center Tampa FL M2Gen Tampa FL 118 The Prognostic Signicance of Inltrating Lymphocytes in Patients with Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Therapy 750 Reza Nejati Daniel M Halperin Jennifer B Goldstein Hua Wang Asif Rashid Matthew H Katz Jeffrey E Lee Jason B Fleming Jaime Rodriguez Canales Jorge Blando Ignacio I Wistuba Anirban Maitra Robert A Wolff Gauri R Varadhachary Huamin Wang The University of Texas M.D. Anderson Cancer Center Houston TX 119 Pancreatic Mesenchymal Chondrosarcoma Harboring HEY1-NCOA2 Gene Fusion 657 Jarish Cohen David Solomon Andrew E Horvai Sanjay Kakar University of California San Francisco San Francisco CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 203NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 203 120 Intestinal Metaplasia of Appendiceal Endometriosis Is Not Uncommon and May Mimic Appendiceal Mucinous Neoplasm 814 Monika Vyas Serena Wong Xuchen Zhang Yale School of Medicine New Haven CT 121 Mucinous Neoplasms of the Appendix Challenges in Grading and Staging with Proposal for a New System 810 S Umetsu N Shazadeh S Kakar UCSF San Francisco CA Kaiser Woodland Hills CA 122 miRNA Analysis Identied PTEN Loss in Goblet Cell Carcinoid of Appendix in Comparison to Well Differentiated Neuroendocrine Tumors 639 Amarpreet Bhalla Shadan Ali Raagini Suresh Manjula Garapati Anthony Shields Philip Philip Fazlul Sarkar Vinod B Shidham Detroit Medical Center WSU SOM Karmanos Cancer Center Detroit MI Indiana University Indianapolis IN Karmanos Cancer Center Detroit MI 123 Immunohistochemical and Molecular Characterization of Colonic Sessile Serrated AdenomasPolyps with Serrated Versus Intestinal Dysplasia 646 Odise Cenaj Robert Odze Monika Vyas Joanna A Gibson Brigham and Womens Hospital Boston MA Yale-New Haven Hospital New Haven CT 124 Clinicopathologic and Outcome Study of Sessile Serrated AdenomasPolyps with Serrated Versus Intestinal Dysplasia 645 Odise Cenaj Robert Odze Monika Vyas Joanna A Gibson Brigham and Womens Hospital Boston MA Yale-New Haven Hospital New Haven CT 125 Extended RAS Mutations and Microsatellite Instability in Patients with Colorectal Cancer 702 Rossana Kazemimood Ma Li Mazur Lech Mike Mihalov University of Illinois at Chicago Chicago IL ACL Laboratories Rosemont IL 126 Dual Stain with SATB2 and CK20 Is Useful to Distinguish Colorectal Carcinoma from Other Tumors 724 Zaibo Li Jonathan Rock Rachel M Roth William L Marsh Adrian A Suarez Wendy L Frankel Ohio State University Columbus OH 127 Immunohistochemistry for the Mismatch Repair Proteins is Concordant between Colorectal Cancer and Corresponding Metastasis 788 Aisha Sethi Sigurdis Haraldsdottir Rachel Roth Heather Hampel Rachel Pearlman Christina A Arnold Wendy L Frankel The Ohio State University Columbus OH 128 Utilization of High Throughput Cancer Hotspot Mutations Screening for the Molecular Proling of Colorectal Cancer 631 Jaudah Al-Maghrabi Ashraf Dallol Abdelbaset Buhmeida Mahmoud Al-Ahwal Adel Abuzenadah Faculty of Medicine King Abdulaziz University Jeddah Saudi Arabia King Abdulaziz University Jeddah Saudi Arabia 129 High FAK in the Background of Low c-MET and Low RON Levels Is Associated with Worse Survival in Stage I-III Colorectal Adenocarcinoma Patients 834 J-Y Yoon Prashant Bavi Sheng-Ben Liang Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 130 Nuclear Maspin Expression Is an Independent Prognostic Marker in Microsatellite Stable Stage II Colorectal Carcinoma 637 Prashant Bavi Qian Yang Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 131 DNA Mutational Signature in Colorectal Cancer Predicts Mismatch Repair Pathway Status 752 Jonathan Nowak Priyanka Shivdasani Agoston Agoston Shuji Ogino Frank Kuo Amitabh Srivastava Fei Dong Brigham and Womens Hospital Boston MA 132 Diagnosing Colorectal Medullary Carcinoma Interobserver Variability and Clinicopathological Implication 719 Lik Hang Lee Bing Ren Rhonda K Yantiss Eran Sadot Efsevia Vakiani Jaclyn Hechtman Sinisa Ivelja Zsoa Stadler Martin Weiser David Klimstra Jinru Shia Memorial Sloan Kettering Cancer Center New York NY Weill Cornell Medical College New York NY 133 Comprehensive Genomic Proling of Advanced Stage Colorectal Carcinoma Reveals Alterations in Epigenetic Regulators 758 Madhu Ouseph Shaolei Lu Shamlal Mangray Alexander Brodsky James Sun Siraj M Ali Jeffrey S Ross Murray B Resnick Evgeny Yakirevich Rhode Island HospitalBrown University Providence RI Foundation Medicine Inc Cambridge MA Albany Medical Center Albany NY 134 Mismatch Repair-Decient Neuroendocrine Carcinomas of the Lower GI Tract 785 Marcela Santos Cavalcanti Lik Hang Lee Efsevia Vakiani Jaclyn F Hechtman David Klimstra Jinru Shia Memorial Sloan Kettering Cancer Center New York NY 135 Mutational Landscape of Anal Melanoma 694 Susan J Hsiao David F Schaeffer David Horst Chi K Lai Helen Remotti Mahesh Mansukhani Basil A Horst Hui-Min Yang Columbia University New York NY University of British Columbia Vancouver BC Canada Ludwig- Maximilians-Universitt Mnchen Munich Germany University of Ottawa Ottawa ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016204 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016204 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 136 Intestinal Follicular Lymphoma Outcomes of Low Versus High Stage Disease 768 Meredith E Pittman Arunima Ghosh Elizabeth A Montgomery Amy S Dufeld Johns Hopkins University Baltimore MD GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 137 Clonality of Urothelial Carcinoma Developing in the Bladder Following Radical Nephroureterectomy 1000 Paari Murugan Eugene K Cha Ying-Bei Chen Sahussapont J Sirintrapun Anuradha Gopalan Samson W Fine Satish K Tickoo Victor E Reuter John P Sfakianos Sasinya N Scott Gopa Iyer Aditya Bagrodia Ronak Shah Dean F Bajorin Jonathan E Rosenberg Michael Berger Bernard H Bochner Jonathan A Coleman David B Solit Hikmat A Al- Ahmadie University of Minnesota Minneapolis MN Memorial Sloan Kettering Cancer Center New York NY 138 Urothelial Carcinoma of the Upper Urinary Tract A Clinicopathologic Study of 100 Cases 923 Syed Gilani Bogdan A Czerniak Charles C Guo MD Anderson Cancer Center Houston TX 139 Integrated Whole Exome and RNA Sequencing Reveals Distinct Genomic and Transcriptomic Landscape of Upper Tract Urothelial Carcinoma 1024 Brian D Robinson Bishoy Faltas Rohan Bareja Himisha Beltran Joanna Cyrta Peyman Tavassoli Manoj Rai Scott T Tagawa David M Nanus Francesca Khani Juan Miguel Mosquera Andrea Sboner Douglas Scherr Olivier Elemento Mark Rubin Weill Cornell Medical College New York NY 140 Comprehensive Molecular Analysis of Small Cell Carcinoma of the Bladder 939 Xueli Hao Matthew T Chang Alexander V Penson Neil Desai Gopa Iyer Victor E Reuter Satish K Tickoo Anuradha Gopalan Sahussapont J Sirintrapun Samson Fine Ying-Bei Chen Jonathan E Rosenberg Anne M Schultheis Britta Weigelt Sasinya N Scott Eugen K Cha Dean F Bajorin Michael F Berger Bernard H Bochner Guido Dalbagni David B Solit Barry S Taylor Hikmat A Al-Ahmadie Memorial Sloan Kettering Cancer Center New York NY UT Southwestern Dallas TX 141 An Immunohistochemical Study of the Molecular Subtypes of Combined Urinary Bladder Urothelial and Small Cell Carcinoma 857 Mary Barrett Pamela Unger Jerome Jean-Gilles Nisha Patel Qi Yang Loralee McMahon Guang-Qian Xiao University of Rochester Medical Center Rochester NY Lenox Hill Hospital - LIJ Northshore Health System New York NY 142 TERT Promoter Mutations in Squamous Cell Carcinoma of the Bladder 887 Morgan Cowan Simeon Springer Doreen Nguyen Diana Taheri Gunes Guner Maria Angelica Mendoza Rodriguez Maria DC Rodriguez Isabela W Cunha Dilek Baydar Yuxuan Wang Kenneth Kinzler Nickolas Papadopoulos Bert Vogelstein George J Netto Johns Hopkins Hospital Baltimore MD Sidney Kimmel Comprehensive Cancer Center Baltimore MD Isfahan University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran AC Camargo Cancer Center Sao Paulo Brazil Hacettepe University Ankara Turkey 143 TERT Promoter Mutations in Urinary Bladder Adenocarcinoma 886 Morgan Cowan Simeon Springer Doreen Nguyen Diana Taheri Gunes Guner Maria Angelica Mendoza Rodriguez Isabela W Cunha Dilek Baydar Stephania Bezerra Christopher J VandenBussche Yuxuan Wang Kenneth Kinzler Nickolas Papadopoulos Bert Vogelstein George J Netto Johns Hopkins Hospital Baltimore MD Isfahan University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran AC Camargo Cancer Centre Sao Paulo Brazil Hacettepe University Ankara Turkey 144 Mutational Prole Using Next Generation Sequencing May Aid in Distinguishing Urachal Adenocarcinoma from Bladder Adenocarcinoma 885 Kristine M Cornejo Gladell P Paner Keith Tomaszewicz Xiuling Meng Vikas Mehta Sahussapont J Sirintrapun Guliz Barkan Ediz F Cosar Lloyd Hutchinson University of Massachusetts Medical School and UMass Memorial Healthcare Worcester MA University of Chicago Chicago IL Loyola University Medical Center Maywood IL Memorial Sloan Kettering Cancer Center New York NY 145 Unraveling the Molecular Characteristics of Urachal Adenocarcinoma Starting from an Extreme-Responder Patient 877 Mireia Castillo-Martin Ana Collazo Lorduy John P Sfakianos Carlos Cordon-Cardo Matthew Galsky Icahn School of Medicine at Mount Sinai New York NY 146 Analysis of Urothelial Carcinomas with Grade Heterogeneity Evidence for an Early Role of CDKN2A Deletions in the FGFR3 Pathway 900 Michelle Downes Berber Weening Bas WG van Rhijn Cherry L Have Kilian M Treurniet Theo Van Der Kwast Sunnybrook Health Sciences Centre Toronto ON Canada University Health Network Toronto ON Canada Erasmus Medical Centre Rotterdam Netherlands Netherlands Cancer Institute Amsterdam Netherlands Academic Medical Centre Amsterdam Netherlands Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 205NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 205 147 Metabolomics Analysis Reveals Distinct Proles of Non-Muscle Invasive and Muscle-Invasive Bladder Cancer 1032 Divya Sahu Yair Lotan Bryan Wittman Bruce Neri Donna Hansel University of California at San Diego San Diego CA Metabolon Inc Durham NC University of Texas Southwestern Medical Center Dallas TX 148 The Ratio of CD8 to Treg Tumor Inltrating Lymphocytes Is Associated with Neoadjuvant Cisplatin Based Chemotherapy Response in Patients with Muscle Invasive Urothelial Carcinomas of the Bladder 856 Alexander Baras Charles Drake Jen-Jane Liu Nilay Gandhi Max Kates Mohamed Hoque Alan Meeker Noah M Hahn Mark Schoenberg Janis Taube Trinity J Bivalacqua George J Netto Johns Hopkins Baltimore MD Monteore Medical Center Bronx NY 149 Human Papillomavirus in Urothelial Carcinoma In-Situ Does It Have a Role in Urothelial Carcinogenesis 859 Sheldon I Bastacky Dinesh Pradhan Somak Roy Rajiv Dhir UPMC Pittsburgh PA 150 Muscularis Mucosae MM Thickness in Cystectomy Specimens A Practical Objective Approach to Distinguishing from Muscularis Propria MP 1007 Swetha Paluru Jonathan I Epstein Johns Hopkins Medical Institute Baltimore MD 151 Utility of Immunohistochemistry for Distinguishing Luminal and Basal Subtypes of Urothelial Carcinoma on Formalin Fixed Parafn Embedded Tissues 1018 Dinesh Pradhan Anthony Green Kimberly A Fuhrer Sheldon I Bastacky Rajiv Dhir Anil Parwani Somak Roy UPMC Pittsburgh PA Wexner Medical Center Columbus OH 152 CK20 and p53 Immunohistochemistry Staining Patterns and Follow Up in Urinary Bladder Specimens with Urothelial Atypia 853 Javier Arias-Stella Alpa B Shah Nilesh S Gupta Sean R Williamson Henry Ford Hospital Detroit MI 153 Clear Cell Urothelial Carcinoma Immunohistochemical and Topographic Studies Are Suggestive of Mesonephric Differentiation 861 Justin Bateman Jason K Wasserman Trevor A Flood Eric C Belanger Bojana Djordjevic Kien T Mai The Ottawa Hospital and University of Ottawa Ottawa ON Canada 154 Clear Cell Urothelial Carcinoma A Clinicopathological Study of Nine Cases and a Review of Literature 860 Justin Bateman Jason K Wasserman Trevor A Flood Bojana Djordjevic Eric C Belanger Kien T Mai The Ottawa Hospital and University of Ottawa Ottawa ON Canada 155 Amyloidosis of the Bladder and Association with Urothelial Carcinoma Report of 18 Cases 986 Daniel J Luthringer Deepika Sirohi Mahul B Amin Cedars Sinai Medical Center Los Angeles CA 156 Neoadjuvant Chemotherapy NAC-Related Histological Changes in Radical Cystectomy RC Assessment Accuracy and Prediction of Response 1070 Hui Jun Wang Wassim Kassouf Fadi Brimo McGill University Health Center Montreal QC Canada 157 The Depth of Tumor Invasion Is Superior to the AJCC UICC Staging System to Predict Patient Outcomes after Radical Cystectomy A Proposal for a New Staging System 1063 Toyonori Tsuzuki Toshinori Nishikimi Yukiko Mori Naoto Sassa Masashi Kato Shin Yamada Kuniaki Tanaka Satoru Takahashi Yasushi Yoshino Ryohei Hattori Momokazu Gotoh Japanese Red Cross Nagoya Daini Hospital Naogya Japan Nagoya City University Nagoya Japan Nagoya University Hospital Naogya Japan Japanese Red Cross Nagoya Daiichi Hospital Naogya Japan Okazaki Municipal Hospital Okazaki Japan Kariya General Hospital Kariya Japan 158 Regional and Racial Disparities in Bladder Cancer Pathology Undergoing Secondary Review at a Tertiary Referral Center in Alabama 884 Robin Collingwood Win Shun Lai Soroush Rais- Bahrami Jennifer B Gordetsky University of Alabama at Birmingham Birmingham AL 159 Prognostic Signicance of Lymphatic Vascular and Perineural Invasion in Bladder Cancer Treated by Radical Cystectomy 999 Prasuna Muppa Sounak Gupta Igor Frank Stephen A Boorjian R Jeffrey Karnes R Houston Thompson Prabin Thapa Robert F Tarrell Loren P Herrera Hernandez Rafael E Jimenez John C Cheville Mayo Clinic Rochester MN 160 Submitting the Entire Packet Increases Lymph Node Yield in Cystectomy Pelvic Lymphadenectomy Specimens 992 Rebekah McIntosh Soroush Rais-Bahrami Jennifer B Gordetsky UAB Birmingham AL 161 Occult Metastases in Pelvic Lymph Nodes Removed during Radical Cystectomy for Urothelial Carcinoma underlineunderline 922 Briana R Gibson James L Ellenburg Todd M Stevens William E Grizzle Soroush Rais-Bahrami Jennifer B Gordetsky University of Alabama at Birmingham Birmingham AL 162 Reduced Survival in Estrogen Receptor Beta Expressing Bladder Cancer Association with Altered PTENmTOR Status 1049 James Solomon Irene Thung David Tacha Ahmed Shabaik Donna Hansel University of California at San Diego San Diego CA Biocare Medical Concord CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016206 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016206 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 163 FOXO1 and p53 Are Associated with Poor Prognosis in Urothelial Cell Carcinoma 948 Silvia Hernandez Alba Font-Tello Nuria Juanpere Marta Lorenzo Lara Nonell Albert Frances Sergio Serrano Josep Lloreta Universitat Pompeu Fabra Barcelona Spain Hospital del Mar-Parc de Salut Mar-IMIM Barcelona Spain Parc de Salut Mar-IMIM Barcelona Spain Hospital del Mar-Parc de Salut Mar-IMIM Barcelona Spain Autonomous University of Barcelona Barcelona Spain 164 HER2 Status in Metastazising Urothelial Bladder Cancers 919 Vera Genitsch Philipp Niederberger Aurel Perren Roland Seiler George N Thalmann Achim Fleischmann University of Bern Bern Switzerland 165 ELK1 Immunohistochemistry in Bladder Cancer as a Predictor of Tumor Progression as Well as Chemosensitivity 963 Takashi Kawahara Hiroki Ide Hasanain Shareef Satoshi Inoue Eiji Kashiwagi George J Netto Alexander Baras Hiroshi Miyamoto Johns Hopkins University Baltimore MD 166 Analysis of PD-L1 Expression Pattern in Advanced Bladder Cancer and Lymph Node Metastasis 1052 Yue Sun Max Vaickus Sandra Cerda Huihui Ye Boston University Medical Center Boston MA Beth Israel Deaconess Medical Center Boston MA 167 Study of KRAS and BRAF Mutations among Different Tumor Types in the Lower Urinary Tract 938 Jen-Fan Hang Chin-Chen Pan Taipei Veterans General Hospital Taipei Taiwan 168 Stathmin1 is a Sensitive and Specic Biomarker for High Grade Urothelial Carcinomas 990 Douglas A Mata Brooke E Howitt Justine A Barletta Michelle Hirsch Brigham and Womens Hospital Boston MA 169 Immunohistochemistry of Prostaglandin Receptors in Bladder Cancer as Predictors of Tumor Progression as Well as Chemosensitivity 961 Eiji Kashiwagi Hiroki Ide Satoshi Inoue Takashi Kawahara George J Netto Alexander Baras Hiroshi Miyamoto Johns Hopkins University Baltimore MD 170 Copper Transporter CTR1 Expression Predicts Platinum Response in Muscle-Invasive Bladder Cancer underline 965 Deepak Kilari Kenneth A Iczkowski Chintan Pandya Adam Robin Edward M Messing Elizabeth Guancial Eric S Kim Medical College of Wisconsin Milwaukee WI University of Rochester Rochester NY 171 Urinary Bladder Paragangliomas Analysis of Succinate Dehydrogenase and Outcome 936 Sounak Gupta Jun Zhang Lori A Erickson Mayo Clinic Rochester MN 172 Clinicopathologic Characteristics and Mutational Status of Succinate Dehydrogenase in Paraganglioma of Urinary Bladder with Emphasis on Malignancy Multi- Institutional Study in Korea 1015 Sanghui Park Ghee Young Kwon Ji Eun Kwon Sang Kyum Kim Ji Yeon Kim Chul Whan Kim Hyun-Jung Kim Kyung Chul Moon Yong Wook Park Won Young Park Eun Su Park Ji Youn Sung Sun Hee Sung Seung Eun Lee Wonae Lee Jong Im Lee Soo Jin Jung Min- Sun Cho Yong Mee Cho Hyun Yee Cho Eun Jung Cha Yang Seok Chae Gheeyoung Choi Yeong Jin Choi Jooryung Huh Jae Y Ro Ewha Womans University Seoul Korea Other Hospitals Korea The Methodist Hospital Houston TX HEAD NECK PATHOLOGY 173 Arrested Pneumatization of the Skull Base A Sheep in Wolfs Clothing 1290 Jean Lewis Carrie Y Inwards Kirk M Welker Mayo Clinic Rochester MN 174 Ameloblastoma Twenty Five Year Experience at a Single Institution 1296 Tatyana Milman Wei Pan Virginia LiVolsi Perelman School of Medicine Philadelphia PA 175 BRAF KIT NRAS and TERT Mutation Analysis in Head and Neck Mucosal Melanomas 1307 Sule Sari Ismail Yilmaz Orhun C Taskin Yasemin Ozluk Nesimi Buyukbabani IU Istanbul Faculty of Medicine Istanbul Turkey GATA Military Hospital Istanbul Turkey 176 The Great Mimicker - Metastatic Breast Carcinoma to the Head and Neck with Emphasis on Unusual Clinical and Pathologic Features 1275 Dikson Dibe Gondim Rebecca Chernock Samir K El- Mofty James Lewis Washington University in St. Louis Saint Louis MO Vanderbilt University Nashville TN 177 Characterization of Inammatory Inltrates and Programmed Death Ligand 1 PD-L1 Expression in Squamous Carcinoma Precursor Lesions in Organ Transplant Recipients 1286 D Anand Rajan Kanagasabapathy Samir K El-Mofty Washington University School of Medicine St Louis MO 178 Human Papillomavirus and Activating EGFR Mutations Alternative Oncogenic Mechanisms in Inverted Sinonasal Papilloma 1268 Noah Brown Aaron Udager Jonathan McHugh Thomas E Carey University of Michigan Health System Ann Arbor MI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 207NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 207 179 Sinonasal Carcinoma Arising in Schneiderian Papilloma Clinicopathological Review of 27 Cases 1300 Asawari Patil Tanvee Kulkarni Ashwini Natu Munita Bal Rajiv Kumar Swapnil Rane Shubhada Kane Tata Memorial Centre Mumbai Maharashtra India 180 JAK2 Overexpression Is a Prognostic Indicator for Worse Outcome in Nasopharyngeal Carcinoma and Is Independent of JAK2 Exon 12 and JAK2 V617F Mutation 1291 Peir-In Liang Chien-Feng Li Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung City Kaohsiung Taiwan Chi Mei Foundation Medical Center Tainan City Tainan Taiwan Southern Taiwan University of Science and Technology Tainan City Tainan Taiwan National Health Research Institutes National Institute of Cancer Research Tainan City Tainan Taiwan 181 Abstract Withdrawn 182 Next Generation Sequencing of Olfactory Neuroblastoma Nominates Potential Oncogenic Drivers Including WntBeta-catenin Signaling FGFR3 and Cyclin D1 1278 Paul W Harms Lorena Lazo de la Vega Andi K Cani Jonathan McHugh Daniel H Hovelson Michaela J Haller Komal Kunder Chia-Jen Liu Scott A Tomlins Department of Pathology Ann Arbor MI Michigan Center for Translational Pathology Ann Arbor MI 183 Sinonasal leiomyosarcoma Analysis of 9 Cases Exploring Their Clinicopathological and Morphological Spectrum with Emphasis on Previous Irradiation and Association with Other Malignancies 1258 Abbas Agaimy Sarina Muller Lester DR Thompson University Hospital of Erlangen Erlangen Germany Woodland Hills Medical Center Woodland Hills CA 184 Clinicopathological Features of Extranodal Follicular Dendritic Cell Sarcoma of Head and Neck Region Report of 18 Cases of an Uncommon Entity 1288 Rajiv Kumar Anuja Pradhan Munita Bal Asawari Patil Prathamesh Pai Sarbani Laskar Jai P Agarwal Anil DCruz Shubhada Kane Tata Memorial Hospital Mumbai India 185 Parapharyngeal Nerve Sheath Tumors A Clinicopathological Study of 34 Cases Including Four Malignant Peripheral Nerve Sheath Tumorsunderline 1315 Jason K Wasserman Akeesha Shah Raja R Seethala Bibianna Purgina University of Ottawa Ottawa ON Canada University of Pittsburgh Medical Centre Pittsburgh PA 186 -catenin Expression Is Frequent in Sinonasal Hemangiopericytoma and Its Mimics 1285 Vickie Y Jo Christopher Fletcher Brigham and Womens Hospital and Harvard Medical School Boston MA 187 The Effects of Chemoradiotherapy on Patient Outcomes and Tumor Viability in Cervical Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma 1309 Kathryn Scherpelz Mark Lingen Nicole A Cipriani University of Chicago Chicago IL 188 Prognostic Signicance of Histological Tumor Regression at Primary Site and Nodal Metastases in Patients with Oral Squamous Cell Carcinoma Treated by Neo-Adjuvant Chemotherapy Followed by Surgery 1297 Ashwini N Kumar Prabhash Shubhada Kane Anil DCruz Munita Bal Rajiv Kaushal Asawari Patil Tata Memorial Centre Mumbai Maharashtra India 189 Lymphovascular Invasion and Pattern of Invasion in Floor of Mouth Squamous Cell Carcinoma An Interobserver Variability Study 1265 Caitlin Beggan Cassie Fives Gerard OLeary Patrick Sheahan Cynthia Heffron Linda Feeley Cork University Hospital Cork Ireland South Inrmary-Victoria University Hospital Cork Ireland 190 Three-Dimensional Histology Spatial Envisioning of Pattern of Invasion 1280 Yan Hu Elliot Yu Claudia Velosa Jessica Xu Qiuying Shi John Tomaszewski Scott Doyle Margaret Brandwein University at Buffalo Buffalo NY Allegheny Health Network Pittsburgh PA University of Kentucky Lexington KY 191 Reliability of Tumor Depth and Thickness Measurements in T1 Oral Cancer 1264 Saad Baqai Norbert Sule Wei Tan Gregory Wilding Mihai Merzianu Roswell Park Cancer Institute Buffalo NY 192 Clinicopathological Immunohistochemical and Molecular Approach of a Series of Multiple Primary Oral Carcinomas 1289 Ana Larque Jorge De la Oliva Marta Bodalo Lara Nonell Carles Marti Alfons Nadal Llucia Alos Hospital Clinic Barcelona Spain Institut Hospital del Mar dInvestigacions Mediques Barcelona Spain 193 Cuniculatum Papillary Verrucous Carcinomas A Comparative Assessment 1310 Akeesha Shah Simion I Chiosea Christopher C Grifth Seungwon Kim Raja R Seethala University of Pittsburgh Pittsburgh PA Emory University Atlanta GA 194 MUC4 Protects Aniokios in Head and Neck Squamous Cell Carcinoma 1322 Xiu Yang Sham S Kakar Muzafar A Macha Surinder K Batra University of Louisville Louisville KY University of Nebraska Omaha NE Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016208 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016208 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 195 The Effect of MGMT and p16 on Prognosis in Oropharyngeal Squamous Cell Carcinomas Is Independent of Tumor Grade and Lymphovascular Invasion 1277 David Fink Sameer Jhavar Marcus Volz Kimberly L Walker Arundhati Rao Baylor Scott and White Temple TX 196 Cutaneous Leishmaniasis Presenting as Facial Midline Lesions A Series of 15 Cases 1259 Elie Alam Ossama Abbas Roger Moukarbel Ibrahim Khalifeh American University of Beirut Medical Center Beirut Lebanon HEMATOPATHOLOGY 197 Peripheral Blood Minimal Residual Disease Analysis by Flow Cytometry Has High Concordance with Bone Marrow Analysis for Adult Patients with Acute Lymphoblastic Leukemia 1433 Alissa Minkovsky Elizabeth A Morgan Karry Charest Ryan Schmidt Debra Briggs Betty Li Olga Pozdnyakova Brigham and Womens Hospital Boston MA Dana- Farber Cancer Institute Boston MA 198 Clinical Implementation of a FISH Panel and Testing Algorithm for Diagnosis of Ph-like B-cell Acute Lymphoblastic 1424 Xinyan Lu Alexandra Reynolds Sergej Naumovich Konopleva Sa Wang Guilin Tang Zhenya Tang Patrick A Zweidler-McKay Jeffrey L Jorgensen Keyur P Patel L Jeffrey Medeiros Pei Lin Marina Konopleva Nitin Jain The University of Texas M.D. Anderson Cancer Center Houston TX TheUniversity of Texas M.D. Anderson Cancer Center Houston TX 199 CD25 Expression in B-Lymphoblastic Leukemia B-LL Is a Biomarker for the Philadelphia Chromosome BCR- ABL1 Translocation and an Adverse Risk Factor in Ph Negative B-LL 1345 Pu Chen Andrew Chu Hamid Zia Prasad Koduru Franklin Fuda Weina Chen UT Southwestern Medical Center at Dallas Dallas TX 200 Mixed Phenotype Acute Leukemia with T-cell Differentiation Demonstrate Immunophenotypic and Genetic Similarities to Early T-cell Precursor Acute Lymphoblastic Leukemia 1420 Yen-Chun Liu Julia T Geyer Wayne Tam Attilio Orazi Weill Cornell Medical College New York NY 201 MLL-Rearranged T-Lymphoblastic Leukemias Are Associated with CD34 and Non-dual CD4 CD8 Phenotype but Not with Unfavorable Outcome in Pediatric Patients 1485 Bradford Siegele Karen Swisshelm Billie J Carstens Xiayuan Liang University of Colorado School of Medicine Aurora CO Childrens Hospital Colorado Aurora CO Colorado Genetics Laboratory Denver CO 202 T Cell Acute Lymphoblastic Leukemias in EVH miR155 Transgenic Mice 1351 Stefan Costinean Lauren R Kauffman Stefano Volinia Cristian Taccioli Kari Green-Church Ji Yuan Carlo Croce Kai Fu University of Nebraska Medical Center Omaha NE Ohio State Wexner Medical Center Columbus OH 203 Comprehensive Genomic Proling CGP of Blastic Plasmacytoid Dendritic Cell Neoplasms BPDCN 1505 Jo-Anne Vergilio Samantha Morley Justin Allen Julia A Elvin James Suh Jie He Rachel Erlich Philip J Stephens Vincent A Miller Jeffrey S Ross Foundation Medicine Inc Cambridge MA Albany Medical College Albany NY 204 Differential Expression of Enhancer of Zeste Homolog 2 EZH2 Protein and Intracellular Signaling Molecules p-ERK MYC and p-STAT3 in Low and High Grade B-Cell Non-Hodgkin Lymphomas 1493 Xuejun Tian Ali Shahsafaei David M Dorfman Brigham and Womens Hospital Harvard Medical School Boston MA 205 Expression of Enhancer of Zeste Homolog 2 EZH2 Protein Correlates with p-ERK p-STAT and MYC Expression in Lymphocyte Predominant LP Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma NLPHL and Reed-Sternberg HRS Cells of Classical Hodgkin Lymphoma CHL 1494 Xuejun Tian Ali Shahsafaei David M Dorfman Brigham and Womens Hospital Harvard Medical School Boston MA 206 Histone Methyltransferase EZH2 Expression Marks Proliferation Rate and Histologic Progression Not Subtype in Chronic Lymphocytic Leukemia in Contrast to Methylated DNA Levels 1529 Weiqiang Zhao Shweta Chaudhary Kara Patterson Guojuan Zhang David Kellough Dan Jones The Ohio State University Wexner Medical Center Columbus OH 207 Chronic Lymphocytic Leukemia Transdifferentiates into Neuroendocrine Carcinoma Really 1342 Diana Castro Subhadra Nandula Weiyi Chen Shahida Ahmed Jin Choe Donghong Cai Rutgers - New Jersey Medical School Newark NJ Cancer Genetics Inc. Rutherford NJ VA New Jersey Medical Center East Orange NJ Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 209NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 209 208 A Study of MUM-1 Expression Pattern in Follicular Lymphoma 1479 Ana Ruano Eric D Hsi Cleveland Clinic Foundation Cleveland OH 209 CXCR4 Expression in Follicular Lymphoma 1329 Maryam D Ameri Jerry T Wong Lawrence Low Yuan Yuan Chen Dennis D Weisenburger Raju Pillai Young S Kim Joo Y Song City Of Hope Natinal Medical Center Duarte CA 210 Correlation Between Isotype Switch and Somatic Hypermutation in Follicular Lymphoma 1397 Chad Hudson Janice M Spence Sapna S Patel Richard Burack University of Rochester Medical Center Rochester NY 211 Role of Autophagy in Follicular Lymphoma 1480 Ana Ruano Juraj Bodo Eric D Hsi Cleveland Clinic Foundation Cleveland OH 212 Coexpression of MYC and BCL2 Proteins Identies a Subset of Follicular Lymphoma That Undergoes Transformation to Diffuse Large B-cell Lymphoma and Correlates with Poor Overall Survival 1423 Lawrence Low Joo Y Song Yuan Y Chen Maria Valle Dennis D Weisenburger Young S Kim City of Hope National Medical Center Duarte CA 213 Gene Expression Signaling Signature Provides Insights into Poor Survival Associated with High Expression of BRIC5 Survivin in Mantle Cell Lymphoma 1361 Ghaleb Elyamany Ariz Akhter Leslie Street Etienne Mahe Ali Matar Al Zahrani Meer-Taher Shabani-Rad Douglas Allan Stewart Adnan Mansoor University of Calgary Calgary Canada Prince Sultan Military Medical City Riyadh Saudi Arabia University of Calgary Calgary Laboratory Services Calgary Canada Alberta Health Services Calgary Canada 214 Immunophenotypically Atypical Mantle Cell Lymphoma aMCL Is Clinically Distinct from Typical Mantle Cell Lymphoma tMCL 1330 Barina Aqil John L Frater Anjum Hassan Marianna B Ruzinova Eric J Duncavage Friederike H Kreisel Washington University School of Medicine St Louis MO 215 A Unique Variant of Indolent Mantle Cell Lymphoma Exclusively Involving Gastrointestinal Tract 1481 Wichit Sae-Ow Janine Pichardo Zhitao Ying Kumar Anita Andrew D Zelenetz Anas Younes Ahmet Dogan MSKCC New York NY Sloan Kettering Institution New York NY 216 Mantle Cell Lymphoma with MYC Rearrangement Best Considered as a Form of Double Hit Lymphoma 1396 Zhihong Hu Wei Wang Zi Chen Guilin Tang Xinyan Lu Shaoying Li L Jeffrey Medeiros Shimin Hu The University of Texas M.D. Anderson Cancer Center Houston TX 217 RNA In Situ Hybridization for underlineIRTA1 underline as a Specic Marker for Marginal Zone Lymphomaunderline 1510 Zhen Wang James R Cook Cleveland Clinic Cleveland OH 218 Chronic Memory B-cell Leukemia Primary Peripheral Blood Presentation of Low-Grade Marginal Zone- Derived B-cell Lymphomas 1530 Mei Zheng Jennifer N Sanmann Warren G Sanger Samuel J Pirruccello University of Nebraska Medical Center Omaha NE 219 EBV Marginal Zone Lymphoma in Immunocompromised Patients Report of Five Cases 1376 Shunyou Gong Karthik A Ganapathi Chad M McCall Genevieve M Crane Liqiang Xi Mark Raffeld Stefania Pittaluga Amy S Dufeld Elaine S Jaffe National Institutes of Health Bethesda MD Johns Hopkins University Baltimore MD 220 AID-Generated IGH Glycosylation Sites but Not Somatic Hypermutation Rate Differentiate Marginal Zone Lymphoma and Follicular Lymphoma 1398 Chad Hudson Hani Katerji Janice M Spence Diana Adlowitz Richard Burack University of Rochester Medical Center Rochester NY 221 Classication of Non-Hodgkin Lymphoma NHL in the Developing World The International NHL Classication Project 1454 Anamarija Perry Jacques Diebold Kenneth MacLennan H Konrad Muller-Hermelink Bharat N Nathwani Eugene Boilesen Martin Bast James Armitage Dennis D Weisenburger City of Hope National Medical Center Duarte CA 222 Burkitt Lymphoma Presenting within the Thyroid Gland Clinicopathologic Features in Seven Patients 1465 Andres Quesada Huifei Liu Roberto Miranda Jeffrey Medeiros Natalia Golardi Shahreen Billah Jesse M Jaso M.D. Anderson Cancer Center Houston TX UTHealth Medical School at Houston Houston TX 223 Post-Treatment Residual Disease Detection by Droplet Digital PCR in Hairy Cell Leukemia Comparison with Allele Specic PCR and Immunohistochemistry 1500 Silvia Uccella Nora Sahnane Roberta Cerutti Francesca Magnoli Leonardo Campiotti Michele Merli Stefano La Rosa Fausto Sessa Daniela Furlan University of Insubria Varese VA Italy Ospedale di Circolo di Varese Varese VA Italy 224 Plasma Cells in Monoclonal Gammopathy of Undetermined Signicance Exhibit Signicantly Fewer Immunophenotypic Aberrancies Than Those of Plasma Cell Myelomaunderline 1381 Sarika Gupta Andrew M Bellizzi Nitin Karandikar Carol Holman University of Iowa Hospitals and Clinics Iowa City IA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016210 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016210 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 225 Cost Effectiveness of Cell Proliferation vs. Cytogenetics for Risk Stratication in Multiple Myeloma 1360 Scott Ely David Tacha Peter Forsberg Ihsane Ouansa Ruben Niesvizky Tomer Mark Weill Cornell New York NY Biocare Inc. Concord CA 226 Cytogenetic Subgroups and Their Clinical Implications in Multiple Myeloma Patients with TP53 Deletion underlineunderline 1385 Suyang Hao Sergej Konoplev Robert Orlowski L Jeffrey Medeiros Shimin Hu Pei Lin Xinyan Lu Houston Methodist Hospital Houston TX UTMD Anderson Cancer Center Houston TX UT MD Anderson Cancer Center Houston TX 227 Immunophenotypic and Cytogenetic Evolution Pattern of the Neoplastic Cells in Relapsed Multiple Myeloma after Stem Cell Transplant 1471 Anton V Rets Reha M Toydemir Jerry W Hussong Mohamed E Salama University of Utah Salt Lake City UT ARUP Laboratories Salt Lake City UT 228 Next Generation Sequencing NGS of Somatic Mutations for Residual Disease Detection of Plasma Cell Neoplasms in Instances of a PCR Negative Immunoglobulin Gene Rearrangement Assays 1523 Wei Xing Xiuling Meng Yiqin Xiong Keith Tomaszewicz Bruce A Woda Ediz F Cosar Lloyd Hutchinson University of Massachusetts Medical School Worcester MA 229 A Quantitative and Qualitative Approach Using a Dual Immunostain to Estimate the Percentage of Tumor Associated Macrophages and Reed-Sternberg Cells in Classical Hodgkin Lymphoma 1344 Catherine Chaudoir Diana Veillon James Cotelingam Menchu Ong John Glawe Chris Pattillo Chris Kevil LSUHSC Shreveport Shreveport LA 230 Epstein Barr Virus-Positive Classical Hodgkin Lymphoma Characterization of Microenvironment Using CD 163 and PD-1 Expression by Immunohistochemistry 1327 Ali Al-Habib Janice Ahn Ryan Okal Jeffrey Vos Flavia G Rosado West Virginia University Morgantown WV 231 PD-L1 Expression and T-Nk Cell Alterations in Staging Bone Marrow Biopsies of Newly Diagnosed Classical Hodgkin Lymphoma Patientsunderline 1524 Wei Xing Karen Dresser Rui Zhang Benjamin J Chen UMass Memorial Medical Center and University of Massachusetts Medical School Worcester MA School of Public Health Boston University Boston MA 232 PD-L1 Expression Correlates with EBV Status in Post- Transplant Lymphoproliferative Disorders 1447 Horatiu Olteanu Paul Hosking Alexandra Harrington Steven Kroft MCW Milwaukee WI 233 Tumor Suppressor IRF-1 Expression Is Decreased in Post-Transplant Lymphoproliferative Disorder 1446 Horatiu Olteanu Wadzanai Mboko Vera Tarakanova Paul Hosking Alexandra Harrington Steven Kroft MCW Milwaukee WI INFECTIOUS DISEASE PATHOLOGY 234 Histologic Features and Immunohistochemical Characterization of Inammatory Inltrates in Eschar Biopsy Specimens from Patients with Rickettsia parkeri Rickettsiosis 1541 Dianna Ng Tara Jones Christopher Paddock Centers for Disease Control and Prevention Atlanta GA 235 NKX3.1 Identies Fungal Organisms from the Esophagus 1543 Martina Pejchal Reetesh K Pai Douglas J Hartman University of Pittsburgh Medical Center Pittsburgh PA 236 Evolution of High-Risk Human Papillomavirus Genotypes in Anal Biopsies from HIV-Positive Patients after Long-Term Follow-Up 1547 Hai Wang Yiang Hui M Ruhul Quddus Jayasimha N Murthy Zakaria Grada Dongfang Yang C James Sung Shaolei Lu Li Juan Wang Warren Alpert Medical School of Brown University Providence RI 237 Development of an RNA In Situ Hybridization Assay for Hepatitis C Virus HCV Detection in Patient FFPE Samples 1542 Emily Park Na Li Hongzhe Sun Jing-min Zhao Shu- hong Liu Mindy Wang Yuling Luo Xiao-Jun Ma Advanced Cell Diagnostics Inc. Hayward CA 302 Military Hospital of China Beijing China 238 Histopathologic Features of T. Pallidum Infection Differ between the Rectum and Anus 1546 Julie Y Tse Vikram Deshpande Judith A Ferry Lawrence Zukerberg Massachusetts General Hospital Boston MA 239 Yersinia Pestis Osteomyelitis An Underreported Complication of Plague 1538 Gillian L Hale Sherif R Zaki Sarah M Dry Centers for Disease Control and Prevention Atlanta GA UCLA Los Angeles CA 240 Investigation of Potential Misdiagnosis of Corynebacteria as Mycobacteria Based on Acid Fast Stains in Surgical Pathology Specimens 1536 Derrick J Chen Scott A Cunningham Elizabeth M Druffel Robin Patel Bobbi Pritt Mayo Clinic Rochester MN 241 Staph Pseudintermedius An Emerging Pathogen 1533 John Biemer Paul Schreckenberger Loyola University Medical Center Maywood IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 211NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 211 242 Morphoproteomics to Dene Targets for Host-Directed Therapy in Tuberculosis 1534 Robert Brown Shen-An Hwang Robert L Hunter University of Texas Health Science Center at Houston Medical School Houston TX 243 Interpretation of HSV Positive Respiratory Specimens Using Quantitative PCR 1545 Christopher Suciu Michelle Stram Jansen Seheult Charles R Rinaldo University of Pittsburgh Medical Center Pittsburgh PA 244 Return of the Great Mimicker Treponema Pallidum in the Gastrointestinal Tract 1540 Jennifer Muir Richard Kirsch Paul Medline Robert H Riddell University of Toronto Toronto ON Canada Mount Sinai Hospital Toronto ON Canada Gamma Dynacare Medical Laboratories Brampton ON Canada 245 Prevalence of Adenovirus Colitis in Stem Cell Transplant Recipients 1532 Andrew Bandy Xiaoming You Haonan Li Jie Liao Sambasiva Rao Guang-Yu Yang Northwestern University Chicago IL PANCREAS BILIARY TREE 246 Morphologic Characterization of Intrahepatic Cholangiocarcinomas ICCs 1759 David Martin Hyejeong Choi Bahar Memis Volkan Adsay Alyssa M Krasinskas Emory University Atlanta GA Ulsan University Hospital Ulsan Republic of Korea 247 Comparative Study of Isocitrate Dehydrogenase 1 Mutations in Intraheptatic Cholangiocarcinoma by Immunohistochemistry and Pyrosequencing 1758 Amy A Lo Helio A Costa Jim Zehnder David Dittman Sam Rao Guang-Yu Yang Nike Beaubier Stanford School of Medicine Stanford CA Northwestern School of Medicine Chicago IL 248 Impact of Training and Experience on Evaluation of Biliary Brushings BDB 1771 Michelle Reid Ezgi Hacihasanoglu Vaidehi Avadhani Adeboye O Osunkoya Uma Krishnamurti Krisztina Z Hanley Alyssa Krasinskas Lauren Daniels Alexa Freedman Michael Goodman Volkan Adsay Emory University Atlanta GA 249 Intraepithelial Neoplasia as a Pitfall in Fine Needle Aspiration of Solid Pancreatic Masses 1744 Jennifer L Dettloff Pamela J Hodul Jason Klapman Cynthia Harris Mokenge P Malafa Domenico Coppola Barbara A Centeno Moftt Cancer Center Tampa FL 250 Bile Duct Brush and EUS FNA Pancreas in Pancreatic- Biliary Disease Management A 5-Year Audit 1777 Lakshmi Venkatraman Alexandra Doyle Paul Kelly Neil H Anderson Belfast Health and Social Care Trust Belfast United Kingdom 251 Signicance of E-cadherin Expression in Pancreatic Intraepithelial Neoplasia and Ductal Adenocarcinoma 1742 Joon H Choi Min J Kim Hyeong C Shin Mi J Gu Young K Bae Yeungnam University College of Medicine Daegu Republic of Korea 252 Molecular Prole of Pancreas Ductal Adenocarcinoma with CancerSCANTM Panel Analysis 1743 Misun Choi Kee-Taek Jang Donghyun Park Woongyang Park Seoung Ho Choi Samsung Medical Center Seoul Republic of Korea Sungkyunkwan University School of Medicine Suwon Gyeonggi-do Republic of Korea 253 Clinicopathological Signicance of MUC13 Expression in Pancreatic Ductal Adenocarcinoma PDAC the Positive Prognostic Marker and Possible Candidate for Molecular Targeted Therapy 1760 Katsuji Marukawa Tomoko Mitsuhashi Yutaka Hatanaka Asami Morooka Daisuke Sato Takeo Nitta Toru Nakamura Satoshi Hirano Yoshihiro Matsuno Hokkaido University Hospital Sapporo Japan 254 SMAD4 Inactivation as Assessed by Diligently Evaluated Immunohistochemistry Is Highly Associated with Adverse Prognosis in Pancreas Cancer 1745 Craig Dunseth Sarah L Mott Jason Hornick James J Mezhir Andrew M Bellizzi University of Iowa Iowa City IA Brigham and Womens Boston MA 255 Long Noncoding RNA MALAT1 Sequesters miR-217 in Nucleus and Acts as a Oncogene in Pancreatic Carcinogenesis 1741 Jie Chen Peking Union Medical College Hospital Beijing China 256 CD13hi Neutrophil-Like Myeloid-Derived Suppressor Cells Exert Immune Suppression through Arginase 1 Expression in Pancreatic Ductal Adenocarcinoma 1782 Jing Zhang Xiongfei Xu Min Shi Ying Chen Danghui Yu Chenyan Zhao Yan Gu Biao Yang Gang Jin Minghua Zhu Changhai Hospital Shanghai China Second Military Medical University Shanghai China Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016212 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016212 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 257 Neoadjuvant Therapy NAT for Borderline Resectable Pancreatic Cancer BRPC Comparison of Histologic Grading Systems of Residual Adenocarcinoma Following Chemotherapy CT Alone 1755 Sunhee S Kim Andrew H Ko Eric K Nakakura Zhen J Wang Carlos U Corvera Hobart W Harris Kimberly S Kirkwood Ryutaro Hirose Margaret A Tempero Grace E Kim UCSF San Francisco CA 258 Lymph Node Yield and Excision Margin Status in Pancreaticoduodenectomy Whipples Specimens A Three and a Half Year Audit Assessing the Impact of Neoadjuvant Therapy 1762 Brianan McGovern Daniele M di Capua Luigi Bonanni Rozana Abdul Rahman Jean Murphy Kieran Sheahan Niall Swan St. Vincents University Hospital Dublin Ireland 259 MicroRNA Expression in Pancreatic Ductal Adenocarcinoma A Comparative Study to Predict Metastasis after Neoadjuvant Chemoradiation 1770 Juan Putra Francine de Abreu Eric B York Scott M Palisoul Arief A Suriawinata Xiaoying Liu Gregory J Tsongalis Dartmouth-Hitchcock Medical Center Lebanon NH 260 Unique Mutational Signature of Pancreatic Neuroendocrine Tumors with Mismatch Repair Mutations 1761 Cheryl A Mather Jenny Qi Emily K Bergsland Grace E Kim Scott A Oakes University of California San Francisco San Francisco CA 261 Loss of MGMT Protein Expression in Pancreatic Neuroendocrine Neoplasms Does Not Affect Overall Survival 1781 Allison J Zemek John Allen Hemamalini Vairamuthu Pamela L Kunz Teri A Longacre Stanford Health Care Stanford CA PATHOBIOLOGY INCLUDING PAN-GENOMICPAN- PROTEOMIC APPROACHES TO CANCER 262 Identication and Validation of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma 1825 Richard L Wu Shadan Ali Artur Rangel-Filho David Andrews Yao-Shan Fan Fazlul Sarkar Rac Beydoun Jackson Memorial Hospital University of Miami Miami FL Detroit Medical Center Wayne State University Detroit MI 263 LINE-1 RNA and ORF1p Protein Are Broadly Co- Expressed in Colon Cancerunderline 1821 Martin Taylor Dipti Sajed Erik Williams David T Ting Vikram Deshpande Massachusetts General Hospital and Harvard Medical School Boston MA 264 20q Gain Is an Oncogenic Driver Event That Occurs Preferentially in KRAS BRAF Wild Type Colorectal Carcinoma 1814 Carlos Pagan Ryan Ptashkin Ahmet Zehir Michael F Berger Jinru Shia Efsevia Vakiani Marc Ladanyi Jaclyn Hechtman Memorial Sloan-Kettering Cancer Center New York NY 265 Recurrent Truncating SOX9 Mutations Are Associated with KRAS and PI3K Pathway Mutations and May Be Oncogenic in Colorectal Carcinoma 1801 Jaclyn Hechtman Breanna M Javier Efsevia Vakiani Jinru Shia Ahmet Zehir Christine Iacobuzio-Donahue Memorial Sloan Kettering Cancer Center New York NY 266 Up-regulated S100A4 Is Associated with Tumor Progression in Signet-Ring Cell Carcinoma 1808 Yihong Ma Gene P Siegal Shi Wei University of Alabama at Birmingham Birmingham AL 267 Correlation between the Expression of Mismatch Repair Proteins MLH1 MSH2 MSH6 and PMS2 and Cell Proliferation Status in Mismatch Repair-Procient Tissues Biological and Pathological Implications 1790 Haiyan Chen Liang Huang Neelima Valluru Xiuzhen Duan Yi Zhou Mohammed Atieh Stefan E Pambuccian Xianzhong Ding Loyola University Medical Center Maywood IL Washington University in St. Louis St. Louis MO 268 Immuno-Proteomics of Colon Cancer PSMA1 Is Implicated in Colorectal Carcinogenesis and Has Prognostic Signicance 1826 Qian Yang Prashant Bavi Julia Y Wang Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 269 Clinician Experience with an NGS Clinical Observation Trial in Oncology 1810 Susan Mockus Cara Statz Petra Helbig Sara E Patterson Victoria Sanders Marek Skacel Gregory J Tsongalis Jens Rueter Jackson Laboratory Farmington CT EEMC Brewer ME Dahl-Chase Pathology Bangor ME DHMC Lebanon NH 270 Validation of a Clinical 1400-Gene Assay for Genomic Proling of Cancer from DNA and RNA 1792 Michael J Clark Martina Lefterova Elena Helman Ravi K Alla Deanna M Church Sean M Boyle Shujun Luo Massimo Morra Jason Harris Nan Leng Christian Haudenschild Richard Chen John West Personalis Menlo Park CA 271 Utility of a Rapid Turnaround Clinically-Relevant Gene Panel for Next Generation Sequencing NGS Analysis of FFPE Solid Tumors 1804 Ravindra Kolhe Alka Chaubey Deepa Jagdale WonSok Lee Ashis K Mondal Andrew Hadd Georgia Regents University Augusta GA Greenwood Genetics Center Greenwood SC Asuragen Inc. Austin TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 213NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 213 272 Are the Genomics in the Cancer Genome Atlas Representative of Patients with Recurrent Cancer That Is Refractory to Standard Therapy 1788 Emily Broaddus Scott Kopetz J Jack Lee Jiexin Zhang Kenna Shaw Russell Broaddus University of Texas Austin TX M.D. Anderson Cancer Center Houston TX 273 Development of Patient Derived Tumor Organoids to Guide Precision Medicine 1816 Chantal Pauli Loredana Puca Brooke Emerling Benjamin Hopkins Michael Augello Andrea Sboner Olivier Elemento David Pisapia Rema Rao Brian D Robinson Juan Miguel Mosquera David Rickman Himisha Beltran Mark Rubin Weill Cornell Medical College-New York Presbyterian Hospital New York NY 274 MET Molecular Epidemiology of Advanced Solid Tumors Candidate to Targeted Therapiesunderline 1813 Paolo Nuciforo Analia Azaro Ludmila Prudkin Roberta Fasani Paola Martinez Maria Diaz Jose Jimenez Wei-Li Liao Alejandra Iglesias Marta Vilaro Debora Moreno Fabiola Cecchi Adele Blackler Todd Hembrough Ana Vivancos Jordi Rodon Vall dHebron Institute of Oncology Barcelona Spain Oncoplex Diagnostics Rockville MD NantOmics Culver City CA 275 Distribution of IDH1 and IDH2 Genomic Alterations across the Landscape of Relapsed and Refractory Solid Tumors and Hematologic Malignancies 1795 Julia A Elvin Jo-Anne Vergilio Garrett Frampton Zachary Chalmers James Suh Laurie Gay Siraj M Ali Vincent A Miller Philip J Stephens Jeffrey S Ross Foundation Medicine Inc. Cambridge MA Albany Medical College Albany NY 276 Differential Expression of PDGFRB and EGFR in Microvascular Proliferation in Glioblastoma 1806 Jianyi Li Guiyan Xu North Shore University Hosiptal and Long Island Jewish Medical Center Lake Success NY Northwell Health Lake Success NY 277 Retrospective Review of Targeted Molecular Genotyping of Lung Adenocarcinomas at Baylor University Medical Center 1812 Stacey L Murthy Cody Thomas Stacia Clement-Kruzel George J Snipes Baylor University Medical Center Dallas TX 278 Frequency of KRAS Subtypes in Non-Small Cell Lung Cancer 1787 Anna Biernacka Peter D Tsongalis Jason D Peterson Francine de Abreu Candice C Black Edward Gutmann Xiaoying Liu Vijayalakshmi Padmanabhan Laura J Tafe Christopher I Amos Gregory J Tsongalis Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center and Geisel School of Medicine at Dartmouth Lebanon and Hanover NH 279 Copy Number Alterations in Primary and Recurrent Breast Tumors 1802 Rahul M Jawale Kevin C Johnson Kristin E Williams Brian T Pentecost Brock C Christensen Christopher N Otis Kathleen F Arcaro Baystate Medical Center Springeld MA Geisel School of Medicine at Dartmouth Hanover NH University of Massachusetts Amherst MA Wadsworth Center NYS DoH Albany NY 280 Shifts in Mutation Proles between Primary and Synchronous Lymph Node Metastases mLN in Triple Negative Breast Cancer 1829 Weiqiang Zhao Kara Patterson Susan Long Kevin Y Zhao Nehad Mohamed Joshua Coleman Yan Tang Bhuvaneswari Ramaswamy Daniel Jones The Ohio State University Wexner Medical Center Columbus OH The Ohio State University James Cancer Center Columbus OH 281 PITPNC1 in Breast Cancer 1824 Phillip Williams Ranju Nair Grace Cheung Naomi A Miller Bruce J Youngson Susan J Done University Health Network Toronto Canada University of Toronto Toronto Canada 282 Multiplex Gene Expression Analysis of Eosinophilic Esophagitis Refractory to Therapy Using Nanostring Technology 1793 David Corney Sonja Chen Yiang Hui Kara A Lombardo Shamlal Mangray Murray B Resnick Andres Matoso Thomas Jefferson Philadelphia PA Rhode Island Hospital and Brown University Providence RI 283 Utility of Oral Fluid Saliva for Molecular Proling in Hematologic Malignancy 1803 Jonathan Killian Maria E Arcila Connie Batlevi Marc Ladanyi Paul Meltzer Ryan Ptashkin Anas Younes National Cancer Institute Bethesda MD Memorial Sloan Kettering Cancer Center New York NY 284 Cigarette Smoke Associated Genetic Alterations Found in Urine Specimens from Patients with Supercial Non-Muscle Invasive High Grade Urothelial Carcinoma 1827 Ming Zhang Sasinya N Scott Nancy Bouvier Michael F Berger Oscar Lin Memorial Sloan Kettering Cancer Center New York NY 285 Combined Molecular Testing Mutational Analysis and MicroRNA Classier Status Advances Understanding of Molecular Pathobiology of Thyroid Follicular Neoplasia 1818 Angela M Sanguino Ramirez Maria L Torres Jan F Silverman Sydney D Finkelstein Allegheny Health Network Pittsburgh PA RedPath Interpace Diagnostics Pittsburgh PA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016214 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016214 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 286 mTOR Pathway Genes Drive Intratumor Heterogeneity and Morphological Progression in Clear Cell Renal Cell Carcinomas 1794 Salvador Diaz-Cano Russel Sutherland Jane Moorhead Alfredo Blanes Richard Dobson Kings College HospitalKings College London London United Kingdom University of Malaga School of Medicine Malaga Spain 287 TGF Is an Upstream Regulator of mTORC2-Dependent Bladder Cancer Migration and Invasion 1800 Sounak Gupta Andrew M Hau Hikmat A Al-Ahmadie Jyoti Harwalkar Aaron C Shoskes Paul Elson Jordan R Beach George S Hussey Thomas T Egelhoff Philip H Howe Donna Hansel Mayo Clinic Rochester MN University of California San Diego La Jolla CA Memorial Sloan Kettering Cancer Center New York NY Cleveland Clinic Cleveland OH Medical University of South Carolina Charleston SC 288 Molecular Proling Reveals That Multiple Merkel Cell Carcinoma Tumors May Represent Either Clonally Related Metastases or Multiple Clonally Distinct Primaries 1805 Lorena Lazo de la Vega Kelly L Harms Daniel H Hovelson Samantha Rahrig Andi K Cani Chia-Jen Liu Douglas R Fullen Timothy M Johnson Scott A Tomlins Paul W Harms University of Michigan Ann Arbor MI 289 Concordance of Anti-BRAF p.V600E immunohistochemistry with BRAF Gene Sequence in Solid Tumors Carrying Diverse BRAF Mutations 1797 Zoran Gatalica Semir Vranic Inga Rose Peggy Teresi Rebecca Feldman Ryan P Bender Caris Life Sciences Phoenix AZ Clinical Center University of Sarajevo Sarajevo Bosnia and Herzegowina 290 Role of SOX4 in PTEN-Mediated Prostate Tumorigenesis 1811 Carlos Moreno Birdal Bilir Walter Wiles Soma Sannigrahi Veronique Lefebvre Pierre Chambon Demetri Spyropoulos David Martin Adeboye O Osunkoya Emory University School of Medicine Atlanta GA Cleveland Clinic Cleveland OH Medical University of South Carolina Charleston SC Institut de Genetique et de Biologie Moleculaire et Cellulaire Strasbourg France 291 The Ataxia-Telangiectasia Mutated and RAD3-Related Protein Kinase Regulates Intracellular Hydrogen Sulde Concentrations 1819 Rodney Shackelford Jei Chen Rabie Shanti Junaid Ansari Moiz Vora LSU Health Sciences Shreveport Shreveport LA LSU Health Sciences Center Shreveport LA Feist Weiller Cancer Center Shreveport LA 292 Role of NOTCH Signaling Molecules in the Development of Barretts Associated Adenocarcinoma 1789 Weibiao Cao Dan Li Fadlallah Habr Jack Wands Rhode Island Hospital and Warren Alpert Medical School of Brown University Providence RI 293 Platelet Cloaking Maintains Migratory and Invasive Characteristics of CTCs 1820 Cathy D Spillane Sinead Skehan Cara M Martin Sharon OToole Orla Sheils John OLeary Trinity College Dublin Dublin Ireland Coombe Women Infants University Hospital Dublin Ireland Dublin City University Dublin Ireland PEDIATRIC PATHOLOGY 294 Botryoid Wilms Tumor A Non-Existent Entity Causing Diagnostic and Staging Difculties 1841 Marco Schiavo Lena Gordan Vujanic San Raffaele Scientic Institute Milano Italy University Hospital of Wales Cardiff United Kingdom 295 Placental Pathology in Small-for-Gestational Age Placentas from Pregnancies with Type 1 Pregestational Diabetes 1835 Mai He Phinnara Has Suzanne DeLaMonte Roman S Starikov Women Infants Hospital of Rhode IslandAlpert Medical School of Brown University Providence RI Women Infants Hospital of Rhode Island Providence RI Rhode Island Hospital Alpert Medical School of Brown University Providence RI Phoenix Perinatal Associates Phonnix AZ 296 BRAF Reactivity and BRAF Mutations in Pediatric Langerhans Cell Histiocytosis 1840 Essia Saiji Christelle Cerato Biderbost Margaret Berczy Anne-Laure Rougemont Geneva University Hospitals Geneva Switzerland 297 Absence of Distinct Immunohistochemical Distribution of Annexin A5 C3b C4d and IgG in Placentas from Patients with Antiphospholipid Antibodies Compared to Preeclampsia and SLE 1838 Cathleen Matrai Jacob H Rand Rebecca Baergen NYPH-Weill Cornell NYC NY 298 Collagen XVIII and Procollagen-lysine 2 oxoglutarate 5-dioxygenase 2 PLOD2 Expression in Human Pediatric and Mouse Rhabdomyosarcomas Exploring Potential Biomarkers of Therapeutic Relevance 1830 Jesse Bond Sakir H Gultekin Christopher Hartley Teagan Settelmeyer Charles Keller Atiya Mansoor Oregon Health and Sciences University Portland OR Childrens Cancer Therapy Development Institute Fort Collins CO Medical College of Wisconsin Milwaukee WI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 215NEXTGENERATION LEARNING 2016 POSTER SESSION IV Tuesday March 15 2016 100 PM - 430 PM CC Exhibit Hall 4ABC 215 299 Prenatal Jarcho-Levin Syndrome 1837 Ana Larque Mar Bennasar Paola Castillo Alfons Nadal Hospital Clinic Barcelona Spain Barcelona Center for Maternal-Fetal Medicine and Neonatology Hospital Clnic Barcelona Spain 300 SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas from Ependymomas but Shows No Differences in Expression Level in Ependymomas from Infant Versus Older Children or between Molecular Subgroups 1839 Abby M Richmond Andrew M Donson Nicholas K Foreman Bette K Kleinschmidt-DeMasters University of Colorado Aurora CO Childrens Hospital Colorado Aurora CO 301 Molecular Characterization of Gliomas in Adolescents and Young Adults 1844 Mariona Sunol Josep Riera Monroig Carmen de Torres Iban Aldecoa Carlota Rovira Cristina Jou Eva Rodriguez Ofelia Cruz Teresa Ribalta Hospital Sant Joan de Deu Barcelona Spain Hospital Clinic Barcelona Spain 302 Will the Quest for a Novel Positive Marker for a Diagnosis of Hirschsprung Disease on Formalin Fixed Rectal Mucosal Biopsies End with a Glucose Transporter A Detailed Dual IHC Panel Study of GLUT1 and Calretinin 1831 Maria F Bukelo Usha Kini Suravi Mohanty Kanishka Das St. Johns Medical College and Hospital Bangalore Karnataka India 303 Clinicopathological Study of Hepatoblastoma with Pulmonary Metastases 1845 Mio Tanaka Misa Yoshida Rieko Ijiri Norihiko Kitagawa Masato Shinkai Hiroaki Goto Yukichi Tanaka Kanagawa Childrens Medical Center Yokohama Japan 304 Tight Junction Dysregulation Is Involved in the Rotavirus Infection Related Diarrhea 1848 Richard L Wu Artur Rangel Monica Garcia Janet M Poulik Jackson Memorial HospitalUniversity of Miami Miami FL Detroit Medical CenterWayne State University Detroit MI 305 Juvenile Laryngeal Papillomatosis Relation between p16 and p63 Expression Human Papilloma Virus Infection and Clinical Evolution 1834 Louise Galmiche Sebastien Pierrot Helene Pere Vincent Couloigner Cecile Badoual Necker Hospital Paris France Georges Pompidou European Hospital Paris France 306 Reevaluation of Histological Features for IntraExtra Pulmonary Sequestration 1846 Mio Tanaka Rieko Ijiri Kumiko Nozawa Noriko Aida Masato Shinkai Yukichi Tanaka Kanagawa Childrens Medical Center Yokohama Japan POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CDPOSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC Board Number Board Number Board Number Board Number BREAST PATHOLOGY 1 Expression of Splicing Variants of Androgen Receptor in Primary and Metastatic Breast Cancer 185 Yehonatan Kane Fang-Ming Deng Yang Zhan Yanfeng Qi Jane D Hon Xichun Liu Haitao Zhang Jinhua Wang Rachel Brody Rosemary Wieczorek Yan Dong Peng Lee Baljit Singhb New York University Langone Medical Center New York NY Tulane University New Orleans MI 2 Androgen Receptor Expression in Triple Negative Breast Cancers A Single Institution Experience 234 Palawinnage Vidarshi U Muthukumarana Sheila E Segura Theresa L Profeta Ramapriya Vidhun Danbury Hospital Danbury CT 3 Integration of Androgen Receptor AR Expression to Predict Survival for Triple-Negative Breast Carcinoma TNBC 109 Kristine Astvatsaturyan Yong Yue Shikha Bose Cedars Sinai Medical Center Los Angeles CA 4 Luminal Androgen Receptor LAR Subtype Breast Cancers Are Not Histologically Dened by Apocrine Morphology 229 Ann M Moyer Xuemei Wu Daniel W Visscher Krishna R Kalari Kevin J Thompson Xiaojia Tang Vera J Suman Travis J Dockter Sarah A McLaughlin Alvaro Moreno-Aspitia Donald W Northfelt Richard J Gray Katie N Jones Amy L Conners Eric D Wieben Liewei Wang Richard M Weinshilboum Matthew Goetz Judy C Boughey Mayo Clinic Rochester MN Mayo Clinic Jacksonville FL Mayo Clinic Scottsdale AZ 5 Molecular and Histopathologic Correlation of BRCA1- and BRCA2-Associated Invasive Breast Carcinoma 280 Tiffany Shao Jordan Lerner-Ellis Martin C Chang Mt Sinai Hospital Toronto ON Canada University of Toronto Toronto ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016216 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016216 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 6 BRCA1 and BRCA2-Associated Breast Cancers Demonstrate Distinct Histopathologic Features Biomarker Expression Patterns and Molecular Subtypes 147 Constance Albarracin Sagar Dhamne Banu Arun Kristin Ward Yun Wu Daniel G Rosen Xiaoyan Cui Erika Resetkova Xiuzhen Duan Hui Chen Isabelle Bedrosian Angelica Gutierrez Barrera MD Anderson Houston TX Loyola University Chicago IL Baylor College Medicine Houston TX University Texas El Paso TX 7 Hyaline Fibrous Involution A Novel Histologic Finding That Is More Common in BRCA Breast Tissue 204 Hee Eun Lee Muhammad Arshad Rushin D Brahmbhat Tanya L Hoskin Stacey Winham Marlene H Frost Derek C Radisky Lori Denison Amy Degnim Daniel W Visscher Mayo Clinic Rochester MN 8 A Functional Assay for Homologous Recombination HR DNA Repair Assessment in Breast Cancers underline 154 Marcia Edelweiss Nadeem Riaz Salvatore Piscuoglio Charlotte KY Ng Britta Weigelt Robert W Mutter Robert Delsite Dilip Giri Tari King Jorge S Reis-Filho Simon Powell MSKCC NY NY 9 Overexpression of FoxO3a Is Associated with Lymph Node Metastasis and Poor Disease-Free Survival in Triple-Negative Breast Cancers 101 Rehman Abdul Yumin Chung Hyein Ahn Jongmin Sim Min Sung Chung Kiseok Jang Hanyang University College of Medicine Seoul Republic of Korea 10 Expression of Cancer Stem Cell Markers Predicts Worse Outcome in Early Stage Triple Negative Invasive Breast Carcinoma 297 Shir-Hwa Ueng Shin-Cheh Chen Yu-Sun Chang Yung- Chang Lin Yun-Feng Lo Hsien-Kun Chang Wen-Yu Chuang Shih-Che Shen Chuen Hsueh Chang Gung Memorial Hospital Linkou Taoyuan Taiwan Chang Gung University Taoyuan Taiwan 11 The Forkhead Box Transcription Factor FOXC1 Further Straties Prognosis of Patients with Triple-Negative Breast Cancer 309 Yong Yue Kristine Astvatsaturyan Xiaojiang Cui Xiao Zhang Benedick Fraass Shikha Bose Cedars-Sinai Medical Center Los Angeles CA 12 Down-Regulation of Fructose-16-Bisphosphatase FBP1 in Triple-Negative Breast Cancer 308 Esther Yoon Kenneth Hennrick Yong Mao Konstantin Volyanskyy Nevenka Dimitrova John T Fallon Minhao Zhong New York Medical College Valhalla NY Philips 345 Scarborough Road NY 13 Triple Negative Breast Cancers vs. Quadruple Negative Breast Cancers The Androgen Receptor Factor 301 Elena Vrotsos Carmen Gomez-Fernandez Mahsa Khanlari Mehrdad Nadji University of Miami Miami FL 14 Subset Populations of Patients with Triple Negative Breast Cancer Exist Possessing Biomarkers for Targeted Therapeutics 225 Wilfrido Mojica Paul Mojica Elizabeth Marchetti University at Buffalo Buffalo NY UCLA Los Angeles CA 15 Loss of PTEN in High Grade Advanced Stage Triple Negative Breast Ductal Cancers in African American Women 187 Farhan Khan Tammey Naab Luisel J Ricks-Santi Yasmine Kanaan Girmay Asgedom Howard University Hospital Washington DC Hampton University Hampton VA 16 Increased BCL2 Expression Predicts Poor Survival in Triple Negative Breast Cancer Patients 177 Jabed Iqbal Aye Aye Thike Takashi Yamasaki Joe Yeong Puay Hoon Tan Singapore General Hospital Singapore Singapore Kobe University School of Medicine Kobe Japan 17 Strong ROR1 Expression Is an Independent Adverse Prognostic Factor in Triple Negative Invasive Breast Carcinoma 173 Chuen Hsueh Hui-Ping Chien Shin-Cheh Chen Yu-Sun Chang Shir-Hwa Ueng Yung-Chang Lin Yun-Feng Lo Hsien-Kun Chang Wen-Yu Chuang Chang Gung Memorial Hospital Linkou Taoyuan Taiwan Chang Gung Memorial Hospital Keelung Keelung Taiwan Chang Gung University College of Medicine Taoyuan Taiwan 18 c-Myc Oncogene Highly Expressed but Not Amplied in High Grade Triple Negative Breast Ductal Cancers in African American Women 235 Tammey Naab Luisel J Ricks-Santi Farhan Khan Ashwini K Esnakula Girmay Asgedom Jeffrey Robinson Howard University Hospital Washington DC Hampton University Hampton VA University of Florida Gainsville FL 19 A Novel Risk-Predictive Metric Straties Triple-Negative Breast Cancers Based on Cell Cycling Kinetics 195 Sergey Klimov Andrew Green Mohammed A Aleskandarany Emad Rakha Ian O Ellis Guilherme Cantuaria Ayodeji O Agboola Michelle Reid Xiaoxian Li Padmashree CG Rida Ritu Aneja Georgia State University Atlanta GA University of Nottingham Nottingham United Kingdom Northside Hospital Cancer Institute Atlanta GA Olabisi Onabanjo University Sagamu Nigeria Emory University Atlanta GA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 217NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 217 20 The Prognostic Value of E-Cadherin and -Catenin in Triple-Negative Breast Cancer TNBC 282 Tiansheng Shen Gene P Siegal Shi Wei University of Alabama at Birmingham Birmingham AL 21 SAE2 Expression in c-MYC Positive Triple-Negative Breast Carcinomas 202 Kimberly Lally Xuemo Sean Fan Serhan Alkan Cedars-Sinai Medical Center Los Angeles CA 22 Retinoic Acid Receptor Alpha Is a Positive Prognostic Biomarker in Triple-Negative Breast Cancer 242 Angela Ogden Andrew Green Mohammed A Aleskandarany Emad Rakha Ian O Ellis Simak Ali Xiaoxian Li Uma Krishnamurti Michelle D Reid Padmashree CG Rida Ritu Aneja Georgia State University Atlanta GA The University of Nottingham Nottingham United Kingdom Emory University Hospital Atlanta GA Imperial College London London United Kingdom 23 High HER3-EGFR Score Predicts Aggressive Disease Course in Triple-Negative Breast Cancer 243 Angela Ogden Andrew Green Mohammed A Aleskandarany Emad Rakha Ian O Ellis Xiaoxian Li Uma Krishnamurti Michelle D Reid Padmashree CG Rida Ritu Aneja Georgia State University Atlanta GA The University of Nottingham Nottingham United Kingdom Emory University Hospital Atlanta GA 24 CD3 and FOXP3 Tumor-Inltrating Lymphocytes Are Associated with Better Prognosis in Triple Negative Breast Cancers 176 Jabed Iqbal Joe Yeong Jeffrey Chun Tatt Lim Puay Hoon Tan Singapore General Hospital Singapore Singapore 25 Comparison of Immune Response and PDL1 Distribution in Triple Negative Invasive Breast Carcinomas in Different Ethnic Populations 171 Jian He Arundhati Rao Arun Sreekumar Baylor Scott White Memorial Hospital Temple TX Baylor College of Medicine Houston TX 26 Tumor Inltrating Lymphocytes TIL in Predicting Neoadjuvant Therapy Response and Survival in HER2 Breast Cancers 106 Caitlin Andrews Elizabeth A Mittendorf Juhee Song Kelly K Hunt Aysegul A Sahin Yun Wu UT MD Anderson Cancer Center Houston TX 27 The Role of a Negative Axillary Fine Needle Aspiration in Identifying Breast Cancer Patients with No Axillary Metastasisunderlineunderline 178 Mark Jabbour Mothana Saadeldine Ghina Berjawi Faek Jamali Jaber Abbas Fouad Boulos American University of Beirut Medical Center Beirut Lebanon 28 Sentinel Lymph Node Status and Patterns of Invasion in Microinvasive Breast Carcinoma 276 Christopher Sebastiano Saipriya Iyer Anibal Cordero George Plitas Dilip Giri Memorial Sloan Kettering Cancer Center NY NY 29 Megakaryocytes in Lymph Nodes of Patients with Breast Cancer A Clinicopathologic Correlation 256 Jennifer Pincus Juehua Gao Megan Sullivan Northwestern University Feinberg School of Medicine Chicago IL CYTOPATHOLOGY 30 Differential Expression of Various Clones of Estrogen Receptor in Cell Block Preparation of Lung Adenocarcinoma 394 Laleh Hakima Kathie Schlesinger Jaya Sunkara Rouzan G Karabakhtsian Monteore Medical Center Bronx NY 31 Morphologic Assessment of Cellularity and Tumor Fraction in Concurrently Acquired Cytology Fine Needle Aspiration and Surgical Core Needle Biopsy for Molecular Analysis 445 Sinchita Roy Chowdhuri Hui Chen Gregg Staerkel John M Stewart The University of Texas MD Anderson Cancer Center Houston TX 32 Fine Needle Aspiration Biopsy Material of Liver Lesions Yields Higher Percentage of Tumor Cells for Molecular Studies A Direct Comparison to Concurrent Core Biopsy 388 Patricia Goldhoff Poonam Vohra Elham Khanafshar Britt-Marie Ljung University of California San Francisco San Francisco CA San Francisco General Hospital San Francisco CA 33 Cytologic Preparations for Next Generation Sequencing An Analysis of Quality Indicators 403 David Hwang Edmund Cibas Lynette M Sholl Brigham and Womens Hospital Boston MA 34 Molecular Adequacy of Fine-Needle Aspiration Cytologic Smears for Next Generation Sequencing in Lung Adenocarcinoma 347 Jordan Arkin Pan Zhang Rana S Hoda Navneet Narula Hanna Rennert Michael J Kluk Helen Fernandes New York Presbyterian Hospital-Weill Cornell New York NY 35 Suitability of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration EBUS-TBNA Samples for Diagnosis Staging and MolecularNGS Testing in Metastatic Malignancies Involving the Mediastinum 424 Valerica Mateescu Ritu Nayar Nike Beaubier Ajit Paintal Northwestern Memorial Hospital Chicago IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016218 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016218 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 36 Molecular Testing MT on Endobronchial Ultrasound EBUS Fine Needle Aspirates FNA Signicance of Appropriate Specimen Triage ST at Start of Procedure 460 Simon Sung John P Crapanzano David DiBardino David Swinarski William A Bulman Anjali Saqi Columbia University Medical Center New York NY 37 Cytomorphologic Features and EGFR Mutational Status of Combined Small Cell Lung Carcinomas 481 Yaxia Zhang Joseph C Cicenia Fadi W Abdul-Karim Cleveland Clinic Cleveland OH 38 Detection of EGFR Mutations ALK and ROS1 Rearrangements in Cytological Specimens An Institutional Experience 434 Rana Naous Shengle Zhang Kamal K Khurana SUNY Upstate Medical University Syracuse NY 39 EGFR Mutation Detection on Non Small Cell Lung Cancer Routine Cytological Samples by Digital PCR 465 Giancarlo Troncone Pasquale Pisapia Elena Vigliar Claudio Bellevicine Umberto Malapelle University of Napies Federico II Napoli Italy 40 EGFR KRAS and ALK Are Really Mutually Exclusive Report of Five Cases Harboring Two Different Theoretically Exclusive Double Mutations Diagnosed by FNA Cytology 421 Maria D Lozano Tania Labiano Jose M Lopez-Picazo Alfonso Gurpide Mercedes Aguirre Maria Eugenia Echarri Maria Amada Maset Nerea Gomez Jorge A Arabe Rodrigo Sanchez Jose I Echeveste Miguel A Idoate Salvador Martin-Algarra University of Navarra Pamplona Spain Complejo Hospitalario de Navarra Pamplona Spain 41 Molecular Proling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma 366 Jamal H Carter James A Miller Zahra Maleki The Johns Hopkins Hospital Baltimore MD 42 MicroRNA Proling of Malignant Mesothelioma Diagnostic Signicance in Cytology Specimens 476 Zhongbo Yang Qingqing Ding Magda Esebua Lester Layeld University of Missouri Columbia MO 43 Diagnostic Accuracy and False Negative Rate of EBUS-TBNA in Detection of Well Differentiated Neuroendocrine Tumors of the Lung 436 Laila Nomani Jordan P Reynolds Cleveland Clinic Cleveland OH 44 Triaging Cases with Clinically Suspicious Nodules and Negative Findings by Electromagnetic Navigational Biopsy Experience from One Tertiary Care Center 477 Alae Yaseen Xiu Yang Houda Alatassi Tanya Wiese Mostafa M Fraig University of Louisville School of Medicine Louisville KY 45 Metastases from Extrapulmonary Sites to Mediastinal Lymph Nodes A 10-Year Retrospective Review of Transbronchial Needle Aspiration Cytology in a Tertiary Care Center 470 Emily Wilding Teklu Legesse Dina Kokh Melissa Sweeney Paul Staats University of Maryland Baltimore MD 46 Lymphoma Diagnosis on Endoscopic Ultrasound Guided Fine Needle Aspiration Specimens of Abdominal Lymphadenopathy a Retrospective Study at an Academic Tertiary Referral Center 343 Roula Albadine Danh Tran-Thanh Antonio Maietta Sarto C Paquin Anand V Sahai Gille Gariepy Centre Hospitalier de lUniversit de Montral Montral QC Canada 47 Follicular Lymphoma Diagnosis by Fine Needle Aspiration Biopsies in a Cancer Center 425 Zula McCroskey Joseph D Khoury John M Stewart Nancy Caraway MD Anderson Cancer Center Houston TX 48 Hodgkin Lymphoma Diagnosed by Fine Needle Aspiration Cytology A Retrospective Review of 110 Consecutive Cases with Histopathologic Correlation 344 Megan Alderman Harvey M Cramer Indiana University School of Medicine Indianapolis IN 49 Fine Needle Aspiration Cytology of Histiocytic Sarcoma with Correlation of Histopathology and Immunohistochemistry 402 Yin Hung Scott B Lovitch Xiaohua Qian Brigham and Womens Hospital Boston MA 50 Challenge of Fine Needle Aspiration Diagnosis of Angiomyolipoma A Study of 33 Cases 485 Haijun Steve Zhou Ming Guo Yun Gong UT MD Anderson Cancer Center Houston TX 51 Utility of Fine Needle Aspiration and Core Needle Biopsy to Pre-Operatively Assess Renal Lesions 355 Aaron N Berg Sara E Monaco Jacqueline Cuda Rajiv Dhir Ronald L Hrebinko Liron Pantanowitz University of Pittsburgh Medical Center Pittsburgh PA 52 Cytomorphology of Clear Cell Papillary Renal Cell Carcinoma 419 Xiaoqi Lin Ximing Yang Northwestern University Chicago IL 53 A Series of Clear Cell Papillary Renal Cell Carcinoma Sampled by Aspiration Cytology 448 Sadia Sayeed Kathryn Lindsey Alexander Baras Christopher R Jackson Celeste N Powers Cora Uram- Tuculescu Steven Smith Virginia Commonwealth University Medical Center Richmond VA Medical University South Carolina Charleston SC Johns Hopkins University Baltimore MD Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 219NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 219 54 Cytomorphologic Features and Immunoprole Useful to Distinguish Clear Cell Papillary Renal Cell Carcinoma from Other Renal Cell Carcinomas in Cytology Specimen 382 Nazneen Fatima Ximing Yang Xiaoqi Lin Northwestern University Feinberg School of Medicine Chicago IL 55 Accuracy of Intraoperative Imprint Cytology Performed Exclusively by Cytopathologists of Sentinel Lymph Nodes in Breast Cancer 451 Tanmay Shah Catherine S Abendroth Penn State Hershey Medical Center Hershey PA 56 HER2 FISH Concordance in Breast Cancer Patients with Both Cytology and Surgical Pathology Specimens 377 Erika E Doxtader Benjamin C Calhoun Charles D Sturgis Christine N Booth Cleveland Clinic Foundation Cleveland OH 57 Comparison of GATA-3 GCDFP-15 and Mammaglobin Expression in Breast Carcinoma in Serous Effusions A Cell Block Microarray Study 391 Jennifer P Ha Mohamed El Hag Rosemary Farag Amad Awadallah Claire W Michael University of Minnesota Medical Center Minneapolis MN Case Western Reserve University University Hospitals Case Medical Center Cleveland OH 58 Utility of GATA3 in Urothelial Cytology 348 Stacy J Arnold F Zahra Aly Hao Chen Jordan M Eldersveld Robert R Klein University of Arizona Tucson AZ 59 Utility and Pitfalls of GATA3 Immunocytochemistry for Diagnosis of Breast and Urothelial Carcinomas in Cytology Specimens 414 Bing Leng Ming Guo Yun Gong The University of Texas MD Anderson Cancer Center Houston TX 60 GATA3 Expression as a Marker for Neuroblastoma Utility in Aspiration Cytology and Limited Tissue Samples 471 Austin Wiles Jorge Almenara Celeste N Powers Steven Smith VCU Health System Richmond VA 61 GATA-3 in the Work-Up of Malignant Effusions A Cell Block Micro-Array Study 379 Mohamed El Hag Rosemary Farag Jennifer P Ha Amad Awadallah Claire W Michael University of Minnesota Medical Center Minneapolis MN Case Western Reserve University University Hospitals Case Medical Center Cleveland OH 62 GATA3 Expression in Malignant Mesothelioma Is a Potential Pitfall in Effusion Cytology 446 Jennifer L Sauter Sarah E Kerr Mayo Clinic Rochester MN 63 Performance Characteristics of Body Fluid Cytology BFC Analysis of 344380 Responses from the College of American Pathologists CAP Non-Gynecologic Cytopathology Education NGC Program 461 Z Laura Tabatabai Ritu Nayar Rhona J Souers Diane D Davey UCSF San Francisco CA Northwestern University Chicago IL CAP Northeld IL University of Central Florida Orlando FL GASTROINTESTINAL PATHOLOGY 64 Identication of Helicobacter pylori in Routine Gastric Biopsies without Reex Ancillary Stains 769 Meredith E Pittman Laura Wood Elizabeth A Montgomery Lysandra Voltaggio Johns Hopkins University Baltimore MD 65 Utilization of H. Pylori Immunostaining in Gastric Biopsies A Cost-Effective Diagnostic Algorithm 704 Nigar Khurram Amir Momeni Boroujeni Elham Youse Constantine Axiotis SUNY DMC Brooklyn NY 66 Portal Hypertensive Gastropathy or Gastric Antral Vascular Ectasia Is an Accurate Diagnosis Possible on Histology 839 Yi Zhou Guilan Chen Haiyan Chen Vamsi Parini Mohammed Atieh Stefan Pambuccian Xianzhong Ding Loyola University Medical Center Maywood IL SSM Health St. Joseph Hospital - St. Charles Saint Charles MO 67 Gastrointestinal Tract Vasculopathy A Single Institution Experience 730 Christine Y Louie Gerald J Berry Teri A Longacre Stanford Hospital Clinics Stanford CA 68 Comparison of the Extra-Ileal Manifestations of Crohns Disease and Non-Specic Ileitis 741 Gregory Miller Ian Brown Envoi Specialist Pathologists Brisbane Queensland Australia 69 Clinical and Pathologic Characteristics of Incidentally Discovered Dysplasia in IBD Patients Resected for Medically Refractory Disease 763 Deepa Patil Erica Savage John R Goldblum Robert Odze Cleveland Clinic Cleveland OH Brigham and Womens Hospital Boston MA 70 Retrospective Review of Colectomy in Patients with Pre-Pouch Ieitis after Surgery for Ulcerative Colitis 745 Prasuna Muppa Saba Yasir Laura E Raffals Thomas C Smyrk Mayo Clinic Rochester MN Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016220 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016220 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 71 A Clinicopathologic Study of Collagenous Enteritis 709 Vanderlene Kung Changqing Ma Ta-Chiang Liu Washington University School of Medicine St. Louis MO University of Pittsburgh Medical Center Pittsburgh PA 72 Histopathologic Findings in Patients with Strongyloides Stercoralis and HTLV-1 Infection 817 Anna-Sophie Weidner Wayne Tam Rhonda K Yantiss Jose Jessurun Weill Cornell Medical College New York NY 73 Peptic Duodenitis Lacks Gastric Histologic Infectious and Pharmocologic Correlates A Review of 225 Consecutive Biopsies 744 Mohamed Mostafa Christopher Hartley Catherine Hagen Medical College of Wisconsin Milwaukee WI 74 Histopathological Findings in Gastrointestinal Tractus in Patients with Common Variable Immunodeciency CVID 766 Burcin Pehlivanoglu Basak Doganavsargil Omur Ardeniz Murat Sezak Adiyaman University Training and Research Hospital Adiyaman Turkey Ege University Faculty of Medicine Izmir Turkey 75 Gastrointestinal Tract Histologic Findings in Patients with Systemic Lupus Erythematosus 681 Arunima Ghosh Whitney Green Maryam Kherad Pezhouh Justin Poling Meredith E Pittman Elizabeth A Montgomery Lysandra Voltaggio Johns Hopkins University Baltimore MD 76 Spectrum of Pathologic Findings in Clinical Liver Cirrhosis without Conrmed Cirrhosis on Histology 654 Margaret Cho Natalie Patel Kisha Mitchell Yale University School of Medicine New Haven CT 77 Lymphatic Invasion and Nodal Metastasis in Dysplasia and Carcinoma of the Stomach Examination of 183 Cases Undergoing Endoscopic Submucosal Dissection Using D2-40 Immunostaining 738 Toshiharu Matsumoto Asumi Sakaguchi Kanako Ogura Juntendo University Nerima Hospital Tokyo Japan 78 HPV is Not Involved in the Pathogenesis of Esophageal Squamous Cell and Adenocarcinomas Analysis Based on a Highly Sensitive and Highly Specic RNA In-Situ Hybridization Technique 626 Agoston Agoston Vikram Deshpande Robert Odze Brigham and Womens Hospital Boston MA Massachusetts General Hospital Boston MA 79 H. pylori Infection Induces Early Expression of CD44 during the Progression of Gastric Cancer 816 Rachel Walker Jaime Mejia Heiko Enderling Jose M Pimiento Mokenge P Malafa Domenico Coppola Moftt Cancer Center Tampa FL Instituto de Patologia Mejia Jimenez Cali Colombia 80 Identication of RhoA and Related Gene Mutation in Diffuse Type Gastric Cancer Distinct Clinicopathological Features and Mucin Expression 760 Do Youn Park So Jeong Lee Chung Su Hwang Young Geum Kim Sangjeong Ahn Ahrong Kim Nari Shin Kyung Un Choi Chang Hun Lee Gi Young Huh Pusan National University Hospital Pusan National University Medical School Busan Seo-Gu Republic of Korea 81 Programmed Death Ligand-1 PD-L1 Expression in Mismatch Repair Decient Gastric Tumors and Gastric Tumors Positive for Epstein-Barr Virus 775 Bing Ren Krishna Patel Fyza Shaikh Benjamin Zhu Weijing Sun Aatur Singhi Changqing Ma University of Pittsburgh Medical Center Pittsburgh PA 82 The Role of Immunohistochemistry in Subtyping Ampullary Adenocarcinoma 658 Danielle Costigan Kieran Sheahan Kevin C Conlon Justin Geoghegan Emir Hoti Donal Maguire Oscar Traynor Dermot OToole Miriam Hayes Emer Burton Jean Murphy Niall Swan St. Vincents University Hospital Dublin Ireland 83 Appendiceal Goblet Cell Carcinoid Common Errors in Staging and Clinical Interpretation with a Proposal for an Improved Terminology 820 K Wen G Hale N Shazadeh A Huang M Hosseini S Kakar UCSF San Francisco CA Kaiser Woodland Hills CA UCSD San Diego CA Vista Pathology Medford OR 84 Completion Resections in LAMN with Extra- Appendiceal Mucin and Appendiceal Margin Involvement 779 Nemencio Ronquillo Saa Rafeeq Keith Fournier Paul Manseld Melissa W Taggart Wai Chin Foo The University of Texas M.D. Anderson Cancer Center Houston TX 85 Conventional Colonic-Type Adenocarcinoma of the Appendix Clinicopathologic Comparison with Cecal Adenocarcinomas 698 Jolanta Jedrzkiewicz Wai Chin Foo Paul Manseld Michael Overman Saa Rafeeq Asif Rashid Melissa W Taggart University of Texas M.D. Anderson Cancer Center Houston TX 86 The Impact of Deeper Levels on the Diagnosis of Hyperplastic Polyps and Sessile Serrated Adenomas 635 Adel Assaad Virginia Mason Medical Center Seattle WA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 221NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 221 87 Pathologic Assessment and Clinicopathologic Correlation of Tumor Microenvironment in Colorectal Carcinomas 707 Joo Young Kim Nam Hee Won Yang-Seok Chae Chul Whan Kim Jeong Hyeon Lee Eunjung Lee Youngseok Lee Korea University Anam Hospital Korea University College of Medicine Seoul Republic of Korea 88 HTRA3 Stromal Expression Is Correlated with Tumor Budding in Stage II Colorectal Cancer 675 Catherine Forse Mahdi Rahimi Eleftherios P Diamandis Naziheh Assarzadegan Heather AE Dawson Andrea Grin Erin Kennedy Brenda OConnor David E Messenger Robert H Riddell George S Karagiannis Richard Kirsch University of Toronto TO ON Canada Mount Sinai Hospital TO ON Canada UHN TO ON Canada Universitat Bern Bern Switzerland St. Michaels Hospital TO ON Canada University Hospitals Bristol NHS Bristol United Kingdom Albert Einstein College of Medicine Bronx NY 89 Fatty Acid Binding Protein1 FABP1 Is Preferentially Lost in Microsatellite Instable and in Medullary Carcinomas of the Colon 823 Stephanie M Wood Kenneth Friedman Alexander S Brodsky Shaolei Lu Kara A Lombardo Dongfang Yang Anthony J Gill Murray B Resnick Rhode Island Hospital and Alpert Medical School at Brown University Providence RI Royal North Shore Hospital St. Leonards Australia 90 Mismatch Repair Protein Deciency Is Not Present at a Higher Rate in HIV-Infected Patients with Colorectal Carcinoma 784 Marcela Santos Cavalcanti Keith Sigel Jinru Shia Tanisha Daniel Efsevia Vakiani Carlie Sigel Memorial Sloan Kettering Cancer Center New York NY Mount Sinai School of Medicine New York NY 91 High PSB7 Expression in Colorectal Cancer Predicts Poor Overall Survival among Older Female Patients and Female Patients Treated with Adjuvant Chemotherapy 833 J-Y Yoon Prashant Bavi Qian Yang Leslie Oldeld Julia Y Wang Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 92 CALD1 and TAGLN Predict Poor Prognosis of Patients with Colon Cancer 832 Mitsuru Yokota Motohiro Kojima Atsushi Ochiai Kurashiki Central Hospital Kurashiki Okayama Japan National Cancer Center Hospital East Kshiwanoha Chiba Japan 93 Dominant Overexpression of Programmed Death- Ligand 1 in MSI-Unstable Colorectal Adenocarcinoma 666 Audrey Deeken-Draisey Haonan Li Xiaoming You Jie Liao Sambasiva Rao Guang-Yu Yang Northwestern Medicine Chicago IL 94 Programmed Cell Death-Ligand 1 PD-L1 in Mismatch Repair Protein Decient Colon Cancer An Immunohistochemical and Genomic Proling Study 716 Hwajeong Lee Katherine Geiersbach Sanaz Ainechi Christine E Sheehan David M Jones Kajsa Affolter Mary P Bronner Jeffrey S Ross Albany Medical Center Albany NY University of Utah Salt Lake City UT 95 Analysis of PD-L1 Expression Pattern in Microsatellite Instability Colon Cancer 804 Yue Sun Max Vaickus Michael OBrien Qing Zhao Boston University Medical Center Boston MA 96 Characterization of the Effect of the Tumor Epigenetic Clonality in the Evolution of Colorectal Cancer 746 Eva Musulen Sebastian Moran Anna Martinez-Cardus Jose Luis Manzano Stefania Landol Elena Elez Josep Tabernero Aurelio Ariza Manel Esteller Hospital Universitari Germans Trias i Pujol Badalona Barcelona Spain Bellvitge Biomedical Research Institute IDIBELL LHospitalet del Llobregat Barcelona Spain Catalan Oncology Institute ICO- Hospital Universitari Germans Trias i Pujol Badalona Barcelona Spain Hospitals Vall dHebron Barcelona Spain Vall dHebron Institute of Oncology Barcelona Spain 97 Overexpression of POSTN in Cancer-Associated Fibroblasts Is a Poor Prognostic Indicator of Colorectal Cancer 753 Hyeon Jeong Oh Jeong Mo Bae Xian-Yu Wen Nam- Yun Cho Gyeong Hoon Kang Seoul National University College of Medicine Seoul Republic of Korea 98 Tumor Expression of C-Met and Plexin B1 May Predict Peritoneal Carcinomatosis Recurrence in Colorectal Cancer 677 Javier Freire Victor Ovejero Pilar Garcia-Berbel Steliana F Racean Emma Linares Alicia Leon del Castillo Saray Pereda Ainara Azueta Javier Gomez- Roman University Hospital Marqus de Valdecilla Santander Spain Sierrallana Hospital Torrelavega Spain 99 Utility of Longitudinal Slicing of Rectal Cancer Specimen in the Evaluation of Resection Margins 739 Rie Matsunaga Motohiro Kojima Mitsuru Yokota Yuji Nishizawa Masaaki Ito Atsushi Ochiai National Cancer Center Hospital East Kashiwa Chiba Japan 100 Potential Therapeutic Targets for Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinoma 818 Vivian L Weiss Raul S Gonzalez Chanjuan Shi Vanderbilt University Medical Center Nashville TN University of Rochester Medical Center Rochester NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016222 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016222 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 101 CK17 Is a Marker of Anal Transition Zone and May Aid in Distinguishing Reactive Anal Transition Zone from High-Grade Squamous Intraepithelial Lesions AIN IIIII 685 Hannah E Goyne Keith Lai Bradley J Fogel Andrew LJ Dunn Matthew R Lindberg Laura W Lamps Charles Quick UAMS Little Rock AR 102 Paired Box 5 PAX5 Expression in Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal and Pancreatobiliary Tract Diagnostic and Potentially Therapeutic Implications 717 Hwajeong Lee Sanaz Ainechi Christine E Sheehan Jingmei Lin Zhaohai Yang Albany Medical Center Albany NY Indiana University Indianapolis IN Penn State Hershey Medical Center Hershey PA 103 Germ Cell Tumor Metastases to the Gastrointestinal Tract A Diagnostic Challenge 771 Justin Poling Arunima Ghosh Whitney Green Maryam Kherad Pezhouh Meredith E Pittman Lysandra Voltaggio Elizabeth A Montgomery Johns Hopkins Medical Institutions Baltimore MD GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 104 The Histological Predictors of Metastasis and ChemotherapyRadiotherapy Response in Pure Classic Seminoma 901 Linnea Duke Zari Dastani Bader AlSaikhan Armen Aprikian Fadi Brimo McGill University Health Center Montreal QC Canada 105 Discrepancy Between Local and Central Pathological Review of Radical Orchiectomy Specimens 941 Saul E Harari Daniel J Sassoon John Eble Thomas M Ulbright David J Grignon Mohammed Idrees Costantine Albany Timothy A Masterson Nasser H Hanna Richard S Foster Lawrence H Einhorn Liang Cheng Indiana University School of Medicine Indianapolis IN 106 Orchidectomies for Testicular Neoplasms Less Than 1cm in Diameter Victims of Modern Imaging Technology 1038 Glenda Scandura Wendy Ansell Jonathan Shamash Daniel Berney Queen Mary University of London London Greater London United Kingdom Barts Health NHS Trust London United Kingdom 107 Testicular Sex CordStromal Tumors of Unclassied Type 1031 Omer AM Saeed Thomas M Ulbright Muhammad T Idrees Indiana University School of Medicine Indianapolis IN 108 Testicular Torsion A Single Tertiary Care Institution Study of 210 Cases 920 Alireza Ghaffarieh Karen Elizabeth Trevino Thomas M Ulbright Muhammad T Idrees Indiana University School of Medicine Indianapolis IN 109 Testicular Appendageal Tumors Evaluated in Orchiectomies a Single Institution Experience 921 Alireza Ghaffarieh Erin Baumgartner Thomas M Ulbright Muhammad T Idrees Indiana University School of Medicine Indianapolis IN University of Louisville Louisville KY 110 Paratesticular Soft Tissue Lesions Identied in Orchiectomies Evaluated at a Single Tertiary Care Center 1020 David Priemer Karen Elizabeth Trevino Thomas M Ulbright Shaoxiong Chen Muhammad T Idrees Indiana University School of Medicine Indianapolis IN 111 TCF3 A Sensitive Marker to Differentiate Seminomatous from Non-Seminomatous Germ Cell Tumors 858 Mary Barrett Asif Shahab Nisha Patel Qi Yang Loralee McMahon Guang-Qian Xiao Faqian Li University of Rochester Medical Center Rochester NY University of Minnesota Minneapolis MN 112 PLZF A Sensitive and Specic Biomarker for Yolk Sac Tumor 1051 Shana Straub David E Burstein Hani Katerji Faqian Li Qi Yang Loralee McMahon Guang-Qian Xiao University of Rochester Rochester NY Mount Sinai School of Medicine New York NY University of Minnesota Minneapolis MN 113 The Utility of HNF 1 Beta Immunohistochemical Staining in the Diagnosis of Malignant Germ Cell Tumors of the Testis 907 Faysal A Fedda Charles Quick Emily Holthoff Neriman Gokden Roni M Cox UAMS Little Rock AR 114 Loss of Expression of INSL3 by immunohistochemistry Predicts Leydig Cell Tumor 973 Nelli Lakis Zakaria Grada Kara A Lombardo Shamlal Mangray Andres Matoso Rhode Island HospitalBrown University Providence RI 115 CDK2 Inhibitory Phosphorylation Regulates Spermatogenesis and Stem Cell Maintenance 879 Xueyan Chen Hui Zhao Bruce Clurman James Roberts Keith Loeb University of Washington Seattle WA Fred Hutchinson Cancer Research Center Seattle WA 116 Lymphomas of the Urinary Tract and Genital Organs An Institutional Study of 50 Cases 1026 Julia A Ross Pei Hui Peter A Humphrey Adebowale Adeniran Yale University School of Medicine New Haven CT Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 223NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 223 117 Histopathological Risk Scoring System as a Tool for Predicting Lymph Nodal Metastasis in Penile Squamous Cell Carcinoma 995 Santosh Menon Aakash Sali Gagan Prakash Ganesh Bakshi Amit Joshi Vedang Murthy Umesh M Mahantshetty Sangeeta Desai Tata Memorial Centre Mumbai India 118 High Correspondence of HPV Genotypes in Penile Intraepithelial Neoplasia PeIN and Invasive Penile Squamous Cell Carcinomas SCC. A Laser Capture Microdissection LCM-PCR Comparative Study of 26 Cases 1035 Diego F Sanchez Soa Canete Nuria Guimera Maria Jose Fernandez-Nestosa Elsa F Velazquez David Jenkins Wim Quint Antonio L Cubilla Facultad de Ciencias Mdicas -UNA Asuncin Paraguay Instituto de Patologa e Investigacin Asuncin Paraguay DDL Diagnostic Laboratory Rijswijk Netherlands Facultad Politcnica - UNA San Lorenzo Paraguay Miraca Life Sciences and Tuft University Boston MA 119 Warty Penile Intraepithelial Neoplasia Morphological and Viral Characterization in 24 Cases Using Laser Capture Microdissection LCM-PCR 909 Maria Jose Fernandez Nestosa Nuria Guimera Diego F Sanchez Soa Canete Elsa F Velazquez David Jenkins Wim Quint Antonio L Cubilla Universidad Nacional de Asuncin Asuncin Paraguay DDL Diagnostic Laboratory Rijswijk Netherlands Instituto de Patologa e Investigacin Asuncin Paraguay Facultad de Ciencias Mdicas- UNA Asuncin Paraguay Miraca Life Sciences and Tufts University Boston MA 120 Frequent Detection of High Risk HPV and Heterogeneity in Condylomas Associated with Penile Intraepithelial Neoplasia PeIN. A Laser Capture Microdissection LCM-PCR Study of 30 Lesions in 6 Patients 870 Soa Canete Maria Jose Fernandez Nestosa Nuria Guimera Diego F Sanchez Ingrid M Rodriguez Jose Barreto David Jenkins Wim Quint Antonio L Cubilla Instituto de Patologa e Investigacin Asuncin Paraguay Universidad Nacional de Asuncin Asuncin Paraguay DDL Diagnostic Laboratory Rijswijk Netherlands Facultad de Ciencias Mdicas- UNA Asuncin Paraguay 121 Inter-Observer Variability among Urologic Pathologists in the Grading of Penile Squamous Cell Carcinoma 1022 Priya Rao Benjamin Naovarat Charles C Guo Kanishka Sircar Miao Zhang Farah Khalil Mike Hernandez Pheroze Tamboli Curtis A Pettaway Philippe E Spiess Jasreman Dhillon MD Anderson Cancer Center Houston TX Moftt Cancer Center Tampa FL 122 Natural History of Human Papillomavirus Infection in Non-Vaccinated Males Low Clearance Probability in High-Risk Genotypes 1003 Gabriella Nesi Tommaso Cai Sandra Mazzoli Raffaella Santi University of Florence Florence Italy Santa Chiara Regional Hospital Trento Italy Santa Maria Annunziata Hospital Florence Italy 123 Prevalence Distribution and Viral Loads of 15 High- Risk HPV Types in Squamous Cell Carcinoma of the Scrotum 975 Marcos Lepe M Ruhul Quddus Pradip Manna Jonathan I Epstein Andres Matoso Rhode Island Hospital and Brown University Providence RI Women and Infants Hospital and Brown University Providence RI Johns Hopkins Hospital Baltimore MD Physicians Reference Laboratory LLC Overland Park KS Brown University Providence RI 124 Poorly Differentiated Solid Medullary Carcinoma A Distinctive HPV-Related Penile Neoplasm. A Report of 12 Cases 871 Soa Canete Omar OC Clavero Diego F Sanchez Arturo Silvero Francisco Abed Ingrid M Rodriguez Laia Alemany Nubia Munoz Silvia de Sanjose Wim Quint Francesc Xavier Bosch Antonio L Cubilla Instituto de Patologa e Investigacin Asuncin Paraguay Institut Catal dOncologia Barcelona Spain Facultad de Ciencias Mdicas-UNA Asuncin Paraguay DDL Diagnostic Laboratory Rijswijk Netherlands 125 Spectrum of PD-L1 Expression in Penile Squamous Cell Carcinoma SqCC 988 Martin J Magers Aaron Udager Tzu-Ying Liu Andrew McDaniel Stephanie L Skala Todd Morgan Ganesh Palapattu Alon Z Weizer Tina Fields Ajjai Alva Jeffrey S Montgomery Arul M Chinnaiyan Scott A Tomlins Hui Jiang Rohit Mehra University of Michigan Health System Ann Arbor MI 126 Programmed Death Ligand-1 PD-L1 Status in North American Cohort of Penile Squamous Cell Carcinoma 883 Margaret Cocks Diana Taheri Mark W Ball Stephania M Bezerra Maria DC Rodriguez Alan Meeker Trinity J Bivalacqua Alcides Chaux Arthur Burnett George J Netto Johns Hopkins Medical Institution Baltimore MD Isfahn University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran 127 PIK3CA MET and TP53 Gene Mutations in Penile Cancer 895 Jasreman Dhillon Philippe E Spiess Elena Ryzhova Yin Xiong Julio Pow-Sang Anthony M Magliocco Moftt Cancer Center Tampa FL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016224 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016224 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 128 GATA3 Is a Sensitive Marker for Extramammary Pagets Diseases of Male Genital Region 876 Dengfeng Cao Yunquan Guo Yan Song Lixin Zhou Junqiu Yue Xun Zhang Ming Zhao Li Sun Zhongwu Li Washington University School of Medicine Saint Louis MO Xinjiang Cancer Hospital Urumqi China Chinese Academy of Medical Sciences Cancer Hospital Beijing China Peking University Cancer Hospital Beijing China Hubei Cancer Hospital Wuhan China Zhejiang Peoples Hospital Hangzhou China 129 Uroplakin 2 A Specic Marker of Urothelial Carcinoma 996 Ioana Moisini Rajiv Dhir Aatur Singhi Aditi Ranade Esther Elishaev David Dabbs Rohit Bhargava Magee-Womens Hospital Pittsburgh PA UPMC Pittsburgh PA UHS Wilson Medical Center Johnson City NY 130 Whole Exome Sequencing Reveals 19q13 Amplication and Actionable Mutations in Carcinosarcoma of the Bladder 1056 Peyman Tavassoli Bishoy S Morris Faltas Joanna Cyrta Juan Miguel Mosquera Brian D Robinson Mark Rubin Weill Cornell Medical College New York NY 131 Meta-Analysis of Mesenchymal Characteristic-Related Gene Expression in Bladder Cancer 848 Waleed Ali Andre Kajdacsy-Balla University of Illinois at Chicago Chicago IL 132 ALK Immunohitochemical Expression in Inammatory Myobroblastic Tumor IMT Using Novel D5F3 Clone in Comparison to ALK1 Clone Antibody 1054 Diana Taheri David J Zahavi Maria DC Rodriguez Abdelrazak Meliti Neda Rezaee Shahaboddin Dolatkhah Yi Ning Justin A Bishop George J Netto Rajni Sharma Johns Hopkins Medical Institution Baltimore MD Isfahan University of Medical Sciences Isfahan Islamic Republic of Iran 133 Clinicopathologic and Immunohistochemical Characteristics of Urinary BladderUB Inammatory Myobroblastic Tumors IMT Including 10 Malignant Cases 850 Isabel Alvarado-Cabrero Narciso Hernandez-Toriz Alejandra Mantilla-Morales Blandina Hernandez-Cruz Raquel Valencia-Cedillo Oncology Hospital Mexican Institute of Social Security DF Mexico 134 Is Mast Cell Inltration Specic to Interstitial Cystitis 844 Yoshiyuki Akiyama Daichi Maeda Graduate School of Medicine the University of Tokyo Tokyo Japan Graduate School of Medicine Akita University Akita Japan 135 Vasitis Nodosa and Related Lesions A Modern Immunohistochemical Staining Prole with Special Emphasis on Diagnostic Dilemmas 964 Brie Kezlarian Liang Cheng Nilesh S Gupta Sean R Williamson Henry Ford Health System Detroit MI Indiana University Indianapolis IN 136 Osseous Metaplasia in GU Organs Pathogenesis Signicance with First Case Report in Bladder Diverticulum 1013 Rugvedita Parakh Funda Vakar-Lopez Maria S Tretiakova University of Washington Seattle WA 137 GSTM1 GSTT1 GSTP1 Polymorphisms Quality of Life Habits Environmental Exposure and Predisposition to Bladder Cancer 1006 Isis Paloppi Ruan CA Pimenta Sabrina T Reis Willian C Nahas Miguel Srougi Jose Cury Mitiko Saiki Katia RM Leite University of Sao Paulo Medical School Sao Paulo Brazil ICESP - Instituto do Cancer de Sao Paulo Sao Paulo Brazil University of Sao Paulo Sao Paulo Brazil 138 Isolated 9p21 Deletion Detected by UroVysionTM Fluorescence In-Situ Hybridization in Urine Samples A Study of 69 Cases with Emphasis on Clinicopathological Features and Outcome 1058 Wei Tian Eric Kroman Wendy L Flejter Rajal Shah Miraca Life Sciences Irving TX 139 Reex FISH Testing of Subdivided Cytologically Atypical Urine Specimens 924 Ryan Glass Dwayne Breining Rubina Cocker North Shore Long Island Jewish New Hyde Park NY GYNECOLOGIC AND OBSTETRIC PATHOLOGY 140 The Clinicopathologic and Immunohistochemical Features of Adenomyomatous Polyps 1239 Kyle C Strickland Bradley J Quade Marisa R Nucci Brooke E Howitt Brigham and Womens Hospital Boston MA 141 Genomewide Copy Number Analysis of Mllerian Adenosarcoma Identied Increased Chromosomal Instability and Chromothripsis-Like Proles in the Aggressive Subgroup 1168 Jen-Chieh Lee Tzu-Pin Lu Chun A Changou Cher-Wei Liang Hsien-Neng Huang Alexandra Lauria Hsuan- Ying Huang Ben Davidson Ming-Chieh Lin Kuan-Ting Kuo National Taiwan University Hospital National Taiwan University College of Medicine Taipei Taiwan National Taiwan University Taipei Taiwan Taipei Medical University Taipei Taiwan Brigham and Womens Hospital and Harvard Medical School Boston MA Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung Taiwan The Norwegian Radium Hospital Oslo University Hospital Oslo Norway Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 225NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 225 142 Uterine Adenosarcomas Are Mesenchymal Neoplasms 1250 Britta Weigelt Salvatore Piscuoglio Kathleen Burke Charlotte KY Ng Anastasios D Papanastasiou Felipe C Geyer Gabriel S Macedo Luciano G Martelotto Ino De Bruijn Maria Rosaria De Filippo Anne M Schultheis Rafael Ioris Douglas A Levine Robert Soslow Brian P Rubin Jorge S Reis-Filho Memorial Sloan Kettering Cancer Center New York NY Cleveland Clinic Cleveland OH 143 Uterine Smooth Muscle Tumor of Uncertain Malignant Potential Clinicopathologic Study of 45 Cases 1237 Sucheta Srivastava Laura Moench Teri A Longacre Stanford Hospital Stanford CA 144 Myxoid Smooth Muscle Tumors of the Uterus Clinicopathologic Study of 40 Cases 1133 Ronald Goh Paola Dal Cin Sarah Chiang Robert H Young Esther Oliva Singapore General Hospital Singapore Singapore Brigham and Womens Hospital Boston MA Memorial Sloan Kettering Cancer Center New York NY Massachusetts General Hospital Boston MA 145 Fumarate Hydratase FH-Decient Uterine Smooth Muscle Neoplasms Can Be Identied by Characteristic Histological Features and Conrmed by FH IHC 1086 Abbas Agaimy David L Wachter Nasa Wilkinson James Bolton Matthias W Beckmann Florian Haller Arndt Hartmann University Hospital of Erlangen Erlangen Germany St Jamess Hospital Beckett Street Leeds LS9 7TF Leeds United Kingdom Central Manchester University Hospitals NHS Foundation Trust Manchester United Kingdom 146 Fumarate Hydratase Alterations Detected by S-2- Succino-Cysteine Expression in 6 Different Types of Uterine Smooth Muscle Tumors 1204 Kate Poropatich Qing Zhang Julianne Martinez de Ubago Norma Frizzell Beihua Kong Jian-Jun Wei Northwestern University Chicago IL University of South Carolina School of Medicine Columbia SC Qilu hospital Jinan Shandong China 147 Utility of Phosphohistone H3 in Uterine Smooth Muscle Tumors An Outcome-Based Assessment 1147 Philip Ip Kin Long Chow Ka Wing Wong Ka Yu Tse Richard WC Wong Alice NH Chan Nancy WF Yuen Annie N Cheung The University of Hong Kong Hong Kong SAR Hong Kong 148 Extra-Uterine Smooth Muscle Tumors of the Female Genital Tract Clinicopathologic Study of 24 Cases 1183 Laura Moench Sucheta Srivastava Teri A Longacre Stanford Medicine Stanford CA 149 ALK-1 Expression in Uterine Leiomyomas with Myxoid Change and Its Utility in Distinguishing from Inammatory Myobroblastic Tumor 1222 T Danielle Samulski Julieta E Barroeta Carolina Reyes Hospital of the University of Pennsylvania Philadelphia PA Pennsylvania Hospital Philadelphia PA 150 Genome-Wide Copy Number Analysis of Uterine Tumors Resembling Ovarian Sex Cord Tumors UTROSCT 1196 Joyce J Ou Umadevi Tantravahi John R Pepperell Danielle B Chau Michele M Lomme C James Sung W Dwayne Lawrence Women Infants Hospital Providence RI Alpert Medical School of Brown University Providence RI 151 The Utility of Next Generation Sequencing-Based Gene Fusion Detection Assay in the Diagnosis of Endometrial Stromal Sarcoma 1170 Xiaodong Li Mona Anand Josh Haimes Namitha Manoj Brian Kudlow Marisa R Nucci Colin JR Stewart Cheng-Han Lee University of Alberta Edmonton AB Canada ArcherDX Inc Boulder CO Brigham and Womens Hospital Boston MA King Edward Memorial Hospital Perth Australia 152 Molecular Characterization of High Grade Endometrial Stromal Sarcoma 1165 Nicholas Ladwig Joseph T Rabban Charles Zaloudek Nancy M Joseph Gregor Krings Karuna Garg University of California San Francisco San Francisco CA 153 Loss of BAF250a ARID1A Expression Is Associated with Progression of Endometriosis-Related Stage I Ovarian Clear Cell Carcinoma 1155 Ayako Kawabata Takako Kiyokawa Nozomu Yanaihara Aikou Okamoto Department of Obstetrics and Gynecology Jikei University School of Medicine Tokyo Japan Department of Pathology Jikei University School of Medicine Tokyo Japan 154 Investigation of Napsin-A in Atypical Versus Usual Endometriosis 1198 Cherie Paquette M Ruhul Quddus C James Sung Joyce J Ou W Dwayne Lawrence Women and Infants Hospital Providence RI Brown University School of Medicine Providence RI 155 Frequent Homozygosity in Both Mature and Immature Ovarian Teratomas A Shared Genetic Basis of Tumorigenesis 1232 Olivia L Snir Maura DeJoseph Natalia Buza Pei Hui Yale University School of Medicine New Haven CT Ofce of the Chief Medical Examiner Farmington CT Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016226 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016226 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 156 Primary Glial and Neuronal Tumors of the Ovary or Peritoneum A Clinicopathologic Study of 11 Cases 1172 Li Liang Adriana Olar Yi Jiang Na Niu Anna Yemelyanova Gregory Fuller Jinsong Liu The University of Texas MD Anderson Cancer Center Houston TX The First Afliated Hospital of Nanjing Medical University Nanjing China 157 Yolk Sac Tumor of the Ovary in Adult Women Analysis of a Case Series 1226 John Schoolmeester Brigitte M Ronnett Robert J Kurman Mayo Clinic Rochester MN The Johns Hopkins Hospital Baltimore MD 158 Yolk Sac Tumor in Extragonadal Gynecologic Sites Still a Diagnostic Challenge 1209 Sanjita Ravishankar Anais Malpica Preetha Ramalingam Elizabeth D Euscher MD Anderson Cancer Center Houston TX 159 Rened Characterization of Hepatoid Differentiation in Gynecologic Tract Neoplasms 1227 Angela R Shih Xiuli Liu Annacarolina Silva Anna Pesci Robert Soslow Vikram Deshpande Esther Oliva Massachusetts General Hospital Boston MA Cleveland Clinic Cleveland OH Memorial Sloan Kettering Cancer Center New York City NY 160 Genomic Analysis of Ovarian PNETs by Next Generation Sequencing Reveals Recurrent Copy Number and TP53 Alterations 1175 Christopher Liverman Nancy M Joseph Charles Zaloudek University of California San Francisco San Francisco CA 161 ESPNETunderline A Potential for Misdiagnosis Clinicopathologic and Molecular Cytogenetic Analysis of 5 Cases with Literature Reviewunderline 1112 Yufan Cheng Rui Bi Bin Chang Wentao Yang Xiaoyu Tu Jian Wang Fudan University Shanghai Cancer Center Shanghai China 162 PAX-8 Expression in Women with Reactive Mesothelial Proliferations of the Peritoneal Cavity 1108 Cody Carter Andrew Sciallis University of Michigan Health System Ann Arbor MI 163 Inactivating BAP1 Mutations Causing Loss of Nuclear Expression Dene the Majority of Malignant Peritoneal Mesotheliomas 1233 David A Solomon Yunn-Yi Chen Charles Zaloudek Nancy Joseph University of California San Francisco San Francisco CA 164 Expression of GATA-3 in Testicular and Gynecological Mesothelial Tissues Neoplastic and Non-Neoplastic 1216 Arash Ronaghy Guang-Qian Xiao Eugene Santagada Adnan Hasanovic Pamela Unger North Shore-LIJ Lenox Hill Hospital New York NY University of Rochester Medical Center Rochester NY 165 Malignant Mesonephric Tumors of the Female Genital Tract A Clinicopathologic Study of 16 Cases Including 4 Cases of Biphasic Tumor with a Sarcomatous Component 1129 Masaharu Fukunaga Jikei University Daisan Hospital Tokyo Japan 166 Twin Placenta with Complete Hydatidiform Mole and Its Mimics in the First Trimester Histologic Diagnosis and Immunohistochemical Study 1128 Masaharu Fukunaga Jikei University Daisan Hospital Tokyo Japan 167 DNA Genotyping of Non-Molar Donor Egg Pregnancies with Abnormal Villous Morphology Recommendations to Prevent Misinterpretation as Dispermic Complete Hydatidiform Moleunderline 1149 Nancy Joseph Caryll Pineda Nam Tran Joseph T Rabban University of California San Francisco San Francisco CA 168 A Reassessment of the Incidence of Hydatidiform Molar Disease as Dened by Histopathologic and Molecular Analysis 1115 Terence Colgan Martin C Chang Shabin Nanji Elena Kolomietz Mount Sinai Hospital Toronto ON Canada 169 The Detection of Aneuploidy in Non-Molar Abortuses through Selective DNA Genotyping in Cases of Suspected Hydatidiform Mole 1116 Terence Colgan Martin C Chang Shabin Nanji Elena Kolomietz Mount Sinai Hospital Toronto ON Canada 170 Rethinking Decidual Vasculopathy of Preeclampsia 1137 Jonathan H Hecht Zsuzsanna K Zsengeller Ananth Karumanchi Seymour Rosen Beth-Israel Deaconess Medical Center Boston MA 171 The Clinical and Pathological Features of Maternal Gastric Adenocarcinoma Metastatic to the Placenta 1249 Ping Wei Mulan Jin Beijing Chao Yang Hospital Capital Medical University Beijing China Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 227NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 227 172 CornualInterstitial Pregnancy Distinction from Conventional Tubal Pregnancy Emphasizing Microscopic Features to Avoid a Potential Diagnostic Pitfall When Accompanied by a Normal Fallopian Tube Specimen 1151 Yuna Kang Joseph T Rabban University of California San Francisco San Francisco CA 173 Histopathologic Features of Post-Ablation Tubal Sterilization Syndrome 1094 Jamen Bartlett Kelly J Butnor University of Vermont Medical Center Burlington VT 174 Heterotopic Steroid Hilus Cells in the Fallopian Tube 1091 John Aranake-Chrisinger Horacio M Maluf Washington University School of Medicine St. Louis MO HEMATOPATHOLOGY 175 ON 01910.Na Inhibits Growth of Diffuse Large B-Cell Lymphoma by Cytoplasmic Sequestration of Sumoylated TRAF6C-MYB Complex 1343 Kung-Chao Chang Wen-Chung Chen Wei-An Liao National Cheng Kung University Hospital Tainan Taiwan 176 BCR-cholesterol-BCR Feedback Loop Is Blocked by AMPK in Diffuse Large B-cell LymphomaDLBCL 1403 Xiangnan Jiang Weige Wang Ting Li Dong Sheng Xiaoyan Zhou Xiaoqiu Li Fudan University Shanghai Cancer Center Shanghai China Shanghai Medical College Fudan University Shanghai China 177 Signicance of Expression of SMO in Diffuse Large B Cell Lymphoma 1495 Youley Tjendra Nitin K Agarwal Kranthi Kunkalla Chae Hwa Kim Alia Gupta Jennifer Chapman Alfredo Torres Juan Alderuccio Steven X Chen Deukwoo Kwon Francisco Vega University of Miami Miami FL Sylvester Cancer Center Miami FL 178 Clinical and Biological Signicance of GLI1 Expression in Diffuse Large B-Cell Lymphoma 1370 David C Gajzer Youley Tjendra Kranthi Kunkalla Chae Hwa Kim Ofong F Ikpatt Jennifer Chapman Sandra Sanchez Gloria Yang Deukwoo Kwon Francisco Vega Nitin K Agarwal University of MiamiSylvester Comprehensive Cancer Center Miami FL 179 CD30 Expression and Its Prognostic Signicance in De Novo Diffuse Large B Cell Lymphoma Treated with Rituximab-EPOCH 1525 Jie Xu Annapurna Saksena Parth Desai Pei Lin Cheng C Yin Guilin Tang M James You L J Medeiros Shaoying Li UT MD Anderson Cancer Center Houston TX 180 PD-L1 Expression in Diffuse Large B-Cell Lymphoma DLBCL with Clinical Correlation 1470 Aseeb Rehman Siddhartha Dalvi Michael Presta Tipu Nazeer Jeffrey S Ross Albany Medical College Albany NY 181 Prognostic Signicance of CD5 Expression in Diffuse Large B-cell Lymphoma in Patients Treated with Rituximab-EPOCH 1492 Beenu Thakral Parth Desai Pei Lin C Cameron Yin Guilin Tang Shimin Hu Joseph D Khoury L Jeffrey Medeiros Shaoying Li UT MD Anderson Cancer Center Houston TX 182 RUNX3 A New Prognostic Marker in Diffuse Large B-Cell Lymphoma 1358 Virginia E Duncan Sooryanarayana Varambally Deniz Peker University of Alabama at Birmingham Birmingham AL 183 TCF3 and ID3 Expression in Diffuse Large B-cell Lymphoma in Burkitt Lymphoma 1439 Pawel Mroz Rashi L Singhal Megan S Lim Ryan A Wilcox Farah Keyoumarsi Kristina L Fields Nathanael G Bailey University of Michigan Ann Arbor MI University of Pennsylvania Perelman School of Medicine Philadelphia PA University of Pittsburgh Pittsburgh PA 184 MEF2B Expression in Diffuse Large B-Cell Lymphoma Correlates with Germinal Center Phenotype 1498 Katherine Tumminello Houda Alatassi Mostafa M Fraig John Lam Elizabeth Chastain Siraj El Jamal University of Mississippi Medical Center Jackson MS University of Louisville Louisville KY 185 Flow Cytometric Detection of CD10 Expression in Diffuse Large B-Cell Lymphoma Can Reduce the Need to Perform the Complete Hans Algorithm by Immunohistochemistry 1452 Sapna S Patel Chad Hudson Richard Burack University of Rochester Medical Center Rochester NY 186 Pathology Review for ECOG 1412 A Comparison of NanoString Gene Expression Proling and Immunohistochemistry for Cell-of-Origin Testing in De- Novo Diffuse Large B-Cell Lymphoma 1408 Rebecca King David W Scott Randy D Gascoyne Marissa A Fitzgibbons Grzegorz S Nowakowski Thomas E Witzig William R Macon Mayo Clinic Rochester MN British Columbia Cancer Agency Vancouver BC Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016228 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016228 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 187 Computerized Image Analysis of EBER-Positive Cells in Polymorphous Diffuse Large B Cell Lymphoma 1527 Shan-Chi Yu Chung-Wu Lin National Taiwan University Hospital Taipei Taiwan 188 ALK-Positive Diffuse Large B-cell Lymphoma ALK- DLBCL A Clinicopathologic Study of 25 Cases with Review of Additional 108 Cases in the Literature 1450 Zenggang Pan Shimin Hu Min Li Yi Zhou Young S Kim Vishnu Reddy Zifen Gao Huan-You Wang Ji Yuan UC Denver Aurora CO MDACC Houston TX Peking Uni HSC Beijing China UWMC Seattle WA City of Hope Duarte CA UAB Birmingham AL UCSD La Jolla CA UNMC Omaha NE 189 Correlation between PD-L1 Protein Expression and 9p24.1 Amplication in EBV-Positive DLBCL of the Elderly 1339 Alan F Brown Mohamad E Salama Jay L Patel Christian N Paxton Xinjie Xu Sherrie L Perkins K David Li University of Utah - ARUP Laboratories Inc. Salt Lake City UT 190 Aggressive B-cell Lymphoma in Extreme Age Groups Review of a Series of 760 Sases 1440 Yalda B Naeini Annie Wu Dennis OMalley UCLA Los Angeles CA Clarient Pathology Services Aliso Viejo CA 191 SNP Arrays and Targeted Genomic Sequencing Identify Distinctive Genomic Alterations In Testicular Diffuse Large B-Cell Lymphoma 1382 Deniz Gur Connie Batlevi Franck Rapaport Lu Wang Achim Jungbluth Janine Pichardo Maria E Arcila Andrew D Zelenetz Anas Younes Ahmet Dogan MSKCC New York NY 192 LeukemicBone Marrow-Based Large B Cell Lymphoma A Distinct Entity with Aggressive Features 1491 Weihua Tang Musharraf Navaid Shari Brown Lauren E Salmon Darla Liles Ridas Juskevicius East Carolina University Greenville NC 193 Immunophenotyic Characterization and Purication of Neoplastic Cells from Lymph Nodes Involved by T-CellHistiocyte Rich Large B Cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting 1367 Jonathan R Fromm University of Washington Seattle WA 194 Impact of Combined Antiretroviral Therapy cART on AIDS-Related Lymphoma ARL Biology 1468 Heidi Rahn Natasha Lewis John V Mitsios Susan Mathew Amy Chadburn Northwestern University - Feinberg School of Medicine Chicago IL Weill Cornell Medical College New York NY 195 HIV-Associated Diffuse Large B-Cell Lymphoma Has a Disproportionate Rate of MYC BCL6 Double Translocations 1490 Yaohong Tan Adrienne Moul Alia Gupta Kyle J White Yao-Shan Fan Ofong Francis Ikpatt Francisco Vega Jennifer Chapman Department of Pathology University of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL 196 Expression of MYC and BCL2 in AIDS-Related High Grade B Cell Non-Hodgkin Lymphomasunderline underline 1441 Anna Nam Amy Chadburn Weill Cornell Medical College-New York Presbyterian Hospital New York NY 197 Double-Hit Diffuse Large B-Cell Lymphomas with MYC Gene Rearrangements More Commonly Involve BCL2 Than BCL6 Gene Rearrangements as the Second Hit A Large Scale Single Institution Study 1431 Lisa McGinnis Scott Powers Dana Bangs Athena Cherry Robert Tibshirani Yasodha Natkunam Stanford Universtiy School of Medicine Stanford CA Stanford University Stanford CA 198 Double-Hit Lymphomas with BCL6 MYC Translocations Are Clinicopathologically Different from Those with IgH-BCL2 MYC and from Triple-Hit Lymphomas 1437 Adrienne Moul Yaohong Tan Nouf Hijazi Sandra Sanchez Ofong F Ikpatt Jennifer Chapman Francisco Vega University of Miami Jackson Memorial Hospital Miami FL 199 Clinicopathologic Features of Large B-cell Lymphomas with Concurrent Cytogenetic Abnormalities in MYC and BCL2 Improved Clinical Behavior with Modern Interventions 1413 Yi-Shan Lee John L Frater Friederike H Kreisel Marianna B Ruzinova Anjum Hassan Washington University School of Medicine Saint Louis MO 200 Prognostic Implications of MYC and BCL2 Expression in Primary Diffuse Large B-cell Lymphoma of the Central Nervous System 1407 Sehui Kim Soo Jeong Nam Dohee Kwon Hannah Kim Tae Min Kim Dae Seog Heo Sung Hye Park Chul Woo Kim Yoon Kyung Jeon Seoul National University Hospital Seoul Republic of Korea Seoul National University College of Medicine Seoul Republic of Moldova Seoul National University Seoul Republic of Korea Korea Cancer Center Hospital Seoul Republic of Korea 201 Immunohistochemical and Genetic Evaluation of Double-Hit Lymphomas 1518 Annie Wu Yalda B Naeini Dennis OMalley UCLA Los Angeles CA Clarient Pathology Services Aliso Viejo CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 229NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 229 202 Correlation of MYC Rearrangement with C-MYC Immunohistochemistry in Aggressive B-cell Lymphomas 1517 Annie Wu Yalda B Naeini Dennis OMalley UCLA Los Angeles CA Clarient Pathology Services Aliso Viejo CA 203 Multi-Color Flow Cytometric Analysis of c-MYC Protein in B-Cell Lymphomas a Correlation Study with Immunohistochemistry and FISH 1326 Khaled Alayed Karen Schweitzer Amad Awadallah Samir Turakhia Howard J Meyerson University Hospitals Case Medical Center Cleveland OH King Saud University Riyadh Saudi Arabia 204 Prognostic Importance of MYC Deletion Detected by Fluorescence In Situ Hybridization in Parafn Sections in Diffuse Large B-cell Lymphoma 1419 Wei Liu Shaoying Li Gary Lu Xinyan Lu Yuan Ji Zi Chen Jeffrey Medeiros Shimin Hu University of Texas MD Anderson Cancer Center Houston TX Weill Cornell Medical College New York NY University of Nebraska Omaha NE 205 Recommendations for Utilization and Reporting of MYC Fluorescence In Situ Hybridization Testing in High Grade B-cell Lymphomas 1334 Amir Behdad Sanaz Gidfar Yanming Zhang Adam Petrich Northwestern University Chicago IL 206 Performance of Commercially Available MAL and CD200 Antibodies in Differentiating Primary Mediastinal Large B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma 1372 Michael Gentry Eric D Hsi James R Cook Cleveland Clinic Cleveland OH 207 RNA In Situ Hybridization for MAL PDL1 and PDL2 in Primary Mediastinal Large B-cell Lymphoma versus Diffuse Large B-cell Lymphoma Not Otherwise Specied 1511 Zhen Wang Michael Gentry Eric D Hsi James R Cook Cleveland Clinic Cleveland OH 208 PDL1 and MUM1 Expression Are Associated with Outcome in Primary Mediastinal Large B-cell Lymphoma 1337 Jacob Bledsoe Robert Redd Lawrence Zukerberg Jeremy Abramson Aliyah R Sohani Massachusetts General Hospital Boston MA Dana Farber Cancer Institute Boston MA 209 Gray Zone Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma A Clinicopathologic Study of 17 Epstein-Barr Virus-Positive Cases 1359 Ahmed Ali Elsayed Akira Satou Ahmed E Eladl Seiichi Kato Naoko Asano Shigeo Nakamura Nagoya University Hospital Nagoya Japan Nagano Prefectural Suzaka Hospital Nagano Japan 210 Plasmablastic Lymphoma Is Characterized by MYC Blimp1 Protein Coexpression 1418 Emma Linares Tomas Z Barrese Sonia Gonzalez de Villambrosia Ana Batlle Tamara Ranchal Laura Cereceda Jose B Revert Maria Rodriguez-Pinilla Miguel A Piris Santiago Montes-Moreno Hospital Universitario Marqus de ValdecillaIDIVAL Santander Cantabria Spain Fundacin Jimnez Daz Madrid Spain IDIVAL Santander Cantabria Spain 211 Plasmablastic Lymphoma Characterization of Tumor Microenvironment by CD163 and PD1 Immunohistochemistry 1325 Janice Ahn Flavia G Rosado Aliyah R Sohani Jeffrey Vos West Virginia University Morgantown WV Massachusetts General Hospital Boston MA LIVER 212 Comparison of C4d Immunostaining Patterns on Posttransplant Liver Biopsies Using Two Different Antibodies 1649 Eunice K Choi Haodong Xu Hanlin L Wang University of California Los Angeles Los Angeles CA 213 Sinusoid Endotheliitis as an Early Histological Parameter for Diagnosing Liver Allograft Rejection 1681 Yu Shi Kun Dong Zu-Hua Gao McGill University Montreal QC Canada Beijing Youan Hospital Beijing China 214 The Effect of Post-Liver Transplantation Therapy with LedipsavirSofosbuvir on the Risk of Acute Graft Rejection 1682 Susan Shyu William S Twaddell University of Maryland School of Medicine Baltimore MD 215 Histologic and Clinical Outcomes after Transplantation of Donor Livers with Small Versus Large Droplet Macrovesicular Steatosisunderline 1651 Won-Tak Choi Kuang-Yu Jen Dongliang Wang Ryan M Gill University of California at San Francisco San Francisco CA SUNY Upstate Medical University Syracuse NY 216 Leptin Signaling-Related Proteins in Nonalcoholic Fatty Liver Disease 1650 Euno Choi Won Kim Byeong Gwan Kim Sun-ju Byeon Sunyoung Park Mee Soo Chang Seoul National University Boramae Hospital Seoul National University College of Medicine Seoul Korea 217 Clinical and Pathologic Features of Nutritional and Herbal Supplements Induced Liver Injury 1629 Gabriel Acosta-Gonzalez Mark Ettel Ogechukwu Eze Shweta Gera Cristina H Hajdu James S Park Samuel Sigal Ruliang Xu NYU Langone Medical Center New York NY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016230 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016230 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 218 Frequency and Pathological Characteristics of Drug- Induced Liver Injury in a Tertiary Medical Center 1654 Mark Ettel Gabriel Acosta-Gonzalez Ogechukwu Eze Shweta Gera Cristina H Hajdu James S Park Samuel Sigal Ruliang Xu NYU Langone Medical Center New York NY 219 Unique Morphologic and Clinical Features of Liver Nodular Regenerative Hyperplasia - Single Institution Large Cohort Studyunderline 1636 Adam Beattie Haonan Li Xiaoming You Jie Liao Sambasiva Rao Guang-Yu Yang Northwestern University Chicago IL 220 Combined Use of Copper Stain and CK7 Immunohistochemistry for Diagnosis of Cholestatic Liver Disease 1634 Dana Balitzer Sanjay Kakar UCSF San Francisco CA 221 Glutamine Synthethase Expression in Liver Biopsies from Patients with Congestive Heart Failure 1664 Bela Horvath John Guirguis Daniela Allende Michael Cruise Deepa Patil Robert OShea John Rivas Reyna Yordanka Nan Lan Xiuli Liu Cleveland Clinic Cleveland OH 222 Programmed Death Ligand-1 Expression on Tumor Cells in Cholangiocarcinoma Is More Frequent in Poorly Differentiated and Intrahepatic Tumors and Tumors with Brisk Tumor Inltrating Lymphocytes 1685 Michael Torbenson Taoc Mounajjed Benjamin R Kipp Robert R McWilliams Rondell Graham Mayo Clinic Rochester MN 223 Clinicopathologic Review and Outcome of 31 Cases of Liver Transplant with Both Hepatocellular and Cholangiocarcinoma 1686 Ghassan Tranesh David Lee Murli Krishna Tushar Patel Justin Nguyen Denise Harnois Raouf E Nakhleh Mayo Clinic Florida Jacksonville FL 224 Role of the Histone Acetyltransferase hMOF and H4K16 Acetylation in Vascular Invasion and Tumor Progression in Hepatocellular Carcinoma 1676 Nicolas Pote Samira Laouirem Miguel Albuquerque Pierre Bedossa Slimane Ait si ali Valerie Paradis Department of Pathology Beaujon Hospital Clichy France INSERM UMR 1149 Centre de Recherche sur lInammation Beaujon Hospital Clichy France UMR7216 CNRS Paris Diderot University Sorbonne Paris Cit Paris France 225 Prognosis of HER2 Expression in Cholangiocarcinoma 1641 Antonio Campos Maria O Begnami Viviane T Fernandes Milton JDBE Silva Maria Begnami A C Camargo Cancer Center Sao Paulo SP Brazil 226 Distinct Clinicopathological and Genetic Features of Two Histologic Subsets of Intrahepatic Cholangiocarcinoma 1660 Akimasa Hayashi Kento Misumi Junji Shibahara Junichi Arita Yoshihiro Sakamoto Kiyoshi Hasegawa Norihiro Kokudo Masashi Fukayama Graduate School of Medicine University of Tokyo Tokyo Japan 227 MUC6 Is a Unique Biomarker for Bile Duct Type of Intrahepatic Cholangiocarcinoma 1652 Todd DeJulio Xiaoming You Haonan Li Jie Liao Sambasiva Rao Nike Beaubier Guang-Yu Yang Northwestern University Chicago IL 228 The Incidence of Steatosis and Steatohepatitis in Intrahepatic Cholangiocarcinoma and Extrahepatic Cholangiocarcinoma 1653 George Eng Lawrence Zukerberg Vikram Deshpande MGH Boston MA 229 Reproducibility of Evaluation of Liver Biopsies from Patients with Congestive Heart Failure 1663 Bela Horvath Hao Xie John Guirguis Daniela Allende Michael Cruise Deepa Patil Robert OShea John Rivas Reyna Yordanka Xiuli Liu Cleveland Clinic Cleveland OH Yale University New Haven CT 230 Are Eosinophilic Glassy Globules in Autoimmune Hepatitis a Histologic Clue to Diagnosis 1674 Mamta Pant Daniel Rowan Kiyoko Oshima Medical College of Wisconsin Milwaukee WI 231 Histological Features of Autoimmune Hepatitis A Critical Appraisal 1659 Ananta Gurung David Assis Tom McCarty Kisha Mitchell James L Boyer Dhanpat Jain Yale University School of Medicine New Haven CT Royal Columbian Hospital New Westminster BC Canada 232 Extramedullary Hematopoiesis Presenting as Focal Lesions in Liver A Pathological and Radiological Study 1647 Gregory Cheeney Matthew Yeh University of Washington Seattle WA 233 Interpretation of Core Biopsy of Liver Mass Lesion A Comparison Study between Cytopathologist and Gastrointestinal Pathologist 1690 Zhaohai Yang Penn State Milton S. Hershey Medical Center Hershey PA 234 Interobserver Variability in Interpreting Liver Biopsies with a Diagnosis of Alcoholic Hepatitis 1662 Bela Horvath Hao Xie John Guirguis Daniela Allende Jennifer Jeung James Lapinski Deepa Patil Arthur McCullough Srinivasan Dasarathy Xiuli Liu Cleveland Clinic Cleveland OH Yale University New Haven CT Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 231NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 231 PULMONARY PATHOLOGY INCLUDING MEDIASTINAL 235 Neoadjuvant Treatment Response Predicts Survival in Non-Small Cell Lung Cancer Resections 1902 Adina Paulk Alexander A Berrebi Allen P Burke University of Maryland Medical Center Baltimore MD 236 Combined High-Grade Neuroendocrine Lung Carcinomas A Clinicopathologic Study of Surgical Resection Cases from a Single Institution 1906 Maheshwari Ramineni Annikka Weissferdt Stephen G Swisher Cesar A Moran Neda Kalhor M.D. Anderson Cancer Center Houston TX 237 Clinico-Pathologic Characteristics of Primary Lung Carcinoma with Hepatoid Differentiation 1899 Prodipto Pal Lucian Chirieac Brigham and Womens Hospital Boston MA 238 Malignancy Risk for the Categories Non-Diagnostic Benign Atypical Suspicious and Malignant Used in the Categorization of Endobronchial Ultrasound Guided- Fine Needle Aspirates of Pulmonary Nodules 1879 Lester Layeld Leslie G Dodd Benjamin Witt University of Missouri Columbia MO University of North Carolina Chapel Hill NC University of Utah Salt Lake City UT 239 HPV Prevalence and Genotype in Squamous Cell Carcinoma of the Lung 1933 Christopher Vytlacil Christina DiCarlo Emily J Smith Matthew A VanDeusen Samantha A Martin Lori A Kelly Ali Zaidi Gene Finley Rodney J Landreneau Blair A Jobe Jan F Silverman Allegheny General Hospital Pittsburgh PA Allegheny Health Network Pittsburgh PA 240 Usefullness of p16 Immunostain and Molecular Testing for HPV in Determining Primary Versus Metastatic Squamous Cell Carcinoma in the Lung 1925 Jamie Steinmetz Brett E Close Larissa V Furtado Aliya N Husain Nicole A Cipriani University of Chicago Chicago IL 241 Expression of P16 and Detection of Subtypes of HPV RNA in Primary Non-Small Cell Lung Cancers NSCLC and Their Potential Clinical Implication 1875 Armen Khararjian Xiao-Jun Ma Zhen Zhang Frederic Askin Edward Gabrielson Yuling Luo Qing Kay Li Johns Hopkins Baltimore MD Advanced Cell Diagnostics Hawyard CA 242 Prognostic Factors and Recurrence in Primary Lung Carcinoid Tumor Treated at a Single Institution 1873 Neda Kalhor Guoping Xu Junya Fujimoto Francesco Stingo Bonnie Glisson Reza J Mehran James C Yao Cesar A Moran MD Anderson Cancer Center Houston TX Dali University Yunnan China 243 Proliferation Activity Evaluation by Ki-67 Labeling Index in Paired Biopsy Samples and Surgical Specimens of Pulmonary Neuroendocrine Tumors A Methodological Approach for Clinical Purposes 1904 Giuseppe Pelosi Mara Cossa Alessandra Fabbri Barbara Valeri Angelica Sonzogni Ugo Pastorino Fondazione IRCCS Istituto Nazionale dei Tumori Milan MI Italy 244 Usefulness and Limitation of Endobronchial Ultrasound Transbronchial Needle Aspiration EBUS Specimen for PD-L1 Companion Diagnosis in Lung Cancer 1915 Rie Sakakibara Noriko Motoi Hironori Ninomiya Kentaro Inamura Makoto Nishio Yuichi Ishikawa The Cancer Institute Japanese Foundation for Cancer Research Koto Tokyo Japan Cancer Institute Hospital JFCR Koto Tokyo Japan 245 PD-L1 PD-1 CD4 and CD8 Expression in Neoplastic and Non-Neoplastic Thymus 1934 Ann E Walts Alberto M Marchevsky Cedars-Sinai Medical Center Los Angeles CA 246 Patchy High Frequency of Nonspecic Abnormal Signals Background Noise A Common Pitfall in Interpretation of ALK FISH Results 1942 Hong Yin Shaobo Zhu Michele K Zelonis Dana R Snyder Zongming E Chen Geisinger Medical Center Danville PA 247 Validation of a Simplied Approach to Detect ALK Translocations in Lung Cancer Samples by FISH 1918 Hans-Ulrich Schildhaus Elke Binot Jurgen Wolf Reinhard Buettner Katja Schmitz University Hospital Goettingen Goettingen Germany University Hospital Cologne Cologne Germany Center for Integrated Oncology Cologne-Bonn Germany Lung Cancer Group Cologne Cologne Germany Comprehensive Cancer Center G-CCC and Lungentumorzentrum LTZ Goettingen Germany 248 Comparison of Mutational Proles in Cytology and Corresponding Surgical Specimens from Patients with Lung Adenocarcinoma 1944 Hamid Zia Alan Marcus Brian E Geraghty Rana S Hoda Navneet Narula Hanna Rennert Helen Fernandes New York Presbyterian Hospital-Weill Cornell Medical College New York NY 249 Clinical Utility of Targeted Next Generation Sequencing in Lung Cancer 1853 Nike Beaubier Valerica Mateescu Julia A Elvin Siraj M Ali Elizabeth Morency Ritu Nayar Northwestern University Chicago IL Foundation Medicine Cambridge MA 250 Simultaneous Detection of Gene Rearrangements and Variants in Non-Small Cell Lung Cancer by Next- Generation Sequencing 1939 Shuo Xu Alexander Boag Mihaela Mates Lina Chen Harriet Feilotter Queens University Kingston ON Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016232 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016232 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 251 Dysregulated miR-185-STIM1 Axis in Obliterative Bronchiolitis 1943 Chen Zhang Guang-Sheng Lei Indiana University School of Medicine Indianapolis IN 252 Histopathologic Findings in the Lungs of Patients Treated with Extracorporeal Membrane Oxygenation 1881 Hee Eun Lee Eunhee S Yi Anja C Roden Mayo Cliinc Rochester MN 253 Immunohistochemical Analysis of p14ARF p15INK4B p16INK4A MTAP and Their Combinations May Predict the Deletion Status of 9p21 in Malignant Pleural Mesothelioma 1868 Tomoyuki Hida Makoto Hamasaki Shinji Matsumoto Ayuko Sato Tohru Tsujimura Kunimitsu Kawahara Yoshinao Oda Kazuki Nabeshima Fukuoka University School of Medicine and Hospital Fukuoka Japan Graduate School of Medical Science Kyushu University Fukuoka Japan Hyogo College of Medicine Nishinomiya Hyogo Japan Osaka Prefectual Medical Center for Respiratory and Allergic Disease Habikino-shi Osaka Japan 254 Interobserver Variability in Assessing Sarcomatoid Components of Biphasic Malignant Mesothelioma BMM Implications for Outcome Measures 1850 Vijayalakshmi Ananthanarayanan Wickii Vigneswaran Diana Kircheva Qudsia Arif Thomas Krausz Aliya N Husain Loyola University Medical Center Maywood IL University of Chicago Chicago IL 255 CTLA-4 Detection in Malignant Mesothelioma Tissues and in Effusions Relevance for Immunotherapy 1861 Franco Fedeli Serena Varesano Paola Ferro Maria Cristiana Franceschini Sandra Salvi Simona Boccardo Jean Louis Ravetti Anna Morabito Alessandro Valentino Silvio Roncella Maria Pia Pistillo ASL5 La Spezia Italy IRCCS AOU San Martino-IST Genoa Italy 256 Favorable Prognostic Implications of FGFR1 Amplication and MYC Amplication or Overexpression in Resected Esophageal Squamous Cell Carcinoma 1877 Dohee Kwon Ji Y Yun Bhumsuk Keam Young T Kim Yoon K Jeon Seoul National University Hospital Seoul National University College of Medicine Seoul Republic of Korea The Tumor Immunity Medical Research Center Cancer Research Center Seoul National University College of Medicine Seoul Republic of Korea QUALITY ASSURANCE 257 Her2neu Testing in Breast Cancer Comparative Analysis of In Situ Hybridization and Immunohistochemistry in a Dual-Testing System 2009 James Solomon Oluwole Fadare Farnaz Hasteh UCSD San Diego CA 258 Impact of 2013 ASCOCAP Guideline Recommendations on HER2 FISH Testing in Breast Cancer 1983 Shivali Marketkar Kamaljeet Singh Cynthia Jackson Jesse Hart Murray B Resnick Yihong Wang Rhode Island Hospital Providence RI Women and Infants Hospital Providence RI 259 Differences in Ki67 Percent Identied during Breast Consult Review Do Not Impact the IHC4 Score A Quality Assurance Study 1949 Gonzalo Barraza Erinn Downs-Kelly Rachel E Factor University of Utah Health Sciences Center Salt Lake City UT 260 Evaluation of Repeated Biomarker Testing In a Breast Consultation Service One Institution Experience 2016 Elena Vrotsos Cesar A Llanos University of Miami Miami FL 261 Tumor Heterogeneity Compromises Studies on the Effect of Prolonged Fixation on Immunohistochemistry IHC Reporting of Breast Biomarkers 2013 Tra Truong Ken Kao LUIS Gai Kim Voisey Memorial University St Johns Newfoundland Canada 262 Upfront Immunohistochemistry to Evaluate Sentinel Lymph Nodes in Malignant Melanoma Burden or Benet 1968 William Frampton Dani S Zander Dipti M Karamchandani Hershey Medical Center Hershey PA 263 Quality Assurance Aspects of implementing BRAFV600E Immunohistochemistry IHC Assay in Universal Lynch Syndrome Screening ULS for Colorectal Cancer CRC A Single Institution Experience 1960 Zongming E Chen Angela Bitting Neze Kip Fan Lin Geisinger Danville PA 264 Cost-Benet Analysis of C4d Immunoourescence and Immunohistochemistry in Evaluation of Pulmonary Allograft Dysfunction 1945 Monica Aldulescu Razvan Lapadat Robyn Essendrop Kamran M Mirza Swati Mehrotra Vijayalakshmi Ananthanarayanan Loyola University Medical Center Maywood IL Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 233NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 233 265 Napsin Expression in Metastatic Colorectal Carcinoma to the Lung a Potential Pitfall in the Immunohistochemical Assessment of Adenocarcinomas in the Lung Identied In Immunohistochemistry Validation 2007 Manmeet Singh Michael Clarke Ashley S Freyre Shiraz S Fidai Melody Lee David Stephen Elizabeth Wiley John V Groth University of Illinois Hospital Health Sciences System Chicago IL 266 The Role of p16 in the Classication of Anal Squamous Intraepithelial Lesions Evaluation of Interobserver Variability 1965 Zachary J Dureau Uma Krishnamurti Mario Mosunjac Talaat S Tadros Marina Mosunjac Emory University School of Medicine Atlanta GA 267 Evaluating the Immunostaining Detection of Cytomegalovirus in Gastrointestinal Biopsies Clinical Pathological Correlation 1980 Xiaoyan Liao Grace Y Lin UCSD San Diego CA 268 Histologic Evaluation of the Effects of Tissue Decalcication on the Immunohistochemical Markers in Bone Marrow Specimen 2006 Marianna Shvartsbeyn Mohamed E Salama Rajan Dewar New York University New York NY University of Utah Salt Lake City UT University of Michigan Ann Arbor MI 269 A Prociency Testing Scheme for IDH1 R132H IHC The cIQc Experience 2020 Jennifer Won Max Signaevski John Garratt Emina Torlakovic Blake Gilks Stephen Yip Canadian Immunohistochemistry Quality Control cIQc Vancouver Canada University of British Columbia Vancouver Canada Vancouver General Hospital Vancouver Canada 270 Quality Assurance of ATRX Immunohistochemistry in a Multi-Centre Diagnostic Neuropathology Initiative 2021 Jennifer Won John Garratt Emina Torlakovic Blake Gilks Stephen Yip Canadian Immunohistochemistry Quality Control cIQc Vancouver Canada University of British Columbia Vancouver Canada Vancouver General Hospital Vancouver Canada 271 Next Generation Sequencing for Epilepsy Mitochondrial Disease and Developmental Delay One Pediatric Hospitals Experience 1962 Jessica L Davis Bonnie Cole Jessie Contra Jane Dickerson Seattle Childrens Hospital Seattle WA 272 Quantifying Protein Levels in Cells by Violin Plots A Facile Readily Visualized Method 1997 Nicholas P Reder Jonathan C Henriksen Lawrence True University of Washington Seattle WA 273 Pre-Analytical Factors Involved in the Clinical Analysis of a Comprehensive Next-Generation Sequencing Panel 2003 Alaa A Salim Rajyalakshmi Luthra Rajesh Singh Keyur P Patel Mark Routbort Bedia A Barkoh Jawad Manekia Sinchita Roy Chowdhuri Russell Broaddus Hui Chen MD Anderson Cancer Center Houston TX 274 Intraoperative Evaluation of Borderline Cystic Ovarian Lesions Are We at Least Concordant with the Final Diagnosis 2019 Kyle J White Andre Pinto University of Miami Jackson Memorial Hospital Miami FL 275 The Impact of Subspecialty Surgical Pathology on Generalized Intraoperative Consultations 1982 Sophia Ma Ketan Patel Kumarasen Cooper Hospital of the University of Pennsylvania Philadelphia PA 276 Accuracy of Intraoperative Consultation Rendered by General Pathologists in a Scenario Where Well-Dened Decision Algorithm Is Followed 2001 Sherine Salama James Richter Tanya Pulver Boris Winterhoff Mahmoud Khalifa University of Toronto Toronto ON Canada University of Minnesota Minneapolis MN 277 The Utility of Intraoperative Gross Examination of Colorectal Resections A Retrospective Review of 200 Sequential Cases 1976 Armen Khararjian Ajuni Choudhary Alexander Baras Johns Hopkins Baltimore MD 278 Initial Validation of Whole Slide Imaging WSI for Use in Frozen Section Consultation at Stanford University 1966 Sebastian Fernandez-Pol Eugene Carneal Mathew Rumery Peyman Samghabadi Brent Tan Stanford University Stanford CA 279 An iOS App to Expedite the Evaluation of Immunohistochemistry Stains 1986 Wilfrido Mojica Gregg Mojica University at Buffalo Buffalo NY Gradology Inc San Francisco CA 280 Is Digital Imaging a Viable Method of Measurement for Breslow Thickness in Invasive Melanomas An Example of Evaluation of Uncertainty in a Critical Value in Cellular Pathology 1977 Yi Ling Khaw Barbara Loftus Tallaght Hospital Dublin Ireland 281 Validation of Digital Whole Slide Imaging System for Intraoperative Breast Sentinel Lymph Node Touch Prep Analysis A Single Institution Experience 1973 Jenny Hoffmann Lisa McGinnis Chrisy T Mafnas Jennifer Ziskin Ann K Folkins Kimberly Allison Robert B West John P Higgins Neeraja Kambham Steven R Long Brent Tan Stanford University Medical Center Stanford CA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016234 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016234 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 282 Can Westgard Rules Identify Trends in Nondiagnostic Rates for Thyroid Fine Needle Aspiration 2014 Janice Tyler Jeffrey Goldsmith Pamela Hartzband James V Hennessey Michiya Nishino Beth Israel Deaconess Medical Center Boston MA Harvard Medical School Boston MA 283 Tumor Area Measurement as a Parameter for Determination of Specimen Adequacy in the Selection of EBUS-FNA Specimens for Mutational Analysis by Targeted Next Generation Sequencing NGS underline 2004 Sadia Sayeed Laura M Warmke Michael O Idowu Celeste N Powers Adele O Kraft Virginia Commonwealth University Medical Center Richmond VA 284 Fine Needle Aspirations of the Lung Impact of Interobserver Variability amongst Cytopathologists Can Affect the Diagnosis 1964 Zachary J Dureau Brian Robinson Momin T Siddiqui Uma Krishnamurti Marina Mosunjac Talaat S Tadros Wei Wei Shi Vaidehi Avadhani Alessandra Schmitt George Birdsong Gabriela M Oprea-Ilies Emory University School of Medicine Atlanta GA 285 Quick Review of Fine Needle Aspiration Accuracy with Focus on Cytohistologic Correlation and Evaluation of Discrepant Cases in a Limited Sample 2022 Somaye Yekezare Niloufar Reisian Xiaoyan Liao Farnaz Hasteh University of California San Diego Health System San Diego CA Kaiser Medical Center San Diego CA 286 Comparison of UroVysion FISH and Urine Cytology with Performance Evaluation of Individual Chromosome Enumeration Probes A Five Year Single Institutional Experience 1988 Paari Murugan Sandhya Dasaraju Amrita Rao Badrinath R Konety Khalid Amin University of Minnesota Minneapolis MN 287 Diagnostic Utility and Concordance of Cytopathology and Flow Cytometry of Cerebrospinal Fluid in Lymphoblastic LeukemiaLymphoma 1993 Nupam Patel Daniela Hoehn Karthik A Ganapathi Govind Bhagat Bachir Alobeid Columbia University Medical Center New York NY 288 Implemenation of a Lean Cytopathology Service - Towards Routine Same-Day Reporting 1972 Ekkehard Hewer Anja M Schmitt University of Bern Bern Switzerland TECHNIQUES INCLUDING ULTRASTRUCTURE 289 Utility of Adenosine Diphosphate ADP Inhibition by Thromboelastography with Platelet Mapping TEG-PM in Predicting Hemorrhagic Stroke in a Level 1 Stroke Center Analysis and Review of Literature 2028 Kelly A Bowers Richard D Hammer University of Missouri Columbia MO 290 High Efciency Prostate Biopsy Evaluation after Training Using Full-Field Optical Coherence Tomography 2090 Chongqing Yang Eugenie Dalimier Anil Parwani Riccardo Riccio Nicolas Barry Delongchamps Arnaud Duc LLTech SAS Paris France Ohio State University Columbus OH Hptal Cochin Paris Descartes University Paris France Beijing Hospital of Health Ministry Beijing China 291 Lymph Node Pooling. A Cost-Effective and Feasible Way of Lymph Node Molecular Staging in Colorectal Carcinoma 2042 Laura Herrero Iban Aldecoa Natalia Rakislova Carla Montironi Nuria Planell Pedro L Fernandez Eva Fernandez Salvadora Delgado Dulce Momblan Antonio Lacy Antoni Castells Miriam Cuatrecasas Hospital Clinic IDIBAPS University of Barcelona Barcelona Spain CIBERehd IDIBAPS University of Barcelona Barcelona Spain 292 Photoacoustic Mapping of Oxygen Saturation and Blood Volume in Ex Vivo Lymph Nodes of Colorectal- Cancer Patients 2068 Emi Saegusa-Beecroft Ashwin Sampathkumar Eugene Yanagihara Junji Machi Ernest J Feleppa University of Hawaii and Kuakini Medical Center Honolulu HI Riverside Research New York NY 293 Pathological Staging of Fibrosis by High- Resolution Magnetic Resonance Imaging of Liver Microarchitecture 2078 Mark Valasek Vera Vavinskaya Mojgan Hosseini Claude Sirlin Graeme Bydder Nicklaus Szeverenyi University of California San Diego San Diego CA 294 Rapid Inexpensive Slide-Free Histology via MUSE Ultraviolet Surface Excitation Microscopy for Imaging Unsectioned Tissue 2053 Richard Levenson Zachary T Harmany Alex R Krueger Farzad Fereidouni UC Davis Medical Center Sacramento CA University of California Davis Davis CA 295 Optimization of Tissue Section Thickness for Evaluation of Mitotic Figures in Whole Slide Imaging WSI 2093 Shabnam Zarei Xuemei Wu Sarah M Jenkins William Flotte Taoc Mounajjed Thomas Flotte Mayo Clinic Rochester MN Brown University Providence RI 296 Cell Tissue Display CTD An Alternative Multipurpose Tool for Microscopy 2074 Nicholas Theodosakis Goran Micevic Marcus W Bosenberg Nemanja Rodic Yale School of Medicine New Haven CT Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 235NEXTGENERATION LEARNING 2016 POSTER SESSION V Wednesday March 16 2016 930 AM - 1200 PM CC Exhibit Hall 4ABC 235 297 Centrosome Amplication CA and Mitotic Frequency Display Poor Concordance between Patient Tumors and Cancer Cells Cultured In Vivo An Analysis of Breast Pancreatic and Bladder Carcinoma 2059 Karuna Mittal Michelle D Reid Angela Ogden Da Hoon Choi Meenakshi Gupta Guilherme Cantuaria Kristin Jonsdottir Emiel AM Janssen Beatrice Knudsen Padmashree CG Rida Ritu Aneja Georgia State University Atlanta GA Emory University Atlanta GA West Georgia Hospital Lagrange GA Northside Hospital Cancer Institute Atlanta GA Georgia Stavanger University Hospital Stavanger Norway Cedars Sinai Medical Center Los Angeles CA 298 Novel 3-D Exploration and Analysis Tool for Surgical Pathology Specimens 2086 Seth Winfree Tarek El-Achkar Kenneth Dunn Carrie L Phillips Indiana University Indianapolis IN 299 Locking Tissue Orientation from Grossing through Microtomy Using Orientation Gels 2089 Douglas T Yamanishi Lydia E Figueroa Cliff Hom Carlos Sanchez Luis Chavez Julie A Galindo Erico von Bueren Sakura Finetek USA Inc. Torrance CA 300 Numbered Agar Bodies to Individualize Needle Biopsy Specimens - A Paradigm Shift in Specimen Identication 2082 Ulrich Vogel University Hospital of Tuebingen Tuebingen Baden- Wuerttemberg Germany 301 Label-Free Identication of Amyloid Deposits in Tissue Using Infrared Spectroscopic Imagingunderline 2036 Bennett Davidson Maria M Picken Michael Walsh University of Illinois at Chicago Chicago IL Loyola University Medical Center Maywood IL 302 A Novel Rapid and Low Cost Method for Preparing Tissues with Metallic Stents for Routine Histology 2044 Thom Jensen Tyler A Jensen Melissa Cessna Dylan Miller Intermountain Biorepository Salt Lake City UT Intermountain Healthcare University of Utah Salt Lake City UT 303 Colour Deconvolution Is Superior to Hue-Saturation- Intensity in Digital Analysis of Atherosclerotic Plaques 2025 Murad Alturkustani J David Spence Catherine Currie Myra Cocker Cathie Crukley Martin J Yaffe Jean- Claude Tardif Cheemun Lum Robert Beanlands Robert Hammond Ali Khan King Abdulaziz University Jeddah Saudi Arabia London Health Sciences Centre and Lawson Research Institute London Canada University of Western Ontario London Canada Robarts Research Institute London Canada Ottawa Heart Institute Ottawa Canada Montreal Heart Institute Montreal Canada Sunnybrook Health Sciences Centre Toronto Canada 304 The Glazed Erasable Tissue Sections. Disaccharides Protect FFPE Tissue Section Antigens from Air-Drying- Induced Masking and Allow Repeated Antibody Removal by Stripping 2066 Susanna Ronchi Giovanna Boi Carla R Scalia Rossella Gendusa Giorgio Cattoretti Universit degli Studi di Milano-Bicocca Via Cadore 48 20900 Monza IT Italy Azienda Ospedaliera San Gerardo Via Pergolesi 33 20900 Monza IT Italy 305 Validation of Placental Preservation for Pathologic Examination Using the TissueSAFE Formalin-Free Vacuum-Sealing System 2092 Richard J Zarbo Michelle Felicella Arthur R Gaba Henry Ford Hospital Detroit MI POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CDPOSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC Board Number Board Number Board Number Board Number BONE SOFT TISSUE PATHOLOGY 1 TLE1 mRNA Chromogenic In Situ Hybridization CISH A Potentially Powerful Diagnostic Tool for Synovial Sarcoma 66 Vadim Khachaturov Rana Naous Zhen Wang John R Goldblum Steven D Billings Brian P Rubin Cleveland Clinic Cleveland OH SUNY Upstate Medical University Syracuse NY 2 KDM2BSetting the Stage for Aberrant Silencing in Synovial Sarcoma 50 Amanda R Dancsok Ana Banito Scott Lowe Torsten O Nielsen University of British Columbia Vancouver BC Canada Memorial Sloan Kettering Cancer Center New York NY 3 Exploring Intra-Tumor Heterogeneity in Neurobromatosis Type 1 Plexiform Neurobromas Integration of Histological and Genomic Data Reveals Correlation between Progressive Loss of CDKN2A and Degree of Cellular Atypia 83 Cleofe Romagosa Meritxell Carrio Ernest Terribas Bernat Gel Cristina Flamerich Teresa Moline Inma Rosas Elisabeth Castellanos Conxi Lazaro Eduard Serra Hospital Universitari Vall dHebron Barcelona Spain Institut de Medicina Predictiva i Personalitzada del Cncer IMPPC Barcelona Spain Hereditary Cancer Program Institut Catal dOncologia ICO-IDIBELL Barcelona Spain Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016236 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016236 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 4 Pediatric Non-Vestibular Schwannomas A Clinicopathologic Study of 22 Patients 42 Cory Broehm Karen Fritchie Mayo Clinic Rochester MN 5 Epithelioid Schwannoma Clinicopathologic Analysis of 63 Cases 62 Vickie Y Jo Christopher Fletcher Brigham and Womens Hospital Harvard Medical School Boston MA 6 Mass Spectrometry Highlights Proteomic and Epigenetic Changes upon PRC2 Loss in MPNST 96 John Wojcik Simone Sidoli Benjamin A Garcia Kumarasen Cooper Hospital of the University of Pennsylvania Philadelphia PA University of Pennsylvania Philadelphia PA 7 HER3 erbB3 as a Potential Therapeutic Target in Peripheral Nerve Sheath Tumors PNST In Vitro and In Vivo Models 49 Sherley Diaz Javier Hernandez Losa Joan Castellsague Claudia Valverde Roso Mares Angel Garcia Cristina Teixido Teresa Moline Juana Fernandez-Rodriguez Eduard Serra Alberto Villanueva Santiago Ramon y Cajal Conxi Lazaro Cleofe Romagosa Vall dHebron University Hospital Barcelona Spain Hereditary Cancer Program Institut Catal de Oncologia Barcelona Spain Institut de Medicina Predictiva i Perzonalitzada del Cancer Barcelona Spain 8 Anastomosing Hemangiomas Arising in Unusual Locations A Clinicopathological Study of 15 Cases Showing a Predilection for the Paraspinal Region 63 Ivy John Andrew L Folpe Mayo Clinic Rochester MN 9 Non-syndromic Low-Flow Mixed VenousLymphatic Malformation of Skeletal Muscle of the Extremity Fibro-Adipose Vascular Anomaly A Clinicopathologic Study of 11 Cases with Emphasis on Distinctive Morphologic Features 90 Michael L Schwalbe Lara N Mrak Paula E North Darya Buehler University of Wisconsin School of Medicine Madison WI Childrens Hospital of Wisconsin Milwaukee WI 10 Immunohistochemical Prole of Littoral Cell Angioma of the Spleen. A Report of 25 Cases Predominantly Associated with Visceral Malignancies 81 Kvetoslava Peckova Michael Michal Ladislav Hadravsky Saul Suster Ivan Damjanov Michal Michal Charles University Medical Faculty and Charles University Hospital Plzen Czech Republic Medical College of Wisconsin Milwaukee WI The University of Kansas School of Medicine Kansas City KS 11 The Diagnostic Utility of CAMTA1 and TFE3 Immunohistochemistry in Epithelioid Vascular Tumors 87 Marta Sbaraglia Marco Gambarotti Alberto Righi Angelo P Dei Tos Treviso Regional Hospital Treviso Italy Rizzoli Institute Bologna Italy 12 CIC-DUX4 Fusion-Positive Round Cell Sarcomas of Soft Tissue and Bone Clinicopthologic and Molecular Analysis from a Single Institution 86 Marta Sbaraglia Marco Gambarotti Stefania Benini Gabriella Gamberi Stefania Cocchi Emanuela Palmerini Davide Donati Piero Picci Daniel Vanel Stefano Ferrari Alberto Righi Angelo P Dei Tos Treviso Regional Hospital Treviso Italy Rizzoli Institute Bologna Italy 13 Evaluation of NKX2-2 Expression in Round Cell Sarcomas Including Those with CIC-DUX4 and BCOR-CCNB3 Fusions and Tumors with EWSR1 Rearrangement Relative Specicity for Ewing Sarcoma 59 Yin Hung Christopher Fletcher Jason L Hornick Brigham and Womens Hospital Boston MA 14 Establishment and Gene Expression Analysis of a Mouse Model for CIC-DUX4 Sarcoma 98 Toyoki Yoshimoto Miwa Tanaka Takuro Nakamura The Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan Toranomon Hospital Tokyo Japan 15 BCOR-CCNB3 Sarcoma of Soft Tissue with Round and Spindle Histology A Study of 4 Cases Highlights the Pitfall of Mimicking Poorly Differentiated Synovial Sarcoma 76 I-Chuang Liao Wan-Shan Li Hsuan-Ying Huang National Cheng Kung University Hospital Tainan Taiwan E-Da Hospital Kaohsiung Taiwan Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan 16 Mutations in Histone H3.3 Variants in Giant Cell Tumor of Bone 54 Brendan C Dickson Leonie G Mikael Tenzin Gayden Ashot Harutyunyan Simon Papillon-Cavanagh Jacek Majewski Nada Jabado Jay S Wunder Mount Sinai Hospital Toronto ON Canada McGill University Montreal QC Canada 17 Histone 3.3 Mutations in Giant Cell Tumor and Giant Cell-Rich Sarcomas of Bone 56 Alessandro Franchi Alberto Righi Marco Gambarotti Piero Picci Angelo Paolo Dei Tos Lisa Simi Irene Mancini University of Florence Florence Italy Rizzoli Institute Bologna Italy Treviso Regional Hospital Treviso Italy Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 237NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 237 18 Histologic Spectrum of Giant Cell Tumor GCT of Bone in Patients 18 Years of Age A Study of 66 Patients 35 Alyaa Al-Ibraheemi Jodi M Carter Riyam T Zreik Carrie Y Inwards Karen Fritchie Mayo Clinic Rochester MN Scott White Healthcare Temple TX 19 Anchored Multiplexed PCR for Targeted Next Generation Sequencing Reveals Recurrent and Novel Gene Fusions in Aneurysmal Bone Cyst and No Fusion in Giant Cell Tumor of the Bone 60 Omar Jaber Natalya Guseva Aaron Stence Benjamin Miller Munir Tanas Deqin Ma University of Iowa Iowa City IA 20 Chondroblastoma of Extracranofacial Bones - Analyses of 103 Cases by Numerical Scoring on Histology 72 Eiichi Konishi Yasuaki Nakashima Masayuki Mano Yasuhiko Tomita Sanae Yamazaki Akio Yanagisawa Kyoto Prefectural University of Medicine Kyoto Japan Kyoto University Kyoto Japan Osaka National Hospital Osaka Japan Osaka Medical Center of Cancer and Cardiovascular Diseases Osaka Japan 21 Extraosseous Extradural Chordomas of the Spine A Unique Chordoma Subset 43 Jodi M Carter Doris E Wenger Carrie Y Inwards Mayo Clinic Rochester MN 22 Histopathology of So-Called Synovial Cysts of the Lumbar Spine 45 Ivan Chebib Connie Y Chang Darcy A Kerr Vikram Deshpande G Petur Nielsen Massachusetts General Hospital and Harvard Medical School Boston MA University of Miami Miller School of Medicine Miami FL 23 Single Institutional Analysis of Prognostic Factors for Soft Tissue Sarcoma Debatable Value of Tumor Depth 93 Yoshiya Sugiura Noriko Motoi Keisuke Ae Hiroaki Kanda Seiichi Matsumoto Rikuo Machinami Yuichi Ishikawa The Cancer Institute Tokyo Japan The Cancer Institute Hospital Tokyo Japan 24 Programmed Death-Ligand 1 Expression in Sarcomas a Clinical a Pathologic Study 78 Stemm Matthew Alexander C Mackinnon Medical College of Wisconsin Milwaukee WI 25 Detection of Sarcoma Oncogenic Fusion Transcripts Using ArcherTM Sequencing Technology 57 Caleb Ho Kerry Mullaney Catherine OReilly George Jour Purvil Sukhadia Lu Wang Michael F Berger Maria E Arcila Marc Ladanyi Meera Hameed Ryma Benayed Memorial Sloan Kettering Cancer Center New York NY University College Cork Cork Ireland MD Anderson Cancer Center Houston TX 26 Utility of a Pan Genomic Fusion Panel 1300 Genes on a Next Generation Sequencing NGS Platform in Evaluation of Bone and Soft Tissue Sarcoma 71 Ravindra Kolhe Karen Fritchie Alka Chaubey Lisa C Watson Claire Attwooll WonSok Lee Deepa Jagdale Ashis K Mondal Georgia Regents University Augusta GA Mayo Clinic Rochester MN Illumina Inc San Diego CA Greenwood Genetic Center Greenwood SC 27 Finding Fusions A Promising Commercially Available NGS Sarcoma Panel 95 Ashley Windham Kimberly L Walker Linden L Watson Arundhati Rao Riyam T Zreik Baylor Scott White Hospital Temple TX BREAST PATHOLOGY 28 Clinicopathologic Factors Associated with Metastatic Breast Cancer BC at Presentation 284 Tiansheng Shen Gene P Siegal Shi Wei University of Alabama at Birmingham Birmingham AL 29 P-Rex1 Expression in Invasive Breast Cancer in Relation to Receptor Status and Metastatic Site 232 Kristen Muller Todd Miller Jonathan Marotti Dartmouth Hitchcock Medical Center Lebanon NH 30 PD-1PD-L1 Expression in Brain Metastases from Breast Cancer 158 Kara Gawelek Nicole Williams Vinay Varadan Lyndsay Harris Hannah Gilmore Case Western Reserve University Cleveland OH University Hospitals Case Medical Center Cleveland OH 31 Sensitivity and Specicity of Five Immunohistochemical Markers in Distinguishing Breast Primary CK7 Lesions from Lung Primary CK7 Lesions 125 Agedi Boto Lori Charette Marina Baine Ugur Ozerdem Malini Harigopal Yale New Haven Hospital New Haven CT 32 Similar Lymphocytic Inltration Patterns in Primary Breast Cancer and Corresponding Distant Metastases 298 Zsuzsanna Varga Bettina Sobottka Holger Moch Institute of Surgical Pathology Zurich Switzerland 33 Assessment of Pathologic Response and Long-Term Follow Up in Locally Advanced Breast Cancers after Neoadjuvant Chemotherapy Comparison between Classicationsunderline 139 Misun Choi Soo Youn Cho Eun Yoon Cho Samsung Medical Center Seoul Korea 34 Mitotic Index after Neoadjuvant Chemotherapy Prognosticates Breast Cancer Recurrence or Metastasis 170 Nicholas Harding-Jackson Christopher Hartley Zainab Basir Medical College of Wisconsin Milwaukee WI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016238 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016238 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 35 Androgen Receptor Status and Prediction of Neoadjuvant Chemotherapy Response in Triple- Negative Breast Cancer 288 Catherine Stoos Shannon Huggins-Puhalla David Dabbs Rohit Bhargava Magee-Womens Hospital Pittsburgh PA 36 Use of an Immunoprole to Predict Response of Invasive Breast Cancer to Neoadjuvant Chemotherapy 222 Lauren E McLemore Joseph Albanese Yungtai Lo Murali Janakiram Susan A Fineberg Monteore Medical Center and the Albert Einstein College of Medicine Bronx NY Albert Einstein College of Medicine Bronx NY 37 PD-L1 Expression and Lymphocytic Response in Neoadjuvant-Treated Breast Cancers 275 Nina Schatz-Siemers Beth Harrison Silvia C Formenti Sandra Demaria NYU Langone Medical Center New York NY Weill Cornell Medical College New York NY 38 Breast Cancer Biomarkers before and after Neoadjuvant Chemotherapy Do Changes in Biomarker Status Impact Therapeutic Management 263 Alexander K Quinones Gary Tozbikian Debra L Zynger The Ohio State University Columbus OH 39 Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 207 Xiaoxian Bill Li Uma Krishnamurti Shristi Bhattarai Sergey Klimov Michelle Reid Ritu Aneja Emory University Atlanta GA Georgia State University Atlanta GA 40 Distinctions in Breast Tumor Recurrence Patterns Post- Therapy among Ethnically Distinct Populations 304 Nikita Wright Jun Xia Remus Osan Pranay Neema Dora IIyasova Sergey Klimov Mildred Jones Padmashree CG Rida Guilherme Cantuaria Ritu Aneja Georgia State University Atlanta GA Northside Hospital Cancer Institute Atlanta GA Northside Hospital Cancer Data Center Institute Atlanta GA 41 Breast Frozen Section of Margins FSM Reduces Reexcision The First 5 Years at an Ambulatory Surgical Center ASC 183 Julie Jorns Michael Sabel Stephanie Daignault Angela Wu University of Michigan Ann Arbor MI 42 Utilizing Mammography of Breast Resection Specimen Slices for Lesion Identication Improves Sampling Efcacy Accurate Assessment of Tumor Pathologic Parameters Margin Assessment and Decrease in Average Overall Turn-Around Time 231 Jeffrey Mueller Raveena Reddy University of Chicago Chicago IL 43 High Peripheral Stromal Lymphocytic Inltration Is Associated with Better Survival in Triple Negative Breast Carcinoma 200 Uma Krishnamurti Ceyda Sonmez Jing Yang Limin Peng Xiaoxian Li Ritu Aneja Emory University Atlanta GA Georgia State University Atlanta GA 44 Does Tumor Inltrating Lymphocyte TIL Count Inuence Oncotype DxTM Recurrence Score and Magee Equation Scores 186 Brie Kezlarian Laura Favazza Javier Arias-Stella Daniel Schultz Dhananjay A Chitale Henry Ford Hospital Detroit MI 45 Microinvasive Carcinoma High Grade-HER2 Pathway Associated with High Tumor Inltrating Lymphocytes 227 Michi Morita Rin Yamaguchi Maki Tanaka Susumu Eguchi Hirohisa Yano Kurume University Medical Center Kurume Japan Kurume University School of Medicine Kurume Japan JCHO Kurume General Hospital Kurume Japan Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan 46 Two Scoring Systems of Tumor Inltrating Lymphocytes in Breast Cancer Evaluating Inter- Observer Variability and TILs Heterogeneity underlineunderline 191 Thaer Khoury Vidya Nagrale Dan Wang Fadi Habib Roswell Park Buffalo NY 47 Loss of LINC00478 Expression Is Associated with Development of Nodal Metastasis in ER Breast Cancer 161 Yesim Gokmen-Polar Maria Zavodszky Xiaowei Chen Xiaoping Gu Chinnappa Kodira Sunil Badve Indiana University School of Medicine Indianapolis IN GE Global Research Niskayuna NY 48 Extracapsular Extension and Lymphovascular Invasion in Breast Cancer Sentinel Lymph Nodes Is Associated with Non Sentinel Lymph Node Metastases 258 Ana S Pires-Luis Joao Lobo Liliana Santos Margarida Caldas Carla Bartosch Conceicao Leal IPO-Porto Porto Portugal ICBAS-UP Porto Portugal 49 Minimal Clinical Impact of Intraoperative Examination of Sentinel Lymph Nodes in Patients with DCIS An Opportunity for Improved Resource Utilization 181 Amy S Joehlin-Price Debra L Zynger The Ohio State University Columbus OH 50 Breast Cancer with Skin Ulceration Should All Cases Be Staged as pT4bunderlineunderline 190 Thaer Khoury Souzan Sanati Zaibo Li Yisheng V Fang Mohamed M Desouki Rouzan G Karabakhtsian Dan Wang Carmelo Gaudioso Rebecca Jacobson Roswell Park Buffalo NY Washington University Saint Louis MO Ohio State University Columbus OH University Texas Southwest Dallas TX Vanderbilt Nashville TN Monteore Bronx NY University Pittsburgh Medical Center Pittsburgh PA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 239NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 239 51 Skin Ulceration in Breast Cancer Carries No Increased Risk of Disease Free or Overall Survival underline underline 189 Thaer Khoury Yisheng V Fang Souzan Sanati Mohamed M Desouki Zaibo Li Rouzan G Karabakhtsian Dan Wang Carmelo Gaudioso Rebecca Jacobson Roswell Park Buffalo NY University Texas Southwest Dallas TX Washington University Saint Louis MO Vanderbilt Nashville TN Ohio State Columbus OH Monteore Bronx NY University Pittsburgh Medical Center Pittsburgh PA 52 Inconsistency in Following the AJCC Reporting Guidelines for T-Staging of Breast Cancer with Skin Ulcerationunderlineunderline 188 Thaer Khoury Rouzan G Karabakhtsian Zaibo Li Mohamed M Desouki Souzan Sanati Yisheng V Fang Dan Wang Carmelo Gaudioso Rebecca Jacobson Roswell Park Buffalo NY Monteore Bronx NY Ohio State Columbus OH Vanderbilt Nashville TN Washington University Saint Louis MO University Texas Southwest Dallas TX University Pittsburgh Medical Center Pittsburgh PA 53 HPV Detection by Chromogenic In Situ Hybridization CISH and p16 Immunohistochemical IHC Staining in Breast Cancer 165 Hua Guo Juan P Idrovo Louis J Auguste Tawqul Bhuiya Silvat Sheikh-Fayyaz Hofstra North Shore LIJ School of Medicine Lake Success NY Hofstra North Shore LIJ School of Medicine New Hyde Park NY 54 Epstein Barr Virus EBV in Triple Negative Breast Cancer A Tertiary Cancer Centre Experience 249 Trupti Pai Sangeeta Desai Mamta Gurav Prerna Walecha Sudeep Gupta Tata Memorial Centre Parel Mumbai Maharashtra India 55 Mass Spectrometry-Based Proteomics Identies Lactotransferrin as Co-Localizing Protein in Amyloidosis of the Breast 163 Karen L Grogg Julie A Vrana Bolette L Caron Jason D Theis Paul J Kurtin Mayo Clinic Rochester MN CYTOPATHOLOGY 56 Interobserver Variability of Cytotechnologists in Papanicolaou Smears of Glandular Lesions of Cervix 380 Reima El Naili Hongbo Wang Marlo Nicolas Diane Avery Kimberly Martinez Kathleen Flannigan Syed Zaidi Daniel Schantz Thomas Prihoda Maria Policarpio-Nicolas University of Texas Health Science Center at San Antonio San Antonio TX 57 Increasing Detection of Non-Squamous Malignancies in Pap Smears in a Medical Center in Taiwan 412 Chiung-Ru Lai Jen-Fan Hang Chih-Yi Hsu Taipei Veterans General Hospital Taipei Taiwan 58 Glandular Findings in Cervical Cytopathology Liquid Based Preparations in Cases of Endometritis A Series of 250 Patients 455 Theresa Smith Andrew Judd Therese Bocklage University of New Mexico Albuquerque NM 59 Stratied Mucin-Producing Intraepithelial Lesions of the Cervix A Diagnostic Challenge in Cytopathology 399 Jennifer Hipp Syed Z Ali University of Michigan Health Systems Ann Arbor MI The Johns Hopkins Hospital Baltimore MD 60 Role of HPV Testing in Atypical Glandular Cells on Pap Smear Diagnosis 398 Kinda Hayek Amy Jencks MHD Fayez Daaboul Amarpreet Bhalla Vinod B Shidham Rouba Ali-Fehmi Sudeshna Bandyopadhyay WSU Detroit MI Indiana University Indianapolis IN 61 Endometrial Cells on Pap Testing Impact of Revisions to the Bethesda System for Reporting Cervical Cytology 463 Pamela Tauchi-Nishi Landon Morikawa David Shimizu The Queens Medical Center Honolulu HI University of Hawaii Honolulu HI 62 Clinical Signicance of Positive Peritoneal Washings Cytology in Patients with Stage I Endometrioid-Type of Endometrial Adenocarcinoma A Community Hospital Experience 356 Boulos Beshai Srinivas Mandavilli Hartford Hospital Hartford CT 63 Clinical Outcome of LSIL Cannot Exclude HSIL Supports the Recommendation of LSIL and ASC-H in the 2014 Bethesda System 395 Jen-Fan Hang Chih-Yi Hsu Chiung-Ru Lai Taipei Veterans General Hospital Taipei Taiwan 64 Comparing Outcomes of hrHPV Positive Pap Tests HPV 1618 Genotypes Versus Non-1618 Genotypes 346 Gazal Alsaati Julio Laureano Mary K Sidawy Jay Zeck MedStar Georgetown University Hospital Washignton DC 65 Prevalence of HPV 1618 Genotypes and Histological Follow-Up Results in Women with Negative Pap CytologyPositive Cervista HPV HR Assay 457 Michelle Stram Dinesh Pradhan Chengquan Zhao University of Pittsburgh Medical Center Pittsburgh PA 66 Cytology and High-Risk HPV DNA Co-Testing in Cervical Cancer Screening Program Outcome of 3-Year Follow-Up in an Academic Institution 474 Jack Yang Olga S Chajewski Jalidsa Pellicier Patricia M Houser Medical University of South Carolina Charleston SC Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016240 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016240 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 67 Informed Cytology and HPV Genotyping Preceding Biopsy Proven HSILAdenocarcinoma Analysis from an Academic Medical Center 383 Nazneen Fatima Kruti Maniar Joseph F Peevey Julia Samolczk Ajit Paintal Ritu Nayar Northwestern University Feinberg School of Medicine Chicago IL 68 Do HPV Types and Infection Patterns Affect the Cytologic Detection of High Grade Cervical Lesions on Pap Test 352 Siavash Azadmanesh Samimi Steven Goodman Yimin Ge Roxanne R Mody Eric Luna Mary R Schwartz Dina R Mody Donna Armylagos Methodist Hospital Houston TX BioReference Laboratories Houston TX 69 Comparing the Histological Follow-Up Results between Positive HC2 HR HPV Test and Cervista HPV HR Assay for Women with ASC-US Cytology in a large Academic Womens Hospital Practice 483 Chengquan Zhao Dinesh Pradhan Michelle Stram University of Pittsburgh Medical Center Pittsburgh PA 70 The Pap Test Reporting Rates for Conventional Pap Tests and Liquid-Based Cervical Cytology from the Largest Academic Womens Hospital in China Analysis of 1248785 Papanicolaou Test Reportsunderline 462 Xiang Tao Marshall R Austin Hao Zhang Jianan Xiao Lihong Zhang Li Wang Xianrong Zhou Chengquan Zhao Obstetrics and Gynecology Hospital of Fudan University Shanghai China Magee-Womens Hospital of University of Pittsburgh Medical Center Pittsburgh PA 71 Prior Pap Test andor HPV Testing Results in 3342 Women with Histologically Diagnosed Cervical Intraepithelial Neoplasia 23 Data from Chinas Largest CAP Certied Clinical Laboratory 472 Tao Wu Christopher C Grifth BaoWen Zheng Xiangdong Ding Yaoming Liang Chengquan Zhao KingMed Diagnostics Guangzhou China Emory University Atlanta GA Magee-Womens Hospital of UPMC Pittsburgh PA 72 High Risk HPV Testing and Report Rate Result from the Largest CAP Certied Independent Laboratory in China 484 BaoWen Zheng Zaibo Li Zhengyu Zeng Congde Chen Jia You Lingyun Tan Chengquan Zhao Guangzhou Kingmed Diagnostics Guangzhou China Ohio State University Medical Center Columbus OH Magee-Womens Hospital of UPMC Pittsburgh PA 73 Prospective Tonsillar Pap Smears with High Risk HPV Testing of 41 Adults with Neck Mass and Unknown Primary 420 Megan G Lockyer Matt Prall Andrew Veyliotti Terry K Morgan OHSU Portland OR 74 HPV Testing of Squamous Cell Carcinomas in Non-Gynecological Cytology Concordance of p16 Immunostaining and In Situ Hybridization for HPV 464 Brian Theisen Liron Pantanowitz Raja R Seethala Alyssa Mahaffey Sara E Monaco University of Pittsburgh Medical Center Pittsburgh PA 75 Fine-Needle Aspiration of Neck MassesLymph Nodes Yields Adequate Material for HPV Testing in Head and Neck Squamous Cell Carcinomas 401 Yanjun Hou Shweta Chaudhary Rulong Shen Zaibo Li The Ohio State University Wexner Medical Center Columbus OH 76 Development of a Diagnostic Model Using Key Cytologic Features in Washed Urine Cytology 459 Ja Hee Suh Heounjeong Go Chang Ohk Sung Seunghee Baek Se Un Jeong Yong Mee Cho University of Ulsan College of Medicine Asan Medical Center Seoul Republic of Korea 77 The Performance of the Paris System for Reporting Urine Cytology PSRUC in Lower and Upper Tract Specimens A Comparative Study of 358 Cases 362 Fadi Brimo Muhannad Hassan Ozlem Fidan-Ozbilgin Shraddha Solanki Yonca Kanber Derin Caglar Stefan E Pambuccian Eva M Wojcik Manon Auger Guliz A Barkan McGill University Health Center Montreal QC Canada Loyola University Medical Center Maywood IL 78 Indenite to Positive and Indenite to Negative Ratios as Potential Quality Measures for Urine Cytology 439 Lynette Parker Dina Kokh Emily Wilding Teklu Legesse Paul Staats University of Maryland Medical Center Baltimore MD 79 Paris System for Reporting Urine Cytology a First Approach 387 Elvia Goez Gutierrez Victor Delacruz Claudia P Rojas Carmen Gomez-Fernandez Merce Jorda Monica Garcia-Buitrago University of Miami Miami FL 80 Comparative Evaluation of the Paris Reporting System for Urine Cytology with Our Original Urine Cytology Reporting System 478 Somaye Yekezare Leili Mirsadraei Xiaoyan Liao Niloufar Reisian Ahmed Shabaik Farnaz Hasteh Universityof California San Diego San Diego CA Kaiser Medical Center San Diego CA 81 The Paris System for Reporting Urine Cytology PSRUC Improves the Prognostic Value of an Atypical Urothelial Cell Diagnosis 397 Muhannad Hassan Derin Caglar Yonca Kanber Shraddha Solanki Manon Auger Fadi Brimo McGill University Health Center Montreal QC Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 241NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 241 82 Diagnostic Utility of UroVysion for Urothelial Carcinoma of the Upper Urinary Tract 405 Hidehiro Iwata Toyonori Tsuzuki Naoto Sassa Nagako Maeda Yota Murase Shuko Seko Ryohei Hattori Momokazu Gotoh Japanese Red Cross Nagoya Daini Hospital Nagoya Japan Nagoya University Hospital Naogya Japan Japanese Red Cross Nagoya Daiichi Hospital Nagoya Japan 83 High Diagnostic Accuracy of Concordant Ucyte and Urovysion Tests 480 Lei Zhang Hui Y Wang Mary Levin Neda A Moatamed Jonathan Said Douglas Bell Jianyu Rao University of California at Los Angeles Los Angeles CA 84 Experience with UroVysion FISH in Suspicious Cases for Urothelial Malignancy from a Large Academic Medical Center 354 Sheldon I Bastacky Dinesh Pradhan Somak Roy Gabriela Quiroga-Garza Kathleen M Cieply Alyssa M Luvison Rajiv Dhir Anil Parwani UPMC Pittsburgh PA Wexner Medical Center Columbus OH 85 Sex and Genetic Alterations in High Grade Urothelial Carcinoma on Urine Cytologic Specimens 363 Darren Buonocore Sasinya N Scott Nancy Bouvier Michael F Berger Oscar Lin Memorial Sloan Kettering Cancer Center New York NY 86 CellDetect a Novel Urine-Based Bladder Cancer Test A Multi-Institutional Validation Study 373 Noa Davis Micromedic Technologies Tel Aviv Israel 87 Label-Free Enumeration Collection and Downstream Cytological and Cytogenetic Analysis of Circulating Tumor Cells 456 Jianyu Rao Manjima Dhar Edward Pao Corinne Renier Derek E Go James Che Rosita Montoya Rachel Conrad Melissa Matsumoto Kyra Heirich Melanie Triboulet Stefanie S Jeffrey Edward Garon Jonathan Goldman Nagesh P Rao Rajan Kulkarni Elodie Sollier Dino Di Carlo UCLA Los Angeles CA Vortex Biosciences Menlo Park CA California NanoSystems Institute Los Angeles CA Jonsson Comprehensive Cancer Center Los Angeles CA UCLA Santa Monica Hematology Oncology Santa Monica CA UCLA Medical Center Los Angeles CA Stanford University School of Medicine Stanford CA 88 An Emerging Role for Cytopathology in Precision Oncology 440 Chantal Pauli Loredana Puca Brian D Robinson Juan Miguel Mosquera Himisha Beltran Mark Rubin Rema Rao Weill Medical College of Cornell University New York NY DERMATOPATHOLOGY 89 Breaking Bad Dogma The Diversity of Spindle Cell Lipomas in Women 506 Jennifer S Ko Brianne H Daniels Patrick Emanuel Vadim Khachaturov Jesse K McKenney John R Goldblum Steven D Billings Cleveland Clinic Cleveland OH UCSF San Francisco CA Auckland Health Board Auckland New Zealand 90 The Pseudoangiomatous Variant of Spindle Cell Lipoma Is Genuinely Lymphangiomatous 532 Toyohiro Tada Takashi Tsuchida Satoshi Baba Hisashi Tateyama Toyokawa City Hospital Toyokawa Japan Hamamatsu Medical University Hamamatsu Japan Kasugai City Hospital Kasugai Japan 91 Cutaneous Intravascular Epithelioid Haemangioma. A Clinico-Pathological Analysis of 21 Lesions 512 Bostjan Luzar Eleni Ieremia Eduardo Calonje Medical Faculty University of Ljubljana Ljubljana Slovenia John Radcliffe Hospital Oxford United Kingdom St Thomass Hospital London United Kingdom 92 The Rich Inammatory Inltrate in Kaposi Sarcoma Contains Phenotypically Dened Tumor Associated Macrophages with Potential Tumor Immune Suppressor and Angiogenetic Functions 491 Gianna Ballon Ethel Cesarman North Shore LIJ Health System Lake Success NY Weill Cornell Medical College New York NY 93 Multinucleate Cell Angiohistiocytoma A Study of 5 Cases of an Enigmatic Entity with Further Insights on Its Clinical Presentation 497 Giovanni Falconieri Deborah Bonazza Maurizio Pinamonti Bostjan Luzar University of Trieste Trieste Italy University of Ljubljana Ljubljana Slovenia 94 The Generalized Eruptive Keratoacanthoma of Grzybowski A Reappraisal of a Challenging Conditions Based on 4 New Cases 498 Giovanni Falconieri Maurizio Pinamonti Deborah Bonazza Joze Pizem Bostjan Luzar Trieste University Trieste Italy Ljubljana University Ljubljana Slovenia 95 DNA Mismatch Repair Status in Keratoacanthoma Immunohistochemistry-Based Study of 1353 Tumors from 1067 Patients 496 Renee Eigsti Carolyn Rysgaard Ashlynne Clark Brian Swick Andrew M Bellizzi University of Iowa Iowa City IA 96 Relationship between p53 Status and Clinicopathologic Variables in Cutaneous Basal Cell Carcinoma 526 Kevin A Pettit John VanBuren Brian Swick Andrew M Bellizzi University of Iowa Iowa City IA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016242 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016242 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 97 Proposal of a New Molecular Classication of Sebaceous Carcinoma with Its Clinical Signicance 522 Hee-Young Na Ji Eun Kim Ji-Young Choe Ji Yun Yun Sun-ah Shin Ho-Kyung Choung Min Joung Lee Seoul National University Hospital Seoul Republic of Korea Seoul Municipal Governmet-Seoul National University Boramae Hospital Seoul Republic of Korea Seoul National University Bundang Hospital Seoul Republic of Korea Hallym University Sacred Hospital Anyang Republic of Korea Seoul Municipal Government-Seoul National University Boramae Hospital Seoul Republic of Korea 98 SOX-10 and DOG1 Expression in Primary Adnexal Tumors and Cutaneous Metastases of Epithelial Origin 510 Cecilia Lezcano Jonhan Ho Raja R Seethala University of Pittsburgh Medical Center Pittsburgh PA 99 Detection of Somatic Mutations in Secondary Tumors Associated with Nevus Sebaceus by Targeted Next Generation Sequencingunderlineunderline 504 Jong T Kim Kimberly J Newsom Wonwoo Shon University of Florida Gainesville FL 100 Whole Exome Sequence of Merkel Cell Carcinoma Reveals a High Degree of Genomic Instability 514 Henry McNett Haley Abel David Larson Viveca Bjornhagen Hong Xie Weng-Onn Lui Eric J Duncavage Washington University St. Louis MO Karolinska Institutet Stockholm Sweden 101 The Composition Density and Location of Immune Inltrates Correlate with Survival in Merkel Cell Carcinoma 535 Michael T Tetzlaff Laurence Feldmeyer Genevieve R Lyons Jonathan L Curry Phyu P Aung Priyadharsini Nagarajan Doina Ivan Carlos A Torres-Cabala Roland L Bassett Jennifer A Wargo Victor G Prieto University of Texas MD Anderson Cancer Center Houston TX 102 Intratumoral Lymphovascular Invasion Detected by D2-40 Correlates with Metastasis in Primary Cutaneous Merkel Cell Carcinoma 488 Rami N Al-Rohil Laurence Feldmeyer Priyadharsini Nagarajan Genevieve R Lyons Jonathan L Curry Carlos A Torres-Cabala Doina Ivan Victor G Prieto Michael T Tetzlaff Phyu P Aung UT MD Anderson Cancer Center Houston TX 103 New Markers for the Recognition of Primary Cutaneous CD8-Positive Epidermotropic Cytotoxic T-cell Lymphoma 527 Steliana F Racean Emma Linares Carmen Gonzalez- Vela Santiago Montes Susana Armesto Pablo Gonzalvo M Asun Gonzalez-Moran Victor Alegre Sonia Alonso Javier Freire Manuela Mollejo Miguel Angel Piris University Hospital Marqus de Valdecilla Santander Spain Hospital Cabuees Gijn Spain University Hospital Len Len Spain University Hospital General de Valencia Valencia Spain University Hospital Elda Elda Spain Hospital Virgen de la Salud Toledo Spain 104 Differential Expression of CD123 in Photoallergic Dermatitis Spongiotic and Lichenoid Dermatoses and Mycosis Fungoides 501 Andy C Hsi Xiaofan Pang Andras Schaffer Washington University School of Medicine St. Louis MO 105 Chilblain Lupus Eythematosus Versus Idiopathic Perniosis Comparative Analysis of Histopathologic Features and CD123 and CD30 Immunostaining 539 Michael Wang May P Chan University of Michigan Ann Arbor MI 106 The Utility of Immunohistochemical and Histological Features to Distinguish between Erythema Multiforme and Cutaneous Graft Versus Host Disease 525 Stephanie Petkiewicz April Deng Patrick ODonnell Kristine M Cornejo University of Massachusetts Worcester MA 107 Keratin 17 Expression and Immune Phenotype of Anti- TNF- Refractory Psoriasis and Anti-TNF- Related Psoriasiform Dermatitis 519 Andrea Moy Mandakolathur Murali Daniela Kroshinsky Thomas Horn Rosalynn Nazarian Massachusetts General Hospital Boston MA 108 Gastrin-Releasing Peptide GRP and Scleroderma A Potential Novel Mechanism of Tissue Fibrosis 513 Elizabeth L McKinnon Mohamad Ibrahim Howard Levinson Mary E Sunday Duke University Hospital Durham NC 109 The Expression of BMP-2 Fetuin-B and MGP in Biopsies of Calciphylaxis 495 Jonathan Davick Andrew Patterson Benjamin Kaffenberger Alejandro Gru The University of Virginia Charlottesville VA The Ohio State University Columbus OH ENDOCRINE PATHOLOGY 110 No Detection of Circulating BRAF Mutant DNA in Thyroid Cancer Patientsunderline 571 Fulvio Basolo Vincenzo Condello Elisabetta Macerola Clara Ugolini Luigi De Napoli University of Pisa Pisa Italy Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 243NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 243 111 Old Versus New Individual and Combined Performance of CK19 HBME-1 CD117 and TROP-2 in Distinguishing a Wide Morphologic Range of Normal Benign and Malignant Thyroid Tissue Cores 572 Peter N Bonneau Christopher Hartley Bryan Hunt Medical College of Wisconsin Milwaukee WI 112 How Reliable Are TTF-1 and PAX8 in Conrming Thyroidal Origin in Undifferentiated Anaplastic Thyroid Carcinomas 582 Daniel N Johnson Tatjana Antic Nicole A Cipriani The University of Chicago Chicago IL 113 C-KIT A Useful Adjunct Marker for the Evaluation of Papillary Thyroid Carcinomaunderline 610 Jaylou Velez Torres Ernesto Martinez Duarte Oleksandr N Kryvenko Jennifer Chapman Darcy A Kerr Christina Kovacs Carmen Gomez Fernandez University of Miami Miller School of Medicine Jackson Memorial Hospital Miami FL 114 Immunohistochemical Detection of NRASQ61R Protein in Follicular-Patterned Thyroid Tumors 597 Naoki Oishi Tetsuo Kondo Huy Vuong Tadao Nakazawa Kunio Mochizuki Kazunari Kasai Tomohiro Inoue Ippei Tahara Mitsuyoshi Hirokawa Akira Miyauchi Ryohei Katoh University of Yamanashi Chuo Yamanashi Japan Kuma Hospital Kobe Hyogo Japan 115 Stage Specic Embryonic Antigen-1 SSEA-1 Expression in Thyroid Tissues 615 Jin Xu Heather A Hardin Ranran Zhang Ricardo V Lloyd University of Wisconsin School of Medicine and Public Health Madison WI 116 Gene Expression Proling by Nanostring nCounter miRGE Assay May Identify Malignant Thyroid Nodules 590 Danielle Meunier Iyare Izevbaye University of Alberta Edmonton AB Canada 117 Clusterin as Ancillary Marker of Medullary Thyroid Carcinoma 593 Najat Mourra Malika Bennis Beatrix Cochand-Priollet Marine Lefevre Charles Lepine Jerzy Klijanienko Fabrice Menegaux Frederique Tissier St-Antoine Hospital Paris France 118 GATA3 Expression in Pituitary Adenomas 586 Mirna Lechpammer Jessica G Rogers Kristin A Olson Kiarash Shahlaie Alexander Borowsky John W Bishop University of California Davis Sacramento CA 119 Mixed Gangliocytoma-Pituitary Adenoma Insights on the Pathogenesis of a Rare Sellar Tumos 587 M Beatriz Lopes Emily A Sloan Julie G Polder University of Virginia Charlottesville VA 120 Calcitonin-Producing Pancreatic Neuroendocrine Neoplasms Clinico-Pathologic Study of 25 Cases 585 Stefano La Rosa Roberta Maragliano Annika Blank Silvia Uccella Aurel Perren Fausto Sessa Ospedale di Circolo Varese Italy University of Insubria Varese Italy University of Bern Bern Switzerland 121 Ki67 Indices and Status of SSTR2 and SSTR5 in the Primary Tumors and in Their Liver Metastases of Gastro-EntericGE and Pancreatic Neuroendocrine NeoplasmsNEN Do They Change When They Metastasize 598 Robert Y Osamura Chie Inomoto Hiroshi Kajiwara Midori Matsuda International University of Health and Welfare Mita Hospital Tokyo Japan Tokai University School of Medicine Isehara Japan 122 Neuroendocrine Neoplasms of the Pancreas and the Lungs Potential Differences in Morphological Characteristics and Cell Cycle Regulation 583 Atsuko Kasajima Samaneh Yazdani Tomoyoshi Tachibana Hirotaka Ishida Kazuma Kobayashi Keigo Murakami Hironobu Sasano Tohoku University Hospital Sendai Miyagi Japan Tohoku University Graduate School of Medicine Sendai Miyagi Japan 123 Pancreatic NENs NEXTGENERATION LEARNING2016244 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016244 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC GASTROINTESTINAL PATHOLOGY 126 Genta Stain Necessity in Diagnostic Accuracy of Detecting Helicobacter Pylori in Gastric Biopsies 656 Lani K Clinton Jared Osaki Hiroko Shinoda David Shimizu University of Hawaii Pathology Residency Program Honolulu HI Queens Medical Center Honolulu HI 127 Incidental Finding of Terminal Ileitis IFTI Indication for Colonoscopy Does Not Predict Outcome 799 Hassan Siddiki Jonathan Leighton Suryakanth Gurudu Shabana F Pasha Dora Lam-Himlin Mayo Clinic Scottsdale AZ 128 Alterations of the Genomic Landscape in Inammatory Bowel Disease-Associated Neoplasia 780 Mary P Rosenblatt Alain Borczuk Alina Iuga Columbia University Medical Center New York NY Weill Cornell Medical College New York NY 129 Dysplasia in Inammatory Bowel Disease Correlation of Biopsy and Resection Findings 765 Deepa Patil Erica Savage John Goldblum Robert Odze Cleveland Clinic Cleveland OH Brigham and Womens Hospital Boston MA 130 Clinicopathologic Characteristics of Systemic Mastocytosis in the Intestine 797 Angela R Shih Vikram Deshpande Judith A Ferry Lawrence Zukerberg Massachusetts General Hospital Boston MA 131 Distinct Expression of MACC1 and MET in Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma 643 Wenqing Cao Bing Ren Zhongren Zhou Jiangzhou Yu New York University Langone Medical Center New York NY University of Rochester Medical Center Rochester NY 132 Histopathologic Features for Prognostication of Supercial Barretts Carcinoma Data from a Multi- Center Study in Japan 628 Junko Aida Tatsuro Ishizaki Tomio Arai Kaiyo Takubo Tokyo Metropolitan Institute of Gerontology Tokyo Japan Japan Research Society for Early Esophageal Cancer and Chromoendoscopy Tokyo Japan Tokyo Metropolitan Geriatric Hospital Tokyo Japan 133 Histologic Predictors of Endoscopic Treatment Failure in Barretts Esophagus-Associated Dysplasia 692 Sara Higgins Meir Mizrahi Marcello M DiStasio Douglas K Pleskow Tyler Berzin Robert Najarian Beth Israel Deaconess Med CenterHarvard Medical School Boston MA Beth Israel Deaconess Medical Center Boston MA 134 High Expression of the Leaky Protein Claudin-2 in Esophageal Carcinoma and Precancerous Lesions Is Signicantly Associated with the Bile Salt Receptors VDR and TGR5 620 Sohaib Abu-Farsakh Tongtong Wu Amy Lalonde Jun Sun Zhongren Zhou University of Rochester Medical Center Rochester NY University of Illinois at Chicago Chicago IL 135 Carbonic Anhydrase IX CA9 Expression in Adenocarcinoma of the Stomach and Esophagus 781 Faisal Saeed Hongfeng Zhang George Kleinman Minghao Zhong Westchester Medical Center Valhalla NY Central Hospital of Wuhan Wuhan China 136 CDX2 as a Prognostic Marker in Gastric Adenocarcinoma 737 Muhammad A Masood Muhammed A Yusuf Asif Loya Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore Punjab Pakistan 137 Prospectively Reported Histologic Tumor Viability Score and Factors Predicting Long Term Survival in Patients Treated with Trimodality Therapy for Primary Esophageal Adenocarcinoma 623 Atin Agarwal Arlene M Correa Huamin Wang Dipen Maru Dongfeng Tan Susan C Abraham Melissa W Taggart Jeannelyn S Estrella Wai Chin Foo Wayne L Hofstetter Asif Rashid University of Texas MD Anderson Cancer Center Houston TX 138 Association between HER2 Status in Gastric Cancer and Clinicopathological Features A Retrospective Study Using Whole-Tissue Sections 711 Renato S Laboissiere Marcelo A Buzelin Debora Balabram Marina De Brot Cristiana B Nunes Rafael M Rocha Monica M Demas Alvares Cabral Helenice Gobbi Federal University of So Joo del-Rei UFSJ So Joo del-Rei Minas Gerais Brazil Federal University of Minas Gerais UFMG Belo Horizonte Minas Gerais Brazil 139 CD44 Expression and Its Clinical and Histologic Associations in Gastric Cancer A Tertiary Care Center Experience 754 Stephen Olsen Ilke Nalbantoglu Washington University in St. Louis School of Medicine Saint Louis MO Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 245NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 245 140 Size Does Matter Tumor Diameter Predicts Lymph Node and Distant Metastases in Gastric Adenocarcinoma 664 Heather Dawson Alexander Novotny Daniel Reim Radu Tutuian Rupert Langer Fatima Carneiro Irene Gullo Magali Svrcek Jean-Francois Flejou Inti Zlobec Alessandro Lugli Institute of Pathology University of Bern Bern Switzerland Klinikum Rechts der Isar Technische Universitt Munich Munich Bavaria Germany Inselspital Bern Bern Switzerland Medical Faculty of Porto and Ipatimup Porto Portugal Assistance Publique-Hpitaux de Paris Paris France 141 Differences between Hereditary and Sporadic Diffuse Type Gastric Cancer Indicating Different Carcinogenetic Pathways 715 Hee Eun Lee Thomas C Smyrk Lizhi Zhang Mayo Clinic Rochester MN 142 MCM2 and Chromogranin Are Markers of Serrated Polyp Progression 676 Danielle Fortuna Bruce M Boman Juan P Palazzo Thomas Jefferson University Hospital Philadelphia PA 143 Digital Image Analysis of Serrated Lesions of the Colorectumunderlineunderline 777 Brian Robinson David Martin Alton B Farris Emory University Atlanta GA 144 Ectopic Crypt Formation Is a Common Histologic Feature in Large Tubular and Tubulovillous Adenomas Not Specic for Traditional Serrated Adenomas 838 Yi Zhou Haiyan Chen Vamsi Parini Mohammed Atieh Stefan E Pambuccian Xianzhong Ding Loyola University Medical Center Maywood IL 145 Yap1 Oncogene Overexpression in Colerectal Polyps and Association with Nuclear -catenin 770 Carolina Polanco Christopher Hartley Catherine Hagen Medical College of Wisconsin Milwaukee WI 146 Glucose Metabolic Reprogramming and Cell Proliferation Arrest in Micropapillary Colorectal Carcinomas 815 Monika Vyas Natalie Patel Margaret Cho Narendra Wajapeyee Dhanpat Jain Xuchen Zhang Yale School of Medicine New Haven CT 147 The Prognostic Signicance of Peritumoral Chronic Inammation in Rectal Adenocarcinoma after Neoadjuvant Treatment 653 Rati Chkheidze Amit Singal Muhammad S Beg Purva Gopal UT Southwestern Medical Center Dallas TX 148 VE1 Immunohistochemistry in Colorectal Cancer Is Homogeneously Expressed and Is a Predictor of BRAF Mutational Status and Worse Survival 663 Heather Dawson Christian Schafroth Jose A Galvan Lena Sokol Gregor Rieger Viktor Koelzer Rupert Langer Alessandro Lugli Inti Zlobec Institute of Pathology University of Bern Bern Switzerland 149 Prognostic Signicance of Venous-Associated Colorectal Cancer Tumor Deposits Identied by Elastic Tissue Staining 734 Mena Mansour Jayalakshmi P Balakrishna Natalie Ciomek Noam Harpaz Icahn School of Medicine at Mount Sinai New York NY 150 Diagnostic Utility of Keratin and Elastic Stains in evaluation of Tumor Invasion of Peritoneal Membranes 648 Jey-Hsin Chen Melissa Borges CellNetix Pathology and Laboratories Seattle WA Swedish Medical Center Seattle WA 151 Low Frequently Mutated Genes in Colo-Rectal Cancer Evidences from Next-Generation Sequencing of 653 Routine Cases 808 Giancarlo Troncone Pasquale Pisapia Elena Vigliar Claudio Bellevicine Umberto Malapelle University of Napies Federico II Napoli Italy 152 Large Size and High Grade Dysplasia Are Strong Predictors of Mismatch Repair Deciency in Lynch Syndrome-Associated Colorectal Adenomas 630 Iban Aldecoa Natalia Rakislova Sabela Carballal Carla Montironi Laura Herrero Ariadna Sanchez Teresa Ocana Maria Pellise Antoni Castells Francesc Balaguer Miriam Cuatrecasas Hospital Clinic Barcelona Spain 153 Clinicopathologic Findings in Gynecologic Proliferations of the Appendix 762 Sapna S Patel Raul S Gonzalez University of Rochester Medicine Rochester NY 154 Adenocarcinoma Ex-Goblet Cell Carcinoid XGC Is a Morphologically Distinct Appendiceal-Type Crypt Cell Adenocarcinoma with Highly Aggressive Behavior and Frequent Association with Peritoneal Intra-Abdominal Dissemination An Analysis of 77 Cases 773 Michelle Reid Olca Basturk Walid Shaib Serdar Balci Hyejeong Choi Gizem Akkas Brian Robinson Bahar Memis Bassel El-Rayes Charles Staley Christopher Staley Joshua Winer Maria Russell Jessica H Knight Michael Goodman Alyssa Krasinskas Volkan Adsay Emory University Atlanta GA MSKCC NY NY 155 Clinical Signicance of Fibroblast Growth Factor Receptor 2 Expression on Residual Disease after Preoperative Chemoradiotherapy for Rectal Cancer A Retrospective Single Institution Study 787 An Na Seo Sol-Min Kim Ji-Young Park GhilSuk Yoon Kyungpook National University Medical Center Kyungpook National University School of Medicine Daegu Republic of Korea 156 Detection of Mismatch Repair Protein MMR Loss by Immunohistochemistry IHC in Colorectal Adenomas from Young Patients An Appraisal of Its Utility in Lynch Syndrome Screening 650 Zongming E Chen Jinhong Li Neze Kip Fan Lin Geisinger Medical Center Danville PA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016246 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016246 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 157 Implementation of a Pathology-Driven Lynch Syndrome Screening Program 624 Diana Agostini-Vulaj Kelly Q McMahon Rebecca Amorese Jennifer Findeis-Hosey University of Rochester Medical Center Rochester NY 158 The Ampulla of Vater a Potential Cancer Hot Spot Higher Cancer Incidence Per Surface Area in Comparison to Other Sites of GI Tract in the Last 4 Decades of SEER 9 Registry 776 Elizabeth Richards Matthew Yeh Monteore Medical Center Bronx NY University of Washington Seattle WA 159 Line-1 Methylation Status Predicts Aggressive Behavior in Pancreatic Endocrine Neoplasms 782 Wesley Samore Krishnan K Mahadevan Vikram Deshpande Massachusetts General Hospital Boston MA 160 Comprehensive Proteomic Characterization of Pancreatic Adenocarcinoma 829 Qian Yang Sheng-Ben Liang Julia Y Wang Michael H Roehrl University Health Network Toronto ON Canada Memorial Sloan Kettering Cancer Center New York NY 161 Reduced Expression of Argininoscuccinate Synthetase 1 Has a Negative Prognostic Impact in Patients with Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Therapy and Pancreaticoduodenectomy 726 Qingqing Liu John M Stewart Hua Wang Asif Rashid Matthew H Katz Jeffery E Lee Jason B Fleming Anirban Maitra Robert A Wolff Gauri R Varadhachary Sunil Krishnan Huamin Wang MD Anderson Cancer Center Houston TX 162 IMP3 Is Similarly Expressed Immunohistochemically in Intrahepatic and Extrahepatic Cholangiocarcinomas 640 Laura Bratton Loralee McMahon Richard F Dunne Rebecca Amorese Jennifer Findeis-Hosey University of Rochester Medical Center Rochester NY 163 SSBP2 Are Associated with Patients Survival in Hepatocellular Carcinoma 706 Hyunsung Kim Yumin Chung Rehman Abdul Seung Sam Paik Dong Ho Choi Kiseok Jang Hanyang University College of Medicine Seoul Korea 164 Utility of Immunolabeling with Stathmin-1 in the Accurate Classication of Anal Squamous Intraepithelial Lesions 1138 Erika Hissong Adela Cimic Edyta C Pirog Weill Cornell Medical College New York NY GENITOURINARY PATHOLOGY INCLUDING RENAL TUMORS 165 Comparative Analysis of Neuroendocrine Phenotype in Metastases from Advanced Prostate Cancer and Their Corresponding Primary Tumor 959 Rafael E Jimenez Jad Abbas John C Cheville Manish Kohli Mayo Clinic Rochester MN 166 Type 10 Soluble Adenyl Cyclase is Signicantly Overexpressed in Small Cell Prostatic Carcinoma Compared to Neuroendocrine Prostatic Carcinoma and Conventional Adenocarcinoma 1055 Peyman Tavassoli Francesca Khani Jonathan H Zippin Brian D Robinson Weill Cornell Medical College New York NY 167 Neuroendocrine Carcinoma A Genomically Distinctive Form of Prostate Cancer 842 Sanaz Ainechi Bryan Firestone Julia A Elvin Siraj M Ali Jo-Anne Vergilio James Suh Badar Mian Hugh Fisher Tipu Nazeer Vincent A Miller Philip J Stephens Jeffrey S Ross Foundation Medicine Inc. Cambridge MA Albany Medical College Albany NY 168 Integrated Molecular Classier Determines Transdifferentiation to Neuroendocrine Prostate Cancer 889 Joanna Cyrta Himisha Beltran Davide Prandi Juan Miguel Mosquera Matteo Benelli Scott A Tomlins Olivier Elemento Andrea Sboner Levi Garraway Mark Rubin Francesca Demichelis Weill Cornell Medicine of Cornell University New York NY University of Trento Trento Italy University of Michigan Ann Arbor MI Dana Farber Cancer Institute Boston MA 169 Very-Small-Nuclear Circulating Tumor Cell vsnCTC as a Putative Biomarker for Visceral Metastasis VM in Metastatic Castration-Resistant Prostate Cancer mCRPC 878 Jie-Fu Chen Hao Ho Elisabeth Hodara Ann Go Alexander Ureno Elizabeth Kaufman Margarit Sievert Daniel Luthringer Zunfu Ke Leland WK Chung Ker- Chau Li Hsian-Rong Tseng Edwin M Posadas Cedars-Sinai Medical Center Los Angeles CA University of California Los Angeles Los Angeles CA 170 Aurora A in Metastatic Castration Resistant Prostate Cancer mCRPC 1001 Daniel Nava Rodrigues Niven Mehra Ines Figueiredo Mateus Crespo Ruth Riisnaes Susana AA Miranda Ana Ferreira Nina Tunariu Raquel Perez-Lopez Gunther Boysen Adam Sharp Diletta Bianchini Michael Kolinsky Pasquale Rescigno Zafeiris Zafeiriou Joaquin Mateo Johann S De Bono ICR London United Kingdom Royal Marsden Hospital London United Kingdom Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 247NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 247 171 Morphological and Molecular Pathway-Based Analysis of Gleason Score 7 Prostate Cancer Using a 17-Gene Expression Assay 868 Michael J Bonham Debbie McCullough Ruixiao Lu John P Bennett Phillip G Febbo Athanasios C Tsiatis Genomic Health Inc. Redwood City CA 172 The Performance of a 17-Gene Genomic Prostate Score GPS PTEN Fluorescence In Situ Hybridization FISH and PTEN Immunohistochemistry IHC as Predictors of Clinical Recurrence cR in Prostate Cancer PCa Following Radical Prostatectomy RP 989 Cristina Magi-Galluzzi Athanasios C Tsiatis Michael J Bonham Dejan Knezevic Tara Maddala Anne Dee Sara Falzarano H Jeffrey Lawrence Phillip G Febbo Eric A Klein Cleveland Clinic Cleveland OH Genomic Health Inc. Redwood City CA 173 A New AR-V7 Rabbit Monoclonal Antibody for Imunohistochemical Application 976 Aihua Li Yuekai Zhang Shihua Sun Jason Law Hongyang Pan Jackie Chan Daniel NavaRodrigues Stephen Plymate Johann S De Bono Taiying Chen Epitomics an Abcam Company Burlingame CA University of Washington Seattle WA Royal Cancer Hospital London United Kingdom 174 Clinical Validation of AR-V7 Detection in Circulating Tumor Cells from Castration-Resistant Prostate Cancer Patients 984 Parvez M Lokhandwala Stacy Riel Christopher D Gocke Ming-Tseh Lin Gang Zheng Emmanuel S Antonarakis Jun Luo James R Eshleman Johns Hopkins University School of Medicine Baltimore MD 175 Analytic Validation of RNA In Situ Hybridization RISH for AR and AR-V7 Expression in Human Prostate Cancer 931 Liana B Guedes Carlos L Morais Qizhi Zheng John Isaacs Emmanuel S Antonarakis Angelo M De Marzo Jun Luo Tamara Lotan Johns Hopkins School of Medicine Baltimore MD 176 ERG and Prostein Expression in Prostate Cancer Identify Different Pathways of Progression 960 Nuria Juanpere Josep Lloreta Alba Font Marta Lorenzo Raquel Albero Ivonne Vazquez Lluis Fumado Lluis Cecchini Sergio Serrano Silvia Hernandez Hospital del Mar-PSMar Barcelona Spain Pompeu Fabra University Barcelona Spain Autonomous University of Barcelona Barcelona Spain 177 PTEN Loss Is Less Frequent in African-American Compared to European-American Prostate Cancers 849 Fawaz Almutairi Carlos L Morais Stephanie Glavaris Jessica Hicks Deb Sundi Angelo M De Marzo Edward M Schaeffer Tamara Lotan Johns Hopkins School of Medicine Baltimore MD 178 Monitoring CHD1 During Prostate Cancer Progression 1002 Daniel Nava Rodrigues Gunther Boysen Joaquin Mateo Rossitza Christova Ruth Riisnaes Mateus Crespo Theresa Y MacDonald Susana AA Miranda Ines Figueiredo Veronica Gil Sara Aziz Niven Mehra Adam Sharp Pasquale Rescigno Juan Miguel Mosquera Christopher E Barbieri Mark Rubin Johann S De Bono ICR London United Kingdom Weil Medical College of Cornell University New York NY 179 Urinary Exosomes with TMAs Validation The Mirror of Prostate Alterations 894 Ines De Torres Tamara Sequeiros Dirk Michiel Pegtel Eduard Sabido Marina Rigau Iolanda Garcia-Grau Jordi Temprana-Salvador Juan Morote Santiago Ramon y Cajal Mireia Olivan Vall dHebron University Hospital Universitat Autnoma de Barcelona UAB Barcelona Spain Centre de Regulaci Genmica CRG Barcelona Spain Vall dHebron Institut de Recerca VHIR Barcelona Spain Vall dHebron University Hospital and Autnomous University of Barcelona UAB Barcelona Spain VU University Medical Center Cancer Center Amsterdam Amsterdan Netherlands 180 MAGI-2 is Associated with Biochemical Recurrence in Prostate Cancer 892 Stephanie N David Shanna Arnold Rajen Goyal Jeffery Goldstein Lan L Gellert Peter E Clark Omar Hameed Giovanna A Giannico Vanderbilt University Medical Center Nashville TN Department of Veterans Affairs Nashville TN 181 Diagnostic Value of Dual Reactivity of STAT6 and ALDH1 in the Differential Diagnosis of Solitary Fibrous Tumor vs Stromal Tumor of Unknown Malignant Potential of the Prostate 934 Gunes Guner Stephania M Bezerra Diana Taheri David J Zahavi Maria Angelica Mendoza Rodriguez Rajni Sharma Justin A Bishop Jonathan I Epstein George J Netto Johns Hopkins Medical Institution Baltimore MD Isfahan University of Medical Sciences Isfahan Kidney Diseases Research Center Isfahan Islamic Republic of Iran 182 Racial Disparity in Prostatic Expression of Pro- inammatory and Paracrine Factors 954 Kenneth A Iczkowski Jim R Lambert Kathleen C Torkko Daniel C Eastwood Robert S Wilson Girish V Shah MS Lucia Medical College of Wisconsin Milwaukee WI University of Colorado Aurora CO University of Louisiana Monroe LA Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016248 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016248 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 183 Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant Intense Androgen Deprivation Therapy 1078 Huihui Ye Adam G Sowalsky Rachel Schaefer Xin Yuan Shao-yong Chen Sean J Gerrin Laleh Montaser Fen Ma Olga Voznesensky Changmeng Cai Rosina Lis Zhenwei Zhang Massimo Loda Mary-Ellen Taplin Steven Balk Beth Israel Deaconess Medical Center Boston MA Dana-Farber Cancer Institute Boston MA 184 The Relationship among ERG PTEN and SPINK1 in Transition and Peripheral Zone Prostate Cancers in Japanese Patients 1037 Shun Sato Hiroyuki Takahashi Takashi Yorozu Takahiro Kimura Masahiro Ikegami Jikei University School of Medicine Tokyo Japan 185 Increased Proliferative Rate and PTEN Loss in Prostate Cancer Are Correlated and Both Associated with Risk of Recurrence in Multivariate Models 1060 Maria S Tretiakova Wei Wei Carlos L Morais Ziding Feng Jesse K McKenney Jeff Simko Dean Troyer Lawrence True Funda Vakar-Lopez Ladan Fazli Peter S Nelson Daniel Lin James D Brooks Tamara Lotan Canary Prostate Investigators University of Washington Seattle WA Canary Foundation Palo Alto CA John Hopkins University Baltimore MD 186 ERGPTEN Status of Isolated PIN Occurring in Cystoprostatectomy Specimens without Invasive Prostatic Adenocarcinoma 930 Liana B Guedes Carlos L Morais Jessica Hicks Angelo M De Marzo Tamara Lotan Johns Hopkins School of Medicine Baltimore MD 187 Expression of miRNAs 200c and 33a That Negatively Control HAS2 and HAS3 in Localized Prostate Cancer 998 Caio M Moura Sabrina T Reis Jose Pontes Nayara Viana Nelson Dip Miguel Srougi Katia RM Leite University of Sao Paulo Medical School Sao Paulo Brazil 188 PIM1 Expression in Prostate Cancer Correlation with ERG Rearrangement bcl-2 and Ki67 Index 893 Silvia de Muga Joan Gil Silvia Hernandez Alba Font Marta Lorenzo Nuria Juanpere Lluis Fumado Lluis Cecchini Laia Serrano Josep Lloreta Universitat Pompeu Fabra Barcelona Spain Hospital del Mar-Parc de Salut Mar-IMIM Barcelona Spain Autonomous University of Barcelona Barcelona Spain 189 Expression of the Glucocorticoid Receptor in Prostatic Adenocarcinoma An Immunohistochemical and Clinicopathologic Study 974 Nelli Lakis Andres Matoso Shamlal Mangray Murray B Resnick Evgeny Yakirevich Rhode Island HospitalBrown University Providence RI 190 Maspin Deciency Promotes Prostatic Intraepithelial Hyperplasia 903 Sijana H Dzinic Ye-Shih Ho Rodrigo Valdivia- Fernandez M Magarida Bernardo Shijie Sheng Wael A Sakr WSU Detroit MI 191 Value of a Genomic Risk Classier GPS Score in Relation to Histopathologic Parameters 929 Nancy Greenland Bradley Stohr Jeffrey P Simko University of California San Francisco CA 192 Ability to Accurately Diagnose Prostate Cancer Gleason Grade Score Using Automated Image Analysis Tools with Multiplex Immunouorescence 908 Gerardo Fernandez Richard Scott Faisal Khan Michael J Donovan Icahn School of Medicine at Mount Sinai Hospital New York NY 193 Better Treatment of Metastases Cannot Fully Explain Prostate Cancer Survival Improvements Associated with PSA Screening 1068 Mitchell S Wachtel Thomas Nelius Allan Haynes Werner T de Riese Texas Tech University Health Sciences Center Lubbock TX 194 The Prognostic Signicance of Perineural Invasion in Prostatic Core Biopsies 916 Manal Gabril Tianzhu Zhang Jonathan Izawa Madeleine Moussa Western University London Health Sciences Centre London ON Canada 195 Presence of Hormone Resistant Intraductal Carcinoma of the Prostate after Neoadjuvant Hormone Therapy Is a Signicant Prognostic Factor for High Risk Prostate Cancer in Radical Prostatectomy Patients 1064 Toyonori Tsuzuki Masashi Kato Kyosuke Kimura Ryo Ishida Naoto Sassa Akitoshi Fukatsu Ryohei Hattori Momokazu Gotoh Japanese Red Cross Nagoya Daini Hospital Nagoya Japan Nagoya University Hospital Nagoya Japan Nagoya Medical Center Naogya Japan Komaki City Hospital Komaki Japan Japanese Red Cross Nagoya Daiichi Hospital Naogya Japan 196 Characterization of Anterior Periprostatic Fat in a Large Cohort of Robotic-Assisted Radical Prostatectomy with Emphasis on Lymph Node Yield and Tumor Metastasis 1021 Brian C Radlinski Eric Raa-Yuan Peter E Clark Giovanna A Giannico Omar Hameed Lan L Gellert Vanderbilt University Medical Center Nashville TN 197 A Comparison of Multiparametric Magnetic Resonance Imaging of the Prostate and Histologic Prostatectomy Findings A Single Institutions Experience 911 Erin Faber Julie Anne Bishop Mostafa M Fraig Albert Seow Houda Alatassi University of Louisville Louisville KY Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 249NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 249 198 Clinicopathological Characteristics of Patients with Fungal Prostatitis 1030 Evita T Sadimin Melanie Parikh Daniel Luthringer Deepika Sirohi Mahul B Amin Jonathan I Epstein Rutgers Cancer Institute of New Jersey New Brunswick NJ Cedars-Sinai Medical Center Los Angeles CA Johns Hopkins Medical Institutions Baltimore MD GYNECOLOGIC AND OBSTETRIC PATHOLOGY 199 Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-Grade Endometrial Cancer 1121 Jessie A Ehrisman Sara Abbott Zach Harmon Angeles Alvarez Secord Andrew Berchuck Paula S Lee Fidel A Valea Gloria Broadwater Xuechan Li Laura J Havrilesky Allison Hall Duke University Medical Center Durham NC 200 A Standardized Endometrial Carcinoma Lymph Node Processing Protocol Increases Lymph Node Counts but Does Not Increase Detection of Metastases 1106 Joseph Carlson Denis Nastic Babylonia Tibert Sahar Salehi Henrik Falconer Karolinska University Hospital Stockholm Sweden 201 Management of Insufcient Endometrial Biopsy for Women with Abnormal Uterine Bleeding To Further Investigate Or Reassure 1085 Wamidh Adwar Ramya Gadde Dhananjay A Chitale Ghassan Allo Daniel Schultz Arthur R Gaba Ziying Zhang Henry Ford Hospital Detroit MI 202 Clinical Outcomes in a Subset of Endometrial Surface Epithelial Lesions with Marked Nuclear Atypia 1157 Elizabeth Kehr Marisa R Nucci Christopher P Crum Brigham and Womens Hospital Boston MA 203 Mucinous Proliferations of the Endometrium Subdiagnostic of Malignancy in Curettages and Biopsies A Clinicopathologic Analysis of 41 Cases underline 1210 Kojo R Rawish Mohamed M Desouki Oluwole Fadare UC San Diego Medical Center San Diego CA Vanderbilt University Nashville TN Vanguard Pathology Associates Austin TX 204 The Impact of Androgen Receptor Expression on Endometrial Carcinoma 1217 Woodlyne Roquiz Vishakha Pardeshi Oudai Hassan Eman Abdulfatah Ankit Modh Nagla Salem MHD Fayez Daaboul Daniel Schultz Mohamed A Elshaikh Sudeshna Bandyopadhyay Rouba Ali-Fehmi Wayne State UniversityDetroit Medical Center Detroit MI Henry Ford Hospital Detroit MI 205 Diagnostic Signicance of Simple Nonatrophic Glands in the Interpretation of Endometrium after Progestin Treatment in Patients with Endometrial Intraepithelial Neoplasia and Endometrioid Adenocarcinoma in Young Women 1163 Kyu-Rae Kim Su Hyun Yoo Stanley J Robboy Asan Medical Center Seoul Korea Duke University Medical Center Durham NC 206 Concordance between Beta-Catenin Immunohistochemistry and Next-Generation Sequencing of the CTNNB1 Gene 1161 Grace Kim Charanjeet Singh Bojana Djordjevic Russell Broaddus MD Anderson Cancer Center Houston TX University of Ottawa Ottawa ON Canada 207 Evaluation of Microsatellite Instability MSI Status in Endometrial Adenocarcinoma by Comprehensive Genomic Proling CGP Identies Subset That May Benet from Immunotherapy 1123 Julia A Elvin Eric M Sanford Zachary Chalmers Garrett Frampton Alessandro D Santin Jo-Anne Vergilio James Suh Laurie Gay Michael Hall Evgeny Yakirevich Alexander Brodsky Siraj M Ali Vincent A Miller Philip J Stephens Jeffrey S Ross James Sun Foundation Medicine Inc. Cambridge MA Yale University School of Medicine New Haven CT Albany Medical College Albany NY Fox Chase Cancer Center Philadelphia PA Brown University Providence RI 208 Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis 1131 Blake Gilks Melissa McConechy Aline Talhouk Samuel Leung Cheng-Han Lee David G Huntsman Jessica N McAlpine University of British Columbia Vancouver Canada University of Alberta Edmonton Canada 209 Immunohistochemical Characterization of Endometrial Carcinomas Grouped by the TCGA Molecular Classication Scheme 1236 Robert Soslow Lien Hoang Angela Cheng Maria Bisogna Narciso Olvera Jessica N McAlpine David G Huntsman Douglas A Levine Blake Gilks Memorial Sloan Kettering Cancer Center New York NY Genetic Pathology Evaluation Center Vancouver BC Canada University of British Columbia Vancouver BC Canada Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016250 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016250 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 210 Endometrial Biopsies Can Be Used Reliably to Predict Final Endometrial Carcinoma Classication Using Both Histopathologic and Molecular Based Strategies 1140 Lien Hoang Melissa McConechy Quentin Nakonechny Joyce M Leo Angela Cheng Sam Leung Aline Talhouk Cheng-Han Lee Martin Kobel David G Huntsman Jessica N McAlpine Robert Soslow Blake Gilks Memorial Sloan Kettering Cancer Center New York NY BC Cancer Agency Vancouver BC Canada Vancouver General Hospital Vancouver BC Canada Genetic Pathology Evaluation Center Vancouver BC Canada University of Edmonton Edmonton AB Canada University of Calgary Calgary AB Canada 211 Clinicopathologic Comparison of Lynch Syndrome- Associated and Lynch-Like Endometrial Carcinomas Identied on Universal Screening Using Mismatch Repair Protein Immunohistochemistry 1181 Anne M Mills Emily A Sloan Martha Thomas Susan C Modesitt Mark H Stoler Kristen A Atkins Christopher A Moskaluk University of Virginia Charlottesville VA 212 Endometrioid Adenocarcinoma and Adjacent Atypical Endometrial Hyperplasia Harbor Identical Somatic Mutations by Next Generation Sequencing 1246 Joshua I Warrick Jordan M Newell Joshua P Kesterson Rebecca Phaeton Nadine Hempel Carrie Hossler James Broach Kathryn E Sheldon Mariano Russo Kenneth R Houser Richard D Bruggeman Richard Zaino Penn State University School of Medicine Hershey PA 213 PD-L1 Expression Is Uncommon in Advanced-Staged Endometrial Carcinoma 1225 Jennifer L Sauter Rondell Graham Jo Marie Janco Andrea Mariani Sarah E Kerr Mayo Clinic Rochester MN Scripps Memorial Hospital La Jolla CA 214 PD-L1 Expression in Malignant Mixed Mullerian Tumors A Potentially Actionable Biomarker 1202 Andre Pinto Nicholas Mackrides Mehrdad Nadji University of Miami Jackson Memorial Hospital Miami FL 215 CD8 FoxP3 and CD45Ro Positive Tumor Inltrating Lymphocytes in Endometrial Carcinomas Is There a Difference between European American and African American Patients 1208 Tariq Rashid Jennifer Young Pierce Elizabeth Garrett- Mayer Laura S Spruill Medical University of South Carolina Charleston SC 216 The Role of T Regulatory Cell Apoptosis in the Progression of Endometrial Hyperplasia to Endometrial Carcinoma 1102 Julie Anne Bishop Mirna B Podoll Zhenglong Wang University of Louisville Louisville KY 217 Multicystic Elongated Fragmented Pattern of Myometrial Invasion Does Not Impact Outcomes of Patients with Low-Grade Endometrial Carcinomas - A Retrospective Study at North Shore - LIJ Health System 1143 Maheen Hossain Shu Liang Peter Farmer Cathy Fan Sharon Liang North Shore - LIJ Health System Lake Success NY DOC of Oregon Salem OR 218 CXCL14-CXCR4 and CXCL12-CXCR4 Axises May Play Important Roles in Achievement of Unique Invasion Process of MELF Pattern Myoinvasive Endometrioid Carcinoma 1223 Sakiko Sanada Kaori Yasuda Sachiko Ogasawara Jun Akiba Hirohisa Yano Kurume University School of Medicine Kurume Japan Cell Innovator Inc. Fukuoka Japan 219 The MELF Pattern of Myometrial Invasion in Endometrial Endometrioid Carcinoma Displays a Mesenchymal Gene Expression Signature A Case Series 1135 Beth Harrison Athena Chen Gemma Toledo Kshitij Arora Vikram Deshpande Esther Oliva Massachusetts General Hospital Boston MA 220 HE4 Has a Role in Treatment Planning in Endometrial Cancer 1191 Sharon OToole Rizmee Shireen Seamus McDonald Lucy Norris Anthony Cooney Feras AbuSaadeh Waseem Kamran Cliona Murphy Nadine Farah Tom DArcy Noreen Gleeson John J OLeary Trinity College Dublin Dublin Ireland St. Jamess Hospital Dublin Ireland Coombe Womens and Infants University Hospital Dublin Ireland 221 SOX17 Is Highly Expressed in Endometrial Adenocarcinoma 1122 Mohamed El Hag Tracy A Stein Bo Ye Prachi Raut Haodong Xu Mahmoud Khalifa Faqian Li University of Minnesota Medical Center Minneapolis MN UCLA Medical Center Los Angeles CA 222 PELP1 Expression in Endometrial Carcinomas Is Associated with FIGO Grade and Histological Subtype 1188 Shuang Niu Yan Peng University of Texas Southwestern Medical Center Dallas TX 223 Gene Expression Proling of Endometrial Carcinoma Type 1 in Mexican Women 1130 Gabriela Soa Gomez Macias Oralia Barboza Raquel Garza Barbara Saenz Hospital Universitario de la UANL Monterrey Nuevo Leon Mexico Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 251NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 251 224 High NRF2 with p62 Co-Expression in PTEN Null Endometrial Endometrioid Carcinomas Is Associated with Different Survival Impact in Early vs Late Stage Disease 1173 Diana Lim Ying Ni Meusia Neo Hoe Meng Chen Charis Eng Joanne Ngeow National University Health System Singapore Singapore Singapore Polytechnic Singapore Singapore Cleveland Clinic Cleveland OH National Cancer Centre Singapore Singapore 225 Immunohistochemical Prole of Pure Endometrial Mucinous Adenocarcinoma 1256 Gloria Zhang Charles V Biscotti Tao Wu Xiangdong Ding Bin Yang Cleveland Clinic Cleveland OH Kingmed Diagnostics Guangzhou OH 226 Evaluating Mixed Endometrial Carcinomas with a Panel of Immunohistochemical Markers 1179 Cathleen Matrai Edyta C Pirog Lora H Ellenson NYPH-Weill Cornell NYC NY 227 Immunohistochemical Proling of Endometrial Serous Carcinoma 1111 Wenqian Chen Arjumand Husain Gregg Nelson Peter Rambau Sandra Lee Maire Duggan Cheng-Han Lee Martin Kobel University of Calgary Calgary AB Canada Tom Baker Cancer Center Calgary AB Canada University of Alberta Edmonton AB Canada Chinook Regional Hospital Lethbridge AB Canada 228 The Use of Immunohistochemistry in Distinction between Clear Cell and Squamous Differentiation in Adenocarcinoma of the Endometrium 1238 Michelle Stram Dinesh Pradhan David Dabbs Rohit Bhargava Agnieszka Onisko Mirka W Jones University of Pittsburgh Pittsburgh PA 229 HNF1 Expression and Loss of ARID1A Correlate with Histological Component in Uterine Carcinosarcomas 1126 Joana Ferreira Rita Luz Fernanda Silva Ana Felix IPOLFG Lisboa Portugal Centro Hospitalar de Setubal Setubal Portugal CEDOC-FCMUNL Lisboa Portugal 230 SATB2 Expression Is Sensitive but Not Specic for Osteosarcomatous Components of Gynecologic GYN Tract Carcinosarcomas CS A Clinicopathologic Study of 60 Cases 1224 Ankur R Sangoi Malti Kshirsagar Andrew E Horvai Andres A Roma El Camino Hospital Mountain View CA UCSF San Francisco CA Cleveland Clinic Cleveland OH 231 CyclinE1 Expression in High Grade Serous Carcinomas and Malignant Mixed Mullerian Tumors 1136 Joseph Hatem Carolina Reyes Hospital of the University of Pennsylvania Philadelphia PA 232 Loss of Expression of SMARCA4 BRG1 and SMARCB1 INI1 in Undifferentiated Carcinoma of the Endometrium Is Not Always Associated with Rhabdoid Morphology 1207 Preetha Ramalingam Sabrina Croce W Glenn McCluggage MD Anderson Cancer Center Houston TX Belfast Health and Social Care Trust Belfast United Kingdom Centre Regional de Lutte Contre Le Cancer Bordeaux France 233 Dedifferentiated Endometrial Carcinoma - A Clinicopathologic Study of 5 Cases 1241 Hongying Tan Chisa Aoyama Olive-View UCLA Medical Center Sylmar CA HEMATOPATHOLOGY 234 ECOG 1412 High Rejection Rate for Submitted Diffuse Large B-cell Lymphomas DLBCLs upon Retrospective Central Pathology Review CPR Results in Protocol Change to Novel Real-Time CPR to Establish Patient Eligibility 1426 William R Macon Rebecca King Mayo Clinic Rochester MN 235 GATA-3 Expression in TNK Cell Neoplasms Determined by Immunohistochemistry 1421 Amanda Lo Serhan Alkan Qin Huang Cedar-Sinai Medical Center Los Angeles CA 236 Routine Comprehensive Genomic Proling of T-Cell Neoplasms Improves Diagnostic Accuracy and Identies Actionable Therapeutic Targets 1375 Juan Gomez-Gelvez Daniel Royston Maria E Arcila Janine Pichardo Alison J Moskowitz Steven M Horwitz Ahmet Dogan Memorial Sloan-Kettering Cancer Center New York NY Weatherall Institute of Molecular Medicine University of Oxford Oxford United Kingdom 237 Frequency and Clinical Signicance of Isolated Tube C Positivity in T-cell Receptor Beta Testing Using BIOMED-2 Primers 1463 Sohail Qayyum Grant C Bullock Steven H Swerdlow Marina Nikiforova Nidhi Aggarwal University of Pittsburgh Medical Center Pittsburgh PA 238 Cytogenetic Analysis Is Crucial in the Early Diagnosis of Indolent T-Cell Prolymphocytic Leukemia 1369 Ramya Gadde Rohit Gulati Kedar V Inamdar Susan Michalowski Madhu Menon Henry Ford Hospital Detroit MI 239 Complex Karyotypes Predict a Poorer Prognosis in T-cell Prolymphocytic Leukemia 1395 Zhihong Hu L Jeffrey Medeiros Guilin Tang Zhenya Tang Shimin Hu Pei Lin Xinyan Lu The University of Texas M.D. Anderson Cancer Center Houston TX Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016252 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016252 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 240 Loss of a Novel Tumor Suppressor KLF9 Identies a Subset of Peripheral T-cell Lymphoma NOS with Increased NOTCH1 Expression 1453 Sudhir Perincheri Gerald Goh Francine M Foss Richard P Lifton Mina L Xu Yale University School of Medicine New Haven CT University College London United Kingdom 241 Patterns of Bone Marrow Involvement by Peripheral T-cell Lymphoma 1365 Natalie S Freed Greiner C Timothy Hina N Qureishi Ji Yuan Catalina Amador-Ortiz University of Nebraska Medical Center Omaha NE 242 Hepatosplenic T-cell Lymphoma Arising in Patients with Immunosuppression A Clinicopathologic Immunophenotypic and Cytogenetic Study of 7 Cases and a Review of 67 Cases in the Literature 1526 Mariko Yabe L Jeffrey Medeiros Yahya Daneshbod Masoud Davanlou Carlos E Bueso-Ramos Elisa J Moran Mark Routbort Ken H Young Roberto Miranda UT MD Anderson Cancer Center Houston TX 243 A Clinicopathologic Analysis of the Signicance of Janus Kinase 3 Activating Mutations in Extranodal Natural KillerT-cell Lymphomas Nasal Type 1392 Jenny Hoffmann Lisa Ma Daniel A Arber Robert S Ohgami Stanford University Medical Center Stanford CA 244 Targeted Sequencing of Mutational Load Supports the Evolutionary Model of Angioimmunoblastic T-Cell Lymphoma 1489 Leonard HC Tan Maarja-Liisa Nairismagi Siok-Bian Ng Tiffany Tang Soon-Thye Lim Singapore General Hospital Singapore Singapore National Cancer Centre Singapore Singapore National University Health System Singapore Singapore 245 A Small Series of Bone Marrow Indolent Clonal CD4- Positive T-Cell Lymphoproliferative Disorder A New Entity 1338 Aleh Bobr Dong Chen William G Morice Karen L Grogg Min Shi Mayo Clinic Rochester MN 246 Bilineal Large Granular Lymphocytic Leukemia A Distinct Subtype of LGL 1442 Jadee L Neff Dragan Jevremovic William G Morice Min Shi Mayo Clinic Rochester MN 247 Clonality Analysis of T-Cell Receptor Gamma Rearrangement TCGR by Next Generation Sequencing NGS in Anaplastic Large Cell Lymphomas ALCL 1386 Rong He Ming Mai David S Viswanatha Andrew L Feldman Mayo Clinic Rochester MN 248 Comprehensive Immunophenotypic Analysis of 64 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma Shows an Activated Cytotoxic with a Silent T-cell Receptor Pattern 1368 Ana Claudia Frota Lopes L Jeffrey Medeiros Mark W Clemens Ming Chai Hui Liu Arianna Di Napoli Stephen Lade Mitual Amin Ken H Young Roberto Miranda The University of Texas MD Anderson Cancer Center Houston TX Universidade de So Paulo So Paulo Brazil Sapienza University of Rome Rome Italy PathWest Laboratory Medicine Nedlands Australia Xuzhou Medical College Xuzhou China Peter MacCallum Cancer Center Melbourne Australia William Beaumont Hospital Royal Oak MI 249 A Proposal for Pathologic Processing of Breast Capsule Specimens of Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma without a Grossly Identiable Mass 1457 Sergio Pina-Oviedo L Jeffrey Medeiros Mark W Clemens Kelly K Hunt Hui Liu Gregg Staerkel Mitual Amin Andres Quesada Adrian Alejandro Carballo- Zarate Alonso Miranda Ignacio I Wistuba Ming Chai Arianna Di Napoli Ken H Young Joseph D Khoury Roberto N Miranda M.D. Anderson Cancer Center Houston TX 250 Dual Antibody Immunohistochemistry A Cost-Efcient and Sensitive New Tool for the Detection of Minimal Residual CLLunderline 1507 Laura M Wake Inhye Ahn Mohammed Farooqui Jamie Hahn Xin Tian Maryalice Stetler-Stevenson Gerald Marti Adrian Wiestner Irina Maric NIHNCI Bethesda MD NIHNHLBI Bethesda MD NIHCCDLM Bethesda MD FDACDRH Bethesda MD 251 Flow Cytometric Evaluation of 371 Mature B-cell Lymphomas Identies an Association of CD13 Expression with Certain Lymphoma Subtypes 1412 Hubert D Lau Robert S Ohgami Stanford University Stanford CA 252 CD164 A Novel Marker Distinguishing Hematopoietic StemProgenitor Cells HSPC from Leukemic Stem Cells 1478 Daniel Royston Qi Gao Montreh Tavakkoli Stephen S Chung Sean Devlin Mikhail Roshal Christopher Park Oxford University Hospitals NHS Trust Oxford United Kingdom Memorial Sloan Kettering Cancer Centre NYC NY 253 Surface CD200 Is Upregulated on CD4CD200 Double Positive T-Cells in Follicular Lymphoma and Hodgkin Lymphoma 1383 Richard D Hammer Kruthi Murthy Dong Chen University of Missouri Columbia MO Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 253NEXTGENERATION LEARNING 2016 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 253 254 PD-1PD-L1 Are Novel Therapeutic Targets for Mastocytosis 1371 Mary Geeze Ellen Hatch Cheyenne Martin Sherrie L Perkins Karin Hartmann Peter Valent Jason Gotlib Diane Lidke Tracy I George University of New Mexico Albuquerque NM University of Utah Salt Lake City UT University of Luebeck Luebeck Germany Medical University of Vienna Vienna Austria Stanford University Stanford CA 255 Histologic and Corresponding Laboratory Findings in Bone Marrow Biopsies of Post-Transplant Patients 1467 Heidi Rahn LoAnn Peterson Amir Behdad Northwestern Memorial Hospital Chicago IL 256 Hematolymphoid Neoplasms Are Common in Bone Marrow Biopsies Performed for Non-Specic Diffuse Marrow Signal Alterations on Magnetic Resonance Imaging MRI 1404 Terrell Jones Aaron J Wyse Sarah E Gibson University of Pittsburgh School of Medicine Pittsburgh PA 257 Langerhans Cell Histiocytosis in Patients with Concurrent Lymphoma A Reactive Process without Evidence of BRAF Mutation 1456 Sergio Pina-Oviedo L Jeffrey Medeiros Shaoying Li Khaled Alayed C Cameron Yin M.D. Anderson Cancer Center Houston TX 258 Langerhans Cell Histiocytosis Expresses Killer Cell Immunoglobulin-Like Receptor 2DL4 CD158d a Possible Target of Antibody Therapy 1406 Tatsuki R Kataoka Chiyuki Ueshima Masahiro Hirata Yusuke Takei Sanju Iwamoto Hironori Haga Kyoto University Kyoto Japan School of Medicine Syowa University Tokyo Japan 259 Angiomyomatous Hamartoma of Lymph Nodes Clinical Morphologic and Immunohistochemical Distinction from Lymph Node Lymphangioleiomyomatosis 1435 Michelle Moh Ankur R Sangoi Joseph T Rabban University of California San Francisco San Francisco CA El Camino Hospital Mountain View CA 260 Spleen Histology in Children with Sickle Cell Disease and Hereditary Spherocytosis 1461 Marco Pizzi Rita Alaggio Laura Sainati Kathrin Ludwig Piergiorgio Gamba Martina Ichino Luisa Santoro University of Padova Padova PD Italy 261 Spectrum of Bone Marrow Features in CANDLE Syndrome 1520 Wenbin Xiao Gina Montealegre Sanchez Bernadette Marrero Adriana Almeida de Jesus Caterina Miniti Shunyou Gong Kristian T Schafernak Raphaela Goldbach-Mansky Katherine R Calvo NIHCC Bethesda MD NIHNIAMS Bethesda MD NHLBI Bethesda MD Lurie Childrens Hospital Chicago IL Phoenix Childrens Hospital Phoenix AZ 262 Signicance of Clonal T-cell Receptor Gene Rearrangements in Diagnosing Refractory Celiac Disease 1401 Shanaz Hussein Tatyana Gindin Carolina Arguelles- Grande Bachir Alobeid Suzanne Lewis Mahesh Mansukhani Peter HR Green Govind Bhagat Columbia University Medical Center New York NY 263 Trauma Patients with Platelet Adenosine Diphosphate ADP Inhibition by Thromboelastography TEG Show Increased Platelet CD62P by Flow Cytometry 1384 Richard D Hammer Cory Johnson Julie Lewis James Clevenger Ashley Bartels Salman Ahmad University of Missouri Columbia MO 264 Multilineage Bone Marrow Response to Eltrombopag in Aplastic Anemiaunderline 1357 Alina Dulau Florea Danielle M Townsley Bogdan Dumitriu Thomas Winkler Janet Valdez Charles Bolan Cynthia Dunbar Neal Young Raul C Braylan Katherine R Calvo NIH Bethesda MD 265 Expression of Glycosylphosphatidylinositol GPI Anchor Protein AP in Bone Marrows of Normal Subjects and Aplastic Anemia Patients with Paroxysmal Nocturnal Hemoglobinuria PNH Clones as Determined by Fluorescent Aerolysin FLAER 1356 Alina Dulau Florea Neal Young Irina Maric Raul C Braylan NIH Bethesda MD NHLBI Bethesda MD 266 Development of a Novel Flow Cytometric Washing Technique for Needle Biopsies Suspicious for Lymphoma 1366 Natalie S Freed Laura Wake Ji Yuan Hina N Qureishi Catalina Amador Timothy C Greiner Scott Rodig Samuel J Pirruccello Kai Fu University of Nebraska Medical Center Omaha NE Brigham and Womens Hospital Boston MA KIDNEYRENAL PATHOLOGY INCLUDING TRANSPLANTATION 267 Prevalence of Glomerular Disease Recurrence in Renal Allografts A Single Center Studyunderline 1593 Brad Barrows Vighnesh Walavalkar Zoltan Laszik Kuang-Yu Jen University of California San Francisco San Francisco CA 268 PLA2R Negative De Novo Membranous Nephropathy Associated with Antibody-Mediated Rejection a Report of 11 Cases with Common Light Microscopic and Ultrastructural Features 1592 Siripron Angchuan Mongkon Charoenpitakchai Jittirat Arksarapuk Agnes B Fogo Paisit Paueksakon Vanderbilt University Medical Center Nashville TN The Queens Medical Center Honolulu HI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING2016254 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016254 POSTER SESSION VI Wednesday March 16 2016 100 PM - 400 PM CC Exhibit Hall 4ABC 269 The Pathology of Pure T-cell Mediated Rejection in the Era of C4d Staining and Testing for Donor Specic Antibodies 1616 Parmjeet Randhawa Gang Huang Simrath Randhawa Gang Zeng John Lunz Xiaomu Zhao The Thomas E. Starzl Transplant Institute Pittsburgh PA 270 Dendritic Cells in Renal Allografts 1603 Meghan Kapp Sharon Phillips Deborah O Crowe Jorge Garces Agnes B Fogo Giovanna A Giannico Vanderbilt University Medical Center Nashville TN Vanderbilt University Nashville TN DCI Transplant Immunology Laboratory Nashville TN Ochsner Health System New Orleans LA 271 Glomerular Complement Factor C4d Deposits Are Structural Markers for Basement Membrane Duplication in Transplant Glomerulopathy and Thrombotic Microangiopathy 1612 Volker Nickeleit Harsharan Singh Adil Gasim Jamie S Chua The University of North Carolina Chapel Hill NC Leiden University Medical Center Leiden Netherlands 272 Glomerular Capillary Wall Staining with C4d Is Associated with Glomerular Proliferation in IgA Nephropathy 1621 Umer Sheikh Cynthia Cohen Thomas E Rogers Alton Farris Hong Qu Carla Ellis Emory University Hospital and School of Medicine Atlanta GA St. John Hospital and Medical Center Detroit MI 273 Quantitative Real-Time PCR as a Surrogate Method to Detect BK Virus BKV in Renal Transplant Biopsies with Negative SV-40 Staining 1605 Tripti Kumar Rebecca Sovoda John Gibson Sarah Britton Andrea J Shaw Bobby Boyanton Dilip Samarapungavan Ping L Zhang Beaumont Health System Royal Oak MI 274 Characterizing the Inammatory Inltrate in Human Kidney Biopsies with TIN 1598 Hae Yoon G Choung Liying Fu Ekaterina Castano Natalie Patel Gilbert Moeckel Yale University School of Medicine New Haven CT Yale School of Medicine New Haven CT 275 Validation of an Automated Platform to Assess the Total Inammatory Load in Kidney Transplant Biopsies Using CD45 Immunohistochemistry and Computer- Assisted Quantitative Image Analysis 1626 Vighnesh Walavalkar Sarah Bowman Hale Kirimlioglu Laura Laszik Brad Barrows Jarish Cohen Daniel E Roberts Zoltan Laszik UC San Francisco San Francisco CA 276 Renal Allograft Biopsy CD3 Cell Quantitation Algorithm Development for Rejection Assessment Utilizing Open Source Image Analysis Software 1609 Andres Moon Geoffrey Smith Thomas E Rogers Carla L Ellis Alton B Farris Emory University School of Medicine Atlanta GA 277 Validation and Utility of underlineTelepathology underline for Immediate underlineunderline Intraoperativeunderlineunderline Consultation of underlineunderlineDonor Kidney Biopsies underlineunderline 1588 Saba Ali Alaa Afy Rajendra Ramsamooj University of California Davis Medical Center Sacramento CA California Northstate University College of Medicine Elk Grove CA 278 Renal Cell Carcinoma in Allograft Kidneys Use of Short Tandem Repeat Analysis to Determine Donor Origin of Cancer 1617 Adam Robin Colin C Hansen Lauren Parsons Christopher Hartley Eric Cohen Alexander C Mackinnon Medical College of Wisconsin Milwaukee WI Board Number Board Number Board Number Board Number NEXTGENERATION LEARNING 2016 255NEXTGENERATION LEARNING 2016 255 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CDABSTRACT ASSIGNMENT COMMITTEE Jason L. Hornick M.D. Ph.D. Chair 2017 Jonathan L. Hecht M.D. Ph.D. 2016 Xiaohua Qian M.D. Ph.D. 2016 Justine Barletta M.D. 2016 Sarah M. Dry M.D. 2016 Simion I. Chiosea M.D. 2016 Daniel J. Brat M.D. Ph.D. 2016 Paul VanderLaan M.D. Ph.D. 2016 Keith K. Lai M.D. 2016 Leona Doyle M.D. 2018 Kristin Jensen M.D. 2018 Dylan V. Miller M.D. 2018 Rajiv Patel M.D. 2018 Raga Ramachandran M.D. Ph.D. 2018 Sean R. Williamson M.D. 2018 Charles M. Quick M.D. 2018 Elizabeth Morgan M.D. 2018 Bobbi S. Pritt M.D. 2018 Shree Sharma M.D. 2018 Alton B. Brad Farris III M.D. 2018 Maria Westerhoff M.D. 2018 Term Ending Term Ending Hikmat Al-Ahmadie David Bahler Ulysses Balis Guliz Barkan Justine Barletta Olca Basturk Dan Berney Ritu Bhalla Justin Bishop Jennifer Black Alexander Borowsky Daniel Brat Thomas Brenn Fadi Brimo Anne Buckley Natalia Buza Ben Calhoun Anthony Chang Andres Chiesa-Vottero Simon Chiosea Brian Collins Lynn Cornell Gregory Davis Robin DeGallo Leona Doyle Sarah Dry Daniel Dye A. Brad Farris Yuri Fedoriw Raymond Felgar Ann Folkins Karen Fritchie Joaquin Garcia Karuna Garg James Gill Ryan Gill Ilyssa Gordon Omar Habeeb Marc Halushka Jonathan Hecht Brooke Howitt David Hudnall David Hwang Michael Idowu Mohammed Idrees Joseph Jakowski Susan Jeffus Kristin Jensen Nicole Johnson Kirk Jones Keith Lai Melinda Lerwill Rebecca Levy Jingmei Lin Michael Linden Kelly Magliocca Joseph Maleszewski Anais Malpica Adrian Marino-Enriquez Rohit Mehra Ozgur Mete Dylan Miller Mari Mino-Kenudson Roberto Miranda Andre Moreira Elizabeth Morgan Juan-Miguel Mosquera Sanjay Mukhopadyay Anna-Marie Mulligan Raouf Nakhleh Ilke Nalbantoglu Ericka Olgaard Horatiu Olteanu Scott Owens Michelle Paessler Reetesh Pai Nicole Panarelli Carlos Parra-Herran Anil Parwani Rajiv Patel Joanna Phillips Jenny Pogoriler Alexi Polydorides Bobbi Pritt Christopher Przybycin Xiaohua Qian Charles Quick Raga Ramachandran Vijaya Reddy Michelle Reid Emily Reisenbichler Jorge Reis-Filho Brian Robinson Anja Roden Michael Roehrl Mike Roh Stephen Rohan Marianna Ruzinova Sandro Santagata Stephen Schmechel Theresa Scognamiglio Michael Seidman Sara Shalin Shree Sharma Steven Shen Chanjuan Shi Konstantin Shilo Steven Smith Aliyah Sohani Paul Staats Heather Stevenson-Lerner Khin Thway Maria Tretiakova Paul VanderLaan Russell Vang Marina Vivero Wei-Lien Wang Yihong Wang Ilan Weinreb Astrid Weins Maria Westerhoff Sean Williamson Laura Wood Wei Xin Xuefeng Zhang Chen Zhang POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD2015-16 ABSTRACT REVIEW BOARD NEXTGENERATION LEARNING2016256 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016256 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 4 Marie Christine Aubry Consultant for Genentech Honorarium. 44 Torsten O Nielsen Consultant for NanoString Technologies Consulting fee. Partner of Bioclassier LLC Ownership. 45 Vikram Deshpande Speaker research support for Affymetrix Research support. 50 Torsten O Nielsen Consultant for NanoString Technologies Consulting fee. Partner of Bioclassier LLC Ownership. 64 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 71 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. 71 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 71 Lisa C Watson Company Employee of Illumina Inc Salary and stocks. 71 Claire Attwooll Salaried Employee of Illumina Inc Salary. 113 Frederick L Baehner Employee of Genomic Health Inc. Salary stock. 113 Debbie McCullough Employee of Genomic Health Inc. Salary stock. 113 Carolyn Mies Employee of Genomic Health Inc. Salary. 113 Helen Bailey Employee of Genomic Health Inc. Salary stock. 146 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 146 Kai Wang Employee of Foundation Medicine Inc. Employmentequity interest. 146 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 146 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 146 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 146 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 146 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 146 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 148 Joel Lefferts Advisory board member for Roche Molecular Diagnostics Consulting fee. 166 Shannon L Puhalla Local trial PI for Incyte Research support. Local trial PI for Pzer Research support. Local trial PI for Lilly Research support. Local trial PI for Novartis Research support. Local trial PI advisory committee for Abbvie Research support. DSMB for Med Immune Honorarium. DSMB for Celldex Honorarium. Local trial PI for Covance Bayer Research support. 210 Hiroaki Nitta Employment of Ventana Medical Systems Inc. Employment. 215 Gabriel Popescu Employee board member for G.P. has nancial interest in Phi Optics Inc. a company developing quantitative phase imaging technology for materials and life science applications Salary stocks. 241 Kai Wang Employee of Foundation Medicine Inc. Employmentequity interest. 241 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 241 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 241 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 241 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 241 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 241 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 241 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 241 Depinder Khaira Employee of Foundation Medicine Inc. Employmentequity interest. 254 Bruno Poulet Speaker and Consultant for ROCHE Consultant fee. 269 Anant Madabhushi Scientic advisory board member scientic Consultant for Inspirata Inc. Equity holder. Scientic advisory board member scientic Consultant for Elucid Bioimaging Equity holder. 271 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 271 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 271 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 271 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 271 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 257NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 257 Abstract Name Relevant Disclosure Information 271 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 271 Adrienne Johnson Employee of Foundation Medicine Inc. Employmentstock ownership. 271 Kai Wang Employee of Foundation Medicine Inc. Employmentequity interest. 271 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 281 Torsten O Nielsen Consultant for NanoString Technologies Consulting fee. Partner of Bioclassier LLC Ownership. 288 Shannon Huggins-Puhalla DSMB for Celldex Honorarium. DSMB for Med Immune Honorarium. Local trial PI advisory committee for Abbvie Research support. Local trial PI for Lilly Research support. Local trial PI for Novartis Research support. Local trial PI for Pzer Research support. Local trial PI for Incyte Research support. Local trial PI for Covance Bayer Research support. 293 Janis Taube Advisory board for Bristol Myers Squibb Honorarium. Investigator-initiated Research for Bristol Myers Squibb Research funding. Advisory board for Astra Zenica Honorarium. 293 Leisha Emens Principal investigator-initiated study for Merck Research funding. Principal investigator- initiated study for Genentech and Roche Inc Research funding. Principal investigator- initiated study for EMD Serono Research funding. Principal investigator-initiated study for Astrazeneca Research funding. 300 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 345 Derek B Allison Research collaboration for Sienna Cancer Diagnostics Ltd. Research materials. 345 Minesh Lalla Program development for RD for Sienna Cancer Diagnostics Ltd. Employee of company. 345 Christopher J VandenBussche Researcher for Sienna Cancer Diagnostics Ltd. Salary support and research materials. 354 Anil Parwani Dr. Parwani also formerly served as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Department of Pathology for Omnyx LLC Dr. Parwani was formerly employed by an afliate of UPMC which owns one half of Omnyx LLC. He received research funding from Omnyx LLC through the Univ. of Pitt and has the right to receive proceeds from the sale of Omnyx or its products. 355 Liron Pantanowitz Consultant for Omnyx Consulting fee. 373 Noa Davis Employee of Micromedic Technologies Ltd. Salary. 390 Claire M Eklund Co-author of Hologic Stock holdings in excess of 5000. 403 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 442 A John Iafrate Preliminary patent application holder with the U.S. Patent Ofce for Anchored Multiplex-PCR technology for Archer Dx Royalties and has equity in the company. 442 Long Le Preliminary patent application holder with the U.S. Patent Ofce for Anchored Multiplex-PCR technology for Archer Dx Royalties and has equity in the company. 456 Elodie Sollier Chief scientic ofcer for Vortex Biosciences Work for the company. 456 Dino Di Carlo Consultant for Vortex Biosciences Shares. 464 Liron Pantanowitz Consultant for Omnyx Consulting fee. 499 David Altree-Tacha Employee of Biocare Medical Salary and minor stock holder. 505 Krystal Brown Employee of Myriad Genetics Inc. Stock salary. 505 Richard J Wenstrup Employee of Myriad Genetics Inc. Stock salary. 505 M Bryan Warf Employee of Myriad Genetic Laboratories Inc. Stock salary. 505 Kathryn A Kolquist Employee of Myriad Genetic Laboratories Inc. Stock salary. 505 Jonathan Nelson Employee of Myriad Genetic Laboratories Inc. Stock salary. 505 Rosalie Elenitsas Textbook editor for Lippincott Williams Wilkins Royalties. 505 Jon A Reed Contracted Research for Myriad Consulting fee. Employeeowner of CellNetix Pathology Labs Salary. 505 Darl D Flake Employee of Myriad Genetics Inc. Stock salary. 505 Loren E Clarke Employee of Myriad Genetic Laboratories Inc. Stock salary. 505 Hillary Kimbrell Employee of Myriad Genetic Laboratories Inc. Stock salary. 505 Benjamin B Roa Employee of Myriad Genetic Laboratories Inc. Stock salary. 508 Barbara R DuPont Speaker for Abbott Travel funds. 508 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. NEXTGENERATION LEARNING2016258 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016258 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 508 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 510 Jonhan Ho Dr. Ho also serves as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Physicians Department of Dermatology for Omnyx LLC Jonhan Ho MD is employed by an afliate of UPMC which owns one half of Omnyx LLC. Dr. Ho has received research funding from Omnyx LLC through the University of Pittsburgh and has the right to receive proceeds from the sale of Omnyx or its products. 528 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 528 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 528 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 528 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 528 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 528 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 528 Mark Bailey Employee of Foundation Medicine Inc. Salarystock options. 528 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 529 Aaron S Manseld Consulting for Celgene Honorarium. Consulting for Genentech Honorarium. 545 Michael Bonert Founder owner of Libre Pathology Limited No nancial benet. Company runs librepathology.org - an open access creative commons licenced pathology wiki - without commercial sponsorship or advertisements. 546 Michael Bonert Founder owner of Libre Pathology Limited No nancial benet. Company runs librepathology.org - an open access creative commons licenced pathology wiki - without commercial sponsorship or advertisements. 589 Virginia A LiVolsi Histopatology consultation for Veracyte Consulting fee. 599 Erik K Alexander Consultant for Veracyte Consulting fee. 609 Guido Rindi Speaker for Novartis Pharma Honorarium. Speaker for Ipsen Pharma Honorarium. Consultant for Bracco Imaging Honorarium. 611 Kyle Fedorchak Employee of Foundation Medicine Inc. Employmentequity interest. 611 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 611 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 611 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 611 Shakti H Ramkissoon Part-time pathologist for Foundation Medicine Payment for work. 611 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 611 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 611 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 611 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 613 Erik K Alexander Consultant for Veracyte Consulting fee. 621 Wade S Samowitz Intellectual property licensed to Ventan for Ventana Royalties for the BRAF V600E antibody. 626 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 627 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 628 Junko Aida Diagnostic committee for Sucampo AG Clinical trial SCMP-8811-201 Consigned research fund. 628 Kaiyo Takubo Diagnostic committee for Sucampo AG Clinical trial SCMP-8811-201 Consigned research fund. 629 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 633 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 649 David L Rimm Investigator Consultant for GenoptixNovartis Support grant honorarium. Consultant for ACD Honorarium. Consultant for BMS Honorarium. Consultant for Perkin-Elmer Honorarium. Consultant for Astra Zenica Honorarium. Investigator for Cepheid Support grant. Consultant for Amgen Honorarium. Investigator for Gilead Sciences Support grant. Consultant for Biocept Honorarium. Consultant for Cernostics Honorarium. Consultant for Metamark Genetics Honorarium. Consultant for MDAgree Honorarium. Consultant for OptraScan Honorarium. Investigator for Kolltan Support grant. Investigator for OncoplexDx Support grant. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 259NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 259 Abstract Name Relevant Disclosure Information 653 Muhammad S Beg Advisory board for Celgene. 667 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 667 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 672 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 672 Simon Schlachter Employee of NinePoint Medical Salary. 672 Jacques JGHM Bergman PI for Olympus Endoscopy Research support for IRB approved studies. PI for Fuji-lm Research support for IRB approved studies. PI Speaker for Cook Medical Research support for IRB approved studies. PI speaker developer of training program for Boston Scientic Research support for IRB approved studies. PI speaker developer of training program for GI solutions Covidien Research support for IRB approved studies. PI for Erbe Research support for IRB approved studies. PI for Ninepoint Medical Research support for IRB approved studies. PI for C2 Therapeutics Research support for IRB approved studies. PI for Cernostics Research support for IRB approved studies. PI for Interpace Research support for IRB approved studies. 672 Brian Sundell Employee of NinePoint Medical Salary. 692 Douglas K Pleskow Consultant for Boston Scientic Honorarium. Consultant for Covidien Honorarium. 701 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 701 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 716 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 728 Wade S Samowitz Intellectual property licensed to Ventan for Ventana Royalties for the BRAF V600E antibody. 749 Anthony M Magliocco Medical advisory committee for Diacarta Travel support and shares. 758 James Sun Employee of Foundation Medicine Inc. Employmentstock ownership. 758 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 758 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 772 Bassel El-Rayes PI of clinical trial for Synta Research support. PI on clinical trial for Novartis Research support. PI on clinical trial for Lily Research support. PI on clinical trial for Roche Genenetech Research support. 773 Bassel El-Rayes PI of clinical trial for Synta Research support. PI on clinical trial for Novartis Research support. PI on clinical trial for Lily Research support. PI on clinical trial for Roche Genenetech Research support. 782 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 792 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 796 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 796 Gregory Y Lauwers Consultant for NinePoint Consultation fee. 797 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 799 Shabana F Pasha Consulting for Covidien Honorarium. Speaker for Covidien Honorarium. Research for Capsovision Research support. 806 Robert Anders Research for BMS Research funding. 806 Janis Taube Advisory board for Bristol Myers Squibb Honorarium. Investigator-initiated Research for Bristol Myers Squibb Research funding. Advisory board for Astra Zenica Honorarium. 811 Jacques JGHM Bergman PI for Olympus Endoscopy Research support for IRB approved studies. PI for Fuji-lm Research support for IRB approved studies. PI Speaker for Cook Medical Research support for IRB approved studies. PI speaker developer of training program for Boston Scientic Research support for IRB approved studies. PI speaker developer of training program for GI solutions Covidien Research support for IRB approved studies. PI for Erbe Research support for IRB approved studies. PI for Ninepoint Medical Research support for IRB approved studies. PI for C2 Therapeutics Research support for IRB approved studies. PI for Cernostics Research support for IRB approved studies. PI for Interpace Research support for IRB approved studies. 812 Nilofer S Azad Investigator for Celgene Research funding. Investigator for Kinex Research funding. Investigator for Astex Pharmaceuticals Research funding. Investigator for Precision Biologics Research funding. Investigator for Agios Research funding. Investigator for Genentech Research funding. Spoke at investigator meeting for Merck Honoraria travel accommodations. Advisory role for DAVAOncology Honoraria. 821 David T Ting Research for Affymetrix Research support. NEXTGENERATION LEARNING2016260 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016260 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 821 Vikram Deshpande Speaker research support for Affymetrix Research support. 822 Alexander Miron CSO for Covariance BiosciencesLLC Ownership interest. 827 Kai Wang Employee of Foundation Medicine Inc. Employmentequity interest. 827 Kyle Gowen Employee of Foundation Medicine Inc. Employmentstock ownership. 827 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 827 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 831 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 842 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 842 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 842 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 842 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 842 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 842 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 842 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 847 Rohit Mehra Patent for Gen-Probe Inc. Royalty. 856 Charles Drake Educational presentations and Consulting for Bristol-Myers-Squibb Honorarium. 856 Janis Taube Advisory board for Bristol Myers Squibb Honorarium. Investigator-initiated Research for Bristol Myers Squibb Research funding. Advisory board for Astra Zenica Honorarium. 868 Michael J Bonham Employee of Genomic Health Inc. Salary stock. 868 John P Bennett Employee of Genomic Health Inc. Salary stock. 868 Phillip G Febbo Employee of Genomic Health Inc. Salary stock. 868 Athanasios C Tsiatis Employee of Genomic Health Inc. Salary stock. 868 Debbie McCullough Employee of Genomic Health Inc. Salary stock. 868 Ruixiao Lu Employee of Genomic Health Inc. Salary stock. 871 Francesc Xavier Bosch Speaker for gsk Research grants conference. Speaker for Merck Research grants conference. Advisor for qiagen Conference. 895 Anthony M Magliocco Medical advisory committee for Diacarta Travel support and shares. 905 Eric A Klein Speaker for Genomic Health Inc. Speaker fee. 929 Jeffrey P Simko onsultant for Genomic Health Inc. Fees paid to my employer UCSF. Research project collaborator for Genomic Health Inc. Unrestricted research funds paid to my employer. Research project collaborator for Myriad Genetics Unrestricted research funds paid to my employer. Consultant for GenomeDx Fees paid to my employer UCSF. Research project collaborator for Genome Dx Unrestricted research funds paid to my employer. Manuscript writing for Maximum medical solutions Honorarium to my employer UCSF. Meeting attendee for Prostate Cancer Foundation Travel reimbursement. Meeting attendee for Canary Foundation Travel reimbursement. Scientic advisory board for 3D biopsy Inc Honorarium. 931 Emmanuel S Antonarakis Paid consultantadvisor for Sano US Paid consultantadvisor. Paid consultantadvisor for Dendreon Paid consultantadvisor. Paid consultantadvisor for Janssen Biotech Paid consultantadvisor. 949 Rajal Shah Employee of Miraca Life Sciences Salary. 975 Pradip Manna Employee of Physicians Reference Lab LLC Salary. 976 Hongyang Pan Employee of Epitomics an Abcam company Employee salary. 976 Jason Law Employee of Abcam Salary. 976 Jackie Chan Employee of Abcam Salary. 976 Yuekai Zhang Employee of Epitomics an Abcam company Employee salary. 976 Taiying Chen Employee of Abcam Salary and stock options. 976 Aihua Li Employee of Abcam Salary. 977 Rajal Shah Employee of Miraca Life Sciences Salary. 977 Savvas Mendrinos Employee of Miraca Life Sciences Salary. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 261NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 261 Abstract Name Relevant Disclosure Information 977 Wei Tian Employee of Miraca Life Sciences Salary. 978 Rajal Shah Employee of Miraca Life Sciences Salary. 979 Wei Tian Employee of Miraca Life Sciences Salary. 979 Rajal Shah Employee of Miraca Life Sciences Salary. 979 Savvas Mendrinos Employee of Miraca Life Sciences Salary. 984 Emmanuel S Antonarakis Paid consultantadvisor for Sano US Paid consultantadvisor. Paid consultantadvisor for Dendreon Paid consultantadvisor. Paid consultantadvisor for Janssen Biotech Paid consultantadvisor. 988 Todd Morgan Advisory board for MDxHealth Honorarium. Advisory board for Genomic Health Honorarium. Advisory board for Myriad Genetics Honorarium. 988 Arul M Chinnaiyan Patent for Gen-Probe Inc. Royalty. 988 Scott A Tomlins Consultant for Ventana Medical Systems and Abbvie Honorarium. Licensced intellectual property for Ventana Medical Systems Patent royalties. Licensced intellectual property for Gen-ProbeHologic Patent royalties. Sponsored research agreement for Compendia BioscienceLife TechnologiesThermoFisher Scientifc Research funding. 988 Rohit Mehra Patent for Gen-Probe Inc. Royalty. 989 Dejan Knezevic Employee of Genomic Health Inc. Salary stock. 989 Michael J Bonham Employee of Genomic Health Inc. Salary stock. 989 Athanasios C Tsiatis Employee of Genomic Health Inc. Salary stock. 989 Tara Maddala Employee of Genomic Health Inc. Salary stock. 989 Anne Dee Employee of Genomic Health Inc. Salary stock. 989 H Jeffrey Lawrence Employee of Genomic Health Inc. Salary stock. 989 Phillip G Febbo Employee of Genomic Health Inc. Salary stock. 989 Eric A Klein Speaker for Genomic Health Inc. Speaker fee. 1018 Anil Parwani Dr. Parwani also formerly served as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Department of Pathology for Omnyx LLC Dr. Parwani was formerly employed by an afliate of UPMC which owns one half of Omnyx LLC. He received research funding from Omnyx LLC through the Univ. of Pitt and has the right to receive proceeds from the sale of Omnyx or its products. 1019 Andrew Evans Consultants role on clinical trial design and product improvementdevelopment for Omnyx LLC Consultant fees. 1025 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1025 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1025 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1025 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1025 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1025 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1025 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1032 Bruce Neri Employee of Metabolon Inc Salary. 1032 Bryan Wittman Employee of Metabolon Inc Salary. 1033 Andrew Evans Consultants role on clinical trial design and product improvementdevelopment for Omnyx LLC Consultant fees. 1041 James Bentley Employee of Miraca Life Sciences Salary. 1041 Monica Chaterjee Employee of Miraca Life Sciences Salary. 1041 Gloria Romerocases Employee of Miraca Life Sciences Salary. 1041 Wei Tian Employee of Miraca Life Sciences Salary. 1041 Yousef Tadros Employee of Miraca Life Sciences Salary. 1041 Jiyoon Yoon Employee of Miraca Life Sciences Salary. 1041 Savvas Mendrinos Employee of Miraca Life Sciences Salary. 1041 Rajal Shah Employee of Miraca Life Sciences Salary. NEXTGENERATION LEARNING2016262 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016262 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 1042 Wei Tian Employee of Miraca Life Sciences Salary. 1042 Rajal Shah Employee of Miraca Life Sciences Salary. 1045 Scott A Tomlins Consultant for Ventana Medical Systems and Abbvie Honorarium. Licensced intellectual property for Ventana Medical Systems Patent royalties. Licensced intellectual property for Gen-ProbeHologic Patent royalties. Sponsored research agreement for Compendia BioscienceLife TechnologiesThermoFisher Scientifc Research funding. 1048 Rohit Mehra Patent for Gen-Probe Inc. Royalty. 1049 David Tacha Employee of Biocare Medical Stock. 1053 Janis Taube Advisory board for Bristol Myers Squibb Honorarium. Investigator-initiated Research for Bristol Myers Squibb Research funding. Advisory board for Astra Zenica Honorarium. 1053 Charles Drake Educational presentations and Consulting for Bristol-Myers-Squibb Honorarium. 1058 Wendy L Flejter Employee of Miraca Life Sciences Salary. 1058 Rajal Shah Employee of Miraca Life Sciences Salary. 1058 Eric Kroman Employee of Miraca Life Sciences Salary. 1058 Wei Tian Employee of Miraca Life Sciences Salary. 1065 Rohit Mehra Patent for Gen-Probe Inc. Royalty. 1065 Arul M Chinnaiyan Patent for Gen-Probe Inc. Royalty. 1066 Arul M Chinnaiyan Patent for Gen-Probe Inc. Royalty. 1066 Rohit Mehra Patent for Gen-Probe Inc. Royalty. 1082 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1092 Robert Makowsky Research work for Response Genetics Inc Regents and instrument. Research work for HTG Molecular Genetics Inc miRNA sequencing. 1092 Chris Roberts Research work for Response Genetics Inc Reagents and instrument. Research work for HTG Molecular Genetics Inc miRNA sequencing. 1092 Miriana Moran Research work for Response Genetics Inc Reagents and instrument. Research work for HTG Molecular Genetics Inc miRNA sequencing. 1092 Craig Stephens Research work for Response Genetics Inc Reagents and instrument. Research work for HTG Molecular Genetics Inc miRNA sequencing. 1092 Stephanie H Astrow Research work for Response Genetics Inc Reagents and instrument. Research work for HTG Molecular Genetics Inc miRNA sequencing. 1096 Drucilla Roberts Author of UpToDate Royalties. 1109 David L Rimm Investigator Consultant for GenoptixNovartis Support grant honorarium. Consultant for ACD Honorarium. Consultant for BMS Honorarium. Consultant for Perkin-Elmer Honorarium. Consultant for Astra Zenica Honorarium. Investigator for Cepheid Support grant. Consultant for Amgen Honorarium. Investigator for Gilead Sciences Support grant. Consultant for Biocept Honorarium. Consultant for Cernostics Honorarium. Consultant for Metamark Genetics Honorarium. Consultant for MDAgree Honorarium. Consultant for OptraScan Honorarium. Investigator for Kolltan Support grant. Investigator for OncoplexDx Support grant. 1123 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1123 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Laurie Gay Employee of Foundation Medicine Inc. Salarystock options. 1123 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Garrett Frampton Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Zachary Chalmers Employee of Foundation Medicine Inc. Employmentequity interest. 1123 Eric M Sanford Employee of Foundation Medicine Inc Compensation and equity interest. 1123 James Sun Employee of Foundation Medicine Inc. Employmentstock ownership. 1123 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1135 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 263NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 263 Abstract Name Relevant Disclosure Information 1144 F Stephen Hodi Consultantclinical Research support to institution for Bristol-Myers Squibb Non-Paid. Consultantclinical Research support to institution for Genentech Non-Paid. Consultant for Merck Honorarium. Consultant for Merck Honorarium. 1144 Margaret A Shipp for Bristol-Myers-Squibb Research funding. 1144 Gordon J Freeman Patent application for the use of 9A11 antibody for diagnostic purposes for Bristol-Myers- Squibb Roche Merck EMD-Serrono Boehringer-Ingelheim AmplimmuneAstraZeneca and Novartis Patent royalties on the PD-1 pathway. 1144 Scott Rodig for Patent application for the use of the 9A11 antibody for diagnostic purposes None. for Bristol-Myers-Squibb Research funding. 1158 Mark H Stoler Consultant for Advanced Cell Diagnostics HPV ISH reagents. 1170 Josh Haimes Employee of ArcherDX Inc Salary. 1170 Namitha Manoj Employee of ArcherDX Inc Salary. 1170 Brian Kudlow Employee of ArcherDX Inc Salary. 1174 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1174 Joel Greenbowe Employee of Foundation Medicine Employee equity. 1174 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1174 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1181 Mark H Stoler Consultant for Advanced Cell Diagnostics HPV ISH reagents. 1182 Mark H Stoler Consultant for Advanced Cell Diagnostics HPV ISH reagents. 1221 Jacob P Crowley Field application scientist for Affymetrix Inc. Salary. 1221 Anthony M Magliocco Medical advisory committee for Diacarta Travel support and shares. 1227 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 1234 Frank Campbell Senior scientist for Covariance Biosciences LLC Salary. 1240 Anthony M Magliocco Medical advisory committee for Diacarta Travel support and shares. 1260 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1260 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Kyle Gowan Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Kyle Fedorchak Employee of Foundation Medicine Inc. Employmentequity interest. 1260 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1260 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1267 Janis Taube Advisory board for Bristol Myers Squibb Honorarium. Investigator-initiated Research for Bristol Myers Squibb Research funding. Advisory board for Astra Zenica Honorarium. 1278 Scott A Tomlins Consultant for Ventana Medical Systems and Abbvie Honorarium. Licensced intellectual property for Ventana Medical Systems Patent royalties. Licensced intellectual property for Gen-ProbeHologic Patent royalties. Sponsored research agreement for Compendia BioscienceLife TechnologiesThermoFisher Scientifc Research funding. 1284 Andrew G Sikora PI for Advaxis Funding of clinical trial. 1287 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1287 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1287 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1287 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1287 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1287 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1287 Kyle Fedorchak Employee of Foundation Medicine Inc. Employmentequity interest. 1287 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1306 Vikram Deshpande Speaker research support for Affymetrix Research support. NEXTGENERATION LEARNING2016264 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016264 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 1331 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1336 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 1340 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1350 Robert S Ohgami Primary Investigator for Agilent Technologies Research grant. Primary Investigator for Foundation Medicine Research support. 1360 David Tacha Employee of Biocare Medical Stock. 1366 Scott Rodig for Patent application for the use of the 9A11 antibody for diagnostic purposes None. for Bristol-Myers-Squibb Research funding. 1371 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1375 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1379 Gordon J Freeman Patent application for the use of 9A11 antibody for diagnostic purposes for Bristol-Myers- Squibb Roche Merck EMD-Serrono Boehringer-Ingelheim AmplimmuneAstraZeneca and Novartis Patent royalties on the PD-1 pathway. 1379 F Stephen Hodi Consultantclinical Research support to institution for Bristol-Myers Squibb Non-Paid. Consultantclinical Research support to institution for Genentech Non-Paid. Consultant for Merck Honorarium. Consultant for Merck Honorarium. 1379 Margaret A Shipp for Bristol-Myers-Squibb Research funding. 1379 Scott Rodig for Patent application for the use of the 9A11 antibody for diagnostic purposes None. for Bristol-Myers-Squibb Research funding. 1382 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1387 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 1387 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1392 Robert S Ohgami Primary Investigator for Agilent Technologies Research grant. Primary Investigator for Foundation Medicine Research support. 1393 Anna Porwit Speaker for Novartis Honorarium. Travel to the Harmonemia Working Group meeting for Beckman Coulter Travel grant. 1408 David W Scott Speaker for Celgene Honorarium. 1408 Randy D Gascoyne Speakers bureau for Seattle Genetics Honorarium. 1409 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. 1409 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 1409 Lisa C Watson Company Employee of Illumina Inc Salary and stocks. 1409 Claire Attwooll Salaried Employee of Illumina Inc Salary. 1412 Robert S Ohgami Primary Investigator for Agilent Technologies Research grant. Primary Investigator for Foundation Medicine Research support. 1427 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1432 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1440 Dennis OMalley Employee of Clarient Pathology Services Salary. 1448 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1462 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1462 Olga Pozdnyakova Consultant for Incyte Honorarium. Consultant for Promedior Honorarium. 1470 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 265NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 265 Abstract Name Relevant Disclosure Information 1473 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1473 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1474 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1475 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1475 Ross Levine Consultant for Foundation Medicine Stipend. 1481 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 1505 Jie He Employee of Foundation Medicine Inc. Employmentstock ownership. 1505 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1505 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1505 Rachel Erlich Employee of Foundation Medicine Inc. Salarystock options. 1505 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1505 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1505 Justin Allen Employee of Foundation Medicine Inc. Salary stocks. 1505 Samantha Morley Employee of Foundation Medicine Inc. Salary stocks. 1505 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1505 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1506 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1508 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1508 Tracy I George PI for Allakos Inc. Research funding for mast cell research. Steering committee for clinical trial mastocytosis for Novartis Inc. Consulting fees. Consultant to plan clinical trial mastocytosis for Blueprint Medicine Consulting fees. AMLMDS database steering committee for Celgene Consulting fees. 1512 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1514 Ross Levine Consultant for Foundation Medicine Stipend. 1516 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1517 Dennis OMalley Employee of Clarient Pathology Services Salary. 1518 Dennis OMalley Employee of Clarient Pathology Services Salary. 1542 Yuling Luo Employee of Advanced Cell Diagnostics Stock. 1542 Xiao-Jun Ma Employee of Advanced Cell Diagnostics Employee. 1543 Douglas J Hartman Consultant for Omnyx Consulting fee. 1549 Michelle Call Employee of Farsight Genome Systems Employee compensation. 1549 Sushama Thakker Employee of Farsight Genome Systems Employee compensation. 1549 Charlie Kim Employee of Farsight Genome Systems Employee compensation. 1549 Glenda Anderson Employee of Farsight Genome Systems Employee compensation. 1555 Jeffrey L Fine Inventor of Omnyx IP agreement. 1557 Jeffrey L Fine Inventor of Omnyx IP agreement. 1557 Liron Pantanowitz Consultant for Omnyx Consulting fee. 1557 Curtis Stratman Employee of Omnyx LLC Salary. 1557 Douglas J Hartman Consultant for Omnyx Consulting fee. 1557 Joe Birsa Employee of Omnyx Salary. 1557 Jonhan Ho Dr. Ho also serves as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Physicians Department of Dermatology for Omnyx LLC Jonhan Ho MD is employed by an afliate of UPMC which owns one half of Omnyx LLC. Dr. Ho has received research funding from Omnyx LLC through the University of Pittsburgh and has the right to receive proceeds from the sale of Omnyx or its products. NEXTGENERATION LEARNING2016266 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016266 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 1557 Mark Nyman Employee of Omnyx LLC Salary. 1560 Liron Pantanowitz Consultant for Omnyx Consulting fee. 1560 Douglas J Hartman Consultant for Omnyx Consulting fee. 1561 Ajay Basavanhally Employee of Inspirata Inc Equity holder salary. 1561 Anant Madabhushi Scientic advisory board member scientic Consultant for Inspirata Inc. Equity holder. Scientic advisory board member scientic Consultant for Elucid Bioimaging Equity holder. 1562 Anant Madabhushi Scientic advisory board member scientic Consultant for Inspirata Inc. Equity holder. Scientic advisory board member scientic Consultant for Elucid Bioimaging Equity holder. 1563 Louis J Auguste Was responsible for digital imaging of the glass slides using the mWSI technique I invented played no part in the design of this study for CEO Co-founder and major share holder in AlexaPath start-up focused on developing low cost medical diagnostic tools No nancial gain related to this project. 1563 Dhaval H Palsana Was responsible for digital imaging of the glass slides using the mWSI technique I invented played no part in the design of this study for CTO co-founder and major share holder in AlexaPath start-up focused on developing low cost medical diagnostic tools No nancial gain related to this project. 1566 Anant Madabhushi Scientic advisory board member scientic Consultant for Inspirata Inc. Equity holder. Scientic advisory board member scientic Consultant for Elucid Bioimaging Equity holder. 1575 Liron Pantanowitz Consultant for Omnyx Consulting fee. 1575 Jeffrey L Fine Inventor of Omnyx IP agreement. 1575 Douglas J Hartman Consultant for Omnyx Consulting fee. 1582 Murray Treloar Work done in the study for Omnyx LLC Hourly for professional services rendered. 1582 Michael Montalto Senior VP of clinical and medical affairs at Omnyx LLC for Omnyx LLC Salary. 1582 Anil Parwani Dr. Parwani also formerly served as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Department of Pathology for Omnyx LLC Dr. Parwani was formerly employed by an afliate of UPMC which owns one half of Omnyx LLC. He received research funding from Omnyx LLC through the Univ. of Pitt and has the right to receive proceeds from the sale of Omnyx or its products. 1582 Katy Wack Lead clinical scientist at Omnyx LLC for Omnyx LLC Salary. 1582 Laura M Drogowski Research Manager at Omnyx LLC for Omnyx LLC Salary. 1582 Jonhan Ho Dr. Ho also serves as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Physicians Department of Dermatology for Omnyx LLC Jonhan Ho MD is employed by an afliate of UPMC which owns one half of Omnyx LLC. Dr. Ho has received research funding from Omnyx LLC through the University of Pittsburgh and has the right to receive proceeds from the sale of Omnyx or its products. 1582 Andrew Evans Consultants role on clinical trial design and product improvementdevelopment for Omnyx LLC Consultant fees. 1583 Anant Madabhushi Scientic advisory board member scientic Consultant for Inspirata Inc. Equity holder. Scientic advisory board member scientic Consultant for Elucid Bioimaging Equity holder. 1584 Olga Pozdnyakova Consultant for Incyte Honorarium. Consultant for Promedior Honorarium. 1584 Robert P Hasserjian Consultant for Incyte Inc. Salary. 1630 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 1653 Vikram Deshpande Speaker research support for Affymetrix Research support. 1685 Benjamin R Kipp Principle Investigator for Abbott Molecular Inc Grant support. 1696 Shakti H Ramkissoon Part-time pathologist for Foundation Medicine Payment for work. 1699 Garrett Frampton Employee of Foundation Medicine Inc. Employmentequity interest. 1699 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1699 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1699 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1699 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1699 Shakti H Ramkissoon Part-time pathologist for Foundation Medicine Payment for work. 1699 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1699 Juliann Chmielecki Employee of Foundation Medicine Inc. Employmentequity interest. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 267NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 267 Abstract Name Relevant Disclosure Information 1699 Zachary Chalmers Employee of Foundation Medicine Inc. Employmentequity interest. 1699 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1711 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. 1711 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 1711 Barbara R DuPont Speaker for Abbott Travel funds. 1712 Richard Levenson Founder of MUSE Microscopy INc Founder shares. Consultant for Agilent Payment. 1724 Benjamin R Kipp Principle Investigator for Abbott Molecular Inc Grant support. 1738 Ralph H Hruban PalB2 invention for Myriad Genetics Royalties. 1747 David T Ting Research for Affymetrix Research support. 1747 Vikram Deshpande Research support to institution for Affymetrix Research support to institution. 1754 Ralph H Hruban PalB2 invention for Myriad Genetics Royalties. 1757 Mari Mino-Kenudson Consultant for Merrimack Pharmaceuticals Consultation fee. 1760 Yutaka Hatanaka Scientic adviser for TAIHO Pharmaceutical Co. Ltd. Consulting fee. Scientic adviser for GeneticLab Co. Ltd. Consulting fee. Principal Investigator for QIAGEN K.K. Japan Collaborative research expense. Principal Investigator for GeneticLab Co. Ltd. Collaborative research expense. 1772 Ralph H Hruban PalB2 invention for Myriad Genetics Royalties. 1775 Randall E Brand Consultant for Myriad Genetics Inc. Honorarium. Scientic advisory board for Asuragnen Inc. Honorarium. 1775 Ralph H Hruban PalB2 invention for Myriad Genetics Royalties. 1776 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1776 Joel Greenbowe Employee of Foundation Medicine Employee equity. 1776 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1785 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1785 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1785 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Juliann Chmielecki Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Lee Albacker Employee of Foundation Medicine Inc. Employmentequity interest. 1785 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1792 Jason Harris Employee of Personalis Inc Salary. 1792 Michael J Clark Employee of Personalis Inc Salary. 1792 John West Employee of Personalis Inc Salary. 1792 Richard Chen Employee of Personalis Inc Salary. 1792 Christian Haudenschild Employee of Personalis Inc Salary. 1792 Nan Leng Employee of Personalis Inc Salary. 1792 Massimo Morra Employee of Personalis Inc Salary. 1792 Shujun Luo Employee of Personalis Inc Salary. 1792 Sean M Boyle Employee of Personalis Inc Salary. 1792 Deanna M Church Employee of Personalis Inc Salary. 1792 Ravi K Alla Employee of Personalis Inc Salary. 1792 Martina Lefterova Employee of Personalis Inc Salary. 1792 Elena Helman Employee of Personalis Inc Salary. 1795 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1795 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. NEXTGENERATION LEARNING2016268 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016268 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 1795 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1795 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Zachary Chalmers Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Garrett Frampton Employee of Foundation Medicine Inc. Employmentequity interest. 1795 Laurie Gay Employee of Foundation Medicine Inc. Salarystock options. 1796 Daniel DeSloover Employee of Color Genomics Salary. 1796 Robert Daber Employee of Bio-Reference Laboratories Salary. 1797 Zoran Gatalica Employee of Caris Life Sciences Salary. 1797 Inga Rose Employee of Caris Life Sciences Salary. 1797 Peggy Teresi Employee of Caris Life Sciences Salary. 1797 Rebecca Feldman Employee of Caris Life Sciences Salary. 1797 Ryan P Bender Employee of Caris Life Sciences Salary. 1804 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 1804 Andrew Hadd Salaried Employee of Asuragen Inc. Salary. 1804 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. 1805 Scott A Tomlins Consultant for Ventana Medical Systems and Abbvie Honorarium. Licensced intellectual property for Ventana Medical Systems Patent royalties. Licensced intellectual property for Gen-ProbeHologic Patent royalties. Sponsored research agreement for Compendia BioscienceLife TechnologiesThermoFisher Scientifc Research funding. 1813 Wei-Li Liao Employee of Oncoplex DiagnosticsNantomics Salary. Employee of Oncoplex Diagnostics Nantomics Stocks. 1813 Fabiola Cecchi Employee of Oncoplex DiagnosticsNantomics Salary. Employee of Oncoplex Diagnostics Nantomics Stocks. 1813 Adele Blackler Employee of Oncoplex DiagnosticsNantomics Salary. Employee of Oncoplex Diagnostics Nantomics Stocks. 1813 Todd Hembrough Employee of Oncoplex DiagnosticsNantomics Salary. Employee of Oncoplex Diagnostics Nantomics Stocks. 1818 Sydney D Finkelstein Employee of RedPath Interpace Diagnostics Salary. 1821 David T Ting Research for Affymetrix Research support. 1821 Vikram Deshpande Speaker research support for Affymetrix Research support. 1853 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1853 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1854 Peter B Illei Scientic advisory board for Genentech Honorarium. Scientic advisory board for Roche Honorarium. Speaker webinar faculty for Roche Diagnostics Honorarium. Speaker - Workshop Faculty at WCLC 2015 for AstraZeneca Honorarium. Scientic advisory board for Myriad Genetics Honorarium. 1855 Benjamin R Kipp Principle Investigator for Abbott Molecular Inc Grant support. 1860 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1863 Scott Boerner Speaker for Pzer Honorarium. 1863 David M Hwang Speaker for Pzer Honorarium. 1863 Ming-Sound Tsao Speaker for Pzer Honorarium. Consultant for Pzer Honorarium. Principal Investigator for Pzer Research grant. Consultant for Novartis Honorarium. 1870 Gary M Hunninghake Consulting for Medna LLC Honorarium. Consulting for George Lehman Group Honorarium. Scientic advisory board for Patients Like Me Honorarium. Scientic advisory board for Genentech Honorarium. 1870 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 1871 Justin F Gainor Consultant for Boehringer Ingelheim Consulting fee. Consultant for Novartis Consulting fee. Consultant for Merck Consulting fee. Consultant for Clovis Oncology Consulting fee. Consultant for Jounce Therapeutics Travel reimbursement. Consultant for Kyowa Hakko Kirin Pharmaceuticals Consulting fee. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 269NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 269 Abstract Name Relevant Disclosure Information 1871 Mari Mino-Kenudson Consultant for Merrimack Pharmaceuticals Consultation fee. 1874 Ryan Hoff Employee of Myriad Genetics Inc. Salt Lake City UT Receives salary and stock options. 1874 Placede Tiemeny Employee of Myriad Genetics Inc. Salt Lake City UT Receives salary and stock options. 1874 Susanne Wagner Employee of Myriad Genetics Inc. Salt Lake City UT Receives salary and stock options. 1875 Xiao-Jun Ma Employee of Advanced Cell Diagnostics Employee. 1875 Yuling Luo Employee of Advanced Cell Diagnostics Stock. 1887 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 1893 Marie Christine Aubry Consultant for Genentech Honorarium. 1896 Dennis OMalley Employee of Clarient Pathology Services Salary. 1900 Bruce E Johnson Consulting for KEW Group-Genomic Testing Company Honoraria. 1900 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 1909 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 1909 Pasi A Janne Consultant commercial research support for AstraZeneca Consulting fee research support. Consultant for Pzer Consulting fee. Consultant for Roche Consulting fee. Consultant for Acea Biosciences Consulting fee. Consultant for Chugai Pharmaceuticals Consulting fee. Commercial research support for Astellas Research support. Stock ownership for Gatekeeper pharmaceuticals Owns stock. On DFCI-owned intellectual property on EGFR mutations licensed to Lab Corp for Lab Corp Post-marketing royalties. 1911 Marie Christine Aubry Consultant for Genentech Honorarium. 1911 Geoffrey B Johnson Advisory panel for Pzer Inc. Honorarium. 1918 Hans-Ulrich Schildhaus Speaker for Abbott Molecular Honorarium. Speaker for ZytoVision Honorarium. Speaker for Pzer Honorarium. 1919 Diana N Ionescu Speaker at CME events for Pzer Honorarium. 1920 Mari Mino-Kenudson Consultant for Merrimack Pharmaceuticals Consultation fee. 1922 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 1922 Cloud Paweletz Speaker for BioRad Honorarium. 1922 Geoffrey R Oxnard Consultant for Sysmex Honorarium. 1927 Jo-Anne Vergilio Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Julia A Elvin Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Jeffrey S Ross Employee research support for Foundation Medicine Employment equity. 1927 Philip J Stephens Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Vincent A Miller Employee of Foundation Medicine Inc. Employmentequity interest. 1927 James Suh Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Juliann Chmielecki Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Garrett Frampton Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Kai Wang Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Siraj M Ali Employee of Foundation Medicine Inc. Employmentequity interest. 1927 Adrienne Johnson Employee of Foundation Medicine Inc. Employmentstock ownership. 1932 Lynette M Sholl Scientic advisory board for Genentech Honorarium. 2026 Bingqing Zhang Employee of Advanced Cell Diagnostics Salary stock. 2026 Xiao-Jun Ma Employee of Advanced Cell Diagnostics Employee. 2026 Yuling Luo Employee of Advanced Cell Diagnostics Stock. 2026 Henry G Lamparski Employee of Advanced Cell Diagnostics Salary stock. 2026 Nan Su Employee of Advanced Cell Diagnostics Salary stock. 2026 Melanie Miller Employee of Advanced Cell Diagnostics Salary stock. 2026 Casey Kernag Employee of Advanced Cell Diagnostics Salary stock. 2026 Thomas Laver Employee of Advanced Cell Diagnostics Salary stock. 2031 Claire Attwooll Salaried Employee of Illumina Inc Salary. NEXTGENERATION LEARNING2016270 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016270 DISCLOSURE INFORMATION Abstract Name Relevant Disclosure Information 2031 Lisa C Watson Company Employee of Illumina Inc Salary and stocks. 2031 Ravindra Kolhe Researcher for Affymetrix Inc. Kits and Reagents no direct nancial benet. 2031 Alka Chaubey Speaker for Affymetrix Travel benets. Speaker for Cartagenia Travel benets. 2039 Clifford C Hoyt Employee of PerkinElmer Salary. 2039 Alejandro Contreras Speaker for PerkinElmer Travel expenses. 2039 Chichung Wang Employee of PerkinElmer Salary. 2048 Sangheum Hwang Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Hyo-Eun Kim Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Sangyong Song Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Sooyoun Cho Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Soohyun Hwang Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Jungin Lee Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2048 Hyemin Shim Researcher for Ministry of Science ICT and Future Planning Government of Republic of Korea Research grant. 2051 Yuling Luo Employee of Advanced Cell Diagnostics Stock. 2051 Keith Young Employee of Advanced Cell Diagnostics Salary stock. 2051 Xiao-Jun Ma Employee of Advanced Cell Diagnostics Employee. 2051 Nan Su Employee of Advanced Cell Diagnostics Salary stock. 2051 Kuang-Jung Chang Employee of Advanced Cell Diagnostics Salary stock. 2051 Casey Kernag Employee of Advanced Cell Diagnostics Salary stock. 2051 Thomas Laver Employee of Advanced Cell Diagnostics Salary stock. 2051 Melanie Miller Employee of Advanced Cell Diagnostics Salary stock. 2051 Henry G Lamparski Employee of Advanced Cell Diagnostics Salary stock. 2051 Daniel Kim Employee of Advanced Cell Diagnostics Salary stock. 2051 Bingqing Zhang Employee of Advanced Cell Diagnostics Salary stock. 2052 Mirian Karbelashvili Employee of Personalis Inc Salary. 2052 Richard Chen Employee of Personalis Inc Salary. 2052 John West Employee of Personalis Inc Salary. 2052 Deanna M Church Employee of Personalis Inc Salary. 2052 Parin Sripakdeevong Employee of Personalis Inc Salary. 2052 Scott Kirk Employee of Personalis Inc Salary. 2052 Elena Helman Employee of Personalis Inc Salary. 2052 Martina Lefterova Employee of Personalis Inc Salary. 2052 Massimo Morra Employee of Personalis Inc Salary. 2052 Shujun Luo Employee of Personalis Inc Salary. 2052 Ravi K Alla Employee of Personalis Inc Salary. 2052 Michael J Clark Employee of Personalis Inc Salary. 2052 Sean M Boyle Employee of Personalis Inc Salary. 2052 Michael P Snyder Membership on advisory committee for Personalis Inc Stock. 2053 Richard Levenson Founder of MUSE Microscopy INc Founder shares. Consultant for Agilent Payment. 2054 Yonghua Zhang Employee of NovoDiax Inc. Employee. 2054 Zhiqing Zhang Employee of NovoDiax Inc. Employee. 2056 James Manseld Employee of PerkinElmer Salary. NEXTGENERATION LEARNING 2016 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD 271NEXTGENERATION LEARNING 2016 DISCLOSURE INFORMATION 271 Abstract Name Relevant Disclosure Information 2057 James Manseld Employee of PerkinElmer Salary. 2057 Kristin Roman Employee of PerkinElmer Salary. 2057 Chichung Wang Employee of PerkinElmer Salary. 2057 Clifford C Hoyt Employee of PerkinElmer Salary. 2062 Ahmet Dogan Consultant for Foundation Medicine Stipend. Advisory board for Cancer Genetics Stipend. 2067 Hartmut Koeppen Full time Employee of Roche Salary options shares. 2067 Chenery Lowe Contractor for Roche Salary. 2067 Sandra Rost Full time Employee of Roche Salary options shares. 2076 Sydney D Finkelstein Employee of RedPath Interpace Diagnostics Salary. 2078 Claude Sirlin Research contract for General Electric Healthcare None. Research contract for Siemens None. 2082 Ulrich Vogel Inventor of Patent application by myself. No company. Nothing. A patent application only costs. 2084 Yonghua Zhang Employee of NovoDiax Inc. Employee. 2084 Zhiqing Zhang Employee of NovoDiax Inc. Employee. 2085 Casey Kernag Employee of Advanced Cell Diagnostics Salary stock. 2085 Xiao-Jun Ma Employee of Advanced Cell Diagnostics Employee. 2085 Nan Su Employee of Advanced Cell Diagnostics Salary stock. 2085 Daniel Kim Employee of Advanced Cell Diagnostics Salary stock. 2085 Yuling Luo Employee of Advanced Cell Diagnostics Stock. 2085 Bingqing Zhang Employee of Advanced Cell Diagnostics Salary stock. 2085 Henry G Lamparski Employee of Advanced Cell Diagnostics Salary stock. 2089 Luis Chavez Employee of Sakura Finetek USA Inc. Salary. 2089 Erico von Bueren Employee of Sakura Finetek USA Inc. Salary. 2089 Julie A Galindo Employee of Sakura Finetek USA Inc. Salary. 2089 Carlos Sanchez Employee of Sakura Finetek USA Inc. Salary. 2089 Cliff Hom Employee of Sakura Finetek USA Inc. Salary. 2089 Douglas T Yamanishi Employee of Sakura Finetek USA Inc. Salary. 2089 Lydia E Figueroa Employee of Sakura Finetek USA Inc. Salary. 2090 Eugenie Dalimier Employee of LLTech Salary. 2090 Anil Parwani Dr. Parwani also formerly served as a consultant to Omnyx LLC through an agreement with the University of Pittsburgh Department of Pathology for Omnyx LLC Dr. Parwani was formerly employed by an afliate of UPMC which owns one half of Omnyx LLC. He received research funding from Omnyx LLC through the Univ. of Pitt and has the right to receive proceeds from the sale of Omnyx or its products. 2090 Arnaud Duc Employee of LLTech Salary. 2091 Jillian Tyrrell Employee of Biocare Medical Salary. 2091 David Tacha Employee of Biocare Medical Stock. NEXTGENERATION LEARNING2016272 POSTER SESSION Monday March 23 2015 930 AM - 1200 PM CC Exhibit Hall CD NEXTGENERATION LEARNING2016272 NOTES 2016 NEXTGENERATION LEARNING INDEX Visit Us Online for Donation Opportunities www.USCAPFoundation.org Reach inside your pocket while thinking inside the box with a gift to the 1003 Campaign. Help USCAP raise 1 million and create a dynamic of inspired giving that means the world to patients. Every gift of 100 assures that pathologists have access to the most relevant information for patient care and will be used to support these state-of-the-art centers that will refine pathologists skills and create better pathologists world-wide. This unique USCAP environment supports personalized learning and global outreach to advance the discipline of pathology for one world. 1003 Campaign Reach inside your pocket while thinking inside the box with a gift to thethinking inside the box with a gift to thethinking inside the box with a gift to the Help USCAP raise 1 million and create a dynamic of inspired giving that means Every gift of 100 assures thatEvery gift of 100 assures that pathologists have access to the mostpathologists have access to the mostpathologists have access to the most relevant information for patient carerelevant information for patient care and will be used to support these state-of-the-art centers that will refine pathologists skills and create better This unique USCAP environment supports personalized learning and global outreach to advanceand global outreach to advance the discipline of pathology forthe discipline of pathology for Campaign When Making a DonationThink Inside the Box NEXTGENERATION LEARNING 2016 INDEX 273 A Aamelfot Christina................. 157 Aas Hans................................. 110 Aas Turid ................................ 110 Abbas Jaber ........................... 217 Abbas Jad............................... 246 Abbas Ossama....................... 208 Abbott Sara ............................ 249 Abbuhl Mary F ....................... 140 Abdel-Wahab Omar............... 196 Abdul Rehman ....... 184 216 246 Abdulameer Shahad.............. 189 Abdulfatah Eman........... 126 141 ................................... 142 179 249 Abdul-Karim Fadi W. ...... 68 115 ................................................... 218 Abe Hiroyuki........................... 174 Abe Sousei ............................. 157 Abed Francisco ...................... 223 Abedalthaga Malak.............. 191 Abel Haley .............................. 242 Abendroth Catherine S.......... 219 Abi-Raad Rita ......................... 143 Aboshady Ibrahim ................. 172 Abou-Ouf Hatem.................... 136 Abraham Ronald.................... 160 Abraham Susan C........ 165 176 ................................................... 244 Abramson Jeremy................. 229 Abreu Francine de ......... 212 213 Abudayyeh Ala....................... 184 Abu-Farsakh Sohaib .............. 244 AbuSaadeh Feras................... 250 Abusada Ellen ........................ 140 Abuzenadah Adel................... 203 Achim Mary............................ 147 Ackerma Michael J. ......... 54 114 Acosta-Gonzalez Gabriel...... 229 ................................................... 230 Adam Benjamin ..................... 131 Adem Patricia V ..................... 197 Adeniran Adebowale....... 95143 .................... 144147 167 178 222 Adeyi Oyedele.................. 94 191 Adlowitz Diana....................... 209 Adsay N. Volkan.... 22 52 91105 132 133 144 156 157 166 167 ................... 175 184 193 211 245 Adusumilli P........................... 136 Adwar Wamidh ...................... 249 Ae Keisuke.............................. 237 Aesif Scott W.......................... 189 Affolter Kajsa.................. 201 221 Afy Alaa ................................ 254 Agaimy Abbas.... 74 76 207 225 Agaram Narasimhan P.... 76 114 ........................................... 168 196 Agarwal Atin .................. 192 244 Agarwal Jai P ......................... 207 Agarwal Nitin K...................... 227 Agboola Ayodeji O................. 216 Aggarwal Gitika ..................... 198 Aggarwal Nidhi...... 129 155 251 Agostini-Vulaj Diana.............. 246 Agoston Agoston.......... 173 202 ........................................... 203 220 Agrawal Tanupriya......... 123 169 Aguayo Gloria........................ 193 Aguilera-Barrantes Irene....... 149 Aguiluz Angela....................... 134 Aguirre Mercedes .................. 218 Ahearn Thomas ..................... 109 Ahlborn Lise........................... 153 Ahmad Salman ...................... 253 Ahmadi Parnian ..................... 196 Ahmadie Hikmat Al................ 177 Ahmed Isthiaque.................... 190 Ahmed Shahida ..................... 208 Ahmed Syed Salahuddin ...... 142 Ahn Hyein............................... 216 Ahn Inhye ............................... 252 Ahn Janice...................... 210 229 Ahn Sangjeong ...... 174 202 220 Ahn Soomin ................... 166 174 Ahrendt Gretchen .................. 170 Ai Di ........................................ 170 Aida Junko ..................... 244 258 Aida Noriko ............................ 215 Ainechi Sanaz................ 121 221 ........................................... 222 246 Aisner Dara......................... 46 95 Aizer Ayal A ............................ 191 Akbani Rehan......................... 163 Akbari Mohammad R ............ 181 Akdas Yasemin....................... 114 Akgul Mahmut ....................... 123 Akgun Hulya........................... 195 Akhter Ariz.............. 129 154 209 Akhter Shabnam .................... 126 Akiba Jun................................ 250 Akiyama Yoshiyuki................. 224 Akkas Gizem................... 193 245 Akki Ashwin............................ 177 Akram Muzaffar ..... 117 137 198 Akslen Lars A ................. 110 157 Alaggio Rita............ 114 168 253 Alago William......................... 190 Al-Ahmadie Hikmat A.... 126 147 .......................... 163 176 204 214 Al-Ahwal Mahmoud .............. 203 Alam Elie ................................ 208 Alatassi Houda.... 144 218 227 248 Alayed Khaled................ 229 253 Albacker Lee................... 194 267 Albadine Roula....................... 218 Al-Badri Osamah.................... 131 Albanese Joseph ................... 238 Albany Costantine.................. 222 Albarello Luca ........................ 140 Albarracin Constance ............ 216 Albero Raquel ........ 135 189 247 Albert Sebastien .................... 153 Albieri Roberta AP ................. 135 Albrecht Hana ........................ 184 Albuquerque Miguel...... 169 230 Alcaraz-Mateos Eduardo....... 145 Al-Dandan Sadeq................... 186 Aldecoa Iban .......... 215 234 245 Al-Del Firas........................... 131 Alden Ryan S.......................... 188 Alderman Megan................... 218 Alderuccio Juan..................... 227 Aldrees Sultan........................ 187 Aldulescu Monica .................. 232 Alegre Victor .......................... 242 Alejo Maria............................. 167 Alemany Laia.................. 167 223 Aleskandarany Mohammed A ..... ................................... 138 216 217 Alex Deepu............................. 197 Alexander Brian M................. 191 Alexander Erik K..... 172 173 258 Alexander Mariam P..... 131 160 ................................................... 184 Alexis Claudine ...................... 140 Alford Sharon H..................... 180 Al-Habib Ali ............................ 210 Al-Haddad Sahar.................... 125 Al-Hilli Zahraa ........................ 109 Ali Asma ......................... 146 153 Ali Saba .................................. 254 Ali Shadan...................... 203 212 Ali Simak ................................ 217 Ali Siraj M... 111116117120121 127 151 159 163 166 175 193 194 198 203 213 231 246 249 256 258 259 260 261262 263 ................................... 267 268 269 Ali Slimane Ait si ................... 230 Ali Syed Z ....................... 144 239 Ali Waleed .............................. 224 Ali-Fehmi Rouba ........... 117 126 ........... 141 142 179 180 239 249 Alikhan Mir............................. 128 Alizadeh Layla........................ 126 Aljinovic Nika ......................... 131 Al-Kawaaz Mustafa................ 183 Alkan Serhan.................. 217 251 Alkapalan Deema................... 140 Alla Ravi K ...... 162 212 267 270 Allaf Mohamad E ........... 178 179 Allard Felicia........................... 132 Allard Michael F. ...................... 28 Al-Ibraheemi Alyaa........ 196 237 Allen Brian.............................. 112 Allen John .............................. 212 Allen Justin .................... 208 265 Allen Peter.............................. 132 Allende Daniela...................... 230 Allison Derek B............... 118 257 Allison Kimberly ...... 101164 233 Allmer Cristine ....................... 165 Allo Ghassan.................. 180 249 Almadani Noorah .................. 126 Al-Maghrabi Jaudah.............. 203 Almeida Madson Q................ 173 Almeida Raquel...................... 150 Almenara Gorge A................. 140 Almenara Jorge ..................... 219 Almutairi Fawaz ..................... 247 Al-Niaimi Ahmed ................... 151 Alobeid Bachir........ 159 234 253 Alomari Ahmed.............. 192 200 Alonso Sonia.......................... 242 Alos Llucia.............................. 207 Alosh Baraa............ 126 141 179 Alpers Charles................ 138 183 Alpert Lindsay................. 42 111 ................................... 185 201 202 Al-Quran Samer Z.................. 126 Al-Rohil Rami N ............. 200 242 Alruwaii Fatimah.................... 179 Alsaati Gazal........................... 239 Alsafadi Muhammad K.......... 141 ................................... 142 148 179 AlSaikhan Bader .................... 222 AlSalihi Suhair A.................... 131 Alsomali Mohammed............ 121 Altree-Tacha David......... 201 257 Alturkustani Murad................ 235 Alva Ajjai ................................ 223 Alvarado Anthony S .............. 183 Alvarado-Cabrero Isabel ....... 171 ........................................... 177 224 Alvarez Maria Martinez-Lage....... ............................................. 43 191 Aly F Zahra ..................... 166 219 Amador Catalina .... 165 252 253 Ambaye Abiy B ...................... 170 Ambelil Manju........................ 131 Ambrosone Christine ............ 171 Ameri Maryam D ................... 209 Amin Ali.................. 124 147 149 Amin Khalid.................... 119 234 Amin Mahul B ........... 25 101 106 .... 125 136 149163 176 205 249 Amin Md Shahrier ......... 118 131 Amin Mitual............................ 252 Amorese Rebecca.................. 246 Amos Christopher I........ 188 213 An Soyeon.............................. 156 Anand Mona........................... 225 Ananthanarayanan Vijayalakshmi ........................................... 134 232 Anastasi John ........ 130 146 194 Andea Aleodor Doru ...... 23 92 ........................................... 192 200 Andeen Nicole........ 123 178 183 Anders Robert... 86 165 174 259 Anderson Benjamin O............. 66 Anderson Blake.............. 124 146 Anderson Carol...................... 145 Anderson Courtney ............... 161 Anderson Glenda........... 183 265 Anderson James.................... 196 Anderson Matthew L............. 112 Anderson Neil H..................... 211 Anderson Virginia.................. 195 Andrada Encarna ................... 179 Andrasova Martina................ 145 Andre Fabrice......................... 194 Andrews Caitlin...................... 217 Andrews David............... 123 212 Andrulis Irene......................... 134 Aneja Ritu...... 116 138 166 198 ........................... 216 217 235 238 Angchuan Siripron ................ 253 Angelini Annalisa................... 118 Angelis Camila M de ............. 146 Angell Trevor.................. 172 173 Angelos Peter......................... 172 Angert David .......................... 118 Angevin Eric........................... 194 Angot Emilie........................... 168 INDEX NEXTGENERATION LEARNING2016274 Anichini Andrea ..................... 243 Anita Kumar ........................... 209 Annan Anand ......................... 134 Ansari Junaid................. 196 214 Ansell Wendy ......................... 222 Anthony Douglas ................... 104 Antic Tatjana.......... 118 123 172 ........................................... 178 243 Antonarakis Emmanuel S .... 247 ........................................... 260 261 Antonescu Cristina ...... 2728 60 7478 114115 127 139 151 168 ................................................... 196 Aoyama Chisa........................ 251 Aplenc Richard....................... 154 Aplin Alfred C......................... 172 Appiah Adams K.................... 165 Appleman Leonard J............. 125 Aprikian Armen...................... 222 Aqil Barina.............................. 209 Arabe Jorge A........................ 218 Arafah Maria .......................... 141 Arai Tomio...................... 172 244 Araki Asuka ............................ 201 Arana Inigo............................. 191 Aranake-Chrisinger John ...... 227 Aranda Derick M .................... 186 Arango Jose Mantilla ............ 116 Araujo Karina S...................... 146 Araya Juan Carlos ......... 157 193 Arber Daniel A....... 22 90 91130 .................... 137153 155 194 252 Arcaro Kathleen F .................. 213 Arcila M .................................. 159 Arcila Maria E................ 162 163 ................... 196 213 228 237 251 Ardeniz Omur......................... 220 Areas Ana Lucia G ................. 135 Arend Lois .............................. 131 Argani Pedram........ 49 116 117 ................................... 125 136 168 Arguelles-Grande Carolina ... 253 Argyris Prokopios .................. 139 Arias-Stella Javier......... 138 148 ........................................... 205 238 Arif Qudsia ............................. 232 Arita Junichi................... 184 230 Ariza Aurelio........................... 221 Arkin Jordan........................... 217 Arksarapuk Jittirat ................. 253 Armesto Susana .................... 242 Armitage James..................... 209 Armylagos Donna.......... 134 240 Arnald David J ....................... 152 Arnason Thomas ................... 122 Arnold Christina A ... 93 121 133 ........................................... 201 203 Arnold Michael............... 121 133 Arnold Shanna....................... 247 Arnold Stacy J................ 166 219 Arnould Laurent..................... 164 Aronson Judith ...................... 195 Arora Arshi............................. 137 Arora Kshitij ................... 123 250 Arps David P........................... 200 Arriola Aileen Grace P........... 152 Arrossi Andrea V............ 114 136 Arshad Muhammad............... 216 Arun Banu .............................. 216 Asa Sylvia L...................... 28 107 Asano Naoko.......................... 229 Asato Marcel A....................... 146 Asatrian Greg......................... 197 Asch-Kendrick Rebecca J...... 117 Asgedom Girmay................... 216 Ash Ryan ................................ 184 Ashok Dhandapani ................ 122 Asioli Soa ..................... 121 140 Asirvatham Jaya R................. 115 Askan Gokce........................... 132 Askin Frederic ........................ 231 Aslanian Harry ....................... 123 Asleh-Aburaya Karama ......... 117 Assaad Adel ................... 139 220 Assarzadegan Naziheh.. 120 221 Assis David............................. 230 Aster Jon C............................. 155 Astrow Stephanie H....... 180 262 Astvatsaturyan Kristine. 215 216 Aswad Bassam....................... 143 Ataya Dana............................. 117 Atieh Mohammed......... 135 212 ........................................... 219 245 Atkins Kristen A ........ 29 116 250 Attwooll Claire ...... 154 161 237 ................................... 256 264 269 Aubry Marie Christine .... 22 105 ... 134 159 189 190 191 256 269 Augello Claudia...................... 187 Augello Michael..................... 213 Auger Manon ......................... 240 Auger Nathalie ....................... 194 Auguste Louis J ..... 131 239 266 Augustin Jeremy ................... 153 Aull Meredith J ...................... 138 Auman Heidi .......................... 109 Aung Phyu P.......... 120 192 200 ........................................... 201 242 Austin Marshall R ........... 111240 Austin Melissa........................ 145 Avadhani Vaidehi.......... 118 120 ................... 144 167 175 211 234 Avery Diane............................ 239 Aviki Emeline M ..................... 149 Avila-Casado Carmen............ 191 Avril Stefanie.......................... 116 Avula Rajeswari ..................... 114 Awad Mark ............................. 136 Awadallah Amad.... 121 219 229 Axiotis Constantine ............... 219 Aya Francisco......................... 158 Ayala Alberto G...................... 178 Ayata Gamze .......................... 132 Aye Le..................................... 180 Aykutlu Umut ......................... 185 Ayob George H ...................... 162 Ayre Gareth ............................ 152 Azad Nilofer S ................ 202 259 Azaro Analia........................... 213 Aziz Mohamed S.................... 143 Aziz Sara................................. 247 Aziz Sura M ............................ 110 Aziz Tariq ................................ 118 Azueta Ainara......................... 221 Azzato Elizabeth M................. 133 B Baba Satoshi .......................... 241 Babayeva Sabina ... 136 158 188 Babushok Daria...................... 130 Bacchi Carlos E ...... 142 151 152 Badoual Cecile ............... 153 215 Badve Sunil ............. 103 198 238 Bae Young K........................... 211 Bae Jeong Mo........................ 221 Baehner Frederick L....... 142 256 Baek Seunghee ...................... 240 Baere Thierry De.................... 194 Baergen Rebecca ................... 214 Baetz Tara ............................... 129 Bagci Pelin.............. 157 166 193 Bagg Adam......... 29 95 130 137 Baggerly Keith........................ 124 Bagnasco Serena................... 131 Bagrodia Aditya ............. 163 204 Bahar Burak.................... 119 123 Bahary Nathan ....................... 193 Bahrami Armita...................... 168 Bai Chunxue........................... 114 Bai Yalai.................................. 179 Bail Brigitte Le........................ 169 Bailey Helen.................... 142 256 Bailey Mark..................... 120 258 Bailey Nathanael G ........ 193 227 Baine Marina.......................... 237 Bains S.................................... 136 Baiocchi Robert...................... 128 Bajaj Renu .............................. 162 Bajorin Dean F................ 163 204 Baker Gabrielle M .......... 116 199 Baker Suzanne J..................... 191 Bakhiet Salih ........